Sample ID	Alterations	Biomarker	Drugs	Diseases	Response	Evidence	Match	Source	BioM	Resist.	Tumor type
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890	only alteration type		PRAD
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP093	KRAS MUT* (--)	KRAS (12,13)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS (12,13,59,61,117,146)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	NCCN guidelines	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	NCCN guidelines	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR inhibitors	Lung	Resistant	A	NO	NCCN guidelines	only alteration type		L
WP093	PDGFB MUT* (--)	PDGFB-COL1A1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Dermatofibrosarcoma	Responsive	A	NO	FDA	only gene		DFS
WP093	TPMT MUT* (--)	TPMT splice acceptor variant	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP093	TPMT MUT* (--)	TPMT biallelic inactivation	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP093	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP093	TPMT MUT* (--)	TPMT splice acceptor variant	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP093	TPMT MUT* (--)	TPMT biallelic inactivation	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP093	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP093	TPMT MUT* (--)	TPMT splice acceptor variant	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP093	TPMT MUT* (--)	TPMT biallelic inactivation	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP093	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP093	TSC1 MUT* (P396)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		GCA
WP093	TSC1 MUT* (P396)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		RA
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022	only alteration type		BRCA
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP093	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP093	FGFR3 MUT* (--)	FGFR3 fusion	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only gene		BLCA
WP093	FGFR3 MUT* (--)	FGFR3 (G370C,R248C,S249C,Y373C)	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only alteration type		BLCA
WP093	IDH1 (R109I)	IDH1 (R132)	Ivosidenib(IDH1 inhibitor)	Cholangiocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf;PMID:34554208;PMID:32416072	only alteration type		CH
WP093	IDH1 (R109I)	IDH1 (R132C,R132G,R132H,R132L,R132S)	Ivosidenib(IDH1 inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf 	only alteration type		AML
WP093	KRAS MUT* (--)	KRAS (G12C)	Sotorasib(RAS GTPase family inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc	only alteration type		NSCLC
WP093	PIK3CA MUT* (--)	PIK3CA (C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R)	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	only alteration type		BRCA
WP093	IDH1 (R109I)	IDH1 (R132C,R132G,R132H,R132L,R132S)	Olutasidenib(IDH1 inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olutasidenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-idh1-mutation	only alteration type		AML
WP093	KRAS MUT* (--)	KRAS (G12C)	Adagrasib(RAS GTPase family inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc	only alteration type		NSCLC
WP093	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Bevacizumab(VEGF mAb inhibitor);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP093	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP093	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Pembrolizumab(PD-1-blocking antibody);Pemetrexed(Chemotherapy);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf	complete		NSCLC
WP093	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Durvalumab(PD-1-blocking antibody);Tremelimumab-actl(CTLA-4 blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non	complete		NSCLC
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP093	ATM MUT* (--)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP093	FANCA MUT* (--)	FANCA oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP093	EGFR wildtype, ALK wildtype, ROS1 wildtype	EGFR wildtype;ALK wildtype;ROS1 wildtype	Cemiplimab-rwlc(PD-1-blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-combination-platinum-based-chemotherapy-non-small-cell-lung-cancer	complete		NSCLC
WP093	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP093	ARAF MUT* (--)	ARAF oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP093	ARAF MUT* (--)	ARAF oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP093	ARAF MUT* (--)	ARAF oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP093	ARAF MUT* (--)	ARAF oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP093	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP093	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP093	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP093	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP093	KRAS MUT* (--)	KRAS (G12C)	Adagrasib(RAS GTPase family inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP093	IDH1 (R109I)	IDH1 oncogenic mutation	Ivosidenib(IDH1 inhibitor)	Chondrosarcoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf	complete		CS
WP093	KRAS MUT* (--)	KRAS (G12C)	Sotorasib(RAS GTPase family inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP093	IDH1 (R109I)	IDH1 oncogenic mutation	Venetoclax(BCL2 inhibitor)	Acute myeloid leukemia	Responsive	A	YES	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf	complete		AML
WP093	AKT1 MUT* (--)	AKT1 (Q79K,E17K)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265152	only alteration type		CM
WP093	ARAF MUT* (--)	ARAF oncogenic mutation	BRAF inhibitor + EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only alteration type		COREAD
WP093	ARAF MUT* (--)	ARAF oncogenic mutation	BRAF inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only alteration type		COREAD
WP093	AKT1 MUT* (--)	AKT1 (E17K)	AKT inhibitors	Any cancer type	Responsive	D	YES	PMID:21464312;PMID:17611497;PMID:23134728; ENA 2015 (abstr B109)	only alteration type		CANCER
WP093	AKT1 MUT* (--)	AKT1 (E17K)	allosteric AKT inhibitors	Any cancer type	Responsive	C	YES	ENA 2015 (abstract B109);PMID:28489509	only alteration type		CANCER
WP093	AKT1 MUT* (--)	AKT1 (E17K)	non-allosteric AKT inhibitors	Any cancer type	Responsive	C	YES	ENA 2015 (abstract B109);PMID:28489509	only alteration type		CANCER
WP093	AKT1 MUT* (--)	AKT1 (E17K)	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26763254	only alteration type		HNSC
WP093	AKT1 MUT* (--)	AKT1 (H238Y)	Everolimus(MTOR inhibitor)	Fibrous histiocytoma	Responsive	C	NO	ASCO 2015 (abstr 11010)	only alteration type		FH
WP093	AKT1 MUT* (--)	AKT1 (E17K)	Tensirolimus(MTOR inhibitor)	Endometrium	Responsive	C	NO	PMID:27016228	only alteration type		ED
WP093	CTNNB1 (V660F)	CTNNB1 oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Resistant	D	NO	PMID:23539443	complete		COREAD
WP093	APC MUT* (--)	APC oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:22440753;PMID:23539443	only alteration type	336.0	COREAD
WP093	ARAF MUT* (--)	ARAF (S214C)	Sorafenib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	http://www.jci.org/articles/view/72763;PMID:24569458	only alteration type		LUAD
WP093	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	complete		CANCER
WP093	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	complete		OV
WP093	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	complete		CANCER
WP093	FGFR3 MUT* (--)	FGFR3 (V555M)	FGFR inhibitors	Myeloma	Resistant	D	YES	PMID:22869148	only alteration type		MYMA
WP093	ATM MUT* (--)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only alteration type		COREAD
WP093	ATM MUT* (--)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
WP093	ATM MUT* (--)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only alteration type		LY
WP093	ATM MUT* (--)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only gene		LY
WP093	ATM MUT* (--)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP093	ATM MUT* (--)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
WP093	ATM MUT* (--)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP093	ATM MUT* (--)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP093	ATM MUT* (--)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP093	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP093	ATM MUT* (--)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Pancreas	No Responsive	C	NO	ASCO 2015 (abstr 4119)	only alteration type		PA
WP093	KRAS MUT* (--)	KRAS (G13D)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	No Responsive	B	NO	PMID:27114605	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	Selumetinib(MEK inhibitor)	Lung	No Responsive	C	NO	PMID:26802155	only alteration type		L
WP093	KRAS MUT* (--)	KRAS amplification	BRAF inhibitor + EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only gene		COREAD
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	PARP inhibitors	Pancreas	Responsive	C	NO	PMID:25366685;PMID:25719666;PMID:19553641;PMID:25366685	only alteration type		PA
WP093	BRCA1 MUT* (--)	BRCA1 deletion	PARP inhibitors	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	C	YES	PMID:25964244	only alteration type		CANCER
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467;PMID:25366685	only alteration type		BRCA
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP093	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP093	KRAS MUT* (--)	KRAS amplification	BRAF inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only gene		COREAD
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR inhibitors	Non-small cell lung	Resistant	D	NO	PMID:19238210	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR mAb inhibitors	Stomach	Resistant	D	NO	PMID:22614881;PMID:22290393	only alteration type		ST
WP093	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP093	CTNNB1 (V660F), CTNNB1 MUT* (D667E)	CTNNB1 (H36Y,S37C,S37Y,D32V)	Everolimus + Letrozole(MTOR inhibitor + Hormonal therapy)	Endometrium	Responsive	C	NO	PMID:25624430	only alteration type		ED
WP093	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP093	DDR2 MUT* (--)	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung squamous cell	Responsive	D	NO	PMID:22328973	only alteration type		LUSC
WP093	DDR2 MUT* (--)	DDR2 (S768R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung squamous cell	Responsive	C	NO	PMID:22328973	only alteration type		LUSC
WP093	DDR2 MUT* (--)	DDR2 (S768R)	Erlotinib(EGFR inhibitor 1st gen)	Lung squamous cell	Responsive	C	NO	PMID:22328973	only alteration type		LUSC
WP093	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP093	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP093	NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP093	PIK3CA MUT* (--)	PIK3CA (E545*)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMC3936420	only alteration type		CM
WP093	PIK3CA MUT* (--)	PIK3CA amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	D	NO	PMID:24366379	only gene		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9054)	only alteration type		L
WP093	FANCA MUT* (--)	FANCA oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP093	FANCA MUT* (--)	FANCA deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only gene		PRAD
WP093	FGFR3 MUT* (--)	FGFR3 fusion	FGFR inhibitors	Glioma	Responsive	C	NO	PMID:26324363	only gene		G
WP093	FGFR3 MUT* (--)	FGFR3 oncogenic mutation	FGFR inhibitors	Bladder	Responsive	C	NO	PMID:27870574	only alteration type		BLCA
WP093	FGFR3 MUT* (--)	FGFR3 (K650,Y373C)	FGFR inhibitors	Myeloma	Responsive	D	YES	PMID:16091734;PMID:20439987;PMID:22869148	only alteration type		MYMA
WP093	FGFR3 MUT* (--)	FGFR3 (S249C,G691R)	FGFR inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:27998968	only alteration type		LUAD
WP093	FGFR3 MUT* (--)	FGFR3 fusion	FGFR inhibitors	Bladder	Responsive	C	NO	PMID:26324363;ASCO 2017 (abstr 2500)	only gene		BLCA
WP093	FGFR3 MUT* (--)	FGFR3 (K650)	Bortezomib(Proteasome inhibitor)	Myeloma	Responsive	D	YES	PMID:19331127;PMID:21273588	only alteration type		MYMA
WP093	FGFR3 MUT* (--)	FGFR3-TACC3 fusion	FGFR inhibitors(,etc)	Non-small cell lung	Responsive	D	NO	PMID:25294908	only gene		NSCLC
WP093	FGFR4 MUT* (H399P)	FGFR4 (N535,V550)	FGFR inhibitors	Rhabdomyosarcoma	Responsive	D	NO	PMID:19809159;PMID:24124571	only alteration type		RHBDS
WP093	FGFR3 MUT* (--)	FGFR3 (Y373C)	Bortezomib(Proteasome inhibitor)	Myeloma	Resistant	D	YES	PMID:19331127;PMID:21273588	only alteration type		MYMA
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP093	NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP093	GATA3 MUT* (--)	GATA3 oncogenic mutation	Aromatase ihibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:24758297	only alteration type		BRCA
WP093	GNAS MUT* (A416)	GNAS (R201)	JAK inhibitors	Any cancer type	Responsive	D	YES	PMID:21835143	only alteration type		CANCER
WP093	HDAC2 MUT* (--)	HDAC2 biallelic inactivation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP093	IDH1 (R109I)	IDH1 oncogenic mutation	BCL2 inhibitors	Acute myeloid leukemia	Responsive	D	YES	PMID:25599133	complete		AML
WP093	IDH1 (R109I)	IDH1 oncogenic mutation	IDH1 inhibitors	Acute myeloid leukemia	Responsive	C	YES	ENA 2014 (abstr 1LBA)	complete		AML
WP093	IDH1 (R109I)	IDH1 (R132)	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:28148839	only alteration type		CANCER
WP093	IDH1 (R109I)	IDH1 oncogenic mutation	AG-120(IDH1 inhibitor)	Glioma	Responsive	C	NO	NCT02073994;PMID:23558169	complete		G
WP093	IDH1 (R109I)	IDH1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Cholangiocarcinoma	Responsive	C	NO	NCT02428855	complete		CH
WP093	IDH1 (R109I)	IDH1 (R132)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Billiary tract	Responsive	D	NO	PMID:27231123	only alteration type		BT
WP093	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP093	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	EZH2 inhibitors	Any cancer type	Resistant	D	YES	PMID:26552009	only alteration type		CANCER
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitors	Endometrium	Resistant	D	NO	PMID:22662154	only alteration type		ED
WP093	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP093	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:19223544;PMID:20619739	only alteration type		COREAD
WP093	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP093	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP093	KRAS MUT* (--)	KRAS (G12)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	C	NO	PMID:24687822	only alteration type		GIST
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	Trastuzumab + Lapatinib(ERBB2 mAb inhibitor + ERBB2 inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	ASCO 2015 (abstr 3508);NCT01104571;EBCC10	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	BET inhibitors	Lung	Responsive	D	NO	PMID:23129625;PMID:24045185	only alteration type		L
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4 inhibitors	Lung	Responsive	D	NO	PMID:20609353	only alteration type		L
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Lung	Responsive	C	NO	AACR 2017 (CT046)	only alteration type		L
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Cervix squamous cell	Responsive	D	NO	PMID:27167191	only alteration type		CESC
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR mAb inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24553387	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	ERK inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23614898	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	FAK inhibitors	Lung	Responsive	D	NO	PMID:23358651	only alteration type		L
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	FAS inhibitors	Lung	Responsive	C	NO	AACR 2016;abstr	only alteration type		L
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	FAS inhibitors	Lung	Responsive	C	NO	AACR 2016, abstr LB214	only alteration type		L
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	HSP90 inhibitor(in combination)s	Lung	Responsive	D	NO	PMID:23012248;PMID:21907929	only alteration type		L
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	JAK/TBK1/IKKÎµ inhibitors	Lung	Responsive	D	NO	PMID:24444711	only alteration type		L
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + BCL-XL inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23245996	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + IGF1R inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24045180	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + PI3K pathway inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:22392911	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitors	Lung, Billiary tract	Responsive	C	NO	PMID:23200175;PMID:24947927;PMID:25667274;PMID:25722381;PMID:23391555	only alteration type		L, BT
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitors	Acute myeloid leukemia, Cervix, Ovary	Responsive	D	YES	PMID:22507781;PMID:22169769;PMID:19018267	only alteration type		AML, CER, OV
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP093	KRAS MUT* (--)	KRAS (G12)	MEK inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:18701506	only alteration type		ALL
WP093	NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	MTOR inhibitor + BH3 mimeticss	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24163374	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	pan-RAF inhibitors	Lung	Responsive	C	NO	AACR 2017 (abstr  CT002)	only alteration type		L
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	pan-RAF inhibitors	Endometrium	Responsive	C	NO	AACR 2016 (abstr CT005);AACR 2017 (abstr CT002)	only alteration type		ED
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Endometrium	Responsive	D	NO	PMID:21984976;PMID:22662154	only alteration type		ED
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Lung	Responsive	C	NO	PMID:25516890	only alteration type		L
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	Abemaciclib(CDK4/6 inhibitor)	Lung	Responsive	C	NO	PMID:27217383	only alteration type		L
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP093	NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP093	NF2 (R376W)	NF2 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Schwannoma	No Responsive	C	NO	PMID:20736812	complete		SCHW
WP093	NF2 (R376W)	NF2 deletion	Erlotinib(EGFR inhibitor 1st gen)	Schwannoma	No Responsive	C	NO	PMID:20736812	only gene		SCHW
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP093	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP093	NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP093	NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP093	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	Decitabine + BCL2 inhibitor(Chemotherapy + BCL2 inhibitor)	Ovary	Responsive	D	NO	PMID:25968887	only alteration type		OV
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP093	NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP093	NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP093	NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP093	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP093	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP093	NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP093	NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP093	NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP093	NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP093	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP093	NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP093	NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP093	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP093	LRP1B MUT* (--)	LRP1B oncogenic mutation	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only alteration type		OV
WP093	LRP1B MUT* (--)	LRP1B deletion	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only gene		OV
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP093	NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP093	NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP093	NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP093	NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP093	NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP093	NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP093	NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP093	NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP093	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP093	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP093	NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP093	NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP093	NF2 (R376W)	NF2 oncogenic mutation	FAK inhibitors	Mesothelioma	Responsive	C	NO	ENA 2012 (abstr 610)	complete		MESO
WP093	NF2 (R376W)	NF2 oncogenic mutation	FAK inhibitors	Mesothelioma, Ovary	Responsive	D	NO	PMID:24848258;PMID:24786638	complete		MESO, OV
WP093	NF2 (R376W)	NF2 deletion	FAK inhibitors	Mesothelioma	Responsive	C	NO	ENA 2012 (abstr 610)	only gene		MESO
WP093	NF2 (R376W)	NF2 deletion	FAK inhibitors	Mesothelioma, Ovary	Responsive	D	NO	PMID:24848258;PMID:24786638	only gene		MESO, OV
WP093	NF2 (R376W)	NF2 oncogenic mutation	HSP90 inhibitors	Meningioma	Responsive	D	NO	PMID:23714726	complete		MEN
WP093	NF2 (R376W)	NF2 deletion	HSP90 inhibitors	Meningioma	Responsive	D	NO	PMID:23714726	only gene		MEN
WP093	NF2 (R376W)	NF2 oncogenic mutation	MEK inhibitors	Thyroid	Responsive	D	NO	PMID:26359368	complete		TH
WP093	NF2 (R376W)	NF2 deletion	MEK inhibitors	Thyroid	Responsive	D	NO	PMID:26359368	only gene		TH
WP093	NF2 (R376W)	NF2 oncogenic mutation	MTOR inhibitors	Meningioma	Responsive	D	NO	PMID:19451225;PMID:2242646	complete		MEN
WP093	NF2 (R376W)	NF2 deletion	MTOR inhibitors	Meningioma	Responsive	D	NO	PMID:19451225;PMID:2242646	only gene		MEN
WP093	NF2 (R376W)	NF2 oncogenic mutation	PAK inhibitors	Schwannoma, Meningioma	Responsive	D	NO	PMID:23960073;PMID:25596744	complete		SCHW, MEN
WP093	NF2 (R376W)	NF2 deletion	PAK inhibitors	Schwannoma, Meningioma	Responsive	D	NO	PMID:23960073;PMID:25596744	only gene		SCHW, MEN
WP093	NF2 (R376W)	NF2 oncogenic mutation	PDK1 inhibitors	Schwannoma	Responsive	D	NO	PMID:19359162	complete		SCHW
WP093	NF2 (R376W)	NF2 deletion	PDK1 inhibitors	Schwannoma	Responsive	D	NO	PMID:19359162	only gene		SCHW
WP093	NF2 (R376W)	NF2 oncogenic mutation	AR42(HDAC inhibitor)	Schwannoma	Responsive	D	NO	PMID:21778190	complete		SCHW
WP093	NF2 (R376W)	NF2 oncogenic mutation	AR42(HDAC inhibitor)	Meningioma	Responsive	C	NO	ASCO 2016 (abstr 2558)	complete		MEN
WP093	NF2 (R376W)	NF2 deletion	AR42(HDAC inhibitor)	Schwannoma	Responsive	D	NO	PMID:21778190	only gene		SCHW
WP093	NF2 (R376W)	NF2 deletion	AR42(HDAC inhibitor)	Meningioma	Responsive	C	NO	ASCO 2016 (abstr 2558)	only gene		MEN
WP093	NF2 (R376W)	NF2 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Schwannoma	Responsive	C	NO	PMID:19587327;PMID:22805104;PMID:26022982	complete		SCHW
WP093	NF2 (R376W)	NF2 deletion	Bevacizumab(VEGFR mAb inhibitor)	Schwannoma	Responsive	C	NO	PMID:19587327;PMID:22805104;PMID:26022982	only gene		SCHW
WP093	NF2 (R376W)	NF2 oncogenic mutation	Everolimus(MTOR inhibitor)	Schwannoma	Responsive	C	NO	PMID:24311643;2556735	complete		SCHW
WP093	NF2 (R376W)	NF2 deletion	Everolimus(MTOR inhibitor)	Schwannoma	Responsive	C	NO	PMID:24311643;2556735	only gene		SCHW
WP093	NF2 (R376W)	NF2 oncogenic mutation	Everolimus + Octreotide(MTOR inhibitor + Somatostatin analog)	Meningioma	Responsive	D	NO	PMID:26015296	complete		MEN
WP093	NF2 (R376W)	NF2 deletion	Everolimus + Octreotide(MTOR inhibitor + Somatostatin analog)	Meningioma	Responsive	D	NO	PMID:26015296	only gene		MEN
WP093	NF2 (R376W)	NF2 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Schwannoma	Responsive	D	NO	PMID:19509233;PMID:2290085	complete		SCHW
WP093	NF2 (R376W)	NF2 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Schwannoma	Responsive	D	NO	PMID:19509233;PMID:2290085	only gene		SCHW
WP093	NF2 (R376W)	NF2 oncogenic mutation	Lapatinib(ERBB2 inhibitor)	Schwannoma, Neurofibroma	Responsive	C	NO	PMID:22844108;NCT00973739	complete		SCHW, NF
WP093	NF2 (R376W)	NF2 deletion	Lapatinib(ERBB2 inhibitor)	Schwannoma, Neurofibroma	Responsive	C	NO	PMID:22844108;NCT00973739	only gene		SCHW, NF
WP093	NF2 (R376W)	NF2 oncogenic mutation	Tensirolimus + Chemotherapy(MTOR inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25878190	complete		BRCA
WP093	NF2 (R376W)	NF2 deletion	Tensirolimus + Chemotherapy(MTOR inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25878190	only gene		BRCA
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	Gemcitabine + MEK inhibitor(Chemotherapy + MEK inhibitor)	Pancreas	Responsive	C	NO	PMID:23583440	only alteration type		PA
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	Selumetinib(MEK inhibitor)	Non-small cell lung	Responsive	C	NO	NCT00890825	only alteration type		NSCLC
WP093	NOTCH1 MUT* (T701P), NOTCH1 MUT* (N685T)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP093	NOTCH1 MUT* (T701P), NOTCH1 MUT* (N685T)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP093	NOTCH1 MUT* (T701P), NOTCH1 MUT* (N685T)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP093	NOTCH1 MUT* (T701P), NOTCH1 MUT* (N685T)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP093	NOTCH1 MUT* (T701P), NOTCH1 MUT* (N685T)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP093	NOTCH1 MUT* (T701P), NOTCH1 MUT* (N685T)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP093	NOTCH1 MUT* (T701P), NOTCH1 MUT* (N685T)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP093	NOTCH1 MUT* (T701P), NOTCH1 MUT* (N685T)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	only alteration type		MCL
WP093	NOTCH1 MUT* (T701P), NOTCH1 MUT* (N685T)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP093	NOTCH1 MUT* (T701P), NOTCH1 MUT* (N685T)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP093	NOTCH1 MUT* (T701P), NOTCH1 MUT* (N685T)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP093	NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP093	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP093	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP093	PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP093	PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP093	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP093	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP093	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP093	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	AKT inhibitors	Breast adenocarcinoma	Responsive	C	NO	ASCO 2015 (abstr 2500)	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitor(alone or in combination)s	Lung, Colorectal adenocarcinoma	Responsive	D	NO	PMID:23136191;PMID:23475782;PMID:22392911	only alteration type		L, COREAD
WP093	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Bladder, Head an neck, Lung	Responsive	C	NO	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	only alteration type		BLCA, HNC, L
WP093	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma, Ovary, Cervix squamous cell, Endometrium	Responsive	C	NO	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	only alteration type		BRCA, OV, CESC, ED
WP093	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26787751;PMID:26763254	only alteration type		HNSC
WP093	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Glioma, Thyroid carcinoma	Responsive	D	NO	PMID:19671762;PMID:21289267	only alteration type		G, THCA
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	Sorafenib + MEK inhibitor(Pan-TK inhibitor + MEK inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:25294897	only alteration type		HC
WP093	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:28331003	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2501)	only alteration type		ST
WP093	POLE MUT* (A1597G), POLE MUT* (--)	POLE (268-471)	PD1 Ab inhibitors	Glioma, Endometrium	Responsive	C	NO	PMID:27001570;PMID:27683556;PMID:27159395	only alteration type		G, ED
WP093	POLE MUT* (A1597G), POLE MUT* (--)	POLE oncogenic mutation	PD1 Ab inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28188185	only alteration type		COREAD
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP093	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP093	NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP093	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP093	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP093	SETD2 MUT* (--), SETD2 MUT* (--)	SETD2 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only alteration type		CANCER
WP093	SETD2 MUT* (--), SETD2 MUT* (--)	SETD2 deletion	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only gene		CANCER
WP093	SF3B1 MUT* (--)	SF3B1 (K700E,K666N)	Spliceosome inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858	only alteration type		CANCER
WP093	SMARCA4 MUT* (V830G)	SMARCA4 oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	C	NO	ESMO 2015 (abstract 302)	only alteration type		OV
WP093	SMARCA4 MUT* (V830G)	SMARCA4 deletion	EZH2 inhibitors	Ovary	Responsive	C	NO	ESMO 2015 (abstract 302)	only gene		OV
WP093	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib + Ponatinib(MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27338794	only alteration type		LUAD
WP093	NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP093	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP093	TERT MUT* (--), TERT MUT* (S274)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP093	TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP093	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP093	TSC1 MUT* (P396)	TSC1 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	only alteration type		RA
WP093	TSC1 MUT* (P396)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	only alteration type		BLCA
WP093	TSC1 MUT* (P396)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;PMID:26859683;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	only alteration type		R
WP093	TSC1 MUT* (P396)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Sarcoma, Stomach	Responsive	C	NO	PMID:26859683	only alteration type		S, ST
WP093	TSC1 MUT* (P396)	TSC1 deletion	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	only gene		R
WP093	BRCA1 MUT* (--)	BRCA1 (G1738R,A1708V,C47G,V1696L,Y1853C,D1739V,F1761I,H1746N,C24Y,K1702E,P1749R,M1775R,W1837C,M1775E,V1736G,V1838E,C44F,A1752V,D1739E,S1715N,.,A1789T,S1164I,T1685A,A1752P,H1686R,H41R,C64G,W1718L,D1692H,V1713A,R1699W,V1653M,Q1756C,C61G,D1739Y,G1770V,V1714G,V1833M,R1835P,R1699Q,G1706E,P1812A,E1836K,C44Y,G1788D,C39Y,M1R,S1715R,Y1703H,F1761S,E33A,M1628V,W1837G,L1705P,M1689R,G1738E,R1751P,V1809F,S1841N,S1722F,I1766S,S1655F,G1788V,L1780P,V1833E,A1708E,E1660G,C27A,Y1703S,I1807S,T1700A,A1843T,F1734L,V1741G,V1810G,F1704S,G1656D,T1685I,L1854P,Q1811R,M18T,C1697R,G1803A,G1743R,G1763V,C24R,T37R,T1773I,D1739G,W1718C,H1686Q,T1691I,L1407P,K1487R,M1652K,S1841R,M1775K,S1841A,F1734S,V1736A,M1689T,W1815X,L1764P,W1837R,T1691K,R1753T,D1692Y,W1718S,L1657P,A1843P,S1715C,R1699L)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/6/summary|oncokb=https://www.oncokb.org/gene/BRCA1	only alteration type		OV
WP093	BRCA1 MUT* (--)	BRCA1 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only gene		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
WP093	BRCA1 MUT* (--)	BRCA1 (G1738R,A1708V,C47G,V1696L,Y1853C,D1739V,F1761I,H1746N,C24Y,K1702E,P1749R,M1775R,W1837C,M1775E,V1736G,V1838E,C44F,A1752V,D1739E,S1715N,.,A1789T,S1164I,T1685A,A1752P,H1686R,H41R,C64G,W1718L,D1692H,V1713A,R1699W,V1653M,Q1756C,C61G,D1739Y,G1770V,V1714G,V1833M,R1835P,R1699Q,G1706E,P1812A,E1836K,C44Y,G1788D,C39Y,M1R,S1715R,Y1703H,F1761S,E33A,M1628V,W1837G,L1705P,M1689R,G1738E,R1751P,V1809F,S1841N,S1722F,I1766S,S1655F,G1788V,L1780P,V1833E,A1708E,E1660G,C27A,Y1703S,I1807S,T1700A,A1843T,F1734L,V1741G,V1810G,F1704S,G1656D,T1685I,L1854P,Q1811R,M18T,C1697R,G1803A,G1743R,G1763V,C24R,T37R,T1773I,D1739G,W1718C,H1686Q,T1691I,L1407P,K1487R,M1652K,S1841R,M1775K,S1841A,F1734S,V1736A,M1689T,L1764P,W1837R,T1691K,R1753T,D1692Y,W1718S,L1657P,A1843P,S1715C,R1699L)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only alteration type		BRCA
WP093	BRCA1 MUT* (--)	BRCA1 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only gene		BRCA
WP093	TSC1 MUT* (P396)	TSC1 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	only gene		RCCC
WP093	TSC1 MUT* (P396)	TSC1 (H105R,H206D,V220F,L180P,F216A,M224R,H68R,.,S35Q,F158C,L117P,L191H)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	only alteration type		RCCC
WP093	KDM6A MUT* (--)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
WP093	KDM6A MUT* (--)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only alteration type		BLCA
WP093	FGFR3 MUT* (--)	FGFR3 (S249C,S371C,R248C,K650.,G380R,Y373C,G370C)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only alteration type		BLCA
WP093	FGFR3 MUT* (--)	FGFR3 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		BLCA
WP093	AKT1 MUT* (--)	AKT1 (E17K)	Azd5363	Breast adenocarcinoma	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/AKT1|CIVIC=https://civicdb.org/genes/2/summary	only alteration type		BRCA
WP093	AKT1 MUT* (--)	AKT1 (E17K)	Azd5363	Endometrial adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/AKT1	only alteration type		EDA
WP093	AKT1 MUT* (--)	AKT1 (E17K)	Azd5363	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/AKT1	only alteration type		OV
WP093	KRAS MUT* (--)	KRAS (D119N,G12F,F156L,G60R,F28L,A18D,Q22K,K147E,D33E,A146T,E62K,A146V,Q61R,Q61H,G12A,G12R,G13E,Q22R,V14I,Y71H,G13D,G12C,T58I,.,D153V,A59G,K117N,S65N,P34L,Y64A,G13V,K5N,Y32S,L19F,T74P,G13C,G12V,G12D,Q22E,Q61L,G12S,P34R)	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/30/summary|oncokb=https://www.oncokb.org/gene/KRAS	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS amplification	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only gene		COREAD
WP093	KRAS MUT* (--)	KRAS (D119N,G12F,F156L,G60R,F28L,A18D,Q22K,K147E,D33E,A146T,E62K,A146V,Q61R,Q61H,G12A,G12R,G13E,Q22R,V14I,Y71H,G13D,G12C,T58I,.,D153V,A59G,K117N,S65N,P34L,Y64A,K5N,Y32S,L19F,T74P,G13C,G12V,G12D,Q22E,Q61L,G12S,P34R)	Cobimetinib + Binimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only alteration type		CANCER
WP093	KRAS MUT* (--)	KRAS amplification	Cobimetinib + Binimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only gene		CANCER
WP093	NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP093	NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP093	ARAF MUT* (--)	ARAF (G322S,S214T,F351L,.,S214C,N217I,S214A,S214F)	Sorafenib	Histiocytoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ARAF	only alteration type		HIS
WP093	PIK3CA MUT* (--)	PIK3CA (P539R,R38H,Q546K,G118D,G106V,Q546E,E579K,N345K,E453K,V344A,E545K,T1025S,E542Q,G1049R,M1043I,E110K,P449T,N1044K,K111E,C378R,H1047R,C420R,E78K,E545A,S629C,D350G,.,G451R,M1043V,E542V,Q546R,E365K,E81K,G106D,R88Q,P366R,R93Q,G914R,H1047Y,K111N,E545Q,E545G,R93W,R108H,G106R,E453Q,E542K,D1029Y,N345I,D549N,A1066V,Q546P,E542G,E453A)	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA amplification	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only gene		BRCA
WP093	ATM MUT* (--)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only alteration type		CANCER
WP093	ATM MUT* (--)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
WP093	FGFR3 MUT* (--)	FGFR3 (M528I,D641N,R669G,Y373C,K650T,G370C,S249C,S371C,A391E,G380R,I538V,D641G,N540K,R248C,V555M,.,K650E,K650R,K650M,G375C,G382D,N540S,Y647C,K650Q,K650N)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only alteration type		CANCER
WP093	FGFR3 MUT* (--)	FGFR3 amplification	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP093	FGFR3 MUT* (--)	FGFR3-BAIAP2L1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP093	FGFR3 MUT* (--)	FGFR3-TACC3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP093	FGFR3 MUT* (--)	FGFR3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP093	FGFR3 MUT* (--)	FGFR3-IGH fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP093	ARAF MUT* (--)	ARAF (G322S,S214T,F351L,.,S214C,N217I,S214A,S214F)	Sorafenib	Non-small cell lung	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ARAF|CIVIC=https://civicdb.org/genes/3/summary	only alteration type		NSCLC
WP093	AKT1 MUT* (--)	AKT1 E17K	Akt Inhibitor MK2206	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/231	only alteration type		BRCA
WP093	AKT1 MUT* (--)	AKT1 E17K	Capivasertib	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/709	only alteration type		BRCA
WP093	AKT1 MUT* (--)	AKT1 E17K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4029	only alteration type		CM
WP093	AKT1 MUT* (--)	AKT1 E17K	Uprosertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/707	only alteration type		CM
WP093	AKT1 MUT* (--)	AKT1 Q79K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/439	only alteration type		CM
WP093	AKT1 MUT* (--)	AKT1 Q79K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4498	only alteration type		CM
WP093	AKT1 MUT* (--)	AKT1 Q79K	Dabrafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6260	only alteration type		CM
WP093	APC MUT* (--)	APC Mutation	G007-LK	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/446	only alteration type		COREAD
WP093	ARAF MUT* (--)	ARAF S214C	Sorafenib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/17	only alteration type		NSCLC
WP093	ARAF MUT* (--)	ARAF S214C	Sorafenib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/40	only alteration type		NSCLC
WP093	ARAF MUT* (--)	ARAF S214C	Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/41	only alteration type		NSCLC
WP093	ARAF MUT* (--)	ARAF S490T	Cetuximab,Irinotecan,Vemurafenib	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1905	only alteration type		COREAD
WP093	ATM MUT* (--)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	only alteration type		CM
WP093	ATM MUT* (--)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	only alteration type		GB
WP093	ATM MUT* (--)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	only alteration type		PRAD
WP093	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP093	BRCA1 MUT* (--)	BRCA1 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/1897	only alteration type		OV
WP093	BRCA1 MUT* (--)	BRCA1 Mutation	Olaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/7275	only alteration type		OV
WP093	BRCA1 MUT* (--)	BRCA1 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11136	only alteration type		OV
WP093	BRCA1 MUT* (--)	BRCA1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11203	only alteration type		PRAD
WP093	BRCA1 MUT* (--)	BRCA1 Q1467*	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2878	only alteration type		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
WP093	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
WP093	DDR2 MUT* (--)	DDR2 G253C	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/266	only alteration type		NSCLC
WP093	DDR2 MUT* (--)	DDR2 G505S	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/267	only alteration type		NSCLC
WP093	DDR2 MUT* (--)	DDR2 G774V	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/268	only alteration type		NSCLC
WP093	DDR2 MUT* (--)	DDR2 I638F	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/269	only alteration type		NSCLC
WP093	DDR2 MUT* (--)	DDR2 L239R	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/270	only alteration type		NSCLC
WP093	DDR2 MUT* (--)	DDR2 L63V	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/271	only alteration type		NSCLC
WP093	DDR2 MUT* (--)	DDR2 S768R	Dasatinib,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/272	only alteration type		NSCLC
WP093	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP093	FGFR3 MUT* (--)	FGFR3 FGFR3::BAIAP2L1	PD173074	Bladder	Responsive	D	NO	https://civicdb.org/links/evidence_items/144	only gene		BLCA
WP093	FGFR3 MUT* (--)	FGFR3 Mutation	Infigratinib	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/1910	only alteration type		BLCA
WP093	FGFR3 MUT* (--)	FGFR3 Mutation	Cisplatin,Gemcitabine	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/7566	only alteration type		BLCA
WP093	GNAS MUT* (A416)	GNAS R201C	Cetuximab,Vemurafenib,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1906	only alteration type		COREAD
WP093	IDH1 (R109I)	IDH1 Mutation	Ivosidenib	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/7278	complete		AML
WP093	IDH1 (R109I)	IDH1 Mutation	Venetoclax	Acute myeloid leukemia	Responsive	C	YES	https://civicdb.org/links/evidence_items/8856	complete		AML
WP093	IDH1 (R109I)	IDH1 Mutation	Ivosidenib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7447	complete		CH
WP093	IDH1 (R109I)	IDH1 R132	Ivosidenib	Cholangiocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/10886	only alteration type		CH
WP093	IDH1 (R109I)	IDH1 R132	Dasatinib	Intrahepatic cholangiocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6439	only alteration type		IHCH
WP093	IDH1 (R109I)	IDH1 R132C	GSK321	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/732	only alteration type		AML
WP093	IDH1 (R109I)	IDH1 R132C	Ivosidenib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/2331	only alteration type		AML
WP093	IDH1 (R109I)	IDH1 R132C	BPTES	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/2332	only alteration type		AML
WP093	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP093	KMT2C MUT* (K2797X), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP093	KRAS MUT* (--)	KRAS A146	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3939	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS A146P	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2225	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS A146T	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2943	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS A146T	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3858	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS A146T	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2206	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS A146V	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2209	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS A146V	Abemaciclib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/794	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS G12/G13	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/134	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12/G13	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/135	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12/G13	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2004	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12/G13	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6293	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12/G13	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6294	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12/G13	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6295	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12/G13	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6296	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12/G13	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6363	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12/G13	Gefitinib,Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/35	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS G12/G13	Trametinib,Gemcitabine	Pancreas adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/622	only alteration type		PAAD
WP093	KRAS MUT* (--)	KRAS G12/G13	Trametinib	Pancreas adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/990	only alteration type		PAAD
WP093	KRAS MUT* (--)	KRAS G12A	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3710	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12A	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4429	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12A	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6319	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12A	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/251	only alteration type		LUAD
WP093	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2009	only alteration type		MM
WP093	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2012	only alteration type		MM
WP093	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2013	only alteration type		MM
WP093	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2014	only alteration type		MM
WP093	KRAS MUT* (--)	KRAS G12C	Gefitinib,Erlotinib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1216	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12C	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2253	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12C	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3967	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12C	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3973	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12C	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2212	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2258	only alteration type		MM
WP093	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2261	only alteration type		MM
WP093	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2262	only alteration type		MM
WP093	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2263	only alteration type		MM
WP093	KRAS MUT* (--)	KRAS G12C	Docetaxel,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1142	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS G12C	Sotorasib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/9431	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS G12D	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3957	only alteration type		CM
WP093	KRAS MUT* (--)	KRAS G12D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2193	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2207	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2236	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12D	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3946	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12D	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6316	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12D	Therapeutic Tumor Infiltrating Lymphocytes	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1898	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12D	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2218	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12D	Vemurafenib	Hairy-Cell leukemia	Resistant	C	YES	https://civicdb.org/links/evidence_items/1580	only alteration type		HCL
WP093	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2247	only alteration type		MM
WP093	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2250	only alteration type		MM
WP093	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2251	only alteration type		MM
WP093	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2252	only alteration type		MM
WP093	KRAS MUT* (--)	KRAS G12D	Dabrafenib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/91	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS G12D	Selumetinib,Dactolisib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/305	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS G12D	Cetuximab	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/3958	only alteration type		OV
WP093	KRAS MUT* (--)	KRAS G12R	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2264	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12R	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3987	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12R	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3989	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12R	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3991	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12S	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2269	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12S	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4006	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12S	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4012	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12S	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6314	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2274	only alteration type		MM
WP093	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2277	only alteration type		MM
WP093	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2278	only alteration type		MM
WP093	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2279	only alteration type		MM
WP093	KRAS MUT* (--)	KRAS G12V	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/136	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12V	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2219	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12V	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2232	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12V	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3824	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12V	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3924	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12V	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6323	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12V	Dactolisib,Selumetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2001	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G12V	Palbociclib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/795	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS G12V	Selumetinib,Docetaxel	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1143	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS G13D	Pictilisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2041	only alteration type		BRCA
WP093	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/806	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1180	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1181	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G13D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2178	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3878	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3881	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3882	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G13D	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3889	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G13D	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6320	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G13D	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6322	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/145	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/306	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G13D	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2183	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS G13V	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6312	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Mutation	Vemurafenib,Dabrafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6264	only alteration type		CM
WP093	KRAS MUT* (--)	KRAS Mutation	Bevacizumab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1139	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Mutation	Ixazomib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1182	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1702	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3704	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	A	NO	https://civicdb.org/links/evidence_items/5345	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Mutation	Immunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/943	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Mutation	Cetuximab,Dasatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/947	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Mutation	B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/988	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Mutation	Trametinib,Afatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/991	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Mutation	MEK Inhibitor RO4987655	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/998	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Mutation	Refametinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1001	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Mutation	Selumetinib,Teprotumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1004	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Mutation	Selumetinib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4866	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Mutation	Palbociclib,Binimetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4869	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Mutation	Temsirolimus,Ridaforolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/894	only alteration type		ED
WP093	KRAS MUT* (--)	KRAS Mutation	Sorafenib,Refametinib	Hepatic carcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1642	only alteration type		HC
WP093	KRAS MUT* (--)	KRAS Mutation	Salirasib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1218	only alteration type		LUAD
WP093	KRAS MUT* (--)	KRAS Mutation	MEK Inhibitor RO4987655	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/997	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2242	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Gefitinib,Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2385	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Selumetinib	Non-small cell lung	Resistant	A	NO	https://civicdb.org/links/evidence_items/2998	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/3895	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/989	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Trametinib,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/992	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/999	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1220	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Erlotinib,Teprotumumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3713	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Abemaciclib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4842	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Pemetrexed,Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4862	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Nivolumab,Atezolizumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4863	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4867	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Erlotinib,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4868	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4996	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Docetaxel	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4997	only alteration type		NSCLC
WP093	KRAS MUT* (--)	KRAS Mutation	Decitabine	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/820	only alteration type		OV
WP093	KRAS MUT* (--)	KRAS Mutation	PI3Kbeta Inhibitor AZD8186,SCH772984	Pancreas adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1003	only alteration type		PAAD
WP093	KRAS MUT* (--)	KRAS Q61	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3917	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Q61H	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3861	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Q61H	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3862	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Q61K	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3872	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Q61L	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3867	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Q61R	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3870	only alteration type		COREAD
WP093	KRAS MUT* (--)	KRAS Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6317	only gene		CM
WP093	MAPK1 MUT* (--)	MAPK1 E322K	Erlotinib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/791	only alteration type		HNSC
WP093	MAPK1 MUT* (--)	MAPK1 Amplification	WZ4002	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/792	only gene		NSCLC
WP093	NF2 (R376W)	NF2 K159fs	Temsirolimus	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/715	only alteration type		BRCA
WP093	NF2 (R376W)	NF2 Loss	Selumetinib	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1742	only gene		THCA
WP093	NOTCH1 MUT* (T701P), NOTCH1 MUT* (N685T)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2346	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8549	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA C420R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2078	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA C420R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1999	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA D350G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4784	only alteration type		CM
WP093	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8007	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E542K	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/310	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E542K	Sirolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/311	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2022	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2026	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2058	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E542K	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7315	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8013	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8016	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E542K	Regorafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/83	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA E542K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4424	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA E542K	Apitolisib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/1549	only alteration type		HNSC
WP093	PIK3CA MUT* (--)	PIK3CA E542K	Perifosine,Temsirolimus	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1626	only alteration type		THCA
WP093	PIK3CA MUT* (--)	PIK3CA E545	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7468	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E545G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3724	only alteration type		CM
WP093	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1453	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2036	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6211	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E545K	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6213	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E545K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8008	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8547	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E545K	Akt Inhibitor MK2206,Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/710	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2034	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2062	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8017	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8018	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA E545K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3722	only alteration type		CM
WP093	PIK3CA MUT* (--)	PIK3CA E545K	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/387	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2037	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2217	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib	Lung adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1171	only alteration type		LUAD
WP093	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1670	only alteration type		LUAD
WP093	PIK3CA MUT* (--)	PIK3CA E545K	PI103	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2040	only alteration type		NSCLC
WP093	PIK3CA MUT* (--)	PIK3CA E545Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2213	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA E81K	Oxaliplatin,Fluorouracil,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4464	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA F930S	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10032	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA G1049R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3847	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA H1047L	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2089	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA H1047L	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8009	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA H1047L	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8019	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA H1047L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4432	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2103	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6204	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6206	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8548	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/314	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Capivasertib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1505	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1506	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Everolimus,Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1623	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2096	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2102	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/258	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/388	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Vemurafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3733	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3841	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Akt Inhibitor MK2206,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8364	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1465	only alteration type		HNSC
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1447	only alteration type		LUAD
WP093	PIK3CA MUT* (--)	PIK3CA H1047R	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1625	only alteration type		THCA
WP093	PIK3CA MUT* (--)	PIK3CA H1047X	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7318	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2867	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8663	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2866	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA K111N	Dactolisib,Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8183	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8662	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA K111N	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2085	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA K111N	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8011	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA K111N	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8020	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA K944N	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10031	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA K966E	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10034	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1384	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2087	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2098	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8536	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Capecitabine,Lapatinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8705	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1296	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1504	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1600	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1607	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1610	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Fulvestrant,Alpelisib	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7313	only alteration type		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/915	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1705	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3732	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6298	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6299	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6300	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6301	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6362	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Cabozantinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/771	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6375	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Ridaforolimus,Temsirolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/892	only alteration type		ED
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Pictilisib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1616	only alteration type		ED
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Radiation Therapy,Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1490	only alteration type		HNSC
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin,Sulindac,Celecoxib	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7185	only alteration type		HNSC
WP093	PIK3CA MUT* (--)	PIK3CA Mutation	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2355	only alteration type		NSCLC
WP093	PIK3CA MUT* (--)	PIK3CA N345K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4047	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA Q546K	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2198	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA R88Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3832	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA R93W	Cetuximab,Fluorouracil,Oxaliplatin	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4467	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA S158L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4463	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA V955G	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10033	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA V955I	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/8063	only alteration type		COREAD
WP093	PIK3CA MUT* (--)	PIK3CA Amplification	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8267	only gene		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA Amplification	Lapatinib,Dactolisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8271	only gene		BRCA
WP093	PIK3CA MUT* (--)	PIK3CA Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6275	only gene		CM
WP093	PIK3CA MUT* (--)	PIK3CA Amplification	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1464	only gene		HNSC
WP093	PIK3CA MUT* (--)	PIK3CA Amplification	Sulindac,Aspirin,Ibuprofen	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7186	only gene		HNSC
WP093	PIK3CA MUT* (--)	PIK3CA Amplification	Pictilisib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/756	only gene		OV
WP093	POLE MUT* (A1597G), POLE MUT* (--)	POLE Mutation	Pembrolizumab	Endometrium	Responsive	C	NO	https://civicdb.org/links/evidence_items/1862	only alteration type		ED
WP093	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP093	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP093	SF3B1 MUT* (--)	SF3B1 K666N	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1418	only alteration type		BRCA
WP093	SF3B1 MUT* (--)	SF3B1 K700E	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1417	only alteration type		BRCA
WP093	SMARCA4 MUT* (V830G)	SMARCA4 Loss	Abemaciclib,Palbociclib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/7155	only gene		NSCLC
WP093	TLK2 MUT* (--)	TLK2 Amplification	Go6983,GF109203X	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6000	only gene		BRCA
WP093	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP093	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP093	TYMS MUT* (--)	TYMS Amplification	Pemetrexed	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/903	only gene		LUAD
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1-BCR fusion	Bosutinib(BCR-ABL inhibitor  3rd gen)	Chronic myeloid leukemia	Responsive	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s024lbl.pdf	only gene		CML
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	Bosutinib(BCR-ABL inhibitor  3rd gen)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1-BCR fusion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf	only gene		CML, ALL
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1-BCR fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	EMA	only gene		CML, ALL
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1-BCR fusion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia	Responsive	A	YES	FDA	only gene		CML
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1-BCR fusion	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	FDA	only gene		CML, ALL
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (T315I)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	FDA	only alteration type		CML, ALL
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (T315I)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	FDA	only gene		LUAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Alectinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK inframe insertion (1151T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165	only alteration type		LUAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK (L1196M,S1206Y,G1269A,I1171T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165;PMID:24327273	only alteration type		LUAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene	758.0	NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Brigatinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc	only gene		NSCLC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E,V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E,V600K)	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s028lbl.pdf	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E,V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf	only alteration type		CM
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890	complete		PRAD
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	complete		OV
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	complete		OV
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP306	CHEK2 (--)	CHEK2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;AACR 2015 (abstr CT322);FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	complete		PRAD
WP306	DNMT3A (G869C), DNMT3A (E463*)	DNMT3A oncogenic mutation	Daunorubicin(Chemotherapy)	Acute myeloid leukemia	Responsive	A	YES	PMID:22417203	complete		AML
WP306	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR (L858R)	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR (L861Q,G719,S768I)	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR (L858R)	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR (L861Q,G719,S768I)	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR (L858R)	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR (L861Q,G719,S768I)	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR (L858R)	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR (T790M)	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf	only alteration type		NSCLC
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Ado-Trastuzumab Emtansine(EGFR mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor);Capecitabine(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s023lbl.pdf;PMID:17192538	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf	only gene		ST, GEJA
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf	only gene		BRCA
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (T315I)	BCR-ABL inhibitor 2nd gens(Nilotinib,Dasatinib,etc)	Chronic myeloid leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (T315I)	Bosutinib(BCR-ABL inhibitor  3rd gen)	Chronic myeloid leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML
WP306	G6PD MUT* (--)	G6PD biallelic inactivation	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP306	G6PD MUT* (--)	G6PD (S218F)	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP306	G6PD MUT* (--), G6PD MUT* (--)	G6PD (V98M) + G6PD (N156D)	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP306	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Myelofibrosis	Responsive	A	YES	FDA	complete		MY
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 9,11,13,14 or 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 9,11,13,14 or 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN	only alteration type		CM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 9,11,13,14 or 17	Regorafenib(Pan-kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 9,11,13,14 or 17	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA	only alteration type		GIST
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML, ALL
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Chronic myeloid leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (D816)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal, Myelodisplasic syndrome, Myelodisplasic proliferative syndrome, Hyper eosinophilic advanced snydrome, Eosinophilic chronic leukemia, Chronic myeloid leukemia, Acute lymphoblastic leukemia, Systemic mastocytosis	Resistant	A	YES	FDA	only alteration type		GIST, MDS, MDPS, HES, ECL, CML, ALL, SM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (T670I)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	A	NO	PMID:24687822	only alteration type		GIST
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Resistant	A	YES	NCCN Guidelines Chronic Myeloid Leukemia 2022;NCCN Guidelines Acute Lymphoblastic Leukemia 2022;PMID:21562040	only alteration type		CML, ALL
WP306	NPM1 MUT* (D178Y)	NPM1 oncogenic mutation	Daunorubicin(Chemotherapy)	Acute myeloid leukemia	Responsive	A	YES	PMID:22417203	only alteration type		AML
WP306	EGFR MUT* (--)	EGFR (T790M)	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome, Eosinophilic chronic leukemia	Responsive	A	YES	EMA	only gene		HES, ECL
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA inframe deletion (I843)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
WP306	EGFR MUT* (--)	EGFR (T790M)	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Regorafenib(Pan-kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
WP306	PDGFB MUT* (--)	PDGFB-COL1A1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Dermatofibrosarcoma	Responsive	A	NO	FDA	only gene		DFS
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET (618,620,634,768,791,891,918,C634W,M918T)	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	A	NO	PMID:20065189;PMID:22025146	only alteration type		THCA
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene	758.0	NSCLC
WP306	TSC1 MUT* (G1006), TSC1 MUT* (--), TSC1 MUT* (--), TSC1 MUT* (A2S)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		GCA
WP306	TSC1 MUT* (G1006), TSC1 MUT* (--), TSC1 MUT* (--), TSC1 MUT* (A2S)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		RA
WP306	TSC2 (W304C), TSC2 (G402V)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    , Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	complete		RA, GCA
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Neratinib(ERBB2 inhibitor) + Capecitabine(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer;PMID:30860945	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Pertuzumab(ERBB2 inhibitor)+ Trastuzumab(ERBB2 inhibitor) + Docetaxel(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor) + Letrozole(Hormone therapy)	Breast adenocarcinoma	Responsive	A	NO	FDA;PMID:19786658	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Margetuximab(ERBB2 inhibitor) 	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Tucatinib(ERBB2 inhibitor) + Trastuzumab(ERBB2 inhibitor) + Capecitabine(chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer;PMID:31825569	only gene		BRCA
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	complete		BRCA
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3-ITD	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia;PMID:28644114	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 (D835,I836)	Gilteritinib(Kinase inhibitor )	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3-ITD	Gilteritinib(Kinase inhibitor )	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation;PMID:31665578	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 (D835,I836)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia; PMID:28644114	only alteration type		AML
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (T315I,V299L,G250E,F317L)	Bosutinib(BCR-ABL inhibitor 3rd gen)	Acute lymphoblastic leukemia, Chronic myeloid leukemia	Resistant	A	YES	NCCN	only alteration type		ALL, CML
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (T315I)	Asciminib(Kinase inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia	only alteration type		CML
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	BCR-ABL1	Asciminib(Kinase inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215358s003lbl.pdf	only gene		CML
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (T315I)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Acute lymphoblastic leukemia	Resistant	A	YES	NCCN Guideline ALL 2022	only alteration type		ALL
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (E255V,Y253H,F359V)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf	only alteration type		CML
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-ret-altered-thyroid-cancers;ASCO 2020 (abstr 109)	only gene		TH
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET oncogenic mutation	Selpercatinib(RET kinase inhibitor)	Thyroid medullary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only alteration type		THM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Trametinib(MEK inhibitor) + Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN Non-Small Cell Lung Cancer guidlines 2022; FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR (S786I,G719, L861Q)	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	complete		OV
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	complete		OV
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP306	EGFR MUT* (--)	EGFR (L858R)	Dacomitinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN Non-Small Cell Lung Cancer guidlines 2022;FDA:https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer-0	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR (T790M)	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 fusion	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only gene		BLCA
WP306	ATM (D58N), ATM (D1371Y), ATM (E1424*)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	complete		PRAD
WP306	BARD1 MUT* (--)	BARD1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP306	BRIP1 (E515*)	BRIP1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	complete		PRAD
WP306	CHEK1 MUT* (--)	CHEK1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP306	FANCL MUT* (E363*), FANCL MUT* (K153), FANCL MUT* (--), FANCL MUT* (L48M)	FANCL oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	complete		PRAD
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3 fusion	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only gene		BLCA
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3 (G370C,R248C,S249C,Y373C)	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only alteration type		BLCA
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation;PMID:31566309	only alteration type		COREAD
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Pembrolizumab(PD-1 blocking antibody) + Trastuzumab(ERBB2 mAb inhibitor) + Fluoropyrimidine (Chemotherapy) + Platinum (Chemotherapy)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer;PMID:34912120	only gene		ST, GEJA
WP306	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP306	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (Y823D,N822,C809G,D820,A829P,D816,T670I)	Ripretinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ripretinib-advanced-gastrointestinal-stromal-tumor;PMID:32511981	only alteration type		GIST
WP306	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Mobocertinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mobocertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Amivantamab(EGFR mAb inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer	only alteration type		NSCLC
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 fusion	Infigratinib(FGFR kinase inhibitor)	Cholangiocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma	only gene		CH
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 fusion	Pemigatinib(FGFR kinase inhibitor)	Cholangiocarcinoma	Responsive	A	NO	FDA;PMID:32203698	only gene		CH
WP306	IDH1 MUT* (G402V)	IDH1 (R132)	Ivosidenib(IDH1 inhibitor)	Cholangiocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf;PMID:34554208;PMID:32416072	only alteration type		CH
WP306	IDH1 MUT* (G402V)	IDH1 (R132C,R132G,R132H,R132L,R132S)	Ivosidenib(IDH1 inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf 	only alteration type		AML
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA exon 18 mutations	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA (D842V)	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation;PMID:32615108	only alteration type		GIST
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 fusion	Entrectinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA;PMID:28183697;ESMO 2019 (abstr 4178) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725s007lbl.pdf	only gene		NSCLC
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (T315I)	Bosutinib(BCR-ABL inhibitor 3rd gen)	Acute lymphoblastic leukemia	Resistant	A	YES	NCCN Guideline ALL 2022	only alteration type		ALL
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	NO	FDA:https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions	only gene		NSCLC
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-non-small-cell-lung	only gene		NSCLC
WP306	PALB2 MUT* (--), PALB2 MUT* (--)	PALB2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP306	RAD51B MUT* (--)	RAD51B oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP306	RAD51C MUT* (--)	RAD51C oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP306	RAD54L MUT* (--), RAD54L MUT* (R380), RAD54L MUT* (--)	RAD54L oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas	only gene		ST, GEJA
WP306	ERBB2 MUT* (L514M)	ERBB2 oncogenic mutation	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung	only alteration type		NSCLC
WP306	NTRK2 MUT* (--)	NTRK2 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
WP306	NTRK3 MUT* (V273), NTRK3 MUT* (--)	NTRK3 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
WP306	NTRK2 MUT* (--)	NTRK2 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
WP306	NTRK3 MUT* (V273), NTRK3 MUT* (--)	NTRK3 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
WP306	NTRK3 MUT* (V273), NTRK3 MUT* (--)	NTRK3 (F617L,G623R,G696A)	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Resistant	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf	only alteration type		SOLID
WP306	IDH1 MUT* (G402V)	IDH1 (R132C,R132G,R132H,R132L,R132S)	Olutasidenib(IDH1 inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olutasidenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-idh1-mutation	only alteration type		AML
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification + KRAS wildtype + NRAS wildtype	Tucatinib(ERBB2 inhibitor);Trastuzumab(ERBB2 inhibitor) 	Colorectal adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer	only gene		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600)	Atezolizumab(PD-L1 blocking antibody);Vemurafenib(BRAF inhibitor);Cobimetinib(MEK inhibitor) 	Cutaneous melanoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-braf-v600-unresectable-or-metastatic-melanoma	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		SOLID
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Lower grade glioma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-trametinib-pediatric-patients-low-grade-glioma-braf-v600e-mutation	only alteration type		LGG
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Anaplastic large cell lymphoma	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large	only gene		ALCL
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only gene		TH
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Solid tumors	Responsive	A	NO	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors	only gene		SOLID
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 fusion	Futibatinib(pan-FGFR inhibitor)	Intrahepatic cholangiocarcinoma	Responsive	A	NO	FDA: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-futibatinib-cholangiocarcinoma	only gene		IHCH
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	complete		PRAD
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP306	ATM (D58N), ATM (D1371Y), ATM (E1424*)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	complete		PRAD
WP306	ATR (R1895I), ATR (D571Y)	ATR oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	complete		PRAD
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	complete		PRAD
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP306	CHEK2 (--)	CHEK2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	complete		PRAD
WP306	FANCA MUT* (--), FANCA MUT* (--), FANCA MUT* (--), FANCA MUT* (--)	FANCA oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP306	MLH1 MUT* (S332R)	MLH1 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP306	NBN MUT* (--)	NBN oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP306	PALB2 MUT* (--), PALB2 MUT* (--)	PALB2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP306	RAD51C MUT* (--)	RAD51C oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-fam-trastuzumab-deruxtecan-nxki-breast-cancer	only gene		BRCA
WP306	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E,V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210496s013lbl.pdf	only alteration type		CM
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
WP306	BTK MUT* (A645S), BTK MUT* (--), BTK MUT* (--)	BTK (C481S)	Ibrutinib(BTK inhibitor)	Chronic lymphocytic leukemia	Resistant	A	YES	PMID: 28418267	only alteration type		CLL
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 (G595R)	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Resistant	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210861s008lbl.pdf	only alteration type		SOLID
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf	only gene		BRCA
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Trastuzumab(ERBB2 inhibitor) + Carboplatin-Taxol(Chemotherapy)	Uterus	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf	only gene		U
WP306	ARAF MUT* (--), ARAF MUT* (L567)	ARAF oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP306	ARAF MUT* (--), ARAF MUT* (L567)	ARAF oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP306	ARAF MUT* (--), ARAF MUT* (L567)	ARAF oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP306	ARAF MUT* (--), ARAF MUT* (L567)	ARAF oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP306	MAP2K1 MUT* (--)	MAP2K1 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP306	MAP2K1 MUT* (--)	MAP2K1 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP306	MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP306	MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP306	MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP306	MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP306	MAP2K1 MUT* (--)	MAP2K1 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP306	MAP2K1 MUT* (--)	MAP2K1 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP306	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Erlotinib(EGFR inhibitor 1st gen);Ramucirumab(VEGFR2 antagonist)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR (L858R)	Erlotinib(EGFR inhibitor 1st gen);Ramucirumab(VEGFR2 antagonist)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf	only alteration type		NSCLC
WP306	ERBB2 MUT* (L514M)	ERBB2 oncogenic mutation	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1-BCR fusion	Bosutinib(BCR-ABL inhibitor  3rd gen)	Acute lymphoblastic leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/all.pdf	only gene		ALL
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3-ITD	Quizartinib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia	only alteration type		AML
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET fusion	Cabozantinib(Kinase inhibitor )	Non-small cell lung	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF(V600E)	Vemurafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600)	Dabrafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1-BCR fusion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Acute lymphoblastic leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/all.pdf	only gene		ALL
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Pertuzumab(ERBB2 inhibitor)+ Trastuzumab(ERBB2 inhibitor) 	Billiary tract	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf	only gene		BT
WP306	IDH1 MUT* (G402V)	IDH1 oncogenic mutation	Ivosidenib(IDH1 inhibitor)	Chondrosarcoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf	only alteration type		CS
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only alteration type		COREAD
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA oncogenic mutations (excluding D842V + exon 18 inframe mutations)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA D842V + exon 18 mutations	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor	only gene		IM
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Alectinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Brigatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Ceritinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Lorlatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Hairy-Cell leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf	only alteration type		HCL
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP306	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	complete		PAAD
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP306	PALB2 MUT* (--), PALB2 MUT* (--)	PALB2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP306	IDH1 MUT* (G402V)	IDH1 oncogenic mutation	Venetoclax(BCL2 inhibitor)	Acute myeloid leukemia	Responsive	A	YES	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf	only alteration type		AML
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-binimetinib-metastatic-non-small-cell-lung-cancer-braf-v600e-mutation	only alteration type		NSCLC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF(V600)	Vemurafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		HISEC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP306	EGFR MUT* (--)	EGFR (S768I,L861Q,G719)	Dacomitinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Dacomitinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	FDA: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer-0	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf	only alteration type		NSCLC
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (T315I)	Axitinib(VEGFR inhibitor)	Any cancer type	Responsive	D	YES	PMID:25686603	only alteration type		CANCER
WP306	ARAF MUT* (--), ARAF MUT* (L567)	ARAF oncogenic mutation	BRAF inhibitor + EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only alteration type		COREAD
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (V299L)	Cabozantinib(Pan-kinase inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (V299L)	Crizotinib(ALK inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type	758.0	CANCER
WP306	ARAF MUT* (--), ARAF MUT* (L567)	ARAF oncogenic mutation	BRAF inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only alteration type		COREAD
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1-BCR fusion	Dasatinib + Venetoclax(BCR-ABL inhibitor 2nd gen + BCL2 inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:27582059	only gene		ALL
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (V299L)	ForetinibÂ (MET inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 (V299L)	Vandetanib(Pan-TK inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E,G469A)	EGFR TK inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:22773810	only alteration type		LUAD
WP306	AKT2 (F310L)	AKT2 amplification	MK2206(Allosteric AKT inhibitor)	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 373)	only gene		CANCER
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	ALK inhibitor + IGF1R inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25173427	only gene		LUAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	ALK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:26301689	only gene		LUAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	ALK inhibitor + SRC inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25394791	only gene		LUAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	ALK inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560	only gene		COREAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23553849	only gene		LUAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	novel ALK inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23639470	only gene		LUAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK (F1174L)	novel ALK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24327273	only alteration type		LUAD
WP306	CCND1 MUT* (S97), CCND1 MUT* (--)	CCND1 amplification	SMO inhibitors	Medulloblastoma	Resistant	D	NO	PMID:24951114	only gene		MB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK amplification	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only gene		LUAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK (E1408V)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK (L1196M)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Ceritinib(ALK inhibitor)	Colorectal adenocarcinoma, Inflammatory myofibroblastic	Responsive	C	YES	PMID:26633560;PMID:26933125;PMID:27742657	only gene		COREAD, IM
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Ceritinib(ALK inhibitor)	Hematologic malignancies	Responsive	C	YES	NCT02186821	only gene		HEMATO
WP306	CTNNB1 (D780Y)	CTNNB1 oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Resistant	D	NO	PMID:23539443	complete		COREAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Lymphoma, Glioblastoma	Responsive	C	YES	PMID:24491302;NCT02270034	only gene		LY, GB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic, Thyroid carcinoma	Responsive	C	YES	PMID:20979472;PMID:24687827	only gene		IM, THCA
WP306	EGFR MUT* (--)	EGFR inframe deletion (30-336)	EGFR inhibitor 1st gens	Glioma	No Responsive	C	NO	PMID:19204207	only alteration type		G
WP306	EGFR MUT* (--)	EGFR amplification	EGFR inhibitor 1st gens	Glioma	No Responsive	C	NO	PMID:16282176;PMID:16278407	only gene		G
WP306	EGFR MUT* (--)	EGFR (D761Y)	EGFR inhibitor 1st gens	Non-small cell lung	Resistant	C	NO	PMID:19680293	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR (T790M)	EGFR inhibitor 1st gens	Non-small cell lung	Resistant	B	NO	PMID:19680293	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR inframe deletion (30-336)	EGFR inhibitor 2nd gens	Glioma	No Responsive	C	NO	PMID:19204207	only alteration type		G
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK (F856S,A348D)	Crizotinib(ALK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:26032424	only alteration type		AML
WP306	EGFR MUT* (--)	EGFR amplification	EGFR inhibitor 2nd gens	Glioma	No Responsive	C	NO	PMID:16282176;PMID:16278407	only gene		G
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK (L1198F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26698910	only alteration type	758.0	LUAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib(ALK inhibitor)	Glioma	Responsive	D	NO	PMID:22072639	only alteration type		G
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Entrectinib(Pan-TK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560;PMID:26933125	only gene		COREAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK (C1156Y)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27401242	only alteration type		LUAD
WP306	APC (S2029Y)	APC oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:22440753;PMID:23539443	complete	336.0	COREAD
WP306	EGFR MUT* (--)	EGFR (T790M)	EGFR inhibitor 2nd gens	Non-small cell lung	Resistant	B	NO	PMID:22452896	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR inframe deletion (30-336)	EGFR inhibitor 3rd gens	Glioma	No Responsive	C	NO	PMID:19204207	only alteration type		G
WP306	EGFR MUT* (--)	EGFR amplification	EGFR inhibitor 3rd gens	Glioma	No Responsive	C	NO	PMID:16282176;PMID:16278407	only gene		G
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	EGFR inhibitors	Lung adenocarcinoma	Resistant	D	NO	PMID:22956644	only gene		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:22586653;PMID:23348520	only gene		COREAD
WP306	ERBB3 MUT* (P845), ERBB3 MUT* (P1247)	ERBB3 amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:25520391	only gene		COREAD
WP306	FBXW7 (V375)	FBXW7 oncogenic mutation	Tubulin inhibitors	Any cancer type	Resistant	D	YES	PMID:21368834	complete		CANCER
WP306	FBXW7 MUT* (L700), FBXW7 MUT* (I605), FBXW7 (V375), FBXW7 MUT* (--)	FBXW7 deletion	Tubulin inhibitors	Any cancer type	Resistant	D	YES	PMID:21368834	only gene		CANCER
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I), FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 (N549H,V564F,K659M,L617V,K641R,R565A) + FGFR2 fusion	FGFR inhibitors	Cholangiocarcinoma	Resistant	C	NO	PMID:28034880;ASCO 2017 (abstr 2500)	only gene		CH
WP306	ARAF MUT* (--), ARAF MUT* (L567)	ARAF (S214C)	Sorafenib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	http://www.jci.org/articles/view/72763;PMID:24569458	only alteration type		LUAD
WP306	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	complete		CANCER
WP306	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	complete		OV
WP306	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	complete		CANCER
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3 (V555M)	FGFR inhibitors	Myeloma	Resistant	D	YES	PMID:22869148	only alteration type		MYMA
WP306	GLI2 MUT* (E538*)	GLI2 amplification	SMO inhibitors	Medulloblastoma	Resistant	D	NO	PMID:24951114	only gene		MB
WP306	ATM (D58N), ATM (D1371Y), ATM (E1424*)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	complete		COREAD
WP306	ATM (D58N), ATM MUT* (L75), ATM MUT* (--), ATM MUT* (E874D), ATM (D1371Y), ATM (E1424*), ATM MUT* (G2709)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
WP306	ATM (D58N), ATM (D1371Y), ATM (E1424*)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	complete		LY
WP306	ATM (D58N), ATM MUT* (L75), ATM MUT* (--), ATM MUT* (E874D), ATM (D1371Y), ATM (E1424*), ATM MUT* (G2709)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only gene		LY
WP306	ATM (D58N), ATM (D1371Y), ATM (E1424*)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	complete		ST
WP306	ATM (D58N), ATM MUT* (L75), ATM MUT* (--), ATM MUT* (E874D), ATM (D1371Y), ATM (E1424*), ATM MUT* (G2709)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
WP306	ATM (D58N), ATM MUT* (L75), ATM MUT* (--), ATM MUT* (E874D), ATM (D1371Y), ATM (E1424*), ATM MUT* (G2709)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	complete		BCL
WP306	ATM (D58N), ATM (D1371Y), ATM (E1424*)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	complete		BLCA
WP306	ATM (D58N), ATM MUT* (L75), ATM MUT* (--), ATM MUT* (E874D), ATM (D1371Y), ATM (E1424*), ATM MUT* (G2709)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP306	ATM (D58N), ATM (D1371Y), ATM (E1424*)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	complete		ST
WP306	ATM (D58N), ATM (D1371Y), ATM (E1424*)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	complete		G
WP306	ATR (R1895I), ATR (D571Y)	ATR oncogenic mutation	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	complete		OV, CANCER
WP306	ATR MUT* (--), ATR MUT* (--), ATR (R1895I), ATR MUT* (R1814I), ATR (D571Y), ATR MUT* (K518N), ATR MUT* (C413F)	ATR deletion	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only gene		OV, CANCER
WP306	ATR (R1895I), ATR (D571Y)	ATR oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	complete		G
WP306	AURKA MUT* (E111D)	AURKA amplification	AURK inhibitors	Prostate adenocarcinoma, Any cancer type	Responsive	D	YES	PMID:22302096;PMID:22389870	only gene		PRAD, CANCER
WP306	BAP1 (D225Y)	BAP1 oncogenic mutation	EZH2 inhibitors	Mesothelioma	Responsive	D	NO	PMID:26437366	complete		MESO
WP306	BAP1 MUT* (--), BAP1 (D225Y)	BAP1 deletion	EZH2 inhibitors	Mesothelioma	Responsive	D	NO	PMID:26437366	only gene		MESO
WP306	BAP1 (D225Y)	BAP1 oncogenic mutation	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22038994	complete		CM
WP306	BAP1 MUT* (--), BAP1 (D225Y)	BAP1 deletion	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22038994	only gene		CM
WP306	BAP1 (D225Y)	BAP1 oncogenic mutation	PARP inhibitors	Renal, Any cancer type	Responsive	D	YES	PMID:22683710	complete		R, CANCER
WP306	BAP1 MUT* (--), BAP1 (D225Y)	BAP1 deletion	PARP inhibitors	Renal, Any cancer type	Responsive	D	YES	PMID:22683710	only gene		R, CANCER
WP306	BCOR (E1611*)	BCOR oncogenic mutation	Enzastaurin(PKCb inhibitor)	Stomach	Responsive	D	NO	PMID:27397505	complete		ST
WP306	JAK1 (L910M)	JAK1 oncogenic mutation	PD1 inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:27903500	complete		COREAD
WP306	JAK1 (L910M)	JAK1 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	complete		CM
WP306	JAK2 (V617F)	JAK2 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	complete		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + CDK2/4 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22997239	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600)	BRAF inhibitor + EGFR mAb inhibitor +/- PI3K inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28363909	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + HSP90 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22351686	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + MEK inhibitors	Thyroid	Responsive	C	NO	ASCO 2013 (abstr 9029)	only alteration type		TH
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF fusion	BRAF inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9072)	only gene		LUAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + PI3K pathway inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22389471;PMID:21156289	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (L597R)	BRAF inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:23715574	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Glioma	Responsive	D	NO	PMID:22038996;PMID:22586120	only alteration type		G
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Ovary	Responsive	C	NO	PMID:22608338	only alteration type		OV
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:23614898;PMID:22997239	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (G469A)	ERK inhibitors	Head an neck squamous	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		HNSC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (L485W)	ERK inhibitors	Billiary tract	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		BT
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		LUAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Thyroid	Responsive	C	NO	PMID:22241789	only alteration type		TH
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Ovary	Responsive	D	NO	PMID:19018267	only alteration type		OV
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Pan-RAF inhibitors	Any cancer type	Responsive	D	YES	PMID:26732095	only alteration type		CANCER
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Pan-RAF inhibitors	Cutaneous melanoma	Responsive	C	NO	ESMO 2015 (abstract 300);AACR 2016 (abstr CT005);AACR 2017 (abstr  CT002)	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF fusion	MEK inhibitors(Trametinib,etc)	Lung adenocarcinoma, Cutaneous melanoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:24727320;PMID:24345920;PMID:20526349	only gene		LUAD, CM, PRAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (K601R,L597R,V600R)	MEK inhibitors(Trametinib,etc)	Cutaneous melanoma	Responsive	C	NO	PMID:23248257;PMID:22805292;PMID:23248257	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Lung adenocarcinoma, Thyroid	Responsive	C	NO	PMID:23524406;PMID:22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);PMID:20818844;PMID:23489023;PMID:27080216	only alteration type		LUAD, TH
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Gastrointestinal stromal	Responsive	C	NO	PMID:23470635;PMID:22608338	only alteration type		GIST
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600R)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:23237741	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26392102;ASCO 2015 (abstr 8006)	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Neuroendocrine	Responsive	C	NO	PMID:27048246	only alteration type		NEU
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (G466V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:22649091	only alteration type		LUAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (Y472C)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	PMID:22649091	only alteration type		LUAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600)	Irinotecan + Vemurafenib + Cetuximab(TOPO1 inhibitor + BRAF inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:27729313	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + BYL719(EGFR mAb inhibitor + BRAF inhibitor + PI3K inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2014 (abstr 11LBA)	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Panitumumab + Dabrafenib + Trametinib(EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103)	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	PLX4720(BRAF inhibitor)	Malignant astrocytoma	Responsive	D	NO	PMC3638050	only alteration type		MA
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF fusion	Selumetinib(MEK inhibitor)	Ovary	Responsive	C	NO	PMID:26324360	only gene		OV
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Selumetinib(MEK inhibitor)	Pediatric glioma	Responsive	C	NO	NCT01089101	only alteration type		PG
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF fusion	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma, Lung adenocarcinoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:238900088;PMID:20526349;PMID:24727320	only gene		CM, LUAD, PRAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (D594G,G469E)	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:18794803	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Lung adenocarcinoma, Hairy-Cell leukemia, Myeloma	Responsive	C	YES	PMID:22743296;PMID:22621641;PMID:23612012	only alteration type		LUAD, HCL, MYMA
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Malignant astrocytoma	Responsive	C	NO	PMID:22586120	only alteration type		MA
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:22608338;PMID:20818844;PMID:23489023	only alteration type		THCA
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--), EGFR MUT* (--)	BRAF (G469A) + EGFR oncogenic mutation	EGFR TK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:22773810	only alteration type		LUAD
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	complete		OV
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	PARP inhibitors	Pancreas	Responsive	C	NO	PMID:25366685;PMID:25719666;PMID:19553641;PMID:25366685	complete		PA
WP306	BRCA1 (L1807M)	BRCA1 deletion	PARP inhibitors	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	C	YES	PMID:25964244	complete		CANCER
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467;PMID:25366685	complete		BRCA
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	complete		BRCA
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	complete		OV
WP306	BRCA1 (L1807M)	BRCA1 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	complete		BRCA
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
WP306	BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP306	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP306	CBL MUT* (S20), CBL MUT* (H38N), CBL (W190C), CBL MUT* (--)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP306	CBL MUT* (S20), CBL MUT* (H38N), CBL (W190C), CBL MUT* (--)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP306	CCND1 MUT* (S97), CCND1 MUT* (--)	CCND1 amplification	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2014 (abstr 2528)	only gene		CM
WP306	CCND1 MUT* (S97), CCND1 MUT* (--)	CCND1 amplification	CDK4/6 inhibitors	Any cancer type	Responsive	D	YES	PMID:22471707	only gene		CANCER
WP306	CCND3 MUT* (--)	CCND3 amplification	CDK4/6 inhibitors	Any cancer type	Responsive	D	YES	PMID:22471707	only gene		CANCER
WP306	CCNE1 MUT* (A279S)	CCNE1 amplification	CDK2 inhibitors	Any cancer type	Responsive	D	YES	PMID:22471707	only gene		CANCER
WP306	CDK4 (P280T)	CDK4 oncogenic mutation	LEE011(CDK4/6 inhibitor)	Liposarcoma, Lymphoma, Any cancer type	Responsive	C	YES	NCT02187783;NCT01237236; http://meetinglibrary.asco.org/content/83791-102	complete		LIP, LY, CANCER
WP306	CDK4 (P280T)	CDK4 amplification	LEE011(CDK4/6 inhibitor)	Liposarcoma, Lymphoma, Any cancer type	Responsive	C	YES	NCT02187783;NCT01237236; http://meetinglibrary.asco.org/content/83791-102	only gene		LIP, LY, CANCER
WP306	CHEK2 MUT* (--), CHEK2 (--)	CHEK2 deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	AACR 2015 (abstr CT322)	only gene		PRAD
WP306	MAP2K1 MUT* (--)	MAP2K1 (P124)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:25370473	only alteration type		CM
WP306	MAP2K1 MUT* (--)	MAP2K1 (Q56P,P124S,P124L;C121S)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:19915144;PMID:21383288	only alteration type		CM
WP306	MAP2K1 MUT* (--)	MAP2K1 oncogenic mutation	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:26030179	only alteration type		COREAD
WP306	MAP2K1 MUT* (--)	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	MEK inhibitors	Any cancer type	Resistant	D	YES	PMID:19915144	only alteration type		CANCER
WP306	MAP2K1 MUT* (--)	MAP2K1 (P124L,K57N,C121S)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:19915144;PMID:23444215;PMID:21383288	only alteration type		CM
WP306	MAP2K1 MUT* (--)	MAP2K1 (Q56P,P124S,P124L)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:19915144	only alteration type		CM
WP306	CSF1R MUT* (--)	CSF1R (Y571D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:18971950	only alteration type		MDPS
WP306	MAP2K2 MUT* (--)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP306	CTNNB1 (D780Y)	CTNNB1 (H36Y,S37C,S37Y,D32V)	Everolimus + Letrozole(MTOR inhibitor + Hormonal therapy)	Endometrium	Responsive	C	NO	PMID:25624430	only alteration type		ED
WP306	MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP306	DDR2 MUT* (--)	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung squamous cell	Responsive	D	NO	PMID:22328973	only alteration type		LUSC
WP306	DDR2 MUT* (--)	DDR2 (S768R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung squamous cell	Responsive	C	NO	PMID:22328973	only alteration type		LUSC
WP306	DDR2 MUT* (--)	DDR2 (S768R)	Erlotinib(EGFR inhibitor 1st gen)	Lung squamous cell	Responsive	C	NO	PMID:22328973	only alteration type		LUSC
WP306	MAP2K2 MUT* (--)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP306	MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP306	MITF MUT* (--)	MITF amplification	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265153	only gene		CM
WP306	MITF MUT* (--)	MITF amplification	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265153	only gene		CM
WP306	MYCN MUT* (E459*)	MYCN amplification	SMO inhibitors	Medulloblastoma	Resistant	D	NO	PMID:24951114	only gene		MB
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP306	EGFR MUT* (--)	EGFR (T790M)	EGFR inhibitor 3rd gens	Lung	Responsive	C	NO	ASCO 2014 (abstr 8009);ENA 2014 (abstr 10LBA);ENA 2014 (abstr 9LBA);ASCO 2015 (abstr 8001)	only alteration type		L
WP306	EGFR MUT* (--)	EGFR amplification	EGFR inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26763254	only gene		HNSC
WP306	EGFR MUT* (--)	EGFR amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Responsive	B	NO	PMID:18794099;PMID:17664472	only gene		COREAD
WP306	EGFR MUT* (--)	EGFR exon 19 insertions	EGFR TK inhibitors	Lung	Responsive	B	NO	PMID:22753918	only alteration type		L
WP306	EGFR MUT* (--)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	EGFR TK inhibitors	Lung	Responsive	B	NO	PMID:22753918	only alteration type		L
WP306	EGFR MUT* (--)	EGFR exon 19 insertions	HSP90 inhibitors	Lung	Responsive	C	NO	ESMO 2012 (abstr 4380)	only alteration type		L
WP306	EGFR MUT* (--)	EGFR exon 20 insertions	HSP90 inhibitors	Lung	Responsive	C	NO	ASCO 2014 (abstr 8015)	only alteration type		L
WP306	EGFR MUT* (--)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	HSP90 inhibitors	Lung	Responsive	C	NO	ESMO 2012 (abstr 4380)	only alteration type		L
WP306	EGFR MUT* (--)	EGFR (T790M)	HSP90 inhibitors	Lung	Responsive	C	NO	ESMO 2012 (abstr 4380)	only alteration type		L
WP306	EGFR MUT* (--)	EGFR exon 19 insertions	MEK inhibitor(alone or in combination)s	Lung	Responsive	D	NO	PMID:23102728	only alteration type		L
WP306	EGFR MUT* (--)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	MEK inhibitor(alone or in combination)s	Lung	Responsive	D	NO	PMID:23102728	only alteration type		L
WP306	EGFR MUT* (--)	EGFR (S492R)	novel EGFR mAb inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:25962717	only alteration type		COREAD
WP306	EGFR MUT* (--)	EGFR (T790M)	EGFR inhibitor 3rd gens(Rociletinib,HM61713,etc)	Non-small cell lung	Responsive	B	NO	NCT02322281	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR exon 19 insertions	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Lung	Responsive	B	NO	PMID:22753918;PMID:25589191	only alteration type		L
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP306	EGFR MUT* (--)	EGFR exon 19 insertions	Afatinib + Cetuximab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	ESMO 2012 (abstr 1289)	only alteration type		L
WP306	EGFR MUT* (--)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	Afatinib + Cetuximab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	ESMO 2012 (abstr 1289)	only alteration type		L
WP306	EGFR MUT* (--)	EGFR (T790M)	Afatinib + Cetuximab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	PMID:25074459	only alteration type		L
WP306	EGFR MUT* (--)	EGFR (T790M)	Afatinib + Nimotuzumab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	PMID:26667485	only alteration type		L
WP306	EGFR MUT* (--)	EGFR (P546S)	Cetuximab(EGFR mAb inhibitor)	Head an neck	Responsive	C	NO	PMID:23578570	only alteration type		HNC
WP306	EGFR MUT* (--)	EGFR (P753S)	Cetuximab + Sirolimus(EGFR mAb inhibitor + MTOR inhibitor)	Head an neck	Responsive	C	NO	PMID:24934779	only alteration type		HNC
WP306	EGFR MUT* (--)	EGFR-RAD51 fusion	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	C	NO	PMID:27102076	only gene		NSCLC
WP306	EGFR MUT* (--)	EGFR-RAD51 fusion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:27102076	only gene		L
WP306	EGFR MUT* (--)	EGFR exon 19 insertions	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:22190593	only alteration type		L
WP306	EGFR MUT* (--)	EGFR inframe insertion (769-770)	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:26773740;PMID:23328547	only alteration type		L
WP306	EGFR MUT* (--)	EGFR (A289V,R108K,G598V,T263P)	Erlotinib(EGFR inhibitor 1st gen)	Glioma	Responsive	D	NO	PMID:17177598	only alteration type		G
WP306	EGFR MUT* (--)	EGFR (K757R,E746G)	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:26773740	only alteration type		L
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA amplification	PDGFR inhibitors	Glioma	No Responsive	D	NO	PMID:23544171	only gene		G
WP306	EGFR MUT* (--)	EGFR amplification	Gefitinib(EGFR inhibitor 1st gen)	Endometrium	Responsive	B	NO	PMID:24950987	only gene		ED
WP306	PIK3CB MUT* (--)	PIK3CB (D1067Y)	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	C	NO	PMID:26759240	only alteration type		BRCA
WP306	EGFR MUT* (--)	EGFR (E690K)	Lapatinib(ERBB2 inhibitor)	Endometrium	Responsive	C	NO	PMID:22885469	only alteration type		ED
WP306	EGFR MUT* (--)	EGFR exon 19 deletions	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Responsive	C	NO	NCT02465060	only alteration type		L
WP306	EGFR MUT* (--)	EGFR (S492R)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:22270724	only alteration type		COREAD
WP306	EGFR MUT* (--)	EGFR inframe deletion (6-273)	Rindopepimut(Vaccine)	Glioblastoma	Responsive	B	NO	NCT01480479	only alteration type		GB
WP306	EPHA3 (E816D)	EPHA3 amplification	EPHA3 inhibitors	Any cancer type	Responsive	D	YES	PMID:25125683	only gene		CANCER
WP306	EPHA3 (E816D)	EPHA3 amplification	EPHA3 inhibitors	Any cancer type	Responsive	D	YES	PMID:25125683	only gene		CANCER
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	ERBB2 inhibitor + CDK4/6 inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26977878	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 proximal exon 20	ERBB2 inhibitors(Afatinib,Lapatinib,Neratinib,etc)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547	only alteration type		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 proximal exon 20	ERBB2 mAb inhibitors(Trastuzumab,etc)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547	only alteration type		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 inframe insertion (A775YVMA),inframe insertion (G776VC)	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 8510)	only alteration type		L
WP306	ERBB2 MUT* (L514M)	ERBB2 (V659E,S310F)	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 8510)	only alteration type		L
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Stomach	Responsive	C	NO	AACR 2014 (abstr CT228)	only gene		ST
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Breast adenocarcinoma	Responsive	B	NO	PMID:20142587;PMID:22418700;PMID:23632474	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	PMID:27044931	only gene		BLCA
WP306	ERBB2 MUT* (L514M)	ERBB2 proximal exon 20	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 (T798I)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Breast adenocarcinoma	Responsive	D	NO	PMID:28274957	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 oncogenic mutation	Dacomitinib(Pan ERBB inhibitor)	Non-small cell lung	Responsive	C	NO	PMID:25899785	only alteration type		NSCLC
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
WP306	ERBB2 MUT* (L514M)	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 (V659E)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma, Lung adenocarcinoma	Responsive	C	NO	PMID:23950206	only alteration type		BRCA, LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 proximal exon 20	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Lapatinib + Chemotherapy(ERBB2 inhibitor + Chemotherapy)	Stomach	Responsive	C	NO	PMID:25694417;NCT02015169	only gene		ST
WP306	ERBB2 MUT* (L514M)	ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 oncogenic mutation	Neratinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ESMO 2014 (abstr LBA39_PR)	only alteration type		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 (K753E)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:27697991	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 proximal exon 20	Neratinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 (L869R)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	C	NO	PMID:28274957	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 (S310,L755,V777)	Neratinib(ERBB2 inhibitor)	Any cancer type	Responsive	C	YES	AACR 2017 (abstr CT001)	only alteration type		CANCER
WP306	ERBB2 MUT* (L514M)	ERBB2 inframe insertion (P780GSP),inframe insertion (781GSP),inframe insertion (A775YVMA),inframe insertion (G776YVMA)	Neratinib(ERBB2 inhibitor)	Any cancer type	Responsive	C	YES	AACR 2017 (abstr CT001)	only alteration type		CANCER
WP306	RAF1 MUT* (R218L), BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	RAF1 (S257P,G361A,P261P) + BRAF oncogenic mutation	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:23737487	only alteration type		CM
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Stomach	Responsive	C	NO	PMID:24960402	only gene		ST
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
WP306	ERBB2 MUT* (L514M)	ERBB2 oncogenic mutation	Tensirolimus(MTOR inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ESMO 2014 (abstr LBA39_PR)	only alteration type		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
WP306	STK11 MUT* (--), STK11 MUT* (--)	STK11 oncogenic mutation	BET inhibitors	Lung	Resistant	D	NO	PMID:23129625;PMID:24045185	only alteration type		L
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Head an neck	Responsive	C	NO	PMID:21380780	only gene		HNC
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Ovary	Responsive	C	NO	PMID:20003286;PMID:12525520	only gene		OV
WP306	ERBB2 MUT* (L514M)	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma, Any cancer type	Responsive	D	YES	PMID:23220880;PMID:22908275	only alteration type		BRCA, CANCER
WP306	ERBB2 MUT* (L514M)	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	Trastuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:22908275	only alteration type		CANCER
WP306	ERBB2 MUT* (L514M)	ERBB2 (G776L)	Trastuzumab(ERBB2 mAb inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:16775247	only alteration type		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 proximal exon 20	Trastuzumab(ERBB2 mAb inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	http://ascopubs.org/doi/full/10.1200/PO.16.00055	only gene		COREAD
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Trastuzumab + Everolimus + Chemotherapy(ERBB2 mAb inhibitor + MTOR inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:21107682;PMID:20975068	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Trastuzumab + HSP90 inhibitor(ERBB2 mAb inhibitor + HSP90 inhibitor)	Breast adenocarcinoma	Responsive	C	NO	PMID:21558407	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Trastuzumab + Lapatinib(ERBB2 mAb inhibitor + ERBB2 inhibitor)	Endometrium	Responsive	D	NO	PMID:25294905	only gene		ED
WP306	ERBB3 MUT* (P845), ERBB3 MUT* (P1247)	ERBB3 (P262H,G284R)	ERBB3 mAb inhibitors	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP306	ERBB3 MUT* (P845), ERBB3 MUT* (P1247)	ERBB3 (P262H,G284R,Q809R)	PI3K pathway inhibitor + MEK inhibitors	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP306	ERBB3 MUT* (P845), ERBB3 MUT* (P1247)	ERBB3 (G284R,R103G)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	ASCO 2015 (abstr e15516)	only alteration type		BLCA
WP306	ERBB3 MUT* (P845), ERBB3 MUT* (P1247)	ERBB3 (G284R,V104M,R103G)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	PMID:27044931	only alteration type		BLCA
WP306	ERBB3 MUT* (P845), ERBB3 MUT* (P1247)	ERBB3 (P262H,G284R,Q809R)	Lapatinib(ERBB2 inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP306	ERBB3 MUT* (P845), ERBB3 MUT* (P1247)	ERBB3 (P262H,G284R)	Pertuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP306	ERBB3 MUT* (P845), ERBB3 MUT* (P1247)	ERBB3 (P262H,G284R,Q809R)	Trastuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP306	ERBB4 (G223V), ERBB4 (G223*), ERBB4 MUT* (--), ERBB4 (--)	ERBB4 (E317K,E452K,R544W,R393W,E872K)	Lapatinib(ERBB2 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:19718025	only alteration type		CM
WP306	ERBB4 (G223V), ERBB4 (G223*), ERBB4 MUT* (--), ERBB4 (--)	ERBB4 fusion	Lapatinib + Afatinib(ERBB2 inhibitor + ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP306	ERCC4 MUT* (--)	ERCC4 oncogenic mutation	Cisplatin(Chemotherapy)	Ovary	Responsive	D	NO	PMID:25634215	only alteration type		OV
WP306	ERCC6 MUT* (S1146N), ERCC6 MUT* (R975), ERCC6 MUT* (V582), ERCC6 MUT* (--)	ERCC6 oncogenic mutation	Cisplatin(Chemotherapy)	Ovary	Responsive	D	NO	PMID:25634215	only alteration type		OV
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 (G595R,G667C)	Pan-TK inhibitors(Entrectinib,etc)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:26546295	only alteration type		COREAD
WP306	ERBB4 (G223V), ERBB4 (G223*), ERBB4 MUT* (--), ERBB4 (--)	ERBB4 (H809G)	ERBB2 inhibitors(Lapatinib,etc)	Breast adenocarcinoma	Resistant	C	NO	PMID:26530965	only alteration type		BRCA
WP306	FANCA MUT* (--), FANCA MUT* (--), FANCA MUT* (--), FANCA MUT* (--)	FANCA oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP306	FANCA MUT* (--), FANCA MUT* (--), FANCA MUT* (--), FANCA MUT* (--)	FANCA deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only gene		PRAD
WP306	FANCC (L261I)	FANCC oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	complete		BLCA
WP306	FANCC MUT* (A448), FANCC MUT* (--), FANCC (L261I)	FANCC deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP306	FAT1 (W4390C), FAT1 (S3384*)	FAT1 oncogenic mutation	BET inhibitors	Head an neck squamous	Responsive	D	NO	PMID:27397505	complete		HNSC
WP306	FBXW7 (V375)	FBXW7 oncogenic mutation	Steroids	Acute lymphoblastic leukemia	Responsive	B	YES	PMID:20861909	complete		ALL
WP306	FBXW7 MUT* (L700), FBXW7 MUT* (I605), FBXW7 (V375), FBXW7 MUT* (--)	FBXW7 deletion	Sirolimus(MTOR inhibitor)	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23558291	only gene		COREAD
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Lung squamous cell	Responsive	C	NO	PMID:27870574	only gene		LUSC
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Endometrium	Responsive	C	NO	ASCO 2017 (abstr 2500)	only gene		ED
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Lung squamous cell	Responsive	C	NO	AACR 2012 (abstr LB-122);AACR 2013 (abstr LB-145)	only gene		LUSC
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Head an neck	Responsive	D	NO	PMID:23418312	only gene		HNC
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors(Lucitanib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:25193991	only gene		BRCA
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 fusion	FGFR inhibitors	Billiary tract	Responsive	C	NO	ASCO 2016 (abstr 109)	only gene		BT
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 inframe insertion (A266),inframe insertion (S267)	FGFR inhibitors	Lung	Responsive	D	NO	PMID:26048680	only alteration type		L
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 amplification	FGFR inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2508)	only gene		ST
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 amplification	FGFR inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:25193991	only gene		BRCA
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 (S252W,N550K)	FGFR inhibitors	Endometrium	Responsive	D	NO	PMID:18552176;PMID:22238366;PMID:23002168	only alteration type		ED
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 (V565I)	FGFR inhibitors	Endometrium	Responsive	D	NO	ENA 2014 (abstr 381)	only alteration type		ED
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 (W290C,S320C,K660N)	FGFR inhibitors	Lung squamous cell	Responsive	D	NO	PMID:23786770;PMID:25035393	only alteration type		LUSC
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 fusion	FGFR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 2500)	only gene		COREAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK (I1171T)	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:25228534	only alteration type		LUAD
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Endometrium	Responsive	D	NO	PMID:23908597	only alteration type		ED
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3 fusion	FGFR inhibitors	Glioma	Responsive	C	NO	PMID:26324363	only gene		G
WP306	FGFR3 (D280E)	FGFR3 oncogenic mutation	FGFR inhibitors	Bladder	Responsive	C	NO	PMID:27870574	complete		BLCA
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3 (K650,Y373C)	FGFR inhibitors	Myeloma	Responsive	D	YES	PMID:16091734;PMID:20439987;PMID:22869148	only alteration type		MYMA
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3 (S249C,G691R)	FGFR inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:27998968	only alteration type		LUAD
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3 fusion	FGFR inhibitors	Bladder	Responsive	C	NO	PMID:26324363;ASCO 2017 (abstr 2500)	only gene		BLCA
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3 (K650)	Bortezomib(Proteasome inhibitor)	Myeloma	Responsive	D	YES	PMID:19331127;PMID:21273588	only alteration type		MYMA
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3-TACC3 fusion	FGFR inhibitors(,etc)	Non-small cell lung	Responsive	D	NO	PMID:25294908	only gene		NSCLC
WP306	FGFR4 MUT* (--), FGFR4 (G632W)	FGFR4 (N535,V550)	FGFR inhibitors	Rhabdomyosarcoma	Responsive	D	NO	PMID:19809159;PMID:24124571	only alteration type		RHBDS
WP306	FLCN MUT* (--)	FLCN oncogenic mutation	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:23995526	only alteration type		R
WP306	FLCN MUT* (--)	FLCN deletion	Everolimus(MTOR inhibitor)	Thyroid	Responsive	C	NO	PMID:25295501	only gene		TH
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3 (Y373C)	Bortezomib(Proteasome inhibitor)	Myeloma	Resistant	D	YES	PMID:19331127;PMID:21273588	only alteration type		MYMA
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3-ITD	FLT3 inhibitors	Acute myeloid leukemia	Responsive	C	YES	PMID:16857985	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 (F691)	novel FLT3 inhibitors	Acute myeloid leukemia	Responsive	D	YES	PMID:25847190	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 (N676)	Crenolanib(FLT3 inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:24619500	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 (D835)	Lestaurtinib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:16857985	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 (D835)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:20733134	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 (N676)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:24619500	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3-ITD	Sorafenib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:19389879;PMID:22368270	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3-ITD	Sorafenib + Azacytidine(Pan-TK inhibitor + Chemotherapy)	Acute myeloid leukemia	Responsive	C	YES	PMID:23613521	only alteration type		AML
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK (G1123S)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:26134233	only alteration type		LUAD
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 (S1986Y,S1986F)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP306	GNA11 MUT* (T169), GNA11 MUT* (--)	GNA11 (Q209L,Q209P)	PI3K pathway inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22733540;PMID:22808163	only alteration type		CM
WP306	GNA11 MUT* (T169), GNA11 MUT* (--)	GNA11 (Q209L,Q209P)	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr CRA9003)	only alteration type		CM
WP306	GNA11 MUT* (T169), GNA11 MUT* (--)	GNA11 (Q209L,Q209P)	Vorinostat(HDAC inhibitor)	Cutaneous melanoma	Responsive	D	NO	NCT01587352	only alteration type		CM
WP306	GNAS MUT* (T407), GNAS MUT* (R646I), GNAS (Q838H)	GNAS (R201)	JAK inhibitors	Any cancer type	Responsive	D	YES	PMID:21835143	only alteration type		CANCER
WP306	HDAC2 MUT* (--), HDAC2 MUT* (M351I), HDAC2 MUT* (--)	HDAC2 biallelic inactivation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
WP306	IDH1 MUT* (G402V)	IDH1 oncogenic mutation	BCL2 inhibitors	Acute myeloid leukemia	Responsive	D	YES	PMID:25599133	only alteration type		AML
WP306	IDH1 MUT* (G402V)	IDH1 oncogenic mutation	IDH1 inhibitors	Acute myeloid leukemia	Responsive	C	YES	ENA 2014 (abstr 1LBA)	only alteration type		AML
WP306	IDH1 MUT* (G402V)	IDH1 (R132)	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:28148839	only alteration type		CANCER
WP306	IDH1 MUT* (G402V)	IDH1 oncogenic mutation	AG-120(IDH1 inhibitor)	Glioma	Responsive	C	NO	NCT02073994;PMID:23558169	only alteration type		G
WP306	IDH1 MUT* (G402V)	IDH1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Cholangiocarcinoma	Responsive	C	NO	NCT02428855	only alteration type		CH
WP306	IDH1 MUT* (G402V)	IDH1 (R132)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Billiary tract	Responsive	D	NO	PMID:27231123	only alteration type		BT
WP306	EGFR MUT* (--)	EGFR (S464L,G465R,I491M)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	D	NO	PMID:25623215	only alteration type		COREAD
WP306	EGFR MUT* (--)	EGFR (S492R,G465R,R451C,K467T)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827	only alteration type		COREAD
WP306	INPP4B MUT* (--), INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP306	INPP4B MUT* (--), INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP306	JAK1 (L910M), JAK1 MUT* (--)	JAK1 (S646F;R683)	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22955920;PMID:18805579	only alteration type		ALL
WP306	JAK2 (V617F)	JAK2 (V617F)	JAK inhibitor(alone or in combination)s	Acute myeloid leukemia	Responsive	D	YES	PMID:22829971	complete		AML
WP306	JAK2 (V617F)	JAK2 amplification	JAK inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27075627	only gene		BRCA
WP306	JAK2 (V617F)	JAK2-BRAF fusion	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22875628;PMID:22899477	only gene		ALL
WP306	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:22422826	complete		AML
WP306	JAK3 MUT* (--), JAK3 MUT* (--), JAK3 MUT* (--)	JAK3 (A572V,A573V)	JAK inhibitors	Lymphoma	Responsive	D	YES	PMID:22705984	only alteration type		LY
WP306	JAK3 MUT* (--), JAK3 MUT* (--), JAK3 MUT* (--)	JAK3 (R657Q,I87T,Q501H)	JAK inhibitors	Megakaryoblastic leukemia	Responsive	D	YES	PMID:18397343	only alteration type		MKB
WP306	KDR (P694T), KDR MUT* (R275), KDR MUT* (--)	KDR (A1065T)	VEGFR inhibitors	Any cancer type	Responsive	D	YES	PMID:24569783	only alteration type		CANCER
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 11	HSP90 inhibitors	Gastrointestinal stromal	Responsive	C	NO	PMID:22898035	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 9 or 17	HSP90 inhibitors	Gastrointestinal stromal	Responsive	D	NO	PMID:21737509	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 9,11,13,14 or 17	Dasatinib(BCR-ABL inhibitor 2nd gen)	Cutaneous melanoma	Responsive	C	NO	PMID:19671763	only alteration type		CM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (D816V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Systemic mastocytosis	Responsive	C	YES	PMID:18559612	only alteration type		SM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (D816V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Acute myeloid leukemia	Responsive	C	YES	PMID:18986703	only alteration type		AML
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (D816Y,D816F,D816V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Any cancer type	Responsive	D	YES	PMID:16397263	only alteration type		CANCER
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (N822K)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Acute myeloid leukemia	Responsive	D	YES	PMID:23149070	only alteration type		AML
WP306	KIT MUT* (--), KIT MUT* (--)	KIT inframe deletion (416-422),inframe insertion (416-422)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:15618474	only alteration type		AML
WP306	KIT MUT* (--), KIT MUT* (--)	KIT inframe deletion (V560)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Thymic	Responsive	C	YES	PMID:15201427	only alteration type		THYM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 9,11,13,14 or 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	B	NO	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812	only alteration type		CM
WP306	MDM2 MUT* (--), MDM2 MUT* (--)	MDM2 amplification	Cisplatin(Chemotherapy)	Male germ cell tumor	Resistant	C	NO	PMID:27646943	only gene		MGCT
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK inframe insertion (1151T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only alteration type		LUAD
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (D820Y)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:23775962	only alteration type		CM
WP306	ALK (G1054D)	ALK oncogenic mutation	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	complete		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only gene		NSCLC
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (Y553N)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Thymic	Responsive	C	YES	PMID:21969494	only alteration type		THYM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 9,11,13,14 or 17	Nilotinib(BCR-ABL inhibitor 2nd gen)	Cutaneous melanoma	Responsive	C	NO	PMID:22068222;PMID:25695690	only alteration type		CM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 17	Nilotinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	C	NO	PMID:22119758;PMID:21456006	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (D820Y)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Cutaneous melanoma	Responsive	C	NO	PMID:25695690	only alteration type		CM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (788-828,829-860,550-592)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2015 (abstr 10517);PMID:25239608;ASCO 2015 (abstr 10535)	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (A829P,V654A,T670I)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	D	NO	PMID:25239608	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT inframe deletion (577-579)	Sorafenib(Pan-TK inhibitor)	Thymic	Responsive	C	YES	PMID:20970876	only alteration type		THYM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 9 or 11	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	PMID:22270258	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (550-592,627-664,788-828,829-860)	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:18936790;PMID:20372153	only alteration type		CM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 17	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	D	NO	PMID:23840364	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (D820E)	Sorafenib(Pan-TK inhibitor)	Thymic	Responsive	C	YES	PMID:19461405	only alteration type		THYM
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only gene		LUAD
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 9,11,13,14 or 17	Sunitinib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	B	NO	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812	only alteration type		CM
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK (C1156Y,L1196M)	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:20979473	only alteration type		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK (F1174L)	Crizotinib(ALK inhibitor)	Glioma	Resistant	D	NO	PMID:22072639	only alteration type		G
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (H697Y)	Sunitinib(Pan-TK inhibitor)	Thymic	Responsive	D	YES	PMID:19861435	only alteration type		THYM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (H697Y)	Sunitinib(Pan-TK inhibitor)	Thymic	Responsive	D	YES	PMID:19861435	only alteration type		THYM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (Y553N)	Sunitinib(Pan-TK inhibitor)	Thymic	Responsive	C	YES	PMID:23375402	only alteration type		THYM
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784;PMID:25228534	only alteration type		LUAD
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 (G2032R)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:23724914;PMID:25688157	only alteration type		LUAD
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 (S1986Y,S1986F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)	Dovitinib(FGFR inhibitor)	Endometrium	Resistant	D	NO	PMID:23908597	only alteration type		ED
WP306	EGFR MUT* (--)	EGFR amplification	Erlotinib(EGFR inhibitor 1st gen)	Lung	No Responsive	C	NO	ASCO2015(abstre19028)	only gene		L
WP306	EGFR MUT* (--)	EGFR (S720)	Erlotinib(EGFR inhibitor 1st gen)	Lung	No Responsive	C	NO	PMID:26773740	only alteration type		L
WP306	IGF1R MUT* (--)	IGF1R amplification	Erlotinib(EGFR inhibitor 1st gen)	Lung adenocarcinoma	Resistant	D	NO	PMID:24458568	only gene		LUAD
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP306	NF2 (Q111K)	NF2 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Schwannoma	No Responsive	C	NO	PMID:20736812	complete		SCHW
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 deletion	Erlotinib(EGFR inhibitor 1st gen)	Schwannoma	No Responsive	C	NO	PMID:20736812	only gene		SCHW
WP306	NF2 (Q111K), EGFR MUT* (--)	NF2 oncogenic mutation + EGFR oncogenic mutation	Erlotinib + Cetuximab(EGFR inhibitor 1st gen + EGFR mAb inhibitor)	Lung	Resistant	C	NO	PMID:24813888	only alteration type		L
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D), EGFR MUT* (--)	NF2 deletion + EGFR oncogenic mutation	Erlotinib + Cetuximab(EGFR inhibitor 1st gen + EGFR mAb inhibitor)	Lung	Resistant	C	NO	PMID:24813888	only gene		L
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR (F2108L)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Resistant	C	NO	PMID:25295501	only alteration type		THCA
WP306	MAP2K1 MUT* (--)	MAP2K1 (F129L,L215P,I103N,P124)	ERK inhibitors	Any cancer type	Responsive	D	YES	PMID:23614898	only alteration type		CANCER
WP306	MAP2K1 MUT* (--)	MAP2K1 (P124)	ERK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:25370473	only alteration type		CM
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP306	MAP2K1 MUT* (--)	MAP2K1 (C121S)	novel MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:24448821	only alteration type		CM
WP306	MAP2K1 MUT* (--)	MAP2K1 (K57T)	Panitumumab + Trametinib(EGFR mAb inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26644315	only alteration type		COREAD
WP306	MAP2K1 MUT* (--)	MAP2K1 inframe deletion (56-60)	Selumetinib(MEK inhibitor)	Ovary	Responsive	C	NO	PMID:26324360	only alteration type		OV
WP306	MAP2K1 MUT* (--)	MAP2K1 (Q56P)	Trametinib(MEK inhibitor)	Any cancer type	Responsive	D	YES	PMID:26582713	only alteration type		CANCER
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP306	MAP2K1 MUT* (--), BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	MAP2K1 (P124S,I111S) + BRAF oncogenic mutation	BRAF inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:22588879	only alteration type		CM
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP306	MDM2 MUT* (--), MDM2 MUT* (--)	MDM2 amplification	MDM2 inhibitors	Liposarcoma	Responsive	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	only gene		LIP
WP306	EGFR MUT* (--)	EGFR inframe deletion (L747),inframe insertion (P753PS)	Gefitinib(EGFR inhibitor 1st gen)	Head an neck	No Responsive	C	NO	PMID:21274259	only alteration type		HNC
WP306	MDM4 MUT* (--), MDM4 MUT* (P212H)	MDM4 amplification	MDM2/MDMX inhibitors	Sarcoma	Responsive	D	NO	PMID:24336067	only gene		S
WP306	EGFR MUT* (--)	EGFR amplification	Gefitinib(EGFR inhibitor 1st gen)	Head an neck	No Responsive	C	NO	PMID:21274259;PMID:22261807	only gene		HNC
WP306	EGFR MUT* (--)	EGFR (V843I)	Gefitinib(EGFR inhibitor 1st gen)	Head an neck	No Responsive	C	NO	PMID:21274259	only alteration type		HNC
WP306	SLC29A1 MUT* (--), SLC29A1 MUT* (--)	SLC29A1 oncogenic mutation	Gemcitabine(Chemotherapy)	Bladder	Resistant	D	NO	PMID:21166756	only alteration type		BLCA
WP306	BTK MUT* (A645S), BTK MUT* (--), BTK MUT* (--)	BTK (C481)	Ibrutinib(BTK inhibitor)	Mantle cell lymphoma	Resistant	C	YES	PMID:25082755	only alteration type		MCL
WP306	PLCG2 (R354L), PLCG2 MUT* (--), PLCG2 MUT* (--), PLCG2 MUT* (R984), PLCG2 (G1069C), PLCG2 (W1113C)	PLCG2 (R665W,L845F)	Ibrutinib(BTK inhibitor)	Chronic lymphocytic leukemia	Resistant	C	YES	PMID:24869598	only alteration type		CLL
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (627-664,664-714,449-514)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458;PMID:18955451;PMID:16624552	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:23840364	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 17 or 18	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:21690468;PMID:21642685	only alteration type		CM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT amplification	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	No Responsive	C	NO	PMID:23775962	only gene		CM
WP306	MPL MUT* (--)	MPL (W515F)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:16834459	only alteration type		MDPS
WP306	MSH3 MUT* (--), MSH3 MUT* (--)	MSH3 oncogenic mutation	DNA-PKc inhibitors	Any cancer type	Responsive	D	YES	PMID:24556366	only alteration type		CANCER
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR (F2108L)	MTOR kinase inhibitors	Any cancer type	Responsive	D	YES	PMID:25295501	only alteration type		CANCER
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR (E2014K,E2419K,N1421D)	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:24625776	only alteration type		BLCA
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:23582185;PMID:21689725;PMID:17259998	only alteration type		GIST
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR (I1973F)	Everolimus(MTOR inhibitor)	Angiosarcoma, Renal	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		AS, R
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR (K1771R)	Everolimus(MTOR inhibitor)	Stomach, Adrenal gland	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		ST, AG
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR (N1421D)	Everolimus(MTOR inhibitor)	Stomach	Responsive	C	NO	PMID:26859683	only alteration type		ST
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR (Q2223K)	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468	only alteration type		R
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR (L1460P,S2215Y,R2505P)	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	D	YES	PMID:24631838	only alteration type		CANCER
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA (T674I)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome	Resistant	C	YES	PMID:12660384	only alteration type		HES
WP306	ERBB2 MUT* (L514M)	ERBB2 (K753E)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma	Resistant	D	NO	PMID:27697991	only alteration type		BRCA
WP306	CRBN MUT* (--)	CRBN oncogenic mutation	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP306	CRBN MUT* (--)	CRBN (Q100*,R283K)	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP306	LRP1B (C4207F), LRP1B (E3379*), LRP1B (C103F), LRP1B (E36*), LRP1B (--)	LRP1B oncogenic mutation	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	complete		OV
WP306	LRP1B (C4207F), LRP1B MUT* (--), LRP1B MUT* (E3458D), LRP1B (E3379*), LRP1B MUT* (--), LRP1B MUT* (--), LRP1B MUT* (--), LRP1B MUT* (--), LRP1B (C103F), LRP1B (E36*), LRP1B MUT* (Q29H), LRP1B (--)	LRP1B deletion	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only gene		OV
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP306	ERBB2 MUT* (L514M)	ERBB2 (T798I)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:28274957	only alteration type		BRCA
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP306	EGFR MUT* (--)	EGFR (C797S)	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Resistant	C	NO	PMID:25939061	only alteration type		L
WP306	EGFR MUT* (--)	EGFR (L718)	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Resistant	C	NO	ASCO 2017 (abstr 2572)	only alteration type		L
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP306	EGFR MUT* (--)	EGFR (L792)	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Resistant	C	NO	ASCO 2017 (abstr 2572)	only alteration type		L
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Osimertinib(3rd generation EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP306	CCND1 MUT* (S97), CCND1 MUT* (--)	CCND1 amplification	Palbociclib(CDK4/6 inhibitor)	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9056)	only gene		L
WP306	CDK4 (P280T)	CDK4 amplification	Palbociclib(CDK4/6 inhibitor)	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9056)	only gene		L
WP306	NF2 (Q111K)	NF2 oncogenic mutation	FAK inhibitors	Mesothelioma	Responsive	C	NO	ENA 2012 (abstr 610)	complete		MESO
WP306	NF2 (Q111K)	NF2 oncogenic mutation	FAK inhibitors	Mesothelioma, Ovary	Responsive	D	NO	PMID:24848258;PMID:24786638	complete		MESO, OV
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 deletion	FAK inhibitors	Mesothelioma	Responsive	C	NO	ENA 2012 (abstr 610)	only gene		MESO
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 deletion	FAK inhibitors	Mesothelioma, Ovary	Responsive	D	NO	PMID:24848258;PMID:24786638	only gene		MESO, OV
WP306	NF2 (Q111K)	NF2 oncogenic mutation	HSP90 inhibitors	Meningioma	Responsive	D	NO	PMID:23714726	complete		MEN
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 deletion	HSP90 inhibitors	Meningioma	Responsive	D	NO	PMID:23714726	only gene		MEN
WP306	NF2 (Q111K)	NF2 oncogenic mutation	MEK inhibitors	Thyroid	Responsive	D	NO	PMID:26359368	complete		TH
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 deletion	MEK inhibitors	Thyroid	Responsive	D	NO	PMID:26359368	only gene		TH
WP306	NF2 (Q111K)	NF2 oncogenic mutation	MTOR inhibitors	Meningioma	Responsive	D	NO	PMID:19451225;PMID:2242646	complete		MEN
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 deletion	MTOR inhibitors	Meningioma	Responsive	D	NO	PMID:19451225;PMID:2242646	only gene		MEN
WP306	NF2 (Q111K)	NF2 oncogenic mutation	PAK inhibitors	Schwannoma, Meningioma	Responsive	D	NO	PMID:23960073;PMID:25596744	complete		SCHW, MEN
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 deletion	PAK inhibitors	Schwannoma, Meningioma	Responsive	D	NO	PMID:23960073;PMID:25596744	only gene		SCHW, MEN
WP306	NF2 (Q111K)	NF2 oncogenic mutation	PDK1 inhibitors	Schwannoma	Responsive	D	NO	PMID:19359162	complete		SCHW
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 deletion	PDK1 inhibitors	Schwannoma	Responsive	D	NO	PMID:19359162	only gene		SCHW
WP306	NF2 (Q111K)	NF2 oncogenic mutation	AR42(HDAC inhibitor)	Schwannoma	Responsive	D	NO	PMID:21778190	complete		SCHW
WP306	NF2 (Q111K)	NF2 oncogenic mutation	AR42(HDAC inhibitor)	Meningioma	Responsive	C	NO	ASCO 2016 (abstr 2558)	complete		MEN
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 deletion	AR42(HDAC inhibitor)	Schwannoma	Responsive	D	NO	PMID:21778190	only gene		SCHW
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 deletion	AR42(HDAC inhibitor)	Meningioma	Responsive	C	NO	ASCO 2016 (abstr 2558)	only gene		MEN
WP306	NF2 (Q111K)	NF2 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Schwannoma	Responsive	C	NO	PMID:19587327;PMID:22805104;PMID:26022982	complete		SCHW
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 deletion	Bevacizumab(VEGFR mAb inhibitor)	Schwannoma	Responsive	C	NO	PMID:19587327;PMID:22805104;PMID:26022982	only gene		SCHW
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
WP306	EGFR MUT* (--)	EGFR (G465R)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:26059438	only alteration type		COREAD
WP306	NF2 (Q111K)	NF2 oncogenic mutation	Everolimus(MTOR inhibitor)	Schwannoma	Responsive	C	NO	PMID:24311643;2556735	complete		SCHW
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 deletion	Everolimus(MTOR inhibitor)	Schwannoma	Responsive	C	NO	PMID:24311643;2556735	only gene		SCHW
WP306	NF2 (Q111K)	NF2 oncogenic mutation	Everolimus + Octreotide(MTOR inhibitor + Somatostatin analog)	Meningioma	Responsive	D	NO	PMID:26015296	complete		MEN
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 deletion	Everolimus + Octreotide(MTOR inhibitor + Somatostatin analog)	Meningioma	Responsive	D	NO	PMID:26015296	only gene		MEN
WP306	NF2 (Q111K)	NF2 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Schwannoma	Responsive	D	NO	PMID:19509233;PMID:2290085	complete		SCHW
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Schwannoma	Responsive	D	NO	PMID:19509233;PMID:2290085	only gene		SCHW
WP306	NF2 (Q111K)	NF2 oncogenic mutation	Lapatinib(ERBB2 inhibitor)	Schwannoma, Neurofibroma	Responsive	C	NO	PMID:22844108;NCT00973739	complete		SCHW, NF
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 deletion	Lapatinib(ERBB2 inhibitor)	Schwannoma, Neurofibroma	Responsive	C	NO	PMID:22844108;NCT00973739	only gene		SCHW, NF
WP306	NF2 (Q111K)	NF2 oncogenic mutation	Tensirolimus + Chemotherapy(MTOR inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25878190	complete		BRCA
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 deletion	Tensirolimus + Chemotherapy(MTOR inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25878190	only gene		BRCA
WP306	NOTCH1 (A2043S), NOTCH1 MUT* (S1891R), NOTCH1 MUT* (D932Y), NOTCH1 MUT* (--), NOTCH1 MUT* (P480H), NOTCH1 MUT* (R217), NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP306	NOTCH1 (A2043S), NOTCH1 MUT* (S1891R), NOTCH1 MUT* (D932Y), NOTCH1 MUT* (--), NOTCH1 MUT* (P480H), NOTCH1 MUT* (R217), NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP306	NOTCH1 (A2043S), NOTCH1 MUT* (S1891R), NOTCH1 MUT* (D932Y), NOTCH1 MUT* (--), NOTCH1 MUT* (P480H), NOTCH1 MUT* (R217), NOTCH1 MUT* (--)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP306	NOTCH1 (A2043S), NOTCH1 MUT* (S1891R), NOTCH1 MUT* (D932Y), NOTCH1 MUT* (--), NOTCH1 MUT* (P480H), NOTCH1 MUT* (R217), NOTCH1 MUT* (--)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP306	NOTCH1 (A2043S), NOTCH1 MUT* (S1891R), NOTCH1 MUT* (D932Y), NOTCH1 MUT* (--), NOTCH1 MUT* (P480H), NOTCH1 MUT* (R217), NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP306	NOTCH1 (A2043S), NOTCH1 MUT* (S1891R), NOTCH1 MUT* (D932Y), NOTCH1 MUT* (--), NOTCH1 MUT* (P480H), NOTCH1 MUT* (R217), NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP306	NOTCH1 (A2043S), NOTCH1 MUT* (S1891R), NOTCH1 MUT* (D932Y), NOTCH1 MUT* (--), NOTCH1 MUT* (P480H), NOTCH1 MUT* (R217), NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP306	NOTCH1 (A2043S)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	complete		MCL
WP306	NOTCH1 (A2043S), NOTCH1 MUT* (S1891R), NOTCH1 MUT* (D932Y), NOTCH1 MUT* (--), NOTCH1 MUT* (P480H), NOTCH1 MUT* (R217), NOTCH1 MUT* (--)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP306	NOTCH1 (A2043S), NOTCH1 MUT* (S1891R), NOTCH1 MUT* (D932Y), NOTCH1 MUT* (--), NOTCH1 MUT* (P480H), NOTCH1 MUT* (R217), NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP306	NOTCH1 (A2043S), NOTCH1 MUT* (S1891R), NOTCH1 MUT* (D932Y), NOTCH1 MUT* (--), NOTCH1 MUT* (P480H), NOTCH1 MUT* (R217), NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP306	NOTCH2 MUT* (P2349H), NOTCH2 MUT* (V776), NOTCH2 MUT* (--), NOTCH2 MUT* (--), NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP306	NOTCH2 MUT* (P2349H), NOTCH2 MUT* (V776), NOTCH2 MUT* (--), NOTCH2 MUT* (--), NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP306	NOTCH2 MUT* (P2349H), NOTCH2 MUT* (V776), NOTCH2 MUT* (--), NOTCH2 MUT* (--), NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP306	NPM1 MUT* (D178Y)	NPM1 oncogenic mutation	DOT1L inhibitors + MLL1 inhibitors	Acute myeloid leukemia	Responsive	D	YES	PMID:27535106	only alteration type		AML
WP306	CRBN MUT* (--)	CRBN oncogenic mutation	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP306	CRBN MUT* (--)	CRBN (Q100*,R283K)	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP306	NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP306	NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 fusion	Pan-TK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24162815	only gene		LUAD
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 fusion	Pan-TKR inhibitors	Any cancer type	Responsive	C	YES	PMID:28183697;ASCO 2017 (LBA2501)	only gene		CANCER
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 fusion	Pan-TK inhibitors(Entrectinib,etc)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26546295	only gene		COREAD
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2013 (abstr 8023)	only gene	758.0	LUAD
WP306	NTRK3 MUT* (V273), NTRK3 MUT* (--)	NTRK3 fusion	IGF1R inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP306	NTRK3 MUT* (V273), NTRK3 MUT* (--)	NTRK3 fusion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP306	NTRK3 MUT* (V273), NTRK3 MUT* (--)	NTRK3 fusion	Midostaurin(Pan-TK inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP306	PAK1 MUT* (--)	PAK1 amplification	PAK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:23535073	only gene		CM
WP306	PALB2 MUT* (--), PALB2 MUT* (--)	PALB2 oncogenic mutation	PARP inhibitors	Prostate adenocarcinoma	Responsive	C	NO	AACR 2015 (abstr CT322);PMID:26510020	only alteration type		PRAD
WP306	PALB2 MUT* (--), PALB2 MUT* (--)	PALB2 oncogenic mutation	PARP inhibitors	Pancreas	Responsive	D	NO	PMID:25263539;NCT01585805	only alteration type		PA
WP306	PALB2 MUT* (--), PALB2 MUT* (--)	PALB2 deletion	PARP inhibitors	Prostate adenocarcinoma	Responsive	C	NO	AACR 2015 (abstr CT322);PMID:26510020	only gene		PRAD
WP306	PALB2 MUT* (--), PALB2 MUT* (--)	PALB2 deletion	PARP inhibitors	Pancreas	Responsive	D	NO	PMID:25263539;NCT01585805	only gene		PA
WP306	PALB2 MUT* (--), PALB2 MUT* (--)	PALB2 oncogenic mutation	Mytomycin C(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:21135251	only alteration type		PA
WP306	PALB2 MUT* (--), PALB2 MUT* (--)	PALB2 deletion	Mytomycin C(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:21135251	only gene		PA
WP306	PALB2 MUT* (--), PALB2 MUT* (--)	PALB2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP306	PALB2 MUT* (--), PALB2 MUT* (--)	PALB2 deletion	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only gene		PA
WP306	PBRM1 MUT* (R595)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP306	PBRM1 MUT* (R595)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA (D842V)	HSP90 inhibitors	Gastrointestinal stromal	Responsive	D	NO	PMID:18794084	only alteration type		GIST
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 (D835,Y842)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Acute myeloid leukemia	Resistant	D	YES	PMID:23430109	only alteration type		AML
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA (D842V)	Crenolanib(FLT3 inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2016 (abstr 11010)	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	Crenolanib(FLT3 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET (I788N)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Resistant	D	NO	PMID:28615362	only alteration type		LUAD
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 (F691,D835,N676,Y842)	Quizartinib(Pan-TK inhibitor)	Acute myeloid leukemia	Resistant	D	YES	PMID:22504184;PMID:23878140	only alteration type		AML
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA (P577S,R841K,H845Y,G853D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
WP306	EGFR MUT* (--)	EGFR (L798I)	Rociletinib(EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27283993	only alteration type		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Rociletinib(3rd generation EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP306	NF1 MUT* (I2129), NF1 MUT* (--), BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	NF1 oncogenic mutation + BRAF oncogenic mutation	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23444215	only alteration type		CM
WP306	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	AKT inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP306	PIK3CB MUT* (--)	PIK3CB (D1067Y)	AKT inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26759240	only alteration type		BRCA
WP306	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	MTORC1/2 inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP306	PIK3CB MUT* (--)	PIK3CB (D1067Y)	MTORC1/2 inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26759240	only alteration type		BRCA
WP306	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP306	NF1 MUT* (I2129), NF1 MUT* (--), BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	NF1 deletion + BRAF oncogenic mutation	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23444215	only gene		CM
WP306	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	AKT inhibitors	Glioma	Responsive	D	NO	PMID:23166678	only alteration type		G
WP306	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	PI3K pathway inhibitors	Endometrium	Responsive	C	NO	ASCO 2015 (abstr 11075)	only alteration type		ED
WP306	POLE MUT* (I2199), POLE (A1814V), POLE (W1685C), POLE MUT* (--)	POLE (268-471)	PD1 Ab inhibitors	Glioma, Endometrium	Responsive	C	NO	PMID:27001570;PMID:27683556;PMID:27159395	only alteration type		G, ED
WP306	POLE (A1814V), POLE (W1685C)	POLE oncogenic mutation	PD1 Ab inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28188185	complete		COREAD
WP306	PRKCH MUT* (R457S), PRKCH MUT* (R457), PRKCH MUT* (--), PRKCH MUT* (--), ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	PRKCH amplification + ABL1-BCR fusion	Trametinib + Imatinib(MEK inhibitor + BCR-ABL inhibitor 1st gen&KIT inhibitor)	Chronic myeloid leukemia	Responsive	D	YES	PMID:25186176	only gene		CML
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 11	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT mutation in exon 17	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:23840364	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT amplification	Sunitinib(Pan-TK inhibitor)	Cutaneous melanoma	No Responsive	C	NO	PMID:22261812	only gene		CM
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA (D842V)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP306	PTPRD MUT* (G1852*), PTPRD MUT* (--), PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP306	RAD50 (R352S), RAD50 MUT* (--), ATM (D58N), ATM MUT* (L75), ATM MUT* (--), ATM MUT* (E874D), ATM (D1371Y), ATM (E1424*), ATM MUT* (G2709)	RAD50 (L1237F) + ATM deletion	Irinotecan + CHK1/2 inhibitor(TOPO1 inhibitor + CHK1/2 inhibitor)	Any cancer type	Responsive	C	YES	PMID:24934408	only gene		CANCER
WP306	RAD51C MUT* (--)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
WP306	RAD51C MUT* (--)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
WP306	RAF1 MUT* (R218L)	RAF1 fusion	Pan-RAF inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:20526349	only gene		PRAD
WP306	RAF1 MUT* (R218L)	RAF1 fusion	Sorafenib(Pan-TK inhibitor)	Prostate adenocarcinoma	Responsive	D	NO	PMID:20526349	only gene		PRAD
WP306	RAF1 MUT* (R218L)	RAF1 fusion	U0126(MEK inhibitor)	Prostate adenocarcinoma	Responsive	D	NO	PMID:20526349	only gene		PRAD
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP306	RB1 MUT* (--), RB1 MUT* (--)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
WP306	RB1 MUT* (--), RB1 MUT* (--)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
WP306	RB1 MUT* (--), RB1 MUT* (--)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
WP306	RB1 MUT* (--), RB1 MUT* (--)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
WP306	RB1 MUT* (--), RB1 MUT* (--)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP306	RB1 MUT* (--), RB1 MUT* (--)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET fusion	RET inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:22327624;PMID:22327622	only gene		LUAD
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET-TPCN1 fusion	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only gene		TH
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET (C634W,M918T)	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only alteration type		TH
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET-TPCN1 fusion	Cabozantinib(Pan-kinase inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET (C634W,M918T)	Cabozantinib(Pan-kinase inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET fusion	Nintedanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26787234	only gene		LUAD
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET fusion	Sunitinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET-TPCN1 fusion	Sunitinib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET (C634W,M918T)	Sunitinib(Pan-TK inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET fusion	Vandetanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET-TPCN1 fusion	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP306	RICTOR MUT* (--), RICTOR MUT* (--), RICTOR MUT* (--), RICTOR MUT* (--)	RICTOR amplification	MTORC1/2 inhibitors	Lung	Responsive	C	NO	PMID:26370156	only gene		L
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:23533265	only gene		LUAD
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27370605	only gene		LUAD
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 (G2032R)	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:25351743	only alteration type		LUAD
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	C	YES	PMID:24875859	only gene		IM
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:25264305	only gene	758.0	LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Endometrium	No Responsive	C	NO	PMID:26099744;PMID:19840887	only gene		ED
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 (S1986Y,S1986F)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27401242	only alteration type		LUAD
WP306	SERPINB3 MUT* (--)	SERPINB3 oncogenic mutation	CTLA4 inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:27668655	only alteration type		CM
WP306	SETD2 (W2422C), SETD2 (H143N)	SETD2 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	complete		CANCER
WP306	SETD2 (W2422C), SETD2 (H143N)	SETD2 deletion	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only gene		CANCER
WP306	SF3B1 (G439C), SF3B1 (T296N), SF3B1 MUT* (E295*)	SF3B1 (K700E,K666N)	Spliceosome inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858	only alteration type		CANCER
WP306	SH2B3 MUT* (--)	SH2B3 oncogenic mutation	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:20404132	only alteration type		MDPS
WP306	SH2B3 MUT* (--)	SH2B3 deletion	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:20404132	only gene		MDPS
WP306	SMARCA1 MUT* (--)	SMARCA1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP306	SMARCA4 (Q822K), SMARCA4 (Q1596H)	SMARCA4 oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	C	NO	ESMO 2015 (abstract 302)	complete		OV
WP306	SMARCA4 MUT* (--), SMARCA4 MUT* (P49Q), SMARCA4 (Q822K), SMARCA4 (Q1596H)	SMARCA4 deletion	EZH2 inhibitors	Ovary	Responsive	C	NO	ESMO 2015 (abstract 302)	only gene		OV
WP306	SMARCB1 MUT* (--), SMARCB1 MUT* (--)	SMARCB1 oncogenic mutation	EZH2 inhibitors	Malignant rhabdoid tumor	Responsive	C	NO	ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302)	only alteration type		MRT
WP306	SMARCB1 MUT* (--), SMARCB1 MUT* (--)	SMARCB1 deletion	EZH2 inhibitors	Malignant rhabdoid tumor	Responsive	C	NO	ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302)	only gene		MRT
WP306	SMARCB1 MUT* (--), SMARCB1 MUT* (--)	SMARCB1 deletion	EZH2 inhibitors	Malignant rhabdoid tumor	Responsive	C	NO	ESMO 2015 (abstract 302)	only gene		MRT
WP306	SMARCB1 MUT* (--), SMARCB1 MUT* (--)	SMARCB1 oncogenic mutation	HDAC inhibitors	Malignant rhabdoid tumor	Responsive	D	NO	PMID:26920892	only alteration type		MRT
WP306	SMO MUT* (R151), SMO MUT* (G214), SMO MUT* (--)	SMO (P641A)	Vismodegib(SHH inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 9062)	only alteration type		L
WP306	STAG2 (L393I), STAG2 (D559Y)	STAG2 oncogenic mutation	PARP inhibitors	Glioma	Responsive	D	NO	PMID:24356817	complete		G
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Vemurafenib(BRAF inhibitor)	Any cancer type	Resistant	D	YES	PMID:26732095	only alteration type		CANCER
WP306	STK11 MUT* (--), STK11 MUT* (--)	STK11 oncogenic mutation	MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:19165201	only alteration type		LUAD
WP306	STK11 MUT* (--), STK11 MUT* (--)	STK11 deletion	MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:19165201	only gene		LUAD
WP306	STK11 MUT* (--), STK11 MUT* (--)	STK11 oncogenic mutation	MTOR inhibitors	Any cancer type	Responsive	D	YES	PMID:19541609	only alteration type		CANCER
WP306	STK11 MUT* (--), STK11 MUT* (--)	STK11 deletion	MTOR inhibitors	Any cancer type	Responsive	D	YES	PMID:19541609	only gene		CANCER
WP306	STK11 MUT* (--), STK11 MUT* (--)	STK11 oncogenic mutation	SRC inhibitor + PI3K/MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:20541700	only alteration type		LUAD
WP306	STK11 MUT* (--), STK11 MUT* (--)	STK11 deletion	SRC inhibitor + PI3K/MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:20541700	only gene		LUAD
WP306	STK11 MUT* (--), STK11 MUT* (--)	STK11 (D194E)	Everolimus(MTOR inhibitor)	Pancreas	Responsive	C	NO	PMID:21189378	only alteration type		PA
WP306	STK11 MUT* (--), STK11 MUT* (--)	STK11 oncogenic mutation	Phenformin(Anti-diabetic)	Lung adenocarcinoma	Responsive	D	NO	PMID:23352126	only alteration type		LUAD
WP306	STK11 MUT* (--), STK11 MUT* (--)	STK11 deletion	Phenformin(Anti-diabetic)	Lung adenocarcinoma	Responsive	D	NO	PMID:23352126	only gene		LUAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600)	Vemurafenib(BRAF inhibitor)	Colorectal adenocarcinoma	No Responsive	C	NO	PMID:26287849	only alteration type		COREAD
WP306	MAP2K1 MUT* (--)	MAP2K1 (E203K,Q56P,K57E)	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23569304	only alteration type		CM
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP306	SYK MUT* (P541), SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP306	TERT MUT* (--)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP306	TMPRSS2 MUT* (D412Y), TMPRSS2 MUT* (--), TMPRSS2 MUT* (S114)	TMPRSS2 fusion	DNA-PKc inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575865	only gene		PRAD
WP306	TMPRSS2 MUT* (D412Y), TMPRSS2 MUT* (--), TMPRSS2 MUT* (S114)	TMPRSS2 fusion	PARP inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575865	only gene		PRAD
WP306	TOP2A MUT* (R1435S), TOP2A MUT* (G642V), TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP306	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP306	NF1 MUT* (I2129), NF1 MUT* (--), BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	NF1 oncogenic mutation + BRAF oncogenic mutation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23288408;PMID:231718	only alteration type		CM
WP306	NF1 MUT* (I2129), NF1 MUT* (--), BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	NF1 deletion + BRAF oncogenic mutation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23288408;PMID:231718	only gene		CM
WP306	NTRK3 MUT* (V273), NTRK3 MUT* (--)	NTRK3 (G623R)	novel TRK inhibitors	Any cancer type	Responsive	C	YES	PMID:28578312	only alteration type		CANCER
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3-ITD	Venetoclax(BCL2 inhibitor)	Acute myeloid leukemia	Resistant	C	YES	PMID:27520294	only alteration type		AML
WP306	TSC1 MUT* (G1006), TSC1 MUT* (--), TSC1 MUT* (--), TSC1 MUT* (A2S)	TSC1 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	only alteration type		RA
WP306	TSC1 MUT* (G1006), TSC1 MUT* (--), TSC1 MUT* (--), TSC1 MUT* (A2S)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	only alteration type		BLCA
WP306	TSC1 MUT* (G1006), TSC1 MUT* (--), TSC1 MUT* (--), TSC1 MUT* (A2S)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;PMID:26859683;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	only alteration type		R
WP306	TSC1 MUT* (G1006), TSC1 MUT* (--), TSC1 MUT* (--), TSC1 MUT* (A2S)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Sarcoma, Stomach	Responsive	C	NO	PMID:26859683	only alteration type		S, ST
WP306	TSC1 MUT* (G1006), TSC1 MUT* (--), TSC1 MUT* (--), TSC1 MUT* (A2S)	TSC1 deletion	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	only gene		R
WP306	TSC2 (W304C), TSC2 (G402V)	TSC2 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	complete		RA
WP306	TSC2 (W304C), TSC2 (G402V)	TSC2 oncogenic mutation	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	complete		LAM
WP306	TSC2 MUT* (A224), TSC2 (W304C), TSC2 (G402V)	TSC2 deletion	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	only gene		LAM
WP306	TSC2 (W304C), TSC2 (G402V)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	complete		BLCA
WP306	TSC2 MUT* (A224), TSC2 (W304C), TSC2 (G402V)	TSC2 (Q1178*)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:25295501	only alteration type		THCA
WP306	TSC2 MUT* (A224), TSC2 (W304C), TSC2 (G402V)	TSC2 (E66K)	Tensirolimus(MTOR inhibitor)	Endometrium	Responsive	C	NO	PMID:27016228	only alteration type		ED
WP306	SMO MUT* (R151), SMO MUT* (G214), SMO MUT* (--)	SMO (D473H)	Vismodegib(SHH inhibitor)	Medulloblastoma	Resistant	C	NO	PMID:19726788;PMID:25759019	only alteration type		MB
WP306	U2AF1 (Q157P)	U2AF1 oncogenic mutation	FLT3 inhibitors	Any cancer type	Responsive	D	YES	PMID:27397505	complete		CANCER
WP306	VEGFA MUT* (--)	VEGFA amplification	Sorafenib(Pan-TK inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24687604	only gene		HC
WP306	SMO MUT* (R151), SMO MUT* (G214), SMO MUT* (--)	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	Vismodegib(SHH inhibitor)	Basal cell carcinoma	Resistant	C	NO	PMID:25759020;PMID:25306392	only alteration type		BCC
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Cholangiocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CH
WP306	BRCA1 (L1807M)	BRCA1 (G1738R,A1708V,C47G,V1696L,Y1853C,D1739V,F1761I,H1746N,C24Y,K1702E,P1749R,M1775R,W1837C,M1775E,V1736G,V1838E,C44F,A1752V,D1739E,S1715N,.,A1789T,S1164I,T1685A,A1752P,H1686R,H41R,C64G,W1718L,D1692H,V1713A,R1699W,V1653M,Q1756C,C61G,D1739Y,G1770V,V1714G,V1833M,R1835P,R1699Q,G1706E,P1812A,E1836K,C44Y,G1788D,C39Y,M1R,S1715R,Y1703H,F1761S,E33A,M1628V,W1837G,L1705P,M1689R,G1738E,R1751P,V1809F,S1841N,S1722F,I1766S,S1655F,G1788V,L1780P,V1833E,A1708E,E1660G,C27A,Y1703S,I1807S,T1700A,A1843T,F1734L,V1741G,V1810G,F1704S,G1656D,T1685I,L1854P,Q1811R,M18T,C1697R,G1803A,G1743R,G1763V,C24R,T37R,T1773I,D1739G,W1718C,H1686Q,T1691I,L1407P,K1487R,M1652K,S1841R,M1775K,S1841A,F1734S,V1736A,M1689T,W1815X,L1764P,W1837R,T1691K,R1753T,D1692Y,W1718S,L1657P,A1843P,S1715C,R1699L)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/6/summary|oncokb=https://www.oncokb.org/gene/BRCA1	complete		OV
WP306	BRCA1 (L1807M)	BRCA1 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only gene		OV
WP306	EWSR1 MUT* (--)	EWSR1-FLI1 fusion	T + K + 2 + 1 + 6	Ewing sarcoma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EWSR1	only gene		EWS
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 amplification	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Lung squamous cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		LUSC
WP306	MAP2K1 MUT* (--)	MAP2K1 (V60E,H119P,L115P,I103N,F53C,R49L,G128V,V60M,L177V,F53S,P124L,T28I,P124S,Q56P,L37P,Y130C,I204T,E203K,I111R,I111A,F53L,.,L177M,V154I,C121S,S123T,P306H,V211D,I111P,K57T,D67N,I111N,P124Q,R47Q,K57N,S218D,F129L,S222D,E144K,L115R,G128D,K57E)	Cobimetinib + Trametinib	Cutaneous melanoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MAP2K1	only alteration type		CM
WP306	EGFR MUT* (--)	EGFR (T790M)	Afatinib + Erlotinib + Gefitinib	Non-small cell lung	Resistant	A	NO	oncokb: oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR (T790M,D761Y)	Gefitinib	Non-small cell lung	Resistant	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/19/summary|oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
WP306	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
WP306	BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
WP306	MDM2 MUT* (--), MDM2 MUT* (--)	MDM2 amplification	Unii-Q8Mi0X869M	Liposarcoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MDM2	only gene		LIP
WP306	CDK4 (P280T)	CDK4 amplification	Abemaciclib + Palbociclib	Dedifferentiated liposarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/CDK4	only gene		DLIP
WP306	CDK4 (P280T)	CDK4 amplification	Abemaciclib + Palbociclib	Liposarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/CDK4	only gene		LIP
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR (L2209V,L1460P,L2427Q)	Temsirolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR (Q2223K)	Everolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK fusion	Crizotinib + Ceritinib	Sarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only gene		S
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK (G1202R,I1171N)	Alectinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only alteration type		NSCLC
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 fusion	Entrectinib	Any cancer type	Responsive	B	YES	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/NTRK1|CIVIC=https://civicdb.org/genes/3983/summary	only gene		CANCER
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (D594.,G466.,G464.,N581.,D287H,K601.,G469.,G596.,L597.,F595L,S467L,V459L)	Plx8394	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CANCER
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (F522C,W557R,N463S,V654A,N822H,A829P,D820A,D572A,P838L,R634W,N822K,Y578C,N822Y,D816G,D816A,T670I,D820G,V560E,K558N,C809G,D820E,D820Y,D816Y,L576P,N822I,W557G,H697Y,I653T,V559A,V530I,V559I,S476I,V559G,D52N,.,N505I,S709F,V559C,D816N,D816V,M541L,V559D,Y823D,C443Y,D816E,Y553N,V560G,V852I,D816F,Y570H,K509I,E490K,D816.,N655K,K642E,V560D,W557C,D60N,D816H)	Sunitinib + Sorafenib	Thymic	Responsive	B	YES	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only alteration type		THYM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (Y823D,T670I,V654A,D820G,C809G,D820A,N822K,D816H)	Imatinib	Gastrointestinal stromal	Resistant	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/KIT|CIVIC=https://civicdb.org/genes/29/summary	only alteration type		GIST
WP306	MAP2K1 MUT* (--)	MAP2K1 (V60E,H119P,L115P,I103N,F53C,R49L,G128V,V60M,L177V,F53S,P124L,T28I,P124S,Q56P,L37P,Y130C,I204T,E203K,I111R,I111A,F53L,.,L177M,V154I,C121S,S123T,P306H,V211D,I111P,K57T,D67N,I111N,P124Q,R47Q,K57N,S218D,F129L,S222D,E144K,L115R,G128D,K57E)	Cobimetinib + Trametinib	Histiocytoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MAP2K1	only alteration type		HIS
WP306	ERBB2 MUT* (L514M)	ERBB2 (T862A,L755S,V842I,V777A,D769H,.,R896C,R678W,R784C,V773A,C630Y,G309E,G292R,E645F,T733I,D769Y,G660R,T686A,D769A,Y803N,L651V,A644F,L674V,V839G,R217C,L869R,E719K,G660D,E265K,L785F,P650S,D277H,D808N,G776V,S653C,R487W,L841V,S310F,L755W,E693K,S335C,V659E,V794M,V659K,E321G,L915M,L866M,C311R,S1002R,D277Y,V659G,Q709L,L726I,G309A,N857S,L755P,T798M,L663P,E812K,S656C,T798I,R683Q,I682G,R678Q,V777L,P780L,A710V,R677L,S310Y,S783P,E717K,E719G,H878Y,G776S,L726F,D821N,V777M,I767M,S649T,C334S)	Neratinib	Breast adenocarcinoma	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ERBB2|CIVIC=https://civicdb.org/genes/20/summary	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Neratinib	Breast adenocarcinoma	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ERBB2|CIVIC=https://civicdb.org/genes/20/summary	only gene		BRCA
WP306	EGFR MUT* (--)	EGFR (R108K,T263P,A289V)	Lapatinib	Glioma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		G
WP306	EGFR MUT* (--)	EGFR (C797G,C797S)	Osimertinib	Non-small cell lung	Resistant	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/19/summary|oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
WP306	BRCA1 (L1807M)	BRCA1 (G1738R,A1708V,C47G,V1696L,Y1853C,D1739V,F1761I,H1746N,C24Y,K1702E,P1749R,M1775R,W1837C,M1775E,V1736G,V1838E,C44F,A1752V,D1739E,S1715N,.,A1789T,S1164I,T1685A,A1752P,H1686R,H41R,C64G,W1718L,D1692H,V1713A,R1699W,V1653M,Q1756C,C61G,D1739Y,G1770V,V1714G,V1833M,R1835P,R1699Q,G1706E,P1812A,E1836K,C44Y,G1788D,C39Y,M1R,S1715R,Y1703H,F1761S,E33A,M1628V,W1837G,L1705P,M1689R,G1738E,R1751P,V1809F,S1841N,S1722F,I1766S,S1655F,G1788V,L1780P,V1833E,A1708E,E1660G,C27A,Y1703S,I1807S,T1700A,A1843T,F1734L,V1741G,V1810G,F1704S,G1656D,T1685I,L1854P,Q1811R,M18T,C1697R,G1803A,G1743R,G1763V,C24R,T37R,T1773I,D1739G,W1718C,H1686Q,T1691I,L1407P,K1487R,M1652K,S1841R,M1775K,S1841A,F1734S,V1736A,M1689T,L1764P,W1837R,T1691K,R1753T,D1692Y,W1718S,L1657P,A1843P,S1715C,R1699L)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	complete		BRCA
WP306	BRCA1 (L1807M)	BRCA1 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only gene		BRCA
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR (E2419K,E2014K)	Everolimus	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		BLCA
WP306	MTOR (R2368L)	MTOR (E2419K,C1483F,L2172M,K1452N,L2230V,L2427Q,L2431P,F1888I,E1799K,L2216P,W1456R,C1483W,A1519T,L1460P,A2210P,T2232I,R2505P,M2327I,C1483R,V2006I,A1428T,Y1463S,I2500M,A1459P,F1888L,S2231W,T1977R,V2006F,T1977K,A2226S,I2500F,L2427R,T1977I,S2215F,.,Q2223K,I1973F,L1433S,F1888V,S2215T,D2512H,E2014K,S2215Y,R2217W,L2209V,V2006L,L2220F,L2427P,S2215P,P2273S,E2288K,C1483Y)	Temsirolimus + Everolimus	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	complete		CANCER
WP306	TSC1 MUT* (G1006), TSC1 MUT* (--), TSC1 MUT* (--), TSC1 MUT* (A2S)	TSC1 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	only gene		RCCC
WP306	TSC1 MUT* (G1006), TSC1 MUT* (--), TSC1 MUT* (--), TSC1 MUT* (A2S)	TSC1 (H105R,H206D,V220F,L180P,F216A,M224R,H68R,.,S35Q,F158C,L117P,L191H)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	only alteration type		RCCC
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib	Gastrointestinal stromal	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP306	NTRK3 MUT* (V273), NTRK3 MUT* (--)	NTRK3 fusion	Entrectinib	Any cancer type	Responsive	B	YES	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/3985/summary|oncokb=https://www.oncokb.org/gene/NTRK3	only gene		CANCER
WP306	KDM6A MUT* (--), KDM6A (E1387*)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
WP306	KDM6A (E1387*)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	complete		BLCA
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + Trametinib	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Encorafenib + Binimetinib + Cetuximab	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		OV
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (F522C,W557R,N463S,V654A,N822H,A829P,D820A,D572A,P838L,R634W,N822K,Y578C,N822Y,D816G,D816A,T670I,D820G,V560E,K558N,C809G,D820E,D820Y,D816Y,L576P,N822I,W557G,H697Y,I653T,V559A,V530I,V559I,S476I,V559G,D52N,.,N505I,S709F,V559C,D816N,D816V,M541L,V559D,Y823D,C443Y,D816E,Y553N,V560G,V852I,D816F,Y570H,K509I,E490K,N655K,V560D,K642E,D816.,W557C,D60N,D816H)	Imatinib	Cutaneous melanoma	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/KIT|CIVIC=https://civicdb.org/genes/29/summary	only alteration type		CM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT amplification	Imatinib	Cutaneous melanoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only gene		CM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT (D816)	Blu-285	Mastocytosis	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only alteration type		MAS
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3 (S249C,S371C,R248C,K650.,G380R,Y373C,G370C)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only alteration type		BLCA
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA (N659K,V561D,V561A,N659S,A633T,H845Y,T674I,S584L,D842V,N659R,D568N,P577S,D846Y,Q579R,D842Y,Y849S,N848K,H650Q,D842I,V469A,Y288C,Y555C,R748G,Y849C,.,R841K,G853D,V536E,V658A)	Imatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA amplification	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA-BCR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA-CDK5RAP2 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA-ETV6 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA-KDR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA-KIF5B fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA-STRN fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP306	TSC2 (W304C), TSC2 (G402V)	TSC2 (S1653P,Q1503P,R905G,L830R,A889P,L146R,T1203K,V1673F,W1610G,V769E,C696Y,F615S,E75G,L448P,V299G,R611W,R1200W,R505Q,Q1554H,G1567D,G1596V,Y1571N,I427M,S1498N,L1584R,P1709L,L844R,V705E,R905Q,Y598C,L410R,R462C,R611Q,R905W,A614D,.,S1653F,P1675L,H1620R,S1036P,H597Y,L493P,T1623I,V1673D,V705M,L826P,L792R,A328P,L493V)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	complete		RCCC
WP306	TSC2 MUT* (A224), TSC2 (W304C), TSC2 (G402V)	TSC2 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	only gene		RCCC
WP306	ERBB2 MUT* (L514M)	ERBB2 (T862A,L755S,V842I,V777A,D769H,.,R896C,R678W,R784C,V773A,C630Y,G309E,G292R,E645F,T733I,D769Y,G660R,T686A,D769A,Y803N,L651V,A644F,L674V,V839G,R217C,L869R,E719K,G660D,E265K,L785F,P650S,D277H,D808N,G776V,S653C,R487W,L841V,S310F,E693K,S335C,V659E,V794M,V659K,E321G,L915M,L866M,C311R,S1002R,D277Y,V659G,Q709L,L726I,G309A,N857S,L755P,T798M,L663P,E812K,S656C,T798I,R683Q,I682G,R678Q,V777L,P780L,A710V,R677L,S310Y,S783P,E717K,E719G,H878Y,G776S,L726F,D821N,V777M,I767M,S649T,C334S)	Ado + Trastuzumab + Neratinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERBB2	only alteration type		NSCLC
WP306	ERBB2 MUT* (L514M)	ERBB2 amplification	Ado + Trastuzumab + Neratinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERBB2	only gene		NSCLC
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		BLCA
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 (N549K,K526E,K641R,I547V,Y375C,D101Y,E219K,E565G,C382R,N549H,W290R,L617M,D530N,M535I,P253R,V564I,F276C,S252W,N549T,E731K,G271E,I642V,K641N,R203C,K659E,.,L617F,M537I,T341P,R678G,M391R,Y381D,V564F,K525E,N549S,R251Q,A648T,K659N)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only alteration type		CANCER
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 amplification	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2-AHCYL1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2-BICC1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2-CCDC6 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2-CIT fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2-FAM76A fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2-KIAA1967 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2-MGEA5 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2-TACC3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		BLCA
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600K,V600.,L597.,K601.,V600E,L597V)	Trametinib	Cutaneous melanoma	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/5/summary|oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CM
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP306	NF1 MUT* (I2129), NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP306	ARAF MUT* (--), ARAF MUT* (L567)	ARAF (G322S,S214T,F351L,.,S214C,N217I,S214A,S214F)	Sorafenib	Histiocytoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ARAF	only alteration type		HIS
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 amplification	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1-BCR fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1-CEP110 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1-CUX1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1-ERLIN2 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1-TACC1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1-FGFR1OP1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP306	FGFR1 (G512D)	FGFR1 (V592M,K687E,.,N577K)	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	complete		CANCER
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1-ZNF198 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP306	ATM (D58N), ATM (D1371Y), ATM (E1424*)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	complete		CANCER
WP306	ATM (D58N), ATM MUT* (L75), ATM MUT* (--), ATM MUT* (E874D), ATM (D1371Y), ATM (E1424*), ATM MUT* (G2709)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
WP306	MAP2K1 MUT* (--)	MAP2K1 (V60E,H119P,L115P,I103N,F53C,R49L,G128V,V60M,L177V,F53S,P124L,T28I,P124S,Q56P,L37P,Y130C,I204T,E203K,I111R,I111A,F53L,.,L177M,V154I,C121S,S123T,P306H,V211D,I111P,K57T,D67N,I111N,P124Q,R47Q,K57N,S218D,F129L,S222D,E144K,L115R,G128D,K57E)	Cobimetinib + Trametinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MAP2K1	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR (T790M,D761Y)	Osimertinib	Non-small cell lung	Responsive	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/19/summary|oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
WP306	JAK2 (V617F)	JAK2-PCM1 fusion	Ruxolitinib	Eosinophilic chronic leukemia	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/JAK2	only gene		ECL
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK (C1156Y,F1174L,L1196M,G1269A)	Crizotinib	Non-small cell lung	Resistant	D	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary	only alteration type		NSCLC
WP306	SMARCB1 MUT* (--), SMARCB1 MUT* (--)	SMARCB1 deletion	Epz-6438	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/SMARCB1	only gene		CANCER
WP306	SMARCB1 MUT* (--), SMARCB1 MUT* (--)	SMARCB1 oncogenic mutation	Epz-6438	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/SMARCB1	only alteration type		CANCER
WP306	NTRK2 MUT* (--)	NTRK2 fusion	Entrectinib	Any cancer type	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK2	only gene		CANCER
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET fusion	Cabozantinib + Vandetanib + Larotrectinib + 292 + 667	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		NSCLC
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET (C618R,C620R,C609Y,E768D,C630R,S904F,E511K,C634S,C634Y,V648I,I852M,S891A,A883T,A883F,C611Y,T338I,C634W,K603Q,D631Y,M918T,A919V,R833C,.,V804M,C634R,V804L,Y806C,M918V,L790F,M848T,R886W,Y791F)	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only alteration type		THM
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET-KIF5B fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET-CCDC6 fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT amplification	Sunitinib + Sorafenib	Thymic	Responsive	B	YES	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only gene		THYM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Cutaneous melanoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		CM
WP306	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
WP306	BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
WP306	FGFR3 (D280E)	FGFR3 (M528I,D641N,R669G,Y373C,K650T,G370C,S249C,S371C,A391E,G380R,I538V,D641G,N540K,R248C,V555M,.,K650E,K650R,K650M,G375C,G382D,N540S,Y647C,K650Q,K650N)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	complete		CANCER
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3 amplification	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3-BAIAP2L1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3-TACC3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3-IGH fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP306	ARAF MUT* (--), ARAF MUT* (L567)	ARAF (G322S,S214T,F351L,.,S214C,N217I,S214A,S214F)	Sorafenib	Non-small cell lung	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ARAF|CIVIC=https://civicdb.org/genes/3/summary	only alteration type		NSCLC
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP306	MAP2K1 MUT* (--)	MAP2K1 (V60E,H119P,L115P,I103N,F53C,R49L,G128V,V60M,L177V,F53S,P124L,T28I,P124S,Q56P,L37P,Y130C,I204T,E203K,I111R,I111A,F53L,.,L177M,V154I,C121S,S123T,P306H,V211D,I111P,K57T,D67N,I111N,P124Q,R47Q,K57N,S218D,F129L,S222D,E144K,L115R,G128D,K57E)	Cobimetinib + Trametinib	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MAP2K1	only alteration type		OV
WP306	EGFR MUT* (--)	EGFR amplification	Lapatinib	Glioma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EGFR	only gene		G
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 (G595R)	Larotrectinib	Any cancer type	Resistant	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK1	only alteration type		CANCER
WP306	NTRK3 MUT* (V273), NTRK3 MUT* (--)	NTRK3 (G623R)	Larotrectinib	Any cancer type	Resistant	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK3	only alteration type		CANCER
WP306	ABCC3 MUT* (--), ABCC3 MUT* (F1201L), ABCC3 MUT* (A1413E)	ABCC3 Amplification	Monomethyl Auristatin E,Paclitaxel	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/951	only gene		BRCA
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 BCR::ABL	Imatinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/232	only gene		AML
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 BCR::ABL	Imatinib	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/259	only gene		AML
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 G340L	Imatinib Mesylate,Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4788	only alteration type		NSCLC
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 R351W	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4787	only alteration type		NSCLC
WP306	ABL1 MUT* (--), ABL1 (W731L), ABL1 MUT* (L928)	ABL1 R351W	Imatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/6376	only alteration type		NSCLC
WP306	AKT2 (F310L)	AKT2 Amplification	Everolimus,Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1621	only gene		LUAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK CAD::ALK	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7481	only gene		COREAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK CLTC::ALK	TAE684	Difuse large B Cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1261	only gene		DLBCL
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK CLTC::ALK	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1265	only gene		DLBCL
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK EML4::ALK	Alectinib	Mesothelioma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9228	only gene		MESO
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/262	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK EML4::ALK	WHI-P154	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1188	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK EML4::ALK	Crizotinib,Retaspimycin Hydrochloride	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1203	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK EML4::ALK	Crizotinib,Alvespimycin	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1206	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1207	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK EML4::ALK	Lorlatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1332	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK F1174L	Crizotinib	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/125	only alteration type		NB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK F1174L	Alectinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/37	only alteration type		NB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/38	only alteration type		NB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK F1174L	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/142	only alteration type		NB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1271	only alteration type		NB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK F1174L	AZD3463	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1327	only alteration type		NB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK F1174L	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1329	only alteration type		NB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK F1174L	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/33	only alteration type		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK F1245C	Crizotinib	Neuroblastoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1333	only alteration type		NB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK F1245C	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1330	only alteration type		NB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK F1245V	Entrectinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2987	only alteration type		NB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1240	only gene		ALCL
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/7361	only gene		ALCL
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	A	YES	https://civicdb.org/links/evidence_items/11218	only gene		ALCL
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1264	only gene		DLBCL
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1691	only gene		LUAD
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Pemetrexed	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/945	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1175	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1187	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1198	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1199	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1200	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1201	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Retaspimycin Hydrochloride	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1202	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1272	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1273	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1279	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1282	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1419	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1577	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4835	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Alectinib,Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4858	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7284	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7285	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Lorlatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7286	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/8657	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11121	only gene		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1283	only alteration type		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK I1171	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1287	only alteration type		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1367	only alteration type		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1284	only alteration type		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK I1171	TAE684	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1285	only alteration type		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1344	only alteration type		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1368	only alteration type		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK I1171T	Ceritinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9404	only alteration type		NB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK KANK4::ALK	Alectinib	Pancreas acinar	Responsive	C	NO	https://civicdb.org/links/evidence_items/10327	only gene		PAAC
WP306	ALK (G1054D)	ALK Mutation	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1237	complete		NSCLC
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1239	only gene		ALCL
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/1241	only gene		ALCL
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK R1275Q	TAE684	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/48	only alteration type		NB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK R1275Q	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/39	only alteration type		NB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/143	only alteration type		NB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1270	only alteration type		NB
WP306	ALK MUT* (L1609), ALK MUT* (--), ALK (G1054D), ALK MUT* (--), ALK MUT* (--)	ALK R1275Q	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1331	only alteration type		NB
WP306	APC (S2029Y)	APC Mutation	G007-LK	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/446	complete		COREAD
WP306	ARAF MUT* (--), ARAF MUT* (L567)	ARAF S214C	Sorafenib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/17	only alteration type		NSCLC
WP306	ARAF MUT* (--), ARAF MUT* (L567)	ARAF S214C	Sorafenib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/40	only alteration type		NSCLC
WP306	ARAF MUT* (--), ARAF MUT* (L567)	ARAF S214C	Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/41	only alteration type		NSCLC
WP306	ARAF MUT* (--), ARAF MUT* (L567)	ARAF S490T	Cetuximab,Irinotecan,Vemurafenib	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1905	only alteration type		COREAD
WP306	ATM (D58N), ATM (D1371Y), ATM (E1424*)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	complete		CM
WP306	ATM (D58N), ATM (D1371Y), ATM (E1424*)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	complete		GB
WP306	ATM (D58N), ATM (D1371Y), ATM (E1424*)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	complete		PRAD
WP306	BAP1 (D225Y)	BAP1 Mutation	Sunitinib,Everolimus	Renal	Resistant	B	NO	https://civicdb.org/links/evidence_items/5339	complete		R
WP306	BAP1 (D225Y)	BAP1 Mutation	Valproic Acid,Trichostatin A,Vorinostat,Panobinostat	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1234	complete		UVM
WP306	BARD1 MUT* (--)	BARD1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11209	only alteration type		PRAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF Non-V600	Trametinib	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/7855	only alteration type		SOLID
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF A598V	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7635	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF AGK::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/724	only gene		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF AGK::BRAF	Sorafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/723	only gene		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF CUX1::BRAF	Vemurafenib	Pancreas	Responsive	C	NO	https://civicdb.org/links/evidence_items/5977	only gene		PA
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF D594G	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1554	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2201	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4472	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF D594K	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6402	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF D594K	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6403	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF G466V	Irinotecan,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7552	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF G466V	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7553	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF G466V	Vemurafenib	Solid tumors	Responsive	D	NO	https://civicdb.org/links/evidence_items/7554	only alteration type		SOLID
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF G469	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7634	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF G596C	Dabrafenib,Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1738	only alteration type		NSCLC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF G596R	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4729	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1668	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1669	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF L597R	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/728	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1704	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2187	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6303	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6304	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6305	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6306	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1404	only alteration type	498.0	COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF PAPSS1::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/725	only gene		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF PAPSS1::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/726	only gene		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF TRIM24::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/727	only gene		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Vemurafenib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5905	only alteration type		CH
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Refametinib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1000	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/93	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1407	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1422	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1750	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Cobimetinib,Vemurafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/6044	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6180	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6937	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6966	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Binimetinib,Encorafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7287	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/88	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Vemurafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1576	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1415	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1598	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Cetuximab,Encorafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6046	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Encorafenib,Alpelisib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6047	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Vemurafenib,Irinotecan,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7355	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1574	only alteration type		NSCLC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600D	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/94	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4488	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4489	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7616	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7629	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5902	only alteration type		CH
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib,Irinotecan,Panitumumab	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5906	only alteration type		CH
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib,Mirdametinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/86	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/90	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/994	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/95	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Pictilisib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/757	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Dactolisib,Selumetinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1005	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1398	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1421	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1749	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2135	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3750	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3755	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3757	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6178	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6938	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6940	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/126	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/816	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2115	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2117	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2118	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2121	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3739	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3827	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Sorafenib,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/89	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	PLX4720,Pictilisib Bismesylate	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/96	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	PLX4720,Nutlin-3	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/97	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/98	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/99	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1405	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Dabrafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1406	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Cetuximab,Gefitinib,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1408	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1413	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	GDC-0879,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1428	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1589	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Irinotecan,Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1902	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5960	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Panitumumab,Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6123	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Panitumumab,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6124	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Cetuximab,Encorafenib,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7260	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7612	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cetuximab,Irinotecan	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8506	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib,Erlotinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8507	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/9851	only alteration type		COREAD
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Hairy-Cell leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/1579	only alteration type		HCL
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5903	only alteration type		IHCH
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5904	only alteration type		IHCH
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1698	only alteration type		MM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1699	only alteration type		MM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Dabrafenib,Trametinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/3017	only alteration type		NSCLC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5958	only alteration type		NSCLC
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/5959	only alteration type		OV
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1399	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1400	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600K	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2505	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600K	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2506	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4180	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6179	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6965	only alteration type		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF ZKSCAN1::BRAF	Trametinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1663	only gene		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF Amplification	Trametinib,Dabrafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/7677	only gene		CM
WP306	BRAF MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	BRAF Amplification	Panitumumab,Dabrafenib	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2929	only gene		COREAD
WP306	BRCA1 (L1807M)	BRCA1 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/1897	complete		OV
WP306	BRCA1 (L1807M)	BRCA1 Mutation	Olaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/7275	complete		OV
WP306	BRCA1 (L1807M)	BRCA1 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11136	complete		OV
WP306	BRCA1 (L1807M)	BRCA1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11203	complete		PRAD
WP306	BRCA1 (L1807M)	BRCA1 Q1467*	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2878	only alteration type		OV
WP306	BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
WP306	BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
WP306	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
WP306	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
WP306	BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
WP306	BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
WP306	BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
WP306	BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
WP306	BRIP1 (E515*)	BRIP1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11208	complete		PRAD
WP306	CCND1 MUT* (S97), CCND1 MUT* (--)	CCND1 Amplification	Tamoxifen	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/858	only gene		BRCA
WP306	CCND1 MUT* (S97), CCND1 MUT* (--)	CCND1 Amplification	Palbociclib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1562	only gene		BRCA
WP306	CCND1 MUT* (S97), CCND1 MUT* (--)	CCND1 Amplification	Palbociclib	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/1599	only gene		OV
WP306	CCND1 MUT* (S97), CCND1 MUT* (--)	CCND1 Amplification	Palbociclib	Renal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1560	only gene		R
WP306	CHEK1 MUT* (--)	CHEK1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11210	only alteration type		PRAD
WP306	CHEK2 (--)	CHEK2 mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11205	complete		PRAD
WP306	CRBN MUT* (--)	CRBN Mutation	Lenalidomide,Pomalidomide	Multiple myeloma	Resistant	C	YES	https://civicdb.org/links/evidence_items/1766	only alteration type		MM
WP306	DDR2 MUT* (--)	DDR2 G253C	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/266	only alteration type		NSCLC
WP306	DDR2 MUT* (--)	DDR2 G505S	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/267	only alteration type		NSCLC
WP306	DDR2 MUT* (--)	DDR2 G774V	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/268	only alteration type		NSCLC
WP306	DDR2 MUT* (--)	DDR2 I638F	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/269	only alteration type		NSCLC
WP306	DDR2 MUT* (--)	DDR2 L239R	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/270	only alteration type		NSCLC
WP306	DDR2 MUT* (--)	DDR2 L63V	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/271	only alteration type		NSCLC
WP306	DDR2 MUT* (--)	DDR2 S768R	Dasatinib,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/272	only alteration type		NSCLC
WP306	DNMT3A (G869C), DNMT3A (E463*)	DNMT3A Mutation	Decitabine	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/1587	complete		AML
WP306	DNMT3A (G869C), DNMT3A (E463*), DNMT3A MUT* (S390R)	DNMT3A R882	Daunorubicin	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/11	only alteration type		AML
WP306	DNMT3A (G869C), DNMT3A (E463*), DNMT3A MUT* (S390R)	DNMT3A R882	Idarubicin	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/18	only alteration type		AML
WP306	EGFR MUT* (--)	EGFR A763_Y764insFQEA	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4497	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR A763_Y764insFQEA	Osimertinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/9225	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR A767_V769dupASV	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4665	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR A767_V769dupASV	Osimertinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/9220	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR A864T	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4495	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR C797S	Osimertinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1396	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR C797S	Osimertinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/964	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR D761Y	Erlotinib,Gefitinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1763	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR D770_N771insG	Osimertinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/9223	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR D770_N771insGL	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4494	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR D770_N771insGT	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4643	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR D770_N771insNPG	Gefitinib,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/5947	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR D770delinsGY	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4801	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR E746G	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1787	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR E746_A750del	Gefitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2625	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR E746_A750del	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4198	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR EGFR::RAD51	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5909	only gene		LUAD
WP306	EGFR MUT* (--)	EGFR EGFR::RAD51	Icotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7314	only gene		LUAD
WP306	EGFR MUT* (--)	EGFR EGFR::RAD51	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11015	only gene		LUAD
WP306	EGFR MUT* (--)	EGFR EGFR::RAD51	Osimertinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11021	only gene		LUAD
WP306	EGFR MUT* (--)	EGFR G465R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1058	only alteration type		COREAD
WP306	EGFR MUT* (--)	EGFR G465R	Futuximab/Modotuximab Mixture	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1057	only alteration type		COREAD
WP306	EGFR MUT* (--)	EGFR G719	Erlotinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1780	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR G719	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4189	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR G719A	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2508	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR G719A	Erlotinib,Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/6181	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR G719D	Gefitinib,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4210	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR G719S	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/787	only alteration type		COREAD
WP306	EGFR MUT* (--)	EGFR G719S	Gefitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/274	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR G719S	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1736	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR G719S	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4190	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR G724S	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/786	only alteration type		COREAD
WP306	EGFR MUT* (--)	EGFR H773_V774insNPH	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4493	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR K467T	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1083	only alteration type		COREAD
WP306	EGFR MUT* (--)	EGFR K467T	Panitumumab,Futuximab/Modotuximab Mixture	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1082	only alteration type		COREAD
WP306	EGFR MUT* (--)	EGFR K757R	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1786	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR K806E	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4239	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR KIF5B::EGFR	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11026	only gene		LUAD
WP306	EGFR MUT* (--)	EGFR L747P	Gefitinib,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4220	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L747_P753delinsS	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4266	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L747_P753delinsS	Erlotinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6005	only alteration type		PAAD
WP306	EGFR MUT* (--)	EGFR L747_S752delinsQ	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4667	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR L838P	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4252	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Afatinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/879	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR L858R	Afatinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/883	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR L858R	Afatinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/982	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR L858R	Gefitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2624	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR L858R	Gefitinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2634	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR L858R	Erlotinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4290	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR L858R	Erlotinib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4291	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR L858R	Cetuximab	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4292	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR L858R	Gefitinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6183	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR L858R	Crizotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/4288	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Gefitinib,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/229	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/275	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Gefitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/276	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/885	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/968	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1665	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2621	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Lapatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2626	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Dacomitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2627	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Neratinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2628	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2629	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Canertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2631	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2632	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/2994	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Afatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/2997	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4284	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4286	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4287	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Osimertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4294	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4860	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L858R	Erlotinib	Small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4293	only alteration type		SCLC
WP306	EGFR MUT* (--)	EGFR L861	Gefitinib,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4298	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L861Q	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/3802	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR L861R	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4669	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR M766_A767insAI	Erlotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/4799	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR Mutation	Afatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1728	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1937	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR Mutation	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2053	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2148	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR Mutation	Afatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2153	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2559	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3016	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR Mutation	Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3794	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR Mutation	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4201	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR Mutation	Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7024	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR N826S	Erlotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/4496	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR N826Y	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4244	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR N842S	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4256	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR P772_H773insYNP	Erlotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/4802	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR R451C	Futuximab/Modotuximab Mixture,Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1081	only alteration type		COREAD
WP306	EGFR MUT* (--)	EGFR R705K	Erlotinib,Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/6182	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR R776C	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4468	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR S492R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/717	only alteration type		COREAD
WP306	EGFR MUT* (--)	EGFR S492R	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1080	only alteration type		COREAD
WP306	EGFR MUT* (--)	EGFR S492R	Panitumumab	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1078	only alteration type		COREAD
WP306	EGFR MUT* (--)	EGFR S492R	Panitumumab,Futuximab/Modotuximab Mixture	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1079	only alteration type		COREAD
WP306	EGFR MUT* (--)	EGFR S720	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1782	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR S768I	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4273	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR S768I	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1394	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR S768I	Gefitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1395	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR S768I	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2906	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1391	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR T790M	Osimertinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1397	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR T790M	Osimertinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2157	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR T790M	Erlotinib	Non-small cell lung	Resistant	A	NO	https://civicdb.org/links/evidence_items/238	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/239	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Dacomitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/240	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/1667	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Afatinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/1863	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Gefitinib,Erlotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/2158	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2159	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Lapatinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/2160	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Pemetrexed,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/277	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Rociletinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/646	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Rociletinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/762	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/963	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/965	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/966	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Rociletinib,Osimertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/967	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1592	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1867	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Dacomitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2161	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Neratinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2162	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2163	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2164	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Canertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2165	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR T790M	Osimertinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6006	only alteration type		PAAD
WP306	EGFR MUT* (--)	EGFR T847I	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4260	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR V742A	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4197	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR V769_D770insASV	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1799	only alteration type		LUAD
WP306	EGFR MUT* (--)	EGFR V774A	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4226	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR V774M	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4231	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR V834I	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4248	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR V851I	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4264	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR Y764_V765insHH	Erlotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/4800	only alteration type		NSCLC
WP306	EGFR MUT* (--)	EGFR Amplification	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/854	only gene	498.0	COREAD
WP306	EGFR MUT* (--)	EGFR Amplification	Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/911	only gene		COREAD
WP306	EGFR MUT* (--)	EGFR Amplification	Platinum Compound,Cetuximab,Fluorouracil	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/691	only gene		HNSC
WP306	EGFR MUT* (--)	EGFR Amplification	Rociletinib,Osimertinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/3015	only gene		NSCLC
WP306	EGFR MUT* (--)	EGFR Amplification	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/948	only gene		NSCLC
WP306	EGFR MUT* (--)	EGFR Amplification	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/977	only gene		NSCLC
WP306	EGFR MUT* (--)	EGFR Amplification	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5924	only gene		NSCLC
WP306	EGFR MUT* (--)	EGFR Amplification	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5925	only gene		NSCLC
WP306	ERBB2 MUT* (L514M)	ERBB2 D769H	Lapatinib,Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/279	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 D769Y	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/280	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 G309A	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/282	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 G776L	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1889	only alteration type		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 G778_P780DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1890	only alteration type		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 G778_P780DUP	Dacomitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1892	only alteration type		NSCLC
WP306	ERBB2 MUT* (L514M)	ERBB2 L755S	Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/241	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 L755S	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/283	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 L755S	Fluorouracil,Trastuzumab,Leucovorin	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4955	only alteration type		COREAD
WP306	ERBB2 MUT* (L514M)	ERBB2 L755W	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/284	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 L755_T759del	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/281	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 M774DELINSWLV	Dacomitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1894	only alteration type		NSCLC
WP306	ERBB2 MUT* (L514M)	ERBB2 Mutation	Platinum Compound	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/1694	only alteration type		BLCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Mutation	Neratinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5338	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Mutation	Trastuzumab,Pertuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5980	only alteration type		NSCLC
WP306	ERBB2 MUT* (L514M)	ERBB2 P780INS	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/285	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 P780INS	Dacomitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1048	only alteration type		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 R678Q	Lapatinib,Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/286	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 R896C	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/287	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 T798I	Osimertinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6174	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 V777L	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/288	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 V842I	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/289	only alteration type		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Y772_A775DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1045	only alteration type		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 Y772_A775DUP	Trastuzumab Emtansine	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1125	only alteration type		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 Y772_A775DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1888	only alteration type		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 Y772_A775DUP	Sirolimus,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/960	only alteration type		NSCLC
WP306	ERBB2 MUT* (L514M)	ERBB2 Y772_A775DUP	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1893	only alteration type		NSCLC
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/5982	only gene		BLCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/528	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/529	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	AKTi-1/2	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/760	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Neratinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/761	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Afatinib,Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/887	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/961	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1006	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1007	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1008	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1009	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1011	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1012	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Afatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1013	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Pertuzumab,Docetaxel,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1077	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Neratinib,Trastuzumab	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/1113	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/1122	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Lapatinib,Capecitabine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1132	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab,Capecitabine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1133	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1159	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1160	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1380	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	A66	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1381	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Tgx 221	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1382	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1432	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab,Docetaxel,Pertuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1437	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1439	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Pilaralisib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1448	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Palbociclib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1561	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1613	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1764	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2071	only gene		BRCA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab,Pertuzumab	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7638	only gene		CH
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Capecitabine,Cetuximab,Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/895	only gene		COREAD
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1686	only gene		COREAD
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1687	only gene		COREAD
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1688	only gene		COREAD
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1993	only gene		COREAD
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab,Lapatinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1689	only gene		COREAD
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5981	only gene		COREAD
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7302	only gene		COREAD
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Afatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7807	only gene		COREAD
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/1098	only gene		ED
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1393	only gene		LUAD
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1041	only gene		NSCLC
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1042	only gene		NSCLC
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab Emtansine	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1050	only gene		NSCLC
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1891	only gene		NSCLC
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Pancreas	Responsive	B	NO	https://civicdb.org/links/evidence_items/5985	only gene		PA
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Afatinib	Pancreas adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/962	only gene		PAAD
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab,Irinotecan	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1044	only gene		SCLC
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Salivary glands	Responsive	B	NO	https://civicdb.org/links/evidence_items/5984	only gene		SG
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/1022	only gene		ST
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Lapatinib	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/1023	only gene		ST
WP306	ERBB2 MUT* (L514M)	ERBB2 Amplification	Trastuzumab	Stomach	Responsive	A	NO	https://civicdb.org/links/evidence_items/1499	only gene		ST
WP306	ERBB3 MUT* (P845), ERBB3 MUT* (P1247)	ERBB3 V855A	Pertuzumab,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1845	only alteration type		NSCLC
WP306	ERBB4 (G223V), ERBB4 (G223*), ERBB4 (--)	ERBB4 Mutation	Lapatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/770	complete		CM
WP306	FBXW7 (V375)	FBXW7 Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/718	complete		COREAD
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 FGFR1OP2::FGFR1	Ponatinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7380	only gene		AML
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 Fusion	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7375	only gene		AML
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 N546K	Pemigatinib	Pilocityc astrocytoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/10325	only alteration type		PIA
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 ZNF198::FGFR1	Midostaurin	Malignant peripheral nerve sheat tumor	Responsive	C	NO	https://civicdb.org/links/evidence_items/1104	only gene		MPN
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 Amplification	Infigratinib	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/1911	only gene		BLCA
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 Amplification	Afimoxifene	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1105	only gene		BRCA
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 Amplification	Infigratinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1909	only gene		BRCA
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 Amplification	Dovitinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1604	only gene		BRCA
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 Amplification	FGFR Inhibitor AZD4547	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1991	only gene		BRCA
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 Amplification	Pazopanib	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7246	only gene		BRCA
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 Amplification	Lucitanib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7488	only gene		BRCA
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 Amplification	PD173074	Lung squamous cell	Responsive	D	NO	https://civicdb.org/links/evidence_items/680	only gene		LUSC
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 Amplification	Infigratinib	Lung squamous cell	Responsive	B	NO	https://civicdb.org/links/evidence_items/1908	only gene		LUSC
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 Amplification	PD173074	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/686	only gene		NSCLC
WP306	FGFR1 MUT* (I591), FGFR1 (G512D), FGFR1 MUT* (--)	FGFR1 Amplification	Dovitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3027	only gene		NSCLC
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 FGFR2::AHCYL1	Infigratinib,PD173074	Cholangiocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1853	only gene		CH
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 FGFR2::BICC1	PD173074,Infigratinib	Cholangiocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1851	only gene		CH
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 FGFR2::BICC1	Erdafitinib	Endometrium	Responsive	C	NO	https://civicdb.org/links/evidence_items/1920	only gene		ED
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 FGFR2::MGEA5	Ponatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/295	only gene		CH
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 FGFR2::TACC3	Pazopanib,Ponatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/296	only gene		CH
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 Fusion	Infigratinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1913	only gene		CH
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 Fusion	Infigratinib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5908	only gene		CH
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 Fusion	Derazantinib	Intrahepatic cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7329	only gene		IHCH
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 Mutation	Infigratinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1912	only alteration type		CH
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 Mutation	Infigratinib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5912	only alteration type		CH
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 Mutation	Ponatinib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1236	only alteration type		ED
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 N550K	PD173074	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1322	only alteration type		ED
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 P253R	Pazopanib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/7833	only alteration type		HNSC
WP306	FGFR2 MUT* (--), FGFR2 MUT* (S148I)	FGFR2 Amplification	Dovitinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1605	only gene		BRCA
WP306	FGFR3 (D280E), FGFR3 MUT* (E362*), FGFR3 MUT* (A491), FGFR3 MUT* (P587)	FGFR3 FGFR3::BAIAP2L1	PD173074	Bladder	Responsive	D	NO	https://civicdb.org/links/evidence_items/144	only gene		BLCA
WP306	FGFR3 (D280E)	FGFR3 Mutation	Infigratinib	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/1910	complete		BLCA
WP306	FGFR3 (D280E)	FGFR3 Mutation	Cisplatin,Gemcitabine	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/7566	complete		BLCA
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835	Quizartinib,Ponatinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1036	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835	SU5614	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1037	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835	Quizartinib,Sorafenib	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/1038	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835	Sorafenib	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/1039	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835H	Sorafenib	Acute myeloid leukemia	Resistant	C	YES	https://civicdb.org/links/evidence_items/1556	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835H	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8517	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835H/Y	Sorafenib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1557	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835I	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8351	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835V	Tandutinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/3007	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835V	Sunitinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3008	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835V	Sunitinib,Cytarabine	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3009	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835V	Daunorubicin,Sunitinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3010	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835V	Quizartinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3012	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835V	AS602868,Tyrphostin AG 1296	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3034	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835V	Sunitinib	Acute myeloid leukemia	Responsive	C	YES	https://civicdb.org/links/evidence_items/4022	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835V	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8518	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 D835Y	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8108	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 F691L	Lestaurtinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8341	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 F691L	Midostaurin	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8342	only alteration type		AML
WP306	FLT3 (G533C)	FLT3 Mutation	Midostaurin	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/5261	complete		AML
WP306	FLT3 (G533C)	FLT3 Mutation	Gilteritinib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/7283	complete		AML
WP306	FLT3 (G533C)	FLT3 Mutation	Gilteritinib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/7728	complete		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 Y842C	FLT3/ABL/Aurora Kinase Inhibitor KW-2449	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8336	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 Y842C	Sorafenib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8337	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 Y842C	Sunitinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8338	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 Y842C	Quizartinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8654	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 Y842C	Lestaurtinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8339	only alteration type		AML
WP306	FLT3 MUT* (--), FLT3 MUT* (--), FLT3 (G533C)	FLT3 Y842C	Midostaurin	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8340	only alteration type		AML
WP306	GNA11 MUT* (T169), GNA11 MUT* (--)	GNA11 Mutation	JQ1	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1211	only alteration type		UVM
WP306	GNA11 MUT* (T169), GNA11 MUT* (--)	GNA11 Mutation	Trametinib	Uveal melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1228	only alteration type		UVM
WP306	GNA11 MUT* (T169), GNA11 MUT* (--)	GNA11 Mutation	Sotrastaurin Acetate,Mirdametinib	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1952	only alteration type		UVM
WP306	GNA11 MUT* (T169), GNA11 MUT* (--)	GNA11 Mutation	Cabozantinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3049	only alteration type		UVM
WP306	GNA11 MUT* (T169), GNA11 MUT* (--)	GNA11 Q209	Selumetinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1212	only alteration type		UVM
WP306	GNAS MUT* (T407), GNAS MUT* (R646I), GNAS (Q838H)	GNAS R201C	Cetuximab,Vemurafenib,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1906	only alteration type		COREAD
WP306	IDH1 MUT* (G402V)	IDH1 Mutation	Ivosidenib	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/7278	only alteration type		AML
WP306	IDH1 MUT* (G402V)	IDH1 Mutation	Venetoclax	Acute myeloid leukemia	Responsive	C	YES	https://civicdb.org/links/evidence_items/8856	only alteration type		AML
WP306	IDH1 MUT* (G402V)	IDH1 Mutation	Ivosidenib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7447	only alteration type		CH
WP306	IDH1 MUT* (G402V)	IDH1 R132	Ivosidenib	Cholangiocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/10886	only alteration type		CH
WP306	IDH1 MUT* (G402V)	IDH1 R132	Dasatinib	Intrahepatic cholangiocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6439	only alteration type		IHCH
WP306	IDH1 MUT* (G402V)	IDH1 R132C	GSK321	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/732	only alteration type		AML
WP306	IDH1 MUT* (G402V)	IDH1 R132C	Ivosidenib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/2331	only alteration type		AML
WP306	IDH1 MUT* (G402V)	IDH1 R132C	BPTES	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/2332	only alteration type		AML
WP306	JAK1 (L910M), JAK1 MUT* (--)	JAK1 S703I	Ruxolitinib	Hepatic carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1900	only alteration type		HC
WP306	JAK2 (V617F)	JAK2 Splice Site (c.1641+2T>G)	Pembrolizumab	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4825	only alteration type		CM
WP306	KDR (P694T), KDR MUT* (R275), KDR MUT* (--)	KDR R1032Q	Cabozantinib,Dovitinib,Axitinib,Lenvatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/9339	only alteration type		COREAD
WP306	KDR (P694T), KDR MUT* (R275), KDR MUT* (--)	KDR R961W	Regorafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1191	only alteration type	775.0	COREAD
WP306	KIT MUT* (--), KIT MUT* (--)	KIT A502_Y503insAY	Regorafenib,Imatinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4630	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT A502_Y503insAY	Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/7392	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT A829P	Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7413	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT A829P	Sunitinib,Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7415	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT C809G	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2920	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT D579del	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4142	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT D816E	Sunitinib,Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4631	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT D816E	Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7401	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT D816H	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2923	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT D816V	Midostaurin	Systemic mastocytosis	Responsive	B	YES	https://civicdb.org/links/evidence_items/1725	only alteration type		SM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT D820A	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2921	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT D820G	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2922	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT D820Y	Imatinib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2886	only alteration type		CM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT D820Y	Sunitinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2888	only alteration type		CM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT D820Y	Regorafenib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/4589	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT K550_K558del	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4062	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT K550_W557del	Ponatinib,Regorafenib,Imatinib,Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4583	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT K558delinsNP	Imatinib,Regorafenib,Sunitinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4594	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT K642E	Dasatinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4147	only alteration type		CM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT K642E	Sunitinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/7397	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT L576P	Nilotinib,Sorafenib,Imatinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/34	only alteration type		CM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT L576P	Dasatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/42	only alteration type		CM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT L576P	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4136	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT L576P	Nilotinib,Dasatinib,Imatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/303	only alteration type		NSCLC
WP306	KIT MUT* (--), KIT MUT* (--)	KIT Mutation	Imatinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1222	only alteration type		CM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT Mutation	Pictilisib,Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/919	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT N822K	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7370	only alteration type		AML
WP306	KIT MUT* (--), KIT MUT* (--)	KIT N822K	Ponatinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7379	only alteration type		AML
WP306	KIT MUT* (--), KIT MUT* (--)	KIT N822K	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2918	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT N822K	Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4167	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT N822K	Regorafenib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4169	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT N822K	Sunitinib,Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7414	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT N822K	Regorafenib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/4595	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT S628N	Imatinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7463	only alteration type		CM
WP306	KIT MUT* (--), KIT MUT* (--)	KIT T670I	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2924	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT T670I	Regorafenib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4510	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT T670I	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7416	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT T670I	Sunitinib,Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7417	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT V559D	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/3028	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT V559D	Imatinib,Regorafenib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4459	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT V560D	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4122	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT V560D	Regorafenib,Ponatinib,Imatinib,Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4127	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT V560G	Ponatinib,Regorafenib,Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/7395	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT V654A	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/249	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT V654A	Sunitinib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/304	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT W557_K558del	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4082	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT W557_K558del	Imatinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4084	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT W557_K558del	Regorafenib,Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4087	only alteration type		GIST
WP306	KIT MUT* (--), KIT MUT* (--)	KIT Y823D	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2919	only alteration type		GIST
WP306	KMT2C MUT* (--), KMT2C (A4099S), KMT2C (A3222S), KMT2C MUT* (R1349), KMT2C MUT* (E765G), KMT2C (R444L)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP306	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP306	MAP2K1 MUT* (--)	MAP2K1 C121S	Vemurafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1602	only alteration type		CM
WP306	MAP2K1 MUT* (--)	MAP2K1 K57N	Selumetinib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2936	only alteration type		LUAD
WP306	MAP2K1 MUT* (--)	MAP2K1 P124S	Selumetinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/12	only alteration type		CM
WP306	MAP2K1 MUT* (--)	MAP2K1 Q56P	Selumetinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/13	only alteration type		CM
WP306	MAPK1 MUT* (R50)	MAPK1 E322K	Erlotinib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/791	only alteration type		HNSC
WP306	MAPK1 MUT* (R50)	MAPK1 Amplification	WZ4002	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/792	only gene		NSCLC
WP306	MRE11 MUT* (--)	MRE11 Loss	Talazoparib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/876	only gene		ED
WP306	MS4A1 MUT* (M119I), MS4A1 MUT* (--)	MS4A1 Mutation	R-CHOP Regimen	Difuse large B Cell lymphoma	Resistant	B	YES	https://civicdb.org/links/evidence_items/10367	only alteration type		DLBCL
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR A2034V	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1547	only alteration type		BRCA
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR A2034V	RapaLink-1,MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1548	only alteration type		BRCA
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR E1799K	Sirolimus	Renal clear cell	Responsive	D	NO	https://civicdb.org/links/evidence_items/1321	only alteration type		RCCC
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR F2108L	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1543	only alteration type		BRCA
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR F2108L	Everolimus	Thyroid carcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1110	only alteration type		THCA
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR H1968Y	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/713	only alteration type		CM
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR M2327I	MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1544	only alteration type		BRCA
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR M2327I	Sirolimus,RapaLink-1	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1545	only alteration type		BRCA
WP306	MTOR (R2368L)	MTOR Mutation	Everolimus,Pazopanib	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/705	complete		BLCA
WP306	MTOR MUT* (--), MTOR (R2368L), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (--), MTOR MUT* (E617D), MTOR MUT* (--)	MTOR P2213S	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/722	only alteration type		CM
WP306	MYCN MUT* (E459*)	MYCN Amplification	FACT Complex-targeting Curaxin CBL0137	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/744	only gene		NB
WP306	MYCN MUT* (E459*)	MYCN Amplification	Panobinostat,JQ1	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6019	only gene		NB
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 K159fs	Temsirolimus	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/715	only alteration type		BRCA
WP306	NF2 MUT* (--), NF2 MUT* (--), NF2 MUT* (L109), NF2 (Q111K), NF2 MUT* (A367S), NF2 MUT* (E474D)	NF2 Loss	Selumetinib	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1742	only gene		THCA
WP306	NOTCH1 (A2043S), NOTCH1 MUT* (S1891R), NOTCH1 MUT* (D932Y), NOTCH1 MUT* (--), NOTCH1 MUT* (P480H), NOTCH1 MUT* (R217), NOTCH1 MUT* (--)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP306	NPM1 MUT* (D178Y)	NPM1 W288FS	NSC348884	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/152	only alteration type		AML
WP306	NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP306	NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP306	NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 Fusion	Larotrectinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/978	only gene		COREAD
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 Fusion	Larotrectinib,Lestaurtinib,Crizotinib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1019	only gene		LUAD
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 Fusion	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/6567	only gene		SOLID
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 Fusion	Entrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/11124	only gene		SOLID
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 LMNA::NTRK1	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2960	only gene		COREAD
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 LMNA::NTRK1	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/8900	only gene		COREAD
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 SQSTM1::NTRK1	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1868	only gene		NSCLC
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 SQSTM1::NTRK1	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2950	only gene		NSCLC
WP306	NTRK1 MUT* (--), NTRK1 MUT* (--)	NTRK1 Amplification	Larotrectinib	Solid tumors	Responsive	C	NO	https://civicdb.org/links/evidence_items/10170	only gene		SOLID
WP306	NTRK2 MUT* (--)	NTRK2 ETV6::NTRK2	Larotrectinib	Acute myeloid leukemia	Responsive	C	YES	https://civicdb.org/links/evidence_items/6396	only gene		AML
WP306	NTRK2 MUT* (--)	NTRK2 Fusion	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/10392	only gene		SOLID
WP306	NTRK2 MUT* (--)	NTRK2 Fusion	Entrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/11222	only gene		SOLID
WP306	NTRK2 MUT* (--)	NTRK2 KANK1::NTRK2	Larotrectinib	Glioblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/10361	only gene		GB
WP306	NTRK3 MUT* (V273), NTRK3 MUT* (--)	NTRK3 EML4::NTRK3	Entrectinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11099	only gene		LUAD
WP306	NTRK3 MUT* (V273), NTRK3 MUT* (--)	NTRK3 EML4::NTRK3	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/10636	only gene		NSCLC
WP306	NTRK3 MUT* (V273), NTRK3 MUT* (--)	NTRK3 ETV6::NTRK3	Entrectinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7994	only gene		AML
WP306	NTRK3 MUT* (V273), NTRK3 MUT* (--)	NTRK3 ETV6::NTRK3	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/7496	only gene		SOLID
WP306	NTRK3 MUT* (V273), NTRK3 MUT* (--)	NTRK3 F617L	Larotrectinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/9592	only alteration type		GIST
WP306	NTRK3 MUT* (V273), NTRK3 MUT* (--)	NTRK3 Fusion	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/6568	only gene		SOLID
WP306	NTRK3 MUT* (V273), NTRK3 MUT* (--)	NTRK3 Fusion	Entrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/11125	only gene		SOLID
WP306	PALB2 MUT* (--), PALB2 MUT* (--)	PALB2 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8504	only alteration type		PRAD
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA D842I	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/43	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/15	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/16	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/651	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/738	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2478	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA D842V	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4597	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA D842V	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/44	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA D842Y	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/45	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA D842_I843delinsVM	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/47	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA FIP1L1::PDGFRA	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7378	only gene		AML
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA G853D	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1977	only alteration type		CM
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA H845Y	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1976	only alteration type		CM
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA I843DEL	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/46	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA I843DEL	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1309	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA Mutation	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2487	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA P577S	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1974	only alteration type		CM
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA R841K	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1975	only alteration type		CM
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA V561A	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/652	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA V561D	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2474	only alteration type		GIST
WP306	PDGFRA MUT* (L532), PDGFRA MUT* (--)	PDGFRA Amplification	Sunitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1771	only gene		NSCLC
WP306	PDGFRB MUT* (--), PDGFRB MUT* (--), PDGFRB MUT* (R113L), PDGFRB MUT* (--)	PDGFRB Fusion	Imatinib	Malignant peripheral nerve sheat tumor	Responsive	A	NO	https://civicdb.org/links/evidence_items/1498	only gene		MPN
WP306	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP306	PIK3R1 MUT* (--)	PIK3R1 Mutation	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1612	only alteration type		BRCA
WP306	POLD1 MUT* (--), POLD1 (S370I), POLD1 MUT* (R507), POLD1 MUT* (--), POLD1 MUT* (V866), POLD1 MUT* (--)	POLD1 C284Y	Pembrolizumab	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4776	only alteration type		LUAD
WP306	POLD1 MUT* (--), POLD1 (S370I), POLD1 MUT* (R507), POLD1 MUT* (--), POLD1 MUT* (V866), POLD1 MUT* (--)	POLD1 E374K	Pembrolizumab	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4777	only alteration type		NSCLC
WP306	POLE (A1814V), POLE (W1685C)	POLE Mutation	Pembrolizumab	Endometrium	Responsive	C	NO	https://civicdb.org/links/evidence_items/1862	complete		ED
WP306	PPP2R2A MUT* (--)	PPP2R2A Mutation	Olaparib	Prostate adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/11206	only alteration type		PRAD
WP306	PREX2 (S734I), PREX2 (A857D), PREX2 (C1111*)	PREX2 R172I	Vemurafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6268	only alteration type		CM
WP306	PTPRD MUT* (G1852*), PTPRD MUT* (--), PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP306	RAD51B MUT* (--)	RAD51B Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11212	only alteration type		PRAD
WP306	RAD54L MUT* (--), RAD54L MUT* (R380), RAD54L MUT* (--)	RAD54L Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11207	only alteration type		PRAD
WP306	RB1 MUT* (--), RB1 MUT* (--)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET CCDC6::RET	Agerafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7480	only gene		COREAD
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET CCDC6::RET	Nintedanib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1601	only gene		NSCLC
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET Fusion	Cabozantinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4847	only gene		LUAD
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4848	only gene		NSCLC
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4849	only gene		NSCLC
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4850	only gene		NSCLC
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7066	only gene		NSCLC
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/8850	only gene		NSCLC
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET Fusion	Pralsetinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11233	only gene		NSCLC
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET Fusion	Selpercatinib	Thyroid carcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8852	only gene		THCA
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET KIF5B::RET	Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/698	only gene		LUAD
WP306	RET MUT* (--), RET MUT* (--), RET MUT* (--)	RET KIF5B::RET	Vandetanib,Everolimus	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1622	only gene		LUAD
WP306	RICTOR MUT* (--), RICTOR MUT* (--), RICTOR MUT* (--), RICTOR MUT* (--)	RICTOR Amplification	Onatasertib,Sapanisertib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1440	only gene		LUAD
WP306	RICTOR MUT* (--), RICTOR MUT* (--), RICTOR MUT* (--), RICTOR MUT* (--)	RICTOR Amplification	Vistusertib	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7449	only gene		SCLC
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 Rearrangement	Ceritinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1248	only gene		LUAD
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 Rearrangement	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1690	only gene		LUAD
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/688	only gene		NSCLC
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1030	only gene		NSCLC
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7933	only gene		NSCLC
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 FUSIONS	Entrectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11123	only gene		NSCLC
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7282	only gene		NSCLC
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 G2032R	Crizotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2934	only alteration type		LUAD
WP306	ROS1 MUT* (--), ROS1 (P659H), ROS1 MUT* (L158M)	ROS1 GOPC::ROS1	Lorlatinib	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7483	only gene		GB
WP306	RSF1 MUT* (G1045V), RSF1 MUT* (D170Y), RSF1 MUT* (D147Y)	RSF1 Amplification	Tamoxifen	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/857	only gene		BRCA
WP306	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP306	SF3B1 (G439C), SF3B1 (T296N), SF3B1 MUT* (E295*)	SF3B1 K666N	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1418	only alteration type		BRCA
WP306	SF3B1 (G439C), SF3B1 (T296N), SF3B1 MUT* (E295*)	SF3B1 K700E	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1417	only alteration type		BRCA
WP306	SMARCA4 MUT* (--), SMARCA4 MUT* (P49Q), SMARCA4 (Q822K), SMARCA4 (Q1596H)	SMARCA4 Loss	Abemaciclib,Palbociclib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/7155	only gene		NSCLC
WP306	SMO MUT* (R151), SMO MUT* (G214), SMO MUT* (--)	SMO D473H	Vismodegib	Basal cell carcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/755	only alteration type		BCC
WP306	SMO MUT* (R151), SMO MUT* (G214), SMO MUT* (--)	SMO L412F	Vismodegib	Basal cell carcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4653	only alteration type		BCC
WP306	SMO MUT* (R151), SMO MUT* (G214), SMO MUT* (--)	SMO L412F	Vismodegib	Basal cell carcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4654	only alteration type		BCC
WP306	SMO MUT* (R151), SMO MUT* (G214), SMO MUT* (--)	SMO Mutation	Vismodegib	Basal cell carcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/746	only alteration type		BCC
WP306	SMO MUT* (R151), SMO MUT* (G214), SMO MUT* (--)	SMO Mutation	Vismodegib,Sonidegib	Basal cell carcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1477	only alteration type		BCC
WP306	SMO MUT* (R151), SMO MUT* (G214), SMO MUT* (--)	SMO Mutation	PSI,Arsenic Trioxide	Basal cell carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/747	only alteration type		BCC
WP306	SOX10 MUT* (--), SOX10 MUT* (H164Y), SOX10 MUT* (R161S)	SOX10 Loss	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1710	only gene		CM
WP306	STK11 MUT* (--), STK11 MUT* (--)	STK11 Mutation	Pembrolizumab,Nivolumab,Atezolizumab	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6441	only alteration type		LUAD
WP306	STK11 MUT* (--), STK11 MUT* (--)	STK11 Loss	Selumetinib,Docetaxel	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1144	only gene		NSCLC
WP306	STK11 MUT* (--), STK11 MUT* (--)	STK11 Loss	Everolimus,Sirolimus	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1620	only gene		NSCLC
WP306	TOP1 MUT* (--), TOP1 MUT* (--)	TOP1 Amplification	Irinotecan	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/888	only gene		COREAD
WP306	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP306	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP306	TSC2 MUT* (A224), TSC2 (W304C), TSC2 (G402V)	TSC2 Q1178*	Everolimus	Thyroid carcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1108	only alteration type		THCA
WP160	ABL1 MUT* (L298)	ABL1-BCR fusion	Bosutinib(BCR-ABL inhibitor  3rd gen)	Chronic myeloid leukemia	Responsive	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s024lbl.pdf	only gene		CML
WP160	ABL1 MUT* (L298)	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	Bosutinib(BCR-ABL inhibitor  3rd gen)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP160	ABL1 MUT* (L298)	ABL1-BCR fusion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf	only gene		CML, ALL
WP160	ABL1 MUT* (L298)	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP160	ABL1 MUT* (L298)	ABL1-BCR fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	EMA	only gene		CML, ALL
WP160	ABL1 MUT* (L298)	ABL1-BCR fusion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia	Responsive	A	YES	FDA	only gene		CML
WP160	ABL1 MUT* (L298)	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP160	ABL1 MUT* (L298)	ABL1-BCR fusion	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	FDA	only gene		CML, ALL
WP160	ABL1 MUT* (L298)	ABL1 (T315I)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	FDA	only alteration type		CML, ALL
WP160	ABL1 MUT* (L298)	ABL1 (T315I)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP160	ALK MUT* (G922)	ALK fusion	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	FDA	only gene		LUAD
WP160	ALK MUT* (G922)	ALK fusion	Alectinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK inframe insertion (1151T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165	only alteration type		LUAD
WP160	ALK MUT* (G922)	ALK (L1196M,S1206Y,G1269A,I1171T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165;PMID:24327273	only alteration type		LUAD
WP160	ALK MUT* (G922)	ALK fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK fusion	Brigatinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc	only gene		NSCLC
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890	complete		PRAD
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	complete		OV
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	complete		OV
WP160	DNMT3A (-848-849X), DNMT3A (V311L)	DNMT3A oncogenic mutation	Daunorubicin(Chemotherapy)	Acute myeloid leukemia	Responsive	A	YES	PMID:22417203	complete		AML
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Ado-Trastuzumab Emtansine(EGFR mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor);Capecitabine(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s023lbl.pdf;PMID:17192538	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf	only gene		ST, GEJA
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf	only gene		BRCA
WP160	ABL1 MUT* (L298)	ABL1 (T315I)	BCR-ABL inhibitor 2nd gens(Nilotinib,Dasatinib,etc)	Chronic myeloid leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML
WP160	ABL1 MUT* (L298)	ABL1 (T315I)	Bosutinib(BCR-ABL inhibitor  3rd gen)	Chronic myeloid leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML
WP160	G6PD MUT* (II35-36IF)	G6PD biallelic inactivation	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP160	G6PD MUT* (II35-36IF)	G6PD (S218F)	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP160	G6PD MUT* (II35-36IF), G6PD MUT* (II35-36IF)	G6PD (V98M) + G6PD (N156D)	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP160	ABL1 MUT* (L298)	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML, ALL
WP160	ABL1 MUT* (L298)	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Chronic myeloid leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML
WP160	ABL1 MUT* (L298)	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Resistant	A	YES	NCCN Guidelines Chronic Myeloid Leukemia 2022;NCCN Guidelines Acute Lymphoblastic Leukemia 2022;PMID:21562040	only alteration type		CML, ALL
WP160	RET MUT* (--)	RET (618,620,634,768,791,891,918,C634W,M918T)	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	A	NO	PMID:20065189;PMID:22025146	only alteration type		THCA
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP160	TSC1 (R160L)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	complete		GCA
WP160	TSC1 (R160L)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	complete		RA
WP160	TSC2 MUT* (A1185S)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    , Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		RA, GCA
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Neratinib(ERBB2 inhibitor) + Capecitabine(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer;PMID:30860945	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 inhibitor)+ Trastuzumab(ERBB2 inhibitor) + Docetaxel(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor) + Letrozole(Hormone therapy)	Breast adenocarcinoma	Responsive	A	NO	FDA;PMID:19786658	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Margetuximab(ERBB2 inhibitor) 	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Tucatinib(ERBB2 inhibitor) + Trastuzumab(ERBB2 inhibitor) + Capecitabine(chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer;PMID:31825569	only gene		BRCA
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	complete		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022	only alteration type		BRCA
WP160	ABL1 MUT* (L298)	ABL1 (T315I,V299L,G250E,F317L)	Bosutinib(BCR-ABL inhibitor 3rd gen)	Acute lymphoblastic leukemia, Chronic myeloid leukemia	Resistant	A	YES	NCCN	only alteration type		ALL, CML
WP160	ABL1 MUT* (L298)	ABL1 (T315I)	Asciminib(Kinase inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia	only alteration type		CML
WP160	ABL1 MUT* (L298)	BCR-ABL1	Asciminib(Kinase inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215358s003lbl.pdf	only gene		CML
WP160	ABL1 MUT* (L298)	ABL1 (T315I)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Acute lymphoblastic leukemia	Resistant	A	YES	NCCN Guideline ALL 2022	only alteration type		ALL
WP160	ABL1 MUT* (L298)	ABL1 (E255V,Y253H,F359V)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf	only alteration type		CML
WP160	RET MUT* (--)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-ret-altered-thyroid-cancers;ASCO 2020 (abstr 109)	only gene		TH
WP160	RET MUT* (--)	RET oncogenic mutation	Selpercatinib(RET kinase inhibitor)	Thyroid medullary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only alteration type		THM
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	complete		OV
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	complete		OV
WP160	ALK MUT* (G922)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP160	CHEK1 MUT* (--)	CHEK1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	complete		PRAD
WP160	FGFR3 MUT* (--)	FGFR3 fusion	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only gene		BLCA
WP160	FGFR3 MUT* (--)	FGFR3 (G370C,R248C,S249C,Y373C)	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only alteration type		BLCA
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Pembrolizumab(PD-1 blocking antibody) + Trastuzumab(ERBB2 mAb inhibitor) + Fluoropyrimidine (Chemotherapy) + Platinum (Chemotherapy)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer;PMID:34912120	only gene		ST, GEJA
WP160	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP160	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Entrectinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA;PMID:28183697;ESMO 2019 (abstr 4178) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725s007lbl.pdf	only gene		NSCLC
WP160	ABL1 MUT* (L298)	ABL1 (T315I)	Bosutinib(BCR-ABL inhibitor 3rd gen)	Acute lymphoblastic leukemia	Resistant	A	YES	NCCN Guideline ALL 2022	only alteration type		ALL
WP160	NTRK1 MUT* (--)	NTRK1 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	NO	FDA:https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
WP160	NTRK1 MUT* (--)	NTRK1 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
WP160	RET MUT* (--)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions	only gene		NSCLC
WP160	RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-non-small-cell-lung	only gene		NSCLC
WP160	PALB2 MUT* (A587S)	PALB2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP160	RAD51C MUT* (G153)	RAD51C oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP160	RAD51D MUT* (A306S)	RAD51D oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP160	PIK3CA MUT* (--)	PIK3CA (C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R)	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas	only gene		ST, GEJA
WP160	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung	only alteration type		NSCLC
WP160	ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype	Tucatinib(ERBB2 inhibitor);Trastuzumab(ERBB2 inhibitor) 	Colorectal adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer	only gene		COREAD
WP160	ALK MUT* (G922)	ALK fusion	Crizotinib(ALK inhibitor)	Anaplastic large cell lymphoma	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large	only gene		ALCL
WP160	RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only gene		TH
WP160	RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Solid tumors	Responsive	A	NO	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors	only gene		SOLID
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	complete		PRAD
WP160	ATR MUT* (L2064I), ATR MUT* (--)	ATR oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	complete		PRAD
WP160	FANCA MUT* (--)	FANCA oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP160	MLH1 MUT* (--)	MLH1 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP160	PALB2 MUT* (A587S)	PALB2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP160	RAD51C MUT* (G153)	RAD51C oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-fam-trastuzumab-deruxtecan-nxki-breast-cancer	only gene		BRCA
WP160	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP160	BTK (E382Q), BTK MUT* (--)	BTK (C481S)	Ibrutinib(BTK inhibitor)	Chronic lymphocytic leukemia	Resistant	A	YES	PMID: 28418267	only alteration type		CLL
WP160	ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype + BRAF wildtype	Trastuzumab(ERBB2 mAb inhibitor) + Lapatinib(ERBB2 inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only gene		COREAD
WP160	NTRK1 MUT* (--)	NTRK1 (G595R)	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Resistant	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210861s008lbl.pdf	only alteration type		SOLID
WP160	ALK MUT* (G922)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf	only gene		BRCA
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 inhibitor) + Carboplatin-Taxol(Chemotherapy)	Uterus	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf	only gene		U
WP160	MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP160	MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP160	MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP160	MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP160	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP160	ABL1 MUT* (L298)	ABL1-BCR fusion	Bosutinib(BCR-ABL inhibitor  3rd gen)	Acute lymphoblastic leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/all.pdf	only gene		ALL
WP160	RET MUT* (--)	RET fusion	Cabozantinib(Kinase inhibitor )	Non-small cell lung	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP160	ABL1 MUT* (L298)	ABL1-BCR fusion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Acute lymphoblastic leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/all.pdf	only gene		ALL
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 inhibitor)+ Trastuzumab(ERBB2 inhibitor) 	Billiary tract	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf	only gene		BT
WP160	ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype + BRAF wildtype	Trastuzumab(ERBB2 mAb inhibitor) + Lapatinib(ERBB2 inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only gene		COREAD
WP160	ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype + BRAF wildtype	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only gene		COREAD
WP160	ALK MUT* (G922)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor	only gene		IM
WP160	ALK MUT* (G922)	ALK fusion	Alectinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP160	ALK MUT* (G922)	ALK fusion	Brigatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP160	ALK MUT* (G922)	ALK fusion	Ceritinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP160	ALK MUT* (G922)	ALK fusion	Lorlatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	complete		PAAD
WP160	PALB2 MUT* (A587S)	PALB2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 (Q79K,E17K)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265152	only alteration type		CM
WP160	ABL1 MUT* (L298)	ABL1 (T315I)	Axitinib(VEGFR inhibitor)	Any cancer type	Responsive	D	YES	PMID:25686603	only alteration type		CANCER
WP160	ABL1 MUT* (L298)	ABL1 (V299L)	Cabozantinib(Pan-kinase inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP160	ABL1 MUT* (L298)	ABL1 (V299L)	Crizotinib(ALK inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP160	ABL1 MUT* (L298)	ABL1-BCR fusion	Dasatinib + Venetoclax(BCR-ABL inhibitor 2nd gen + BCL2 inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:27582059	only gene		ALL
WP160	ABL1 MUT* (L298)	ABL1 (V299L)	ForetinibÂ (MET inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP160	ABL1 MUT* (L298)	ABL1 (V299L)	Vandetanib(Pan-TK inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 (E17K)	AKT inhibitors	Any cancer type	Responsive	D	YES	PMID:21464312;PMID:17611497;PMID:23134728; ENA 2015 (abstr B109)	only alteration type		CANCER
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 (E17K)	allosteric AKT inhibitors	Any cancer type	Responsive	C	YES	ENA 2015 (abstract B109);PMID:28489509	only alteration type		CANCER
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 (E17K)	non-allosteric AKT inhibitors	Any cancer type	Responsive	C	YES	ENA 2015 (abstract B109);PMID:28489509	only alteration type		CANCER
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 (E17K)	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26763254	only alteration type		HNSC
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 (H238Y)	Everolimus(MTOR inhibitor)	Fibrous histiocytoma	Responsive	C	NO	ASCO 2015 (abstr 11010)	only alteration type		FH
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 (E17K)	Tensirolimus(MTOR inhibitor)	Endometrium	Responsive	C	NO	PMID:27016228	only alteration type		ED
WP160	ALK MUT* (G922)	ALK fusion	ALK inhibitor + IGF1R inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25173427	only gene		LUAD
WP160	ALK MUT* (G922)	ALK fusion	ALK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:26301689	only gene		LUAD
WP160	ALK MUT* (G922)	ALK fusion	ALK inhibitor + SRC inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25394791	only gene		LUAD
WP160	ALK MUT* (G922)	ALK fusion	ALK inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560	only gene		COREAD
WP160	ALK MUT* (G922)	ALK fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23553849	only gene		LUAD
WP160	ALK MUT* (G922)	ALK fusion	novel ALK inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23639470	only gene		LUAD
WP160	ALK MUT* (G922)	ALK (F1174L)	novel ALK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24327273	only alteration type		LUAD
WP160	ALK MUT* (G922)	ALK amplification	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only gene		LUAD
WP160	ALK MUT* (G922)	ALK (E1408V)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP160	ALK MUT* (G922)	ALK (L1196M)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP160	ALK MUT* (G922)	ALK fusion	Ceritinib(ALK inhibitor)	Colorectal adenocarcinoma, Inflammatory myofibroblastic	Responsive	C	YES	PMID:26633560;PMID:26933125;PMID:27742657	only gene		COREAD, IM
WP160	ALK MUT* (G922)	ALK fusion	Ceritinib(ALK inhibitor)	Hematologic malignancies	Responsive	C	YES	NCT02186821	only gene		HEMATO
WP160	CTNNB1 MUT* (H267N)	CTNNB1 oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Resistant	D	NO	PMID:23539443	only alteration type		COREAD
WP160	ALK MUT* (G922)	ALK fusion	Crizotinib(ALK inhibitor)	Lymphoma, Glioblastoma	Responsive	C	YES	PMID:24491302;NCT02270034	only gene		LY, GB
WP160	ALK MUT* (G922)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic, Thyroid carcinoma	Responsive	C	YES	PMID:20979472;PMID:24687827	only gene		IM, THCA
WP160	ALK MUT* (G922)	ALK (F856S,A348D)	Crizotinib(ALK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:26032424	only alteration type		AML
WP160	ALK MUT* (G922)	ALK (L1198F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26698910	only alteration type		LUAD
WP160	ALK MUT* (G922)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib(ALK inhibitor)	Glioma	Responsive	D	NO	PMID:22072639	only alteration type		G
WP160	ALK MUT* (G922)	ALK fusion	Entrectinib(Pan-TK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560;PMID:26933125	only gene		COREAD
WP160	ALK MUT* (G922)	ALK (C1156Y)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27401242	only alteration type		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 amplification	EGFR inhibitors	Lung adenocarcinoma	Resistant	D	NO	PMID:22956644	only gene		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:22586653;PMID:23348520	only gene		COREAD
WP160	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	complete		CANCER
WP160	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	complete		OV
WP160	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	complete		CANCER
WP160	FGFR3 MUT* (--)	FGFR3 (V555M)	FGFR inhibitors	Myeloma	Resistant	D	YES	PMID:22869148	only alteration type		MYMA
WP160	ATR MUT* (L2064I), ATR MUT* (--)	ATR oncogenic mutation	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only alteration type		OV, CANCER
WP160	ATR MUT* (L2064I), ATR MUT* (--)	ATR deletion	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only gene		OV, CANCER
WP160	ATR MUT* (L2064I), ATR MUT* (--)	ATR oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	complete		OV
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	PARP inhibitors	Pancreas	Responsive	C	NO	PMID:25366685;PMID:25719666;PMID:19553641;PMID:25366685	complete		PA
WP160	BRCA1 MUT* (--), BRCA1 (R71M)	BRCA1 deletion	PARP inhibitors	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	C	YES	PMID:25964244	complete		CANCER
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467;PMID:25366685	complete		BRCA
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	complete		BRCA
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	complete		OV
WP160	BRCA1 (R71M)	BRCA1 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	complete		BRCA
WP160	CBL MUT* (--)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP160	CBL MUT* (--)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP160	CDKN1A MUT* (R9S)	CDKN1A oncogenic mutation	CDK2/4 inhibitors	Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22997239	only alteration type		CANCER
WP160	CDKN1A MUT* (R9S)	CDKN1A deletion	CDK2/4 inhibitors	Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22997239	only gene		CANCER
WP160	MAP2K2 MUT* (--)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP160	CTNNB1 MUT* (H267N)	CTNNB1 (H36Y,S37C,S37Y,D32V)	Everolimus + Letrozole(MTOR inhibitor + Hormonal therapy)	Endometrium	Responsive	C	NO	PMID:25624430	only alteration type		ED
WP160	MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP160	MAP2K2 MUT* (--)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP160	MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP160	NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP160	PIK3CA MUT* (--)	PIK3CA (E545*)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMC3936420	only alteration type		CM
WP160	PIK3CA MUT* (--)	PIK3CA amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	D	NO	PMID:24366379	only gene		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9054)	only alteration type		L
WP160	EPHA2 MUT* (--)	EPHA2 (G391R)	MTOR inhibitors	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
WP160	EPHA2 MUT* (--)	EPHA2 (G391R)	MTOR inhibitors	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
WP160	EPHA2 MUT* (--)	EPHA2 amplification	Dasatinib(BCR-ABL inhibitor 2nd gen)	Any cancer type	Responsive	D	YES	PMID:18047674;PMID:19010823;PMID:19861960	only gene		CANCER
WP160	EPHA2 MUT* (--)	EPHA2 amplification	Dasatinib(BCR-ABL inhibitor 2nd gen)	Any cancer type	Responsive	D	YES	PMID:18047674;PMID:19010823;PMID:19861960	only gene		CANCER
WP160	EPHA2 MUT* (--)	EPHA2 (G391R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
WP160	EPHA2 MUT* (--)	EPHA2 (G391R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
WP160	ERBB2 MUT* (--)	ERBB2 amplification	ERBB2 inhibitor + CDK4/6 inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26977878	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 proximal exon 20	ERBB2 inhibitors(Afatinib,Lapatinib,Neratinib,etc)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547	only alteration type		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 proximal exon 20	ERBB2 mAb inhibitors(Trastuzumab,etc)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547	only alteration type		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 inframe insertion (A775YVMA),inframe insertion (G776VC)	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 8510)	only alteration type		L
WP160	ERBB2 MUT* (--)	ERBB2 (V659E,S310F)	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 8510)	only alteration type		L
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Stomach	Responsive	C	NO	AACR 2014 (abstr CT228)	only gene		ST
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Breast adenocarcinoma	Responsive	B	NO	PMID:20142587;PMID:22418700;PMID:23632474	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	PMID:27044931	only gene		BLCA
WP160	ERBB2 MUT* (--)	ERBB2 proximal exon 20	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 (T798I)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Breast adenocarcinoma	Responsive	D	NO	PMID:28274957	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Dacomitinib(Pan ERBB inhibitor)	Non-small cell lung	Responsive	C	NO	PMID:25899785	only alteration type		NSCLC
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
WP160	ERBB2 MUT* (--)	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 (V659E)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma, Lung adenocarcinoma	Responsive	C	NO	PMID:23950206	only alteration type		BRCA, LUAD
WP160	ERBB2 MUT* (--)	ERBB2 proximal exon 20	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib + Chemotherapy(ERBB2 inhibitor + Chemotherapy)	Stomach	Responsive	C	NO	PMID:25694417;NCT02015169	only gene		ST
WP160	ERBB2 MUT* (--)	ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Neratinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ESMO 2014 (abstr LBA39_PR)	only alteration type		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 (K753E)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:27697991	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 proximal exon 20	Neratinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 (L869R)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	C	NO	PMID:28274957	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 (S310,L755,V777)	Neratinib(ERBB2 inhibitor)	Any cancer type	Responsive	C	YES	AACR 2017 (abstr CT001)	only alteration type		CANCER
WP160	ERBB2 MUT* (--)	ERBB2 inframe insertion (P780GSP),inframe insertion (781GSP),inframe insertion (A775YVMA),inframe insertion (G776YVMA)	Neratinib(ERBB2 inhibitor)	Any cancer type	Responsive	C	YES	AACR 2017 (abstr CT001)	only alteration type		CANCER
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Stomach	Responsive	C	NO	PMID:24960402	only gene		ST
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
WP160	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Tensirolimus(MTOR inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ESMO 2014 (abstr LBA39_PR)	only alteration type		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Head an neck	Responsive	C	NO	PMID:21380780	only gene		HNC
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Ovary	Responsive	C	NO	PMID:20003286;PMID:12525520	only gene		OV
WP160	ERBB2 MUT* (--)	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma, Any cancer type	Responsive	D	YES	PMID:23220880;PMID:22908275	only alteration type		BRCA, CANCER
WP160	ERBB2 MUT* (--)	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	Trastuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:22908275	only alteration type		CANCER
WP160	ERBB2 MUT* (--)	ERBB2 (G776L)	Trastuzumab(ERBB2 mAb inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:16775247	only alteration type		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 proximal exon 20	Trastuzumab(ERBB2 mAb inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	http://ascopubs.org/doi/full/10.1200/PO.16.00055	only gene		COREAD
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab + Everolimus + Chemotherapy(ERBB2 mAb inhibitor + MTOR inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:21107682;PMID:20975068	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab + HSP90 inhibitor(ERBB2 mAb inhibitor + HSP90 inhibitor)	Breast adenocarcinoma	Responsive	C	NO	PMID:21558407	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab + Lapatinib(ERBB2 mAb inhibitor + ERBB2 inhibitor)	Endometrium	Responsive	D	NO	PMID:25294905	only gene		ED
WP160	ERBB4 MUT* (--), ERBB4 MUT* (--)	ERBB4 (E317K,E452K,R544W,R393W,E872K)	Lapatinib(ERBB2 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:19718025	only alteration type		CM
WP160	ERBB4 MUT* (--), ERBB4 MUT* (--)	ERBB4 fusion	Lapatinib + Afatinib(ERBB2 inhibitor + ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP160	ERCC2 (D500E)	ERCC2 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:25096233	complete		BLCA
WP160	ERCC4 (E814*)	ERCC4 oncogenic mutation	Cisplatin(Chemotherapy)	Ovary	Responsive	D	NO	PMID:25634215	complete		OV
WP160	ERCC6 MUT* (L923M)	ERCC6 oncogenic mutation	Cisplatin(Chemotherapy)	Ovary	Responsive	D	NO	PMID:25634215	only alteration type		OV
WP160	NTRK1 MUT* (--)	NTRK1 (G595R,G667C)	Pan-TK inhibitors(Entrectinib,etc)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:26546295	only alteration type		COREAD
WP160	ERBB4 MUT* (--), ERBB4 MUT* (--)	ERBB4 (H809G)	ERBB2 inhibitors(Lapatinib,etc)	Breast adenocarcinoma	Resistant	C	NO	PMID:26530965	only alteration type		BRCA
WP160	FANCA MUT* (--)	FANCA oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP160	FANCA MUT* (--)	FANCA deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only gene		PRAD
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Lung squamous cell	Responsive	C	NO	PMID:27870574	only gene		LUSC
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Endometrium	Responsive	C	NO	ASCO 2017 (abstr 2500)	only gene		ED
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Lung squamous cell	Responsive	C	NO	AACR 2012 (abstr LB-122);AACR 2013 (abstr LB-145)	only gene		LUSC
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Head an neck	Responsive	D	NO	PMID:23418312	only gene		HNC
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors(Lucitanib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:25193991	only gene		BRCA
WP160	ALK MUT* (G922)	ALK (I1171T)	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:25228534	only alteration type		LUAD
WP160	FGFR3 MUT* (--)	FGFR3 fusion	FGFR inhibitors	Glioma	Responsive	C	NO	PMID:26324363	only gene		G
WP160	FGFR3 MUT* (--)	FGFR3 oncogenic mutation	FGFR inhibitors	Bladder	Responsive	C	NO	PMID:27870574	only alteration type		BLCA
WP160	FGFR3 MUT* (--)	FGFR3 (K650,Y373C)	FGFR inhibitors	Myeloma	Responsive	D	YES	PMID:16091734;PMID:20439987;PMID:22869148	only alteration type		MYMA
WP160	FGFR3 MUT* (--)	FGFR3 (S249C,G691R)	FGFR inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:27998968	only alteration type		LUAD
WP160	FGFR3 MUT* (--)	FGFR3 fusion	FGFR inhibitors	Bladder	Responsive	C	NO	PMID:26324363;ASCO 2017 (abstr 2500)	only gene		BLCA
WP160	FGFR3 MUT* (--)	FGFR3 (K650)	Bortezomib(Proteasome inhibitor)	Myeloma	Responsive	D	YES	PMID:19331127;PMID:21273588	only alteration type		MYMA
WP160	FGFR3 MUT* (--)	FGFR3-TACC3 fusion	FGFR inhibitors(,etc)	Non-small cell lung	Responsive	D	NO	PMID:25294908	only gene		NSCLC
WP160	FGFR3 MUT* (--)	FGFR3 (Y373C)	Bortezomib(Proteasome inhibitor)	Myeloma	Resistant	D	YES	PMID:19331127;PMID:21273588	only alteration type		MYMA
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP160	NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP160	ALK MUT* (G922)	ALK (G1123S)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:26134233	only alteration type		LUAD
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP160	GNAS MUT* (P97H)	GNAS (R201)	JAK inhibitors	Any cancer type	Responsive	D	YES	PMID:21835143	only alteration type		CANCER
WP160	HDAC2 MUT* (--)	HDAC2 biallelic inactivation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP160	INPP4B MUT* (--), INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP160	INPP4B MUT* (--), INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP160	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP160	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:19223544;PMID:20619739	only alteration type		COREAD
WP160	ALK MUT* (G922)	ALK inframe insertion (1151T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only alteration type		LUAD
WP160	ALK MUT* (G922)	ALK oncogenic mutation	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only alteration type		NSCLC
WP160	ALK MUT* (G922)	ALK amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only gene		NSCLC
WP160	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP160	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP160	ALK MUT* (G922)	ALK amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only gene		LUAD
WP160	ALK MUT* (G922)	ALK (C1156Y,L1196M)	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:20979473	only alteration type		NSCLC
WP160	ALK MUT* (G922)	ALK (F1174L)	Crizotinib(ALK inhibitor)	Glioma	Resistant	D	NO	PMID:22072639	only alteration type		G
WP160	ALK MUT* (G922)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784;PMID:25228534	only alteration type		LUAD
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 (G2032R)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:23724914;PMID:25688157	only alteration type		LUAD
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP160	NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP160	IGF1R MUT* (E931*), IGF1R MUT* (R1246)	IGF1R amplification	Erlotinib(EGFR inhibitor 1st gen)	Lung adenocarcinoma	Resistant	D	NO	PMID:24458568	only gene		LUAD
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP160	NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP160	MTOR (L2508I)	MTOR (F2108L)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Resistant	C	NO	PMID:25295501	only alteration type		THCA
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP160	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP160	NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP160	NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP160	BTK (E382Q), BTK MUT* (--)	BTK (C481)	Ibrutinib(BTK inhibitor)	Mantle cell lymphoma	Resistant	C	YES	PMID:25082755	only alteration type		MCL
WP160	PLCG2 MUT* (--), PLCG2 MUT* (--)	PLCG2 (R665W,L845F)	Ibrutinib(BTK inhibitor)	Chronic lymphocytic leukemia	Resistant	C	YES	PMID:24869598	only alteration type		CLL
WP160	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP160	MTOR (L2508I)	MTOR (F2108L)	MTOR kinase inhibitors	Any cancer type	Responsive	D	YES	PMID:25295501	only alteration type		CANCER
WP160	MTOR (L2508I)	MTOR (E2014K,E2419K,N1421D)	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:24625776	only alteration type		BLCA
WP160	MTOR (L2508I)	MTOR (I1973F)	Everolimus(MTOR inhibitor)	Angiosarcoma, Renal	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		AS, R
WP160	MTOR (L2508I)	MTOR (K1771R)	Everolimus(MTOR inhibitor)	Stomach, Adrenal gland	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		ST, AG
WP160	MTOR (L2508I)	MTOR (N1421D)	Everolimus(MTOR inhibitor)	Stomach	Responsive	C	NO	PMID:26859683	only alteration type		ST
WP160	MTOR (L2508I)	MTOR (Q2223K)	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468	only alteration type		R
WP160	MTOR (L2508I)	MTOR (L1460P,S2215Y,R2505P)	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	D	YES	PMID:24631838	only alteration type		CANCER
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP160	NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP160	NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP160	NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP160	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP160	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP160	NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP160	NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP160	NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP160	NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP160	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP160	NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP160	ERBB2 MUT* (--)	ERBB2 (K753E)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma	Resistant	D	NO	PMID:27697991	only alteration type		BRCA
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP160	NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP160	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP160	LRP1B (S2431Y)	LRP1B oncogenic mutation	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	complete		OV
WP160	LRP1B (S2431Y)	LRP1B deletion	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only gene		OV
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP160	NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP160	NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP160	NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP160	NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP160	NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP160	NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP160	NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP160	NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP160	ERBB2 MUT* (--)	ERBB2 (T798I)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:28274957	only alteration type		BRCA
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP160	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP160	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP160	NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP160	NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Osimertinib(3rd generation EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP160	NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP160	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP160	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP160	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP160	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP160	NTRK1 MUT* (--)	NTRK1 fusion	Pan-TK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24162815	only gene		LUAD
WP160	NTRK1 MUT* (--)	NTRK1 fusion	Pan-TKR inhibitors	Any cancer type	Responsive	C	YES	PMID:28183697;ASCO 2017 (LBA2501)	only gene		CANCER
WP160	NTRK1 MUT* (--)	NTRK1 fusion	Pan-TK inhibitors(Entrectinib,etc)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26546295	only gene		COREAD
WP160	NTRK1 MUT* (--)	NTRK1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2013 (abstr 8023)	only gene		LUAD
WP160	PALB2 MUT* (A587S)	PALB2 oncogenic mutation	PARP inhibitors	Prostate adenocarcinoma	Responsive	C	NO	AACR 2015 (abstr CT322);PMID:26510020	only alteration type		PRAD
WP160	PALB2 MUT* (A587S)	PALB2 oncogenic mutation	PARP inhibitors	Pancreas	Responsive	D	NO	PMID:25263539;NCT01585805	only alteration type		PA
WP160	PALB2 MUT* (A587S)	PALB2 deletion	PARP inhibitors	Prostate adenocarcinoma	Responsive	C	NO	AACR 2015 (abstr CT322);PMID:26510020	only gene		PRAD
WP160	PALB2 MUT* (A587S)	PALB2 deletion	PARP inhibitors	Pancreas	Responsive	D	NO	PMID:25263539;NCT01585805	only gene		PA
WP160	PALB2 MUT* (A587S)	PALB2 oncogenic mutation	Mytomycin C(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:21135251	only alteration type		PA
WP160	PALB2 MUT* (A587S)	PALB2 deletion	Mytomycin C(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:21135251	only gene		PA
WP160	PALB2 MUT* (A587S)	PALB2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP160	PALB2 MUT* (A587S)	PALB2 deletion	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only gene		PA
WP160	PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP160	PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP160	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP160	RET MUT* (--)	RET (I788N)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Resistant	D	NO	PMID:28615362	only alteration type		LUAD
WP160	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP160	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP160	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	AKT inhibitors	Breast adenocarcinoma	Responsive	C	NO	ASCO 2015 (abstr 2500)	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Rociletinib(3rd generation EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP160	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitor(alone or in combination)s	Lung, Colorectal adenocarcinoma	Responsive	D	NO	PMID:23136191;PMID:23475782;PMID:22392911	only alteration type		L, COREAD
WP160	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Bladder, Head an neck, Lung	Responsive	C	NO	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	only alteration type		BLCA, HNC, L
WP160	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma, Ovary, Cervix squamous cell, Endometrium	Responsive	C	NO	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	only alteration type		BRCA, OV, CESC, ED
WP160	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26787751;PMID:26763254	only alteration type		HNSC
WP160	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Glioma, Thyroid carcinoma	Responsive	D	NO	PMID:19671762;PMID:21289267	only alteration type		G, THCA
WP160	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:28331003	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2501)	only alteration type		ST
WP160	PIK3CA MUT* (--), ERBB2 MUT* (--)	PIK3CA oncogenic mutation + ERBB2 amplification	Everolimus + Trastuzumab + Chemotherapy(MTOR inhibitor + ERBB2 mAb inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:27091708	only gene		BRCA
WP160	PIK3R1 MUT* (--), PIK3R1 MUT* (N325Y), PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	AKT inhibitors	Glioma	Responsive	D	NO	PMID:23166678	only alteration type		G
WP160	PIK3R1 MUT* (--), PIK3R1 MUT* (N325Y), PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	PI3K pathway inhibitors	Endometrium	Responsive	C	NO	ASCO 2015 (abstr 11075)	only alteration type		ED
WP160	PIK3R2 MUT* (--)	PIK3R2 (A171V,N561D)	MTOR inhibitors	Endometrium	Responsive	D	NO	PMID:21984976;PMID:19962665	only alteration type		ED
WP160	POLE (W1802C), POLE MUT* (--)	POLE (268-471)	PD1 Ab inhibitors	Glioma, Endometrium	Responsive	C	NO	PMID:27001570;PMID:27683556;PMID:27159395	only alteration type		G, ED
WP160	POLE (W1802C)	POLE oncogenic mutation	PD1 Ab inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28188185	complete		COREAD
WP160	PRKCH MUT* (--), PRKCH MUT* (--), ABL1 MUT* (L298)	PRKCH amplification + ABL1-BCR fusion	Trametinib + Imatinib(MEK inhibitor + BCR-ABL inhibitor 1st gen&KIT inhibitor)	Chronic myeloid leukemia	Responsive	D	YES	PMID:25186176	only gene		CML
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP160	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP160	NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP160	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP160	RAD51C MUT* (G153)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
WP160	RAD51C MUT* (G153)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
WP160	RAF1 MUT* (--)	RAF1 fusion	Pan-RAF inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:20526349	only gene		PRAD
WP160	RAF1 MUT* (--)	RAF1 fusion	Sorafenib(Pan-TK inhibitor)	Prostate adenocarcinoma	Responsive	D	NO	PMID:20526349	only gene		PRAD
WP160	RAF1 MUT* (--)	RAF1 fusion	U0126(MEK inhibitor)	Prostate adenocarcinoma	Responsive	D	NO	PMID:20526349	only gene		PRAD
WP160	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP160	RB1 MUT* (--), RB1 MUT* (--)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
WP160	RB1 MUT* (--), RB1 MUT* (--)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
WP160	RB1 MUT* (--), RB1 MUT* (--)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
WP160	RB1 MUT* (--), RB1 MUT* (--)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
WP160	RB1 MUT* (--), RB1 MUT* (--)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP160	RB1 MUT* (--), RB1 MUT* (--)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP160	RET MUT* (--)	RET fusion	RET inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:22327624;PMID:22327622	only gene		LUAD
WP160	RET MUT* (--)	RET-TPCN1 fusion	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only gene		TH
WP160	RET MUT* (--)	RET (C634W,M918T)	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only alteration type		TH
WP160	RET MUT* (--)	RET fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP160	RET MUT* (--)	RET-TPCN1 fusion	Cabozantinib(Pan-kinase inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP160	RET MUT* (--)	RET (C634W,M918T)	Cabozantinib(Pan-kinase inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP160	RET MUT* (--)	RET fusion	Nintedanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26787234	only gene		LUAD
WP160	RET MUT* (--)	RET fusion	Sunitinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP160	RET MUT* (--)	RET-TPCN1 fusion	Sunitinib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP160	RET MUT* (--)	RET (C634W,M918T)	Sunitinib(Pan-TK inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP160	RET MUT* (--)	RET fusion	Vandetanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP160	RET MUT* (--)	RET-TPCN1 fusion	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP160	RICTOR MUT* (--)	RICTOR amplification	MTORC1/2 inhibitors	Lung	Responsive	C	NO	PMID:26370156	only gene		L
WP160	RNF43 (G705C)	RNF43 oncogenic mutation	Porcupine inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr C45)	complete		COREAD
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:23533265	only gene		LUAD
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27370605	only gene		LUAD
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 (G2032R)	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:25351743	only alteration type		LUAD
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	C	YES	PMID:24875859	only gene		IM
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:25264305	only gene		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Endometrium	No Responsive	C	NO	PMID:26099744;PMID:19840887	only gene		ED
WP160	HGF (A659S), ERBB2 MUT* (--)	HGF amplification + ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:22850551	only gene		BRCA
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27401242	only alteration type		LUAD
WP160	SF3B1 MUT* (--), SF3B1 MUT* (--)	SF3B1 (K700E,K666N)	Spliceosome inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858	only alteration type		CANCER
WP160	SMARCA1 (F620L)	SMARCA1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	complete		CANCER
WP160	NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP160	TERT MUT* (H925Q)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP160	TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP160	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP160	TSC1 (R160L)	TSC1 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	complete		RA
WP160	TSC1 (R160L)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	complete		BLCA
WP160	TSC1 (R160L)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;PMID:26859683;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	complete		R
WP160	TSC1 (R160L)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Sarcoma, Stomach	Responsive	C	NO	PMID:26859683	complete		S, ST
WP160	TSC1 (R160L)	TSC1 deletion	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	only gene		R
WP160	TSC2 MUT* (A1185S)	TSC2 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	only alteration type		RA
WP160	TSC2 MUT* (A1185S)	TSC2 oncogenic mutation	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	only alteration type		LAM
WP160	TSC2 MUT* (A1185S)	TSC2 deletion	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	only gene		LAM
WP160	TSC2 MUT* (A1185S)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	only alteration type		BLCA
WP160	TSC2 MUT* (A1185S)	TSC2 (Q1178*)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:25295501	only alteration type		THCA
WP160	TSC2 MUT* (A1185S)	TSC2 (E66K)	Tensirolimus(MTOR inhibitor)	Endometrium	Responsive	C	NO	PMID:27016228	only alteration type		ED
WP160	BRCA1 (R71M)	BRCA1 (G1738R,A1708V,C47G,V1696L,Y1853C,D1739V,F1761I,H1746N,C24Y,K1702E,P1749R,M1775R,W1837C,M1775E,V1736G,V1838E,C44F,A1752V,D1739E,S1715N,.,A1789T,S1164I,T1685A,A1752P,H1686R,H41R,C64G,W1718L,D1692H,V1713A,R1699W,V1653M,Q1756C,C61G,D1739Y,G1770V,V1714G,V1833M,R1835P,R1699Q,G1706E,P1812A,E1836K,C44Y,G1788D,C39Y,M1R,S1715R,Y1703H,F1761S,E33A,M1628V,W1837G,L1705P,M1689R,G1738E,R1751P,V1809F,S1841N,S1722F,I1766S,S1655F,G1788V,L1780P,V1833E,A1708E,E1660G,C27A,Y1703S,I1807S,T1700A,A1843T,F1734L,V1741G,V1810G,F1704S,G1656D,T1685I,L1854P,Q1811R,M18T,C1697R,G1803A,G1743R,G1763V,C24R,T37R,T1773I,D1739G,W1718C,H1686Q,T1691I,L1407P,K1487R,M1652K,S1841R,M1775K,S1841A,F1734S,V1736A,M1689T,W1815X,L1764P,W1837R,T1691K,R1753T,D1692Y,W1718S,L1657P,A1843P,S1715C,R1699L)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/6/summary|oncokb=https://www.oncokb.org/gene/BRCA1	complete		OV
WP160	BRCA1 MUT* (--), BRCA1 (R71M)	BRCA1 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only gene		OV
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 amplification	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Lung squamous cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		LUSC
WP160	MTOR (L2508I)	MTOR (L2209V,L1460P,L2427Q)	Temsirolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
WP160	MTOR (L2508I)	MTOR (Q2223K)	Everolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
WP160	ERCC2 (D500E)	ERCC2 (G665A,P463L,R601Q,A717G,D423N,R487W,E606G,R631C,V242F,V536M,.,L461V,D609E,Y24C,D513Y,D609G,N238S)	Cisplatin	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERCC2	complete		BLCA
WP160	ALK MUT* (G922)	ALK fusion	Crizotinib + Ceritinib	Sarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only gene		S
WP160	ALK MUT* (G922)	ALK (G1202R,I1171N)	Alectinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only alteration type		NSCLC
WP160	NTRK1 MUT* (--)	NTRK1 fusion	Entrectinib	Any cancer type	Responsive	B	YES	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/NTRK1|CIVIC=https://civicdb.org/genes/3983/summary	only gene		CANCER
WP160	ERBB2 MUT* (--)	ERBB2 (T862A,L755S,V842I,V777A,D769H,.,R896C,R678W,R784C,V773A,C630Y,G309E,G292R,E645F,T733I,D769Y,G660R,T686A,D769A,Y803N,L651V,A644F,L674V,V839G,R217C,L869R,E719K,G660D,E265K,L785F,P650S,D277H,D808N,G776V,S653C,R487W,L841V,S310F,L755W,E693K,S335C,V659E,V794M,V659K,E321G,L915M,L866M,C311R,S1002R,D277Y,V659G,Q709L,L726I,G309A,N857S,L755P,T798M,L663P,E812K,S656C,T798I,R683Q,I682G,R678Q,V777L,P780L,A710V,R677L,S310Y,S783P,E717K,E719G,H878Y,G776S,L726F,D821N,V777M,I767M,S649T,C334S)	Neratinib	Breast adenocarcinoma	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ERBB2|CIVIC=https://civicdb.org/genes/20/summary	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Neratinib	Breast adenocarcinoma	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ERBB2|CIVIC=https://civicdb.org/genes/20/summary	only gene		BRCA
WP160	BRCA1 (R71M)	BRCA1 (G1738R,A1708V,C47G,V1696L,Y1853C,D1739V,F1761I,H1746N,C24Y,K1702E,P1749R,M1775R,W1837C,M1775E,V1736G,V1838E,C44F,A1752V,D1739E,S1715N,.,A1789T,S1164I,T1685A,A1752P,H1686R,H41R,C64G,W1718L,D1692H,V1713A,R1699W,V1653M,Q1756C,C61G,D1739Y,G1770V,V1714G,V1833M,R1835P,R1699Q,G1706E,P1812A,E1836K,C44Y,G1788D,C39Y,M1R,S1715R,Y1703H,F1761S,E33A,M1628V,W1837G,L1705P,M1689R,G1738E,R1751P,V1809F,S1841N,S1722F,I1766S,S1655F,G1788V,L1780P,V1833E,A1708E,E1660G,C27A,Y1703S,I1807S,T1700A,A1843T,F1734L,V1741G,V1810G,F1704S,G1656D,T1685I,L1854P,Q1811R,M18T,C1697R,G1803A,G1743R,G1763V,C24R,T37R,T1773I,D1739G,W1718C,H1686Q,T1691I,L1407P,K1487R,M1652K,S1841R,M1775K,S1841A,F1734S,V1736A,M1689T,L1764P,W1837R,T1691K,R1753T,D1692Y,W1718S,L1657P,A1843P,S1715C,R1699L)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	complete		BRCA
WP160	BRCA1 MUT* (--), BRCA1 (R71M)	BRCA1 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only gene		BRCA
WP160	MTOR (L2508I)	MTOR (E2419K,E2014K)	Everolimus	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		BLCA
WP160	MTOR (L2508I)	MTOR (E2419K,C1483F,L2172M,K1452N,L2230V,L2427Q,L2431P,F1888I,E1799K,L2216P,W1456R,C1483W,A1519T,L1460P,A2210P,T2232I,R2505P,M2327I,C1483R,V2006I,A1428T,Y1463S,I2500M,A1459P,F1888L,S2231W,T1977R,V2006F,T1977K,A2226S,I2500F,L2427R,T1977I,S2215F,.,Q2223K,I1973F,L1433S,F1888V,S2215T,D2512H,E2014K,S2215Y,R2217W,L2209V,V2006L,L2220F,L2427P,S2215P,P2273S,E2288K,C1483Y)	Temsirolimus + Everolimus	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	complete		CANCER
WP160	TSC1 (R160L)	TSC1 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	only gene		RCCC
WP160	TSC1 (R160L)	TSC1 (H105R,H206D,V220F,L180P,F216A,M224R,H68R,.,S35Q,F158C,L117P,L191H)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	complete		RCCC
WP160	KDM6A MUT* (--)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
WP160	KDM6A MUT* (--)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only alteration type		BLCA
WP160	FGFR3 MUT* (--)	FGFR3 (S249C,S371C,R248C,K650.,G380R,Y373C,G370C)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only alteration type		BLCA
WP160	TSC2 MUT* (A1185S)	TSC2 (S1653P,Q1503P,R905G,L830R,A889P,L146R,T1203K,V1673F,W1610G,V769E,C696Y,F615S,E75G,L448P,V299G,R611W,R1200W,R505Q,Q1554H,G1567D,G1596V,Y1571N,I427M,S1498N,L1584R,P1709L,L844R,V705E,R905Q,Y598C,L410R,R462C,R611Q,R905W,A614D,.,S1653F,P1675L,H1620R,S1036P,H597Y,L493P,T1623I,V1673D,V705M,L826P,L792R,A328P,L493V)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	only alteration type		RCCC
WP160	TSC2 MUT* (A1185S)	TSC2 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	only gene		RCCC
WP160	ERBB2 MUT* (--)	ERBB2 (T862A,L755S,V842I,V777A,D769H,.,R896C,R678W,R784C,V773A,C630Y,G309E,G292R,E645F,T733I,D769Y,G660R,T686A,D769A,Y803N,L651V,A644F,L674V,V839G,R217C,L869R,E719K,G660D,E265K,L785F,P650S,D277H,D808N,G776V,S653C,R487W,L841V,S310F,E693K,S335C,V659E,V794M,V659K,E321G,L915M,L866M,C311R,S1002R,D277Y,V659G,Q709L,L726I,G309A,N857S,L755P,T798M,L663P,E812K,S656C,T798I,R683Q,I682G,R678Q,V777L,P780L,A710V,R677L,S310Y,S783P,E717K,E719G,H878Y,G776S,L726F,D821N,V777M,I767M,S649T,C334S)	Ado + Trastuzumab + Neratinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERBB2	only alteration type		NSCLC
WP160	ERBB2 MUT* (--)	ERBB2 amplification	Ado + Trastuzumab + Neratinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERBB2	only gene		NSCLC
WP160	FGFR3 MUT* (--)	FGFR3 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		BLCA
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 (E17K)	Azd5363	Breast adenocarcinoma	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/AKT1|CIVIC=https://civicdb.org/genes/2/summary	only alteration type		BRCA
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 (E17K)	Azd5363	Endometrial adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/AKT1	only alteration type		EDA
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 (E17K)	Azd5363	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/AKT1	only alteration type		OV
WP160	NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP160	NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 amplification	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1-BCR fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1-CEP110 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1-CUX1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1-ERLIN2 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1-TACC1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1-FGFR1OP1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP160	FGFR1 (E517D)	FGFR1 (V592M,K687E,.,N577K)	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	complete		CANCER
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1-ZNF198 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP160	PIK3CA MUT* (--)	PIK3CA (P539R,R38H,Q546K,G118D,G106V,Q546E,E579K,N345K,E453K,V344A,E545K,T1025S,E542Q,G1049R,M1043I,E110K,P449T,N1044K,K111E,C378R,H1047R,C420R,E78K,E545A,S629C,D350G,.,G451R,M1043V,E542V,Q546R,E365K,E81K,G106D,R88Q,P366R,R93Q,G914R,H1047Y,K111N,E545Q,E545G,R93W,R108H,G106R,E453Q,E542K,D1029Y,N345I,D549N,A1066V,Q546P,E542G,E453A)	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA amplification	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only gene		BRCA
WP160	ALK MUT* (G922)	ALK (C1156Y,F1174L,L1196M,G1269A)	Crizotinib	Non-small cell lung	Resistant	D	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary	only alteration type		NSCLC
WP160	RET MUT* (--)	RET fusion	Cabozantinib + Vandetanib + Larotrectinib + 292 + 667	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		NSCLC
WP160	RET MUT* (--)	RET (C618R,C620R,C609Y,E768D,C630R,S904F,E511K,C634S,C634Y,V648I,I852M,S891A,A883T,A883F,C611Y,T338I,C634W,K603Q,D631Y,M918T,A919V,R833C,.,V804M,C634R,V804L,Y806C,M918V,L790F,M848T,R886W,Y791F)	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only alteration type		THM
WP160	RET MUT* (--)	RET fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP160	RET MUT* (--)	RET-KIF5B fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP160	RET MUT* (--)	RET-CCDC6 fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP160	FGFR3 MUT* (--)	FGFR3 (M528I,D641N,R669G,Y373C,K650T,G370C,S249C,S371C,A391E,G380R,I538V,D641G,N540K,R248C,V555M,.,K650E,K650R,K650M,G375C,G382D,N540S,Y647C,K650Q,K650N)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only alteration type		CANCER
WP160	FGFR3 MUT* (--)	FGFR3 amplification	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP160	FGFR3 MUT* (--)	FGFR3-BAIAP2L1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP160	FGFR3 MUT* (--)	FGFR3-TACC3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP160	FGFR3 MUT* (--)	FGFR3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP160	FGFR3 MUT* (--)	FGFR3-IGH fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP160	NTRK1 MUT* (--)	NTRK1 (G595R)	Larotrectinib	Any cancer type	Resistant	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK1	only alteration type		CANCER
WP160	ABL1 MUT* (L298)	ABL1 BCR::ABL	Imatinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/232	only gene		AML
WP160	ABL1 MUT* (L298)	ABL1 BCR::ABL	Imatinib	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/259	only gene		AML
WP160	ABL1 MUT* (L298)	ABL1 G340L	Imatinib Mesylate,Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4788	only alteration type		NSCLC
WP160	ABL1 MUT* (L298)	ABL1 R351W	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4787	only alteration type		NSCLC
WP160	ABL1 MUT* (L298)	ABL1 R351W	Imatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/6376	only alteration type		NSCLC
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 E17K	Akt Inhibitor MK2206	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/231	only alteration type		BRCA
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 E17K	Capivasertib	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/709	only alteration type		BRCA
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 E17K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4029	only alteration type		CM
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 E17K	Uprosertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/707	only alteration type		CM
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 Q79K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/439	only alteration type		CM
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 Q79K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4498	only alteration type		CM
WP160	AKT1 MUT* (--), AKT1 MUT* (--)	AKT1 Q79K	Dabrafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6260	only alteration type		CM
WP160	ALK MUT* (G922)	ALK CAD::ALK	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7481	only gene		COREAD
WP160	ALK MUT* (G922)	ALK CLTC::ALK	TAE684	Difuse large B Cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1261	only gene		DLBCL
WP160	ALK MUT* (G922)	ALK CLTC::ALK	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1265	only gene		DLBCL
WP160	ALK MUT* (G922)	ALK EML4::ALK	Alectinib	Mesothelioma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9228	only gene		MESO
WP160	ALK MUT* (G922)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/262	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK EML4::ALK	WHI-P154	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1188	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK EML4::ALK	Crizotinib,Retaspimycin Hydrochloride	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1203	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK EML4::ALK	Crizotinib,Alvespimycin	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1206	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1207	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK EML4::ALK	Lorlatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1332	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK F1174L	Crizotinib	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/125	only alteration type		NB
WP160	ALK MUT* (G922)	ALK F1174L	Alectinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/37	only alteration type		NB
WP160	ALK MUT* (G922)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/38	only alteration type		NB
WP160	ALK MUT* (G922)	ALK F1174L	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/142	only alteration type		NB
WP160	ALK MUT* (G922)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1271	only alteration type		NB
WP160	ALK MUT* (G922)	ALK F1174L	AZD3463	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1327	only alteration type		NB
WP160	ALK MUT* (G922)	ALK F1174L	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1329	only alteration type		NB
WP160	ALK MUT* (G922)	ALK F1174L	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/33	only alteration type		NSCLC
WP160	ALK MUT* (G922)	ALK F1245C	Crizotinib	Neuroblastoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1333	only alteration type		NB
WP160	ALK MUT* (G922)	ALK F1245C	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1330	only alteration type		NB
WP160	ALK MUT* (G922)	ALK F1245V	Entrectinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2987	only alteration type		NB
WP160	ALK MUT* (G922)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1240	only gene		ALCL
WP160	ALK MUT* (G922)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/7361	only gene		ALCL
WP160	ALK MUT* (G922)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	A	YES	https://civicdb.org/links/evidence_items/11218	only gene		ALCL
WP160	ALK MUT* (G922)	ALK Fusion	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1264	only gene		DLBCL
WP160	ALK MUT* (G922)	ALK Fusion	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1691	only gene		LUAD
WP160	ALK MUT* (G922)	ALK Fusion	Pemetrexed	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/945	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1175	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1187	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1198	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1199	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1200	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1201	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Retaspimycin Hydrochloride	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1202	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1272	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1273	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1279	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1282	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1419	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1577	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4835	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Alectinib,Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4858	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7284	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7285	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Lorlatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7286	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/8657	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11121	only gene		NSCLC
WP160	ALK MUT* (G922)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1283	only alteration type		NSCLC
WP160	ALK MUT* (G922)	ALK I1171	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1287	only alteration type		NSCLC
WP160	ALK MUT* (G922)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1367	only alteration type		NSCLC
WP160	ALK MUT* (G922)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1284	only alteration type		NSCLC
WP160	ALK MUT* (G922)	ALK I1171	TAE684	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1285	only alteration type		NSCLC
WP160	ALK MUT* (G922)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1344	only alteration type		NSCLC
WP160	ALK MUT* (G922)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1368	only alteration type		NSCLC
WP160	ALK MUT* (G922)	ALK I1171T	Ceritinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9404	only alteration type		NB
WP160	ALK MUT* (G922)	ALK KANK4::ALK	Alectinib	Pancreas acinar	Responsive	C	NO	https://civicdb.org/links/evidence_items/10327	only gene		PAAC
WP160	ALK MUT* (G922)	ALK Mutation	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1237	only alteration type		NSCLC
WP160	ALK MUT* (G922)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1239	only gene		ALCL
WP160	ALK MUT* (G922)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/1241	only gene		ALCL
WP160	ALK MUT* (G922)	ALK R1275Q	TAE684	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/48	only alteration type		NB
WP160	ALK MUT* (G922)	ALK R1275Q	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/39	only alteration type		NB
WP160	ALK MUT* (G922)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/143	only alteration type		NB
WP160	ALK MUT* (G922)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1270	only alteration type		NB
WP160	ALK MUT* (G922)	ALK R1275Q	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1331	only alteration type		NB
WP160	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP160	BRCA1 (R71M)	BRCA1 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/1897	complete		OV
WP160	BRCA1 (R71M)	BRCA1 Mutation	Olaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/7275	complete		OV
WP160	BRCA1 (R71M)	BRCA1 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11136	complete		OV
WP160	BRCA1 (R71M)	BRCA1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11203	complete		PRAD
WP160	BRCA1 MUT* (--), BRCA1 (R71M)	BRCA1 Q1467*	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2878	only alteration type		OV
WP160	CHEK1 MUT* (--)	CHEK1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11210	only alteration type		PRAD
WP160	DNMT3A (-848-849X), DNMT3A (V311L)	DNMT3A Mutation	Decitabine	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/1587	complete		AML
WP160	DNMT3A (-848-849X), DNMT3A (V311L)	DNMT3A R882	Daunorubicin	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/11	only alteration type		AML
WP160	DNMT3A (-848-849X), DNMT3A (V311L)	DNMT3A R882	Idarubicin	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/18	only alteration type		AML
WP160	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP160	ERBB2 MUT* (--)	ERBB2 D769H	Lapatinib,Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/279	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 D769Y	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/280	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 G309A	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/282	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 G776L	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1889	only alteration type		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 G778_P780DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1890	only alteration type		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 G778_P780DUP	Dacomitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1892	only alteration type		NSCLC
WP160	ERBB2 MUT* (--)	ERBB2 L755S	Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/241	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 L755S	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/283	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 L755S	Fluorouracil,Trastuzumab,Leucovorin	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4955	only alteration type		COREAD
WP160	ERBB2 MUT* (--)	ERBB2 L755W	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/284	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 L755_T759del	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/281	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 M774DELINSWLV	Dacomitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1894	only alteration type		NSCLC
WP160	ERBB2 MUT* (--)	ERBB2 Mutation	Platinum Compound	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/1694	only alteration type		BLCA
WP160	ERBB2 MUT* (--)	ERBB2 Mutation	Neratinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5338	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Mutation	Trastuzumab,Pertuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5980	only alteration type		NSCLC
WP160	ERBB2 MUT* (--)	ERBB2 P780INS	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/285	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 P780INS	Dacomitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1048	only alteration type		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 R678Q	Lapatinib,Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/286	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 R896C	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/287	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 T798I	Osimertinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6174	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 V777L	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/288	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 V842I	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/289	only alteration type		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1045	only alteration type		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Trastuzumab Emtansine	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1125	only alteration type		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1888	only alteration type		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Sirolimus,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/960	only alteration type		NSCLC
WP160	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1893	only alteration type		NSCLC
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/5982	only gene		BLCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/528	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/529	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	AKTi-1/2	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/760	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Neratinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/761	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib,Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/887	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/961	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1006	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1007	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1008	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1009	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1011	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1012	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1013	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Docetaxel,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1077	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Neratinib,Trastuzumab	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/1113	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/1122	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib,Capecitabine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1132	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Capecitabine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1133	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1159	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1160	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1380	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	A66	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1381	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Tgx 221	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1382	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1432	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Docetaxel,Pertuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1437	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1439	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Pilaralisib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1448	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Palbociclib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1561	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1613	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1764	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2071	only gene		BRCA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Pertuzumab	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7638	only gene		CH
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Capecitabine,Cetuximab,Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/895	only gene		COREAD
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1686	only gene		COREAD
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1687	only gene		COREAD
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1688	only gene		COREAD
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1993	only gene		COREAD
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1689	only gene		COREAD
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5981	only gene		COREAD
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7302	only gene		COREAD
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7807	only gene		COREAD
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/1098	only gene		ED
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1393	only gene		LUAD
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1041	only gene		NSCLC
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1042	only gene		NSCLC
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1050	only gene		NSCLC
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1891	only gene		NSCLC
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Pancreas	Responsive	B	NO	https://civicdb.org/links/evidence_items/5985	only gene		PA
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Pancreas adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/962	only gene		PAAD
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Irinotecan	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1044	only gene		SCLC
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Salivary glands	Responsive	B	NO	https://civicdb.org/links/evidence_items/5984	only gene		SG
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/1022	only gene		ST
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/1023	only gene		ST
WP160	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Stomach	Responsive	A	NO	https://civicdb.org/links/evidence_items/1499	only gene		ST
WP160	ERBB4 MUT* (--), ERBB4 MUT* (--)	ERBB4 Mutation	Lapatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/770	only alteration type		CM
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 FGFR1OP2::FGFR1	Ponatinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7380	only gene		AML
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 Fusion	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7375	only gene		AML
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 N546K	Pemigatinib	Pilocityc astrocytoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/10325	only alteration type		PIA
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 ZNF198::FGFR1	Midostaurin	Malignant peripheral nerve sheat tumor	Responsive	C	NO	https://civicdb.org/links/evidence_items/1104	only gene		MPN
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 Amplification	Infigratinib	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/1911	only gene		BLCA
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 Amplification	Afimoxifene	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1105	only gene		BRCA
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 Amplification	Infigratinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1909	only gene		BRCA
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 Amplification	Dovitinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1604	only gene		BRCA
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 Amplification	FGFR Inhibitor AZD4547	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1991	only gene		BRCA
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 Amplification	Pazopanib	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7246	only gene		BRCA
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 Amplification	Lucitanib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7488	only gene		BRCA
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 Amplification	PD173074	Lung squamous cell	Responsive	D	NO	https://civicdb.org/links/evidence_items/680	only gene		LUSC
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 Amplification	Infigratinib	Lung squamous cell	Responsive	B	NO	https://civicdb.org/links/evidence_items/1908	only gene		LUSC
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 Amplification	PD173074	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/686	only gene		NSCLC
WP160	FGFR1 (E517D), FGFR1 MUT* (--)	FGFR1 Amplification	Dovitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3027	only gene		NSCLC
WP160	FGFR3 MUT* (--)	FGFR3 FGFR3::BAIAP2L1	PD173074	Bladder	Responsive	D	NO	https://civicdb.org/links/evidence_items/144	only gene		BLCA
WP160	FGFR3 MUT* (--)	FGFR3 Mutation	Infigratinib	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/1910	only alteration type		BLCA
WP160	FGFR3 MUT* (--)	FGFR3 Mutation	Cisplatin,Gemcitabine	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/7566	only alteration type		BLCA
WP160	GNAS MUT* (P97H)	GNAS R201C	Cetuximab,Vemurafenib,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1906	only alteration type		COREAD
WP160	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP160	KMT2C MUT* (S806), KMT2C MUT* (G315S), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP160	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP160	MTOR (L2508I)	MTOR A2034V	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1547	only alteration type		BRCA
WP160	MTOR (L2508I)	MTOR A2034V	RapaLink-1,MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1548	only alteration type		BRCA
WP160	MTOR (L2508I)	MTOR E1799K	Sirolimus	Renal clear cell	Responsive	D	NO	https://civicdb.org/links/evidence_items/1321	only alteration type		RCCC
WP160	MTOR (L2508I)	MTOR F2108L	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1543	only alteration type		BRCA
WP160	MTOR (L2508I)	MTOR F2108L	Everolimus	Thyroid carcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1110	only alteration type		THCA
WP160	MTOR (L2508I)	MTOR H1968Y	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/713	only alteration type		CM
WP160	MTOR (L2508I)	MTOR M2327I	MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1544	only alteration type		BRCA
WP160	MTOR (L2508I)	MTOR M2327I	Sirolimus,RapaLink-1	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1545	only alteration type		BRCA
WP160	MTOR (L2508I)	MTOR Mutation	Everolimus,Pazopanib	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/705	complete		BLCA
WP160	MTOR (L2508I)	MTOR P2213S	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/722	only alteration type		CM
WP160	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP160	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP160	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP160	NTRK1 MUT* (--)	NTRK1 Fusion	Larotrectinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/978	only gene		COREAD
WP160	NTRK1 MUT* (--)	NTRK1 Fusion	Larotrectinib,Lestaurtinib,Crizotinib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1019	only gene		LUAD
WP160	NTRK1 MUT* (--)	NTRK1 Fusion	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/6567	only gene		SOLID
WP160	NTRK1 MUT* (--)	NTRK1 Fusion	Entrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/11124	only gene		SOLID
WP160	NTRK1 MUT* (--)	NTRK1 LMNA::NTRK1	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2960	only gene		COREAD
WP160	NTRK1 MUT* (--)	NTRK1 LMNA::NTRK1	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/8900	only gene		COREAD
WP160	NTRK1 MUT* (--)	NTRK1 SQSTM1::NTRK1	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1868	only gene		NSCLC
WP160	NTRK1 MUT* (--)	NTRK1 SQSTM1::NTRK1	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2950	only gene		NSCLC
WP160	NTRK1 MUT* (--)	NTRK1 Amplification	Larotrectinib	Solid tumors	Responsive	C	NO	https://civicdb.org/links/evidence_items/10170	only gene		SOLID
WP160	PALB2 MUT* (A587S)	PALB2 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8504	only alteration type		PRAD
WP160	PDGFRB MUT* (P1001)	PDGFRB Fusion	Imatinib	Malignant peripheral nerve sheat tumor	Responsive	A	NO	https://civicdb.org/links/evidence_items/1498	only gene		MPN
WP160	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2346	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8549	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA C420R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2078	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA C420R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1999	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA D350G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4784	only alteration type		CM
WP160	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8007	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E542K	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/310	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E542K	Sirolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/311	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2022	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2026	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2058	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E542K	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7315	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8013	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8016	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E542K	Regorafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/83	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA E542K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4424	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA E542K	Apitolisib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/1549	only alteration type		HNSC
WP160	PIK3CA MUT* (--)	PIK3CA E542K	Perifosine,Temsirolimus	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1626	only alteration type		THCA
WP160	PIK3CA MUT* (--)	PIK3CA E545	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7468	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E545G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3724	only alteration type		CM
WP160	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1453	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2036	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6211	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E545K	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6213	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E545K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8008	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8547	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E545K	Akt Inhibitor MK2206,Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/710	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2034	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2062	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8017	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8018	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA E545K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3722	only alteration type		CM
WP160	PIK3CA MUT* (--)	PIK3CA E545K	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/387	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2037	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2217	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib	Lung adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1171	only alteration type		LUAD
WP160	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1670	only alteration type		LUAD
WP160	PIK3CA MUT* (--)	PIK3CA E545K	PI103	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2040	only alteration type		NSCLC
WP160	PIK3CA MUT* (--)	PIK3CA E545Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2213	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA E81K	Oxaliplatin,Fluorouracil,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4464	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA F930S	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10032	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA G1049R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3847	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA H1047L	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2089	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA H1047L	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8009	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA H1047L	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8019	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA H1047L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4432	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2103	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6204	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6206	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8548	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/314	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Capivasertib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1505	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1506	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Everolimus,Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1623	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2096	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2102	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/258	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/388	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Vemurafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3733	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3841	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Akt Inhibitor MK2206,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8364	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1465	only alteration type		HNSC
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1447	only alteration type		LUAD
WP160	PIK3CA MUT* (--)	PIK3CA H1047R	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1625	only alteration type		THCA
WP160	PIK3CA MUT* (--)	PIK3CA H1047X	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7318	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2867	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8663	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2866	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA K111N	Dactolisib,Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8183	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8662	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA K111N	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2085	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA K111N	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8011	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA K111N	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8020	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA K944N	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10031	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA K966E	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10034	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1384	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2087	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2098	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8536	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Capecitabine,Lapatinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8705	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1296	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1504	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1600	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1607	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1610	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Fulvestrant,Alpelisib	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7313	only alteration type		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/915	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1705	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3732	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6298	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6299	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6300	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6301	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6362	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Cabozantinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/771	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6375	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Ridaforolimus,Temsirolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/892	only alteration type		ED
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Pictilisib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1616	only alteration type		ED
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Radiation Therapy,Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1490	only alteration type		HNSC
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin,Sulindac,Celecoxib	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7185	only alteration type		HNSC
WP160	PIK3CA MUT* (--)	PIK3CA Mutation	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2355	only alteration type		NSCLC
WP160	PIK3CA MUT* (--)	PIK3CA N345K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4047	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA Q546K	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2198	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA R88Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3832	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA R93W	Cetuximab,Fluorouracil,Oxaliplatin	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4467	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA S158L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4463	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA V955G	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10033	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA V955I	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/8063	only alteration type		COREAD
WP160	PIK3CA MUT* (--)	PIK3CA Amplification	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8267	only gene		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA Amplification	Lapatinib,Dactolisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8271	only gene		BRCA
WP160	PIK3CA MUT* (--)	PIK3CA Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6275	only gene		CM
WP160	PIK3CA MUT* (--)	PIK3CA Amplification	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1464	only gene		HNSC
WP160	PIK3CA MUT* (--)	PIK3CA Amplification	Sulindac,Aspirin,Ibuprofen	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7186	only gene		HNSC
WP160	PIK3CA MUT* (--)	PIK3CA Amplification	Pictilisib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/756	only gene		OV
WP160	PIK3R1 MUT* (--), PIK3R1 MUT* (N325Y), PIK3R1 MUT* (--)	PIK3R1 Mutation	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1612	only alteration type		BRCA
WP160	PIK3R2 MUT* (--)	PIK3R2 N561D	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4783	only alteration type		CM
WP160	POLE (W1802C)	POLE Mutation	Pembrolizumab	Endometrium	Responsive	C	NO	https://civicdb.org/links/evidence_items/1862	complete		ED
WP160	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP160	RAC1 MUT* (--)	RAC1 P29S	Dabrafenib,Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/873	only alteration type		CM
WP160	RAD51D MUT* (A306S)	RAD51D Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11214	only alteration type		PRAD
WP160	RB1 MUT* (--), RB1 MUT* (--)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
WP160	RET MUT* (--)	RET CCDC6::RET	Agerafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7480	only gene		COREAD
WP160	RET MUT* (--)	RET CCDC6::RET	Nintedanib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1601	only gene		NSCLC
WP160	RET MUT* (--)	RET Fusion	Cabozantinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4847	only gene		LUAD
WP160	RET MUT* (--)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4848	only gene		NSCLC
WP160	RET MUT* (--)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4849	only gene		NSCLC
WP160	RET MUT* (--)	RET Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4850	only gene		NSCLC
WP160	RET MUT* (--)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7066	only gene		NSCLC
WP160	RET MUT* (--)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/8850	only gene		NSCLC
WP160	RET MUT* (--)	RET Fusion	Pralsetinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11233	only gene		NSCLC
WP160	RET MUT* (--)	RET Fusion	Selpercatinib	Thyroid carcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8852	only gene		THCA
WP160	RET MUT* (--)	RET KIF5B::RET	Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/698	only gene		LUAD
WP160	RET MUT* (--)	RET KIF5B::RET	Vandetanib,Everolimus	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1622	only gene		LUAD
WP160	RICTOR MUT* (--)	RICTOR Amplification	Onatasertib,Sapanisertib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1440	only gene		LUAD
WP160	RICTOR MUT* (--)	RICTOR Amplification	Vistusertib	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7449	only gene		SCLC
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Rearrangement	Ceritinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1248	only gene		LUAD
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1690	only gene		LUAD
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/688	only gene		NSCLC
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1030	only gene		NSCLC
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7933	only gene		NSCLC
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 FUSIONS	Entrectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11123	only gene		NSCLC
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7282	only gene		NSCLC
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 G2032R	Crizotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2934	only alteration type		LUAD
WP160	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 GOPC::ROS1	Lorlatinib	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7483	only gene		GB
WP160	RSF1 MUT* (--)	RSF1 Amplification	Tamoxifen	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/857	only gene		BRCA
WP160	SF3B1 MUT* (--), SF3B1 MUT* (--)	SF3B1 K666N	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1418	only alteration type		BRCA
WP160	SF3B1 MUT* (--), SF3B1 MUT* (--)	SF3B1 K700E	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1417	only alteration type		BRCA
WP160	SMAD4 MUT* (--)	SMAD4 Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/719	only alteration type		COREAD
WP160	TOP1 MUT* (--)	TOP1 Amplification	Irinotecan	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/888	only gene		COREAD
WP160	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP160	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP160	TSC2 MUT* (A1185S)	TSC2 Q1178*	Everolimus	Thyroid carcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1108	only alteration type		THCA
WP066	DNMT3A (P625X)	DNMT3A oncogenic mutation	Daunorubicin(Chemotherapy)	Acute myeloid leukemia	Responsive	A	YES	PMID:22417203	complete		AML
WP066	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Myelofibrosis	Responsive	A	YES	FDA	complete		MY
WP066	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP066	TPMT MUT* (--)	TPMT splice acceptor variant	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP066	TPMT MUT* (--)	TPMT biallelic inactivation	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP066	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP066	TPMT MUT* (--)	TPMT splice acceptor variant	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP066	TPMT MUT* (--)	TPMT biallelic inactivation	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP066	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP066	TPMT MUT* (--)	TPMT splice acceptor variant	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP066	TPMT MUT* (--)	TPMT biallelic inactivation	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP066	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP066	FLT3 MUT* (--)	FLT3-ITD	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia;PMID:28644114	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 (D835,I836)	Gilteritinib(Kinase inhibitor )	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3-ITD	Gilteritinib(Kinase inhibitor )	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation;PMID:31665578	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 (D835,I836)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia; PMID:28644114	only alteration type		AML
WP066	FGFR2 MUT* (--)	FGFR2 fusion	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only gene		BLCA
WP066	BRIP1 MUT* (--)	BRIP1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP066	CHEK1 MUT* (--)	CHEK1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP066	FANCL MUT* (--)	FANCL oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP066	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP066	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP066	FGFR2 MUT* (--)	FGFR2 fusion	Infigratinib(FGFR kinase inhibitor)	Cholangiocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma	only gene		CH
WP066	FGFR2 MUT* (--)	FGFR2 fusion	Pemigatinib(FGFR kinase inhibitor)	Cholangiocarcinoma	Responsive	A	NO	FDA;PMID:32203698	only gene		CH
WP066	ROS1 MUT* (--)	ROS1 fusion	Entrectinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA;PMID:28183697;ESMO 2019 (abstr 4178) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725s007lbl.pdf	only gene		NSCLC
WP066	RAD51C MUT* (G153)	RAD51C oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP066	RAD54L MUT* (--)	RAD54L oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP066	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Bevacizumab(VEGF mAb inhibitor);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP066	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP066	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Pembrolizumab(PD-1-blocking antibody);Pemetrexed(Chemotherapy);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf	complete		NSCLC
WP066	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Durvalumab(PD-1-blocking antibody);Tremelimumab-actl(CTLA-4 blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non	complete		NSCLC
WP066	FGFR2 MUT* (--)	FGFR2 fusion	Futibatinib(pan-FGFR inhibitor)	Intrahepatic cholangiocarcinoma	Responsive	A	NO	FDA: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-futibatinib-cholangiocarcinoma	only gene		IHCH
WP066	ATR MUT* (--)	ATR oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP066	RAD51C MUT* (G153)	RAD51C oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP066	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP066	FLT3 MUT* (--)	FLT3-ITD	Quizartinib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia	only alteration type		AML
WP066	ROS1 MUT* (--)	ROS1 fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP066	ROS1 MUT* (--)	ROS1 fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP066	CTNNB1 MUT* (--)	CTNNB1 oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Resistant	D	NO	PMID:23539443	only alteration type		COREAD
WP066	FGFR2 MUT* (--), FGFR2 MUT* (--)	FGFR2 (N549H,V564F,K659M,L617V,K641R,R565A) + FGFR2 fusion	FGFR inhibitors	Cholangiocarcinoma	Resistant	C	NO	PMID:28034880;ASCO 2017 (abstr 2500)	only gene		CH
WP066	ATR MUT* (--)	ATR oncogenic mutation	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only alteration type		OV, CANCER
WP066	ATR MUT* (--)	ATR deletion	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only gene		OV, CANCER
WP066	ATR MUT* (--)	ATR oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP066	JAK2 (V617F)	JAK2 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	complete		CM
WP066	CBL MUT* (--)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP066	CBL MUT* (--)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP066	CTNNB1 MUT* (--)	CTNNB1 (H36Y,S37C,S37Y,D32V)	Everolimus + Letrozole(MTOR inhibitor + Hormonal therapy)	Endometrium	Responsive	C	NO	PMID:25624430	only alteration type		ED
WP066	MCL1 MUT* (--)	MCL1 amplification	Tubulin inhibitors	Any cancer type	Resistant	D	YES	PMID:21368834	only gene		CANCER
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP066	NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP066	ERCC6 MUT* (--)	ERCC6 oncogenic mutation	Cisplatin(Chemotherapy)	Ovary	Responsive	D	NO	PMID:25634215	only alteration type		OV
WP066	FGFR2 MUT* (--)	FGFR2 fusion	FGFR inhibitors	Billiary tract	Responsive	C	NO	ASCO 2016 (abstr 109)	only gene		BT
WP066	FGFR2 MUT* (--)	FGFR2 inframe insertion (A266),inframe insertion (S267)	FGFR inhibitors	Lung	Responsive	D	NO	PMID:26048680	only alteration type		L
WP066	FGFR2 MUT* (--)	FGFR2 amplification	FGFR inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2508)	only gene		ST
WP066	FGFR2 MUT* (--)	FGFR2 amplification	FGFR inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:25193991	only gene		BRCA
WP066	FGFR2 MUT* (--)	FGFR2 (S252W,N550K)	FGFR inhibitors	Endometrium	Responsive	D	NO	PMID:18552176;PMID:22238366;PMID:23002168	only alteration type		ED
WP066	FGFR2 MUT* (--)	FGFR2 (V565I)	FGFR inhibitors	Endometrium	Responsive	D	NO	ENA 2014 (abstr 381)	only alteration type		ED
WP066	FGFR2 MUT* (--)	FGFR2 (W290C,S320C,K660N)	FGFR inhibitors	Lung squamous cell	Responsive	D	NO	PMID:23786770;PMID:25035393	only alteration type		LUSC
WP066	FGFR2 MUT* (--)	FGFR2 fusion	FGFR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 2500)	only gene		COREAD
WP066	FGFR2 MUT* (--)	FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Endometrium	Responsive	D	NO	PMID:23908597	only alteration type		ED
WP066	FLT3 MUT* (--)	FLT3-ITD	FLT3 inhibitors	Acute myeloid leukemia	Responsive	C	YES	PMID:16857985	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 (F691)	novel FLT3 inhibitors	Acute myeloid leukemia	Responsive	D	YES	PMID:25847190	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 (N676)	Crenolanib(FLT3 inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:24619500	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 (D835)	Lestaurtinib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:16857985	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 (D835)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:20733134	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 (N676)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:24619500	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3-ITD	Sorafenib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:19389879;PMID:22368270	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3-ITD	Sorafenib + Azacytidine(Pan-TK inhibitor + Chemotherapy)	Acute myeloid leukemia	Responsive	C	YES	PMID:23613521	only alteration type		AML
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP066	NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP066	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP066	INPP4B MUT* (--), INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP066	INPP4B MUT* (--), INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP066	JAK2 (V617F)	JAK2 (V617F)	JAK inhibitor(alone or in combination)s	Acute myeloid leukemia	Responsive	D	YES	PMID:22829971	complete		AML
WP066	JAK2 (V617F)	JAK2 amplification	JAK inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27075627	only gene		BRCA
WP066	JAK2 (V617F)	JAK2-BRAF fusion	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22875628;PMID:22899477	only gene		ALL
WP066	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:22422826	complete		AML
WP066	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP066	MDM2 MUT* (--)	MDM2 amplification	Cisplatin(Chemotherapy)	Male germ cell tumor	Resistant	C	NO	PMID:27646943	only gene		MGCT
WP066	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP066	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP066	ROS1 MUT* (--)	ROS1 (G2032R)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:23724914;PMID:25688157	only alteration type		LUAD
WP066	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP066	NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP066	FGFR2 MUT* (--)	FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)	Dovitinib(FGFR inhibitor)	Endometrium	Resistant	D	NO	PMID:23908597	only alteration type		ED
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP066	NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP066	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP066	NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP066	NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP066	MDM2 MUT* (--)	MDM2 amplification	MDM2 inhibitors	Liposarcoma	Responsive	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	only gene		LIP
WP066	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP066	NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP066	NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP066	NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP066	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP066	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP066	NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP066	NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP066	NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP066	NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP066	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP066	NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP066	CRBN MUT* (--)	CRBN oncogenic mutation	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP066	CRBN MUT* (--)	CRBN (Q100*,R283K)	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP066	NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP066	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP066	NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP066	NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP066	NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP066	NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP066	NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP066	NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP066	NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP066	NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP066	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP066	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP066	NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP066	NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP066	NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP066	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP066	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP066	CRBN MUT* (--)	CRBN oncogenic mutation	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP066	CRBN MUT* (--)	CRBN (Q100*,R283K)	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP066	NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP066	NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP066	PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP066	PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP066	FLT3 MUT* (--)	FLT3 (D835,Y842)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Acute myeloid leukemia	Resistant	D	YES	PMID:23430109	only alteration type		AML
WP066	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP066	FLT3 MUT* (--)	FLT3 (F691,D835,N676,Y842)	Quizartinib(Pan-TK inhibitor)	Acute myeloid leukemia	Resistant	D	YES	PMID:22504184;PMID:23878140	only alteration type		AML
WP066	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP066	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP066	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP066	NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP066	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP066	RAD51C MUT* (G153)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
WP066	RAD51C MUT* (G153)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
WP066	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP066	RB1 MUT* (--)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
WP066	RB1 MUT* (--)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
WP066	RB1 MUT* (--)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
WP066	RB1 MUT* (--)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
WP066	RB1 MUT* (--)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP066	RB1 MUT* (--)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP066	ROS1 MUT* (--)	ROS1 fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:23533265	only gene		LUAD
WP066	ROS1 MUT* (--)	ROS1 fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27370605	only gene		LUAD
WP066	ROS1 MUT* (--)	ROS1 (G2032R)	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:25351743	only alteration type		LUAD
WP066	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	C	YES	PMID:24875859	only gene		IM
WP066	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:25264305	only gene		LUAD
WP066	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27401242	only alteration type		LUAD
WP066	NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP066	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP066	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP066	FLT3 MUT* (--)	FLT3-ITD	Venetoclax(BCL2 inhibitor)	Acute myeloid leukemia	Resistant	C	YES	PMID:27520294	only alteration type		AML
WP066	FGFR2 MUT* (--)	FGFR2 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Cholangiocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CH
WP066	MDM2 MUT* (--)	MDM2 amplification	Unii-Q8Mi0X869M	Liposarcoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MDM2	only gene		LIP
WP066	FGFR2 MUT* (--)	FGFR2 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		BLCA
WP066	FGFR2 MUT* (--)	FGFR2 (N549K,K526E,K641R,I547V,Y375C,D101Y,E219K,E565G,C382R,N549H,W290R,L617M,D530N,M535I,P253R,V564I,F276C,S252W,N549T,E731K,G271E,I642V,K641N,R203C,K659E,.,L617F,M537I,T341P,R678G,M391R,Y381D,V564F,K525E,N549S,R251Q,A648T,K659N)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only alteration type		CANCER
WP066	FGFR2 MUT* (--)	FGFR2 amplification	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP066	FGFR2 MUT* (--)	FGFR2-AHCYL1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP066	FGFR2 MUT* (--)	FGFR2-BICC1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP066	FGFR2 MUT* (--)	FGFR2-CCDC6 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP066	FGFR2 MUT* (--)	FGFR2-CIT fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP066	FGFR2 MUT* (--)	FGFR2-FAM76A fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP066	FGFR2 MUT* (--)	FGFR2-KIAA1967 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP066	FGFR2 MUT* (--)	FGFR2-MGEA5 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP066	FGFR2 MUT* (--)	FGFR2-TACC3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP066	FGFR2 MUT* (--)	FGFR2 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP066	NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP066	NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP066	JAK2 (V617F)	JAK2-PCM1 fusion	Ruxolitinib	Eosinophilic chronic leukemia	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/JAK2	only gene		ECL
WP066	ABCC3 MUT* (--)	ABCC3 Amplification	Monomethyl Auristatin E,Paclitaxel	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/951	only gene		BRCA
WP066	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP066	BRIP1 MUT* (--)	BRIP1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11208	only alteration type		PRAD
WP066	CHEK1 MUT* (--)	CHEK1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11210	only alteration type		PRAD
WP066	CRBN MUT* (--)	CRBN Mutation	Lenalidomide,Pomalidomide	Multiple myeloma	Resistant	C	YES	https://civicdb.org/links/evidence_items/1766	only alteration type		MM
WP066	DNMT3A (P625X)	DNMT3A Mutation	Decitabine	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/1587	complete		AML
WP066	DNMT3A (P625X)	DNMT3A R882	Daunorubicin	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/11	only alteration type		AML
WP066	DNMT3A (P625X)	DNMT3A R882	Idarubicin	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/18	only alteration type		AML
WP066	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP066	FGFR2 MUT* (--)	FGFR2 FGFR2::AHCYL1	Infigratinib,PD173074	Cholangiocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1853	only gene		CH
WP066	FGFR2 MUT* (--)	FGFR2 FGFR2::BICC1	PD173074,Infigratinib	Cholangiocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1851	only gene		CH
WP066	FGFR2 MUT* (--)	FGFR2 FGFR2::BICC1	Erdafitinib	Endometrium	Responsive	C	NO	https://civicdb.org/links/evidence_items/1920	only gene		ED
WP066	FGFR2 MUT* (--)	FGFR2 FGFR2::MGEA5	Ponatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/295	only gene		CH
WP066	FGFR2 MUT* (--)	FGFR2 FGFR2::TACC3	Pazopanib,Ponatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/296	only gene		CH
WP066	FGFR2 MUT* (--)	FGFR2 Fusion	Infigratinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1913	only gene		CH
WP066	FGFR2 MUT* (--)	FGFR2 Fusion	Infigratinib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5908	only gene		CH
WP066	FGFR2 MUT* (--)	FGFR2 Fusion	Derazantinib	Intrahepatic cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7329	only gene		IHCH
WP066	FGFR2 MUT* (--)	FGFR2 Mutation	Infigratinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1912	only alteration type		CH
WP066	FGFR2 MUT* (--)	FGFR2 Mutation	Infigratinib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5912	only alteration type		CH
WP066	FGFR2 MUT* (--)	FGFR2 Mutation	Ponatinib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1236	only alteration type		ED
WP066	FGFR2 MUT* (--)	FGFR2 N550K	PD173074	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1322	only alteration type		ED
WP066	FGFR2 MUT* (--)	FGFR2 P253R	Pazopanib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/7833	only alteration type		HNSC
WP066	FGFR2 MUT* (--)	FGFR2 Amplification	Dovitinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1605	only gene		BRCA
WP066	FLT3 MUT* (--)	FLT3 D835	Quizartinib,Ponatinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1036	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 D835	SU5614	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1037	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 D835	Quizartinib,Sorafenib	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/1038	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 D835	Sorafenib	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/1039	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 D835H	Sorafenib	Acute myeloid leukemia	Resistant	C	YES	https://civicdb.org/links/evidence_items/1556	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 D835H	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8517	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 D835H/Y	Sorafenib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1557	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 D835I	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8351	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 D835V	Tandutinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/3007	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 D835V	Sunitinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3008	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 D835V	Sunitinib,Cytarabine	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3009	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 D835V	Daunorubicin,Sunitinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3010	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 D835V	Quizartinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3012	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 D835V	AS602868,Tyrphostin AG 1296	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3034	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 D835V	Sunitinib	Acute myeloid leukemia	Responsive	C	YES	https://civicdb.org/links/evidence_items/4022	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 D835V	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8518	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 D835Y	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8108	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 F691L	Lestaurtinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8341	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 F691L	Midostaurin	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8342	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 Mutation	Midostaurin	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/5261	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 Mutation	Gilteritinib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/7283	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 Mutation	Gilteritinib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/7728	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 Y842C	FLT3/ABL/Aurora Kinase Inhibitor KW-2449	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8336	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 Y842C	Sorafenib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8337	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 Y842C	Sunitinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8338	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 Y842C	Quizartinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8654	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 Y842C	Lestaurtinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8339	only alteration type		AML
WP066	FLT3 MUT* (--)	FLT3 Y842C	Midostaurin	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8340	only alteration type		AML
WP066	JAK2 (V617F)	JAK2 Splice Site (c.1641+2T>G)	Pembrolizumab	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4825	only alteration type		CM
WP066	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP066	KMT2C MUT* (K2797X), KMT2C MUT* (S806)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP066	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP066	NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP066	NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP066	NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP066	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP066	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP066	RAD54L MUT* (--)	RAD54L Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11207	only alteration type		PRAD
WP066	RB1 MUT* (--)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
WP066	ROS1 MUT* (--)	ROS1 Rearrangement	Ceritinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1248	only gene		LUAD
WP066	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1690	only gene		LUAD
WP066	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/688	only gene		NSCLC
WP066	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1030	only gene		NSCLC
WP066	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7933	only gene		NSCLC
WP066	ROS1 MUT* (--)	ROS1 FUSIONS	Entrectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11123	only gene		NSCLC
WP066	ROS1 MUT* (--)	ROS1 Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7282	only gene		NSCLC
WP066	ROS1 MUT* (--)	ROS1 G2032R	Crizotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2934	only alteration type		LUAD
WP066	ROS1 MUT* (--)	ROS1 GOPC::ROS1	Lorlatinib	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7483	only gene		GB
WP066	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP066	SMAD4 MUT* (H291P)	SMAD4 Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/719	only alteration type		COREAD
WP066	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP066	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP285	ABL1 MUT* (--)	ABL1-BCR fusion	Bosutinib(BCR-ABL inhibitor  3rd gen)	Chronic myeloid leukemia	Responsive	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s024lbl.pdf	only gene		CML
WP285	ABL1 MUT* (--)	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	Bosutinib(BCR-ABL inhibitor  3rd gen)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP285	ABL1 MUT* (--)	ABL1-BCR fusion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf	only gene		CML, ALL
WP285	ABL1 MUT* (--)	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP285	ABL1 MUT* (--)	ABL1-BCR fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	EMA	only gene		CML, ALL
WP285	ABL1 MUT* (--)	ABL1-BCR fusion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia	Responsive	A	YES	FDA	only gene		CML
WP285	ABL1 MUT* (--)	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP285	ABL1 MUT* (--)	ABL1-BCR fusion	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	FDA	only gene		CML, ALL
WP285	ABL1 MUT* (--)	ABL1 (T315I)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	FDA	only alteration type		CML, ALL
WP285	ABL1 MUT* (--)	ABL1 (T315I)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP285	KRAS MUT* (--)	KRAS (12,13)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP285	ABL1 MUT* (--)	ABL1 (T315I)	BCR-ABL inhibitor 2nd gens(Nilotinib,Dasatinib,etc)	Chronic myeloid leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML
WP285	ABL1 MUT* (--)	ABL1 (T315I)	Bosutinib(BCR-ABL inhibitor  3rd gen)	Chronic myeloid leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML
WP285	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Myelofibrosis	Responsive	A	YES	FDA	complete		MY
WP285	KRAS MUT* (--)	KRAS (12,13,59,61,117,146)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	NCCN guidelines	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	NCCN guidelines	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR inhibitors	Lung	Resistant	A	NO	NCCN guidelines	only alteration type		L
WP285	ABL1 MUT* (--)	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML, ALL
WP285	ABL1 MUT* (--)	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Chronic myeloid leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML
WP285	ABL1 MUT* (--)	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Resistant	A	YES	NCCN Guidelines Chronic Myeloid Leukemia 2022;NCCN Guidelines Acute Lymphoblastic Leukemia 2022;PMID:21562040	only alteration type		CML, ALL
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome, Eosinophilic chronic leukemia	Responsive	A	YES	EMA	only gene		HES, ECL
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA inframe deletion (I843)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type	862.0	GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type	862.0	GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Regorafenib(Pan-kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
WP285	ABL1 MUT* (--)	ABL1 (T315I,V299L,G250E,F317L)	Bosutinib(BCR-ABL inhibitor 3rd gen)	Acute lymphoblastic leukemia, Chronic myeloid leukemia	Resistant	A	YES	NCCN	only alteration type		ALL, CML
WP285	ABL1 MUT* (--)	ABL1 (T315I)	Asciminib(Kinase inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia	only alteration type		CML
WP285	ABL1 MUT* (--)	BCR-ABL1	Asciminib(Kinase inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215358s003lbl.pdf	only gene		CML
WP285	ABL1 MUT* (--)	ABL1 (T315I)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Acute lymphoblastic leukemia	Resistant	A	YES	NCCN Guideline ALL 2022	only alteration type		ALL
WP285	ABL1 MUT* (--)	ABL1 (E255V,Y253H,F359V)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf	only alteration type		CML
WP285	KRAS MUT* (--)	KRAS (G12C)	Sotorasib(RAS GTPase family inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc	only alteration type		NSCLC
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA exon 18 mutations	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation;PMID:32615108	only alteration type		GIST
WP285	MET MUT* (--)	MET exon 14 skipping mutations	Tepotinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer;PMID:31279006;PMID:34036238	only alteration type		NSCLC
WP285	MET MUT* (--)	MET exon 14 skipping mutations	Capmatinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capmatinib-metastatic-non-small-cell-lung-cancer	only alteration type		NSCLC
WP285	ABL1 MUT* (--)	ABL1 (T315I)	Bosutinib(BCR-ABL inhibitor 3rd gen)	Acute lymphoblastic leukemia	Resistant	A	YES	NCCN Guideline ALL 2022	only alteration type		ALL
WP285	PALB2 MUT* (S1082I)	PALB2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP285	RAD51D MUT* (--)	RAD51D oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP285	KRAS MUT* (--)	KRAS (G12C)	Adagrasib(RAS GTPase family inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc	only alteration type		NSCLC
WP285	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Bevacizumab(VEGF mAb inhibitor);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP285	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP285	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Pembrolizumab(PD-1-blocking antibody);Pemetrexed(Chemotherapy);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf	complete		NSCLC
WP285	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Durvalumab(PD-1-blocking antibody);Tremelimumab-actl(CTLA-4 blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non	complete		NSCLC
WP285	ATR MUT* (--)	ATR oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP285	FANCA MUT* (--)	FANCA oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP285	PALB2 MUT* (S1082I)	PALB2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP285	EGFR wildtype, ALK wildtype, ROS1 wildtype	EGFR wildtype;ALK wildtype;ROS1 wildtype	Cemiplimab-rwlc(PD-1-blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-combination-platinum-based-chemotherapy-non-small-cell-lung-cancer	complete		NSCLC
WP285	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
WP285	IDH2 MUT* (--)	IDH2 oncogenic mutation	Enasidenib(IDH2 inhibitor)	Acute lymphoblastic leukemia	Responsive	A	YES	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209606s004lbl.pdf	only alteration type		ALL
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP285	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP285	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP285	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP285	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP285	KRAS MUT* (--)	KRAS (G12C)	Adagrasib(RAS GTPase family inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP285	ABL1 MUT* (--)	ABL1-BCR fusion	Bosutinib(BCR-ABL inhibitor  3rd gen)	Acute lymphoblastic leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/all.pdf	only gene		ALL
WP285	ABL1 MUT* (--)	ABL1-BCR fusion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Acute lymphoblastic leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/all.pdf	only gene		ALL
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA oncogenic mutations (excluding D842V + exon 18 inframe mutations)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type	862.0	GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V + exon 18 mutations	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
WP285	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP285	MET MUT* (--)	MET amplification	Capmatinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP285	MET MUT* (--)	MET amplification	Tepotinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP285	MET MUT* (--)	MET exon 14 skipping mutations	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS (G12C)	Sotorasib(RAS GTPase family inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP285	PALB2 MUT* (S1082I)	PALB2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP285	IDH2 MUT* (--)	IDH2 oncogenic mutation	Venetoclax(BCL2 inhibitor)	Acute myeloid leukemia	Responsive	A	YES	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf	only alteration type		AML
WP285	ABL1 MUT* (--)	ABL1 (T315I)	Axitinib(VEGFR inhibitor)	Any cancer type	Responsive	D	YES	PMID:25686603	only alteration type		CANCER
WP285	ABL1 MUT* (--)	ABL1 (V299L)	Cabozantinib(Pan-kinase inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP285	ABL1 MUT* (--)	ABL1 (V299L)	Crizotinib(ALK inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP285	ABL1 MUT* (--)	ABL1-BCR fusion	Dasatinib + Venetoclax(BCR-ABL inhibitor 2nd gen + BCL2 inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:27582059	only gene		ALL
WP285	ABL1 MUT* (--)	ABL1 (V299L)	ForetinibÂ (MET inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP285	ABL1 MUT* (--)	ABL1 (V299L)	Vandetanib(Pan-TK inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP285	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	complete		CANCER
WP285	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	complete		OV
WP285	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	complete		CANCER
WP285	ATR MUT* (--)	ATR oncogenic mutation	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only alteration type		OV, CANCER
WP285	ATR MUT* (--)	ATR deletion	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only gene		OV, CANCER
WP285	ATR MUT* (--)	ATR oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP285	JAK2 (V617F)	JAK2 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	complete		CM
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Pancreas	No Responsive	C	NO	ASCO 2015 (abstr 4119)	only alteration type		PA
WP285	KRAS MUT* (--)	KRAS (G13D)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	No Responsive	B	NO	PMID:27114605	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	Selumetinib(MEK inhibitor)	Lung	No Responsive	C	NO	PMID:26802155	only alteration type		L
WP285	KRAS MUT* (--)	KRAS amplification	BRAF inhibitor + EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only gene		COREAD
WP285	KRAS MUT* (--)	KRAS amplification	BRAF inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only gene		COREAD
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR inhibitors	Non-small cell lung	Resistant	D	NO	PMID:19238210	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR mAb inhibitors	Stomach	Resistant	D	NO	PMID:22614881;PMID:22290393	only alteration type		ST
WP285	MAP2K2 (V85G)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP285	MAP2K2 (V85G)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP285	MAP2K2 (V85G)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP285	MAP2K2 (V85G)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP285	MET MUT* (--)	MET amplification	EGFR inhibitor 1st gens	Non-small cell lung, Colorectal adenocarcinoma	Resistant	C	NO	PMID:22189054;PMID:23729478	only gene		NSCLC, COREAD
WP285	MET MUT* (--)	MET amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:23729478	only gene		COREAD
WP285	MET MUT* (--)	MET (D1246V)	MET inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:27694386	only alteration type		LUAD
WP285	MITF MUT* (T95)	MITF amplification	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265153	only gene		CM
WP285	MITF MUT* (T95)	MITF amplification	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265153	only gene		CM
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA amplification	PDGFR inhibitors	Glioma	No Responsive	D	NO	PMID:23544171	only gene		G
WP285	TP53 MUT* (--)	TP53 oncogenic mutation	MDM2 inhibitors	Liposarcoma	Resistant	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	only alteration type		LIP
WP285	FANCA MUT* (--)	FANCA oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP285	FANCA MUT* (--)	FANCA deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only gene		PRAD
WP285	TP53 MUT* (--)	TP53 oncogenic mutation	Abemaciclib(CDK4/CDK6 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:27217383	only alteration type		BRCA
WP285	HDAC2 MUT* (--)	HDAC2 biallelic inactivation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP285	IDH2 MUT* (--)	IDH2 (R140K,R172K)	AG-221(IDH2 inhibitor)	Hematologic malignancies	Responsive	C	YES	AACR 2014 (abstr CT103)	only alteration type		HEMATO
WP285	IDH2 MUT* (--)	IDH2 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Cholangiocarcinoma	Responsive	C	NO	NCT02428855	only alteration type		CH
WP285	IDH2 MUT* (--)	IDH2 (R172)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Billiary tract	Responsive	D	NO	PMID:27231123	only alteration type		BT
WP285	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP285	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	EZH2 inhibitors	Any cancer type	Resistant	D	YES	PMID:26552009	only alteration type		CANCER
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitors	Endometrium	Resistant	D	NO	PMID:22662154	only alteration type		ED
WP285	JAK2 (V617F)	JAK2 (V617F)	JAK inhibitor(alone or in combination)s	Acute myeloid leukemia	Responsive	D	YES	PMID:22829971	complete		AML
WP285	JAK2 (V617F)	JAK2 amplification	JAK inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27075627	only gene		BRCA
WP285	JAK2 (V617F)	JAK2-BRAF fusion	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22875628;PMID:22899477	only gene		ALL
WP285	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:22422826	complete		AML
WP285	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP285	TP53 MUT* (--)	TP53 oncogenic mutation	Cisplatin(Chemotherapy)	Female germ cell tumor, Male germ cell tumor	Resistant	C	NO	PMID:27646943	only alteration type		FGCT, MGCT
WP285	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP285	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP285	KRAS MUT* (--)	KRAS (G12)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	C	NO	PMID:24687822	only alteration type		GIST
WP285	MET MUT* (--)	MET (Y1230C,Y1235D)	Crizotinib(ALK inhibitor)	Any cancer type	Resistant	D	YES	PMID:17483355	only alteration type		CANCER
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	Trastuzumab + Lapatinib(ERBB2 mAb inhibitor + ERBB2 inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	ASCO 2015 (abstr 3508);NCT01104571;EBCC10	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	BET inhibitors	Lung	Responsive	D	NO	PMID:23129625;PMID:24045185	only alteration type		L
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4 inhibitors	Lung	Responsive	D	NO	PMID:20609353	only alteration type		L
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Lung	Responsive	C	NO	AACR 2017 (CT046)	only alteration type		L
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Cervix squamous cell	Responsive	D	NO	PMID:27167191	only alteration type		CESC
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR mAb inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24553387	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	ERK inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23614898	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	FAK inhibitors	Lung	Responsive	D	NO	PMID:23358651	only alteration type		L
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	FAS inhibitors	Lung	Responsive	C	NO	AACR 2016;abstr	only alteration type		L
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	FAS inhibitors	Lung	Responsive	C	NO	AACR 2016, abstr LB214	only alteration type		L
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	HSP90 inhibitor(in combination)s	Lung	Responsive	D	NO	PMID:23012248;PMID:21907929	only alteration type		L
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	JAK/TBK1/IKKÎµ inhibitors	Lung	Responsive	D	NO	PMID:24444711	only alteration type		L
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + BCL-XL inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23245996	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + IGF1R inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24045180	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + PI3K pathway inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:22392911	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitors	Lung, Billiary tract	Responsive	C	NO	PMID:23200175;PMID:24947927;PMID:25667274;PMID:25722381;PMID:23391555	only alteration type		L, BT
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitors	Acute myeloid leukemia, Cervix, Ovary	Responsive	D	YES	PMID:22507781;PMID:22169769;PMID:19018267	only alteration type		AML, CER, OV
WP285	KRAS MUT* (--)	KRAS (G12)	MEK inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:18701506	only alteration type		ALL
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	MTOR inhibitor + BH3 mimeticss	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24163374	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	pan-RAF inhibitors	Lung	Responsive	C	NO	AACR 2017 (abstr  CT002)	only alteration type		L
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	pan-RAF inhibitors	Endometrium	Responsive	C	NO	AACR 2016 (abstr CT005);AACR 2017 (abstr CT002)	only alteration type		ED
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Endometrium	Responsive	D	NO	PMID:21984976;PMID:22662154	only alteration type		ED
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Lung	Responsive	C	NO	PMID:25516890	only alteration type		L
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	Abemaciclib(CDK4/6 inhibitor)	Lung	Responsive	C	NO	PMID:27217383	only alteration type		L
WP285	MTOR MUT* (--)	MTOR (F2108L)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Resistant	C	NO	PMID:25295501	only alteration type		THCA
WP285	MET MUT* (--)	MET kinase domain mutation	Savolitinib(MET inhibitor)	Renal	Responsive	C	NO	PMID:28644771	only alteration type		R
WP285	MET MUT* (--)	MET amplification	BCL2 inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:27397505	only gene		COREAD
WP285	MET MUT* (--)	MET amplification	MET inhibitors	Hepatic carcinoma	Responsive	C	NO	ENA 2015 (abstract A55)	only gene		HC
WP285	MET MUT* (--)	MET amplification	MET inhibitors	Stomach	Responsive	D	NO	PMID:22729845;PMID:23327903	only gene		ST
WP285	MET MUT* (--)	MET amplification	MET inhibitors	Renal	Responsive	C	NO	PMID:23213094;AACR 2016 (abstr CT2006)	only gene		R
WP285	MET MUT* (--)	MET (H1112R)	MET inhibitors	Renal	Responsive	C	NO	PMID:23213094	only alteration type		R
WP285	MET MUT* (--)	MET (M1268T)	MET inhibitors	Renal	Responsive	C	NO	PMID:23610116	only alteration type		R
WP285	MET MUT* (--)	MET (H1112L)	MET inhibitors(Crizotinib,etc)	Any cancer type	Responsive	D	YES	AACR 2012 (abstr 1786)	only alteration type		CANCER
WP285	MET MUT* (--)	MET amplification	Cabozantinib + Panitumumab(Pan-kinase inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A52)	only gene		COREAD
WP285	MET MUT* (--)	MET fusion	Crizotinib(ALK inhibitor)	Glioma	Responsive	C	NO	PMID:27748748	only gene		G
WP285	MET MUT* (--)	MET mutation in exon 16-19	Crizotinib(ALK inhibitor)	Renal	Responsive	C	NO	AACR 2016 (abstr CT2006)	only alteration type		R
WP285	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma, Stomach	Responsive	C	NO	ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1)	only gene		LUAD, ST
WP285	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Glioma	Responsive	C	NO	PMID:22162573	only gene		G
WP285	MET MUT* (--)	MET (V1110I,H1112R,M1268T,R988C,T1010I)	Crizotinib(ALK inhibitor)	Any cancer type	Responsive	D	YES	PMID:17483355	only alteration type		CANCER
WP285	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP285	MSH3 MUT* (--)	MSH3 oncogenic mutation	DNA-PKc inhibitors	Any cancer type	Responsive	D	YES	PMID:24556366	only alteration type		CANCER
WP285	MTOR MUT* (--)	MTOR (F2108L)	MTOR kinase inhibitors	Any cancer type	Responsive	D	YES	PMID:25295501	only alteration type		CANCER
WP285	MTOR MUT* (--)	MTOR (E2014K,E2419K,N1421D)	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:24625776	only alteration type		BLCA
WP285	MTOR MUT* (--)	MTOR (I1973F)	Everolimus(MTOR inhibitor)	Angiosarcoma, Renal	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		AS, R
WP285	MTOR MUT* (--)	MTOR (K1771R)	Everolimus(MTOR inhibitor)	Stomach, Adrenal gland	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		ST, AG
WP285	MTOR MUT* (--)	MTOR (N1421D)	Everolimus(MTOR inhibitor)	Stomach	Responsive	C	NO	PMID:26859683	only alteration type		ST
WP285	MTOR MUT* (--)	MTOR (Q2223K)	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468	only alteration type		R
WP285	MTOR MUT* (--)	MTOR (L1460P,S2215Y,R2505P)	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	D	YES	PMID:24631838	only alteration type		CANCER
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	Decitabine + BCL2 inhibitor(Chemotherapy + BCL2 inhibitor)	Ovary	Responsive	D	NO	PMID:25968887	only alteration type		OV
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (T674I)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome	Resistant	C	YES	PMID:12660384	only alteration type		HES
WP285	CRBN MUT* (--)	CRBN oncogenic mutation	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP285	CRBN MUT* (--)	CRBN (Q100*,R283K)	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP285	MET MUT* (--)	MET amplification	EGFR inhibitor 3rd gens(Osimertinib,etc)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	Gemcitabine + MEK inhibitor(Chemotherapy + MEK inhibitor)	Pancreas	Responsive	C	NO	PMID:23583440	only alteration type		PA
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	Selumetinib(MEK inhibitor)	Non-small cell lung	Responsive	C	NO	NCT00890825	only alteration type		NSCLC
WP285	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP285	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP285	NOTCH1 MUT* (--)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP285	NOTCH1 MUT* (--)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP285	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP285	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP285	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP285	NOTCH1 MUT* (--)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	only alteration type		MCL
WP285	NOTCH1 MUT* (--)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP285	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP285	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP285	NOTCH2 MUT* (P6X)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP285	NOTCH2 MUT* (P6X)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP285	NOTCH2 MUT* (P6X)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP285	CRBN MUT* (--)	CRBN oncogenic mutation	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP285	CRBN MUT* (--)	CRBN (Q100*,R283K)	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP285	NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP285	NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP285	PALB2 MUT* (S1082I)	PALB2 oncogenic mutation	PARP inhibitors	Prostate adenocarcinoma	Responsive	C	NO	AACR 2015 (abstr CT322);PMID:26510020	only alteration type		PRAD
WP285	PALB2 MUT* (S1082I)	PALB2 oncogenic mutation	PARP inhibitors	Pancreas	Responsive	D	NO	PMID:25263539;NCT01585805	only alteration type		PA
WP285	PALB2 MUT* (S1082I)	PALB2 deletion	PARP inhibitors	Prostate adenocarcinoma	Responsive	C	NO	AACR 2015 (abstr CT322);PMID:26510020	only gene		PRAD
WP285	PALB2 MUT* (S1082I)	PALB2 deletion	PARP inhibitors	Pancreas	Responsive	D	NO	PMID:25263539;NCT01585805	only gene		PA
WP285	PALB2 MUT* (S1082I)	PALB2 oncogenic mutation	Mytomycin C(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:21135251	only alteration type		PA
WP285	PALB2 MUT* (S1082I)	PALB2 deletion	Mytomycin C(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:21135251	only gene		PA
WP285	PALB2 MUT* (S1082I)	PALB2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP285	PALB2 MUT* (S1082I)	PALB2 deletion	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only gene		PA
WP285	PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP285	PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	HSP90 inhibitors	Gastrointestinal stromal	Responsive	D	NO	PMID:18794084	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Crenolanib(FLT3 inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2016 (abstr 11010)	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	Crenolanib(FLT3 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (P577S,R841K,H845Y,G853D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
WP285	MET MUT* (--)	MET amplification	EGFR inhibitor 3rd gens(Rociletinib,etc)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	Sorafenib + MEK inhibitor(Pan-TK inhibitor + MEK inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:25294897	only alteration type		HC
WP285	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	AKT inhibitors	Glioma	Responsive	D	NO	PMID:23166678	only alteration type		G
WP285	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	PI3K pathway inhibitors	Endometrium	Responsive	C	NO	ASCO 2015 (abstr 11075)	only alteration type		ED
WP285	PRKCH MUT* (--), PRKCH MUT* (--), ABL1 MUT* (--)	PRKCH amplification + ABL1-BCR fusion	Trametinib + Imatinib(MEK inhibitor + BCR-ABL inhibitor 1st gen&KIT inhibitor)	Chronic myeloid leukemia	Responsive	D	YES	PMID:25186176	only gene		CML
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
WP285	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP285	RB1 MUT* (--)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
WP285	RB1 MUT* (--)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
WP285	RB1 MUT* (--)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
WP285	RB1 MUT* (--)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
WP285	RB1 MUT* (--)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP285	RB1 MUT* (--)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP285	RICTOR MUT* (--)	RICTOR amplification	MTORC1/2 inhibitors	Lung	Responsive	C	NO	PMID:26370156	only gene		L
WP285	SETD2 MUT* (--), SETD2 MUT* (--)	SETD2 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only alteration type		CANCER
WP285	SETD2 MUT* (--), SETD2 MUT* (--)	SETD2 deletion	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only gene		CANCER
WP285	SH2B3 (A375P)	SH2B3 oncogenic mutation	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:20404132	complete		MDPS
WP285	SH2B3 (A375P)	SH2B3 deletion	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:20404132	only gene		MDPS
WP285	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib + Ponatinib(MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27338794	only alteration type		LUAD
WP285	SMO MUT* (GL16-17G)	SMO (P641A)	Vismodegib(SHH inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 9062)	only alteration type		L
WP285	TERT MUT* (--)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP285	TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP285	TP53 MUT* (--)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
WP285	TP53 MUT* (--)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
WP285	TP53 MUT* (--)	TP53 oncogenic mutation	WEE1 inhibitors	Head an neck	Responsive	D	NO	PMID:25125259	only alteration type		HNC
WP285	TP53 MUT* (--)	TP53 oncogenic mutation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP285	TP53 MUT* (--)	TP53 deletion	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only gene		BCL
WP285	TP53 MUT* (--)	TP53 oncogenic mutation	Decitabine(Chemotherapy)	Acute myeloid leukemia, Myelodisplasic proliferative syndrome	Responsive	C	YES	PMID:27959731	only alteration type		AML, MDPS
WP285	TP53 MUT* (--)	TP53 oncogenic mutation	Doxorubicin(Anthracycline antitumor antibiotic)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP285	TP53 MUT* (--)	TP53 oncogenic mutation	Gemcitabine(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP285	TP53 MUT* (--)	TP53 oncogenic mutation	Mitomycin C(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP285	TP53 MUT* (--)	TP53 oncogenic mutation	WEE1 inhibitors	Ovary	Responsive	C	NO	PMID:27998224	only alteration type		OV
WP285	TP53 MUT* (--)	TP53 oncogenic mutation	Pramlintide(Amylin analogue)	Thymic	Responsive	D	YES	PMID:25409149	only alteration type		THYM
WP285	TP53 MUT* (--)	TP53 deletion	Pramlintide(Amylin analogue)	Thymic	Responsive	D	YES	PMID:25409149	only gene		THYM
WP285	SMO MUT* (GL16-17G)	SMO (D473H)	Vismodegib(SHH inhibitor)	Medulloblastoma	Resistant	C	NO	PMID:19726788;PMID:25759019	only alteration type		MB
WP285	SMO MUT* (GL16-17G)	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	Vismodegib(SHH inhibitor)	Basal cell carcinoma	Resistant	C	NO	PMID:25759020;PMID:25306392	only alteration type		BCC
WP285	MTOR MUT* (--)	MTOR (L2209V,L1460P,L2427Q)	Temsirolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
WP285	MTOR MUT* (--)	MTOR (Q2223K)	Everolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
WP285	MET MUT* (--)	MET amplification	Crizotinib	Non-small cell lung	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/52/summary|oncokb=https://www.oncokb.org/gene/MET	only gene		NSCLC
WP285	MET MUT* (--)	MET (D1010H,Y1003N,D1010N,Y1003F,Y1003C,D1010Y)	Crizotinib	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP285	MTOR MUT* (--)	MTOR (E2419K,E2014K)	Everolimus	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		BLCA
WP285	MTOR MUT* (--)	MTOR (E2419K,C1483F,L2172M,K1452N,L2230V,L2427Q,L2431P,F1888I,E1799K,L2216P,W1456R,C1483W,A1519T,L1460P,A2210P,T2232I,R2505P,M2327I,C1483R,V2006I,A1428T,Y1463S,I2500M,A1459P,F1888L,S2231W,T1977R,V2006F,T1977K,A2226S,I2500F,L2427R,T1977I,S2215F,.,Q2223K,I1973F,L1433S,F1888V,S2215T,D2512H,E2014K,S2215Y,R2217W,L2209V,V2006L,L2220F,L2427P,S2215P,P2273S,E2288K,C1483Y)	Temsirolimus + Everolimus	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		CANCER
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib	Gastrointestinal stromal	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP285	KDM6A MUT* (--)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
WP285	KDM6A MUT* (--)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only alteration type		BLCA
WP285	MET MUT* (--)	MET (D1010H,Y1003N,D1010N,Y1003F,Y1003C,D1010Y)	Cabozantinib + Capmatinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (N659K,V561D,V561A,N659S,A633T,H845Y,T674I,S584L,D842V,N659R,D568N,P577S,D846Y,Q579R,D842Y,Y849S,N848K,H650Q,D842I,V469A,Y288C,Y555C,R748G,Y849C,.,R841K,G853D,V536E,V658A)	Imatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA amplification	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-BCR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-CDK5RAP2 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-ETV6 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-KDR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-KIF5B fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-STRN fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP285	KRAS MUT* (--)	KRAS (D119N,G12F,F156L,G60R,F28L,A18D,Q22K,K147E,D33E,A146T,E62K,A146V,Q61R,Q61H,G12A,G12R,G13E,Q22R,V14I,Y71H,G13D,G12C,T58I,.,D153V,A59G,K117N,S65N,P34L,Y64A,G13V,K5N,Y32S,L19F,T74P,G13C,G12V,G12D,Q22E,Q61L,G12S,P34R)	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/30/summary|oncokb=https://www.oncokb.org/gene/KRAS	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS amplification	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only gene		COREAD
WP285	KRAS MUT* (--)	KRAS (D119N,G12F,F156L,G60R,F28L,A18D,Q22K,K147E,D33E,A146T,E62K,A146V,Q61R,Q61H,G12A,G12R,G13E,Q22R,V14I,Y71H,G13D,G12C,T58I,.,D153V,A59G,K117N,S65N,P34L,Y64A,K5N,Y32S,L19F,T74P,G13C,G12V,G12D,Q22E,Q61L,G12S,P34R)	Cobimetinib + Binimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only alteration type		CANCER
WP285	KRAS MUT* (--)	KRAS amplification	Cobimetinib + Binimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only gene		CANCER
WP285	MET MUT* (--)	MET amplification	Erlotinib + Gefitinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only gene		NSCLC
WP285	JAK2 (V617F)	JAK2-PCM1 fusion	Ruxolitinib	Eosinophilic chronic leukemia	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/JAK2	only gene		ECL
WP285	MET MUT* (--)	MET (D1228N)	Crizotinib + Cabozantinib + Capmatinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP285	MET MUT* (--)	MET amplification	Cabozantinib	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only gene		RCCC
WP285	MET MUT* (--)	MET (Y1230H)	Crizotinib + Capmatinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP285	ABL1 MUT* (--)	ABL1 BCR::ABL	Imatinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/232	only gene		AML
WP285	ABL1 MUT* (--)	ABL1 BCR::ABL	Imatinib	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/259	only gene		AML
WP285	ABL1 MUT* (--)	ABL1 G340L	Imatinib Mesylate,Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4788	only alteration type		NSCLC
WP285	ABL1 MUT* (--)	ABL1 R351W	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4787	only alteration type		NSCLC
WP285	ABL1 MUT* (--)	ABL1 R351W	Imatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/6376	only alteration type		NSCLC
WP285	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP285	CRBN MUT* (--)	CRBN Mutation	Lenalidomide,Pomalidomide	Multiple myeloma	Resistant	C	YES	https://civicdb.org/links/evidence_items/1766	only alteration type		MM
WP285	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP285	IDH2 MUT* (--)	IDH2 Mutation	Enasidenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/4833	only alteration type		AML
WP285	IDH2 MUT* (--)	IDH2 Mutation	Enasidenib	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/5069	only alteration type		AML
WP285	IDH2 MUT* (--)	IDH2 Mutation	Venetoclax	Acute myeloid leukemia	Responsive	C	YES	https://civicdb.org/links/evidence_items/8857	only alteration type		AML
WP285	JAK2 (V617F)	JAK2 Splice Site (c.1641+2T>G)	Pembrolizumab	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4825	only alteration type		CM
WP285	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP285	KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP285	KRAS MUT* (--)	KRAS A146	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3939	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS A146P	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2225	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS A146T	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2943	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS A146T	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3858	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS A146T	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2206	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS A146V	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2209	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS A146V	Abemaciclib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/794	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS G12/G13	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/134	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12/G13	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/135	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12/G13	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2004	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12/G13	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6293	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12/G13	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6294	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12/G13	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6295	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12/G13	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6296	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12/G13	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6363	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12/G13	Gefitinib,Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/35	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS G12/G13	Trametinib,Gemcitabine	Pancreas adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/622	only alteration type		PAAD
WP285	KRAS MUT* (--)	KRAS G12/G13	Trametinib	Pancreas adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/990	only alteration type		PAAD
WP285	KRAS MUT* (--)	KRAS G12A	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3710	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12A	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4429	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12A	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6319	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12A	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/251	only alteration type		LUAD
WP285	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2009	only alteration type		MM
WP285	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2012	only alteration type		MM
WP285	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2013	only alteration type		MM
WP285	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2014	only alteration type		MM
WP285	KRAS MUT* (--)	KRAS G12C	Gefitinib,Erlotinib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1216	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12C	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2253	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12C	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3967	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12C	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3973	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12C	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2212	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2258	only alteration type		MM
WP285	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2261	only alteration type		MM
WP285	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2262	only alteration type		MM
WP285	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2263	only alteration type		MM
WP285	KRAS MUT* (--)	KRAS G12C	Docetaxel,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1142	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS G12C	Sotorasib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/9431	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS G12D	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3957	only alteration type		CM
WP285	KRAS MUT* (--)	KRAS G12D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2193	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2207	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2236	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12D	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3946	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12D	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6316	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12D	Therapeutic Tumor Infiltrating Lymphocytes	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1898	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12D	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2218	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12D	Vemurafenib	Hairy-Cell leukemia	Resistant	C	YES	https://civicdb.org/links/evidence_items/1580	only alteration type		HCL
WP285	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2247	only alteration type		MM
WP285	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2250	only alteration type		MM
WP285	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2251	only alteration type		MM
WP285	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2252	only alteration type		MM
WP285	KRAS MUT* (--)	KRAS G12D	Dabrafenib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/91	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS G12D	Selumetinib,Dactolisib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/305	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS G12D	Cetuximab	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/3958	only alteration type		OV
WP285	KRAS MUT* (--)	KRAS G12R	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2264	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12R	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3987	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12R	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3989	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12R	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3991	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12S	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2269	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12S	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4006	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12S	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4012	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12S	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6314	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2274	only alteration type		MM
WP285	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2277	only alteration type		MM
WP285	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2278	only alteration type		MM
WP285	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2279	only alteration type		MM
WP285	KRAS MUT* (--)	KRAS G12V	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/136	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12V	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2219	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12V	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2232	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12V	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3824	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12V	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3924	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12V	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6323	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12V	Dactolisib,Selumetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2001	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G12V	Palbociclib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/795	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS G12V	Selumetinib,Docetaxel	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1143	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS G13D	Pictilisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2041	only alteration type		BRCA
WP285	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/806	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1180	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1181	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G13D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2178	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3878	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3881	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3882	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G13D	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3889	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G13D	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6320	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G13D	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6322	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/145	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/306	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G13D	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2183	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS G13V	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6312	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Mutation	Vemurafenib,Dabrafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6264	only alteration type		CM
WP285	KRAS MUT* (--)	KRAS Mutation	Bevacizumab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1139	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Mutation	Ixazomib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1182	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1702	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3704	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	A	NO	https://civicdb.org/links/evidence_items/5345	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Mutation	Immunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/943	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Mutation	Cetuximab,Dasatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/947	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Mutation	B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/988	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Mutation	Trametinib,Afatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/991	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Mutation	MEK Inhibitor RO4987655	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/998	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Mutation	Refametinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1001	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Mutation	Selumetinib,Teprotumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1004	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Mutation	Selumetinib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4866	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Mutation	Palbociclib,Binimetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4869	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Mutation	Temsirolimus,Ridaforolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/894	only alteration type		ED
WP285	KRAS MUT* (--)	KRAS Mutation	Sorafenib,Refametinib	Hepatic carcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1642	only alteration type		HC
WP285	KRAS MUT* (--)	KRAS Mutation	Salirasib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1218	only alteration type		LUAD
WP285	KRAS MUT* (--)	KRAS Mutation	MEK Inhibitor RO4987655	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/997	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2242	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Gefitinib,Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2385	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Selumetinib	Non-small cell lung	Resistant	A	NO	https://civicdb.org/links/evidence_items/2998	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/3895	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/989	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Trametinib,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/992	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/999	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1220	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Erlotinib,Teprotumumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3713	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Abemaciclib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4842	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Pemetrexed,Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4862	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Nivolumab,Atezolizumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4863	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4867	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Erlotinib,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4868	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4996	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Docetaxel	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4997	only alteration type		NSCLC
WP285	KRAS MUT* (--)	KRAS Mutation	Decitabine	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/820	only alteration type		OV
WP285	KRAS MUT* (--)	KRAS Mutation	PI3Kbeta Inhibitor AZD8186,SCH772984	Pancreas adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1003	only alteration type		PAAD
WP285	KRAS MUT* (--)	KRAS Q61	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3917	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Q61H	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3861	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Q61H	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3862	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Q61K	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3872	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Q61L	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3867	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Q61R	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3870	only alteration type		COREAD
WP285	KRAS MUT* (--)	KRAS Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6317	only gene		CM
WP285	MET MUT* (--)	MET D1228N	Crizotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1652	only alteration type		NSCLC
WP285	MET MUT* (--)	MET D1228V	Savolitinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1865	only alteration type		NSCLC
WP285	MET MUT* (--)	MET D1228V	Cabozantinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1864	only alteration type		NSCLC
WP285	MET MUT* (--)	MET MET::ATXN7L1	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7793	only gene		NSCLC
WP285	MET MUT* (--)	MET Amplification	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1971	only gene		COREAD
WP285	MET MUT* (--)	MET Amplification	Vemurafenib,Crizotinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1588	only gene		COREAD
WP285	MET MUT* (--)	MET Amplification	Crizotinib,Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1979	only gene		COREAD
WP285	MET MUT* (--)	MET Amplification	Crizotinib	Glioblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1565	only gene		GB
WP285	MET MUT* (--)	MET Amplification	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1392	only gene		LUAD
WP285	MET MUT* (--)	MET Amplification	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/836	only gene		LUAD
WP285	MET MUT* (--)	MET Amplification	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1692	only gene		LUAD
WP285	MET MUT* (--)	MET Amplification	Crizotinib	Lung squamous cell	Responsive	C	NO	https://civicdb.org/links/evidence_items/890	only gene		LUSC
WP285	MET MUT* (--)	MET Amplification	Gefitinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/733	only gene		NSCLC
WP285	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/735	only gene		NSCLC
WP285	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1566	only gene		NSCLC
WP285	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1713	only gene		NSCLC
WP285	MET MUT* (--)	MET Amplification	Onartuzumab	Stomach	Responsive	C	NO	https://civicdb.org/links/evidence_items/689	only gene		ST
WP285	MTOR MUT* (--)	MTOR A2034V	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1547	only alteration type		BRCA
WP285	MTOR MUT* (--)	MTOR A2034V	RapaLink-1,MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1548	only alteration type		BRCA
WP285	MTOR MUT* (--)	MTOR E1799K	Sirolimus	Renal clear cell	Responsive	D	NO	https://civicdb.org/links/evidence_items/1321	only alteration type		RCCC
WP285	MTOR MUT* (--)	MTOR F2108L	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1543	only alteration type		BRCA
WP285	MTOR MUT* (--)	MTOR F2108L	Everolimus	Thyroid carcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1110	only alteration type		THCA
WP285	MTOR MUT* (--)	MTOR H1968Y	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/713	only alteration type		CM
WP285	MTOR MUT* (--)	MTOR M2327I	MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1544	only alteration type		BRCA
WP285	MTOR MUT* (--)	MTOR M2327I	Sirolimus,RapaLink-1	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1545	only alteration type		BRCA
WP285	MTOR MUT* (--)	MTOR Mutation	Everolimus,Pazopanib	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/705	only alteration type		BLCA
WP285	MTOR MUT* (--)	MTOR P2213S	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/722	only alteration type		CM
WP285	NOTCH1 MUT* (--)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP285	NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP285	NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP285	NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP285	PALB2 MUT* (S1082I)	PALB2 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8504	only alteration type		PRAD
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842I	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/43	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/15	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/16	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/651	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/738	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2478	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4597	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/44	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842Y	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/45	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842_I843delinsVM	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/47	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA FIP1L1::PDGFRA	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7378	only gene		AML
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA G853D	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1977	only alteration type		CM
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA H845Y	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1976	only alteration type		CM
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA I843DEL	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/46	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA I843DEL	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1309	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA Mutation	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2487	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA P577S	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1974	only alteration type		CM
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA R841K	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1975	only alteration type		CM
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA V561A	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/652	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA V561D	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2474	only alteration type		GIST
WP285	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA Amplification	Sunitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1771	only gene		NSCLC
WP285	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP285	PIK3R1 MUT* (--)	PIK3R1 Mutation	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1612	only alteration type		BRCA
WP285	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP285	RAD51D MUT* (--)	RAD51D Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11214	only alteration type		PRAD
WP285	RB1 MUT* (--)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
WP285	RICTOR MUT* (--)	RICTOR Amplification	Onatasertib,Sapanisertib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1440	only gene		LUAD
WP285	RICTOR MUT* (--)	RICTOR Amplification	Vistusertib	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7449	only gene		SCLC
WP285	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP285	SMO MUT* (GL16-17G)	SMO D473H	Vismodegib	Basal cell carcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/755	only alteration type		BCC
WP285	SMO MUT* (GL16-17G)	SMO L412F	Vismodegib	Basal cell carcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4653	only alteration type		BCC
WP285	SMO MUT* (GL16-17G)	SMO L412F	Vismodegib	Basal cell carcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4654	only alteration type		BCC
WP285	SMO MUT* (GL16-17G)	SMO Mutation	Vismodegib	Basal cell carcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/746	only alteration type		BCC
WP285	SMO MUT* (GL16-17G)	SMO Mutation	Vismodegib,Sonidegib	Basal cell carcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1477	only alteration type		BCC
WP285	SMO MUT* (GL16-17G)	SMO Mutation	PSI,Arsenic Trioxide	Basal cell carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/747	only alteration type		BCC
WP285	TLK2 MUT* (--)	TLK2 Amplification	Go6983,GF109203X	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6000	only gene		BRCA
WP285	TP53 MUT* (--)	TP53 M237I	MDM2 Inhibitor AMGMDS3	Glioblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4885	only alteration type		GB
WP285	TP53 MUT* (--)	TP53 Mutation	Tamoxifen	Breast adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2784	only alteration type		BRCA
WP285	TP53 MUT* (--)	TP53 Mutation	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/851	only alteration type		BRCA
WP285	TP53 MUT* (--)	TP53 Mutation	Selumetinib,Docetaxel	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1145	only alteration type		NSCLC
WP285	TP53 MUT* (--)	TP53 Mutation	Pazopanib,Vorinostat	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/7540	only alteration type		SOLID
WP285	TP53 MUT* (--)	TP53 Mutation	Chemotherapy	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/850	only alteration type		ST
WP285	TP53 MUT* (--)	TP53 R175H	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/319	only alteration type		BRCA
WP285	TP53 MUT* (--)	TP53 R249	Doxorubicin	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/399	only alteration type		BRCA
WP285	TP53 MUT* (--)	TP53 R273H	Methotrexate,Doxorubicin	Osteosarcoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/7430	only alteration type		OS
WP285	TP53 MUT* (--)	TP53 R273L	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2286	only alteration type		OV
WP285	TP53 MUT* (--)	TP53 Y234C	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2745	only alteration type		OV
WP285	TP53 MUT* (--)	TP53 Loss	Docetaxel	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1146	only gene		NSCLC
WP072	DPYD MUT* (--)	DPYD splice donor variant	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
WP072	DPYD MUT* (--)	DPYD biallelic inactivation	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
WP072	DPYD MUT* (--)	DPYD (I560S,D949V)	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
WP072	DPYD MUT* (--)	DPYD splice donor variant	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
WP072	DPYD MUT* (--)	DPYD biallelic inactivation	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
WP072	DPYD MUT* (--)	DPYD (I560S,D949V)	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
WP072	DPYD MUT* (--)	DPYD splice donor variant	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
WP072	DPYD MUT* (--)	DPYD biallelic inactivation	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
WP072	DPYD MUT* (--)	DPYD (I560S,D949V)	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
WP072	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR (L858R)	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR (L861Q,G719,S768I)	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR (L858R)	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR (L861Q,G719,S768I)	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR (L858R)	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR (L861Q,G719,S768I)	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR (L858R)	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR (T790M)	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf	only alteration type		NSCLC
WP072	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Myelofibrosis	Responsive	A	YES	FDA	complete		MY
WP072	EGFR MUT* (--)	EGFR (T790M)	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR (T790M)	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP072	TPMT MUT* (--)	TPMT splice acceptor variant	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP072	TPMT MUT* (--)	TPMT biallelic inactivation	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP072	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP072	TPMT MUT* (--)	TPMT splice acceptor variant	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP072	TPMT MUT* (--)	TPMT biallelic inactivation	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP072	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP072	TPMT MUT* (--)	TPMT splice acceptor variant	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP072	TPMT MUT* (--)	TPMT biallelic inactivation	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP072	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP072	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022	only alteration type		BRCA
WP072	FLT3 MUT* (--)	FLT3-ITD	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia;PMID:28644114	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 (D835,I836)	Gilteritinib(Kinase inhibitor )	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3-ITD	Gilteritinib(Kinase inhibitor )	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation;PMID:31665578	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 (D835,I836)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia; PMID:28644114	only alteration type		AML
WP072	EGFR MUT* (--)	EGFR (S786I,G719, L861Q)	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR (L858R)	Dacomitinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN Non-Small Cell Lung Cancer guidlines 2022;FDA:https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer-0	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR (T790M)	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP072	FANCL MUT* (--)	FANCL oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP072	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP072	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP072	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Mobocertinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mobocertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Amivantamab(EGFR mAb inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer	only alteration type		NSCLC
WP072	IDH1 MUT* (--)	IDH1 (R132)	Ivosidenib(IDH1 inhibitor)	Cholangiocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf;PMID:34554208;PMID:32416072	only alteration type		CH
WP072	IDH1 MUT* (--)	IDH1 (R132C,R132G,R132H,R132L,R132S)	Ivosidenib(IDH1 inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf 	only alteration type		AML
WP072	RAD51D MUT* (--)	RAD51D oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP072	PIK3CA MUT* (--)	PIK3CA (C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R)	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	only alteration type		BRCA
WP072	IDH1 MUT* (--)	IDH1 (R132C,R132G,R132H,R132L,R132S)	Olutasidenib(IDH1 inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olutasidenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-idh1-mutation	only alteration type		AML
WP072	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP072	IDH2 MUT* (--)	IDH2 oncogenic mutation	Enasidenib(IDH2 inhibitor)	Acute lymphoblastic leukemia	Responsive	A	YES	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209606s004lbl.pdf	only alteration type		ALL
WP072	ARAF (H366N)	ARAF oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP072	ARAF (H366N)	ARAF oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP072	ARAF (H366N)	ARAF oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP072	ARAF (H366N)	ARAF oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP072	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Erlotinib(EGFR inhibitor 1st gen);Ramucirumab(VEGFR2 antagonist)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR (L858R)	Erlotinib(EGFR inhibitor 1st gen);Ramucirumab(VEGFR2 antagonist)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf	only alteration type		NSCLC
WP072	FLT3 MUT* (--)	FLT3-ITD	Quizartinib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia	only alteration type		AML
WP072	IDH1 MUT* (--)	IDH1 oncogenic mutation	Ivosidenib(IDH1 inhibitor)	Chondrosarcoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf	only alteration type		CS
WP072	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP072	IDH1 MUT* (--)	IDH1 oncogenic mutation	Venetoclax(BCL2 inhibitor)	Acute myeloid leukemia	Responsive	A	YES	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf	only alteration type		AML
WP072	IDH2 MUT* (--)	IDH2 oncogenic mutation	Venetoclax(BCL2 inhibitor)	Acute myeloid leukemia	Responsive	A	YES	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf	only alteration type		AML
WP072	EGFR MUT* (--)	EGFR (S768I,L861Q,G719)	Dacomitinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Dacomitinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	FDA: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer-0	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf	only alteration type		NSCLC
WP072	AKT1 MUT* (--)	AKT1 (Q79K,E17K)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265152	only alteration type		CM
WP072	ARAF (H366N)	ARAF oncogenic mutation	BRAF inhibitor + EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	complete		COREAD
WP072	ARAF (H366N)	ARAF oncogenic mutation	BRAF inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	complete		COREAD
WP072	AKT1 MUT* (--)	AKT1 (E17K)	AKT inhibitors	Any cancer type	Responsive	D	YES	PMID:21464312;PMID:17611497;PMID:23134728; ENA 2015 (abstr B109)	only alteration type		CANCER
WP072	AKT1 MUT* (--)	AKT1 (E17K)	allosteric AKT inhibitors	Any cancer type	Responsive	C	YES	ENA 2015 (abstract B109);PMID:28489509	only alteration type		CANCER
WP072	AKT1 MUT* (--)	AKT1 (E17K)	non-allosteric AKT inhibitors	Any cancer type	Responsive	C	YES	ENA 2015 (abstract B109);PMID:28489509	only alteration type		CANCER
WP072	AKT1 MUT* (--)	AKT1 (E17K)	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26763254	only alteration type		HNSC
WP072	AKT1 MUT* (--)	AKT1 (H238Y)	Everolimus(MTOR inhibitor)	Fibrous histiocytoma	Responsive	C	NO	ASCO 2015 (abstr 11010)	only alteration type		FH
WP072	AKT1 MUT* (--)	AKT1 (E17K)	Tensirolimus(MTOR inhibitor)	Endometrium	Responsive	C	NO	PMID:27016228	only alteration type		ED
WP072	CTNNB1 (V660F)	CTNNB1 oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Resistant	D	NO	PMID:23539443	complete		COREAD
WP072	EGFR MUT* (--)	EGFR inframe deletion (30-336)	EGFR inhibitor 1st gens	Glioma	No Responsive	C	NO	PMID:19204207	only alteration type		G
WP072	EGFR MUT* (--)	EGFR amplification	EGFR inhibitor 1st gens	Glioma	No Responsive	C	NO	PMID:16282176;PMID:16278407	only gene		G
WP072	EGFR MUT* (--)	EGFR (D761Y)	EGFR inhibitor 1st gens	Non-small cell lung	Resistant	C	NO	PMID:19680293	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR (T790M)	EGFR inhibitor 1st gens	Non-small cell lung	Resistant	B	NO	PMID:19680293	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR inframe deletion (30-336)	EGFR inhibitor 2nd gens	Glioma	No Responsive	C	NO	PMID:19204207	only alteration type		G
WP072	EGFR MUT* (--)	EGFR amplification	EGFR inhibitor 2nd gens	Glioma	No Responsive	C	NO	PMID:16282176;PMID:16278407	only gene		G
WP072	EGFR MUT* (--)	EGFR (T790M)	EGFR inhibitor 2nd gens	Non-small cell lung	Resistant	B	NO	PMID:22452896	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR inframe deletion (30-336)	EGFR inhibitor 3rd gens	Glioma	No Responsive	C	NO	PMID:19204207	only alteration type		G
WP072	EGFR MUT* (--)	EGFR amplification	EGFR inhibitor 3rd gens	Glioma	No Responsive	C	NO	PMID:16282176;PMID:16278407	only gene		G
WP072	ARAF (H366N)	ARAF (S214C)	Sorafenib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	http://www.jci.org/articles/view/72763;PMID:24569458	only alteration type		LUAD
WP072	JAK2 (V617F)	JAK2 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	complete		CM
WP072	CTNNB1 MUT* (--), CTNNB1 (V660F)	CTNNB1 (H36Y,S37C,S37Y,D32V)	Everolimus + Letrozole(MTOR inhibitor + Hormonal therapy)	Endometrium	Responsive	C	NO	PMID:25624430	only alteration type		ED
WP072	MCL1 MUT* (--)	MCL1 amplification	Tubulin inhibitors	Any cancer type	Resistant	D	YES	PMID:21368834	only gene		CANCER
WP072	EGFR MUT* (--)	EGFR (T790M)	EGFR inhibitor 3rd gens	Lung	Responsive	C	NO	ASCO 2014 (abstr 8009);ENA 2014 (abstr 10LBA);ENA 2014 (abstr 9LBA);ASCO 2015 (abstr 8001)	only alteration type		L
WP072	EGFR MUT* (--)	EGFR amplification	EGFR inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26763254	only gene		HNSC
WP072	EGFR MUT* (--)	EGFR amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Responsive	B	NO	PMID:18794099;PMID:17664472	only gene		COREAD
WP072	EGFR MUT* (--)	EGFR exon 19 insertions	EGFR TK inhibitors	Lung	Responsive	B	NO	PMID:22753918	only alteration type		L
WP072	EGFR MUT* (--)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	EGFR TK inhibitors	Lung	Responsive	B	NO	PMID:22753918	only alteration type		L
WP072	EGFR MUT* (--)	EGFR exon 19 insertions	HSP90 inhibitors	Lung	Responsive	C	NO	ESMO 2012 (abstr 4380)	only alteration type		L
WP072	EGFR MUT* (--)	EGFR exon 20 insertions	HSP90 inhibitors	Lung	Responsive	C	NO	ASCO 2014 (abstr 8015)	only alteration type		L
WP072	EGFR MUT* (--)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	HSP90 inhibitors	Lung	Responsive	C	NO	ESMO 2012 (abstr 4380)	only alteration type		L
WP072	EGFR MUT* (--)	EGFR (T790M)	HSP90 inhibitors	Lung	Responsive	C	NO	ESMO 2012 (abstr 4380)	only alteration type		L
WP072	EGFR MUT* (--)	EGFR exon 19 insertions	MEK inhibitor(alone or in combination)s	Lung	Responsive	D	NO	PMID:23102728	only alteration type		L
WP072	EGFR MUT* (--)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	MEK inhibitor(alone or in combination)s	Lung	Responsive	D	NO	PMID:23102728	only alteration type		L
WP072	EGFR MUT* (--)	EGFR (S492R)	novel EGFR mAb inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:25962717	only alteration type		COREAD
WP072	EGFR MUT* (--)	EGFR (T790M)	EGFR inhibitor 3rd gens(Rociletinib,HM61713,etc)	Non-small cell lung	Responsive	B	NO	NCT02322281	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR exon 19 insertions	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Lung	Responsive	B	NO	PMID:22753918;PMID:25589191	only alteration type		L
WP072	EGFR MUT* (--)	EGFR exon 19 insertions	Afatinib + Cetuximab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	ESMO 2012 (abstr 1289)	only alteration type		L
WP072	EGFR MUT* (--)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	Afatinib + Cetuximab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	ESMO 2012 (abstr 1289)	only alteration type		L
WP072	EGFR MUT* (--)	EGFR (T790M)	Afatinib + Cetuximab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	PMID:25074459	only alteration type		L
WP072	EGFR MUT* (--)	EGFR (T790M)	Afatinib + Nimotuzumab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	PMID:26667485	only alteration type		L
WP072	EGFR MUT* (--)	EGFR (P546S)	Cetuximab(EGFR mAb inhibitor)	Head an neck	Responsive	C	NO	PMID:23578570	only alteration type		HNC
WP072	EGFR MUT* (--)	EGFR (P753S)	Cetuximab + Sirolimus(EGFR mAb inhibitor + MTOR inhibitor)	Head an neck	Responsive	C	NO	PMID:24934779	only alteration type		HNC
WP072	EGFR MUT* (--)	EGFR-RAD51 fusion	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	C	NO	PMID:27102076	only gene		NSCLC
WP072	EGFR MUT* (--)	EGFR-RAD51 fusion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:27102076	only gene		L
WP072	EGFR MUT* (--)	EGFR exon 19 insertions	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:22190593	only alteration type		L
WP072	EGFR MUT* (--)	EGFR inframe insertion (769-770)	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:26773740;PMID:23328547	only alteration type		L
WP072	EGFR MUT* (--)	EGFR (A289V,R108K,G598V,T263P)	Erlotinib(EGFR inhibitor 1st gen)	Glioma	Responsive	D	NO	PMID:17177598	only alteration type		G
WP072	EGFR MUT* (--)	EGFR (K757R,E746G)	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:26773740	only alteration type		L
WP072	PIK3CA MUT* (--)	PIK3CA (E545*)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMC3936420	only alteration type		CM
WP072	PIK3CA MUT* (--)	PIK3CA amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	D	NO	PMID:24366379	only gene		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9054)	only alteration type		L
WP072	EGFR MUT* (--)	EGFR amplification	Gefitinib(EGFR inhibitor 1st gen)	Endometrium	Responsive	B	NO	PMID:24950987	only gene		ED
WP072	EGFR MUT* (--)	EGFR (E690K)	Lapatinib(ERBB2 inhibitor)	Endometrium	Responsive	C	NO	PMID:22885469	only alteration type		ED
WP072	EGFR MUT* (--)	EGFR exon 19 deletions	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Responsive	C	NO	NCT02465060	only alteration type		L
WP072	PTEN MUT* (--)	PTEN oncogenic mutation	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	B	NO	PMID:21163703;PMID:19398573	only alteration type		COREAD
WP072	PTEN MUT* (--)	PTEN deletion	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	B	NO	PMID:21163703;PMID:19398573	only gene		COREAD
WP072	PTEN MUT* (--)	PTEN oncogenic mutation	MTOR inhibitors	Endometrium	No Responsive	C	NO	PMID:21788564;PMID:23238879	only alteration type		ED
WP072	PTEN MUT* (--)	PTEN deletion	MTOR inhibitors	Endometrium	No Responsive	C	NO	PMID:21788564;PMID:23238879	only gene		ED
WP072	EGFR MUT* (--)	EGFR (S492R)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:22270724	only alteration type		COREAD
WP072	EGFR MUT* (--)	EGFR inframe deletion (6-273)	Rindopepimut(Vaccine)	Glioblastoma	Responsive	B	NO	NCT01480479	only alteration type		GB
WP072	ERBB4 MUT* (--)	ERBB4 (E317K,E452K,R544W,R393W,E872K)	Lapatinib(ERBB2 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:19718025	only alteration type		CM
WP072	ERBB4 MUT* (--)	ERBB4 fusion	Lapatinib + Afatinib(ERBB2 inhibitor + ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP072	ERBB4 MUT* (--)	ERBB4 (H809G)	ERBB2 inhibitors(Lapatinib,etc)	Breast adenocarcinoma	Resistant	C	NO	PMID:26530965	only alteration type		BRCA
WP072	FLT3 MUT* (--)	FLT3-ITD	FLT3 inhibitors	Acute myeloid leukemia	Responsive	C	YES	PMID:16857985	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 (F691)	novel FLT3 inhibitors	Acute myeloid leukemia	Responsive	D	YES	PMID:25847190	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 (N676)	Crenolanib(FLT3 inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:24619500	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 (D835)	Lestaurtinib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:16857985	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 (D835)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:20733134	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 (N676)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:24619500	only alteration type		AML
WP072	PTEN MUT* (--)	PTEN biallelic inactivation	BYL719(PIK3CA inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:25409150	only alteration type		BRCA
WP072	FLT3 MUT* (--)	FLT3-ITD	Sorafenib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:19389879;PMID:22368270	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3-ITD	Sorafenib + Azacytidine(Pan-TK inhibitor + Chemotherapy)	Acute myeloid leukemia	Responsive	C	YES	PMID:23613521	only alteration type		AML
WP072	GATA3 MUT* (--)	GATA3 oncogenic mutation	Aromatase ihibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:24758297	only alteration type		BRCA
WP072	IDH1 MUT* (--)	IDH1 oncogenic mutation	BCL2 inhibitors	Acute myeloid leukemia	Responsive	D	YES	PMID:25599133	only alteration type		AML
WP072	IDH1 MUT* (--)	IDH1 oncogenic mutation	IDH1 inhibitors	Acute myeloid leukemia	Responsive	C	YES	ENA 2014 (abstr 1LBA)	only alteration type		AML
WP072	IDH1 MUT* (--)	IDH1 (R132)	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:28148839	only alteration type		CANCER
WP072	IDH1 MUT* (--)	IDH1 oncogenic mutation	AG-120(IDH1 inhibitor)	Glioma	Responsive	C	NO	NCT02073994;PMID:23558169	only alteration type		G
WP072	IDH1 MUT* (--)	IDH1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Cholangiocarcinoma	Responsive	C	NO	NCT02428855	only alteration type		CH
WP072	IDH1 MUT* (--)	IDH1 (R132)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Billiary tract	Responsive	D	NO	PMID:27231123	only alteration type		BT
WP072	IDH2 MUT* (--)	IDH2 (R140K,R172K)	AG-221(IDH2 inhibitor)	Hematologic malignancies	Responsive	C	YES	AACR 2014 (abstr CT103)	only alteration type		HEMATO
WP072	IDH2 MUT* (--)	IDH2 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Cholangiocarcinoma	Responsive	C	NO	NCT02428855	only alteration type		CH
WP072	IDH2 MUT* (--)	IDH2 (R172)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Billiary tract	Responsive	D	NO	PMID:27231123	only alteration type		BT
WP072	EGFR MUT* (--)	EGFR (S464L,G465R,I491M)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	D	NO	PMID:25623215	only alteration type		COREAD
WP072	EGFR MUT* (--)	EGFR (S492R,G465R,R451C,K467T)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827	only alteration type		COREAD
WP072	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP072	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP072	JAK2 (V617F)	JAK2 (V617F)	JAK inhibitor(alone or in combination)s	Acute myeloid leukemia	Responsive	D	YES	PMID:22829971	complete		AML
WP072	JAK2 (V617F)	JAK2 amplification	JAK inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27075627	only gene		BRCA
WP072	JAK2 (V617F)	JAK2-BRAF fusion	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22875628;PMID:22899477	only gene		ALL
WP072	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:22422826	complete		AML
WP072	JAK3 MUT* (--)	JAK3 (A572V,A573V)	JAK inhibitors	Lymphoma	Responsive	D	YES	PMID:22705984	only alteration type		LY
WP072	JAK3 MUT* (--)	JAK3 (R657Q,I87T,Q501H)	JAK inhibitors	Megakaryoblastic leukemia	Responsive	D	YES	PMID:18397343	only alteration type		MKB
WP072	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP072	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:19223544;PMID:20619739	only alteration type		COREAD
WP072	PTEN MUT* (--)	PTEN biallelic inactivation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	Caris molecular intelligence	only alteration type		COREAD
WP072	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP072	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP072	EGFR MUT* (--)	EGFR amplification	Erlotinib(EGFR inhibitor 1st gen)	Lung	No Responsive	C	NO	ASCO2015(abstre19028)	only gene		L
WP072	EGFR MUT* (--)	EGFR (S720)	Erlotinib(EGFR inhibitor 1st gen)	Lung	No Responsive	C	NO	PMID:26773740	only alteration type		L
WP072	EGFR MUT* (--)	EGFR inframe deletion (L747),inframe insertion (P753PS)	Gefitinib(EGFR inhibitor 1st gen)	Head an neck	No Responsive	C	NO	PMID:21274259	only alteration type		HNC
WP072	EGFR MUT* (--)	EGFR amplification	Gefitinib(EGFR inhibitor 1st gen)	Head an neck	No Responsive	C	NO	PMID:21274259;PMID:22261807	only gene		HNC
WP072	EGFR MUT* (--)	EGFR (V843I)	Gefitinib(EGFR inhibitor 1st gen)	Head an neck	No Responsive	C	NO	PMID:21274259	only alteration type		HNC
WP072	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP072	MSH3 MUT* (A145T)	MSH3 oncogenic mutation	DNA-PKc inhibitors	Any cancer type	Responsive	D	YES	PMID:24556366	only alteration type		CANCER
WP072	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP072	LRP1B MUT* (--)	LRP1B oncogenic mutation	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only alteration type		OV
WP072	LRP1B MUT* (--)	LRP1B deletion	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only gene		OV
WP072	EGFR MUT* (--)	EGFR (C797S)	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Resistant	C	NO	PMID:25939061	only alteration type		L
WP072	EGFR MUT* (--)	EGFR (L718)	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Resistant	C	NO	ASCO 2017 (abstr 2572)	only alteration type		L
WP072	EGFR MUT* (--)	EGFR (L792)	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Resistant	C	NO	ASCO 2017 (abstr 2572)	only alteration type		L
WP072	EGFR MUT* (--)	EGFR (G465R)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:26059438	only alteration type		COREAD
WP072	NOTCH2 MUT* (P6X)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP072	NOTCH2 MUT* (P6X)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP072	NOTCH2 MUT* (P6X)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP072	PTEN MUT* (--)	PTEN biallelic inactivation	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	Caris molecular intelligence	only alteration type		COREAD
WP072	NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP072	NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP072	PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP072	PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP072	FLT3 MUT* (--)	FLT3 (D835,Y842)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Acute myeloid leukemia	Resistant	D	YES	PMID:23430109	only alteration type		AML
WP072	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP072	FLT3 MUT* (--)	FLT3 (F691,D835,N676,Y842)	Quizartinib(Pan-TK inhibitor)	Acute myeloid leukemia	Resistant	D	YES	PMID:22504184;PMID:23878140	only alteration type		AML
WP072	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP072	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP072	EGFR MUT* (--)	EGFR (L798I)	Rociletinib(EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27283993	only alteration type		LUAD
WP072	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	AKT inhibitors	Breast adenocarcinoma	Responsive	C	NO	ASCO 2015 (abstr 2500)	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitor(alone or in combination)s	Lung, Colorectal adenocarcinoma	Responsive	D	NO	PMID:23136191;PMID:23475782;PMID:22392911	only alteration type		L, COREAD
WP072	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Bladder, Head an neck, Lung	Responsive	C	NO	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	only alteration type		BLCA, HNC, L
WP072	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma, Ovary, Cervix squamous cell, Endometrium	Responsive	C	NO	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	only alteration type		BRCA, OV, CESC, ED
WP072	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26787751;PMID:26763254	only alteration type		HNSC
WP072	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Glioma, Thyroid carcinoma	Responsive	D	NO	PMID:19671762;PMID:21289267	only alteration type		G, THCA
WP072	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:28331003	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2501)	only alteration type		ST
WP072	PTEN MUT* (--)	PTEN oncogenic mutation	AKT inhibitors	Pancreas	Responsive	C	NO	PMID:22025163	only alteration type		PA
WP072	PTEN MUT* (--)	PTEN deletion	AKT inhibitors	Pancreas	Responsive	C	NO	PMID:22025163	only gene		PA
WP072	PTEN MUT* (--)	PTEN oncogenic mutation	ATM inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27397505	only alteration type		BRCA
WP072	PTEN MUT* (--)	PTEN oncogenic mutation	PARP inhibitors	Endometrium	Responsive	C	NO	PMID:21468130;PMID:20944090	only alteration type		ED
WP072	PTEN MUT* (--)	PTEN deletion	PARP inhibitors	Endometrium	Responsive	C	NO	PMID:21468130;PMID:20944090	only gene		ED
WP072	PTEN MUT* (--)	PTEN oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26645196	only alteration type		CM
WP072	PTEN MUT* (--)	PTEN deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26645196	only gene		CM
WP072	PTEN MUT* (--)	PTEN oncogenic mutation	PI3K pathway inhibitor + AR antagonists	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575859	only alteration type		PRAD
WP072	PTEN MUT* (--)	PTEN deletion	PI3K pathway inhibitor + AR antagonists	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575859	only gene		PRAD
WP072	PTEN MUT* (--)	PTEN oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Ovary	Responsive	D	NO	PMID:21632463	only alteration type		OV
WP072	PTEN MUT* (--)	PTEN deletion	PI3K pathway inhibitor + MEK inhibitors	Ovary	Responsive	D	NO	PMID:21632463	only gene		OV
WP072	PTEN MUT* (--)	PTEN oncogenic mutation	PI3K pathway inhibitors	Thyroid, Glioma, Lung, Ovary, Breast adenocarcinoma, Any cancer type, Endometrium	Responsive	D	YES	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669	only alteration type		TH, G, L, OV, BRCA, CANCER, ED
WP072	PTEN MUT* (--)	PTEN deletion	PI3K pathway inhibitors	Thyroid, Glioma, Lung, Ovary, Breast adenocarcinoma, Any cancer type, Endometrium	Responsive	D	YES	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669	only gene		TH, G, L, OV, BRCA, CANCER, ED
WP072	PTEN MUT* (--)	PTEN oncogenic mutation	PIK3CB inhibitors	Prostate adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 2514)	only alteration type		PRAD
WP072	PTEN MUT* (--)	PTEN deletion	PIK3CB inhibitors	Prostate adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 2514)	only gene		PRAD
WP072	PTEN MUT* (--)	PTEN oncogenic mutation	Everolimus(MTOR inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:23582881	only alteration type		PRAD
WP072	PTEN MUT* (--)	PTEN deletion	Everolimus(MTOR inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:23582881	only gene		PRAD
WP072	PTEN MUT* (--)	PTEN oncogenic mutation	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	C	YES	ASCO 2013 (abstr 2532)	only alteration type		CANCER
WP072	PTEN MUT* (--)	PTEN deletion	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	C	YES	ASCO 2013 (abstr 2532)	only gene		CANCER
WP072	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP072	RB1 MUT* (--)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
WP072	RB1 MUT* (--)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
WP072	RB1 MUT* (--)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
WP072	RB1 MUT* (--)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
WP072	RB1 MUT* (--)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP072	RB1 MUT* (--)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP072	SMARCB1 MUT* (--)	SMARCB1 oncogenic mutation	EZH2 inhibitors	Malignant rhabdoid tumor	Responsive	C	NO	ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302)	only alteration type		MRT
WP072	SMARCB1 MUT* (--)	SMARCB1 deletion	EZH2 inhibitors	Malignant rhabdoid tumor	Responsive	C	NO	ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302)	only gene		MRT
WP072	SMARCB1 MUT* (--)	SMARCB1 deletion	EZH2 inhibitors	Malignant rhabdoid tumor	Responsive	C	NO	ESMO 2015 (abstract 302)	only gene		MRT
WP072	SMARCB1 MUT* (--)	SMARCB1 oncogenic mutation	HDAC inhibitors	Malignant rhabdoid tumor	Responsive	D	NO	PMID:26920892	only alteration type		MRT
WP072	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP072	TERT MUT* (--)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP072	TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP072	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP072	FLT3 MUT* (--)	FLT3-ITD	Venetoclax(BCL2 inhibitor)	Acute myeloid leukemia	Resistant	C	YES	PMID:27520294	only alteration type		AML
WP072	PTEN MUT* (--)	PTEN (D326N,G165R,T277A,T160I,G129E,G165V,N48K,H93Y,N94I,D92E,D92G,F21A,R173P,L112R,K289E,L108P,R335L,H123Y,R130G,D92V,G251C,R15S,L181P,V133I,C124R,T131A,.,V343L,A126V,T131L,L112P,R173C,G129A,H61D,C136R,H123Q,H61R,P96Q,D331G,M134L,N276S,K342N,Y68H,D92N,M35R,Y68D,P95S,R130Q,R173H,Y155C,H123D,G20E,K62R,R159G,S10N,L23F,C105F,D162G,T319A,Y16C,A126D,H93R,K128Q,I122S,Y65C,F154L,K128T,R130K,R130L,V343E,G36R,A126S,D252G,G127N,F347L,G127E,K125E,A39P,S170N,G165E,P169H,Y27S,V217D,D162H,H118P,D92A,A34D,D24Y,L345Q,T131I,D92H,K128N,T167A,S170R,T401I,P95L,C124S,P38L,S227F,C124N,A121P,G129D,K128R,C136Y,F341V,K125L,R130A,D24N,H93D,L325F,C71Y,E157G,L42R,Y174N,A121E,A126G,G129R,R161G,G44D,I168F,R15K,H93Q,I122L,F241S,D107Y,K125M,L320S)	Gsk2636771 + Azd8186	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/PTEN	only alteration type		CANCER
WP072	PTEN MUT* (--)	PTEN deletion	Gsk2636771 + Azd8186	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/PTEN	only gene		CANCER
WP072	EWSR1 MUT* (--)	EWSR1-FLI1 fusion	T + K + 2 + 1 + 6	Ewing sarcoma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EWSR1	only gene		EWS
WP072	EGFR MUT* (--)	EGFR (T790M)	Afatinib + Erlotinib + Gefitinib	Non-small cell lung	Resistant	A	NO	oncokb: oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR (T790M,D761Y)	Gefitinib	Non-small cell lung	Resistant	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/19/summary|oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR (R108K,T263P,A289V)	Lapatinib	Glioma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		G
WP072	EGFR MUT* (--)	EGFR (C797G,C797S)	Osimertinib	Non-small cell lung	Resistant	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/19/summary|oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
WP072	KDM6A MUT* (--)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
WP072	KDM6A MUT* (--)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only alteration type		BLCA
WP072	AKT1 MUT* (--)	AKT1 (E17K)	Azd5363	Breast adenocarcinoma	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/AKT1|CIVIC=https://civicdb.org/genes/2/summary	only alteration type		BRCA
WP072	AKT1 MUT* (--)	AKT1 (E17K)	Azd5363	Endometrial adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/AKT1	only alteration type		EDA
WP072	AKT1 MUT* (--)	AKT1 (E17K)	Azd5363	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/AKT1	only alteration type		OV
WP072	ARAF (H366N)	ARAF (G322S,S214T,F351L,.,S214C,N217I,S214A,S214F)	Sorafenib	Histiocytoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ARAF	complete		HIS
WP072	PIK3CA MUT* (--)	PIK3CA (P539R,R38H,Q546K,G118D,G106V,Q546E,E579K,N345K,E453K,V344A,E545K,T1025S,E542Q,G1049R,M1043I,E110K,P449T,N1044K,K111E,C378R,H1047R,C420R,E78K,E545A,S629C,D350G,.,G451R,M1043V,E542V,Q546R,E365K,E81K,G106D,R88Q,P366R,R93Q,G914R,H1047Y,K111N,E545Q,E545G,R93W,R108H,G106R,E453Q,E542K,D1029Y,N345I,D549N,A1066V,Q546P,E542G,E453A)	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA amplification	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only gene		BRCA
WP072	EGFR MUT* (--)	EGFR (T790M,D761Y)	Osimertinib	Non-small cell lung	Responsive	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/19/summary|oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
WP072	JAK2 (V617F)	JAK2-PCM1 fusion	Ruxolitinib	Eosinophilic chronic leukemia	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/JAK2	only gene		ECL
WP072	SMARCB1 MUT* (--)	SMARCB1 deletion	Epz-6438	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/SMARCB1	only gene		CANCER
WP072	SMARCB1 MUT* (--)	SMARCB1 oncogenic mutation	Epz-6438	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/SMARCB1	only alteration type		CANCER
WP072	ARAF (H366N)	ARAF (G322S,S214T,F351L,.,S214C,N217I,S214A,S214F)	Sorafenib	Non-small cell lung	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ARAF|CIVIC=https://civicdb.org/genes/3/summary	complete		NSCLC
WP072	EGFR MUT* (--)	EGFR amplification	Lapatinib	Glioma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EGFR	only gene		G
WP072	AKT1 MUT* (--)	AKT1 E17K	Akt Inhibitor MK2206	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/231	only alteration type		BRCA
WP072	AKT1 MUT* (--)	AKT1 E17K	Capivasertib	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/709	only alteration type		BRCA
WP072	AKT1 MUT* (--)	AKT1 E17K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4029	only alteration type		CM
WP072	AKT1 MUT* (--)	AKT1 E17K	Uprosertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/707	only alteration type		CM
WP072	AKT1 MUT* (--)	AKT1 Q79K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/439	only alteration type		CM
WP072	AKT1 MUT* (--)	AKT1 Q79K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4498	only alteration type		CM
WP072	AKT1 MUT* (--)	AKT1 Q79K	Dabrafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6260	only alteration type		CM
WP072	ARAF (H366N)	ARAF S214C	Sorafenib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/17	only alteration type		NSCLC
WP072	ARAF (H366N)	ARAF S214C	Sorafenib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/40	only alteration type		NSCLC
WP072	ARAF (H366N)	ARAF S214C	Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/41	only alteration type		NSCLC
WP072	ARAF (H366N)	ARAF S490T	Cetuximab,Irinotecan,Vemurafenib	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1905	only alteration type		COREAD
WP072	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP072	EGFR MUT* (--)	EGFR A763_Y764insFQEA	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4497	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR A763_Y764insFQEA	Osimertinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/9225	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR A767_V769dupASV	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4665	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR A767_V769dupASV	Osimertinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/9220	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR A864T	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4495	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR C797S	Osimertinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1396	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR C797S	Osimertinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/964	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR D761Y	Erlotinib,Gefitinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1763	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR D770_N771insG	Osimertinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/9223	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR D770_N771insGL	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4494	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR D770_N771insGT	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4643	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR D770_N771insNPG	Gefitinib,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/5947	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR D770delinsGY	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4801	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR E746G	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1787	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR E746_A750del	Gefitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2625	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR E746_A750del	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4198	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR EGFR::RAD51	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5909	only gene		LUAD
WP072	EGFR MUT* (--)	EGFR EGFR::RAD51	Icotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7314	only gene		LUAD
WP072	EGFR MUT* (--)	EGFR EGFR::RAD51	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11015	only gene		LUAD
WP072	EGFR MUT* (--)	EGFR EGFR::RAD51	Osimertinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11021	only gene		LUAD
WP072	EGFR MUT* (--)	EGFR G465R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1058	only alteration type		COREAD
WP072	EGFR MUT* (--)	EGFR G465R	Futuximab/Modotuximab Mixture	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1057	only alteration type		COREAD
WP072	EGFR MUT* (--)	EGFR G719	Erlotinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1780	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR G719	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4189	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR G719A	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2508	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR G719A	Erlotinib,Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/6181	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR G719D	Gefitinib,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4210	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR G719S	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/787	only alteration type		COREAD
WP072	EGFR MUT* (--)	EGFR G719S	Gefitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/274	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR G719S	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1736	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR G719S	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4190	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR G724S	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/786	only alteration type		COREAD
WP072	EGFR MUT* (--)	EGFR H773_V774insNPH	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4493	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR K467T	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1083	only alteration type		COREAD
WP072	EGFR MUT* (--)	EGFR K467T	Panitumumab,Futuximab/Modotuximab Mixture	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1082	only alteration type		COREAD
WP072	EGFR MUT* (--)	EGFR K757R	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1786	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR K806E	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4239	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR KIF5B::EGFR	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11026	only gene		LUAD
WP072	EGFR MUT* (--)	EGFR L747P	Gefitinib,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4220	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L747_P753delinsS	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4266	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L747_P753delinsS	Erlotinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6005	only alteration type		PAAD
WP072	EGFR MUT* (--)	EGFR L747_S752delinsQ	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4667	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR L838P	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4252	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Afatinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/879	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR L858R	Afatinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/883	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR L858R	Afatinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/982	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR L858R	Gefitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2624	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR L858R	Gefitinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2634	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR L858R	Erlotinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4290	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR L858R	Erlotinib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4291	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR L858R	Cetuximab	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4292	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR L858R	Gefitinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6183	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR L858R	Crizotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/4288	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Gefitinib,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/229	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/275	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Gefitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/276	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/885	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/968	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1665	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2621	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Lapatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2626	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Dacomitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2627	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Neratinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2628	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2629	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Canertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2631	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2632	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/2994	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Afatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/2997	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4284	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4286	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4287	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Osimertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4294	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4860	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L858R	Erlotinib	Small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4293	only alteration type		SCLC
WP072	EGFR MUT* (--)	EGFR L861	Gefitinib,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4298	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L861Q	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/3802	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR L861R	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4669	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR M766_A767insAI	Erlotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/4799	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR Mutation	Afatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1728	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1937	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR Mutation	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2053	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2148	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR Mutation	Afatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2153	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2559	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3016	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR Mutation	Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3794	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR Mutation	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4201	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR Mutation	Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7024	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR N826S	Erlotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/4496	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR N826Y	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4244	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR N842S	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4256	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR P772_H773insYNP	Erlotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/4802	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR R451C	Futuximab/Modotuximab Mixture,Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1081	only alteration type		COREAD
WP072	EGFR MUT* (--)	EGFR R705K	Erlotinib,Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/6182	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR R776C	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4468	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR S492R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/717	only alteration type		COREAD
WP072	EGFR MUT* (--)	EGFR S492R	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1080	only alteration type		COREAD
WP072	EGFR MUT* (--)	EGFR S492R	Panitumumab	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1078	only alteration type		COREAD
WP072	EGFR MUT* (--)	EGFR S492R	Panitumumab,Futuximab/Modotuximab Mixture	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1079	only alteration type		COREAD
WP072	EGFR MUT* (--)	EGFR S720	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1782	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR S768I	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4273	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR S768I	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1394	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR S768I	Gefitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1395	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR S768I	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2906	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1391	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR T790M	Osimertinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1397	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR T790M	Osimertinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2157	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR T790M	Erlotinib	Non-small cell lung	Resistant	A	NO	https://civicdb.org/links/evidence_items/238	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/239	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Dacomitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/240	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/1667	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Afatinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/1863	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Gefitinib,Erlotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/2158	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2159	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Lapatinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/2160	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Pemetrexed,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/277	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Rociletinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/646	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Rociletinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/762	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/963	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/965	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/966	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Rociletinib,Osimertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/967	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1592	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1867	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Dacomitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2161	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Neratinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2162	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2163	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2164	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Canertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2165	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR T790M	Osimertinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6006	only alteration type		PAAD
WP072	EGFR MUT* (--)	EGFR T847I	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4260	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR V742A	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4197	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR V769_D770insASV	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1799	only alteration type		LUAD
WP072	EGFR MUT* (--)	EGFR V774A	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4226	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR V774M	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4231	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR V834I	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4248	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR V851I	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4264	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR Y764_V765insHH	Erlotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/4800	only alteration type		NSCLC
WP072	EGFR MUT* (--)	EGFR Amplification	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/854	only gene		COREAD
WP072	EGFR MUT* (--)	EGFR Amplification	Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/911	only gene		COREAD
WP072	EGFR MUT* (--)	EGFR Amplification	Platinum Compound,Cetuximab,Fluorouracil	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/691	only gene		HNSC
WP072	EGFR MUT* (--)	EGFR Amplification	Rociletinib,Osimertinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/3015	only gene		NSCLC
WP072	EGFR MUT* (--)	EGFR Amplification	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/948	only gene		NSCLC
WP072	EGFR MUT* (--)	EGFR Amplification	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/977	only gene		NSCLC
WP072	EGFR MUT* (--)	EGFR Amplification	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5924	only gene		NSCLC
WP072	EGFR MUT* (--)	EGFR Amplification	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5925	only gene		NSCLC
WP072	ERBB4 MUT* (--)	ERBB4 Mutation	Lapatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/770	only alteration type		CM
WP072	FLT3 MUT* (--)	FLT3 D835	Quizartinib,Ponatinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1036	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 D835	SU5614	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1037	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 D835	Quizartinib,Sorafenib	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/1038	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 D835	Sorafenib	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/1039	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 D835H	Sorafenib	Acute myeloid leukemia	Resistant	C	YES	https://civicdb.org/links/evidence_items/1556	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 D835H	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8517	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 D835H/Y	Sorafenib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1557	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 D835I	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8351	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 D835V	Tandutinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/3007	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 D835V	Sunitinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3008	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 D835V	Sunitinib,Cytarabine	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3009	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 D835V	Daunorubicin,Sunitinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3010	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 D835V	Quizartinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3012	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 D835V	AS602868,Tyrphostin AG 1296	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3034	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 D835V	Sunitinib	Acute myeloid leukemia	Responsive	C	YES	https://civicdb.org/links/evidence_items/4022	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 D835V	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8518	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 D835Y	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8108	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 F691L	Lestaurtinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8341	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 F691L	Midostaurin	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8342	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 Mutation	Midostaurin	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/5261	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 Mutation	Gilteritinib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/7283	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 Mutation	Gilteritinib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/7728	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 Y842C	FLT3/ABL/Aurora Kinase Inhibitor KW-2449	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8336	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 Y842C	Sorafenib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8337	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 Y842C	Sunitinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8338	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 Y842C	Quizartinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8654	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 Y842C	Lestaurtinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8339	only alteration type		AML
WP072	FLT3 MUT* (--)	FLT3 Y842C	Midostaurin	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8340	only alteration type		AML
WP072	IDH1 MUT* (--)	IDH1 Mutation	Ivosidenib	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/7278	only alteration type		AML
WP072	IDH1 MUT* (--)	IDH1 Mutation	Venetoclax	Acute myeloid leukemia	Responsive	C	YES	https://civicdb.org/links/evidence_items/8856	only alteration type		AML
WP072	IDH1 MUT* (--)	IDH1 Mutation	Ivosidenib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7447	only alteration type		CH
WP072	IDH1 MUT* (--)	IDH1 R132	Ivosidenib	Cholangiocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/10886	only alteration type		CH
WP072	IDH1 MUT* (--)	IDH1 R132	Dasatinib	Intrahepatic cholangiocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6439	only alteration type		IHCH
WP072	IDH1 MUT* (--)	IDH1 R132C	GSK321	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/732	only alteration type		AML
WP072	IDH1 MUT* (--)	IDH1 R132C	Ivosidenib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/2331	only alteration type		AML
WP072	IDH1 MUT* (--)	IDH1 R132C	BPTES	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/2332	only alteration type		AML
WP072	IDH2 MUT* (--)	IDH2 Mutation	Enasidenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/4833	only alteration type		AML
WP072	IDH2 MUT* (--)	IDH2 Mutation	Enasidenib	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/5069	only alteration type		AML
WP072	IDH2 MUT* (--)	IDH2 Mutation	Venetoclax	Acute myeloid leukemia	Responsive	C	YES	https://civicdb.org/links/evidence_items/8857	only alteration type		AML
WP072	JAK2 (V617F)	JAK2 Splice Site (c.1641+2T>G)	Pembrolizumab	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4825	only alteration type		CM
WP072	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP072	KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (S806), KMT2C MUT* (S768), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP072	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP072	NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP072	NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP072	NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP072	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2346	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8549	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA C420R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2078	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA C420R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1999	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA D350G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4784	only alteration type		CM
WP072	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8007	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E542K	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/310	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E542K	Sirolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/311	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2022	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2026	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2058	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E542K	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7315	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8013	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8016	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E542K	Regorafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/83	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA E542K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4424	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA E542K	Apitolisib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/1549	only alteration type		HNSC
WP072	PIK3CA MUT* (--)	PIK3CA E542K	Perifosine,Temsirolimus	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1626	only alteration type		THCA
WP072	PIK3CA MUT* (--)	PIK3CA E545	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7468	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E545G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3724	only alteration type		CM
WP072	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1453	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2036	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6211	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E545K	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6213	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E545K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8008	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8547	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E545K	Akt Inhibitor MK2206,Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/710	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2034	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2062	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8017	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8018	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA E545K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3722	only alteration type		CM
WP072	PIK3CA MUT* (--)	PIK3CA E545K	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/387	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2037	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2217	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib	Lung adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1171	only alteration type		LUAD
WP072	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1670	only alteration type		LUAD
WP072	PIK3CA MUT* (--)	PIK3CA E545K	PI103	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2040	only alteration type		NSCLC
WP072	PIK3CA MUT* (--)	PIK3CA E545Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2213	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA E81K	Oxaliplatin,Fluorouracil,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4464	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA F930S	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10032	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA G1049R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3847	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA H1047L	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2089	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA H1047L	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8009	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA H1047L	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8019	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA H1047L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4432	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2103	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6204	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6206	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8548	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/314	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Capivasertib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1505	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1506	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Everolimus,Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1623	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2096	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2102	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/258	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/388	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Vemurafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3733	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3841	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Akt Inhibitor MK2206,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8364	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1465	only alteration type		HNSC
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1447	only alteration type		LUAD
WP072	PIK3CA MUT* (--)	PIK3CA H1047R	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1625	only alteration type		THCA
WP072	PIK3CA MUT* (--)	PIK3CA H1047X	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7318	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2867	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8663	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2866	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA K111N	Dactolisib,Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8183	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8662	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA K111N	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2085	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA K111N	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8011	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA K111N	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8020	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA K944N	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10031	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA K966E	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10034	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1384	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2087	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2098	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8536	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Capecitabine,Lapatinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8705	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1296	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1504	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1600	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1607	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1610	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Fulvestrant,Alpelisib	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7313	only alteration type		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/915	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1705	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3732	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6298	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6299	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6300	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6301	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6362	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Cabozantinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/771	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6375	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Ridaforolimus,Temsirolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/892	only alteration type		ED
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Pictilisib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1616	only alteration type		ED
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Radiation Therapy,Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1490	only alteration type		HNSC
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin,Sulindac,Celecoxib	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7185	only alteration type		HNSC
WP072	PIK3CA MUT* (--)	PIK3CA Mutation	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2355	only alteration type		NSCLC
WP072	PIK3CA MUT* (--)	PIK3CA N345K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4047	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA Q546K	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2198	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA R88Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3832	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA R93W	Cetuximab,Fluorouracil,Oxaliplatin	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4467	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA S158L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4463	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA V955G	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10033	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA V955I	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/8063	only alteration type		COREAD
WP072	PIK3CA MUT* (--)	PIK3CA Amplification	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8267	only gene		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA Amplification	Lapatinib,Dactolisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8271	only gene		BRCA
WP072	PIK3CA MUT* (--)	PIK3CA Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6275	only gene		CM
WP072	PIK3CA MUT* (--)	PIK3CA Amplification	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1464	only gene		HNSC
WP072	PIK3CA MUT* (--)	PIK3CA Amplification	Sulindac,Aspirin,Ibuprofen	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7186	only gene		HNSC
WP072	PIK3CA MUT* (--)	PIK3CA Amplification	Pictilisib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/756	only gene		OV
WP072	POLD1 MUT* (--)	POLD1 C284Y	Pembrolizumab	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4776	only alteration type		LUAD
WP072	POLD1 MUT* (--)	POLD1 E374K	Pembrolizumab	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4777	only alteration type		NSCLC
WP072	PTEN MUT* (--)	PTEN Mutation	Taselisib	Head an neck squamous	Resistant	D	NO	https://civicdb.org/links/evidence_items/1467	only alteration type		HNSC
WP072	PTEN MUT* (--)	PTEN R130*	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1627	only alteration type		THCA
WP072	PTEN MUT* (--)	PTEN R233*	MTOR Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/317	only alteration type		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Everolimus	Bladder	Resistant	B	NO	https://civicdb.org/links/evidence_items/644	only gene		BLCA
WP072	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/645	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Alpelisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/716	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1383	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1385	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1386	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2035	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2043	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	PI3Ka/Di	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8022	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8274	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8275	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8276	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Dactolisib,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8278	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Trastuzumab,Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8279	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8706	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	PI3Kbeta Inhibitor AZD8186	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/711	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1297	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	PI3K/BET Inhibitor LY294002,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1455	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1611	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2045	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2074	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8012	only gene		BRCA
WP072	PTEN MUT* (--)	PTEN Loss	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6271	only gene		CM
WP072	PTEN MUT* (--)	PTEN Loss	Uprosertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/708	only gene		CM
WP072	PTEN MUT* (--)	PTEN Loss	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/506	only gene		COREAD
WP072	PTEN MUT* (--)	PTEN Loss	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6315	only gene		COREAD
WP072	PTEN MUT* (--)	PTEN Loss	Ridaforolimus,Temsirolimus	Endometrium	Resistant	B	NO	https://civicdb.org/links/evidence_items/893	only gene		ED
WP072	PTEN MUT* (--)	PTEN Loss	Temsirolimus	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1614	only gene		ED
WP072	PTEN MUT* (--)	PTEN Loss	Cisplatin	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/1492	only gene		OV
WP072	PTEN MUT* (--)	PTEN Loss	Buparlisib,Paclitaxel,Carboplatin	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/5957	only gene		SOLID
WP072	PTEN MUT* (--)	PTEN Loss	Trastuzumab,Lapatinib	Stomach	Resistant	B	NO	https://civicdb.org/links/evidence_items/864	only gene		ST
WP072	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP072	RAD51D MUT* (--)	RAD51D Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11214	only alteration type		PRAD
WP072	RB1 MUT* (--)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
WP072	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP072	TLK2 MUT* (--)	TLK2 Amplification	Go6983,GF109203X	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6000	only gene		BRCA
WP072	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP072	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP170	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP170	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF (V600E,V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF (V600E,V600K)	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s028lbl.pdf	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP170	BRAF MUT* (--)	BRAF (V600E,V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf	only alteration type		CM
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP170	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Myelofibrosis	Responsive	A	YES	FDA	complete		MY
WP170	PDGFB MUT* (--)	PDGFB-COL1A1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Dermatofibrosarcoma	Responsive	A	NO	FDA	only gene		DFS
WP170	PTCH1 MUT* (I1055)	PTCH1 oncogenic mutation	Vismodegib(SHH inhibitor)	Basal cell carcinoma, Medulloblastoma	Responsive	A	NO	PMID:19726763;PMID:19726761	only alteration type		BCC, MB
WP170	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022	only alteration type		BRCA
WP170	BRAF MUT* (--)	BRAF (V600E)	Trametinib(MEK inhibitor) + Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN Non-Small Cell Lung Cancer guidlines 2022; FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		NSCLC
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP170	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP170	BRIP1 MUT* (--)	BRIP1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP170	FGFR3 MUT* (--)	FGFR3 fusion	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only gene		BLCA
WP170	FGFR3 MUT* (--)	FGFR3 (G370C,R248C,S249C,Y373C)	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only alteration type		BLCA
WP170	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation;PMID:31566309	only alteration type		COREAD
WP170	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP170	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP170	ROS1 MUT* (--)	ROS1 fusion	Entrectinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA;PMID:28183697;ESMO 2019 (abstr 4178) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725s007lbl.pdf	only gene		NSCLC
WP170	PIK3CA MUT* (--)	PIK3CA (C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R)	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	only alteration type		BRCA
WP170	BRAF MUT* (--)	BRAF (V600)	Atezolizumab(PD-L1 blocking antibody);Vemurafenib(BRAF inhibitor);Cobimetinib(MEK inhibitor) 	Cutaneous melanoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-braf-v600-unresectable-or-metastatic-melanoma	only alteration type		CM
WP170	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Bevacizumab(VEGF mAb inhibitor);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP170	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP170	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Pembrolizumab(PD-1-blocking antibody);Pemetrexed(Chemotherapy);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf	complete		NSCLC
WP170	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		SOLID
WP170	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Lower grade glioma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-trametinib-pediatric-patients-low-grade-glioma-braf-v600e-mutation	only alteration type		LGG
WP170	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Durvalumab(PD-1-blocking antibody);Tremelimumab-actl(CTLA-4 blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non	complete		NSCLC
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP170	ATM MUT* (--)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP170	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP170	BRAF MUT* (--)	BRAF (V600E,V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210496s013lbl.pdf	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP170	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP170	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP170	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP170	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP170	BRAF MUT* (--)	BRAF(V600E)	Vemurafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP170	BRAF MUT* (--)	BRAF (V600)	Dabrafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP170	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Hairy-Cell leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf	only alteration type		HCL
WP170	ROS1 MUT* (--)	ROS1 fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP170	ROS1 MUT* (--)	ROS1 fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP170	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-binimetinib-metastatic-non-small-cell-lung-cancer-braf-v600e-mutation	only alteration type		NSCLC
WP170	BRAF MUT* (--)	BRAF(V600)	Vemurafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		HISEC
WP170	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF (V600E,G469A)	EGFR TK inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:22773810	only alteration type		LUAD
WP170	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	complete		CANCER
WP170	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	complete		OV
WP170	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	complete		CANCER
WP170	FGFR3 MUT* (--)	FGFR3 (V555M)	FGFR inhibitors	Myeloma	Resistant	D	YES	PMID:22869148	only alteration type		MYMA
WP170	ATM MUT* (--)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only alteration type		COREAD
WP170	ATM MUT* (--)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
WP170	ATM MUT* (--)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only alteration type		LY
WP170	ATM MUT* (--)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only gene		LY
WP170	ATM MUT* (--)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP170	ATM MUT* (--)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
WP170	ATM MUT* (--)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP170	ATM MUT* (--)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP170	ATM MUT* (--)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP170	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP170	ATM MUT* (--)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP170	BCOR MUT* (--)	BCOR oncogenic mutation	Enzastaurin(PKCb inhibitor)	Stomach	Responsive	D	NO	PMID:27397505	only alteration type		ST
WP170	JAK2 (V617F)	JAK2 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	complete		CM
WP170	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + CDK2/4 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22997239	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF (V600)	BRAF inhibitor + EGFR mAb inhibitor +/- PI3K inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28363909	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + HSP90 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22351686	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + MEK inhibitors	Thyroid	Responsive	C	NO	ASCO 2013 (abstr 9029)	only alteration type		TH
WP170	BRAF MUT* (--)	BRAF fusion	BRAF inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9072)	only gene		LUAD
WP170	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + PI3K pathway inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22389471;PMID:21156289	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF (L597R)	BRAF inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:23715574	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Glioma	Responsive	D	NO	PMID:22038996;PMID:22586120	only alteration type		G
WP170	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Ovary	Responsive	C	NO	PMID:22608338	only alteration type		OV
WP170	BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:23614898;PMID:22997239	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF (G469A)	ERK inhibitors	Head an neck squamous	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		HNSC
WP170	BRAF MUT* (--)	BRAF (L485W)	ERK inhibitors	Billiary tract	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		BT
WP170	BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		LUAD
WP170	BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Thyroid	Responsive	C	NO	PMID:22241789	only alteration type		TH
WP170	BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Ovary	Responsive	D	NO	PMID:19018267	only alteration type		OV
WP170	BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Pan-RAF inhibitors	Any cancer type	Responsive	D	YES	PMID:26732095	only alteration type		CANCER
WP170	BRAF MUT* (--)	BRAF (V600E)	Pan-RAF inhibitors	Cutaneous melanoma	Responsive	C	NO	ESMO 2015 (abstract 300);AACR 2016 (abstr CT005);AACR 2017 (abstr  CT002)	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF fusion	MEK inhibitors(Trametinib,etc)	Lung adenocarcinoma, Cutaneous melanoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:24727320;PMID:24345920;PMID:20526349	only gene		LUAD, CM, PRAD
WP170	BRAF MUT* (--)	BRAF (K601R,L597R,V600R)	MEK inhibitors(Trametinib,etc)	Cutaneous melanoma	Responsive	C	NO	PMID:23248257;PMID:22805292;PMID:23248257	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Lung adenocarcinoma, Thyroid	Responsive	C	NO	PMID:23524406;PMID:22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);PMID:20818844;PMID:23489023;PMID:27080216	only alteration type		LUAD, TH
WP170	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Gastrointestinal stromal	Responsive	C	NO	PMID:23470635;PMID:22608338	only alteration type		GIST
WP170	BRAF MUT* (--)	BRAF (V600R)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:23237741	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26392102;ASCO 2015 (abstr 8006)	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Neuroendocrine	Responsive	C	NO	PMID:27048246	only alteration type		NEU
WP170	BRAF MUT* (--)	BRAF (G466V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:22649091	only alteration type		LUAD
WP170	BRAF MUT* (--)	BRAF (Y472C)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	PMID:22649091	only alteration type		LUAD
WP170	BRAF MUT* (--)	BRAF (V600)	Irinotecan + Vemurafenib + Cetuximab(TOPO1 inhibitor + BRAF inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:27729313	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + BYL719(EGFR mAb inhibitor + BRAF inhibitor + PI3K inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2014 (abstr 11LBA)	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF (V600E)	Panitumumab + Dabrafenib + Trametinib(EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103)	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF (V600E)	PLX4720(BRAF inhibitor)	Malignant astrocytoma	Responsive	D	NO	PMC3638050	only alteration type		MA
WP170	BRAF MUT* (--)	BRAF fusion	Selumetinib(MEK inhibitor)	Ovary	Responsive	C	NO	PMID:26324360	only gene		OV
WP170	BRAF MUT* (--)	BRAF (V600E)	Selumetinib(MEK inhibitor)	Pediatric glioma	Responsive	C	NO	NCT01089101	only alteration type		PG
WP170	BRAF MUT* (--)	BRAF fusion	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma, Lung adenocarcinoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:238900088;PMID:20526349;PMID:24727320	only gene		CM, LUAD, PRAD
WP170	BRAF MUT* (--)	BRAF (D594G,G469E)	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:18794803	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Lung adenocarcinoma, Hairy-Cell leukemia, Myeloma	Responsive	C	YES	PMID:22743296;PMID:22621641;PMID:23612012	only alteration type		LUAD, HCL, MYMA
WP170	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Malignant astrocytoma	Responsive	C	NO	PMID:22586120	only alteration type		MA
WP170	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:22608338;PMID:20818844;PMID:23489023	only alteration type		THCA
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
WP170	BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP170	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA (E545*)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMC3936420	only alteration type		CM
WP170	PIK3CA MUT* (--)	PIK3CA amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	D	NO	PMID:24366379	only gene		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9054)	only alteration type		L
WP170	STK11 MUT* (--)	STK11 oncogenic mutation	BET inhibitors	Lung	Resistant	D	NO	PMID:23129625;PMID:24045185	only alteration type		L
WP170	FGFR3 MUT* (--)	FGFR3 fusion	FGFR inhibitors	Glioma	Responsive	C	NO	PMID:26324363	only gene		G
WP170	FGFR3 MUT* (--)	FGFR3 oncogenic mutation	FGFR inhibitors	Bladder	Responsive	C	NO	PMID:27870574	only alteration type		BLCA
WP170	FGFR3 MUT* (--)	FGFR3 (K650,Y373C)	FGFR inhibitors	Myeloma	Responsive	D	YES	PMID:16091734;PMID:20439987;PMID:22869148	only alteration type		MYMA
WP170	FGFR3 MUT* (--)	FGFR3 (S249C,G691R)	FGFR inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:27998968	only alteration type		LUAD
WP170	FGFR3 MUT* (--)	FGFR3 fusion	FGFR inhibitors	Bladder	Responsive	C	NO	PMID:26324363;ASCO 2017 (abstr 2500)	only gene		BLCA
WP170	FGFR3 MUT* (--)	FGFR3 (K650)	Bortezomib(Proteasome inhibitor)	Myeloma	Responsive	D	YES	PMID:19331127;PMID:21273588	only alteration type		MYMA
WP170	FGFR3 MUT* (--)	FGFR3-TACC3 fusion	FGFR inhibitors(,etc)	Non-small cell lung	Responsive	D	NO	PMID:25294908	only gene		NSCLC
WP170	FGFR3 MUT* (--)	FGFR3 (Y373C)	Bortezomib(Proteasome inhibitor)	Myeloma	Resistant	D	YES	PMID:19331127;PMID:21273588	only alteration type		MYMA
WP170	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP170	GNAQ MUT* (--)	GNAQ (Q209)	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	NCT01587352	only alteration type		CM
WP170	GNAQ MUT* (--)	GNAQ (Q209)	PI3K pathway inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22733540;PMID:22808163	only alteration type		CM
WP170	GNAQ MUT* (--)	GNAQ (Q209)	PKC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22653968;PMID:22253748	only alteration type		CM
WP170	GNAQ MUT* (--)	GNAQ (Q209)	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr CRA9003)	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF (V600E)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
WP170	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP170	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP170	JAK2 (V617F)	JAK2 (V617F)	JAK inhibitor(alone or in combination)s	Acute myeloid leukemia	Responsive	D	YES	PMID:22829971	complete		AML
WP170	JAK2 (V617F)	JAK2 amplification	JAK inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27075627	only gene		BRCA
WP170	JAK2 (V617F)	JAK2-BRAF fusion	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22875628;PMID:22899477	only gene		ALL
WP170	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:22422826	complete		AML
WP170	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP170	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:19223544;PMID:20619739	only alteration type		COREAD
WP170	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP170	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP170	ROS1 MUT* (--)	ROS1 (G2032R)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:23724914;PMID:25688157	only alteration type		LUAD
WP170	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP170	MDM4 MUT* (--)	MDM4 amplification	MDM2/MDMX inhibitors	Sarcoma	Responsive	D	NO	PMID:24336067	only gene		S
WP170	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP170	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP170	LRP1B MUT* (--)	LRP1B oncogenic mutation	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only alteration type		OV
WP170	LRP1B MUT* (--)	LRP1B deletion	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only gene		OV
WP170	BRAF MUT* (--)	BRAF (V600E)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
WP170	NOTCH2 MUT* (P6X)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP170	NOTCH2 MUT* (P6X)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP170	NOTCH2 MUT* (P6X)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP170	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP170	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP170	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP170	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	AKT inhibitors	Breast adenocarcinoma	Responsive	C	NO	ASCO 2015 (abstr 2500)	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitor(alone or in combination)s	Lung, Colorectal adenocarcinoma	Responsive	D	NO	PMID:23136191;PMID:23475782;PMID:22392911	only alteration type		L, COREAD
WP170	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Bladder, Head an neck, Lung	Responsive	C	NO	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	only alteration type		BLCA, HNC, L
WP170	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma, Ovary, Cervix squamous cell, Endometrium	Responsive	C	NO	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	only alteration type		BRCA, OV, CESC, ED
WP170	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26787751;PMID:26763254	only alteration type		HNSC
WP170	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Glioma, Thyroid carcinoma	Responsive	D	NO	PMID:19671762;PMID:21289267	only alteration type		G, THCA
WP170	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:28331003	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2501)	only alteration type		ST
WP170	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	AKT inhibitors	Glioma	Responsive	D	NO	PMID:23166678	only alteration type		G
WP170	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	PI3K pathway inhibitors	Endometrium	Responsive	C	NO	ASCO 2015 (abstr 11075)	only alteration type		ED
WP170	PTCH1 MUT* (I1055)	PTCH1 oncogenic mutation	SMO inhibitors	Medulloblastoma	Responsive	D	NO	PMID:24651015	only alteration type		MB
WP170	PTCH1 MUT* (I1055)	PTCH1 oncogenic mutation	Foretinib(MET inhibitor)	Medulloblastoma	Responsive	D	NO	PMID:25391241	only alteration type		MB
WP170	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP170	RAD50 MUT* (--), ATM MUT* (--)	RAD50 (L1237F) + ATM deletion	Irinotecan + CHK1/2 inhibitor(TOPO1 inhibitor + CHK1/2 inhibitor)	Any cancer type	Responsive	C	YES	PMID:24934408	only gene		CANCER
WP170	ROS1 MUT* (--)	ROS1 fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:23533265	only gene		LUAD
WP170	ROS1 MUT* (--)	ROS1 fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27370605	only gene		LUAD
WP170	ROS1 MUT* (--)	ROS1 (G2032R)	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:25351743	only alteration type		LUAD
WP170	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	C	YES	PMID:24875859	only gene		IM
WP170	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:25264305	only gene		LUAD
WP170	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27401242	only alteration type		LUAD
WP170	SF3B1 (K700E)	SF3B1 (K700E,K666N)	Spliceosome inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858	complete		CANCER
WP170	BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Vemurafenib(BRAF inhibitor)	Any cancer type	Resistant	D	YES	PMID:26732095	only alteration type		CANCER
WP170	STK11 MUT* (--)	STK11 oncogenic mutation	MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:19165201	only alteration type		LUAD
WP170	STK11 MUT* (--)	STK11 deletion	MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:19165201	only gene		LUAD
WP170	STK11 MUT* (--)	STK11 oncogenic mutation	MTOR inhibitors	Any cancer type	Responsive	D	YES	PMID:19541609	only alteration type		CANCER
WP170	STK11 MUT* (--)	STK11 deletion	MTOR inhibitors	Any cancer type	Responsive	D	YES	PMID:19541609	only gene		CANCER
WP170	STK11 MUT* (--)	STK11 oncogenic mutation	SRC inhibitor + PI3K/MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:20541700	only alteration type		LUAD
WP170	STK11 MUT* (--)	STK11 deletion	SRC inhibitor + PI3K/MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:20541700	only gene		LUAD
WP170	STK11 MUT* (--)	STK11 (D194E)	Everolimus(MTOR inhibitor)	Pancreas	Responsive	C	NO	PMID:21189378	only alteration type		PA
WP170	STK11 MUT* (--)	STK11 oncogenic mutation	Phenformin(Anti-diabetic)	Lung adenocarcinoma	Responsive	D	NO	PMID:23352126	only alteration type		LUAD
WP170	STK11 MUT* (--)	STK11 deletion	Phenformin(Anti-diabetic)	Lung adenocarcinoma	Responsive	D	NO	PMID:23352126	only gene		LUAD
WP170	BRAF MUT* (--)	BRAF (V600)	Vemurafenib(BRAF inhibitor)	Colorectal adenocarcinoma	No Responsive	C	NO	PMID:26287849	only alteration type		COREAD
WP170	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP170	TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP170	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP170	EWSR1 MUT* (G509)	EWSR1-FLI1 fusion	T + K + 2 + 1 + 6	Ewing sarcoma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EWSR1	only gene		EWS
WP170	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
WP170	BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
WP170	BRAF MUT* (--)	BRAF (D594.,G466.,G464.,N581.,D287H,K601.,G469.,G596.,L597.,F595L,S467L,V459L)	Plx8394	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CANCER
WP170	KDM6A MUT* (--)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
WP170	KDM6A MUT* (--)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only alteration type		BLCA
WP170	BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + Trametinib	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF (V600E)	Encorafenib + Binimetinib + Cetuximab	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		OV
WP170	FGFR3 MUT* (--)	FGFR3 (S249C,S371C,R248C,K650.,G380R,Y373C,G370C)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only alteration type		BLCA
WP170	FGFR3 MUT* (--)	FGFR3 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		BLCA
WP170	BRAF MUT* (--)	BRAF (V600K,V600.,L597.,K601.,V600E,L597V)	Trametinib	Cutaneous melanoma	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/5/summary|oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CM
WP170	PIK3CA MUT* (--)	PIK3CA (P539R,R38H,Q546K,G118D,G106V,Q546E,E579K,N345K,E453K,V344A,E545K,T1025S,E542Q,G1049R,M1043I,E110K,P449T,N1044K,K111E,C378R,H1047R,C420R,E78K,E545A,S629C,D350G,.,G451R,M1043V,E542V,Q546R,E365K,E81K,G106D,R88Q,P366R,R93Q,G914R,H1047Y,K111N,E545Q,E545G,R93W,R108H,G106R,E453Q,E542K,D1029Y,N345I,D549N,A1066V,Q546P,E542G,E453A)	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA amplification	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only gene		BRCA
WP170	ATM MUT* (--)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only alteration type		CANCER
WP170	ATM MUT* (--)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
WP170	JAK2 (V617F)	JAK2-PCM1 fusion	Ruxolitinib	Eosinophilic chronic leukemia	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/JAK2	only gene		ECL
WP170	BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Cutaneous melanoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		CM
WP170	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
WP170	BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
WP170	FGFR3 MUT* (--)	FGFR3 (M528I,D641N,R669G,Y373C,K650T,G370C,S249C,S371C,A391E,G380R,I538V,D641G,N540K,R248C,V555M,.,K650E,K650R,K650M,G375C,G382D,N540S,Y647C,K650Q,K650N)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only alteration type		CANCER
WP170	FGFR3 MUT* (--)	FGFR3 amplification	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP170	FGFR3 MUT* (--)	FGFR3-BAIAP2L1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP170	FGFR3 MUT* (--)	FGFR3-TACC3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP170	FGFR3 MUT* (--)	FGFR3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP170	FGFR3 MUT* (--)	FGFR3-IGH fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP170	ATM MUT* (--)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	only alteration type		CM
WP170	ATM MUT* (--)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	only alteration type		GB
WP170	ATM MUT* (--)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	only alteration type		PRAD
WP170	BRAF MUT* (--)	BRAF Non-V600	Trametinib	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/7855	only alteration type		SOLID
WP170	BRAF MUT* (--)	BRAF A598V	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7635	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF AGK::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/724	only gene		CM
WP170	BRAF MUT* (--)	BRAF AGK::BRAF	Sorafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/723	only gene		CM
WP170	BRAF MUT* (--)	BRAF CUX1::BRAF	Vemurafenib	Pancreas	Responsive	C	NO	https://civicdb.org/links/evidence_items/5977	only gene		PA
WP170	BRAF MUT* (--)	BRAF D594G	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1554	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2201	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4472	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF D594K	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6402	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF D594K	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6403	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF G466V	Irinotecan,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7552	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF G466V	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7553	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF G466V	Vemurafenib	Solid tumors	Responsive	D	NO	https://civicdb.org/links/evidence_items/7554	only alteration type		SOLID
WP170	BRAF MUT* (--)	BRAF G469	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7634	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF G596C	Dabrafenib,Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1738	only alteration type		NSCLC
WP170	BRAF MUT* (--)	BRAF G596R	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4729	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1668	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1669	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF L597R	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/728	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1704	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2187	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6303	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6304	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6305	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6306	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1404	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF PAPSS1::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/725	only gene		CM
WP170	BRAF MUT* (--)	BRAF PAPSS1::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/726	only gene		CM
WP170	BRAF MUT* (--)	BRAF TRIM24::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/727	only gene		CM
WP170	BRAF MUT* (--)	BRAF V600	Vemurafenib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5905	only alteration type		CH
WP170	BRAF MUT* (--)	BRAF V600	Refametinib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1000	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/93	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1407	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1422	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1750	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600	Cobimetinib,Vemurafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/6044	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6180	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6937	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6966	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600	Binimetinib,Encorafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7287	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/88	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600	Vemurafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1576	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1415	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1598	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600	Cetuximab,Encorafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6046	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600	Encorafenib,Alpelisib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6047	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600	Vemurafenib,Irinotecan,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7355	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1574	only alteration type		NSCLC
WP170	BRAF MUT* (--)	BRAF V600D	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/94	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4488	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4489	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7616	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7629	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5902	only alteration type		CH
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Irinotecan,Panitumumab	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5906	only alteration type		CH
WP170	BRAF MUT* (--)	BRAF V600E	Trametinib,Mirdametinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/86	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/90	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/994	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/95	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	Pictilisib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/757	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	Dactolisib,Selumetinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1005	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1398	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1421	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1749	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2135	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3750	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3755	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3757	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6178	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6938	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6940	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600E	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/126	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/816	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2115	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2117	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2118	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2121	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3739	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3827	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Sorafenib,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/89	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	PLX4720,Pictilisib Bismesylate	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/96	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	PLX4720,Nutlin-3	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/97	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/98	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/99	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1405	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Dabrafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1406	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Cetuximab,Gefitinib,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1408	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1413	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	GDC-0879,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1428	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1589	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Irinotecan,Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1902	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5960	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Panitumumab,Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6123	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Panitumumab,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6124	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Cetuximab,Encorafenib,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7260	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7612	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cetuximab,Irinotecan	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8506	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Erlotinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8507	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/9851	only alteration type		COREAD
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Hairy-Cell leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/1579	only alteration type		HCL
WP170	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5903	only alteration type		IHCH
WP170	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5904	only alteration type		IHCH
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1698	only alteration type		MM
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1699	only alteration type		MM
WP170	BRAF MUT* (--)	BRAF V600E	Dabrafenib,Trametinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/3017	only alteration type		NSCLC
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5958	only alteration type		NSCLC
WP170	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/5959	only alteration type		OV
WP170	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1399	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1400	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600K	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2505	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600K	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2506	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4180	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6179	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6965	only alteration type		CM
WP170	BRAF MUT* (--)	BRAF ZKSCAN1::BRAF	Trametinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1663	only gene		CM
WP170	BRAF MUT* (--)	BRAF Amplification	Trametinib,Dabrafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/7677	only gene		CM
WP170	BRAF MUT* (--)	BRAF Amplification	Panitumumab,Dabrafenib	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2929	only gene		COREAD
WP170	BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
WP170	BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
WP170	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
WP170	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
WP170	BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
WP170	BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
WP170	BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
WP170	BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
WP170	BRIP1 MUT* (--)	BRIP1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11208	only alteration type		PRAD
WP170	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP170	FGFR3 MUT* (--)	FGFR3 FGFR3::BAIAP2L1	PD173074	Bladder	Responsive	D	NO	https://civicdb.org/links/evidence_items/144	only gene		BLCA
WP170	FGFR3 MUT* (--)	FGFR3 Mutation	Infigratinib	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/1910	only alteration type		BLCA
WP170	FGFR3 MUT* (--)	FGFR3 Mutation	Cisplatin,Gemcitabine	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/7566	only alteration type		BLCA
WP170	GNAQ MUT* (--)	GNAQ Mutation	JQ1	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1210	only alteration type		UVM
WP170	GNAQ MUT* (--)	GNAQ Mutation	Trametinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1229	only alteration type		UVM
WP170	GNAQ MUT* (--)	GNAQ Mutation	Mirdametinib,Sotrastaurin Acetate	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1953	only alteration type		UVM
WP170	GNAQ MUT* (--)	GNAQ Mutation	Cabozantinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5068	only alteration type		UVM
WP170	GNAQ MUT* (--)	GNAQ Q209	Selumetinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1213	only alteration type		UVM
WP170	GNAQ MUT* (--)	GNAQ Q209	Refametinib	Uveal melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1233	only alteration type		UVM
WP170	JAK2 (V617F)	JAK2 Splice Site (c.1641+2T>G)	Pembrolizumab	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4825	only alteration type		CM
WP170	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP170	KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP170	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2346	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8549	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA C420R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2078	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA C420R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1999	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA D350G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4784	only alteration type		CM
WP170	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8007	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E542K	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/310	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E542K	Sirolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/311	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2022	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2026	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2058	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E542K	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7315	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8013	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8016	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E542K	Regorafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/83	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA E542K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4424	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA E542K	Apitolisib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/1549	only alteration type		HNSC
WP170	PIK3CA MUT* (--)	PIK3CA E542K	Perifosine,Temsirolimus	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1626	only alteration type		THCA
WP170	PIK3CA MUT* (--)	PIK3CA E545	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7468	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E545G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3724	only alteration type		CM
WP170	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1453	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2036	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6211	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E545K	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6213	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E545K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8008	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8547	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E545K	Akt Inhibitor MK2206,Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/710	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2034	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2062	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8017	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8018	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA E545K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3722	only alteration type		CM
WP170	PIK3CA MUT* (--)	PIK3CA E545K	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/387	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2037	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2217	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib	Lung adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1171	only alteration type		LUAD
WP170	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1670	only alteration type		LUAD
WP170	PIK3CA MUT* (--)	PIK3CA E545K	PI103	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2040	only alteration type		NSCLC
WP170	PIK3CA MUT* (--)	PIK3CA E545Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2213	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA E81K	Oxaliplatin,Fluorouracil,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4464	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA F930S	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10032	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA G1049R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3847	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA H1047L	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2089	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA H1047L	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8009	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA H1047L	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8019	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA H1047L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4432	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2103	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6204	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6206	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8548	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/314	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Capivasertib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1505	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1506	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Everolimus,Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1623	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2096	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2102	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/258	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/388	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Vemurafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3733	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3841	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Akt Inhibitor MK2206,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8364	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1465	only alteration type		HNSC
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1447	only alteration type		LUAD
WP170	PIK3CA MUT* (--)	PIK3CA H1047R	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1625	only alteration type		THCA
WP170	PIK3CA MUT* (--)	PIK3CA H1047X	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7318	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2867	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8663	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2866	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA K111N	Dactolisib,Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8183	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8662	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA K111N	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2085	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA K111N	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8011	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA K111N	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8020	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA K944N	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10031	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA K966E	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10034	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1384	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2087	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2098	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8536	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Capecitabine,Lapatinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8705	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1296	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1504	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1600	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1607	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1610	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Fulvestrant,Alpelisib	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7313	only alteration type		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/915	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1705	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3732	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6298	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6299	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6300	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6301	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6362	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Cabozantinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/771	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6375	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Ridaforolimus,Temsirolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/892	only alteration type		ED
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Pictilisib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1616	only alteration type		ED
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Radiation Therapy,Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1490	only alteration type		HNSC
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin,Sulindac,Celecoxib	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7185	only alteration type		HNSC
WP170	PIK3CA MUT* (--)	PIK3CA Mutation	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2355	only alteration type		NSCLC
WP170	PIK3CA MUT* (--)	PIK3CA N345K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4047	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA Q546K	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2198	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA R88Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3832	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA R93W	Cetuximab,Fluorouracil,Oxaliplatin	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4467	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA S158L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4463	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA V955G	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10033	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA V955I	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/8063	only alteration type		COREAD
WP170	PIK3CA MUT* (--)	PIK3CA Amplification	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8267	only gene		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA Amplification	Lapatinib,Dactolisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8271	only gene		BRCA
WP170	PIK3CA MUT* (--)	PIK3CA Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6275	only gene		CM
WP170	PIK3CA MUT* (--)	PIK3CA Amplification	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1464	only gene		HNSC
WP170	PIK3CA MUT* (--)	PIK3CA Amplification	Sulindac,Aspirin,Ibuprofen	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7186	only gene		HNSC
WP170	PIK3CA MUT* (--)	PIK3CA Amplification	Pictilisib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/756	only gene		OV
WP170	PIK3R1 MUT* (--)	PIK3R1 Mutation	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1612	only alteration type		BRCA
WP170	POLD1 MUT* (--)	POLD1 C284Y	Pembrolizumab	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4776	only alteration type		LUAD
WP170	POLD1 MUT* (--)	POLD1 E374K	Pembrolizumab	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4777	only alteration type		NSCLC
WP170	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP170	ROS1 MUT* (--)	ROS1 Rearrangement	Ceritinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1248	only gene		LUAD
WP170	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1690	only gene		LUAD
WP170	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/688	only gene		NSCLC
WP170	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1030	only gene		NSCLC
WP170	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7933	only gene		NSCLC
WP170	ROS1 MUT* (--)	ROS1 FUSIONS	Entrectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11123	only gene		NSCLC
WP170	ROS1 MUT* (--)	ROS1 Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7282	only gene		NSCLC
WP170	ROS1 MUT* (--)	ROS1 G2032R	Crizotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2934	only alteration type		LUAD
WP170	ROS1 MUT* (--)	ROS1 GOPC::ROS1	Lorlatinib	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7483	only gene		GB
WP170	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP170	SF3B1 (K700E)	SF3B1 K666N	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1418	only alteration type		BRCA
WP170	SF3B1 (K700E)	SF3B1 K700E	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1417	complete		BRCA
WP170	STK11 MUT* (--)	STK11 Mutation	Pembrolizumab,Nivolumab,Atezolizumab	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6441	only alteration type		LUAD
WP170	STK11 MUT* (--)	STK11 Loss	Selumetinib,Docetaxel	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1144	only gene		NSCLC
WP170	STK11 MUT* (--)	STK11 Loss	Everolimus,Sirolimus	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1620	only gene		NSCLC
WP170	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP170	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP274	ALK (G920V)	ALK fusion	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	FDA	only gene		LUAD
WP274	ALK (G920V)	ALK fusion	Alectinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	only gene		NSCLC
WP274	ALK (G920V)	ALK fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	only gene		NSCLC
WP274	ALK (G920V)	ALK inframe insertion (1151T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165	only alteration type		LUAD
WP274	ALK (G920V)	ALK (L1196M,S1206Y,G1269A,I1171T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165;PMID:24327273	only alteration type		LUAD
WP274	ALK (G920V)	ALK fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene	758.0	NSCLC
WP274	ALK (G920V)	ALK fusion	Brigatinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc	only gene		NSCLC
WP274	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP274	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF (V600E,V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF (V600E,V600K)	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s028lbl.pdf	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP274	BRAF MUT* (--)	BRAF (V600E,V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf	only alteration type		CM
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP274	G6PD MUT* (--)	G6PD biallelic inactivation	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP274	G6PD MUT* (--)	G6PD (S218F)	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP274	G6PD MUT* (--), G6PD MUT* (--)	G6PD (V98M) + G6PD (N156D)	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP274	BRAF MUT* (--)	BRAF (V600E)	Trametinib(MEK inhibitor) + Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN Non-Small Cell Lung Cancer guidlines 2022; FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		NSCLC
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP274	ALK (G920V)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP274	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP274	CHEK1 MUT* (G67)	CHEK1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP274	FANCL MUT* (--)	FANCL oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP274	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation;PMID:31566309	only alteration type		COREAD
WP274	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP274	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP274	RAD51D MUT* (--)	RAD51D oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP274	BRAF MUT* (--)	BRAF (V600)	Atezolizumab(PD-L1 blocking antibody);Vemurafenib(BRAF inhibitor);Cobimetinib(MEK inhibitor) 	Cutaneous melanoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-braf-v600-unresectable-or-metastatic-melanoma	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		SOLID
WP274	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Lower grade glioma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-trametinib-pediatric-patients-low-grade-glioma-braf-v600e-mutation	only alteration type		LGG
WP274	ALK (G920V)	ALK fusion	Crizotinib(ALK inhibitor)	Anaplastic large cell lymphoma	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large	only gene		ALCL
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP274	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP274	ATR MUT* (--)	ATR oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP274	FANCA MUT* (--)	FANCA oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP274	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP274	BRAF MUT* (--)	BRAF (V600E,V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210496s013lbl.pdf	only alteration type		CM
WP274	ALK (G920V)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP274	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP274	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP274	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP274	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP274	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP274	BRAF MUT* (--)	BRAF(V600E)	Vemurafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP274	BRAF MUT* (--)	BRAF (V600)	Dabrafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP274	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only alteration type		COREAD
WP274	ALK (G920V)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor	only gene		IM
WP274	ALK (G920V)	ALK fusion	Alectinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP274	ALK (G920V)	ALK fusion	Brigatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP274	ALK (G920V)	ALK fusion	Ceritinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP274	ALK (G920V)	ALK fusion	Lorlatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP274	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Hairy-Cell leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf	only alteration type		HCL
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP274	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-binimetinib-metastatic-non-small-cell-lung-cancer-braf-v600e-mutation	only alteration type		NSCLC
WP274	BRAF MUT* (--)	BRAF(V600)	Vemurafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		HISEC
WP274	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF (V600E,G469A)	EGFR TK inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:22773810	only alteration type		LUAD
WP274	AKT3 MUT* (--)	AKT3 fusion	ATP competitive AKT inhibitors(AZD5363,GSK2141795,etc)	Breast adenocarcinoma	Responsive	D	NO	PMID:22722202	only gene		BRCA
WP274	ALK (G920V)	ALK fusion	ALK inhibitor + IGF1R inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25173427	only gene		LUAD
WP274	ALK (G920V)	ALK fusion	ALK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:26301689	only gene		LUAD
WP274	ALK (G920V)	ALK fusion	ALK inhibitor + SRC inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25394791	only gene		LUAD
WP274	ALK (G920V)	ALK fusion	ALK inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560	only gene		COREAD
WP274	ALK (G920V)	ALK fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23553849	only gene		LUAD
WP274	ALK (G920V)	ALK fusion	novel ALK inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23639470	only gene		LUAD
WP274	ALK (G920V)	ALK (F1174L)	novel ALK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24327273	only alteration type		LUAD
WP274	ALK (G920V)	ALK amplification	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only gene		LUAD
WP274	ALK (G920V)	ALK (E1408V)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP274	ALK (G920V)	ALK (L1196M)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP274	ALK (G920V)	ALK fusion	Ceritinib(ALK inhibitor)	Colorectal adenocarcinoma, Inflammatory myofibroblastic	Responsive	C	YES	PMID:26633560;PMID:26933125;PMID:27742657	only gene		COREAD, IM
WP274	ALK (G920V)	ALK fusion	Ceritinib(ALK inhibitor)	Hematologic malignancies	Responsive	C	YES	NCT02186821	only gene		HEMATO
WP274	ALK (G920V)	ALK fusion	Crizotinib(ALK inhibitor)	Lymphoma, Glioblastoma	Responsive	C	YES	PMID:24491302;NCT02270034	only gene		LY, GB
WP274	ALK (G920V)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic, Thyroid carcinoma	Responsive	C	YES	PMID:20979472;PMID:24687827	only gene		IM, THCA
WP274	ALK (G920V)	ALK (F856S,A348D)	Crizotinib(ALK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:26032424	only alteration type		AML
WP274	ALK (G920V)	ALK (L1198F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26698910	only alteration type	758.0	LUAD
WP274	ALK (G920V)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib(ALK inhibitor)	Glioma	Responsive	D	NO	PMID:22072639	only alteration type		G
WP274	ALK (G920V)	ALK fusion	Entrectinib(Pan-TK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560;PMID:26933125	only gene		COREAD
WP274	ALK (G920V)	ALK (C1156Y)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27401242	only alteration type		LUAD
WP274	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only alteration type		COREAD
WP274	ATM MUT* (--), ATM MUT* (--)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
WP274	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only alteration type		LY
WP274	ATM MUT* (--), ATM MUT* (--)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only gene		LY
WP274	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP274	ATM MUT* (--), ATM MUT* (--)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
WP274	ATM MUT* (--), ATM MUT* (--)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP274	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP274	ATM MUT* (--), ATM MUT* (--)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP274	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP274	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP274	ATR MUT* (--)	ATR oncogenic mutation	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only alteration type		OV, CANCER
WP274	ATR MUT* (--)	ATR deletion	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only gene		OV, CANCER
WP274	ATR MUT* (--)	ATR oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP274	BCOR MUT* (--)	BCOR oncogenic mutation	Enzastaurin(PKCb inhibitor)	Stomach	Responsive	D	NO	PMID:27397505	only alteration type		ST
WP274	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + CDK2/4 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22997239	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF (V600)	BRAF inhibitor + EGFR mAb inhibitor +/- PI3K inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28363909	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + HSP90 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22351686	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + MEK inhibitors	Thyroid	Responsive	C	NO	ASCO 2013 (abstr 9029)	only alteration type		TH
WP274	BRAF MUT* (--)	BRAF fusion	BRAF inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9072)	only gene		LUAD
WP274	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + PI3K pathway inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22389471;PMID:21156289	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF (L597R)	BRAF inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:23715574	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Glioma	Responsive	D	NO	PMID:22038996;PMID:22586120	only alteration type		G
WP274	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Ovary	Responsive	C	NO	PMID:22608338	only alteration type		OV
WP274	BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:23614898;PMID:22997239	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF (G469A)	ERK inhibitors	Head an neck squamous	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		HNSC
WP274	BRAF MUT* (--)	BRAF (L485W)	ERK inhibitors	Billiary tract	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		BT
WP274	BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		LUAD
WP274	BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Thyroid	Responsive	C	NO	PMID:22241789	only alteration type		TH
WP274	BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Ovary	Responsive	D	NO	PMID:19018267	only alteration type		OV
WP274	BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Pan-RAF inhibitors	Any cancer type	Responsive	D	YES	PMID:26732095	only alteration type		CANCER
WP274	BRAF MUT* (--)	BRAF (V600E)	Pan-RAF inhibitors	Cutaneous melanoma	Responsive	C	NO	ESMO 2015 (abstract 300);AACR 2016 (abstr CT005);AACR 2017 (abstr  CT002)	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF fusion	MEK inhibitors(Trametinib,etc)	Lung adenocarcinoma, Cutaneous melanoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:24727320;PMID:24345920;PMID:20526349	only gene		LUAD, CM, PRAD
WP274	BRAF MUT* (--)	BRAF (K601R,L597R,V600R)	MEK inhibitors(Trametinib,etc)	Cutaneous melanoma	Responsive	C	NO	PMID:23248257;PMID:22805292;PMID:23248257	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Lung adenocarcinoma, Thyroid	Responsive	C	NO	PMID:23524406;PMID:22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);PMID:20818844;PMID:23489023;PMID:27080216	only alteration type		LUAD, TH
WP274	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Gastrointestinal stromal	Responsive	C	NO	PMID:23470635;PMID:22608338	only alteration type		GIST
WP274	BRAF MUT* (--)	BRAF (V600R)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:23237741	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26392102;ASCO 2015 (abstr 8006)	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Neuroendocrine	Responsive	C	NO	PMID:27048246	only alteration type		NEU
WP274	BRAF MUT* (--)	BRAF (G466V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:22649091	only alteration type		LUAD
WP274	BRAF MUT* (--)	BRAF (Y472C)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	PMID:22649091	only alteration type		LUAD
WP274	BRAF MUT* (--)	BRAF (V600)	Irinotecan + Vemurafenib + Cetuximab(TOPO1 inhibitor + BRAF inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:27729313	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + BYL719(EGFR mAb inhibitor + BRAF inhibitor + PI3K inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2014 (abstr 11LBA)	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF (V600E)	Panitumumab + Dabrafenib + Trametinib(EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103)	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF (V600E)	PLX4720(BRAF inhibitor)	Malignant astrocytoma	Responsive	D	NO	PMC3638050	only alteration type		MA
WP274	BRAF MUT* (--)	BRAF fusion	Selumetinib(MEK inhibitor)	Ovary	Responsive	C	NO	PMID:26324360	only gene		OV
WP274	BRAF MUT* (--)	BRAF (V600E)	Selumetinib(MEK inhibitor)	Pediatric glioma	Responsive	C	NO	NCT01089101	only alteration type		PG
WP274	BRAF MUT* (--)	BRAF fusion	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma, Lung adenocarcinoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:238900088;PMID:20526349;PMID:24727320	only gene		CM, LUAD, PRAD
WP274	BRAF MUT* (--)	BRAF (D594G,G469E)	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:18794803	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Lung adenocarcinoma, Hairy-Cell leukemia, Myeloma	Responsive	C	YES	PMID:22743296;PMID:22621641;PMID:23612012	only alteration type		LUAD, HCL, MYMA
WP274	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Malignant astrocytoma	Responsive	C	NO	PMID:22586120	only alteration type		MA
WP274	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:22608338;PMID:20818844;PMID:23489023	only alteration type		THCA
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
WP274	BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP274	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP274	CBL MUT* (--)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP274	CBL MUT* (--)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP274	CDKN2A (D74A)	CDKN2A oncogenic mutation	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr 2500)	complete		CM
WP274	CDKN2A (D74A)	CDKN2A oncogenic mutation	CDK4/6 inhibitors	Glioma, Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22586120;PMID:22711607	complete		G, CANCER
WP274	CDKN2A (D74A)	CDKN2A deletion	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr 2500)	only gene		CM
WP274	CDKN2A (D74A)	CDKN2A deletion	CDK4/6 inhibitors	Glioma, Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22586120;PMID:22711607	only gene		G, CANCER
WP274	CDKN2A (D74A)	CDKN2A oncogenic mutation	Ilorasertib(AURKA-VEGF inhibitor)	Any cancer type	Responsive	C	YES	NCT02478320	complete		CANCER
WP274	CDKN2A (D74A)	CDKN2A deletion	Ilorasertib(AURKA-VEGF inhibitor)	Any cancer type	Responsive	C	YES	NCT02478320	only gene		CANCER
WP274	FANCA MUT* (--)	FANCA oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP274	FANCA MUT* (--)	FANCA deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only gene		PRAD
WP274	ALK (G920V)	ALK (I1171T)	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:25228534	only alteration type		LUAD
WP274	ALK (G920V)	ALK (G1123S)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:26134233	only alteration type		LUAD
WP274	GNAQ MUT* (E245D), GNAQ MUT* (T96S)	GNAQ (Q209)	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	NCT01587352	only alteration type		CM
WP274	GNAQ MUT* (E245D), GNAQ MUT* (T96S)	GNAQ (Q209)	PI3K pathway inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22733540;PMID:22808163	only alteration type		CM
WP274	GNAQ MUT* (E245D), GNAQ MUT* (T96S)	GNAQ (Q209)	PKC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22653968;PMID:22253748	only alteration type		CM
WP274	GNAQ MUT* (E245D), GNAQ MUT* (T96S)	GNAQ (Q209)	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr CRA9003)	only alteration type		CM
WP274	GNAS MUT* (--)	GNAS (R201)	JAK inhibitors	Any cancer type	Responsive	D	YES	PMID:21835143	only alteration type		CANCER
WP274	BRAF MUT* (--)	BRAF (V600E)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
WP274	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP274	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP274	JAK3 MUT* (--)	JAK3 (A572V,A573V)	JAK inhibitors	Lymphoma	Responsive	D	YES	PMID:22705984	only alteration type		LY
WP274	JAK3 MUT* (--)	JAK3 (R657Q,I87T,Q501H)	JAK inhibitors	Megakaryoblastic leukemia	Responsive	D	YES	PMID:18397343	only alteration type		MKB
WP274	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP274	ALK (G920V)	ALK inframe insertion (1151T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only alteration type		LUAD
WP274	ALK (G920V)	ALK oncogenic mutation	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	complete		NSCLC
WP274	ALK (G920V)	ALK amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only gene		NSCLC
WP274	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP274	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP274	ALK (G920V)	ALK amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only gene		LUAD
WP274	ALK (G920V)	ALK (C1156Y,L1196M)	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:20979473	only alteration type		NSCLC
WP274	ALK (G920V)	ALK (F1174L)	Crizotinib(ALK inhibitor)	Glioma	Resistant	D	NO	PMID:22072639	only alteration type		G
WP274	ALK (G920V)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784;PMID:25228534	only alteration type		LUAD
WP274	MTOR MUT* (--)	MTOR (F2108L)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Resistant	C	NO	PMID:25295501	only alteration type		THCA
WP274	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP274	MTOR MUT* (--)	MTOR (F2108L)	MTOR kinase inhibitors	Any cancer type	Responsive	D	YES	PMID:25295501	only alteration type		CANCER
WP274	MTOR MUT* (--)	MTOR (E2014K,E2419K,N1421D)	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:24625776	only alteration type		BLCA
WP274	MTOR MUT* (--)	MTOR (I1973F)	Everolimus(MTOR inhibitor)	Angiosarcoma, Renal	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		AS, R
WP274	MTOR MUT* (--)	MTOR (K1771R)	Everolimus(MTOR inhibitor)	Stomach, Adrenal gland	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		ST, AG
WP274	MTOR MUT* (--)	MTOR (N1421D)	Everolimus(MTOR inhibitor)	Stomach	Responsive	C	NO	PMID:26859683	only alteration type		ST
WP274	MTOR MUT* (--)	MTOR (Q2223K)	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468	only alteration type		R
WP274	MTOR MUT* (--)	MTOR (L1460P,S2215Y,R2505P)	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	D	YES	PMID:24631838	only alteration type		CANCER
WP274	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP274	BRAF MUT* (--)	BRAF (V600E)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
WP274	NOTCH1 MUT* (PQ2415-2416Q)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP274	NOTCH1 MUT* (PQ2415-2416Q)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP274	NOTCH1 MUT* (PQ2415-2416Q)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP274	NOTCH1 MUT* (PQ2415-2416Q)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP274	NOTCH1 MUT* (PQ2415-2416Q)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP274	NOTCH1 MUT* (PQ2415-2416Q)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP274	NOTCH1 MUT* (PQ2415-2416Q)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP274	NOTCH1 MUT* (PQ2415-2416Q)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	only alteration type		MCL
WP274	NOTCH1 MUT* (PQ2415-2416Q)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP274	NOTCH1 MUT* (PQ2415-2416Q)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP274	NOTCH1 MUT* (PQ2415-2416Q)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP274	NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP274	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP274	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP274	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP274	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP274	PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP274	PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP274	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP274	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP274	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP274	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	AKT inhibitors	Glioma	Responsive	D	NO	PMID:23166678	only alteration type		G
WP274	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	PI3K pathway inhibitors	Endometrium	Responsive	C	NO	ASCO 2015 (abstr 11075)	only alteration type		ED
WP274	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP274	RAD50 MUT* (--), ATM MUT* (--), ATM MUT* (--)	RAD50 (L1237F) + ATM deletion	Irinotecan + CHK1/2 inhibitor(TOPO1 inhibitor + CHK1/2 inhibitor)	Any cancer type	Responsive	C	YES	PMID:24934408	only gene		CANCER
WP274	BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Vemurafenib(BRAF inhibitor)	Any cancer type	Resistant	D	YES	PMID:26732095	only alteration type		CANCER
WP274	BRAF MUT* (--)	BRAF (V600)	Vemurafenib(BRAF inhibitor)	Colorectal adenocarcinoma	No Responsive	C	NO	PMID:26287849	only alteration type		COREAD
WP274	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP274	TMPRSS2 MUT* (--)	TMPRSS2 fusion	DNA-PKc inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575865	only gene		PRAD
WP274	TMPRSS2 MUT* (--)	TMPRSS2 fusion	PARP inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575865	only gene		PRAD
WP274	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP274	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
WP274	BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
WP274	MTOR MUT* (--)	MTOR (L2209V,L1460P,L2427Q)	Temsirolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
WP274	MTOR MUT* (--)	MTOR (Q2223K)	Everolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
WP274	ALK (G920V)	ALK fusion	Crizotinib + Ceritinib	Sarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only gene		S
WP274	ALK (G920V)	ALK (G1202R,I1171N)	Alectinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only alteration type		NSCLC
WP274	BRAF MUT* (--)	BRAF (D594.,G466.,G464.,N581.,D287H,K601.,G469.,G596.,L597.,F595L,S467L,V459L)	Plx8394	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CANCER
WP274	MTOR MUT* (--)	MTOR (E2419K,E2014K)	Everolimus	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		BLCA
WP274	MTOR MUT* (--)	MTOR (E2419K,C1483F,L2172M,K1452N,L2230V,L2427Q,L2431P,F1888I,E1799K,L2216P,W1456R,C1483W,A1519T,L1460P,A2210P,T2232I,R2505P,M2327I,C1483R,V2006I,A1428T,Y1463S,I2500M,A1459P,F1888L,S2231W,T1977R,V2006F,T1977K,A2226S,I2500F,L2427R,T1977I,S2215F,.,Q2223K,I1973F,L1433S,F1888V,S2215T,D2512H,E2014K,S2215Y,R2217W,L2209V,V2006L,L2220F,L2427P,S2215P,P2273S,E2288K,C1483Y)	Temsirolimus + Everolimus	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		CANCER
WP274	KDM6A MUT* (--)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
WP274	KDM6A MUT* (--)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only alteration type		BLCA
WP274	BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + Trametinib	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF (V600E)	Encorafenib + Binimetinib + Cetuximab	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		OV
WP274	CDKN2A (D74A)	CDKN2A (R87P,E69G,P48L,R112G,E88K,M53I,R87L,R80L,R99P,V118D,D108N,T77P,A36P,I49S,G101W,R80P,H83N,Q50P,A68T,A60R,G67S,G67R,G35R,L16P,D108H,R87W,N71I,L32P,N71K,P81L,.,R24P,H83Y,D74Y,G35V,G35A,D84Y,G23D,P73L,V126D,S56I,D84N,D74N,D84H,P114L,P114S,D84V,A60V,G93W,N71S,L97R,P81T,R79P,D84G)	Abemaciclib + Palbociclib + Ribociclib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/CDKN2A	complete		CANCER
WP274	CDKN2A (D74A)	CDKN2A deletion	Abemaciclib + Palbociclib + Ribociclib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/CDKN2A	only gene		CANCER
WP274	BRAF MUT* (--)	BRAF (V600K,V600.,L597.,K601.,V600E,L597V)	Trametinib	Cutaneous melanoma	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/5/summary|oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CM
WP274	ATM MUT* (--), ATM MUT* (--)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only alteration type		CANCER
WP274	ATM MUT* (--), ATM MUT* (--)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
WP274	ALK (G920V)	ALK (C1156Y,F1174L,L1196M,G1269A)	Crizotinib	Non-small cell lung	Resistant	D	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary	only alteration type		NSCLC
WP274	BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Cutaneous melanoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		CM
WP274	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
WP274	BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
WP274	AKT3 MUT* (--)	AKT3 E17K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4521	only alteration type		CM
WP274	ALK (G920V)	ALK CAD::ALK	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7481	only gene		COREAD
WP274	ALK (G920V)	ALK CLTC::ALK	TAE684	Difuse large B Cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1261	only gene		DLBCL
WP274	ALK (G920V)	ALK CLTC::ALK	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1265	only gene		DLBCL
WP274	ALK (G920V)	ALK EML4::ALK	Alectinib	Mesothelioma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9228	only gene		MESO
WP274	ALK (G920V)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/262	only gene		NSCLC
WP274	ALK (G920V)	ALK EML4::ALK	WHI-P154	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1188	only gene		NSCLC
WP274	ALK (G920V)	ALK EML4::ALK	Crizotinib,Retaspimycin Hydrochloride	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1203	only gene		NSCLC
WP274	ALK (G920V)	ALK EML4::ALK	Crizotinib,Alvespimycin	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1206	only gene		NSCLC
WP274	ALK (G920V)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1207	only gene		NSCLC
WP274	ALK (G920V)	ALK EML4::ALK	Lorlatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1332	only gene		NSCLC
WP274	ALK (G920V)	ALK F1174L	Crizotinib	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/125	only alteration type		NB
WP274	ALK (G920V)	ALK F1174L	Alectinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/37	only alteration type		NB
WP274	ALK (G920V)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/38	only alteration type		NB
WP274	ALK (G920V)	ALK F1174L	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/142	only alteration type		NB
WP274	ALK (G920V)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1271	only alteration type		NB
WP274	ALK (G920V)	ALK F1174L	AZD3463	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1327	only alteration type		NB
WP274	ALK (G920V)	ALK F1174L	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1329	only alteration type		NB
WP274	ALK (G920V)	ALK F1174L	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/33	only alteration type		NSCLC
WP274	ALK (G920V)	ALK F1245C	Crizotinib	Neuroblastoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1333	only alteration type		NB
WP274	ALK (G920V)	ALK F1245C	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1330	only alteration type		NB
WP274	ALK (G920V)	ALK F1245V	Entrectinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2987	only alteration type		NB
WP274	ALK (G920V)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1240	only gene		ALCL
WP274	ALK (G920V)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/7361	only gene		ALCL
WP274	ALK (G920V)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	A	YES	https://civicdb.org/links/evidence_items/11218	only gene		ALCL
WP274	ALK (G920V)	ALK Fusion	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1264	only gene		DLBCL
WP274	ALK (G920V)	ALK Fusion	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1691	only gene		LUAD
WP274	ALK (G920V)	ALK Fusion	Pemetrexed	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/945	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1175	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1187	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1198	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1199	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1200	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1201	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Retaspimycin Hydrochloride	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1202	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1272	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1273	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1279	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1282	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1419	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1577	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4835	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Alectinib,Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4858	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7284	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7285	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Lorlatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7286	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/8657	only gene		NSCLC
WP274	ALK (G920V)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11121	only gene		NSCLC
WP274	ALK (G920V)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1283	only alteration type		NSCLC
WP274	ALK (G920V)	ALK I1171	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1287	only alteration type		NSCLC
WP274	ALK (G920V)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1367	only alteration type		NSCLC
WP274	ALK (G920V)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1284	only alteration type		NSCLC
WP274	ALK (G920V)	ALK I1171	TAE684	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1285	only alteration type		NSCLC
WP274	ALK (G920V)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1344	only alteration type		NSCLC
WP274	ALK (G920V)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1368	only alteration type		NSCLC
WP274	ALK (G920V)	ALK I1171T	Ceritinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9404	only alteration type		NB
WP274	ALK (G920V)	ALK KANK4::ALK	Alectinib	Pancreas acinar	Responsive	C	NO	https://civicdb.org/links/evidence_items/10327	only gene		PAAC
WP274	ALK (G920V)	ALK Mutation	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1237	complete		NSCLC
WP274	ALK (G920V)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1239	only gene		ALCL
WP274	ALK (G920V)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/1241	only gene		ALCL
WP274	ALK (G920V)	ALK R1275Q	TAE684	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/48	only alteration type		NB
WP274	ALK (G920V)	ALK R1275Q	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/39	only alteration type		NB
WP274	ALK (G920V)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/143	only alteration type		NB
WP274	ALK (G920V)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1270	only alteration type		NB
WP274	ALK (G920V)	ALK R1275Q	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1331	only alteration type		NB
WP274	ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	only alteration type		CM
WP274	ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	only alteration type		GB
WP274	ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	only alteration type		PRAD
WP274	BRAF MUT* (--)	BRAF Non-V600	Trametinib	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/7855	only alteration type		SOLID
WP274	BRAF MUT* (--)	BRAF A598V	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7635	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF AGK::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/724	only gene		CM
WP274	BRAF MUT* (--)	BRAF AGK::BRAF	Sorafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/723	only gene		CM
WP274	BRAF MUT* (--)	BRAF CUX1::BRAF	Vemurafenib	Pancreas	Responsive	C	NO	https://civicdb.org/links/evidence_items/5977	only gene		PA
WP274	BRAF MUT* (--)	BRAF D594G	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1554	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2201	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4472	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF D594K	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6402	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF D594K	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6403	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF G466V	Irinotecan,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7552	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF G466V	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7553	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF G466V	Vemurafenib	Solid tumors	Responsive	D	NO	https://civicdb.org/links/evidence_items/7554	only alteration type		SOLID
WP274	BRAF MUT* (--)	BRAF G469	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7634	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF G596C	Dabrafenib,Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1738	only alteration type		NSCLC
WP274	BRAF MUT* (--)	BRAF G596R	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4729	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1668	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1669	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF L597R	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/728	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1704	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2187	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6303	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6304	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6305	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6306	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1404	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF PAPSS1::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/725	only gene		CM
WP274	BRAF MUT* (--)	BRAF PAPSS1::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/726	only gene		CM
WP274	BRAF MUT* (--)	BRAF TRIM24::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/727	only gene		CM
WP274	BRAF MUT* (--)	BRAF V600	Vemurafenib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5905	only alteration type		CH
WP274	BRAF MUT* (--)	BRAF V600	Refametinib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1000	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/93	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1407	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1422	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1750	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600	Cobimetinib,Vemurafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/6044	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6180	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6937	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6966	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600	Binimetinib,Encorafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7287	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/88	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600	Vemurafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1576	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1415	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1598	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600	Cetuximab,Encorafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6046	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600	Encorafenib,Alpelisib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6047	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600	Vemurafenib,Irinotecan,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7355	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1574	only alteration type		NSCLC
WP274	BRAF MUT* (--)	BRAF V600D	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/94	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4488	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4489	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7616	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7629	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5902	only alteration type		CH
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Irinotecan,Panitumumab	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5906	only alteration type		CH
WP274	BRAF MUT* (--)	BRAF V600E	Trametinib,Mirdametinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/86	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/90	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/994	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/95	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	Pictilisib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/757	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	Dactolisib,Selumetinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1005	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1398	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1421	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1749	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2135	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3750	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3755	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3757	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6178	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6938	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6940	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600E	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/126	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/816	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2115	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2117	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2118	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2121	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3739	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3827	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Sorafenib,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/89	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	PLX4720,Pictilisib Bismesylate	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/96	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	PLX4720,Nutlin-3	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/97	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/98	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/99	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1405	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Dabrafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1406	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Cetuximab,Gefitinib,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1408	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1413	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	GDC-0879,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1428	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1589	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Irinotecan,Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1902	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5960	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Panitumumab,Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6123	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Panitumumab,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6124	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Cetuximab,Encorafenib,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7260	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7612	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cetuximab,Irinotecan	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8506	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Erlotinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8507	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/9851	only alteration type		COREAD
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Hairy-Cell leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/1579	only alteration type		HCL
WP274	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5903	only alteration type		IHCH
WP274	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5904	only alteration type		IHCH
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1698	only alteration type		MM
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1699	only alteration type		MM
WP274	BRAF MUT* (--)	BRAF V600E	Dabrafenib,Trametinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/3017	only alteration type		NSCLC
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5958	only alteration type		NSCLC
WP274	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/5959	only alteration type		OV
WP274	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1399	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1400	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600K	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2505	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600K	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2506	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4180	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6179	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6965	only alteration type		CM
WP274	BRAF MUT* (--)	BRAF ZKSCAN1::BRAF	Trametinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1663	only gene		CM
WP274	BRAF MUT* (--)	BRAF Amplification	Trametinib,Dabrafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/7677	only gene		CM
WP274	BRAF MUT* (--)	BRAF Amplification	Panitumumab,Dabrafenib	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2929	only gene		COREAD
WP274	BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
WP274	BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
WP274	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
WP274	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
WP274	BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
WP274	BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
WP274	BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
WP274	BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
WP274	CDKN2A (D74A)	CDKN2A Mutation	Palbociclib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7300	complete		CH
WP274	CDKN2A (D74A)	CDKN2A Mutation	Palbociclib	Pancreas	Responsive	B	NO	https://civicdb.org/links/evidence_items/7299	complete		PA
WP274	CDKN2A (D74A)	CDKN2A Loss	Linsitinib,Palbociclib	Ewing sarcoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1879	only gene		EWS
WP274	CDKN2A (D74A)	CDKN2A Loss	Palbociclib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/7444	only gene		NSCLC
WP274	CDKN2A (D74A)	CDKN2A Loss	Palbociclib	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/1377	only gene		OV
WP274	CDKN2A (D74A)	CDKN2A Loss	Palbociclib	Renal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1373	only gene		R
WP274	CHEK1 MUT* (G67)	CHEK1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11210	only alteration type		PRAD
WP274	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP274	GNAQ MUT* (E245D), GNAQ MUT* (T96S)	GNAQ Mutation	JQ1	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1210	only alteration type		UVM
WP274	GNAQ MUT* (E245D), GNAQ MUT* (T96S)	GNAQ Mutation	Trametinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1229	only alteration type		UVM
WP274	GNAQ MUT* (E245D), GNAQ MUT* (T96S)	GNAQ Mutation	Mirdametinib,Sotrastaurin Acetate	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1953	only alteration type		UVM
WP274	GNAQ MUT* (E245D), GNAQ MUT* (T96S)	GNAQ Mutation	Cabozantinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5068	only alteration type		UVM
WP274	GNAQ MUT* (E245D), GNAQ MUT* (T96S)	GNAQ Q209	Selumetinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1213	only alteration type		UVM
WP274	GNAQ MUT* (E245D), GNAQ MUT* (T96S)	GNAQ Q209	Refametinib	Uveal melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1233	only alteration type		UVM
WP274	GNAS MUT* (--)	GNAS R201C	Cetuximab,Vemurafenib,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1906	only alteration type		COREAD
WP274	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP274	KMT2C MUT* (P309S), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP274	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP274	MTOR MUT* (--)	MTOR A2034V	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1547	only alteration type		BRCA
WP274	MTOR MUT* (--)	MTOR A2034V	RapaLink-1,MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1548	only alteration type		BRCA
WP274	MTOR MUT* (--)	MTOR E1799K	Sirolimus	Renal clear cell	Responsive	D	NO	https://civicdb.org/links/evidence_items/1321	only alteration type		RCCC
WP274	MTOR MUT* (--)	MTOR F2108L	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1543	only alteration type		BRCA
WP274	MTOR MUT* (--)	MTOR F2108L	Everolimus	Thyroid carcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1110	only alteration type		THCA
WP274	MTOR MUT* (--)	MTOR H1968Y	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/713	only alteration type		CM
WP274	MTOR MUT* (--)	MTOR M2327I	MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1544	only alteration type		BRCA
WP274	MTOR MUT* (--)	MTOR M2327I	Sirolimus,RapaLink-1	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1545	only alteration type		BRCA
WP274	MTOR MUT* (--)	MTOR Mutation	Everolimus,Pazopanib	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/705	only alteration type		BLCA
WP274	MTOR MUT* (--)	MTOR P2213S	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/722	only alteration type		CM
WP274	NFE2L2 MUT* (--)	NFE2L2 Mutation	Sapanisertib	Lung squamous cell	Responsive	B	NO	https://civicdb.org/links/evidence_items/7446	only alteration type		LUSC
WP274	NOTCH1 MUT* (PQ2415-2416Q)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP274	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP274	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP274	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP274	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP274	PIK3R1 MUT* (--)	PIK3R1 Mutation	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1612	only alteration type		BRCA
WP274	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP274	RAD51D MUT* (--)	RAD51D Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11214	only alteration type		PRAD
WP274	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP274	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	FDA	only gene		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Alectinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK inframe insertion (1151T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165	only alteration type		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK (L1196M,S1206Y,G1269A,I1171T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165;PMID:24327273	only alteration type		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Brigatinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc	only gene		NSCLC
WP212	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP212	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF (V600E,V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF (V600E,V600K)	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s028lbl.pdf	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP212	BRAF MUT* (--)	BRAF (V600E,V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf	only alteration type		CM
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP212	PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome, Eosinophilic chronic leukemia	Responsive	A	YES	EMA	only gene		HES, ECL
WP212	PDGFRA MUT* (--)	PDGFRA inframe deletion (I843)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type	862.0	GIST
WP212	PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type	862.0	GIST
WP212	PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Regorafenib(Pan-kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
WP212	TPMT MUT* (--)	TPMT splice acceptor variant	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP212	TPMT MUT* (--)	TPMT biallelic inactivation	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP212	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP212	TPMT MUT* (--)	TPMT splice acceptor variant	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP212	TPMT MUT* (--)	TPMT biallelic inactivation	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP212	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP212	TPMT MUT* (--)	TPMT splice acceptor variant	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP212	TPMT MUT* (--)	TPMT biallelic inactivation	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP212	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP212	BRAF MUT* (--)	BRAF (V600E)	Trametinib(MEK inhibitor) + Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN Non-Small Cell Lung Cancer guidlines 2022; FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		NSCLC
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP212	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation;PMID:31566309	only alteration type		COREAD
WP212	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP212	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP212	PDGFRA MUT* (--)	PDGFRA exon 18 mutations	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA (D842V)	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation;PMID:32615108	only alteration type		GIST
WP212	MET MUT* (--)	MET exon 14 skipping mutations	Tepotinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer;PMID:31279006;PMID:34036238	only alteration type		NSCLC
WP212	MET MUT* (--)	MET exon 14 skipping mutations	Capmatinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capmatinib-metastatic-non-small-cell-lung-cancer	only alteration type		NSCLC
WP212	RAD51C MUT* (G153)	RAD51C oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP212	RAD54L MUT* (--)	RAD54L oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP212	BRAF MUT* (--)	BRAF (V600)	Atezolizumab(PD-L1 blocking antibody);Vemurafenib(BRAF inhibitor);Cobimetinib(MEK inhibitor) 	Cutaneous melanoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-braf-v600-unresectable-or-metastatic-melanoma	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		SOLID
WP212	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Lower grade glioma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-trametinib-pediatric-patients-low-grade-glioma-braf-v600e-mutation	only alteration type		LGG
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Crizotinib(ALK inhibitor)	Anaplastic large cell lymphoma	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large	only gene		ALCL
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP212	RAD51C MUT* (G153)	RAD51C oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP212	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP212	BRAF MUT* (--)	BRAF (V600E,V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210496s013lbl.pdf	only alteration type		CM
WP212	PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP212	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP212	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP212	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP212	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP212	MAP2K1 MUT* (R291S)	MAP2K1 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP212	MAP2K1 MUT* (R291S)	MAP2K1 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP212	MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP212	MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP212	MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP212	MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP212	MAP2K1 MUT* (R291S)	MAP2K1 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP212	MAP2K1 MUT* (R291S)	MAP2K1 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP212	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP212	BRAF MUT* (--)	BRAF(V600E)	Vemurafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP212	BRAF MUT* (--)	BRAF (V600)	Dabrafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP212	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only alteration type		COREAD
WP212	PDGFRA MUT* (--)	PDGFRA oncogenic mutations (excluding D842V + exon 18 inframe mutations)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type	862.0	GIST
WP212	PDGFRA MUT* (--)	PDGFRA D842V + exon 18 mutations	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor	only gene		IM
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Alectinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Brigatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Ceritinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Lorlatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP212	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Hairy-Cell leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf	only alteration type		HCL
WP212	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP212	MET MUT* (--)	MET amplification	Capmatinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP212	MET MUT* (--)	MET amplification	Tepotinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP212	MET MUT* (--)	MET exon 14 skipping mutations	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP212	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-binimetinib-metastatic-non-small-cell-lung-cancer-braf-v600e-mutation	only alteration type		NSCLC
WP212	BRAF MUT* (--)	BRAF(V600)	Vemurafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		HISEC
WP212	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF (V600E,G469A)	EGFR TK inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:22773810	only alteration type		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	ALK inhibitor + IGF1R inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25173427	only gene		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	ALK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:26301689	only gene		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	ALK inhibitor + SRC inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25394791	only gene		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	ALK inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560	only gene		COREAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23553849	only gene		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	novel ALK inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23639470	only gene		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK (F1174L)	novel ALK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24327273	only alteration type		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK amplification	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only gene		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK (E1408V)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK (L1196M)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Ceritinib(ALK inhibitor)	Colorectal adenocarcinoma, Inflammatory myofibroblastic	Responsive	C	YES	PMID:26633560;PMID:26933125;PMID:27742657	only gene		COREAD, IM
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Ceritinib(ALK inhibitor)	Hematologic malignancies	Responsive	C	YES	NCT02186821	only gene		HEMATO
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Crizotinib(ALK inhibitor)	Lymphoma, Glioblastoma	Responsive	C	YES	PMID:24491302;NCT02270034	only gene		LY, GB
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic, Thyroid carcinoma	Responsive	C	YES	PMID:20979472;PMID:24687827	only gene		IM, THCA
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK (F856S,A348D)	Crizotinib(ALK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:26032424	only alteration type		AML
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK (L1198F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26698910	only alteration type		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib(ALK inhibitor)	Glioma	Responsive	D	NO	PMID:22072639	only alteration type		G
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Entrectinib(Pan-TK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560;PMID:26933125	only gene		COREAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK (C1156Y)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27401242	only alteration type		LUAD
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only alteration type		COREAD
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only alteration type		LY
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only gene		LY
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP212	BCOR MUT* (--)	BCOR oncogenic mutation	Enzastaurin(PKCb inhibitor)	Stomach	Responsive	D	NO	PMID:27397505	only alteration type		ST
WP212	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + CDK2/4 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22997239	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF (V600)	BRAF inhibitor + EGFR mAb inhibitor +/- PI3K inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28363909	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + HSP90 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22351686	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + MEK inhibitors	Thyroid	Responsive	C	NO	ASCO 2013 (abstr 9029)	only alteration type		TH
WP212	BRAF MUT* (--)	BRAF fusion	BRAF inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9072)	only gene		LUAD
WP212	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + PI3K pathway inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22389471;PMID:21156289	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF (L597R)	BRAF inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:23715574	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Glioma	Responsive	D	NO	PMID:22038996;PMID:22586120	only alteration type		G
WP212	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Ovary	Responsive	C	NO	PMID:22608338	only alteration type		OV
WP212	BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:23614898;PMID:22997239	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF (G469A)	ERK inhibitors	Head an neck squamous	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		HNSC
WP212	BRAF MUT* (--)	BRAF (L485W)	ERK inhibitors	Billiary tract	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		BT
WP212	BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		LUAD
WP212	BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Thyroid	Responsive	C	NO	PMID:22241789	only alteration type		TH
WP212	BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Ovary	Responsive	D	NO	PMID:19018267	only alteration type		OV
WP212	BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Pan-RAF inhibitors	Any cancer type	Responsive	D	YES	PMID:26732095	only alteration type		CANCER
WP212	BRAF MUT* (--)	BRAF (V600E)	Pan-RAF inhibitors	Cutaneous melanoma	Responsive	C	NO	ESMO 2015 (abstract 300);AACR 2016 (abstr CT005);AACR 2017 (abstr  CT002)	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF fusion	MEK inhibitors(Trametinib,etc)	Lung adenocarcinoma, Cutaneous melanoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:24727320;PMID:24345920;PMID:20526349	only gene		LUAD, CM, PRAD
WP212	BRAF MUT* (--)	BRAF (K601R,L597R,V600R)	MEK inhibitors(Trametinib,etc)	Cutaneous melanoma	Responsive	C	NO	PMID:23248257;PMID:22805292;PMID:23248257	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Lung adenocarcinoma, Thyroid	Responsive	C	NO	PMID:23524406;PMID:22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);PMID:20818844;PMID:23489023;PMID:27080216	only alteration type		LUAD, TH
WP212	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Gastrointestinal stromal	Responsive	C	NO	PMID:23470635;PMID:22608338	only alteration type		GIST
WP212	BRAF MUT* (--)	BRAF (V600R)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:23237741	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26392102;ASCO 2015 (abstr 8006)	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Neuroendocrine	Responsive	C	NO	PMID:27048246	only alteration type		NEU
WP212	BRAF MUT* (--)	BRAF (G466V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:22649091	only alteration type		LUAD
WP212	BRAF MUT* (--)	BRAF (Y472C)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	PMID:22649091	only alteration type		LUAD
WP212	BRAF MUT* (--)	BRAF (V600)	Irinotecan + Vemurafenib + Cetuximab(TOPO1 inhibitor + BRAF inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:27729313	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + BYL719(EGFR mAb inhibitor + BRAF inhibitor + PI3K inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2014 (abstr 11LBA)	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF (V600E)	Panitumumab + Dabrafenib + Trametinib(EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103)	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF (V600E)	PLX4720(BRAF inhibitor)	Malignant astrocytoma	Responsive	D	NO	PMC3638050	only alteration type		MA
WP212	BRAF MUT* (--)	BRAF fusion	Selumetinib(MEK inhibitor)	Ovary	Responsive	C	NO	PMID:26324360	only gene		OV
WP212	BRAF MUT* (--)	BRAF (V600E)	Selumetinib(MEK inhibitor)	Pediatric glioma	Responsive	C	NO	NCT01089101	only alteration type		PG
WP212	BRAF MUT* (--)	BRAF fusion	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma, Lung adenocarcinoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:238900088;PMID:20526349;PMID:24727320	only gene		CM, LUAD, PRAD
WP212	BRAF MUT* (--)	BRAF (D594G,G469E)	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:18794803	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Lung adenocarcinoma, Hairy-Cell leukemia, Myeloma	Responsive	C	YES	PMID:22743296;PMID:22621641;PMID:23612012	only alteration type		LUAD, HCL, MYMA
WP212	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Malignant astrocytoma	Responsive	C	NO	PMID:22586120	only alteration type		MA
WP212	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:22608338;PMID:20818844;PMID:23489023	only alteration type		THCA
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
WP212	BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP212	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP212	CCNE1 MUT* (T395P)	CCNE1 amplification	CDK2 inhibitors	Any cancer type	Responsive	D	YES	PMID:22471707	only gene		CANCER
WP212	MAP2K1 MUT* (R291S)	MAP2K1 (P124)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:25370473	only alteration type		CM
WP212	MAP2K1 MUT* (R291S)	MAP2K1 (Q56P,P124S,P124L;C121S)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:19915144;PMID:21383288	only alteration type		CM
WP212	MAP2K1 MUT* (R291S)	MAP2K1 oncogenic mutation	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:26030179	only alteration type		COREAD
WP212	MAP2K1 MUT* (R291S)	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	MEK inhibitors	Any cancer type	Resistant	D	YES	PMID:19915144	only alteration type		CANCER
WP212	MAP2K1 MUT* (R291S)	MAP2K1 (P124L,K57N,C121S)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:19915144;PMID:23444215;PMID:21383288	only alteration type		CM
WP212	MAP2K1 MUT* (R291S)	MAP2K1 (Q56P,P124S,P124L)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:19915144	only alteration type		CM
WP212	MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP212	MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP212	MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP212	MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP212	MET MUT* (--)	MET amplification	EGFR inhibitor 1st gens	Non-small cell lung, Colorectal adenocarcinoma	Resistant	C	NO	PMID:22189054;PMID:23729478	only gene		NSCLC, COREAD
WP212	MET MUT* (--)	MET amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:23729478	only gene		COREAD
WP212	MET MUT* (--)	MET (D1246V)	MET inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:27694386	only alteration type		LUAD
WP212	PDGFRA MUT* (--)	PDGFRA amplification	PDGFR inhibitors	Glioma	No Responsive	D	NO	PMID:23544171	only gene		G
WP212	PIK3CB MUT* (--)	PIK3CB (D1067Y)	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	C	NO	PMID:26759240	only alteration type		BRCA
WP212	PTEN MUT* (--)	PTEN oncogenic mutation	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	B	NO	PMID:21163703;PMID:19398573	only alteration type		COREAD
WP212	PTEN MUT* (--)	PTEN deletion	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	B	NO	PMID:21163703;PMID:19398573	only gene		COREAD
WP212	PTEN MUT* (--)	PTEN oncogenic mutation	MTOR inhibitors	Endometrium	No Responsive	C	NO	PMID:21788564;PMID:23238879	only alteration type		ED
WP212	PTEN MUT* (--)	PTEN deletion	MTOR inhibitors	Endometrium	No Responsive	C	NO	PMID:21788564;PMID:23238879	only gene		ED
WP212	PTEN MUT* (--), BRAF MUT* (--)	PTEN oncogenic mutation + BRAF oncogenic mutation	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	http://ascopubs.org/doi/abs/10.1200/PO.16.00054	only alteration type		CM
WP212	PTEN MUT* (--), BRAF MUT* (--)	PTEN deletion + BRAF oncogenic mutation	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	http://ascopubs.org/doi/abs/10.1200/PO.16.00054	only gene		CM
WP212	PTEN MUT* (--), BRAF MUT* (--)	PTEN oncogenic mutation + BRAF oncogenic mutation	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:23039341	only alteration type		CM
WP212	PTEN MUT* (--), BRAF MUT* (--)	PTEN deletion + BRAF oncogenic mutation	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:23039341	only gene		CM
WP212	ERBB4 MUT* (--), ERBB4 MUT* (--)	ERBB4 (E317K,E452K,R544W,R393W,E872K)	Lapatinib(ERBB2 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:19718025	only alteration type		CM
WP212	ERBB4 MUT* (--), ERBB4 MUT* (--)	ERBB4 fusion	Lapatinib + Afatinib(ERBB2 inhibitor + ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP212	TP53 MUT* (--)	TP53 oncogenic mutation	MDM2 inhibitors	Liposarcoma	Resistant	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	only alteration type		LIP
WP212	ERBB4 MUT* (--), ERBB4 MUT* (--)	ERBB4 (H809G)	ERBB2 inhibitors(Lapatinib,etc)	Breast adenocarcinoma	Resistant	C	NO	PMID:26530965	only alteration type		BRCA
WP212	TP53 MUT* (--)	TP53 oncogenic mutation	Abemaciclib(CDK4/CDK6 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:27217383	only alteration type		BRCA
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK (I1171T)	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:25228534	only alteration type		LUAD
WP212	PTEN MUT* (--)	PTEN biallelic inactivation	BYL719(PIK3CA inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:25409150	only alteration type		BRCA
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK (G1123S)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:26134233	only alteration type		LUAD
WP212	GATA3 MUT* (--)	GATA3 oncogenic mutation	Aromatase ihibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:24758297	only alteration type		BRCA
WP212	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35), GNAQ MUT* (--)	GNAQ (Q209)	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	NCT01587352	only alteration type		CM
WP212	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35), GNAQ MUT* (--)	GNAQ (Q209)	PI3K pathway inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22733540;PMID:22808163	only alteration type		CM
WP212	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35), GNAQ MUT* (--)	GNAQ (Q209)	PKC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22653968;PMID:22253748	only alteration type		CM
WP212	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35), GNAQ MUT* (--)	GNAQ (Q209)	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr CRA9003)	only alteration type		CM
WP212	HDAC2 MUT* (--)	HDAC2 biallelic inactivation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP212	BRAF MUT* (--)	BRAF (V600E)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
WP212	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP212	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP212	JAK3 MUT* (--)	JAK3 (A572V,A573V)	JAK inhibitors	Lymphoma	Responsive	D	YES	PMID:22705984	only alteration type		LY
WP212	JAK3 MUT* (--)	JAK3 (R657Q,I87T,Q501H)	JAK inhibitors	Megakaryoblastic leukemia	Responsive	D	YES	PMID:18397343	only alteration type		MKB
WP212	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP212	PTEN MUT* (--)	PTEN biallelic inactivation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	Caris molecular intelligence	only alteration type		COREAD
WP212	MDM2 MUT* (--)	MDM2 amplification	Cisplatin(Chemotherapy)	Male germ cell tumor	Resistant	C	NO	PMID:27646943	only gene		MGCT
WP212	TP53 MUT* (--)	TP53 oncogenic mutation	Cisplatin(Chemotherapy)	Female germ cell tumor, Male germ cell tumor	Resistant	C	NO	PMID:27646943	only alteration type		FGCT, MGCT
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK inframe insertion (1151T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only alteration type		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK oncogenic mutation	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only alteration type		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only gene		NSCLC
WP212	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP212	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only gene		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK (C1156Y,L1196M)	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:20979473	only alteration type		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK (F1174L)	Crizotinib(ALK inhibitor)	Glioma	Resistant	D	NO	PMID:22072639	only alteration type		G
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784;PMID:25228534	only alteration type		LUAD
WP212	MET MUT* (--)	MET (Y1230C,Y1235D)	Crizotinib(ALK inhibitor)	Any cancer type	Resistant	D	YES	PMID:17483355	only alteration type		CANCER
WP212	MTOR MUT* (--)	MTOR (F2108L)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Resistant	C	NO	PMID:25295501	only alteration type		THCA
WP212	MAP2K1 MUT* (R291S)	MAP2K1 (F129L,L215P,I103N,P124)	ERK inhibitors	Any cancer type	Responsive	D	YES	PMID:23614898	only alteration type		CANCER
WP212	MAP2K1 MUT* (R291S)	MAP2K1 (P124)	ERK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:25370473	only alteration type		CM
WP212	MAP2K1 MUT* (R291S)	MAP2K1 (C121S)	novel MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:24448821	only alteration type		CM
WP212	MAP2K1 MUT* (R291S)	MAP2K1 (K57T)	Panitumumab + Trametinib(EGFR mAb inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26644315	only alteration type		COREAD
WP212	MAP2K1 MUT* (R291S)	MAP2K1 inframe deletion (56-60)	Selumetinib(MEK inhibitor)	Ovary	Responsive	C	NO	PMID:26324360	only alteration type		OV
WP212	MAP2K1 MUT* (R291S)	MAP2K1 (Q56P)	Trametinib(MEK inhibitor)	Any cancer type	Responsive	D	YES	PMID:26582713	only alteration type		CANCER
WP212	MAP2K1 MUT* (R291S), BRAF MUT* (--)	MAP2K1 (P124S,I111S) + BRAF oncogenic mutation	BRAF inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:22588879	only alteration type		CM
WP212	MDM2 MUT* (--)	MDM2 amplification	MDM2 inhibitors	Liposarcoma	Responsive	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	only gene		LIP
WP212	MET MUT* (--)	MET kinase domain mutation	Savolitinib(MET inhibitor)	Renal	Responsive	C	NO	PMID:28644771	only alteration type		R
WP212	MET MUT* (--)	MET amplification	BCL2 inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:27397505	only gene		COREAD
WP212	MET MUT* (--)	MET amplification	MET inhibitors	Hepatic carcinoma	Responsive	C	NO	ENA 2015 (abstract A55)	only gene		HC
WP212	MET MUT* (--)	MET amplification	MET inhibitors	Stomach	Responsive	D	NO	PMID:22729845;PMID:23327903	only gene		ST
WP212	MET MUT* (--)	MET amplification	MET inhibitors	Renal	Responsive	C	NO	PMID:23213094;AACR 2016 (abstr CT2006)	only gene		R
WP212	MET MUT* (--)	MET (H1112R)	MET inhibitors	Renal	Responsive	C	NO	PMID:23213094	only alteration type		R
WP212	MET MUT* (--)	MET (M1268T)	MET inhibitors	Renal	Responsive	C	NO	PMID:23610116	only alteration type		R
WP212	MET MUT* (--)	MET (H1112L)	MET inhibitors(Crizotinib,etc)	Any cancer type	Responsive	D	YES	AACR 2012 (abstr 1786)	only alteration type		CANCER
WP212	MET MUT* (--)	MET amplification	Cabozantinib + Panitumumab(Pan-kinase inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A52)	only gene		COREAD
WP212	MET MUT* (--)	MET fusion	Crizotinib(ALK inhibitor)	Glioma	Responsive	C	NO	PMID:27748748	only gene		G
WP212	MET MUT* (--)	MET mutation in exon 16-19	Crizotinib(ALK inhibitor)	Renal	Responsive	C	NO	AACR 2016 (abstr CT2006)	only alteration type		R
WP212	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma, Stomach	Responsive	C	NO	ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1)	only gene		LUAD, ST
WP212	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Glioma	Responsive	C	NO	PMID:22162573	only gene		G
WP212	MET MUT* (--)	MET (V1110I,H1112R,M1268T,R988C,T1010I)	Crizotinib(ALK inhibitor)	Any cancer type	Responsive	D	YES	PMID:17483355	only alteration type		CANCER
WP212	MET MUT* (--), BRAF MUT* (--)	MET amplification + BRAF (V600E)	Crizotinib + Vemurafenib(ALK inhibitor + BRAF inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:27325282	only gene		COREAD
WP212	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP212	MTOR MUT* (--)	MTOR (F2108L)	MTOR kinase inhibitors	Any cancer type	Responsive	D	YES	PMID:25295501	only alteration type		CANCER
WP212	MTOR MUT* (--)	MTOR (E2014K,E2419K,N1421D)	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:24625776	only alteration type		BLCA
WP212	MTOR MUT* (--)	MTOR (I1973F)	Everolimus(MTOR inhibitor)	Angiosarcoma, Renal	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		AS, R
WP212	MTOR MUT* (--)	MTOR (K1771R)	Everolimus(MTOR inhibitor)	Stomach, Adrenal gland	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		ST, AG
WP212	MTOR MUT* (--)	MTOR (N1421D)	Everolimus(MTOR inhibitor)	Stomach	Responsive	C	NO	PMID:26859683	only alteration type		ST
WP212	MTOR MUT* (--)	MTOR (Q2223K)	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468	only alteration type		R
WP212	MTOR MUT* (--)	MTOR (L1460P,S2215Y,R2505P)	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	D	YES	PMID:24631838	only alteration type		CANCER
WP212	PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA (T674I)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome	Resistant	C	YES	PMID:12660384	only alteration type		HES
WP212	LRP1B MUT* (--)	LRP1B oncogenic mutation	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only alteration type		OV
WP212	LRP1B MUT* (--)	LRP1B deletion	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only gene		OV
WP212	MET MUT* (--)	MET amplification	EGFR inhibitor 3rd gens(Osimertinib,etc)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP212	BRAF MUT* (--)	BRAF (V600E)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
WP212	NOTCH1 MUT* (T349P), NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP212	NOTCH1 MUT* (T349P), NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP212	NOTCH1 MUT* (T349P), NOTCH1 MUT* (T311P)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP212	NOTCH1 MUT* (T349P), NOTCH1 MUT* (T311P)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP212	NOTCH1 MUT* (T349P), NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP212	NOTCH1 MUT* (T349P), NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP212	NOTCH1 MUT* (T349P), NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP212	NOTCH1 MUT* (T349P), NOTCH1 MUT* (T311P)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	only alteration type		MCL
WP212	NOTCH1 MUT* (T349P), NOTCH1 MUT* (T311P)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP212	NOTCH1 MUT* (T349P), NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP212	NOTCH1 MUT* (T349P), NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP212	NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP212	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP212	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP212	PTEN MUT* (--)	PTEN biallelic inactivation	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	Caris molecular intelligence	only alteration type		COREAD
WP212	PBRM1 MUT* (--), PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP212	PBRM1 MUT* (--), PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP212	PDGFRA MUT* (--)	PDGFRA (D842V)	HSP90 inhibitors	Gastrointestinal stromal	Responsive	D	NO	PMID:18794084	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA (D842V)	Crenolanib(FLT3 inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2016 (abstr 11010)	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	Crenolanib(FLT3 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
WP212	PDGFRA MUT* (--)	PDGFRA (P577S,R841K,H845Y,G853D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
WP212	MET MUT* (--)	MET amplification	EGFR inhibitor 3rd gens(Rociletinib,etc)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP212	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	AKT inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP212	PIK3CB MUT* (--)	PIK3CB (D1067Y)	AKT inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26759240	only alteration type		BRCA
WP212	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	MTORC1/2 inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP212	PIK3CB MUT* (--)	PIK3CB (D1067Y)	MTORC1/2 inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26759240	only alteration type		BRCA
WP212	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP212	PTEN MUT* (--)	PTEN oncogenic mutation	AKT inhibitors	Pancreas	Responsive	C	NO	PMID:22025163	only alteration type		PA
WP212	PTEN MUT* (--)	PTEN deletion	AKT inhibitors	Pancreas	Responsive	C	NO	PMID:22025163	only gene		PA
WP212	PTEN MUT* (--)	PTEN oncogenic mutation	ATM inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27397505	only alteration type		BRCA
WP212	PTEN MUT* (--)	PTEN oncogenic mutation	PARP inhibitors	Endometrium	Responsive	C	NO	PMID:21468130;PMID:20944090	only alteration type		ED
WP212	PTEN MUT* (--)	PTEN deletion	PARP inhibitors	Endometrium	Responsive	C	NO	PMID:21468130;PMID:20944090	only gene		ED
WP212	PTEN MUT* (--)	PTEN oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26645196	only alteration type		CM
WP212	PTEN MUT* (--)	PTEN deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26645196	only gene		CM
WP212	PTEN MUT* (--)	PTEN oncogenic mutation	PI3K pathway inhibitor + AR antagonists	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575859	only alteration type		PRAD
WP212	PTEN MUT* (--)	PTEN deletion	PI3K pathway inhibitor + AR antagonists	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575859	only gene		PRAD
WP212	PTEN MUT* (--)	PTEN oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Ovary	Responsive	D	NO	PMID:21632463	only alteration type		OV
WP212	PTEN MUT* (--)	PTEN deletion	PI3K pathway inhibitor + MEK inhibitors	Ovary	Responsive	D	NO	PMID:21632463	only gene		OV
WP212	PTEN MUT* (--)	PTEN oncogenic mutation	PI3K pathway inhibitors	Thyroid, Glioma, Lung, Ovary, Breast adenocarcinoma, Any cancer type, Endometrium	Responsive	D	YES	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669	only alteration type		TH, G, L, OV, BRCA, CANCER, ED
WP212	PTEN MUT* (--)	PTEN deletion	PI3K pathway inhibitors	Thyroid, Glioma, Lung, Ovary, Breast adenocarcinoma, Any cancer type, Endometrium	Responsive	D	YES	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669	only gene		TH, G, L, OV, BRCA, CANCER, ED
WP212	PTEN MUT* (--)	PTEN oncogenic mutation	PIK3CB inhibitors	Prostate adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 2514)	only alteration type		PRAD
WP212	PTEN MUT* (--)	PTEN deletion	PIK3CB inhibitors	Prostate adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 2514)	only gene		PRAD
WP212	PTEN MUT* (--)	PTEN oncogenic mutation	Everolimus(MTOR inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:23582881	only alteration type		PRAD
WP212	PTEN MUT* (--)	PTEN deletion	Everolimus(MTOR inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:23582881	only gene		PRAD
WP212	PTEN MUT* (--)	PTEN oncogenic mutation	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	C	YES	ASCO 2013 (abstr 2532)	only alteration type		CANCER
WP212	PTEN MUT* (--)	PTEN deletion	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	C	YES	ASCO 2013 (abstr 2532)	only gene		CANCER
WP212	PDGFRA MUT* (--)	PDGFRA (D842V)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
WP212	PTPRD MUT* (--), PTPRD MUT* (--), PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP212	RAD51C MUT* (G153)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
WP212	RAD51C MUT* (G153)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
WP212	RICTOR MUT* (--)	RICTOR amplification	MTORC1/2 inhibitors	Lung	Responsive	C	NO	PMID:26370156	only gene		L
WP212	SETD2 MUT* (--), SETD2 MUT* (--)	SETD2 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only alteration type		CANCER
WP212	SETD2 MUT* (--), SETD2 MUT* (--)	SETD2 deletion	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only gene		CANCER
WP212	SF3B1 MUT* (--)	SF3B1 (K700E,K666N)	Spliceosome inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858	only alteration type		CANCER
WP212	SRSF2 (P95H)	SRSF2 oncogenic mutation	Spliceosome inhibitors	Acute myeloid leukemia	Responsive	D	YES	PMID:27135740	complete		AML
WP212	BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Vemurafenib(BRAF inhibitor)	Any cancer type	Resistant	D	YES	PMID:26732095	only alteration type		CANCER
WP212	BRAF MUT* (--)	BRAF (V600)	Vemurafenib(BRAF inhibitor)	Colorectal adenocarcinoma	No Responsive	C	NO	PMID:26287849	only alteration type		COREAD
WP212	MAP2K1 MUT* (R291S)	MAP2K1 (E203K,Q56P,K57E)	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23569304	only alteration type		CM
WP212	TP53 MUT* (--)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
WP212	TP53 MUT* (--)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
WP212	TP53 MUT* (--)	TP53 oncogenic mutation	WEE1 inhibitors	Head an neck	Responsive	D	NO	PMID:25125259	only alteration type		HNC
WP212	TP53 MUT* (--)	TP53 oncogenic mutation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP212	TP53 MUT* (--)	TP53 deletion	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only gene		BCL
WP212	TP53 MUT* (--)	TP53 oncogenic mutation	Decitabine(Chemotherapy)	Acute myeloid leukemia, Myelodisplasic proliferative syndrome	Responsive	C	YES	PMID:27959731	only alteration type		AML, MDPS
WP212	TP53 MUT* (--)	TP53 oncogenic mutation	Doxorubicin(Anthracycline antitumor antibiotic)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP212	TP53 MUT* (--)	TP53 oncogenic mutation	Gemcitabine(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP212	TP53 MUT* (--)	TP53 oncogenic mutation	Mitomycin C(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP212	TP53 MUT* (--)	TP53 oncogenic mutation	WEE1 inhibitors	Ovary	Responsive	C	NO	PMID:27998224	only alteration type		OV
WP212	TP53 MUT* (--)	TP53 oncogenic mutation	Pramlintide(Amylin analogue)	Thymic	Responsive	D	YES	PMID:25409149	only alteration type		THYM
WP212	TP53 MUT* (--)	TP53 deletion	Pramlintide(Amylin analogue)	Thymic	Responsive	D	YES	PMID:25409149	only gene		THYM
WP212	MET MUT* (--), BRAF MUT* (--)	MET amplification + BRAF (V600E)	Vemurafenib + Panitumumab(BRAF inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:27325282	only gene		COREAD
WP212	PTEN MUT* (--)	PTEN (D326N,G165R,T277A,T160I,G129E,G165V,N48K,H93Y,N94I,D92E,D92G,F21A,R173P,L112R,K289E,L108P,R335L,H123Y,R130G,D92V,G251C,R15S,L181P,V133I,C124R,T131A,.,V343L,A126V,T131L,L112P,R173C,G129A,H61D,C136R,H123Q,H61R,P96Q,D331G,M134L,N276S,K342N,Y68H,D92N,M35R,Y68D,P95S,R130Q,R173H,Y155C,H123D,G20E,K62R,R159G,S10N,L23F,C105F,D162G,T319A,Y16C,A126D,H93R,K128Q,I122S,Y65C,F154L,K128T,R130K,R130L,V343E,G36R,A126S,D252G,G127N,F347L,G127E,K125E,A39P,S170N,G165E,P169H,Y27S,V217D,D162H,H118P,D92A,A34D,D24Y,L345Q,T131I,D92H,K128N,T167A,S170R,T401I,P95L,C124S,P38L,S227F,C124N,A121P,G129D,K128R,C136Y,F341V,K125L,R130A,D24N,H93D,L325F,C71Y,E157G,L42R,Y174N,A121E,A126G,G129R,R161G,G44D,I168F,R15K,H93Q,I122L,F241S,D107Y,K125M,L320S)	Gsk2636771 + Azd8186	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/PTEN	only alteration type		CANCER
WP212	PTEN MUT* (--)	PTEN deletion	Gsk2636771 + Azd8186	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/PTEN	only gene		CANCER
WP212	MAP2K1 MUT* (R291S)	MAP2K1 (V60E,H119P,L115P,I103N,F53C,R49L,G128V,V60M,L177V,F53S,P124L,T28I,P124S,Q56P,L37P,Y130C,I204T,E203K,I111R,I111A,F53L,.,L177M,V154I,C121S,S123T,P306H,V211D,I111P,K57T,D67N,I111N,P124Q,R47Q,K57N,S218D,F129L,S222D,E144K,L115R,G128D,K57E)	Cobimetinib + Trametinib	Cutaneous melanoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MAP2K1	only alteration type		CM
WP212	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
WP212	BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
WP212	MDM2 MUT* (--)	MDM2 amplification	Unii-Q8Mi0X869M	Liposarcoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MDM2	only gene		LIP
WP212	MTOR MUT* (--)	MTOR (L2209V,L1460P,L2427Q)	Temsirolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
WP212	MTOR MUT* (--)	MTOR (Q2223K)	Everolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK fusion	Crizotinib + Ceritinib	Sarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only gene		S
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK (G1202R,I1171N)	Alectinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only alteration type		NSCLC
WP212	MET MUT* (--)	MET amplification	Crizotinib	Non-small cell lung	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/52/summary|oncokb=https://www.oncokb.org/gene/MET	only gene		NSCLC
WP212	MET MUT* (--)	MET (D1010H,Y1003N,D1010N,Y1003F,Y1003C,D1010Y)	Crizotinib	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP212	BRAF MUT* (--)	BRAF (D594.,G466.,G464.,N581.,D287H,K601.,G469.,G596.,L597.,F595L,S467L,V459L)	Plx8394	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CANCER
WP212	MAP2K1 MUT* (R291S)	MAP2K1 (V60E,H119P,L115P,I103N,F53C,R49L,G128V,V60M,L177V,F53S,P124L,T28I,P124S,Q56P,L37P,Y130C,I204T,E203K,I111R,I111A,F53L,.,L177M,V154I,C121S,S123T,P306H,V211D,I111P,K57T,D67N,I111N,P124Q,R47Q,K57N,S218D,F129L,S222D,E144K,L115R,G128D,K57E)	Cobimetinib + Trametinib	Histiocytoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MAP2K1	only alteration type		HIS
WP212	MTOR MUT* (--)	MTOR (E2419K,E2014K)	Everolimus	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		BLCA
WP212	MTOR MUT* (--)	MTOR (E2419K,C1483F,L2172M,K1452N,L2230V,L2427Q,L2431P,F1888I,E1799K,L2216P,W1456R,C1483W,A1519T,L1460P,A2210P,T2232I,R2505P,M2327I,C1483R,V2006I,A1428T,Y1463S,I2500M,A1459P,F1888L,S2231W,T1977R,V2006F,T1977K,A2226S,I2500F,L2427R,T1977I,S2215F,.,Q2223K,I1973F,L1433S,F1888V,S2215T,D2512H,E2014K,S2215Y,R2217W,L2209V,V2006L,L2220F,L2427P,S2215P,P2273S,E2288K,C1483Y)	Temsirolimus + Everolimus	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		CANCER
WP212	PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib	Gastrointestinal stromal	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP212	KDM6A MUT* (--)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
WP212	KDM6A MUT* (--)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only alteration type		BLCA
WP212	MET MUT* (--)	MET (D1010H,Y1003N,D1010N,Y1003F,Y1003C,D1010Y)	Cabozantinib + Capmatinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP212	BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + Trametinib	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF (V600E)	Encorafenib + Binimetinib + Cetuximab	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		OV
WP212	PDGFRA MUT* (--)	PDGFRA (N659K,V561D,V561A,N659S,A633T,H845Y,T674I,S584L,D842V,N659R,D568N,P577S,D846Y,Q579R,D842Y,Y849S,N848K,H650Q,D842I,V469A,Y288C,Y555C,R748G,Y849C,.,R841K,G853D,V536E,V658A)	Imatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA amplification	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP212	PDGFRA MUT* (--)	PDGFRA-BCR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP212	PDGFRA MUT* (--)	PDGFRA-CDK5RAP2 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP212	PDGFRA MUT* (--)	PDGFRA-ETV6 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP212	PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP212	PDGFRA MUT* (--)	PDGFRA fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP212	PDGFRA MUT* (--)	PDGFRA-KDR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP212	PDGFRA MUT* (--)	PDGFRA-KIF5B fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP212	PDGFRA MUT* (--)	PDGFRA-STRN fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP212	MET MUT* (--)	MET amplification	Erlotinib + Gefitinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only gene		NSCLC
WP212	BRAF MUT* (--)	BRAF (V600K,V600.,L597.,K601.,V600E,L597V)	Trametinib	Cutaneous melanoma	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/5/summary|oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CM
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only alteration type		CANCER
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
WP212	MAP2K1 MUT* (R291S)	MAP2K1 (V60E,H119P,L115P,I103N,F53C,R49L,G128V,V60M,L177V,F53S,P124L,T28I,P124S,Q56P,L37P,Y130C,I204T,E203K,I111R,I111A,F53L,.,L177M,V154I,C121S,S123T,P306H,V211D,I111P,K57T,D67N,I111N,P124Q,R47Q,K57N,S218D,F129L,S222D,E144K,L115R,G128D,K57E)	Cobimetinib + Trametinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MAP2K1	only alteration type		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK (C1156Y,F1174L,L1196M,G1269A)	Crizotinib	Non-small cell lung	Resistant	D	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary	only alteration type		NSCLC
WP212	MET MUT* (--)	MET (D1228N)	Crizotinib + Cabozantinib + Capmatinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP212	BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Cutaneous melanoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		CM
WP212	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
WP212	BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
WP212	PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP212	MAP2K1 MUT* (R291S)	MAP2K1 (V60E,H119P,L115P,I103N,F53C,R49L,G128V,V60M,L177V,F53S,P124L,T28I,P124S,Q56P,L37P,Y130C,I204T,E203K,I111R,I111A,F53L,.,L177M,V154I,C121S,S123T,P306H,V211D,I111P,K57T,D67N,I111N,P124Q,R47Q,K57N,S218D,F129L,S222D,E144K,L115R,G128D,K57E)	Cobimetinib + Trametinib	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MAP2K1	only alteration type		OV
WP212	MET MUT* (--)	MET amplification	Cabozantinib	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only gene		RCCC
WP212	MET MUT* (--)	MET (Y1230H)	Crizotinib + Capmatinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK CAD::ALK	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7481	only gene		COREAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK CLTC::ALK	TAE684	Difuse large B Cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1261	only gene		DLBCL
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK CLTC::ALK	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1265	only gene		DLBCL
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK EML4::ALK	Alectinib	Mesothelioma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9228	only gene		MESO
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/262	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK EML4::ALK	WHI-P154	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1188	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK EML4::ALK	Crizotinib,Retaspimycin Hydrochloride	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1203	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK EML4::ALK	Crizotinib,Alvespimycin	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1206	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1207	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK EML4::ALK	Lorlatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1332	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK F1174L	Crizotinib	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/125	only alteration type		NB
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK F1174L	Alectinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/37	only alteration type		NB
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/38	only alteration type		NB
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK F1174L	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/142	only alteration type		NB
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1271	only alteration type		NB
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK F1174L	AZD3463	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1327	only alteration type		NB
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK F1174L	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1329	only alteration type		NB
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK F1174L	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/33	only alteration type		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK F1245C	Crizotinib	Neuroblastoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1333	only alteration type		NB
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK F1245C	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1330	only alteration type		NB
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK F1245V	Entrectinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2987	only alteration type		NB
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1240	only gene		ALCL
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/7361	only gene		ALCL
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	A	YES	https://civicdb.org/links/evidence_items/11218	only gene		ALCL
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1264	only gene		DLBCL
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1691	only gene		LUAD
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Pemetrexed	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/945	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1175	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1187	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1198	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1199	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1200	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1201	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Retaspimycin Hydrochloride	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1202	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1272	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1273	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1279	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1282	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1419	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1577	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4835	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Alectinib,Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4858	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7284	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7285	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Lorlatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7286	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/8657	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11121	only gene		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1283	only alteration type		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK I1171	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1287	only alteration type		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1367	only alteration type		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1284	only alteration type		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK I1171	TAE684	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1285	only alteration type		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1344	only alteration type		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1368	only alteration type		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK I1171T	Ceritinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9404	only alteration type		NB
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK KANK4::ALK	Alectinib	Pancreas acinar	Responsive	C	NO	https://civicdb.org/links/evidence_items/10327	only gene		PAAC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK Mutation	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1237	only alteration type		NSCLC
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1239	only gene		ALCL
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/1241	only gene		ALCL
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK R1275Q	TAE684	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/48	only alteration type		NB
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK R1275Q	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/39	only alteration type		NB
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/143	only alteration type		NB
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1270	only alteration type		NB
WP212	ALK MUT* (P1027R), ALK MUT* (T1026P)	ALK R1275Q	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1331	only alteration type		NB
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	only alteration type		CM
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	only alteration type		GB
WP212	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	only alteration type		PRAD
WP212	BRAF MUT* (--)	BRAF Non-V600	Trametinib	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/7855	only alteration type		SOLID
WP212	BRAF MUT* (--)	BRAF A598V	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7635	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF AGK::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/724	only gene		CM
WP212	BRAF MUT* (--)	BRAF AGK::BRAF	Sorafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/723	only gene		CM
WP212	BRAF MUT* (--)	BRAF CUX1::BRAF	Vemurafenib	Pancreas	Responsive	C	NO	https://civicdb.org/links/evidence_items/5977	only gene		PA
WP212	BRAF MUT* (--)	BRAF D594G	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1554	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2201	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4472	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF D594K	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6402	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF D594K	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6403	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF G466V	Irinotecan,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7552	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF G466V	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7553	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF G466V	Vemurafenib	Solid tumors	Responsive	D	NO	https://civicdb.org/links/evidence_items/7554	only alteration type		SOLID
WP212	BRAF MUT* (--)	BRAF G469	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7634	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF G596C	Dabrafenib,Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1738	only alteration type		NSCLC
WP212	BRAF MUT* (--)	BRAF G596R	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4729	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1668	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1669	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF L597R	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/728	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1704	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2187	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6303	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6304	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6305	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6306	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1404	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF PAPSS1::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/725	only gene		CM
WP212	BRAF MUT* (--)	BRAF PAPSS1::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/726	only gene		CM
WP212	BRAF MUT* (--)	BRAF TRIM24::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/727	only gene		CM
WP212	BRAF MUT* (--)	BRAF V600	Vemurafenib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5905	only alteration type		CH
WP212	BRAF MUT* (--)	BRAF V600	Refametinib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1000	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/93	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1407	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1422	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1750	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600	Cobimetinib,Vemurafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/6044	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6180	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6937	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6966	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600	Binimetinib,Encorafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7287	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/88	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600	Vemurafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1576	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1415	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1598	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600	Cetuximab,Encorafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6046	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600	Encorafenib,Alpelisib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6047	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600	Vemurafenib,Irinotecan,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7355	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1574	only alteration type		NSCLC
WP212	BRAF MUT* (--)	BRAF V600D	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/94	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4488	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4489	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7616	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7629	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5902	only alteration type		CH
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Irinotecan,Panitumumab	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5906	only alteration type		CH
WP212	BRAF MUT* (--)	BRAF V600E	Trametinib,Mirdametinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/86	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/90	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/994	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/95	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	Pictilisib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/757	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	Dactolisib,Selumetinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1005	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1398	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1421	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1749	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2135	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3750	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3755	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3757	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6178	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6938	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6940	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600E	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/126	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/816	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2115	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2117	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2118	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2121	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3739	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3827	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Sorafenib,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/89	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	PLX4720,Pictilisib Bismesylate	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/96	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	PLX4720,Nutlin-3	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/97	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/98	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/99	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1405	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Dabrafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1406	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Cetuximab,Gefitinib,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1408	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1413	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	GDC-0879,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1428	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1589	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Irinotecan,Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1902	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5960	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Panitumumab,Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6123	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Panitumumab,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6124	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Cetuximab,Encorafenib,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7260	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7612	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cetuximab,Irinotecan	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8506	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Erlotinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8507	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/9851	only alteration type		COREAD
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Hairy-Cell leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/1579	only alteration type		HCL
WP212	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5903	only alteration type		IHCH
WP212	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5904	only alteration type		IHCH
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1698	only alteration type		MM
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1699	only alteration type		MM
WP212	BRAF MUT* (--)	BRAF V600E	Dabrafenib,Trametinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/3017	only alteration type		NSCLC
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5958	only alteration type		NSCLC
WP212	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/5959	only alteration type		OV
WP212	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1399	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1400	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600K	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2505	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600K	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2506	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4180	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6179	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6965	only alteration type		CM
WP212	BRAF MUT* (--)	BRAF ZKSCAN1::BRAF	Trametinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1663	only gene		CM
WP212	BRAF MUT* (--)	BRAF Amplification	Trametinib,Dabrafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/7677	only gene		CM
WP212	BRAF MUT* (--)	BRAF Amplification	Panitumumab,Dabrafenib	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2929	only gene		COREAD
WP212	BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
WP212	BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
WP212	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
WP212	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
WP212	BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
WP212	BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
WP212	BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
WP212	BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
WP212	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP212	ERBB4 MUT* (--), ERBB4 MUT* (--)	ERBB4 Mutation	Lapatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/770	only alteration type		CM
WP212	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35), GNAQ MUT* (--)	GNAQ Mutation	JQ1	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1210	only alteration type		UVM
WP212	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35), GNAQ MUT* (--)	GNAQ Mutation	Trametinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1229	only alteration type		UVM
WP212	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35), GNAQ MUT* (--)	GNAQ Mutation	Mirdametinib,Sotrastaurin Acetate	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1953	only alteration type		UVM
WP212	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35), GNAQ MUT* (--)	GNAQ Mutation	Cabozantinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5068	only alteration type		UVM
WP212	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35), GNAQ MUT* (--)	GNAQ Q209	Selumetinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1213	only alteration type		UVM
WP212	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35), GNAQ MUT* (--)	GNAQ Q209	Refametinib	Uveal melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1233	only alteration type		UVM
WP212	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP212	KMT2C MUT* (K2797X), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP212	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP212	MAP2K1 MUT* (R291S)	MAP2K1 C121S	Vemurafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1602	only alteration type		CM
WP212	MAP2K1 MUT* (R291S)	MAP2K1 K57N	Selumetinib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2936	only alteration type		LUAD
WP212	MAP2K1 MUT* (R291S)	MAP2K1 P124S	Selumetinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/12	only alteration type		CM
WP212	MAP2K1 MUT* (R291S)	MAP2K1 Q56P	Selumetinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/13	only alteration type		CM
WP212	MET MUT* (--)	MET D1228N	Crizotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1652	only alteration type		NSCLC
WP212	MET MUT* (--)	MET D1228V	Savolitinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1865	only alteration type		NSCLC
WP212	MET MUT* (--)	MET D1228V	Cabozantinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1864	only alteration type		NSCLC
WP212	MET MUT* (--)	MET MET::ATXN7L1	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7793	only gene		NSCLC
WP212	MET MUT* (--)	MET Amplification	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1971	only gene		COREAD
WP212	MET MUT* (--)	MET Amplification	Vemurafenib,Crizotinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1588	only gene		COREAD
WP212	MET MUT* (--)	MET Amplification	Crizotinib,Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1979	only gene		COREAD
WP212	MET MUT* (--)	MET Amplification	Crizotinib	Glioblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1565	only gene		GB
WP212	MET MUT* (--)	MET Amplification	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1392	only gene		LUAD
WP212	MET MUT* (--)	MET Amplification	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/836	only gene		LUAD
WP212	MET MUT* (--)	MET Amplification	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1692	only gene		LUAD
WP212	MET MUT* (--)	MET Amplification	Crizotinib	Lung squamous cell	Responsive	C	NO	https://civicdb.org/links/evidence_items/890	only gene		LUSC
WP212	MET MUT* (--)	MET Amplification	Gefitinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/733	only gene		NSCLC
WP212	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/735	only gene		NSCLC
WP212	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1566	only gene		NSCLC
WP212	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1713	only gene		NSCLC
WP212	MET MUT* (--)	MET Amplification	Onartuzumab	Stomach	Responsive	C	NO	https://civicdb.org/links/evidence_items/689	only gene		ST
WP212	MTOR MUT* (--)	MTOR A2034V	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1547	only alteration type		BRCA
WP212	MTOR MUT* (--)	MTOR A2034V	RapaLink-1,MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1548	only alteration type		BRCA
WP212	MTOR MUT* (--)	MTOR E1799K	Sirolimus	Renal clear cell	Responsive	D	NO	https://civicdb.org/links/evidence_items/1321	only alteration type		RCCC
WP212	MTOR MUT* (--)	MTOR F2108L	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1543	only alteration type		BRCA
WP212	MTOR MUT* (--)	MTOR F2108L	Everolimus	Thyroid carcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1110	only alteration type		THCA
WP212	MTOR MUT* (--)	MTOR H1968Y	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/713	only alteration type		CM
WP212	MTOR MUT* (--)	MTOR M2327I	MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1544	only alteration type		BRCA
WP212	MTOR MUT* (--)	MTOR M2327I	Sirolimus,RapaLink-1	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1545	only alteration type		BRCA
WP212	MTOR MUT* (--)	MTOR Mutation	Everolimus,Pazopanib	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/705	only alteration type		BLCA
WP212	MTOR MUT* (--)	MTOR P2213S	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/722	only alteration type		CM
WP212	NOTCH1 MUT* (T349P), NOTCH1 MUT* (T311P)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP212	PDGFRA MUT* (--)	PDGFRA D842I	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/43	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/15	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/16	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/651	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/738	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2478	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA D842V	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4597	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA D842V	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/44	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA D842Y	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/45	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA D842_I843delinsVM	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/47	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA FIP1L1::PDGFRA	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7378	only gene		AML
WP212	PDGFRA MUT* (--)	PDGFRA G853D	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1977	only alteration type		CM
WP212	PDGFRA MUT* (--)	PDGFRA H845Y	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1976	only alteration type		CM
WP212	PDGFRA MUT* (--)	PDGFRA I843DEL	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/46	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA I843DEL	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1309	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA Mutation	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2487	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA P577S	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1974	only alteration type		CM
WP212	PDGFRA MUT* (--)	PDGFRA R841K	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1975	only alteration type		CM
WP212	PDGFRA MUT* (--)	PDGFRA V561A	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/652	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA V561D	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2474	only alteration type		GIST
WP212	PDGFRA MUT* (--)	PDGFRA Amplification	Sunitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1771	only gene		NSCLC
WP212	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP212	POLD1 MUT* (--)	POLD1 C284Y	Pembrolizumab	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4776	only alteration type		LUAD
WP212	POLD1 MUT* (--)	POLD1 E374K	Pembrolizumab	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4777	only alteration type		NSCLC
WP212	PTEN MUT* (--)	PTEN Mutation	Taselisib	Head an neck squamous	Resistant	D	NO	https://civicdb.org/links/evidence_items/1467	only alteration type		HNSC
WP212	PTEN MUT* (--)	PTEN R130*	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1627	only alteration type		THCA
WP212	PTEN MUT* (--)	PTEN R233*	MTOR Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/317	only alteration type		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Everolimus	Bladder	Resistant	B	NO	https://civicdb.org/links/evidence_items/644	only gene		BLCA
WP212	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/645	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Alpelisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/716	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1383	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1385	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1386	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2035	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2043	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	PI3Ka/Di	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8022	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8274	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8275	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8276	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Dactolisib,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8278	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Trastuzumab,Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8279	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8706	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	PI3Kbeta Inhibitor AZD8186	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/711	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1297	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	PI3K/BET Inhibitor LY294002,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1455	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1611	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2045	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2074	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8012	only gene		BRCA
WP212	PTEN MUT* (--)	PTEN Loss	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6271	only gene		CM
WP212	PTEN MUT* (--)	PTEN Loss	Uprosertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/708	only gene		CM
WP212	PTEN MUT* (--)	PTEN Loss	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/506	only gene		COREAD
WP212	PTEN MUT* (--)	PTEN Loss	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6315	only gene		COREAD
WP212	PTEN MUT* (--)	PTEN Loss	Ridaforolimus,Temsirolimus	Endometrium	Resistant	B	NO	https://civicdb.org/links/evidence_items/893	only gene		ED
WP212	PTEN MUT* (--)	PTEN Loss	Temsirolimus	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1614	only gene		ED
WP212	PTEN MUT* (--)	PTEN Loss	Cisplatin	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/1492	only gene		OV
WP212	PTEN MUT* (--)	PTEN Loss	Buparlisib,Paclitaxel,Carboplatin	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/5957	only gene		SOLID
WP212	PTEN MUT* (--)	PTEN Loss	Trastuzumab,Lapatinib	Stomach	Resistant	B	NO	https://civicdb.org/links/evidence_items/864	only gene		ST
WP212	PTPRD MUT* (--), PTPRD MUT* (--), PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP212	RAD54L MUT* (--)	RAD54L Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11207	only alteration type		PRAD
WP212	RICTOR MUT* (--)	RICTOR Amplification	Onatasertib,Sapanisertib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1440	only gene		LUAD
WP212	RICTOR MUT* (--)	RICTOR Amplification	Vistusertib	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7449	only gene		SCLC
WP212	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP212	SF3B1 MUT* (--)	SF3B1 K666N	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1418	only alteration type		BRCA
WP212	SF3B1 MUT* (--)	SF3B1 K700E	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1417	only alteration type		BRCA
WP212	TLK2 MUT* (--)	TLK2 Amplification	Go6983,GF109203X	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6000	only gene		BRCA
WP212	TP53 MUT* (--)	TP53 M237I	MDM2 Inhibitor AMGMDS3	Glioblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4885	only alteration type		GB
WP212	TP53 MUT* (--)	TP53 Mutation	Tamoxifen	Breast adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2784	only alteration type		BRCA
WP212	TP53 MUT* (--)	TP53 Mutation	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/851	only alteration type		BRCA
WP212	TP53 MUT* (--)	TP53 Mutation	Selumetinib,Docetaxel	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1145	only alteration type		NSCLC
WP212	TP53 MUT* (--)	TP53 Mutation	Pazopanib,Vorinostat	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/7540	only alteration type		SOLID
WP212	TP53 MUT* (--)	TP53 Mutation	Chemotherapy	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/850	only alteration type		ST
WP212	TP53 MUT* (--)	TP53 R175H	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/319	only alteration type		BRCA
WP212	TP53 MUT* (--)	TP53 R249	Doxorubicin	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/399	only alteration type		BRCA
WP212	TP53 MUT* (--)	TP53 R273H	Methotrexate,Doxorubicin	Osteosarcoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/7430	only alteration type		OS
WP212	TP53 MUT* (--)	TP53 R273L	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2286	only alteration type		OV
WP212	TP53 MUT* (--)	TP53 Y234C	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2745	only alteration type		OV
WP212	TP53 MUT* (--)	TP53 Loss	Docetaxel	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1146	only gene		NSCLC
WP295	ALK (A1051S)	ALK fusion	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	FDA	only gene		LUAD
WP295	ALK (A1051S)	ALK fusion	Alectinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	only gene		NSCLC
WP295	ALK (A1051S)	ALK fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	only gene		NSCLC
WP295	ALK (A1051S)	ALK inframe insertion (1151T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165	only alteration type		LUAD
WP295	ALK (A1051S)	ALK (L1196M,S1206Y,G1269A,I1171T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165;PMID:24327273	only alteration type		LUAD
WP295	ALK (A1051S)	ALK fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene	758.0	NSCLC
WP295	ALK (A1051S)	ALK fusion	Brigatinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc	only gene		NSCLC
WP295	NRAS MUT* (--)	NRAS (12,13,59,61,117,146)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	PMID:24024839;PMID:20619739;PMID:23325582	only alteration type		COREAD
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP295	KRAS MUT* (--)	KRAS (12,13)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP295	DNMT3A (F734L)	DNMT3A oncogenic mutation	Daunorubicin(Chemotherapy)	Acute myeloid leukemia	Responsive	A	YES	PMID:22417203	complete		AML
WP295	NRAS MUT* (--)	NRAS (12,13,59,61,117,146)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP295	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Myelofibrosis	Responsive	A	YES	FDA	complete		MY
WP295	KRAS MUT* (--)	KRAS (12,13,59,61,117,146)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	NCCN guidelines	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	NCCN guidelines	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR inhibitors	Lung	Resistant	A	NO	NCCN guidelines	only alteration type		L
WP295	NPM1 MUT* (--), NPM1 MUT* (--), NPM1 MUT* (--)	NPM1 oncogenic mutation	Daunorubicin(Chemotherapy)	Acute myeloid leukemia	Responsive	A	YES	PMID:22417203	only alteration type		AML
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome, Eosinophilic chronic leukemia	Responsive	A	YES	EMA	only gene		HES, ECL
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA inframe deletion (I843)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type	862.0	GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type	862.0	GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Regorafenib(Pan-kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
WP295	PTCH1 MUT* (T314)	PTCH1 oncogenic mutation	Vismodegib(SHH inhibitor)	Basal cell carcinoma, Medulloblastoma	Responsive	A	NO	PMID:19726763;PMID:19726761	only alteration type		BCC, MB
WP295	TPMT MUT* (--)	TPMT splice acceptor variant	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP295	TPMT MUT* (--)	TPMT biallelic inactivation	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP295	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP295	TPMT MUT* (--)	TPMT splice acceptor variant	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP295	TPMT MUT* (--)	TPMT biallelic inactivation	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP295	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP295	TPMT MUT* (--)	TPMT splice acceptor variant	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP295	TPMT MUT* (--)	TPMT biallelic inactivation	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP295	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP295	TSC2 (P1493Q)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    , Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	complete		RA, GCA
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP295	ALK (A1051S)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP295	BARD1 (P84Q), BARD1 (C78F)	BARD1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	complete		PRAD
WP295	CHEK1 MUT* (--)	CHEK1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP295	FGFR3 MUT* (V14)	FGFR3 fusion	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only gene		BLCA
WP295	FGFR3 MUT* (V14)	FGFR3 (G370C,R248C,S249C,Y373C)	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only alteration type		BLCA
WP295	KRAS MUT* (--)	KRAS (G12C)	Sotorasib(RAS GTPase family inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc	only alteration type		NSCLC
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA exon 18 mutations	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation;PMID:32615108	only alteration type		GIST
WP295	RAD51C MUT* (G153)	RAD51C oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP295	NTRK3 MUT* (--)	NTRK3 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
WP295	NTRK3 MUT* (--)	NTRK3 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
WP295	NTRK3 MUT* (--)	NTRK3 (F617L,G623R,G696A)	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Resistant	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf	only alteration type		SOLID
WP295	KRAS MUT* (--)	KRAS (G12C)	Adagrasib(RAS GTPase family inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc	only alteration type		NSCLC
WP295	ALK (A1051S)	ALK fusion	Crizotinib(ALK inhibitor)	Anaplastic large cell lymphoma	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large	only gene		ALCL
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP295	FANCA MUT* (--), FANCA MUT* (--), FANCA MUT* (--), FANCA MUT* (--)	FANCA oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP295	RAD51C MUT* (G153)	RAD51C oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
WP295	BTK MUT* (P178T)	BTK (C481S)	Ibrutinib(BTK inhibitor)	Chronic lymphocytic leukemia	Resistant	A	YES	PMID: 28418267	only alteration type		CLL
WP295	ALK (A1051S)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP295	IDH2 MUT* (--)	IDH2 oncogenic mutation	Enasidenib(IDH2 inhibitor)	Acute lymphoblastic leukemia	Responsive	A	YES	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209606s004lbl.pdf	only alteration type		ALL
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP295	NRAS MUT* (--)	NRAS oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP295	NRAS MUT* (--)	NRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP295	NRAS MUT* (--)	NRAS oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP295	NRAS MUT* (--)	NRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP295	KRAS MUT* (--)	KRAS (G12C)	Adagrasib(RAS GTPase family inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA oncogenic mutations (excluding D842V + exon 18 inframe mutations)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type	862.0	GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V + exon 18 mutations	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
WP295	ALK (A1051S)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor	only gene		IM
WP295	ALK (A1051S)	ALK fusion	Alectinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP295	ALK (A1051S)	ALK fusion	Brigatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP295	ALK (A1051S)	ALK fusion	Ceritinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP295	ALK (A1051S)	ALK fusion	Lorlatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP295	KRAS MUT* (--)	KRAS (G12C)	Sotorasib(RAS GTPase family inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP295	IDH2 MUT* (--)	IDH2 oncogenic mutation	Venetoclax(BCL2 inhibitor)	Acute myeloid leukemia	Responsive	A	YES	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf	only alteration type		AML
WP295	ALK (A1051S)	ALK fusion	ALK inhibitor + IGF1R inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25173427	only gene		LUAD
WP295	ALK (A1051S)	ALK fusion	ALK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:26301689	only gene		LUAD
WP295	ALK (A1051S)	ALK fusion	ALK inhibitor + SRC inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25394791	only gene		LUAD
WP295	ALK (A1051S)	ALK fusion	ALK inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560	only gene		COREAD
WP295	ALK (A1051S)	ALK fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23553849	only gene		LUAD
WP295	ALK (A1051S)	ALK fusion	novel ALK inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23639470	only gene		LUAD
WP295	ALK (A1051S)	ALK (F1174L)	novel ALK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24327273	only alteration type		LUAD
WP295	ALK (A1051S)	ALK amplification	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only gene		LUAD
WP295	ALK (A1051S)	ALK (E1408V)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP295	ALK (A1051S)	ALK (L1196M)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP295	ALK (A1051S)	ALK fusion	Ceritinib(ALK inhibitor)	Colorectal adenocarcinoma, Inflammatory myofibroblastic	Responsive	C	YES	PMID:26633560;PMID:26933125;PMID:27742657	only gene		COREAD, IM
WP295	ALK (A1051S)	ALK fusion	Ceritinib(ALK inhibitor)	Hematologic malignancies	Responsive	C	YES	NCT02186821	only gene		HEMATO
WP295	ALK (A1051S)	ALK fusion	Crizotinib(ALK inhibitor)	Lymphoma, Glioblastoma	Responsive	C	YES	PMID:24491302;NCT02270034	only gene		LY, GB
WP295	ALK (A1051S)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic, Thyroid carcinoma	Responsive	C	YES	PMID:20979472;PMID:24687827	only gene		IM, THCA
WP295	ALK (A1051S)	ALK (F856S,A348D)	Crizotinib(ALK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:26032424	only alteration type		AML
WP295	ALK (A1051S)	ALK (L1198F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26698910	only alteration type	758.0	LUAD
WP295	ALK (A1051S)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib(ALK inhibitor)	Glioma	Responsive	D	NO	PMID:22072639	only alteration type		G
WP295	ALK (A1051S)	ALK fusion	Entrectinib(Pan-TK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560;PMID:26933125	only gene		COREAD
WP295	ALK (A1051S)	ALK (C1156Y)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27401242	only alteration type		LUAD
WP295	ERBB3 MUT* (--)	ERBB3 amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:25520391	only gene		COREAD
WP295	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	complete		CANCER
WP295	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	complete		OV
WP295	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	complete		CANCER
WP295	FGFR3 MUT* (V14)	FGFR3 (V555M)	FGFR inhibitors	Myeloma	Resistant	D	YES	PMID:22869148	only alteration type		MYMA
WP295	JAK2 (V617F)	JAK2 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	complete		CM
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Pancreas	No Responsive	C	NO	ASCO 2015 (abstr 4119)	only alteration type		PA
WP295	KRAS MUT* (--)	KRAS (G13D)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	No Responsive	B	NO	PMID:27114605	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	Selumetinib(MEK inhibitor)	Lung	No Responsive	C	NO	PMID:26802155	only alteration type		L
WP295	KRAS MUT* (--)	KRAS amplification	BRAF inhibitor + EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only gene		COREAD
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP295	KRAS MUT* (--)	KRAS amplification	BRAF inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only gene		COREAD
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR inhibitors	Non-small cell lung	Resistant	D	NO	PMID:19238210	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR mAb inhibitors	Stomach	Resistant	D	NO	PMID:22614881;PMID:22290393	only alteration type		ST
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP295	NRAS MUT* (--)	NRAS (Q61)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:23569304;PMID:24265153	only alteration type		CM
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA amplification	PDGFR inhibitors	Glioma	No Responsive	D	NO	PMID:23544171	only gene		G
WP295	EPHA2 MUT* (T908)	EPHA2 (G391R)	MTOR inhibitors	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
WP295	EPHA2 MUT* (T908)	EPHA2 (G391R)	MTOR inhibitors	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
WP295	EPHA2 MUT* (T908)	EPHA2 amplification	Dasatinib(BCR-ABL inhibitor 2nd gen)	Any cancer type	Responsive	D	YES	PMID:18047674;PMID:19010823;PMID:19861960	only gene		CANCER
WP295	EPHA2 MUT* (T908)	EPHA2 amplification	Dasatinib(BCR-ABL inhibitor 2nd gen)	Any cancer type	Responsive	D	YES	PMID:18047674;PMID:19010823;PMID:19861960	only gene		CANCER
WP295	EPHA2 MUT* (T908)	EPHA2 (G391R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
WP295	EPHA2 MUT* (T908)	EPHA2 (G391R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
WP295	STK11 MUT* (T13)	STK11 oncogenic mutation	BET inhibitors	Lung	Resistant	D	NO	PMID:23129625;PMID:24045185	only alteration type		L
WP295	STK11 MUT* (T13), KRAS MUT* (--)	STK11 oncogenic mutation + KRAS oncogenic mutation	PD1 Ab inhibitors	Lung adenocarcinoma	Resistant	C	NO	ASCO 2017 (abstr 9016)	only alteration type		LUAD
WP295	ERBB3 MUT* (--)	ERBB3 (P262H,G284R)	ERBB3 mAb inhibitors	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP295	ERBB3 MUT* (--)	ERBB3 (P262H,G284R,Q809R)	PI3K pathway inhibitor + MEK inhibitors	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP295	ERBB3 MUT* (--)	ERBB3 (G284R,R103G)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	ASCO 2015 (abstr e15516)	only alteration type		BLCA
WP295	ERBB3 MUT* (--)	ERBB3 (G284R,V104M,R103G)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	PMID:27044931	only alteration type		BLCA
WP295	ERBB3 MUT* (--)	ERBB3 (P262H,G284R,Q809R)	Lapatinib(ERBB2 inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP295	ERBB3 MUT* (--)	ERBB3 (P262H,G284R)	Pertuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP295	ERBB3 MUT* (--)	ERBB3 (P262H,G284R,Q809R)	Trastuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP295	STK11 MUT* (T13), KRAS MUT* (--)	STK11 deletion + KRAS oncogenic mutation	PD1 Ab inhibitors	Lung adenocarcinoma	Resistant	C	NO	ASCO 2017 (abstr 9016)	only gene		LUAD
WP295	ERBB4 MUT* (--)	ERBB4 (E317K,E452K,R544W,R393W,E872K)	Lapatinib(ERBB2 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:19718025	only alteration type		CM
WP295	ERBB4 MUT* (--)	ERBB4 fusion	Lapatinib + Afatinib(ERBB2 inhibitor + ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP295	TP53 MUT* (T377P)	TP53 oncogenic mutation	MDM2 inhibitors	Liposarcoma	Resistant	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	only alteration type		LIP
WP295	ERCC4 MUT* (--)	ERCC4 oncogenic mutation	Cisplatin(Chemotherapy)	Ovary	Responsive	D	NO	PMID:25634215	only alteration type		OV
WP295	ERBB4 MUT* (--)	ERBB4 (H809G)	ERBB2 inhibitors(Lapatinib,etc)	Breast adenocarcinoma	Resistant	C	NO	PMID:26530965	only alteration type		BRCA
WP295	FANCA MUT* (--), FANCA MUT* (--), FANCA MUT* (--), FANCA MUT* (--)	FANCA oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP295	FANCA MUT* (--), FANCA MUT* (--), FANCA MUT* (--), FANCA MUT* (--)	FANCA deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only gene		PRAD
WP295	TP53 MUT* (T377P)	TP53 oncogenic mutation	Abemaciclib(CDK4/CDK6 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:27217383	only alteration type		BRCA
WP295	FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Lung squamous cell	Responsive	C	NO	PMID:27870574	only gene		LUSC
WP295	FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Endometrium	Responsive	C	NO	ASCO 2017 (abstr 2500)	only gene		ED
WP295	FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Lung squamous cell	Responsive	C	NO	AACR 2012 (abstr LB-122);AACR 2013 (abstr LB-145)	only gene		LUSC
WP295	FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Head an neck	Responsive	D	NO	PMID:23418312	only gene		HNC
WP295	FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors(Lucitanib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:25193991	only gene		BRCA
WP295	ALK (A1051S)	ALK (I1171T)	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:25228534	only alteration type		LUAD
WP295	FGFR3 MUT* (V14)	FGFR3 fusion	FGFR inhibitors	Glioma	Responsive	C	NO	PMID:26324363	only gene		G
WP295	FGFR3 MUT* (V14)	FGFR3 oncogenic mutation	FGFR inhibitors	Bladder	Responsive	C	NO	PMID:27870574	only alteration type		BLCA
WP295	FGFR3 MUT* (V14)	FGFR3 (K650,Y373C)	FGFR inhibitors	Myeloma	Responsive	D	YES	PMID:16091734;PMID:20439987;PMID:22869148	only alteration type		MYMA
WP295	FGFR3 MUT* (V14)	FGFR3 (S249C,G691R)	FGFR inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:27998968	only alteration type		LUAD
WP295	FGFR3 MUT* (V14)	FGFR3 fusion	FGFR inhibitors	Bladder	Responsive	C	NO	PMID:26324363;ASCO 2017 (abstr 2500)	only gene		BLCA
WP295	FGFR3 MUT* (V14)	FGFR3 (K650)	Bortezomib(Proteasome inhibitor)	Myeloma	Responsive	D	YES	PMID:19331127;PMID:21273588	only alteration type		MYMA
WP295	FGFR3 MUT* (V14)	FGFR3-TACC3 fusion	FGFR inhibitors(,etc)	Non-small cell lung	Responsive	D	NO	PMID:25294908	only gene		NSCLC
WP295	FGFR4 MUT* (--)	FGFR4 (N535,V550)	FGFR inhibitors	Rhabdomyosarcoma	Responsive	D	NO	PMID:19809159;PMID:24124571	only alteration type		RHBDS
WP295	FGFR3 MUT* (V14)	FGFR3 (Y373C)	Bortezomib(Proteasome inhibitor)	Myeloma	Resistant	D	YES	PMID:19331127;PMID:21273588	only alteration type		MYMA
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP295	ALK (A1051S)	ALK (G1123S)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:26134233	only alteration type		LUAD
WP295	FRS2 MUT* (--)	FRS2 amplification	FGFR inhibitors	Liposarcoma	Responsive	D	NO	PMID:23393200	only gene		LIP
WP295	IDH2 MUT* (--)	IDH2 (R140K,R172K)	AG-221(IDH2 inhibitor)	Hematologic malignancies	Responsive	C	YES	AACR 2014 (abstr CT103)	only alteration type		HEMATO
WP295	IDH2 MUT* (--)	IDH2 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Cholangiocarcinoma	Responsive	C	NO	NCT02428855	only alteration type		CH
WP295	IDH2 MUT* (--)	IDH2 (R172)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Billiary tract	Responsive	D	NO	PMID:27231123	only alteration type		BT
WP295	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP295	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	EZH2 inhibitors	Any cancer type	Resistant	D	YES	PMID:26552009	only alteration type		CANCER
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitors	Endometrium	Resistant	D	NO	PMID:22662154	only alteration type		ED
WP295	JAK2 (V617F)	JAK2 (V617F)	JAK inhibitor(alone or in combination)s	Acute myeloid leukemia	Responsive	D	YES	PMID:22829971	complete		AML
WP295	JAK2 (V617F)	JAK2 amplification	JAK inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27075627	only gene		BRCA
WP295	JAK2 (V617F)	JAK2-BRAF fusion	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22875628;PMID:22899477	only gene		ALL
WP295	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:22422826	complete		AML
WP295	JAK3 MUT* (--), JAK3 MUT* (L131M)	JAK3 (A572V,A573V)	JAK inhibitors	Lymphoma	Responsive	D	YES	PMID:22705984	only alteration type		LY
WP295	JAK3 MUT* (--), JAK3 MUT* (L131M)	JAK3 (R657Q,I87T,Q501H)	JAK inhibitors	Megakaryoblastic leukemia	Responsive	D	YES	PMID:18397343	only alteration type		MKB
WP295	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP295	MDM2 MUT* (--)	MDM2 amplification	Cisplatin(Chemotherapy)	Male germ cell tumor	Resistant	C	NO	PMID:27646943	only gene		MGCT
WP295	TP53 MUT* (T377P)	TP53 oncogenic mutation	Cisplatin(Chemotherapy)	Female germ cell tumor, Male germ cell tumor	Resistant	C	NO	PMID:27646943	only alteration type		FGCT, MGCT
WP295	ALK (A1051S)	ALK inframe insertion (1151T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only alteration type		LUAD
WP295	ALK (A1051S)	ALK oncogenic mutation	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	complete		NSCLC
WP295	ALK (A1051S)	ALK amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only gene		NSCLC
WP295	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP295	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP295	ALK (A1051S)	ALK amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only gene		LUAD
WP295	ALK (A1051S)	ALK (C1156Y,L1196M)	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:20979473	only alteration type		NSCLC
WP295	ALK (A1051S)	ALK (F1174L)	Crizotinib(ALK inhibitor)	Glioma	Resistant	D	NO	PMID:22072639	only alteration type		G
WP295	KRAS MUT* (--)	KRAS (G12)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	C	NO	PMID:24687822	only alteration type		GIST
WP295	ALK (A1051S)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784;PMID:25228534	only alteration type		LUAD
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	Trastuzumab + Lapatinib(ERBB2 mAb inhibitor + ERBB2 inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	ASCO 2015 (abstr 3508);NCT01104571;EBCC10	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	BET inhibitors	Lung	Responsive	D	NO	PMID:23129625;PMID:24045185	only alteration type		L
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4 inhibitors	Lung	Responsive	D	NO	PMID:20609353	only alteration type		L
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Lung	Responsive	C	NO	AACR 2017 (CT046)	only alteration type		L
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Cervix squamous cell	Responsive	D	NO	PMID:27167191	only alteration type		CESC
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR mAb inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24553387	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	ERK inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23614898	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	FAK inhibitors	Lung	Responsive	D	NO	PMID:23358651	only alteration type		L
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	FAS inhibitors	Lung	Responsive	C	NO	AACR 2016;abstr	only alteration type		L
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	FAS inhibitors	Lung	Responsive	C	NO	AACR 2016, abstr LB214	only alteration type		L
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	HSP90 inhibitor(in combination)s	Lung	Responsive	D	NO	PMID:23012248;PMID:21907929	only alteration type		L
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	JAK/TBK1/IKKÎµ inhibitors	Lung	Responsive	D	NO	PMID:24444711	only alteration type		L
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + BCL-XL inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23245996	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + IGF1R inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24045180	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + PI3K pathway inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:22392911	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitors	Lung, Billiary tract	Responsive	C	NO	PMID:23200175;PMID:24947927;PMID:25667274;PMID:25722381;PMID:23391555	only alteration type		L, BT
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitors	Acute myeloid leukemia, Cervix, Ovary	Responsive	D	YES	PMID:22507781;PMID:22169769;PMID:19018267	only alteration type		AML, CER, OV
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP295	KRAS MUT* (--)	KRAS (G12)	MEK inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:18701506	only alteration type		ALL
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	MTOR inhibitor + BH3 mimeticss	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24163374	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	pan-RAF inhibitors	Lung	Responsive	C	NO	AACR 2017 (abstr  CT002)	only alteration type		L
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	pan-RAF inhibitors	Endometrium	Responsive	C	NO	AACR 2016 (abstr CT005);AACR 2017 (abstr CT002)	only alteration type		ED
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Endometrium	Responsive	D	NO	PMID:21984976;PMID:22662154	only alteration type		ED
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Lung	Responsive	C	NO	PMID:25516890	only alteration type		L
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	Abemaciclib(CDK4/6 inhibitor)	Lung	Responsive	C	NO	PMID:27217383	only alteration type		L
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP295	MDM2 MUT* (--)	MDM2 amplification	MDM2 inhibitors	Liposarcoma	Responsive	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	only gene		LIP
WP295	BTK MUT* (P178T)	BTK (C481)	Ibrutinib(BTK inhibitor)	Mantle cell lymphoma	Resistant	C	YES	PMID:25082755	only alteration type		MCL
WP295	PLCG2 MUT* (--)	PLCG2 (R665W,L845F)	Ibrutinib(BTK inhibitor)	Chronic lymphocytic leukemia	Resistant	C	YES	PMID:24869598	only alteration type		CLL
WP295	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP295	MPL MUT* (P468T), MPL MUT* (P473R)	MPL (W515F)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:16834459	only alteration type		MDPS
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	Decitabine + BCL2 inhibitor(Chemotherapy + BCL2 inhibitor)	Ovary	Responsive	D	NO	PMID:25968887	only alteration type		OV
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (T674I)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome	Resistant	C	YES	PMID:12660384	only alteration type		HES
WP295	CRBN MUT* (--)	CRBN oncogenic mutation	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP295	CRBN MUT* (--)	CRBN (Q100*,R283K)	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP295	LRP1B MUT* (--)	LRP1B oncogenic mutation	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only alteration type		OV
WP295	LRP1B MUT* (--)	LRP1B deletion	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only gene		OV
WP295	STK11 MUT* (T13), KRAS MUT* (--)	STK11 oncogenic mutation + KRAS oncogenic mutation	MEK inhibitor + Docetaxel(MEK inhibitor + Chemotherapy)	Lung adenocarcinoma	Resistant	D	NO	PMID:22425996	only alteration type		LUAD
WP295	STK11 MUT* (T13), KRAS MUT* (--)	STK11 deletion + KRAS oncogenic mutation	MEK inhibitor + Docetaxel(MEK inhibitor + Chemotherapy)	Lung adenocarcinoma	Resistant	D	NO	PMID:22425996	only gene		LUAD
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	Gemcitabine + MEK inhibitor(Chemotherapy + MEK inhibitor)	Pancreas	Responsive	C	NO	PMID:23583440	only alteration type		PA
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	Selumetinib(MEK inhibitor)	Non-small cell lung	Responsive	C	NO	NCT00890825	only alteration type		NSCLC
WP295	NOTCH1 (P913T), NOTCH1 (G193V), NOTCH1 (C111F)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP295	NOTCH1 (P913T), NOTCH1 (G193V), NOTCH1 (C111F)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP295	NOTCH1 (P913T), NOTCH1 (G193V), NOTCH1 (C111F)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP295	NOTCH1 (P913T), NOTCH1 (G193V), NOTCH1 (C111F)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP295	NOTCH1 (P913T), NOTCH1 (G193V), NOTCH1 (C111F)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP295	NOTCH1 (P913T), NOTCH1 (G193V), NOTCH1 (C111F)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP295	NOTCH1 (P913T), NOTCH1 (G193V), NOTCH1 (C111F)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP295	NOTCH1 (P913T), NOTCH1 (G193V), NOTCH1 (C111F)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	complete		MCL
WP295	NOTCH1 (P913T), NOTCH1 (G193V), NOTCH1 (C111F)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP295	NOTCH1 (P913T), NOTCH1 (G193V), NOTCH1 (C111F)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP295	NOTCH1 (P913T), NOTCH1 (G193V), NOTCH1 (C111F)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP295	NOTCH2 MUT* (H385N), NOTCH2 MUT* (--), NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP295	NOTCH2 MUT* (H385N), NOTCH2 MUT* (--), NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP295	NOTCH2 MUT* (H385N), NOTCH2 MUT* (--), NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP295	NPM1 MUT* (--), NPM1 MUT* (--), NPM1 MUT* (--)	NPM1 oncogenic mutation	DOT1L inhibitors + MLL1 inhibitors	Acute myeloid leukemia	Responsive	D	YES	PMID:27535106	only alteration type		AML
WP295	NRAS MUT* (--)	NRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26658964;NCT01781572;NCT02065063;NCT02022982;ASCO 2014 (abstr 9009)	only alteration type		CM
WP295	NRAS MUT* (--)	NRAS (G12C)	ERK inhibitors	Any cancer type	Responsive	D	YES	PMID:23614898	only alteration type		CANCER
WP295	NRAS MUT* (--)	NRAS oncogenic mutation	ERK inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		CM
WP295	NRAS MUT* (--)	NRAS oncogenic mutation	HSP90 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:23538902	only alteration type		CM
WP295	NRAS MUT* (--)	NRAS oncogenic mutation	MEK inhibitor +/- PI3K pathway inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23274911;PMID:22392911	only alteration type		COREAD
WP295	NRAS MUT* (--)	NRAS oncogenic mutation	MEK inhibitors	Acute myeloid leukemia, Lung adenocarcinoma, Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22507781;PMID:23515407;PMID:18701506	only alteration type		AML, LUAD, ALL
WP295	NRAS MUT* (--)	NRAS (Q61)	MEK inhibitors	Cutaneous melanoma	Responsive	B	NO	PMID:23414587,ASCO 2016 (abstr 9500)	only alteration type		CM
WP295	NRAS MUT* (--)	NRAS oncogenic mutation	Pan-RAF inhibitors	Cutaneous melanoma	Responsive	C	NO	ESMO 2015 (abstract 300);AACR 2017 (abstr CT002)	only alteration type		CM
WP295	NRAS MUT* (--)	NRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Myeloma	Responsive	D	YES	PMID:22985491	only alteration type		MYMA
WP295	CRBN MUT* (--)	CRBN oncogenic mutation	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP295	CRBN MUT* (--)	CRBN (Q100*,R283K)	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP295	NRAS MUT* (--)	NRAS oncogenic mutation	Sorafenib + MEK inhibitor(Pan-TK inhibitor + MEK inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:25294897	only alteration type		HC
WP295	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP295	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP295	NTRK3 MUT* (--)	NTRK3 fusion	IGF1R inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP295	NTRK3 MUT* (--)	NTRK3 fusion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP295	NTRK3 MUT* (--)	NTRK3 fusion	Midostaurin(Pan-TK inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP295	PBRM1 MUT* (--), PBRM1 MUT* (--), PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP295	PBRM1 MUT* (--), PBRM1 MUT* (--), PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	HSP90 inhibitors	Gastrointestinal stromal	Responsive	D	NO	PMID:18794084	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Crenolanib(FLT3 inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2016 (abstr 11010)	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	Crenolanib(FLT3 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (P577S,R841K,H845Y,G853D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	Sorafenib + MEK inhibitor(Pan-TK inhibitor + MEK inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:25294897	only alteration type		HC
WP295	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	AKT inhibitors	Glioma	Responsive	D	NO	PMID:23166678	only alteration type		G
WP295	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	PI3K pathway inhibitors	Endometrium	Responsive	C	NO	ASCO 2015 (abstr 11075)	only alteration type		ED
WP295	PTCH1 MUT* (T314)	PTCH1 oncogenic mutation	SMO inhibitors	Medulloblastoma	Responsive	D	NO	PMID:24651015	only alteration type		MB
WP295	PTCH1 MUT* (T314)	PTCH1 oncogenic mutation	Foretinib(MET inhibitor)	Medulloblastoma	Responsive	D	NO	PMID:25391241	only alteration type		MB
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP295	RAD51C MUT* (G153)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
WP295	RAD51C MUT* (G153)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP295	SERPINB3 MUT* (--), SERPINB3 MUT* (--)	SERPINB3 oncogenic mutation	CTLA4 inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:27668655	only alteration type		CM
WP295	SMARCA4 (R1387L)	SMARCA4 oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	C	NO	ESMO 2015 (abstract 302)	complete		OV
WP295	SMARCA4 (R1387L), SMARCA4 MUT* (--)	SMARCA4 deletion	EZH2 inhibitors	Ovary	Responsive	C	NO	ESMO 2015 (abstract 302)	only gene		OV
WP295	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib + Ponatinib(MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27338794	only alteration type		LUAD
WP295	STAG2 MUT* (--)	STAG2 oncogenic mutation	PARP inhibitors	Glioma	Responsive	D	NO	PMID:24356817	only alteration type		G
WP295	STK11 MUT* (T13)	STK11 oncogenic mutation	MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:19165201	only alteration type		LUAD
WP295	STK11 MUT* (T13)	STK11 deletion	MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:19165201	only gene		LUAD
WP295	STK11 MUT* (T13)	STK11 oncogenic mutation	MTOR inhibitors	Any cancer type	Responsive	D	YES	PMID:19541609	only alteration type		CANCER
WP295	STK11 MUT* (T13)	STK11 deletion	MTOR inhibitors	Any cancer type	Responsive	D	YES	PMID:19541609	only gene		CANCER
WP295	STK11 MUT* (T13)	STK11 oncogenic mutation	SRC inhibitor + PI3K/MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:20541700	only alteration type		LUAD
WP295	STK11 MUT* (T13)	STK11 deletion	SRC inhibitor + PI3K/MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:20541700	only gene		LUAD
WP295	STK11 MUT* (T13)	STK11 (D194E)	Everolimus(MTOR inhibitor)	Pancreas	Responsive	C	NO	PMID:21189378	only alteration type		PA
WP295	STK11 MUT* (T13)	STK11 oncogenic mutation	Phenformin(Anti-diabetic)	Lung adenocarcinoma	Responsive	D	NO	PMID:23352126	only alteration type		LUAD
WP295	STK11 MUT* (T13)	STK11 deletion	Phenformin(Anti-diabetic)	Lung adenocarcinoma	Responsive	D	NO	PMID:23352126	only gene		LUAD
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP295	SUZ12 (D496Y)	SUZ12 oncogenic mutation	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	complete		CANCER
WP295	SUZ12 (D496Y)	SUZ12 deletion	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only gene		CANCER
WP295	TMPRSS2 MUT* (--)	TMPRSS2 fusion	DNA-PKc inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575865	only gene		PRAD
WP295	TMPRSS2 MUT* (--)	TMPRSS2 fusion	PARP inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575865	only gene		PRAD
WP295	TOP2A MUT* (I699)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP295	TP53 MUT* (T377P)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
WP295	TP53 MUT* (T377P)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
WP295	TP53 MUT* (T377P)	TP53 oncogenic mutation	WEE1 inhibitors	Head an neck	Responsive	D	NO	PMID:25125259	only alteration type		HNC
WP295	TP53 MUT* (T377P)	TP53 oncogenic mutation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP295	TP53 MUT* (T377P)	TP53 deletion	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only gene		BCL
WP295	NRAS MUT* (--)	NRAS oncogenic mutation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:20179705	only alteration type		CM
WP295	TP53 MUT* (T377P)	TP53 oncogenic mutation	Decitabine(Chemotherapy)	Acute myeloid leukemia, Myelodisplasic proliferative syndrome	Responsive	C	YES	PMID:27959731	only alteration type		AML, MDPS
WP295	TP53 MUT* (T377P)	TP53 oncogenic mutation	Doxorubicin(Anthracycline antitumor antibiotic)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP295	TP53 MUT* (T377P)	TP53 oncogenic mutation	Gemcitabine(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP295	TP53 MUT* (T377P)	TP53 oncogenic mutation	Mitomycin C(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP295	TP53 MUT* (T377P)	TP53 oncogenic mutation	WEE1 inhibitors	Ovary	Responsive	C	NO	PMID:27998224	only alteration type		OV
WP295	TP53 MUT* (T377P)	TP53 oncogenic mutation	Pramlintide(Amylin analogue)	Thymic	Responsive	D	YES	PMID:25409149	only alteration type		THYM
WP295	TP53 MUT* (T377P)	TP53 deletion	Pramlintide(Amylin analogue)	Thymic	Responsive	D	YES	PMID:25409149	only gene		THYM
WP295	NTRK3 MUT* (--)	NTRK3 (G623R)	novel TRK inhibitors	Any cancer type	Responsive	C	YES	PMID:28578312	only alteration type		CANCER
WP295	TSC2 (P1493Q)	TSC2 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	complete		RA
WP295	TSC2 (P1493Q)	TSC2 oncogenic mutation	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	complete		LAM
WP295	TSC2 MUT* (--), TSC2 MUT* (--), TSC2 MUT* (--), TSC2 (P1493Q)	TSC2 deletion	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	only gene		LAM
WP295	TSC2 (P1493Q)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	complete		BLCA
WP295	TSC2 MUT* (--), TSC2 MUT* (--), TSC2 MUT* (--), TSC2 (P1493Q)	TSC2 (Q1178*)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:25295501	only alteration type		THCA
WP295	TSC2 MUT* (--), TSC2 MUT* (--), TSC2 MUT* (--), TSC2 (P1493Q)	TSC2 (E66K)	Tensirolimus(MTOR inhibitor)	Endometrium	Responsive	C	NO	PMID:27016228	only alteration type		ED
WP295	EWSR1 MUT* (--), EWSR1 MUT* (R495S)	EWSR1-FLI1 fusion	T + K + 2 + 1 + 6	Ewing sarcoma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EWSR1	only gene		EWS
WP295	FGFR1 MUT* (--)	FGFR1 amplification	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Lung squamous cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		LUSC
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
WP295	MDM2 MUT* (--)	MDM2 amplification	Unii-Q8Mi0X869M	Liposarcoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MDM2	only gene		LIP
WP295	ALK (A1051S)	ALK fusion	Crizotinib + Ceritinib	Sarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only gene		S
WP295	ALK (A1051S)	ALK (G1202R,I1171N)	Alectinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only alteration type		NSCLC
WP295	NRAS MUT* (--)	NRAS (Q61K,T50I,G13D,G60E,G12C,G12V,T58I,.,Q61H,G12R,G12D,Q61L,G13V,Q61R)	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	oncokb: oncokb=https://www.oncokb.org/gene/NRAS	only alteration type		COREAD
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib	Gastrointestinal stromal	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP295	NTRK3 MUT* (--)	NTRK3 fusion	Entrectinib	Any cancer type	Responsive	B	YES	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/3985/summary|oncokb=https://www.oncokb.org/gene/NTRK3	only gene		CANCER
WP295	KDM6A MUT* (--), KDM6A MUT* (--)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
WP295	KDM6A MUT* (--), KDM6A MUT* (--)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only alteration type		BLCA
WP295	NRAS MUT* (--)	NRAS (Q61K,T50I,G13D,G60E,G12C,G12V,T58I,.,Q61H,G12R,G12D,Q61L,G13V,Q61R)	Binimetinib + Binimetinib + Ribociclib	Cutaneous melanoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/NRAS	only alteration type		CM
WP295	FGFR3 MUT* (V14)	FGFR3 (S249C,S371C,R248C,K650.,G380R,Y373C,G370C)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only alteration type		BLCA
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (N659K,V561D,V561A,N659S,A633T,H845Y,T674I,S584L,D842V,N659R,D568N,P577S,D846Y,Q579R,D842Y,Y849S,N848K,H650Q,D842I,V469A,Y288C,Y555C,R748G,Y849C,.,R841K,G853D,V536E,V658A)	Imatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA amplification	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-BCR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-CDK5RAP2 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-ETV6 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-KDR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-KIF5B fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-STRN fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP295	TSC2 (P1493Q)	TSC2 (S1653P,Q1503P,R905G,L830R,A889P,L146R,T1203K,V1673F,W1610G,V769E,C696Y,F615S,E75G,L448P,V299G,R611W,R1200W,R505Q,Q1554H,G1567D,G1596V,Y1571N,I427M,S1498N,L1584R,P1709L,L844R,V705E,R905Q,Y598C,L410R,R462C,R611Q,R905W,A614D,.,S1653F,P1675L,H1620R,S1036P,H597Y,L493P,T1623I,V1673D,V705M,L826P,L792R,A328P,L493V)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	complete		RCCC
WP295	TSC2 MUT* (--), TSC2 MUT* (--), TSC2 MUT* (--), TSC2 (P1493Q)	TSC2 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	only gene		RCCC
WP295	FGFR3 MUT* (V14)	FGFR3 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		BLCA
WP295	KRAS MUT* (--)	KRAS (D119N,G12F,F156L,G60R,F28L,A18D,Q22K,K147E,D33E,A146T,E62K,A146V,Q61R,Q61H,G12A,G12R,G13E,Q22R,V14I,Y71H,G13D,G12C,T58I,.,D153V,A59G,K117N,S65N,P34L,Y64A,G13V,K5N,Y32S,L19F,T74P,G13C,G12V,G12D,Q22E,Q61L,G12S,P34R)	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/30/summary|oncokb=https://www.oncokb.org/gene/KRAS	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS amplification	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only gene		COREAD
WP295	KRAS MUT* (--)	KRAS (D119N,G12F,F156L,G60R,F28L,A18D,Q22K,K147E,D33E,A146T,E62K,A146V,Q61R,Q61H,G12A,G12R,G13E,Q22R,V14I,Y71H,G13D,G12C,T58I,.,D153V,A59G,K117N,S65N,P34L,Y64A,K5N,Y32S,L19F,T74P,G13C,G12V,G12D,Q22E,Q61L,G12S,P34R)	Cobimetinib + Binimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only alteration type		CANCER
WP295	KRAS MUT* (--)	KRAS amplification	Cobimetinib + Binimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only gene		CANCER
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP295	NF1 MUT* (--), NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP295	FGFR1 MUT* (--)	FGFR1 amplification	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP295	FGFR1 MUT* (--)	FGFR1-BCR fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP295	FGFR1 MUT* (--)	FGFR1-CEP110 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP295	FGFR1 MUT* (--)	FGFR1-CUX1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP295	FGFR1 MUT* (--)	FGFR1-ERLIN2 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP295	FGFR1 MUT* (--)	FGFR1-TACC1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP295	FGFR1 MUT* (--)	FGFR1-FGFR1OP1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP295	FGFR1 MUT* (--)	FGFR1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP295	FGFR1 MUT* (--)	FGFR1 (V592M,K687E,.,N577K)	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only alteration type		CANCER
WP295	FGFR1 MUT* (--)	FGFR1-ZNF198 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP295	JAK2 (V617F)	JAK2-PCM1 fusion	Ruxolitinib	Eosinophilic chronic leukemia	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/JAK2	only gene		ECL
WP295	ALK (A1051S)	ALK (C1156Y,F1174L,L1196M,G1269A)	Crizotinib	Non-small cell lung	Resistant	D	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary	only alteration type		NSCLC
WP295	NRAS MUT* (--)	NRAS (Q61K,T50I,G13D,G60E,G12C,G12V,T58I,.,Q61H,G12R,G12D,Q61L,G13V,Q61R)	Selumetinib	Thyroid carcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/NRAS	only alteration type		THCA
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
WP295	FGFR3 MUT* (V14)	FGFR3 (M528I,D641N,R669G,Y373C,K650T,G370C,S249C,S371C,A391E,G380R,I538V,D641G,N540K,R248C,V555M,.,K650E,K650R,K650M,G375C,G382D,N540S,Y647C,K650Q,K650N)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only alteration type		CANCER
WP295	FGFR3 MUT* (V14)	FGFR3 amplification	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP295	FGFR3 MUT* (V14)	FGFR3-BAIAP2L1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP295	FGFR3 MUT* (V14)	FGFR3-TACC3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP295	FGFR3 MUT* (V14)	FGFR3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP295	FGFR3 MUT* (V14)	FGFR3-IGH fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP295	NTRK3 MUT* (--)	NTRK3 (G623R)	Larotrectinib	Any cancer type	Resistant	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK3	only alteration type		CANCER
WP295	ALK (A1051S)	ALK CAD::ALK	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7481	only gene		COREAD
WP295	ALK (A1051S)	ALK CLTC::ALK	TAE684	Difuse large B Cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1261	only gene		DLBCL
WP295	ALK (A1051S)	ALK CLTC::ALK	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1265	only gene		DLBCL
WP295	ALK (A1051S)	ALK EML4::ALK	Alectinib	Mesothelioma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9228	only gene		MESO
WP295	ALK (A1051S)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/262	only gene		NSCLC
WP295	ALK (A1051S)	ALK EML4::ALK	WHI-P154	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1188	only gene		NSCLC
WP295	ALK (A1051S)	ALK EML4::ALK	Crizotinib,Retaspimycin Hydrochloride	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1203	only gene		NSCLC
WP295	ALK (A1051S)	ALK EML4::ALK	Crizotinib,Alvespimycin	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1206	only gene		NSCLC
WP295	ALK (A1051S)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1207	only gene		NSCLC
WP295	ALK (A1051S)	ALK EML4::ALK	Lorlatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1332	only gene		NSCLC
WP295	ALK (A1051S)	ALK F1174L	Crizotinib	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/125	only alteration type		NB
WP295	ALK (A1051S)	ALK F1174L	Alectinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/37	only alteration type		NB
WP295	ALK (A1051S)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/38	only alteration type		NB
WP295	ALK (A1051S)	ALK F1174L	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/142	only alteration type		NB
WP295	ALK (A1051S)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1271	only alteration type		NB
WP295	ALK (A1051S)	ALK F1174L	AZD3463	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1327	only alteration type		NB
WP295	ALK (A1051S)	ALK F1174L	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1329	only alteration type		NB
WP295	ALK (A1051S)	ALK F1174L	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/33	only alteration type		NSCLC
WP295	ALK (A1051S)	ALK F1245C	Crizotinib	Neuroblastoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1333	only alteration type		NB
WP295	ALK (A1051S)	ALK F1245C	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1330	only alteration type		NB
WP295	ALK (A1051S)	ALK F1245V	Entrectinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2987	only alteration type		NB
WP295	ALK (A1051S)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1240	only gene		ALCL
WP295	ALK (A1051S)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/7361	only gene		ALCL
WP295	ALK (A1051S)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	A	YES	https://civicdb.org/links/evidence_items/11218	only gene		ALCL
WP295	ALK (A1051S)	ALK Fusion	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1264	only gene		DLBCL
WP295	ALK (A1051S)	ALK Fusion	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1691	only gene		LUAD
WP295	ALK (A1051S)	ALK Fusion	Pemetrexed	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/945	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1175	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1187	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1198	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1199	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1200	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1201	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Retaspimycin Hydrochloride	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1202	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1272	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1273	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1279	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1282	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1419	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1577	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4835	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Alectinib,Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4858	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7284	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7285	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Lorlatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7286	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/8657	only gene		NSCLC
WP295	ALK (A1051S)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11121	only gene		NSCLC
WP295	ALK (A1051S)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1283	only alteration type		NSCLC
WP295	ALK (A1051S)	ALK I1171	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1287	only alteration type		NSCLC
WP295	ALK (A1051S)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1367	only alteration type		NSCLC
WP295	ALK (A1051S)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1284	only alteration type		NSCLC
WP295	ALK (A1051S)	ALK I1171	TAE684	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1285	only alteration type		NSCLC
WP295	ALK (A1051S)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1344	only alteration type		NSCLC
WP295	ALK (A1051S)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1368	only alteration type		NSCLC
WP295	ALK (A1051S)	ALK I1171T	Ceritinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9404	only alteration type		NB
WP295	ALK (A1051S)	ALK KANK4::ALK	Alectinib	Pancreas acinar	Responsive	C	NO	https://civicdb.org/links/evidence_items/10327	only gene		PAAC
WP295	ALK (A1051S)	ALK Mutation	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1237	complete		NSCLC
WP295	ALK (A1051S)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1239	only gene		ALCL
WP295	ALK (A1051S)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/1241	only gene		ALCL
WP295	ALK (A1051S)	ALK R1275Q	TAE684	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/48	only alteration type		NB
WP295	ALK (A1051S)	ALK R1275Q	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/39	only alteration type		NB
WP295	ALK (A1051S)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/143	only alteration type		NB
WP295	ALK (A1051S)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1270	only alteration type		NB
WP295	ALK (A1051S)	ALK R1275Q	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1331	only alteration type		NB
WP295	ASNS MUT* (K65N)	ASNS Amplification	Asparaginase	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/953	only gene		OV
WP295	BARD1 (P84Q), BARD1 (C78F)	BARD1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11209	complete		PRAD
WP295	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
WP295	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
WP295	CHEK1 MUT* (--)	CHEK1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11210	only alteration type		PRAD
WP295	CRBN MUT* (--)	CRBN Mutation	Lenalidomide,Pomalidomide	Multiple myeloma	Resistant	C	YES	https://civicdb.org/links/evidence_items/1766	only alteration type		MM
WP295	DNMT3A (F734L)	DNMT3A Mutation	Decitabine	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/1587	complete		AML
WP295	DNMT3A (F734L)	DNMT3A R882	Daunorubicin	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/11	only alteration type		AML
WP295	DNMT3A (F734L)	DNMT3A R882	Idarubicin	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/18	only alteration type		AML
WP295	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP295	ERBB3 MUT* (--)	ERBB3 V855A	Pertuzumab,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1845	only alteration type		NSCLC
WP295	ERBB4 MUT* (--)	ERBB4 Mutation	Lapatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/770	only alteration type		CM
WP295	FGFR1 MUT* (--)	FGFR1 FGFR1OP2::FGFR1	Ponatinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7380	only gene		AML
WP295	FGFR1 MUT* (--)	FGFR1 Fusion	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7375	only gene		AML
WP295	FGFR1 MUT* (--)	FGFR1 N546K	Pemigatinib	Pilocityc astrocytoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/10325	only alteration type		PIA
WP295	FGFR1 MUT* (--)	FGFR1 ZNF198::FGFR1	Midostaurin	Malignant peripheral nerve sheat tumor	Responsive	C	NO	https://civicdb.org/links/evidence_items/1104	only gene		MPN
WP295	FGFR1 MUT* (--)	FGFR1 Amplification	Infigratinib	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/1911	only gene		BLCA
WP295	FGFR1 MUT* (--)	FGFR1 Amplification	Afimoxifene	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1105	only gene		BRCA
WP295	FGFR1 MUT* (--)	FGFR1 Amplification	Infigratinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1909	only gene		BRCA
WP295	FGFR1 MUT* (--)	FGFR1 Amplification	Dovitinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1604	only gene		BRCA
WP295	FGFR1 MUT* (--)	FGFR1 Amplification	FGFR Inhibitor AZD4547	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1991	only gene		BRCA
WP295	FGFR1 MUT* (--)	FGFR1 Amplification	Pazopanib	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7246	only gene		BRCA
WP295	FGFR1 MUT* (--)	FGFR1 Amplification	Lucitanib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7488	only gene		BRCA
WP295	FGFR1 MUT* (--)	FGFR1 Amplification	PD173074	Lung squamous cell	Responsive	D	NO	https://civicdb.org/links/evidence_items/680	only gene		LUSC
WP295	FGFR1 MUT* (--)	FGFR1 Amplification	Infigratinib	Lung squamous cell	Responsive	B	NO	https://civicdb.org/links/evidence_items/1908	only gene		LUSC
WP295	FGFR1 MUT* (--)	FGFR1 Amplification	PD173074	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/686	only gene		NSCLC
WP295	FGFR1 MUT* (--)	FGFR1 Amplification	Dovitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3027	only gene		NSCLC
WP295	FGFR3 MUT* (V14)	FGFR3 FGFR3::BAIAP2L1	PD173074	Bladder	Responsive	D	NO	https://civicdb.org/links/evidence_items/144	only gene		BLCA
WP295	FGFR3 MUT* (V14)	FGFR3 Mutation	Infigratinib	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/1910	only alteration type		BLCA
WP295	FGFR3 MUT* (V14)	FGFR3 Mutation	Cisplatin,Gemcitabine	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/7566	only alteration type		BLCA
WP295	IDH2 MUT* (--)	IDH2 Mutation	Enasidenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/4833	only alteration type		AML
WP295	IDH2 MUT* (--)	IDH2 Mutation	Enasidenib	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/5069	only alteration type		AML
WP295	IDH2 MUT* (--)	IDH2 Mutation	Venetoclax	Acute myeloid leukemia	Responsive	C	YES	https://civicdb.org/links/evidence_items/8857	only alteration type		AML
WP295	JAK2 (V617F)	JAK2 Splice Site (c.1641+2T>G)	Pembrolizumab	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4825	only alteration type		CM
WP295	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP295	KMT2C MUT* (K2797X), KMT2C MUT* (--), KMT2C MUT* (S806), KMT2C MUT* (G315S), KMT2C MUT* (P309S), KMT2C MUT* (R284Q), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP295	KRAS MUT* (--)	KRAS A146	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3939	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS A146P	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2225	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS A146T	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2943	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS A146T	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3858	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS A146T	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2206	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS A146V	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2209	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS A146V	Abemaciclib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/794	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS G12/G13	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/134	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12/G13	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/135	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12/G13	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2004	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12/G13	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6293	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12/G13	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6294	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12/G13	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6295	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12/G13	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6296	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12/G13	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6363	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12/G13	Gefitinib,Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/35	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS G12/G13	Trametinib,Gemcitabine	Pancreas adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/622	only alteration type		PAAD
WP295	KRAS MUT* (--)	KRAS G12/G13	Trametinib	Pancreas adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/990	only alteration type		PAAD
WP295	KRAS MUT* (--)	KRAS G12A	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3710	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12A	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4429	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12A	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6319	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12A	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/251	only alteration type		LUAD
WP295	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2009	only alteration type		MM
WP295	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2012	only alteration type		MM
WP295	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2013	only alteration type		MM
WP295	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2014	only alteration type		MM
WP295	KRAS MUT* (--)	KRAS G12C	Gefitinib,Erlotinib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1216	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12C	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2253	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12C	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3967	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12C	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3973	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12C	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2212	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2258	only alteration type		MM
WP295	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2261	only alteration type		MM
WP295	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2262	only alteration type		MM
WP295	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2263	only alteration type		MM
WP295	KRAS MUT* (--)	KRAS G12C	Docetaxel,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1142	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS G12C	Sotorasib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/9431	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS G12D	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3957	only alteration type		CM
WP295	KRAS MUT* (--)	KRAS G12D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2193	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2207	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2236	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12D	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3946	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12D	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6316	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12D	Therapeutic Tumor Infiltrating Lymphocytes	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1898	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12D	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2218	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12D	Vemurafenib	Hairy-Cell leukemia	Resistant	C	YES	https://civicdb.org/links/evidence_items/1580	only alteration type		HCL
WP295	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2247	only alteration type		MM
WP295	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2250	only alteration type		MM
WP295	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2251	only alteration type		MM
WP295	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2252	only alteration type		MM
WP295	KRAS MUT* (--)	KRAS G12D	Dabrafenib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/91	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS G12D	Selumetinib,Dactolisib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/305	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS G12D	Cetuximab	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/3958	only alteration type		OV
WP295	KRAS MUT* (--)	KRAS G12R	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2264	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12R	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3987	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12R	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3989	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12R	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3991	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12S	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2269	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12S	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4006	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12S	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4012	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12S	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6314	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2274	only alteration type		MM
WP295	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2277	only alteration type		MM
WP295	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2278	only alteration type		MM
WP295	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2279	only alteration type		MM
WP295	KRAS MUT* (--)	KRAS G12V	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/136	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12V	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2219	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12V	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2232	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12V	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3824	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12V	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3924	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12V	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6323	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12V	Dactolisib,Selumetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2001	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G12V	Palbociclib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/795	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS G12V	Selumetinib,Docetaxel	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1143	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS G13D	Pictilisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2041	only alteration type		BRCA
WP295	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/806	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1180	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1181	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G13D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2178	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3878	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3881	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3882	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G13D	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3889	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G13D	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6320	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G13D	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6322	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/145	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/306	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G13D	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2183	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS G13V	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6312	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Mutation	Vemurafenib,Dabrafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6264	only alteration type		CM
WP295	KRAS MUT* (--)	KRAS Mutation	Bevacizumab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1139	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Mutation	Ixazomib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1182	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1702	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3704	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	A	NO	https://civicdb.org/links/evidence_items/5345	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Mutation	Immunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/943	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Mutation	Cetuximab,Dasatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/947	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Mutation	B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/988	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Mutation	Trametinib,Afatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/991	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Mutation	MEK Inhibitor RO4987655	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/998	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Mutation	Refametinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1001	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Mutation	Selumetinib,Teprotumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1004	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Mutation	Selumetinib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4866	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Mutation	Palbociclib,Binimetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4869	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Mutation	Temsirolimus,Ridaforolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/894	only alteration type		ED
WP295	KRAS MUT* (--)	KRAS Mutation	Sorafenib,Refametinib	Hepatic carcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1642	only alteration type		HC
WP295	KRAS MUT* (--)	KRAS Mutation	Salirasib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1218	only alteration type		LUAD
WP295	KRAS MUT* (--)	KRAS Mutation	MEK Inhibitor RO4987655	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/997	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2242	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Gefitinib,Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2385	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Selumetinib	Non-small cell lung	Resistant	A	NO	https://civicdb.org/links/evidence_items/2998	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/3895	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/989	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Trametinib,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/992	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/999	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1220	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Erlotinib,Teprotumumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3713	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Abemaciclib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4842	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Pemetrexed,Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4862	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Nivolumab,Atezolizumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4863	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4867	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Erlotinib,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4868	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4996	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Docetaxel	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4997	only alteration type		NSCLC
WP295	KRAS MUT* (--)	KRAS Mutation	Decitabine	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/820	only alteration type		OV
WP295	KRAS MUT* (--)	KRAS Mutation	PI3Kbeta Inhibitor AZD8186,SCH772984	Pancreas adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1003	only alteration type		PAAD
WP295	KRAS MUT* (--)	KRAS Q61	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3917	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Q61H	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3861	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Q61H	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3862	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Q61K	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3872	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Q61L	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3867	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Q61R	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3870	only alteration type		COREAD
WP295	KRAS MUT* (--)	KRAS Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6317	only gene		CM
WP295	MAPK1 MUT* (--), MAPK1 MUT* (--)	MAPK1 E322K	Erlotinib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/791	only alteration type		HNSC
WP295	MAPK1 MUT* (--), MAPK1 MUT* (--)	MAPK1 Amplification	WZ4002	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/792	only gene		NSCLC
WP295	MRE11 MUT* (--)	MRE11 Loss	Talazoparib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/876	only gene		ED
WP295	NOTCH1 (P913T), NOTCH1 (G193V), NOTCH1 (C111F)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP295	NPM1 MUT* (--), NPM1 MUT* (--), NPM1 MUT* (--)	NPM1 W288FS	NSC348884	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/152	only alteration type		AML
WP295	NRAS MUT* (--)	NRAS G12C	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3845	only alteration type		COREAD
WP295	NRAS MUT* (--)	NRAS G12D	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2002	only alteration type		COREAD
WP295	NRAS MUT* (--)	NRAS G12D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3693	only alteration type		COREAD
WP295	NRAS MUT* (--)	NRAS G13D	Tanespimycin	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/21	only alteration type		CM
WP295	NRAS MUT* (--)	NRAS G13R	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2204	only alteration type		COREAD
WP295	NRAS MUT* (--)	NRAS G13R	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3842	only alteration type		COREAD
WP295	NRAS MUT* (--)	NRAS Mutation	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/996	only alteration type		CM
WP295	NRAS MUT* (--)	NRAS Mutation	Dabrafenib,Vemurafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6263	only alteration type		CM
WP295	NRAS MUT* (--)	NRAS Mutation	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1227	only alteration type		CM
WP295	NRAS MUT* (--)	NRAS Mutation	Trametinib,Omipalisib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1429	only alteration type		CM
WP295	NRAS MUT* (--)	NRAS Mutation	Binimetinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1509	only alteration type		CM
WP295	NRAS MUT* (--)	NRAS Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1703	only alteration type		COREAD
WP295	NRAS MUT* (--)	NRAS Mutation	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2210	only alteration type		COREAD
WP295	NRAS MUT* (--)	NRAS Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	A	NO	https://civicdb.org/links/evidence_items/5344	only alteration type		COREAD
WP295	NRAS MUT* (--)	NRAS Q179X	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4785	only alteration type		COREAD
WP295	NRAS MUT* (--)	NRAS Q61	Vemurafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/14	only alteration type		CM
WP295	NRAS MUT* (--)	NRAS Q61	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/36	only alteration type		COREAD
WP295	NRAS MUT* (--)	NRAS Q61	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/124	only alteration type		COREAD
WP295	NRAS MUT* (--)	NRAS Q61H	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3690	only alteration type		COREAD
WP295	NRAS MUT* (--)	NRAS Q61K	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2189	only alteration type		COREAD
WP295	NRAS MUT* (--)	NRAS Q61K	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2192	only alteration type		COREAD
WP295	NRAS MUT* (--)	NRAS Q61K	Everolimus,Binimetinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1002	only alteration type		NB
WP295	NRAS MUT* (--)	NRAS Q61K	Selumetinib,Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2907	only alteration type		NSCLC
WP295	NRAS MUT* (--)	NRAS Q61L	Temozolomide	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/22	only alteration type		CM
WP295	NRAS MUT* (--)	NRAS Q61L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2181	only alteration type		COREAD
WP295	NRAS MUT* (--)	NRAS Q61R	Temozolomide	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/23	only alteration type		CM
WP295	NRAS MUT* (--)	NRAS Q61R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2184	only alteration type		COREAD
WP295	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP295	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP295	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP295	NTRK3 MUT* (--)	NTRK3 EML4::NTRK3	Entrectinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11099	only gene		LUAD
WP295	NTRK3 MUT* (--)	NTRK3 EML4::NTRK3	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/10636	only gene		NSCLC
WP295	NTRK3 MUT* (--)	NTRK3 ETV6::NTRK3	Entrectinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7994	only gene		AML
WP295	NTRK3 MUT* (--)	NTRK3 ETV6::NTRK3	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/7496	only gene		SOLID
WP295	NTRK3 MUT* (--)	NTRK3 F617L	Larotrectinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/9592	only alteration type		GIST
WP295	NTRK3 MUT* (--)	NTRK3 Fusion	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/6568	only gene		SOLID
WP295	NTRK3 MUT* (--)	NTRK3 Fusion	Entrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/11125	only gene		SOLID
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842I	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/43	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/15	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/16	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/651	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/738	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2478	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4597	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/44	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842Y	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/45	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842_I843delinsVM	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/47	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA FIP1L1::PDGFRA	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7378	only gene		AML
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA G853D	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1977	only alteration type		CM
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA H845Y	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1976	only alteration type		CM
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA I843DEL	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/46	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA I843DEL	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1309	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA Mutation	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2487	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA P577S	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1974	only alteration type		CM
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA R841K	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1975	only alteration type		CM
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA V561A	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/652	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA V561D	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2474	only alteration type		GIST
WP295	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA Amplification	Sunitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1771	only gene		NSCLC
WP295	PDGFRB MUT* (--)	PDGFRB Fusion	Imatinib	Malignant peripheral nerve sheat tumor	Responsive	A	NO	https://civicdb.org/links/evidence_items/1498	only gene		MPN
WP295	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP295	PIK3R1 MUT* (--)	PIK3R1 Mutation	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1612	only alteration type		BRCA
WP295	POLD1 MUT* (--)	POLD1 C284Y	Pembrolizumab	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4776	only alteration type		LUAD
WP295	POLD1 MUT* (--)	POLD1 E374K	Pembrolizumab	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4777	only alteration type		NSCLC
WP295	RAC1 MUT* (--)	RAC1 P29S	Dabrafenib,Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/873	only alteration type		CM
WP295	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP295	SMARCA4 (R1387L), SMARCA4 MUT* (--)	SMARCA4 Loss	Abemaciclib,Palbociclib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/7155	only gene		NSCLC
WP295	STK11 MUT* (T13)	STK11 Mutation	Pembrolizumab,Nivolumab,Atezolizumab	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6441	only alteration type		LUAD
WP295	STK11 MUT* (T13)	STK11 Loss	Selumetinib,Docetaxel	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1144	only gene		NSCLC
WP295	STK11 MUT* (T13)	STK11 Loss	Everolimus,Sirolimus	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1620	only gene		NSCLC
WP295	TOP1 MUT* (--)	TOP1 Amplification	Irinotecan	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/888	only gene		COREAD
WP295	TP53 MUT* (T377P)	TP53 M237I	MDM2 Inhibitor AMGMDS3	Glioblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4885	only alteration type		GB
WP295	TP53 MUT* (T377P)	TP53 Mutation	Tamoxifen	Breast adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2784	only alteration type		BRCA
WP295	TP53 MUT* (T377P)	TP53 Mutation	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/851	only alteration type		BRCA
WP295	TP53 MUT* (T377P)	TP53 Mutation	Selumetinib,Docetaxel	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1145	only alteration type		NSCLC
WP295	TP53 MUT* (T377P)	TP53 Mutation	Pazopanib,Vorinostat	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/7540	only alteration type		SOLID
WP295	TP53 MUT* (T377P)	TP53 Mutation	Chemotherapy	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/850	only alteration type		ST
WP295	TP53 MUT* (T377P)	TP53 R175H	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/319	only alteration type		BRCA
WP295	TP53 MUT* (T377P)	TP53 R249	Doxorubicin	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/399	only alteration type		BRCA
WP295	TP53 MUT* (T377P)	TP53 R273H	Methotrexate,Doxorubicin	Osteosarcoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/7430	only alteration type		OS
WP295	TP53 MUT* (T377P)	TP53 R273L	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2286	only alteration type		OV
WP295	TP53 MUT* (T377P)	TP53 Y234C	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2745	only alteration type		OV
WP295	TP53 MUT* (T377P)	TP53 Loss	Docetaxel	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1146	only gene		NSCLC
WP295	TSC2 MUT* (--), TSC2 MUT* (--), TSC2 MUT* (--), TSC2 (P1493Q)	TSC2 Q1178*	Everolimus	Thyroid carcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1108	only alteration type		THCA
WP297	ALK MUT* (T1026P)	ALK fusion	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	FDA	only gene		LUAD
WP297	ALK MUT* (T1026P)	ALK fusion	Alectinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK inframe insertion (1151T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165	only alteration type		LUAD
WP297	ALK MUT* (T1026P)	ALK (L1196M,S1206Y,G1269A,I1171T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165;PMID:24327273	only alteration type		LUAD
WP297	ALK MUT* (T1026P)	ALK fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK fusion	Brigatinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc	only gene		NSCLC
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP297	KRAS MUT* (--)	KRAS (12,13)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS (12,13,59,61,117,146)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	NCCN guidelines	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	NCCN guidelines	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR inhibitors	Lung	Resistant	A	NO	NCCN guidelines	only alteration type		L
WP297	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP297	TPMT MUT* (--)	TPMT splice acceptor variant	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP297	TPMT MUT* (--)	TPMT biallelic inactivation	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP297	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP297	TPMT MUT* (--)	TPMT splice acceptor variant	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP297	TPMT MUT* (--)	TPMT biallelic inactivation	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP297	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP297	TPMT MUT* (--)	TPMT splice acceptor variant	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP297	TPMT MUT* (--)	TPMT biallelic inactivation	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP297	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP297	ALK MUT* (T1026P)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP297	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP297	KRAS MUT* (--)	KRAS (G12C)	Sotorasib(RAS GTPase family inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc	only alteration type		NSCLC
WP297	ROS1 MUT* (--)	ROS1 fusion	Entrectinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA;PMID:28183697;ESMO 2019 (abstr 4178) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725s007lbl.pdf	only gene		NSCLC
WP297	KRAS MUT* (--)	KRAS (G12C)	Adagrasib(RAS GTPase family inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc	only alteration type		NSCLC
WP297	ALK MUT* (T1026P)	ALK fusion	Crizotinib(ALK inhibitor)	Anaplastic large cell lymphoma	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large	only gene		ALCL
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP297	ATM MUT* (--)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP297	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP297	ALK MUT* (T1026P)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP297	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP297	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP297	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP297	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP297	KRAS MUT* (--)	KRAS (G12C)	Adagrasib(RAS GTPase family inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP297	ALK MUT* (T1026P)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor	only gene		IM
WP297	ALK MUT* (T1026P)	ALK fusion	Alectinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP297	ALK MUT* (T1026P)	ALK fusion	Brigatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP297	ALK MUT* (T1026P)	ALK fusion	Ceritinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP297	ALK MUT* (T1026P)	ALK fusion	Lorlatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP297	ROS1 MUT* (--)	ROS1 fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP297	ROS1 MUT* (--)	ROS1 fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP297	KRAS MUT* (--)	KRAS (G12C)	Sotorasib(RAS GTPase family inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP297	AKT2 MUT* (--)	AKT2 amplification	MK2206(Allosteric AKT inhibitor)	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 373)	only gene		CANCER
WP297	ALK MUT* (T1026P)	ALK fusion	ALK inhibitor + IGF1R inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25173427	only gene		LUAD
WP297	ALK MUT* (T1026P)	ALK fusion	ALK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:26301689	only gene		LUAD
WP297	ALK MUT* (T1026P)	ALK fusion	ALK inhibitor + SRC inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25394791	only gene		LUAD
WP297	ALK MUT* (T1026P)	ALK fusion	ALK inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560	only gene		COREAD
WP297	ALK MUT* (T1026P)	ALK fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23553849	only gene		LUAD
WP297	ALK MUT* (T1026P)	ALK fusion	novel ALK inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23639470	only gene		LUAD
WP297	ALK MUT* (T1026P)	ALK (F1174L)	novel ALK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24327273	only alteration type		LUAD
WP297	ALK MUT* (T1026P)	ALK amplification	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only gene		LUAD
WP297	ALK MUT* (T1026P)	ALK (E1408V)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP297	ALK MUT* (T1026P)	ALK (L1196M)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP297	ALK MUT* (T1026P)	ALK fusion	Ceritinib(ALK inhibitor)	Colorectal adenocarcinoma, Inflammatory myofibroblastic	Responsive	C	YES	PMID:26633560;PMID:26933125;PMID:27742657	only gene		COREAD, IM
WP297	ALK MUT* (T1026P)	ALK fusion	Ceritinib(ALK inhibitor)	Hematologic malignancies	Responsive	C	YES	NCT02186821	only gene		HEMATO
WP297	ALK MUT* (T1026P)	ALK fusion	Crizotinib(ALK inhibitor)	Lymphoma, Glioblastoma	Responsive	C	YES	PMID:24491302;NCT02270034	only gene		LY, GB
WP297	ALK MUT* (T1026P)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic, Thyroid carcinoma	Responsive	C	YES	PMID:20979472;PMID:24687827	only gene		IM, THCA
WP297	ALK MUT* (T1026P)	ALK (F856S,A348D)	Crizotinib(ALK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:26032424	only alteration type		AML
WP297	ALK MUT* (T1026P)	ALK (L1198F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26698910	only alteration type		LUAD
WP297	ALK MUT* (T1026P)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib(ALK inhibitor)	Glioma	Responsive	D	NO	PMID:22072639	only alteration type		G
WP297	ALK MUT* (T1026P)	ALK fusion	Entrectinib(Pan-TK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560;PMID:26933125	only gene		COREAD
WP297	ALK MUT* (T1026P)	ALK (C1156Y)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27401242	only alteration type		LUAD
WP297	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	complete		CANCER
WP297	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	complete		OV
WP297	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	complete		CANCER
WP297	ATM MUT* (--)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only alteration type		COREAD
WP297	ATM MUT* (--)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
WP297	ATM MUT* (--)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only alteration type		LY
WP297	ATM MUT* (--)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only gene		LY
WP297	ATM MUT* (--)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP297	ATM MUT* (--)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
WP297	ATM MUT* (--)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP297	ATM MUT* (--)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP297	ATM MUT* (--)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP297	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP297	ATM MUT* (--)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP297	JAK1 MUT* (G898)	JAK1 oncogenic mutation	PD1 inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:27903500	only alteration type		COREAD
WP297	JAK1 MUT* (G898)	JAK1 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	only alteration type		CM
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Pancreas	No Responsive	C	NO	ASCO 2015 (abstr 4119)	only alteration type		PA
WP297	KRAS MUT* (--)	KRAS (G13D)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	No Responsive	B	NO	PMID:27114605	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	Selumetinib(MEK inhibitor)	Lung	No Responsive	C	NO	PMID:26802155	only alteration type		L
WP297	KRAS MUT* (--)	KRAS amplification	BRAF inhibitor + EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only gene		COREAD
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP297	KRAS MUT* (--)	KRAS amplification	BRAF inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only gene		COREAD
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR inhibitors	Non-small cell lung	Resistant	D	NO	PMID:19238210	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR mAb inhibitors	Stomach	Resistant	D	NO	PMID:22614881;PMID:22290393	only alteration type		ST
WP297	MAP2K2 (V85G)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP297	MAP2K2 (V85G)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP297	MAP2K2 (V85G)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP297	MAP2K2 (V85G)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP297	MITF MUT* (T95)	MITF amplification	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265153	only gene		CM
WP297	MITF MUT* (T95)	MITF amplification	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265153	only gene		CM
WP297	FANCC MUT* (--)	FANCC oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP297	FANCC MUT* (--)	FANCC deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP297	ALK MUT* (T1026P)	ALK (I1171T)	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:25228534	only alteration type		LUAD
WP297	ALK MUT* (T1026P)	ALK (G1123S)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:26134233	only alteration type		LUAD
WP297	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP297	GNAQ MUT* (T96S)	GNAQ (Q209)	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	NCT01587352	only alteration type		CM
WP297	GNAQ MUT* (T96S)	GNAQ (Q209)	PI3K pathway inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22733540;PMID:22808163	only alteration type		CM
WP297	GNAQ MUT* (T96S)	GNAQ (Q209)	PKC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22653968;PMID:22253748	only alteration type		CM
WP297	GNAQ MUT* (T96S)	GNAQ (Q209)	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr CRA9003)	only alteration type		CM
WP297	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP297	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	EZH2 inhibitors	Any cancer type	Resistant	D	YES	PMID:26552009	only alteration type		CANCER
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitors	Endometrium	Resistant	D	NO	PMID:22662154	only alteration type		ED
WP297	JAK1 MUT* (G898)	JAK1 (S646F;R683)	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22955920;PMID:18805579	only alteration type		ALL
WP297	JAK3 MUT* (--), JAK3 MUT* (--)	JAK3 (A572V,A573V)	JAK inhibitors	Lymphoma	Responsive	D	YES	PMID:22705984	only alteration type		LY
WP297	JAK3 MUT* (--), JAK3 MUT* (--)	JAK3 (R657Q,I87T,Q501H)	JAK inhibitors	Megakaryoblastic leukemia	Responsive	D	YES	PMID:18397343	only alteration type		MKB
WP297	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP297	ALK MUT* (T1026P)	ALK inframe insertion (1151T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only alteration type		LUAD
WP297	ALK MUT* (T1026P)	ALK oncogenic mutation	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only alteration type		NSCLC
WP297	ALK MUT* (T1026P)	ALK amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only gene		NSCLC
WP297	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP297	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP297	ALK MUT* (T1026P)	ALK amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only gene		LUAD
WP297	ALK MUT* (T1026P)	ALK (C1156Y,L1196M)	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:20979473	only alteration type		NSCLC
WP297	ALK MUT* (T1026P)	ALK (F1174L)	Crizotinib(ALK inhibitor)	Glioma	Resistant	D	NO	PMID:22072639	only alteration type		G
WP297	KRAS MUT* (--)	KRAS (G12)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	C	NO	PMID:24687822	only alteration type		GIST
WP297	ALK MUT* (T1026P)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784;PMID:25228534	only alteration type		LUAD
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	Trastuzumab + Lapatinib(ERBB2 mAb inhibitor + ERBB2 inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	ASCO 2015 (abstr 3508);NCT01104571;EBCC10	only alteration type		COREAD
WP297	ROS1 MUT* (--)	ROS1 (G2032R)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:23724914;PMID:25688157	only alteration type		LUAD
WP297	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	BET inhibitors	Lung	Responsive	D	NO	PMID:23129625;PMID:24045185	only alteration type		L
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4 inhibitors	Lung	Responsive	D	NO	PMID:20609353	only alteration type		L
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Lung	Responsive	C	NO	AACR 2017 (CT046)	only alteration type		L
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Cervix squamous cell	Responsive	D	NO	PMID:27167191	only alteration type		CESC
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR mAb inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24553387	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	ERK inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23614898	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	FAK inhibitors	Lung	Responsive	D	NO	PMID:23358651	only alteration type		L
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	FAS inhibitors	Lung	Responsive	C	NO	AACR 2016;abstr	only alteration type		L
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	FAS inhibitors	Lung	Responsive	C	NO	AACR 2016, abstr LB214	only alteration type		L
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	HSP90 inhibitor(in combination)s	Lung	Responsive	D	NO	PMID:23012248;PMID:21907929	only alteration type		L
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	JAK/TBK1/IKKÎµ inhibitors	Lung	Responsive	D	NO	PMID:24444711	only alteration type		L
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + BCL-XL inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23245996	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + IGF1R inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24045180	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + PI3K pathway inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:22392911	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitors	Lung, Billiary tract	Responsive	C	NO	PMID:23200175;PMID:24947927;PMID:25667274;PMID:25722381;PMID:23391555	only alteration type		L, BT
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitors	Acute myeloid leukemia, Cervix, Ovary	Responsive	D	YES	PMID:22507781;PMID:22169769;PMID:19018267	only alteration type		AML, CER, OV
WP297	KRAS MUT* (--)	KRAS (G12)	MEK inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:18701506	only alteration type		ALL
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	MTOR inhibitor + BH3 mimeticss	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24163374	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	pan-RAF inhibitors	Lung	Responsive	C	NO	AACR 2017 (abstr  CT002)	only alteration type		L
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	pan-RAF inhibitors	Endometrium	Responsive	C	NO	AACR 2016 (abstr CT005);AACR 2017 (abstr CT002)	only alteration type		ED
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Endometrium	Responsive	D	NO	PMID:21984976;PMID:22662154	only alteration type		ED
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Lung	Responsive	C	NO	PMID:25516890	only alteration type		L
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	Abemaciclib(CDK4/6 inhibitor)	Lung	Responsive	C	NO	PMID:27217383	only alteration type		L
WP297	MDM4 MUT* (--)	MDM4 amplification	MDM2/MDMX inhibitors	Sarcoma	Responsive	D	NO	PMID:24336067	only gene		S
WP297	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	Decitabine + BCL2 inhibitor(Chemotherapy + BCL2 inhibitor)	Ovary	Responsive	D	NO	PMID:25968887	only alteration type		OV
WP297	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP297	CRBN MUT* (--)	CRBN oncogenic mutation	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP297	CRBN MUT* (--)	CRBN (Q100*,R283K)	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	Gemcitabine + MEK inhibitor(Chemotherapy + MEK inhibitor)	Pancreas	Responsive	C	NO	PMID:23583440	only alteration type		PA
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	Selumetinib(MEK inhibitor)	Non-small cell lung	Responsive	C	NO	NCT00890825	only alteration type		NSCLC
WP297	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP297	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP297	NOTCH1 MUT* (T311P)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP297	NOTCH1 MUT* (T311P)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP297	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP297	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP297	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP297	NOTCH1 MUT* (T311P)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	only alteration type		MCL
WP297	NOTCH1 MUT* (T311P)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP297	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP297	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP297	CRBN MUT* (--)	CRBN oncogenic mutation	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP297	CRBN MUT* (--)	CRBN (Q100*,R283K)	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP297	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP297	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP297	PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP297	PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP297	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP297	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP297	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	Sorafenib + MEK inhibitor(Pan-TK inhibitor + MEK inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:25294897	only alteration type		HC
WP297	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	AKT inhibitors	Glioma	Responsive	D	NO	PMID:23166678	only alteration type		G
WP297	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	PI3K pathway inhibitors	Endometrium	Responsive	C	NO	ASCO 2015 (abstr 11075)	only alteration type		ED
WP297	POLE MUT* (--)	POLE (268-471)	PD1 Ab inhibitors	Glioma, Endometrium	Responsive	C	NO	PMID:27001570;PMID:27683556;PMID:27159395	only alteration type		G, ED
WP297	POLE MUT* (--)	POLE oncogenic mutation	PD1 Ab inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28188185	only alteration type		COREAD
WP297	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP297	ROS1 MUT* (--)	ROS1 fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:23533265	only gene		LUAD
WP297	ROS1 MUT* (--)	ROS1 fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27370605	only gene		LUAD
WP297	ROS1 MUT* (--)	ROS1 (G2032R)	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:25351743	only alteration type		LUAD
WP297	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	C	YES	PMID:24875859	only gene		IM
WP297	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:25264305	only gene		LUAD
WP297	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27401242	only alteration type		LUAD
WP297	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib + Ponatinib(MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27338794	only alteration type		LUAD
WP297	TERT MUT* (--)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP297	TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP297	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
WP297	ALK MUT* (T1026P)	ALK fusion	Crizotinib + Ceritinib	Sarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only gene		S
WP297	ALK MUT* (T1026P)	ALK (G1202R,I1171N)	Alectinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only alteration type		NSCLC
WP297	KDM6A MUT* (--)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
WP297	KDM6A MUT* (--)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only alteration type		BLCA
WP297	KRAS MUT* (--)	KRAS (D119N,G12F,F156L,G60R,F28L,A18D,Q22K,K147E,D33E,A146T,E62K,A146V,Q61R,Q61H,G12A,G12R,G13E,Q22R,V14I,Y71H,G13D,G12C,T58I,.,D153V,A59G,K117N,S65N,P34L,Y64A,G13V,K5N,Y32S,L19F,T74P,G13C,G12V,G12D,Q22E,Q61L,G12S,P34R)	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/30/summary|oncokb=https://www.oncokb.org/gene/KRAS	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS amplification	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only gene		COREAD
WP297	KRAS MUT* (--)	KRAS (D119N,G12F,F156L,G60R,F28L,A18D,Q22K,K147E,D33E,A146T,E62K,A146V,Q61R,Q61H,G12A,G12R,G13E,Q22R,V14I,Y71H,G13D,G12C,T58I,.,D153V,A59G,K117N,S65N,P34L,Y64A,K5N,Y32S,L19F,T74P,G13C,G12V,G12D,Q22E,Q61L,G12S,P34R)	Cobimetinib + Binimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only alteration type		CANCER
WP297	KRAS MUT* (--)	KRAS amplification	Cobimetinib + Binimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only gene		CANCER
WP297	ATM MUT* (--)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only alteration type		CANCER
WP297	ATM MUT* (--)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
WP297	ALK MUT* (T1026P)	ALK (C1156Y,F1174L,L1196M,G1269A)	Crizotinib	Non-small cell lung	Resistant	D	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary	only alteration type		NSCLC
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
WP297	AKT2 MUT* (--)	AKT2 Amplification	Everolimus,Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1621	only gene		LUAD
WP297	ALK MUT* (T1026P)	ALK CAD::ALK	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7481	only gene		COREAD
WP297	ALK MUT* (T1026P)	ALK CLTC::ALK	TAE684	Difuse large B Cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1261	only gene		DLBCL
WP297	ALK MUT* (T1026P)	ALK CLTC::ALK	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1265	only gene		DLBCL
WP297	ALK MUT* (T1026P)	ALK EML4::ALK	Alectinib	Mesothelioma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9228	only gene		MESO
WP297	ALK MUT* (T1026P)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/262	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK EML4::ALK	WHI-P154	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1188	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK EML4::ALK	Crizotinib,Retaspimycin Hydrochloride	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1203	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK EML4::ALK	Crizotinib,Alvespimycin	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1206	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1207	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK EML4::ALK	Lorlatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1332	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK F1174L	Crizotinib	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/125	only alteration type		NB
WP297	ALK MUT* (T1026P)	ALK F1174L	Alectinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/37	only alteration type		NB
WP297	ALK MUT* (T1026P)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/38	only alteration type		NB
WP297	ALK MUT* (T1026P)	ALK F1174L	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/142	only alteration type		NB
WP297	ALK MUT* (T1026P)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1271	only alteration type		NB
WP297	ALK MUT* (T1026P)	ALK F1174L	AZD3463	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1327	only alteration type		NB
WP297	ALK MUT* (T1026P)	ALK F1174L	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1329	only alteration type		NB
WP297	ALK MUT* (T1026P)	ALK F1174L	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/33	only alteration type		NSCLC
WP297	ALK MUT* (T1026P)	ALK F1245C	Crizotinib	Neuroblastoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1333	only alteration type		NB
WP297	ALK MUT* (T1026P)	ALK F1245C	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1330	only alteration type		NB
WP297	ALK MUT* (T1026P)	ALK F1245V	Entrectinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2987	only alteration type		NB
WP297	ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1240	only gene		ALCL
WP297	ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/7361	only gene		ALCL
WP297	ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	A	YES	https://civicdb.org/links/evidence_items/11218	only gene		ALCL
WP297	ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1264	only gene		DLBCL
WP297	ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1691	only gene		LUAD
WP297	ALK MUT* (T1026P)	ALK Fusion	Pemetrexed	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/945	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1175	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1187	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1198	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1199	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1200	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1201	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Retaspimycin Hydrochloride	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1202	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1272	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1273	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1279	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1282	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1419	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1577	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4835	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Alectinib,Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4858	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7284	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7285	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Lorlatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7286	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/8657	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11121	only gene		NSCLC
WP297	ALK MUT* (T1026P)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1283	only alteration type		NSCLC
WP297	ALK MUT* (T1026P)	ALK I1171	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1287	only alteration type		NSCLC
WP297	ALK MUT* (T1026P)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1367	only alteration type		NSCLC
WP297	ALK MUT* (T1026P)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1284	only alteration type		NSCLC
WP297	ALK MUT* (T1026P)	ALK I1171	TAE684	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1285	only alteration type		NSCLC
WP297	ALK MUT* (T1026P)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1344	only alteration type		NSCLC
WP297	ALK MUT* (T1026P)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1368	only alteration type		NSCLC
WP297	ALK MUT* (T1026P)	ALK I1171T	Ceritinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9404	only alteration type		NB
WP297	ALK MUT* (T1026P)	ALK KANK4::ALK	Alectinib	Pancreas acinar	Responsive	C	NO	https://civicdb.org/links/evidence_items/10327	only gene		PAAC
WP297	ALK MUT* (T1026P)	ALK Mutation	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1237	only alteration type		NSCLC
WP297	ALK MUT* (T1026P)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1239	only gene		ALCL
WP297	ALK MUT* (T1026P)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/1241	only gene		ALCL
WP297	ALK MUT* (T1026P)	ALK R1275Q	TAE684	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/48	only alteration type		NB
WP297	ALK MUT* (T1026P)	ALK R1275Q	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/39	only alteration type		NB
WP297	ALK MUT* (T1026P)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/143	only alteration type		NB
WP297	ALK MUT* (T1026P)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1270	only alteration type		NB
WP297	ALK MUT* (T1026P)	ALK R1275Q	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1331	only alteration type		NB
WP297	ATM MUT* (--)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	only alteration type		CM
WP297	ATM MUT* (--)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	only alteration type		GB
WP297	ATM MUT* (--)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	only alteration type		PRAD
WP297	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
WP297	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
WP297	CRBN MUT* (--)	CRBN Mutation	Lenalidomide,Pomalidomide	Multiple myeloma	Resistant	C	YES	https://civicdb.org/links/evidence_items/1766	only alteration type		MM
WP297	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP297	GNAQ MUT* (T96S)	GNAQ Mutation	JQ1	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1210	only alteration type		UVM
WP297	GNAQ MUT* (T96S)	GNAQ Mutation	Trametinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1229	only alteration type		UVM
WP297	GNAQ MUT* (T96S)	GNAQ Mutation	Mirdametinib,Sotrastaurin Acetate	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1953	only alteration type		UVM
WP297	GNAQ MUT* (T96S)	GNAQ Mutation	Cabozantinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5068	only alteration type		UVM
WP297	GNAQ MUT* (T96S)	GNAQ Q209	Selumetinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1213	only alteration type		UVM
WP297	GNAQ MUT* (T96S)	GNAQ Q209	Refametinib	Uveal melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1233	only alteration type		UVM
WP297	JAK1 MUT* (G898)	JAK1 S703I	Ruxolitinib	Hepatic carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1900	only alteration type		HC
WP297	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP297	KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (S768), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP297	KRAS MUT* (--)	KRAS A146	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3939	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS A146P	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2225	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS A146T	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2943	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS A146T	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3858	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS A146T	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2206	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS A146V	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2209	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS A146V	Abemaciclib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/794	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS G12/G13	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/134	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12/G13	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/135	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12/G13	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2004	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12/G13	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6293	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12/G13	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6294	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12/G13	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6295	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12/G13	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6296	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12/G13	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6363	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12/G13	Gefitinib,Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/35	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS G12/G13	Trametinib,Gemcitabine	Pancreas adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/622	only alteration type		PAAD
WP297	KRAS MUT* (--)	KRAS G12/G13	Trametinib	Pancreas adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/990	only alteration type		PAAD
WP297	KRAS MUT* (--)	KRAS G12A	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3710	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12A	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4429	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12A	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6319	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12A	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/251	only alteration type		LUAD
WP297	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2009	only alteration type		MM
WP297	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2012	only alteration type		MM
WP297	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2013	only alteration type		MM
WP297	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2014	only alteration type		MM
WP297	KRAS MUT* (--)	KRAS G12C	Gefitinib,Erlotinib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1216	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12C	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2253	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12C	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3967	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12C	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3973	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12C	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2212	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2258	only alteration type		MM
WP297	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2261	only alteration type		MM
WP297	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2262	only alteration type		MM
WP297	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2263	only alteration type		MM
WP297	KRAS MUT* (--)	KRAS G12C	Docetaxel,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1142	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS G12C	Sotorasib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/9431	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS G12D	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3957	only alteration type		CM
WP297	KRAS MUT* (--)	KRAS G12D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2193	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2207	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2236	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12D	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3946	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12D	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6316	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12D	Therapeutic Tumor Infiltrating Lymphocytes	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1898	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12D	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2218	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12D	Vemurafenib	Hairy-Cell leukemia	Resistant	C	YES	https://civicdb.org/links/evidence_items/1580	only alteration type		HCL
WP297	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2247	only alteration type		MM
WP297	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2250	only alteration type		MM
WP297	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2251	only alteration type		MM
WP297	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2252	only alteration type		MM
WP297	KRAS MUT* (--)	KRAS G12D	Dabrafenib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/91	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS G12D	Selumetinib,Dactolisib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/305	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS G12D	Cetuximab	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/3958	only alteration type		OV
WP297	KRAS MUT* (--)	KRAS G12R	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2264	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12R	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3987	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12R	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3989	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12R	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3991	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12S	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2269	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12S	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4006	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12S	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4012	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12S	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6314	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2274	only alteration type		MM
WP297	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2277	only alteration type		MM
WP297	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2278	only alteration type		MM
WP297	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2279	only alteration type		MM
WP297	KRAS MUT* (--)	KRAS G12V	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/136	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12V	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2219	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12V	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2232	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12V	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3824	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12V	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3924	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12V	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6323	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12V	Dactolisib,Selumetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2001	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G12V	Palbociclib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/795	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS G12V	Selumetinib,Docetaxel	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1143	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS G13D	Pictilisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2041	only alteration type		BRCA
WP297	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/806	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1180	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1181	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G13D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2178	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3878	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3881	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3882	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G13D	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3889	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G13D	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6320	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G13D	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6322	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/145	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/306	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G13D	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2183	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS G13V	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6312	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Mutation	Vemurafenib,Dabrafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6264	only alteration type		CM
WP297	KRAS MUT* (--)	KRAS Mutation	Bevacizumab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1139	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Mutation	Ixazomib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1182	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1702	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3704	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	A	NO	https://civicdb.org/links/evidence_items/5345	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Mutation	Immunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/943	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Mutation	Cetuximab,Dasatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/947	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Mutation	B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/988	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Mutation	Trametinib,Afatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/991	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Mutation	MEK Inhibitor RO4987655	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/998	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Mutation	Refametinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1001	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Mutation	Selumetinib,Teprotumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1004	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Mutation	Selumetinib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4866	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Mutation	Palbociclib,Binimetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4869	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Mutation	Temsirolimus,Ridaforolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/894	only alteration type		ED
WP297	KRAS MUT* (--)	KRAS Mutation	Sorafenib,Refametinib	Hepatic carcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1642	only alteration type		HC
WP297	KRAS MUT* (--)	KRAS Mutation	Salirasib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1218	only alteration type		LUAD
WP297	KRAS MUT* (--)	KRAS Mutation	MEK Inhibitor RO4987655	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/997	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2242	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Gefitinib,Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2385	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Selumetinib	Non-small cell lung	Resistant	A	NO	https://civicdb.org/links/evidence_items/2998	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/3895	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/989	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Trametinib,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/992	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/999	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1220	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Erlotinib,Teprotumumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3713	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Abemaciclib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4842	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Pemetrexed,Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4862	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Nivolumab,Atezolizumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4863	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4867	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Erlotinib,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4868	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4996	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Docetaxel	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4997	only alteration type		NSCLC
WP297	KRAS MUT* (--)	KRAS Mutation	Decitabine	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/820	only alteration type		OV
WP297	KRAS MUT* (--)	KRAS Mutation	PI3Kbeta Inhibitor AZD8186,SCH772984	Pancreas adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1003	only alteration type		PAAD
WP297	KRAS MUT* (--)	KRAS Q61	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3917	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Q61H	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3861	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Q61H	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3862	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Q61K	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3872	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Q61L	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3867	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Q61R	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3870	only alteration type		COREAD
WP297	KRAS MUT* (--)	KRAS Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6317	only gene		CM
WP297	NOTCH1 MUT* (T311P)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP297	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP297	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP297	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP297	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP297	PIK3R1 MUT* (--)	PIK3R1 Mutation	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1612	only alteration type		BRCA
WP297	POLE MUT* (--)	POLE Mutation	Pembrolizumab	Endometrium	Responsive	C	NO	https://civicdb.org/links/evidence_items/1862	only alteration type		ED
WP297	PREX2 MUT* (--)	PREX2 R172I	Vemurafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6268	only alteration type		CM
WP297	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP297	RAC1 MUT* (--)	RAC1 P29S	Dabrafenib,Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/873	only alteration type		CM
WP297	ROS1 MUT* (--)	ROS1 Rearrangement	Ceritinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1248	only gene		LUAD
WP297	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1690	only gene		LUAD
WP297	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/688	only gene		NSCLC
WP297	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1030	only gene		NSCLC
WP297	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7933	only gene		NSCLC
WP297	ROS1 MUT* (--)	ROS1 FUSIONS	Entrectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11123	only gene		NSCLC
WP297	ROS1 MUT* (--)	ROS1 Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7282	only gene		NSCLC
WP297	ROS1 MUT* (--)	ROS1 G2032R	Crizotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2934	only alteration type		LUAD
WP297	ROS1 MUT* (--)	ROS1 GOPC::ROS1	Lorlatinib	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7483	only gene		GB
WP297	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP297	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	FDA	only gene		LUAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Alectinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK inframe insertion (1151T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165	only alteration type		LUAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK (L1196M,S1206Y,G1269A,I1171T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165;PMID:24327273	only alteration type		LUAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene	758.0	NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Brigatinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc	only gene		NSCLC
WP126	DNMT3A MUT* (P282S)	DNMT3A oncogenic mutation	Daunorubicin(Chemotherapy)	Acute myeloid leukemia	Responsive	A	YES	PMID:22417203	only alteration type		AML
WP126	G6PD MUT* (--)	G6PD biallelic inactivation	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP126	G6PD MUT* (--)	G6PD (S218F)	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP126	G6PD MUT* (--), G6PD MUT* (--)	G6PD (V98M) + G6PD (N156D)	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP126	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Myelofibrosis	Responsive	A	YES	FDA	complete		MY
WP126	RET MUT* (G792)	RET (618,620,634,768,791,891,918,C634W,M918T)	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	A	NO	PMID:20065189;PMID:22025146	only alteration type		THCA
WP126	RET MUT* (G792)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-ret-altered-thyroid-cancers;ASCO 2020 (abstr 109)	only gene		TH
WP126	RET MUT* (G792)	RET oncogenic mutation	Selpercatinib(RET kinase inhibitor)	Thyroid medullary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only alteration type		THM
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP126	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP126	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP126	MET MUT* (--)	MET exon 14 skipping mutations	Tepotinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer;PMID:31279006;PMID:34036238	only alteration type		NSCLC
WP126	MET MUT* (--)	MET exon 14 skipping mutations	Capmatinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capmatinib-metastatic-non-small-cell-lung-cancer	only alteration type		NSCLC
WP126	RET MUT* (G792)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions	only gene		NSCLC
WP126	RET MUT* (G792)	RET fusion	Selpercatinib(RET kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-non-small-cell-lung	only gene		NSCLC
WP126	RAD51D MUT* (--)	RAD51D oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP126	NTRK3 MUT* (--)	NTRK3 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
WP126	NTRK3 MUT* (--)	NTRK3 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
WP126	NTRK3 MUT* (--)	NTRK3 (F617L,G623R,G696A)	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Resistant	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf	only alteration type		SOLID
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Crizotinib(ALK inhibitor)	Anaplastic large cell lymphoma	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large	only gene		ALCL
WP126	RET MUT* (G792)	RET fusion	Selpercatinib(RET kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only gene		TH
WP126	RET MUT* (G792)	RET fusion	Selpercatinib(RET kinase inhibitor)	Solid tumors	Responsive	A	NO	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors	only gene		SOLID
WP126	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP126	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP126	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP126	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP126	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP126	RET MUT* (G792)	RET fusion	Cabozantinib(Kinase inhibitor )	Non-small cell lung	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor	only gene		IM
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Alectinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Brigatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Ceritinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Lorlatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP126	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene	758.0	NSCLC
WP126	MET MUT* (--)	MET amplification	Capmatinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP126	MET MUT* (--)	MET amplification	Tepotinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP126	MET MUT* (--)	MET exon 14 skipping mutations	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type	758.0	NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	ALK inhibitor + IGF1R inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25173427	only gene		LUAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	ALK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:26301689	only gene		LUAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	ALK inhibitor + SRC inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25394791	only gene		LUAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	ALK inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560	only gene		COREAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23553849	only gene		LUAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	novel ALK inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23639470	only gene		LUAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK (F1174L)	novel ALK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24327273	only alteration type		LUAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK amplification	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only gene		LUAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK (E1408V)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK (L1196M)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Ceritinib(ALK inhibitor)	Colorectal adenocarcinoma, Inflammatory myofibroblastic	Responsive	C	YES	PMID:26633560;PMID:26933125;PMID:27742657	only gene		COREAD, IM
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Ceritinib(ALK inhibitor)	Hematologic malignancies	Responsive	C	YES	NCT02186821	only gene		HEMATO
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Crizotinib(ALK inhibitor)	Lymphoma, Glioblastoma	Responsive	C	YES	PMID:24491302;NCT02270034	only gene		LY, GB
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic, Thyroid carcinoma	Responsive	C	YES	PMID:20979472;PMID:24687827	only gene		IM, THCA
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK (F856S,A348D)	Crizotinib(ALK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:26032424	only alteration type		AML
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK (L1198F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26698910	only alteration type	758.0	LUAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib(ALK inhibitor)	Glioma	Responsive	D	NO	PMID:22072639	only alteration type		G
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Entrectinib(Pan-TK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560;PMID:26933125	only gene		COREAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK (C1156Y)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27401242	only alteration type		LUAD
WP126	JAK2 (V617F)	JAK2 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	complete		CM
WP126	MAP2K2 (V85G)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP126	MAP2K2 (V85G)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP126	MAP2K2 (V85G)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP126	MAP2K2 (V85G)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP126	MET MUT* (--)	MET amplification	EGFR inhibitor 1st gens	Non-small cell lung, Colorectal adenocarcinoma	Resistant	C	NO	PMID:22189054;PMID:23729478	only gene		NSCLC, COREAD
WP126	MET MUT* (--)	MET amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:23729478	only gene		COREAD
WP126	MET MUT* (--)	MET (D1246V)	MET inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:27694386	only alteration type		LUAD
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP126	NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP126	EPHA2 MUT* (--)	EPHA2 (G391R)	MTOR inhibitors	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
WP126	EPHA2 MUT* (--)	EPHA2 (G391R)	MTOR inhibitors	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
WP126	EPHA2 MUT* (--)	EPHA2 amplification	Dasatinib(BCR-ABL inhibitor 2nd gen)	Any cancer type	Responsive	D	YES	PMID:18047674;PMID:19010823;PMID:19861960	only gene		CANCER
WP126	EPHA2 MUT* (--)	EPHA2 amplification	Dasatinib(BCR-ABL inhibitor 2nd gen)	Any cancer type	Responsive	D	YES	PMID:18047674;PMID:19010823;PMID:19861960	only gene		CANCER
WP126	EPHA2 MUT* (--)	EPHA2 (G391R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
WP126	EPHA2 MUT* (--)	EPHA2 (G391R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK (I1171T)	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:25228534	only alteration type		LUAD
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP126	NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK (G1123S)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:26134233	only alteration type		LUAD
WP126	GNAQ MUT* (--)	GNAQ (Q209)	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	NCT01587352	only alteration type		CM
WP126	GNAQ MUT* (--)	GNAQ (Q209)	PI3K pathway inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22733540;PMID:22808163	only alteration type		CM
WP126	GNAQ MUT* (--)	GNAQ (Q209)	PKC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22653968;PMID:22253748	only alteration type		CM
WP126	GNAQ MUT* (--)	GNAQ (Q209)	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr CRA9003)	only alteration type		CM
WP126	GNAS MUT* (--)	GNAS (R201)	JAK inhibitors	Any cancer type	Responsive	D	YES	PMID:21835143	only alteration type		CANCER
WP126	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP126	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP126	JAK2 (V617F)	JAK2 (V617F)	JAK inhibitor(alone or in combination)s	Acute myeloid leukemia	Responsive	D	YES	PMID:22829971	complete		AML
WP126	JAK2 (V617F)	JAK2 amplification	JAK inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27075627	only gene		BRCA
WP126	JAK2 (V617F)	JAK2-BRAF fusion	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22875628;PMID:22899477	only gene		ALL
WP126	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:22422826	complete		AML
WP126	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK inframe insertion (1151T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only alteration type		LUAD
WP126	ALK (F921L), ALK (G920V)	ALK oncogenic mutation	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	complete		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only gene		NSCLC
WP126	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP126	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only gene		LUAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK (C1156Y,L1196M)	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:20979473	only alteration type		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK (F1174L)	Crizotinib(ALK inhibitor)	Glioma	Resistant	D	NO	PMID:22072639	only alteration type		G
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784;PMID:25228534	only alteration type		LUAD
WP126	MET MUT* (--)	MET (Y1230C,Y1235D)	Crizotinib(ALK inhibitor)	Any cancer type	Resistant	D	YES	PMID:17483355	only alteration type		CANCER
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP126	NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP126	NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP126	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP126	NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP126	NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP126	MET MUT* (--)	MET kinase domain mutation	Savolitinib(MET inhibitor)	Renal	Responsive	C	NO	PMID:28644771	only alteration type		R
WP126	MET MUT* (--)	MET amplification	BCL2 inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:27397505	only gene		COREAD
WP126	MET MUT* (--)	MET amplification	MET inhibitors	Hepatic carcinoma	Responsive	C	NO	ENA 2015 (abstract A55)	only gene		HC
WP126	MET MUT* (--)	MET amplification	MET inhibitors	Stomach	Responsive	D	NO	PMID:22729845;PMID:23327903	only gene		ST
WP126	MET MUT* (--)	MET amplification	MET inhibitors	Renal	Responsive	C	NO	PMID:23213094;AACR 2016 (abstr CT2006)	only gene		R
WP126	MET MUT* (--)	MET (H1112R)	MET inhibitors	Renal	Responsive	C	NO	PMID:23213094	only alteration type		R
WP126	MET MUT* (--)	MET (M1268T)	MET inhibitors	Renal	Responsive	C	NO	PMID:23610116	only alteration type		R
WP126	MET MUT* (--)	MET (H1112L)	MET inhibitors(Crizotinib,etc)	Any cancer type	Responsive	D	YES	AACR 2012 (abstr 1786)	only alteration type		CANCER
WP126	MET MUT* (--)	MET amplification	Cabozantinib + Panitumumab(Pan-kinase inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A52)	only gene		COREAD
WP126	MET MUT* (--)	MET fusion	Crizotinib(ALK inhibitor)	Glioma	Responsive	C	NO	PMID:27748748	only gene		G
WP126	MET MUT* (--)	MET mutation in exon 16-19	Crizotinib(ALK inhibitor)	Renal	Responsive	C	NO	AACR 2016 (abstr CT2006)	only alteration type		R
WP126	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma, Stomach	Responsive	C	NO	ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1)	only gene	758.0	LUAD, ST
WP126	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Glioma	Responsive	C	NO	PMID:22162573	only gene		G
WP126	MET MUT* (--)	MET (V1110I,H1112R,M1268T,R988C,T1010I)	Crizotinib(ALK inhibitor)	Any cancer type	Responsive	D	YES	PMID:17483355	only alteration type	758.0	CANCER
WP126	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP126	NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP126	NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP126	NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP126	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP126	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP126	NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP126	NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP126	NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP126	NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP126	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP126	NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP126	NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP126	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP126	NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP126	NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP126	NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP126	NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP126	NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP126	NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP126	NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP126	NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP126	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP126	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP126	NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP126	NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP126	MET MUT* (--)	MET amplification	EGFR inhibitor 3rd gens(Osimertinib,etc)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP126	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP126	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP126	NOTCH1 MUT* (T311P)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP126	NOTCH1 MUT* (T311P)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP126	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP126	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP126	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP126	NOTCH1 MUT* (T311P)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	only alteration type		MCL
WP126	NOTCH1 MUT* (T311P)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP126	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP126	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP126	NTRK3 MUT* (--)	NTRK3 fusion	IGF1R inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP126	NTRK3 MUT* (--)	NTRK3 fusion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP126	NTRK3 MUT* (--)	NTRK3 fusion	Midostaurin(Pan-TK inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP126	PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP126	PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP126	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP126	RET MUT* (G792)	RET (I788N)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Resistant	D	NO	PMID:28615362	only alteration type		LUAD
WP126	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP126	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP126	MET MUT* (--)	MET amplification	EGFR inhibitor 3rd gens(Rociletinib,etc)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP126	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	AKT inhibitors	Glioma	Responsive	D	NO	PMID:23166678	only alteration type		G
WP126	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	PI3K pathway inhibitors	Endometrium	Responsive	C	NO	ASCO 2015 (abstr 11075)	only alteration type		ED
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP126	NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP126	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP126	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP126	RET MUT* (G792)	RET fusion	RET inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:22327624;PMID:22327622	only gene		LUAD
WP126	RET MUT* (G792)	RET-TPCN1 fusion	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only gene		TH
WP126	RET MUT* (G792)	RET (C634W,M918T)	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only alteration type		TH
WP126	RET MUT* (G792)	RET fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP126	RET MUT* (G792)	RET-TPCN1 fusion	Cabozantinib(Pan-kinase inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP126	RET MUT* (G792)	RET (C634W,M918T)	Cabozantinib(Pan-kinase inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP126	RET MUT* (G792)	RET fusion	Nintedanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26787234	only gene		LUAD
WP126	RET MUT* (G792)	RET fusion	Sunitinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP126	RET MUT* (G792)	RET-TPCN1 fusion	Sunitinib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP126	RET MUT* (G792)	RET (C634W,M918T)	Sunitinib(Pan-TK inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP126	RET MUT* (G792)	RET fusion	Vandetanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP126	RET MUT* (G792)	RET-TPCN1 fusion	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP126	RICTOR MUT* (--)	RICTOR amplification	MTORC1/2 inhibitors	Lung	Responsive	C	NO	PMID:26370156	only gene		L
WP126	STAG2 MUT* (--)	STAG2 oncogenic mutation	PARP inhibitors	Glioma	Responsive	D	NO	PMID:24356817	only alteration type		G
WP126	NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP126	SUZ12 MUT* (--)	SUZ12 oncogenic mutation	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only alteration type		CANCER
WP126	SUZ12 MUT* (--)	SUZ12 deletion	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only gene		CANCER
WP126	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP126	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP126	NTRK3 MUT* (--)	NTRK3 (G623R)	novel TRK inhibitors	Any cancer type	Responsive	C	YES	PMID:28578312	only alteration type		CANCER
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK fusion	Crizotinib + Ceritinib	Sarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only gene		S
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK (G1202R,I1171N)	Alectinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only alteration type		NSCLC
WP126	MET MUT* (--)	MET amplification	Crizotinib	Non-small cell lung	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/52/summary|oncokb=https://www.oncokb.org/gene/MET	only gene		NSCLC
WP126	MET MUT* (--)	MET (D1010H,Y1003N,D1010N,Y1003F,Y1003C,D1010Y)	Crizotinib	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP126	NTRK3 MUT* (--)	NTRK3 fusion	Entrectinib	Any cancer type	Responsive	B	YES	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/3985/summary|oncokb=https://www.oncokb.org/gene/NTRK3	only gene		CANCER
WP126	MET MUT* (--)	MET (D1010H,Y1003N,D1010N,Y1003F,Y1003C,D1010Y)	Cabozantinib + Capmatinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP126	MET MUT* (--)	MET amplification	Erlotinib + Gefitinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only gene		NSCLC
WP126	NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP126	NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP126	JAK2 (V617F)	JAK2-PCM1 fusion	Ruxolitinib	Eosinophilic chronic leukemia	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/JAK2	only gene		ECL
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK (C1156Y,F1174L,L1196M,G1269A)	Crizotinib	Non-small cell lung	Resistant	D	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary	only alteration type		NSCLC
WP126	RET MUT* (G792)	RET fusion	Cabozantinib + Vandetanib + Larotrectinib + 292 + 667	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		NSCLC
WP126	RET MUT* (G792)	RET (C618R,C620R,C609Y,E768D,C630R,S904F,E511K,C634S,C634Y,V648I,I852M,S891A,A883T,A883F,C611Y,T338I,C634W,K603Q,D631Y,M918T,A919V,R833C,.,V804M,C634R,V804L,Y806C,M918V,L790F,M848T,R886W,Y791F)	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only alteration type		THM
WP126	RET MUT* (G792)	RET fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP126	RET MUT* (G792)	RET-KIF5B fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP126	RET MUT* (G792)	RET-CCDC6 fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP126	MET MUT* (--)	MET (D1228N)	Crizotinib + Cabozantinib + Capmatinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP126	NTRK3 MUT* (--)	NTRK3 (G623R)	Larotrectinib	Any cancer type	Resistant	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK3	only alteration type		CANCER
WP126	MET MUT* (--)	MET amplification	Cabozantinib	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only gene		RCCC
WP126	MET MUT* (--)	MET (Y1230H)	Crizotinib + Capmatinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK CAD::ALK	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7481	only gene		COREAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK CLTC::ALK	TAE684	Difuse large B Cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1261	only gene		DLBCL
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK CLTC::ALK	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1265	only gene		DLBCL
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK EML4::ALK	Alectinib	Mesothelioma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9228	only gene		MESO
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/262	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK EML4::ALK	WHI-P154	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1188	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK EML4::ALK	Crizotinib,Retaspimycin Hydrochloride	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1203	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK EML4::ALK	Crizotinib,Alvespimycin	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1206	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1207	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK EML4::ALK	Lorlatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1332	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK F1174L	Crizotinib	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/125	only alteration type		NB
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK F1174L	Alectinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/37	only alteration type		NB
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/38	only alteration type		NB
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK F1174L	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/142	only alteration type		NB
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1271	only alteration type		NB
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK F1174L	AZD3463	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1327	only alteration type		NB
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK F1174L	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1329	only alteration type		NB
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK F1174L	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/33	only alteration type		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK F1245C	Crizotinib	Neuroblastoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1333	only alteration type		NB
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK F1245C	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1330	only alteration type		NB
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK F1245V	Entrectinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2987	only alteration type		NB
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1240	only gene		ALCL
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/7361	only gene		ALCL
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	A	YES	https://civicdb.org/links/evidence_items/11218	only gene		ALCL
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1264	only gene		DLBCL
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1691	only gene		LUAD
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Pemetrexed	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/945	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1175	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1187	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1198	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1199	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1200	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1201	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Retaspimycin Hydrochloride	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1202	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1272	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1273	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1279	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1282	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1419	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1577	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4835	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Alectinib,Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4858	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7284	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7285	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Lorlatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7286	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/8657	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11121	only gene		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1283	only alteration type		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK I1171	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1287	only alteration type		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1367	only alteration type		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1284	only alteration type		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK I1171	TAE684	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1285	only alteration type		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1344	only alteration type		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1368	only alteration type		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK I1171T	Ceritinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9404	only alteration type		NB
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK KANK4::ALK	Alectinib	Pancreas acinar	Responsive	C	NO	https://civicdb.org/links/evidence_items/10327	only gene		PAAC
WP126	ALK (F921L), ALK (G920V)	ALK Mutation	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1237	complete		NSCLC
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1239	only gene		ALCL
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/1241	only gene		ALCL
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK R1275Q	TAE684	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/48	only alteration type		NB
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK R1275Q	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/39	only alteration type		NB
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/143	only alteration type		NB
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1270	only alteration type		NB
WP126	ALK MUT* (G922), ALK (F921L), ALK (G920V)	ALK R1275Q	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1331	only alteration type		NB
WP126	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP126	DNMT3A MUT* (P282S)	DNMT3A Mutation	Decitabine	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/1587	only alteration type		AML
WP126	DNMT3A MUT* (P282S)	DNMT3A R882	Daunorubicin	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/11	only alteration type		AML
WP126	DNMT3A MUT* (P282S)	DNMT3A R882	Idarubicin	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/18	only alteration type		AML
WP126	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP126	GNAQ MUT* (--)	GNAQ Mutation	JQ1	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1210	only alteration type		UVM
WP126	GNAQ MUT* (--)	GNAQ Mutation	Trametinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1229	only alteration type		UVM
WP126	GNAQ MUT* (--)	GNAQ Mutation	Mirdametinib,Sotrastaurin Acetate	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1953	only alteration type		UVM
WP126	GNAQ MUT* (--)	GNAQ Mutation	Cabozantinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5068	only alteration type		UVM
WP126	GNAQ MUT* (--)	GNAQ Q209	Selumetinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1213	only alteration type		UVM
WP126	GNAQ MUT* (--)	GNAQ Q209	Refametinib	Uveal melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1233	only alteration type		UVM
WP126	GNAS MUT* (--)	GNAS R201C	Cetuximab,Vemurafenib,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1906	only alteration type		COREAD
WP126	JAK2 (V617F)	JAK2 Splice Site (c.1641+2T>G)	Pembrolizumab	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4825	only alteration type		CM
WP126	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP126	KMT2C MUT* (K2797X), KMT2C MUT* (S806), KMT2C MUT* (P335), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP126	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP126	MET MUT* (--)	MET D1228N	Crizotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1652	only alteration type		NSCLC
WP126	MET MUT* (--)	MET D1228V	Savolitinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1865	only alteration type		NSCLC
WP126	MET MUT* (--)	MET D1228V	Cabozantinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1864	only alteration type		NSCLC
WP126	MET MUT* (--)	MET MET::ATXN7L1	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7793	only gene		NSCLC
WP126	MET MUT* (--)	MET Amplification	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1971	only gene		COREAD
WP126	MET MUT* (--)	MET Amplification	Vemurafenib,Crizotinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1588	only gene		COREAD
WP126	MET MUT* (--)	MET Amplification	Crizotinib,Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1979	only gene		COREAD
WP126	MET MUT* (--)	MET Amplification	Crizotinib	Glioblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1565	only gene		GB
WP126	MET MUT* (--)	MET Amplification	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1392	only gene		LUAD
WP126	MET MUT* (--)	MET Amplification	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/836	only gene		LUAD
WP126	MET MUT* (--)	MET Amplification	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1692	only gene		LUAD
WP126	MET MUT* (--)	MET Amplification	Crizotinib	Lung squamous cell	Responsive	C	NO	https://civicdb.org/links/evidence_items/890	only gene		LUSC
WP126	MET MUT* (--)	MET Amplification	Gefitinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/733	only gene		NSCLC
WP126	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/735	only gene		NSCLC
WP126	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1566	only gene		NSCLC
WP126	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1713	only gene		NSCLC
WP126	MET MUT* (--)	MET Amplification	Onartuzumab	Stomach	Responsive	C	NO	https://civicdb.org/links/evidence_items/689	only gene		ST
WP126	MRE11 MUT* (--)	MRE11 Loss	Talazoparib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/876	only gene		ED
WP126	MS4A1 MUT* (--)	MS4A1 Mutation	R-CHOP Regimen	Difuse large B Cell lymphoma	Resistant	B	YES	https://civicdb.org/links/evidence_items/10367	only alteration type		DLBCL
WP126	NOTCH1 MUT* (T311P)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP126	NTRK3 MUT* (--)	NTRK3 EML4::NTRK3	Entrectinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11099	only gene		LUAD
WP126	NTRK3 MUT* (--)	NTRK3 EML4::NTRK3	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/10636	only gene		NSCLC
WP126	NTRK3 MUT* (--)	NTRK3 ETV6::NTRK3	Entrectinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7994	only gene		AML
WP126	NTRK3 MUT* (--)	NTRK3 ETV6::NTRK3	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/7496	only gene		SOLID
WP126	NTRK3 MUT* (--)	NTRK3 F617L	Larotrectinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/9592	only alteration type		GIST
WP126	NTRK3 MUT* (--)	NTRK3 Fusion	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/6568	only gene		SOLID
WP126	NTRK3 MUT* (--)	NTRK3 Fusion	Entrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/11125	only gene		SOLID
WP126	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP126	PIK3R1 MUT* (--)	PIK3R1 Mutation	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1612	only alteration type		BRCA
WP126	RAD51D MUT* (--)	RAD51D Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11214	only alteration type		PRAD
WP126	RET MUT* (G792)	RET CCDC6::RET	Agerafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7480	only gene		COREAD
WP126	RET MUT* (G792)	RET CCDC6::RET	Nintedanib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1601	only gene		NSCLC
WP126	RET MUT* (G792)	RET Fusion	Cabozantinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4847	only gene		LUAD
WP126	RET MUT* (G792)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4848	only gene		NSCLC
WP126	RET MUT* (G792)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4849	only gene		NSCLC
WP126	RET MUT* (G792)	RET Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4850	only gene		NSCLC
WP126	RET MUT* (G792)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7066	only gene		NSCLC
WP126	RET MUT* (G792)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/8850	only gene		NSCLC
WP126	RET MUT* (G792)	RET Fusion	Pralsetinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11233	only gene		NSCLC
WP126	RET MUT* (G792)	RET Fusion	Selpercatinib	Thyroid carcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8852	only gene		THCA
WP126	RET MUT* (G792)	RET KIF5B::RET	Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/698	only gene		LUAD
WP126	RET MUT* (G792)	RET KIF5B::RET	Vandetanib,Everolimus	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1622	only gene		LUAD
WP126	RICTOR MUT* (--)	RICTOR Amplification	Onatasertib,Sapanisertib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1440	only gene		LUAD
WP126	RICTOR MUT* (--)	RICTOR Amplification	Vistusertib	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7449	only gene		SCLC
WP126	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP126	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP126	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	FDA	only gene		LUAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Alectinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK inframe insertion (1151T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165	only alteration type		LUAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK (L1196M,S1206Y,G1269A,I1171T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165;PMID:24327273	only alteration type		LUAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene	758.0	NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Brigatinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc	only gene		NSCLC
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890	only alteration type		PRAD
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP162	DPYD MUT* (--)	DPYD splice donor variant	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
WP162	DPYD MUT* (--)	DPYD biallelic inactivation	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
WP162	DPYD MUT* (--)	DPYD (I560S,D949V)	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
WP162	DPYD MUT* (--)	DPYD splice donor variant	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
WP162	DPYD MUT* (--)	DPYD biallelic inactivation	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
WP162	DPYD MUT* (--)	DPYD (I560S,D949V)	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
WP162	DPYD MUT* (--)	DPYD splice donor variant	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
WP162	DPYD MUT* (--)	DPYD biallelic inactivation	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
WP162	DPYD MUT* (--)	DPYD (I560S,D949V)	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Ado-Trastuzumab Emtansine(EGFR mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor);Capecitabine(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s023lbl.pdf;PMID:17192538	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf	only gene		ST, GEJA
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf	only gene		BRCA
WP162	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Myelofibrosis	Responsive	A	YES	FDA	complete		MY
WP162	KIT MUT* (H650Q)	KIT mutation in exon 9,11,13,14 or 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA	complete	863.0	GIST
WP162	KIT MUT* (H650Q)	KIT mutation in exon 9,11,13,14 or 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN	complete		CM
WP162	KIT MUT* (H650Q)	KIT mutation in exon 9,11,13,14 or 17	Regorafenib(Pan-kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA	complete		GIST
WP162	KIT MUT* (H650Q)	KIT mutation in exon 9,11,13,14 or 17	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA	complete		GIST
WP162	KIT MUT* (H650Q)	KIT (D816)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal, Myelodisplasic syndrome, Myelodisplasic proliferative syndrome, Hyper eosinophilic advanced snydrome, Eosinophilic chronic leukemia, Chronic myeloid leukemia, Acute lymphoblastic leukemia, Systemic mastocytosis	Resistant	A	YES	FDA	only alteration type		GIST, MDS, MDPS, HES, ECL, CML, ALL, SM
WP162	KIT MUT* (H650Q)	KIT (T670I)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	A	NO	PMID:24687822	only alteration type		GIST
WP162	PDGFB MUT* (--)	PDGFB-COL1A1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Dermatofibrosarcoma	Responsive	A	NO	FDA	only gene		DFS
WP162	TPMT MUT* (--)	TPMT splice acceptor variant	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP162	TPMT MUT* (--)	TPMT biallelic inactivation	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP162	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP162	TPMT MUT* (--)	TPMT splice acceptor variant	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP162	TPMT MUT* (--)	TPMT biallelic inactivation	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP162	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP162	TPMT MUT* (--)	TPMT splice acceptor variant	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP162	TPMT MUT* (--)	TPMT biallelic inactivation	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP162	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP162	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		GCA
WP162	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		RA
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Neratinib(ERBB2 inhibitor) + Capecitabine(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer;PMID:30860945	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 inhibitor)+ Trastuzumab(ERBB2 inhibitor) + Docetaxel(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor) + Letrozole(Hormone therapy)	Breast adenocarcinoma	Responsive	A	NO	FDA;PMID:19786658	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Margetuximab(ERBB2 inhibitor) 	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Tucatinib(ERBB2 inhibitor) + Trastuzumab(ERBB2 inhibitor) + Capecitabine(chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer;PMID:31825569	only gene		BRCA
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Pembrolizumab(PD-1 blocking antibody) + Trastuzumab(ERBB2 mAb inhibitor) + Fluoropyrimidine (Chemotherapy) + Platinum (Chemotherapy)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer;PMID:34912120	only gene		ST, GEJA
WP162	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP162	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP162	KIT MUT* (H650Q)	KIT (Y823D,N822,C809G,D820,A829P,D816,T670I)	Ripretinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ripretinib-advanced-gastrointestinal-stromal-tumor;PMID:32511981	only alteration type		GIST
WP162	NTRK1 MUT* (--)	NTRK1 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	NO	FDA:https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
WP162	NTRK1 MUT* (--)	NTRK1 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas	only gene		ST, GEJA
WP162	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung	only alteration type		NSCLC
WP162	NTRK3 MUT* (--)	NTRK3 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
WP162	NTRK3 MUT* (--)	NTRK3 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
WP162	NTRK3 MUT* (--)	NTRK3 (F617L,G623R,G696A)	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Resistant	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf	only alteration type		SOLID
WP162	ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype	Tucatinib(ERBB2 inhibitor);Trastuzumab(ERBB2 inhibitor) 	Colorectal adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer	only gene		COREAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Crizotinib(ALK inhibitor)	Anaplastic large cell lymphoma	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large	only gene		ALCL
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP162	ATR (D584Y)	ATR oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	complete		PRAD
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP162	FANCA MUT* (--)	FANCA oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP162	MLH1 MUT* (P705H)	MLH1 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-fam-trastuzumab-deruxtecan-nxki-breast-cancer	only gene		BRCA
WP162	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP162	ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype + BRAF wildtype	Trastuzumab(ERBB2 mAb inhibitor) + Lapatinib(ERBB2 inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only gene		COREAD
WP162	NTRK1 MUT* (--)	NTRK1 (G595R)	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Resistant	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210861s008lbl.pdf	only alteration type		SOLID
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 inhibitor) + Carboplatin-Taxol(Chemotherapy)	Uterus	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf	only gene		U
WP162	ARAF MUT* (A12D)	ARAF oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP162	ARAF MUT* (A12D)	ARAF oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP162	ARAF MUT* (A12D)	ARAF oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP162	ARAF MUT* (A12D)	ARAF oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP162	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 inhibitor)+ Trastuzumab(ERBB2 inhibitor) 	Billiary tract	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf	only gene		BT
WP162	ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype + BRAF wildtype	Trastuzumab(ERBB2 mAb inhibitor) + Lapatinib(ERBB2 inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only gene		COREAD
WP162	ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype + BRAF wildtype	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only gene		COREAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor	only gene		IM
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Alectinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Brigatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Ceritinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Lorlatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP162	ARAF MUT* (A12D)	ARAF oncogenic mutation	BRAF inhibitor + EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only alteration type		COREAD
WP162	ARAF MUT* (A12D)	ARAF oncogenic mutation	BRAF inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only alteration type		COREAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	ALK inhibitor + IGF1R inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25173427	only gene		LUAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	ALK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:26301689	only gene		LUAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	ALK inhibitor + SRC inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25394791	only gene		LUAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	ALK inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560	only gene		COREAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23553849	only gene		LUAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	novel ALK inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23639470	only gene		LUAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK (F1174L)	novel ALK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24327273	only alteration type		LUAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK amplification	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only gene		LUAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK (E1408V)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK (L1196M)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Ceritinib(ALK inhibitor)	Colorectal adenocarcinoma, Inflammatory myofibroblastic	Responsive	C	YES	PMID:26633560;PMID:26933125;PMID:27742657	only gene		COREAD, IM
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Ceritinib(ALK inhibitor)	Hematologic malignancies	Responsive	C	YES	NCT02186821	only gene		HEMATO
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Crizotinib(ALK inhibitor)	Lymphoma, Glioblastoma	Responsive	C	YES	PMID:24491302;NCT02270034	only gene		LY, GB
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic, Thyroid carcinoma	Responsive	C	YES	PMID:20979472;PMID:24687827	only gene		IM, THCA
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK (F856S,A348D)	Crizotinib(ALK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:26032424	only alteration type		AML
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK (L1198F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26698910	only alteration type	758.0	LUAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib(ALK inhibitor)	Glioma	Responsive	D	NO	PMID:22072639	only alteration type		G
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Entrectinib(Pan-TK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560;PMID:26933125	only gene		COREAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK (C1156Y)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27401242	only alteration type		LUAD
WP162	APC (P1432S)	APC oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:22440753;PMID:23539443	complete		COREAD
WP162	ERBB2 MUT* (--)	ERBB2 amplification	EGFR inhibitors	Lung adenocarcinoma	Resistant	D	NO	PMID:22956644	only gene		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:22586653;PMID:23348520	only gene		COREAD
WP162	ARAF MUT* (A12D)	ARAF (S214C)	Sorafenib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	http://www.jci.org/articles/view/72763;PMID:24569458	only alteration type		LUAD
WP162	ATR (D584Y)	ATR oncogenic mutation	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	complete		OV, CANCER
WP162	ATR MUT* (G592), ATR (D584Y)	ATR deletion	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only gene		OV, CANCER
WP162	ATR (D584Y)	ATR oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	complete		G
WP162	BAP1 MUT* (--), BAP1 MUT* (--)	BAP1 oncogenic mutation	EZH2 inhibitors	Mesothelioma	Responsive	D	NO	PMID:26437366	only alteration type		MESO
WP162	BAP1 MUT* (--), BAP1 MUT* (--)	BAP1 deletion	EZH2 inhibitors	Mesothelioma	Responsive	D	NO	PMID:26437366	only gene		MESO
WP162	BAP1 MUT* (--), BAP1 MUT* (--)	BAP1 oncogenic mutation	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22038994	only alteration type		CM
WP162	BAP1 MUT* (--), BAP1 MUT* (--)	BAP1 deletion	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22038994	only gene		CM
WP162	BAP1 MUT* (--), BAP1 MUT* (--)	BAP1 oncogenic mutation	PARP inhibitors	Renal, Any cancer type	Responsive	D	YES	PMID:22683710	only alteration type		R, CANCER
WP162	BAP1 MUT* (--), BAP1 MUT* (--)	BAP1 deletion	PARP inhibitors	Renal, Any cancer type	Responsive	D	YES	PMID:22683710	only gene		R, CANCER
WP162	JAK2 (V617F)	JAK2 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	complete		CM
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	PARP inhibitors	Pancreas	Responsive	C	NO	PMID:25366685;PMID:25719666;PMID:19553641;PMID:25366685	only alteration type		PA
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 deletion	PARP inhibitors	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	C	YES	PMID:25964244	only alteration type		CANCER
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467;PMID:25366685	only alteration type		BRCA
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP162	CBL MUT* (--)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP162	CBL MUT* (--)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP162	CD274 MUT* (--), CD274 MUT* (--)	CD274 (PD-L1) amplification	PD1 Ab inhibitors	Basal cell carcinoma	Responsive	C	NO	PMID:27942391	only gene		BCC
WP162	CD274 MUT* (--), CD274 MUT* (--)	CD274 (PD-L1) amplification	PDL1 inhibitors	Any cancer type	Responsive	D	YES	PMID:25079317	only gene		CANCER
WP162	CSF1R MUT* (P453Q)	CSF1R (Y571D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:18971950	only alteration type		MDPS
WP162	ERBB2 MUT* (--)	ERBB2 amplification	ERBB2 inhibitor + CDK4/6 inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26977878	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 proximal exon 20	ERBB2 inhibitors(Afatinib,Lapatinib,Neratinib,etc)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547	only alteration type		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 proximal exon 20	ERBB2 mAb inhibitors(Trastuzumab,etc)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547	only alteration type		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 inframe insertion (A775YVMA),inframe insertion (G776VC)	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 8510)	only alteration type		L
WP162	ERBB2 MUT* (--)	ERBB2 (V659E,S310F)	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 8510)	only alteration type		L
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Stomach	Responsive	C	NO	AACR 2014 (abstr CT228)	only gene		ST
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Breast adenocarcinoma	Responsive	B	NO	PMID:20142587;PMID:22418700;PMID:23632474	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	PMID:27044931	only gene		BLCA
WP162	ERBB2 MUT* (--)	ERBB2 proximal exon 20	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 (T798I)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Breast adenocarcinoma	Responsive	D	NO	PMID:28274957	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Dacomitinib(Pan ERBB inhibitor)	Non-small cell lung	Responsive	C	NO	PMID:25899785	only alteration type		NSCLC
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
WP162	ERBB2 MUT* (--)	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 (V659E)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma, Lung adenocarcinoma	Responsive	C	NO	PMID:23950206	only alteration type		BRCA, LUAD
WP162	ERBB2 MUT* (--)	ERBB2 proximal exon 20	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib + Chemotherapy(ERBB2 inhibitor + Chemotherapy)	Stomach	Responsive	C	NO	PMID:25694417;NCT02015169	only gene		ST
WP162	ERBB2 MUT* (--)	ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Neratinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ESMO 2014 (abstr LBA39_PR)	only alteration type		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 (K753E)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:27697991	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 proximal exon 20	Neratinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 (L869R)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	C	NO	PMID:28274957	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 (S310,L755,V777)	Neratinib(ERBB2 inhibitor)	Any cancer type	Responsive	C	YES	AACR 2017 (abstr CT001)	only alteration type		CANCER
WP162	ERBB2 MUT* (--)	ERBB2 inframe insertion (P780GSP),inframe insertion (781GSP),inframe insertion (A775YVMA),inframe insertion (G776YVMA)	Neratinib(ERBB2 inhibitor)	Any cancer type	Responsive	C	YES	AACR 2017 (abstr CT001)	only alteration type		CANCER
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Stomach	Responsive	C	NO	PMID:24960402	only gene		ST
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
WP162	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Tensirolimus(MTOR inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ESMO 2014 (abstr LBA39_PR)	only alteration type		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Head an neck	Responsive	C	NO	PMID:21380780	only gene		HNC
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Ovary	Responsive	C	NO	PMID:20003286;PMID:12525520	only gene		OV
WP162	ERBB2 MUT* (--)	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma, Any cancer type	Responsive	D	YES	PMID:23220880;PMID:22908275	only alteration type		BRCA, CANCER
WP162	ERBB2 MUT* (--)	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	Trastuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:22908275	only alteration type		CANCER
WP162	ERBB2 MUT* (--)	ERBB2 (G776L)	Trastuzumab(ERBB2 mAb inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:16775247	only alteration type		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 proximal exon 20	Trastuzumab(ERBB2 mAb inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	http://ascopubs.org/doi/full/10.1200/PO.16.00055	only gene		COREAD
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab + Everolimus + Chemotherapy(ERBB2 mAb inhibitor + MTOR inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:21107682;PMID:20975068	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab + HSP90 inhibitor(ERBB2 mAb inhibitor + HSP90 inhibitor)	Breast adenocarcinoma	Responsive	C	NO	PMID:21558407	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab + Lapatinib(ERBB2 mAb inhibitor + ERBB2 inhibitor)	Endometrium	Responsive	D	NO	PMID:25294905	only gene		ED
WP162	ERBB4 MUT* (--)	ERBB4 (E317K,E452K,R544W,R393W,E872K)	Lapatinib(ERBB2 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:19718025	only alteration type		CM
WP162	ERBB4 MUT* (--)	ERBB4 fusion	Lapatinib + Afatinib(ERBB2 inhibitor + ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP162	ERCC6 MUT* (--)	ERCC6 oncogenic mutation	Cisplatin(Chemotherapy)	Ovary	Responsive	D	NO	PMID:25634215	only alteration type		OV
WP162	NTRK1 MUT* (--)	NTRK1 (G595R,G667C)	Pan-TK inhibitors(Entrectinib,etc)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:26546295	only alteration type		COREAD
WP162	ERBB4 MUT* (--)	ERBB4 (H809G)	ERBB2 inhibitors(Lapatinib,etc)	Breast adenocarcinoma	Resistant	C	NO	PMID:26530965	only alteration type		BRCA
WP162	FANCA MUT* (--)	FANCA oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP162	FANCA MUT* (--)	FANCA deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only gene		PRAD
WP162	FANCC MUT* (--)	FANCC oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP162	FANCC MUT* (--)	FANCC deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK (I1171T)	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:25228534	only alteration type		LUAD
WP162	FLCN (--)	FLCN oncogenic mutation	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:23995526	complete		R
WP162	FLCN (--)	FLCN deletion	Everolimus(MTOR inhibitor)	Thyroid	Responsive	C	NO	PMID:25295501	only gene		TH
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK (G1123S)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:26134233	only alteration type		LUAD
WP162	FOXA1 MUT* (--)	FOXA1 amplification	BCL2 inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:27397505	only gene		COREAD
WP162	INPP4B MUT* (--), INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP162	INPP4B MUT* (--), INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP162	JAK2 (V617F)	JAK2 (V617F)	JAK inhibitor(alone or in combination)s	Acute myeloid leukemia	Responsive	D	YES	PMID:22829971	complete		AML
WP162	JAK2 (V617F)	JAK2 amplification	JAK inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27075627	only gene		BRCA
WP162	JAK2 (V617F)	JAK2-BRAF fusion	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22875628;PMID:22899477	only gene		ALL
WP162	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:22422826	complete		AML
WP162	KDR MUT* (--)	KDR (A1065T)	VEGFR inhibitors	Any cancer type	Responsive	D	YES	PMID:24569783	only alteration type		CANCER
WP162	KIT MUT* (H650Q)	KIT mutation in exon 11	HSP90 inhibitors	Gastrointestinal stromal	Responsive	C	NO	PMID:22898035	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT mutation in exon 9 or 17	HSP90 inhibitors	Gastrointestinal stromal	Responsive	D	NO	PMID:21737509	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT mutation in exon 9,11,13,14 or 17	Dasatinib(BCR-ABL inhibitor 2nd gen)	Cutaneous melanoma	Responsive	C	NO	PMID:19671763	complete		CM
WP162	KIT MUT* (H650Q)	KIT (D816V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Systemic mastocytosis	Responsive	C	YES	PMID:18559612	only alteration type		SM
WP162	KIT MUT* (H650Q)	KIT (D816V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Acute myeloid leukemia	Responsive	C	YES	PMID:18986703	only alteration type		AML
WP162	KIT MUT* (H650Q)	KIT (D816Y,D816F,D816V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Any cancer type	Responsive	D	YES	PMID:16397263	only alteration type		CANCER
WP162	KIT MUT* (H650Q)	KIT (N822K)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Acute myeloid leukemia	Responsive	D	YES	PMID:23149070	only alteration type		AML
WP162	KIT MUT* (H650Q)	KIT inframe deletion (416-422),inframe insertion (416-422)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:15618474	only alteration type		AML
WP162	KIT MUT* (H650Q)	KIT inframe deletion (V560)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Thymic	Responsive	C	YES	PMID:15201427	only alteration type		THYM
WP162	KIT MUT* (H650Q)	KIT mutation in exon 9,11,13,14 or 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	B	NO	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812	complete		CM
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK inframe insertion (1151T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only alteration type		LUAD
WP162	KIT MUT* (H650Q)	KIT (D820Y)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:23775962	only alteration type		CM
WP162	ALK (G562R)	ALK oncogenic mutation	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	complete		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only gene		NSCLC
WP162	KIT MUT* (H650Q)	KIT (Y553N)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Thymic	Responsive	C	YES	PMID:21969494	only alteration type		THYM
WP162	KIT MUT* (H650Q)	KIT mutation in exon 9,11,13,14 or 17	Nilotinib(BCR-ABL inhibitor 2nd gen)	Cutaneous melanoma	Responsive	C	NO	PMID:22068222;PMID:25695690	complete		CM
WP162	KIT MUT* (H650Q)	KIT mutation in exon 17	Nilotinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	C	NO	PMID:22119758;PMID:21456006	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT (D820Y)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Cutaneous melanoma	Responsive	C	NO	PMID:25695690	only alteration type		CM
WP162	KIT MUT* (H650Q)	KIT (788-828,829-860,550-592)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2015 (abstr 10517);PMID:25239608;ASCO 2015 (abstr 10535)	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT (A829P,V654A,T670I)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	D	NO	PMID:25239608	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT inframe deletion (577-579)	Sorafenib(Pan-TK inhibitor)	Thymic	Responsive	C	YES	PMID:20970876	only alteration type		THYM
WP162	KIT MUT* (H650Q)	KIT mutation in exon 9 or 11	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	PMID:22270258	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT (550-592,627-664,788-828,829-860)	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:18936790;PMID:20372153	complete		CM
WP162	KIT MUT* (H650Q)	KIT mutation in exon 17	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	D	NO	PMID:23840364	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT (D820E)	Sorafenib(Pan-TK inhibitor)	Thymic	Responsive	C	YES	PMID:19461405	only alteration type		THYM
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only gene		LUAD
WP162	KIT MUT* (H650Q)	KIT mutation in exon 9,11,13,14 or 17	Sunitinib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	B	NO	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812	complete		CM
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK (C1156Y,L1196M)	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:20979473	only alteration type		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK (F1174L)	Crizotinib(ALK inhibitor)	Glioma	Resistant	D	NO	PMID:22072639	only alteration type		G
WP162	KIT MUT* (H650Q)	KIT (H697Y)	Sunitinib(Pan-TK inhibitor)	Thymic	Responsive	D	YES	PMID:19861435	only alteration type		THYM
WP162	KIT MUT* (H650Q)	KIT (H697Y)	Sunitinib(Pan-TK inhibitor)	Thymic	Responsive	D	YES	PMID:19861435	only alteration type		THYM
WP162	KIT MUT* (H650Q)	KIT (Y553N)	Sunitinib(Pan-TK inhibitor)	Thymic	Responsive	C	YES	PMID:23375402	only alteration type		THYM
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784;PMID:25228534	only alteration type		LUAD
WP162	SLC29A1 MUT* (I433)	SLC29A1 oncogenic mutation	Gemcitabine(Chemotherapy)	Bladder	Resistant	D	NO	PMID:21166756	only alteration type		BLCA
WP162	PLCG2 (K988N), PLCG2 MUT* (--)	PLCG2 (R665W,L845F)	Ibrutinib(BTK inhibitor)	Chronic lymphocytic leukemia	Resistant	C	YES	PMID:24869598	only alteration type		CLL
WP162	KIT MUT* (H650Q)	KIT (627-664,664-714,449-514)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458;PMID:18955451;PMID:16624552	complete		GIST
WP162	KIT MUT* (H650Q)	KIT mutation in exon 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:23840364	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT mutation in exon 17 or 18	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:21690468;PMID:21642685	only alteration type		CM
WP162	KIT MUT* (H650Q)	KIT amplification	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	No Responsive	C	NO	PMID:23775962	only gene		CM
WP162	KIT MUT* (H650Q)	KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:23582185;PMID:21689725;PMID:17259998	only alteration type		GIST
WP162	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP162	ERBB2 MUT* (--)	ERBB2 (K753E)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma	Resistant	D	NO	PMID:27697991	only alteration type		BRCA
WP162	LRP1B MUT* (--), LRP1B MUT* (--), LRP1B MUT* (--)	LRP1B oncogenic mutation	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only alteration type		OV
WP162	LRP1B MUT* (--), LRP1B MUT* (--), LRP1B MUT* (--)	LRP1B deletion	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only gene		OV
WP162	ERBB2 MUT* (--)	ERBB2 (T798I)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:28274957	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Osimertinib(3rd generation EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP162	NOTCH2 MUT* (--), NOTCH2 MUT* (P6X)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP162	NOTCH2 MUT* (--), NOTCH2 MUT* (P6X)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP162	NOTCH2 MUT* (--), NOTCH2 MUT* (P6X)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP162	NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP162	NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP162	NTRK1 MUT* (--)	NTRK1 fusion	Pan-TK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24162815	only gene		LUAD
WP162	NTRK1 MUT* (--)	NTRK1 fusion	Pan-TKR inhibitors	Any cancer type	Responsive	C	YES	PMID:28183697;ASCO 2017 (LBA2501)	only gene		CANCER
WP162	NTRK1 MUT* (--)	NTRK1 fusion	Pan-TK inhibitors(Entrectinib,etc)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26546295	only gene		COREAD
WP162	NTRK1 MUT* (--)	NTRK1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2013 (abstr 8023)	only gene	758.0	LUAD
WP162	NTRK3 MUT* (--)	NTRK3 fusion	IGF1R inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP162	NTRK3 MUT* (--)	NTRK3 fusion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP162	NTRK3 MUT* (--)	NTRK3 fusion	Midostaurin(Pan-TK inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP162	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP162	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP162	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP162	PDPK1 MUT* (--)	PDPK1 amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:19602588	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Rociletinib(3rd generation EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP162	KIT MUT* (H650Q)	KIT mutation in exon 11	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT mutation in exon 17	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:23840364	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT amplification	Sunitinib(Pan-TK inhibitor)	Cutaneous melanoma	No Responsive	C	NO	PMID:22261812	only gene		CM
WP162	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP162	RB1 MUT* (--)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
WP162	RB1 MUT* (--)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
WP162	RB1 MUT* (--)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
WP162	RB1 MUT* (--)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
WP162	RB1 MUT* (--)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP162	RB1 MUT* (--)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP162	RICTOR MUT* (--)	RICTOR amplification	MTORC1/2 inhibitors	Lung	Responsive	C	NO	PMID:26370156	only gene		L
WP162	RNF43 MUT* (I47V)	RNF43 oncogenic mutation	Porcupine inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr C45)	only alteration type		COREAD
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Endometrium	No Responsive	C	NO	PMID:26099744;PMID:19840887	only gene		ED
WP162	HGF MUT* (--), ERBB2 MUT* (--)	HGF amplification + ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:22850551	only gene		BRCA
WP162	SF3B1 MUT* (E688*)	SF3B1 (K700E,K666N)	Spliceosome inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858	only alteration type		CANCER
WP162	SMO MUT* (--)	SMO (P641A)	Vismodegib(SHH inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 9062)	only alteration type		L
WP162	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP162	TERT MUT* (--)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP162	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP162	NTRK3 MUT* (--)	NTRK3 (G623R)	novel TRK inhibitors	Any cancer type	Responsive	C	YES	PMID:28578312	only alteration type		CANCER
WP162	TSC1 MUT* (--)	TSC1 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	only alteration type		RA
WP162	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	only alteration type		BLCA
WP162	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;PMID:26859683;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	only alteration type		R
WP162	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Sarcoma, Stomach	Responsive	C	NO	PMID:26859683	only alteration type		S, ST
WP162	TSC1 MUT* (--)	TSC1 deletion	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	only gene		R
WP162	SMO MUT* (--)	SMO (D473H)	Vismodegib(SHH inhibitor)	Medulloblastoma	Resistant	C	NO	PMID:19726788;PMID:25759019	only alteration type		MB
WP162	SMO MUT* (--)	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	Vismodegib(SHH inhibitor)	Basal cell carcinoma	Resistant	C	NO	PMID:25759020;PMID:25306392	only alteration type		BCC
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 (G1738R,A1708V,C47G,V1696L,Y1853C,D1739V,F1761I,H1746N,C24Y,K1702E,P1749R,M1775R,W1837C,M1775E,V1736G,V1838E,C44F,A1752V,D1739E,S1715N,.,A1789T,S1164I,T1685A,A1752P,H1686R,H41R,C64G,W1718L,D1692H,V1713A,R1699W,V1653M,Q1756C,C61G,D1739Y,G1770V,V1714G,V1833M,R1835P,R1699Q,G1706E,P1812A,E1836K,C44Y,G1788D,C39Y,M1R,S1715R,Y1703H,F1761S,E33A,M1628V,W1837G,L1705P,M1689R,G1738E,R1751P,V1809F,S1841N,S1722F,I1766S,S1655F,G1788V,L1780P,V1833E,A1708E,E1660G,C27A,Y1703S,I1807S,T1700A,A1843T,F1734L,V1741G,V1810G,F1704S,G1656D,T1685I,L1854P,Q1811R,M18T,C1697R,G1803A,G1743R,G1763V,C24R,T37R,T1773I,D1739G,W1718C,H1686Q,T1691I,L1407P,K1487R,M1652K,S1841R,M1775K,S1841A,F1734S,V1736A,M1689T,W1815X,L1764P,W1837R,T1691K,R1753T,D1692Y,W1718S,L1657P,A1843P,S1715C,R1699L)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/6/summary|oncokb=https://www.oncokb.org/gene/BRCA1	only alteration type		OV
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only gene		OV
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK fusion	Crizotinib + Ceritinib	Sarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only gene		S
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK (G1202R,I1171N)	Alectinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only alteration type		NSCLC
WP162	NTRK1 MUT* (--)	NTRK1 fusion	Entrectinib	Any cancer type	Responsive	B	YES	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/NTRK1|CIVIC=https://civicdb.org/genes/3983/summary	only gene		CANCER
WP162	KIT MUT* (H650Q)	KIT (F522C,W557R,N463S,V654A,N822H,A829P,D820A,D572A,P838L,R634W,N822K,Y578C,N822Y,D816G,D816A,T670I,D820G,V560E,K558N,C809G,D820E,D820Y,D816Y,L576P,N822I,W557G,H697Y,I653T,V559A,V530I,V559I,S476I,V559G,D52N,.,N505I,S709F,V559C,D816N,D816V,M541L,V559D,Y823D,C443Y,D816E,Y553N,V560G,V852I,D816F,Y570H,K509I,E490K,D816.,N655K,K642E,V560D,W557C,D60N,D816H)	Sunitinib + Sorafenib	Thymic	Responsive	B	YES	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only alteration type		THYM
WP162	KIT MUT* (H650Q)	KIT (Y823D,T670I,V654A,D820G,C809G,D820A,N822K,D816H)	Imatinib	Gastrointestinal stromal	Resistant	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/KIT|CIVIC=https://civicdb.org/genes/29/summary	only alteration type		GIST
WP162	ERBB2 MUT* (--)	ERBB2 (T862A,L755S,V842I,V777A,D769H,.,R896C,R678W,R784C,V773A,C630Y,G309E,G292R,E645F,T733I,D769Y,G660R,T686A,D769A,Y803N,L651V,A644F,L674V,V839G,R217C,L869R,E719K,G660D,E265K,L785F,P650S,D277H,D808N,G776V,S653C,R487W,L841V,S310F,L755W,E693K,S335C,V659E,V794M,V659K,E321G,L915M,L866M,C311R,S1002R,D277Y,V659G,Q709L,L726I,G309A,N857S,L755P,T798M,L663P,E812K,S656C,T798I,R683Q,I682G,R678Q,V777L,P780L,A710V,R677L,S310Y,S783P,E717K,E719G,H878Y,G776S,L726F,D821N,V777M,I767M,S649T,C334S)	Neratinib	Breast adenocarcinoma	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ERBB2|CIVIC=https://civicdb.org/genes/20/summary	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Neratinib	Breast adenocarcinoma	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ERBB2|CIVIC=https://civicdb.org/genes/20/summary	only gene		BRCA
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 (G1738R,A1708V,C47G,V1696L,Y1853C,D1739V,F1761I,H1746N,C24Y,K1702E,P1749R,M1775R,W1837C,M1775E,V1736G,V1838E,C44F,A1752V,D1739E,S1715N,.,A1789T,S1164I,T1685A,A1752P,H1686R,H41R,C64G,W1718L,D1692H,V1713A,R1699W,V1653M,Q1756C,C61G,D1739Y,G1770V,V1714G,V1833M,R1835P,R1699Q,G1706E,P1812A,E1836K,C44Y,G1788D,C39Y,M1R,S1715R,Y1703H,F1761S,E33A,M1628V,W1837G,L1705P,M1689R,G1738E,R1751P,V1809F,S1841N,S1722F,I1766S,S1655F,G1788V,L1780P,V1833E,A1708E,E1660G,C27A,Y1703S,I1807S,T1700A,A1843T,F1734L,V1741G,V1810G,F1704S,G1656D,T1685I,L1854P,Q1811R,M18T,C1697R,G1803A,G1743R,G1763V,C24R,T37R,T1773I,D1739G,W1718C,H1686Q,T1691I,L1407P,K1487R,M1652K,S1841R,M1775K,S1841A,F1734S,V1736A,M1689T,L1764P,W1837R,T1691K,R1753T,D1692Y,W1718S,L1657P,A1843P,S1715C,R1699L)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only alteration type		BRCA
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only gene		BRCA
WP162	TSC1 MUT* (--)	TSC1 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	only gene		RCCC
WP162	TSC1 MUT* (--)	TSC1 (H105R,H206D,V220F,L180P,F216A,M224R,H68R,.,S35Q,F158C,L117P,L191H)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	only alteration type		RCCC
WP162	NTRK3 MUT* (--)	NTRK3 fusion	Entrectinib	Any cancer type	Responsive	B	YES	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/3985/summary|oncokb=https://www.oncokb.org/gene/NTRK3	only gene		CANCER
WP162	KIT MUT* (H650Q)	KIT (F522C,W557R,N463S,V654A,N822H,A829P,D820A,D572A,P838L,R634W,N822K,Y578C,N822Y,D816G,D816A,T670I,D820G,V560E,K558N,C809G,D820E,D820Y,D816Y,L576P,N822I,W557G,H697Y,I653T,V559A,V530I,V559I,S476I,V559G,D52N,.,N505I,S709F,V559C,D816N,D816V,M541L,V559D,Y823D,C443Y,D816E,Y553N,V560G,V852I,D816F,Y570H,K509I,E490K,N655K,V560D,K642E,D816.,W557C,D60N,D816H)	Imatinib	Cutaneous melanoma	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/KIT|CIVIC=https://civicdb.org/genes/29/summary	only alteration type		CM
WP162	KIT MUT* (H650Q)	KIT amplification	Imatinib	Cutaneous melanoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only gene		CM
WP162	KIT MUT* (H650Q)	KIT (D816)	Blu-285	Mastocytosis	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only alteration type		MAS
WP162	ERBB2 MUT* (--)	ERBB2 (T862A,L755S,V842I,V777A,D769H,.,R896C,R678W,R784C,V773A,C630Y,G309E,G292R,E645F,T733I,D769Y,G660R,T686A,D769A,Y803N,L651V,A644F,L674V,V839G,R217C,L869R,E719K,G660D,E265K,L785F,P650S,D277H,D808N,G776V,S653C,R487W,L841V,S310F,E693K,S335C,V659E,V794M,V659K,E321G,L915M,L866M,C311R,S1002R,D277Y,V659G,Q709L,L726I,G309A,N857S,L755P,T798M,L663P,E812K,S656C,T798I,R683Q,I682G,R678Q,V777L,P780L,A710V,R677L,S310Y,S783P,E717K,E719G,H878Y,G776S,L726F,D821N,V777M,I767M,S649T,C334S)	Ado + Trastuzumab + Neratinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERBB2	only alteration type		NSCLC
WP162	ERBB2 MUT* (--)	ERBB2 amplification	Ado + Trastuzumab + Neratinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERBB2	only gene		NSCLC
WP162	ARAF MUT* (A12D)	ARAF (G322S,S214T,F351L,.,S214C,N217I,S214A,S214F)	Sorafenib	Histiocytoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ARAF	only alteration type		HIS
WP162	JAK2 (V617F)	JAK2-PCM1 fusion	Ruxolitinib	Eosinophilic chronic leukemia	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/JAK2	only gene		ECL
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK (C1156Y,F1174L,L1196M,G1269A)	Crizotinib	Non-small cell lung	Resistant	D	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary	only alteration type		NSCLC
WP162	KIT MUT* (H650Q)	KIT amplification	Sunitinib + Sorafenib	Thymic	Responsive	B	YES	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only gene		THYM
WP162	ARAF MUT* (A12D)	ARAF (G322S,S214T,F351L,.,S214C,N217I,S214A,S214F)	Sorafenib	Non-small cell lung	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ARAF|CIVIC=https://civicdb.org/genes/3/summary	only alteration type		NSCLC
WP162	NTRK1 MUT* (--)	NTRK1 (G595R)	Larotrectinib	Any cancer type	Resistant	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK1	only alteration type		CANCER
WP162	NTRK3 MUT* (--)	NTRK3 (G623R)	Larotrectinib	Any cancer type	Resistant	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK3	only alteration type		CANCER
WP162	ABCC3 MUT* (--)	ABCC3 Amplification	Monomethyl Auristatin E,Paclitaxel	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/951	only gene		BRCA
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK CAD::ALK	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7481	only gene		COREAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK CLTC::ALK	TAE684	Difuse large B Cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1261	only gene		DLBCL
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK CLTC::ALK	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1265	only gene		DLBCL
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK EML4::ALK	Alectinib	Mesothelioma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9228	only gene		MESO
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/262	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK EML4::ALK	WHI-P154	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1188	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK EML4::ALK	Crizotinib,Retaspimycin Hydrochloride	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1203	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK EML4::ALK	Crizotinib,Alvespimycin	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1206	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1207	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK EML4::ALK	Lorlatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1332	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK F1174L	Crizotinib	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/125	only alteration type		NB
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK F1174L	Alectinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/37	only alteration type		NB
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/38	only alteration type		NB
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK F1174L	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/142	only alteration type		NB
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1271	only alteration type		NB
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK F1174L	AZD3463	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1327	only alteration type		NB
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK F1174L	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1329	only alteration type		NB
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK F1174L	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/33	only alteration type		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK F1245C	Crizotinib	Neuroblastoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1333	only alteration type		NB
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK F1245C	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1330	only alteration type		NB
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK F1245V	Entrectinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2987	only alteration type		NB
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1240	only gene		ALCL
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/7361	only gene		ALCL
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	A	YES	https://civicdb.org/links/evidence_items/11218	only gene		ALCL
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1264	only gene		DLBCL
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1691	only gene		LUAD
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Pemetrexed	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/945	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1175	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1187	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1198	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1199	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1200	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1201	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Retaspimycin Hydrochloride	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1202	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1272	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1273	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1279	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1282	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1419	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1577	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4835	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Alectinib,Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4858	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7284	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7285	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Lorlatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7286	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/8657	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11121	only gene		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1283	only alteration type		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK I1171	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1287	only alteration type		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1367	only alteration type		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1284	only alteration type		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK I1171	TAE684	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1285	only alteration type		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1344	only alteration type		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1368	only alteration type		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK I1171T	Ceritinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9404	only alteration type		NB
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK KANK4::ALK	Alectinib	Pancreas acinar	Responsive	C	NO	https://civicdb.org/links/evidence_items/10327	only gene		PAAC
WP162	ALK (G562R)	ALK Mutation	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1237	complete		NSCLC
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1239	only gene		ALCL
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/1241	only gene		ALCL
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK R1275Q	TAE684	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/48	only alteration type		NB
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK R1275Q	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/39	only alteration type		NB
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/143	only alteration type		NB
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1270	only alteration type		NB
WP162	ALK MUT* (--), ALK MUT* (--), ALK (G562R)	ALK R1275Q	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1331	only alteration type		NB
WP162	APC (P1432S)	APC Mutation	G007-LK	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/446	complete		COREAD
WP162	ARAF MUT* (A12D)	ARAF S214C	Sorafenib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/17	only alteration type		NSCLC
WP162	ARAF MUT* (A12D)	ARAF S214C	Sorafenib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/40	only alteration type		NSCLC
WP162	ARAF MUT* (A12D)	ARAF S214C	Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/41	only alteration type		NSCLC
WP162	ARAF MUT* (A12D)	ARAF S490T	Cetuximab,Irinotecan,Vemurafenib	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1905	only alteration type		COREAD
WP162	BAP1 MUT* (--), BAP1 MUT* (--)	BAP1 Mutation	Sunitinib,Everolimus	Renal	Resistant	B	NO	https://civicdb.org/links/evidence_items/5339	only alteration type		R
WP162	BAP1 MUT* (--), BAP1 MUT* (--)	BAP1 Mutation	Valproic Acid,Trichostatin A,Vorinostat,Panobinostat	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1234	only alteration type		UVM
WP162	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/1897	only alteration type		OV
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 Mutation	Olaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/7275	only alteration type		OV
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11136	only alteration type		OV
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11203	only alteration type		PRAD
WP162	BRCA1 MUT* (--), BRCA1 MUT* (K1183R)	BRCA1 Q1467*	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2878	only alteration type		OV
WP162	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP162	ERBB2 MUT* (--)	ERBB2 D769H	Lapatinib,Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/279	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 D769Y	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/280	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 G309A	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/282	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 G776L	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1889	only alteration type		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 G778_P780DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1890	only alteration type		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 G778_P780DUP	Dacomitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1892	only alteration type		NSCLC
WP162	ERBB2 MUT* (--)	ERBB2 L755S	Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/241	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 L755S	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/283	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 L755S	Fluorouracil,Trastuzumab,Leucovorin	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4955	only alteration type		COREAD
WP162	ERBB2 MUT* (--)	ERBB2 L755W	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/284	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 L755_T759del	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/281	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 M774DELINSWLV	Dacomitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1894	only alteration type		NSCLC
WP162	ERBB2 MUT* (--)	ERBB2 Mutation	Platinum Compound	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/1694	only alteration type		BLCA
WP162	ERBB2 MUT* (--)	ERBB2 Mutation	Neratinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5338	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Mutation	Trastuzumab,Pertuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5980	only alteration type		NSCLC
WP162	ERBB2 MUT* (--)	ERBB2 P780INS	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/285	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 P780INS	Dacomitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1048	only alteration type		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 R678Q	Lapatinib,Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/286	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 R896C	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/287	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 T798I	Osimertinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6174	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 V777L	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/288	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 V842I	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/289	only alteration type		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1045	only alteration type		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Trastuzumab Emtansine	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1125	only alteration type		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1888	only alteration type		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Sirolimus,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/960	only alteration type		NSCLC
WP162	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1893	only alteration type		NSCLC
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/5982	only gene		BLCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/528	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/529	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	AKTi-1/2	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/760	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Neratinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/761	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib,Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/887	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/961	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1006	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1007	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1008	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1009	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1011	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1012	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1013	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Docetaxel,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1077	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Neratinib,Trastuzumab	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/1113	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/1122	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib,Capecitabine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1132	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Capecitabine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1133	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1159	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1160	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1380	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	A66	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1381	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Tgx 221	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1382	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1432	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Docetaxel,Pertuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1437	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1439	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Pilaralisib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1448	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Palbociclib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1561	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1613	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1764	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2071	only gene		BRCA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Pertuzumab	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7638	only gene		CH
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Capecitabine,Cetuximab,Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/895	only gene		COREAD
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1686	only gene		COREAD
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1687	only gene		COREAD
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1688	only gene		COREAD
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1993	only gene		COREAD
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1689	only gene		COREAD
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5981	only gene		COREAD
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7302	only gene		COREAD
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7807	only gene		COREAD
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/1098	only gene		ED
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1393	only gene		LUAD
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1041	only gene		NSCLC
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1042	only gene		NSCLC
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1050	only gene		NSCLC
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1891	only gene		NSCLC
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Pancreas	Responsive	B	NO	https://civicdb.org/links/evidence_items/5985	only gene		PA
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Pancreas adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/962	only gene		PAAD
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Irinotecan	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1044	only gene		SCLC
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Salivary glands	Responsive	B	NO	https://civicdb.org/links/evidence_items/5984	only gene		SG
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/1022	only gene		ST
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/1023	only gene		ST
WP162	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Stomach	Responsive	A	NO	https://civicdb.org/links/evidence_items/1499	only gene		ST
WP162	ERBB4 MUT* (--)	ERBB4 Mutation	Lapatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/770	only alteration type		CM
WP162	JAK2 (V617F)	JAK2 Splice Site (c.1641+2T>G)	Pembrolizumab	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4825	only alteration type		CM
WP162	KDR MUT* (--)	KDR R1032Q	Cabozantinib,Dovitinib,Axitinib,Lenvatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/9339	only alteration type		COREAD
WP162	KDR MUT* (--)	KDR R961W	Regorafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1191	only alteration type	775.0	COREAD
WP162	KIT MUT* (H650Q)	KIT A502_Y503insAY	Regorafenib,Imatinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4630	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT A502_Y503insAY	Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/7392	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT A829P	Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7413	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT A829P	Sunitinib,Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7415	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT C809G	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2920	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT D579del	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4142	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT D816E	Sunitinib,Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4631	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT D816E	Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7401	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT D816H	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2923	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT D816V	Midostaurin	Systemic mastocytosis	Responsive	B	YES	https://civicdb.org/links/evidence_items/1725	only alteration type		SM
WP162	KIT MUT* (H650Q)	KIT D820A	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2921	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT D820G	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2922	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT D820Y	Imatinib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2886	only alteration type		CM
WP162	KIT MUT* (H650Q)	KIT D820Y	Sunitinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2888	only alteration type		CM
WP162	KIT MUT* (H650Q)	KIT D820Y	Regorafenib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/4589	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT K550_K558del	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4062	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT K550_W557del	Ponatinib,Regorafenib,Imatinib,Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4583	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT K558delinsNP	Imatinib,Regorafenib,Sunitinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4594	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT K642E	Dasatinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4147	only alteration type		CM
WP162	KIT MUT* (H650Q)	KIT K642E	Sunitinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/7397	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT L576P	Nilotinib,Sorafenib,Imatinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/34	only alteration type		CM
WP162	KIT MUT* (H650Q)	KIT L576P	Dasatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/42	only alteration type		CM
WP162	KIT MUT* (H650Q)	KIT L576P	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4136	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT L576P	Nilotinib,Dasatinib,Imatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/303	only alteration type		NSCLC
WP162	KIT MUT* (H650Q)	KIT Mutation	Imatinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1222	only alteration type		CM
WP162	KIT MUT* (H650Q)	KIT Mutation	Pictilisib,Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/919	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT N822K	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7370	only alteration type		AML
WP162	KIT MUT* (H650Q)	KIT N822K	Ponatinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7379	only alteration type		AML
WP162	KIT MUT* (H650Q)	KIT N822K	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2918	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT N822K	Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4167	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT N822K	Regorafenib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4169	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT N822K	Sunitinib,Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7414	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT N822K	Regorafenib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/4595	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT S628N	Imatinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7463	only alteration type		CM
WP162	KIT MUT* (H650Q)	KIT T670I	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2924	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT T670I	Regorafenib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4510	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT T670I	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7416	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT T670I	Sunitinib,Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7417	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT V559D	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/3028	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT V559D	Imatinib,Regorafenib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4459	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT V560D	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4122	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT V560D	Regorafenib,Ponatinib,Imatinib,Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4127	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT V560G	Ponatinib,Regorafenib,Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/7395	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT V654A	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/249	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT V654A	Sunitinib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/304	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT W557_K558del	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4082	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT W557_K558del	Imatinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4084	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT W557_K558del	Regorafenib,Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4087	only alteration type		GIST
WP162	KIT MUT* (H650Q)	KIT Y823D	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2919	only alteration type		GIST
WP162	KMT2C MUT* (K2797X), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (R284Q), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP162	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP162	NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP162	NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP162	NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP162	NTRK1 MUT* (--)	NTRK1 Fusion	Larotrectinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/978	only gene		COREAD
WP162	NTRK1 MUT* (--)	NTRK1 Fusion	Larotrectinib,Lestaurtinib,Crizotinib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1019	only gene		LUAD
WP162	NTRK1 MUT* (--)	NTRK1 Fusion	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/6567	only gene		SOLID
WP162	NTRK1 MUT* (--)	NTRK1 Fusion	Entrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/11124	only gene		SOLID
WP162	NTRK1 MUT* (--)	NTRK1 LMNA::NTRK1	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2960	only gene		COREAD
WP162	NTRK1 MUT* (--)	NTRK1 LMNA::NTRK1	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/8900	only gene		COREAD
WP162	NTRK1 MUT* (--)	NTRK1 SQSTM1::NTRK1	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1868	only gene		NSCLC
WP162	NTRK1 MUT* (--)	NTRK1 SQSTM1::NTRK1	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2950	only gene		NSCLC
WP162	NTRK1 MUT* (--)	NTRK1 Amplification	Larotrectinib	Solid tumors	Responsive	C	NO	https://civicdb.org/links/evidence_items/10170	only gene		SOLID
WP162	NTRK3 MUT* (--)	NTRK3 EML4::NTRK3	Entrectinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11099	only gene		LUAD
WP162	NTRK3 MUT* (--)	NTRK3 EML4::NTRK3	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/10636	only gene		NSCLC
WP162	NTRK3 MUT* (--)	NTRK3 ETV6::NTRK3	Entrectinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7994	only gene		AML
WP162	NTRK3 MUT* (--)	NTRK3 ETV6::NTRK3	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/7496	only gene		SOLID
WP162	NTRK3 MUT* (--)	NTRK3 F617L	Larotrectinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/9592	only alteration type		GIST
WP162	NTRK3 MUT* (--)	NTRK3 Fusion	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/6568	only gene		SOLID
WP162	NTRK3 MUT* (--)	NTRK3 Fusion	Entrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/11125	only gene		SOLID
WP162	PDGFRB MUT* (--)	PDGFRB Fusion	Imatinib	Malignant peripheral nerve sheat tumor	Responsive	A	NO	https://civicdb.org/links/evidence_items/1498	only gene		MPN
WP162	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP162	PREX2 MUT* (--)	PREX2 R172I	Vemurafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6268	only alteration type		CM
WP162	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP162	RB1 MUT* (--)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
WP162	RICTOR MUT* (--)	RICTOR Amplification	Onatasertib,Sapanisertib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1440	only gene		LUAD
WP162	RICTOR MUT* (--)	RICTOR Amplification	Vistusertib	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7449	only gene		SCLC
WP162	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP162	SF3B1 MUT* (E688*)	SF3B1 K666N	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1418	only alteration type		BRCA
WP162	SF3B1 MUT* (E688*)	SF3B1 K700E	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1417	only alteration type		BRCA
WP162	SMO MUT* (--)	SMO D473H	Vismodegib	Basal cell carcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/755	only alteration type		BCC
WP162	SMO MUT* (--)	SMO L412F	Vismodegib	Basal cell carcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4653	only alteration type		BCC
WP162	SMO MUT* (--)	SMO L412F	Vismodegib	Basal cell carcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4654	only alteration type		BCC
WP162	SMO MUT* (--)	SMO Mutation	Vismodegib	Basal cell carcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/746	only alteration type		BCC
WP162	SMO MUT* (--)	SMO Mutation	Vismodegib,Sonidegib	Basal cell carcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1477	only alteration type		BCC
WP162	SMO MUT* (--)	SMO Mutation	PSI,Arsenic Trioxide	Basal cell carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/747	only alteration type		BCC
WP162	SOX10 MUT* (--)	SOX10 Loss	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1710	only gene		CM
WP162	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP162	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Ado-Trastuzumab Emtansine(EGFR mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor);Capecitabine(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s023lbl.pdf;PMID:17192538	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf	only gene		ST, GEJA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf	only gene		BRCA
WP056	TPMT MUT* (--)	TPMT splice acceptor variant	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP056	TPMT MUT* (--)	TPMT biallelic inactivation	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP056	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP056	TPMT MUT* (--)	TPMT splice acceptor variant	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP056	TPMT MUT* (--)	TPMT biallelic inactivation	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP056	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP056	TPMT MUT* (--)	TPMT splice acceptor variant	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP056	TPMT MUT* (--)	TPMT biallelic inactivation	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP056	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Neratinib(ERBB2 inhibitor) + Capecitabine(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer;PMID:30860945	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 inhibitor)+ Trastuzumab(ERBB2 inhibitor) + Docetaxel(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor) + Letrozole(Hormone therapy)	Breast adenocarcinoma	Responsive	A	NO	FDA;PMID:19786658	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Margetuximab(ERBB2 inhibitor) 	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Tucatinib(ERBB2 inhibitor) + Trastuzumab(ERBB2 inhibitor) + Capecitabine(chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer;PMID:31825569	only gene		BRCA
WP056	FLT3 MUT* (--)	FLT3-ITD	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia;PMID:28644114	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 (D835,I836)	Gilteritinib(Kinase inhibitor )	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3-ITD	Gilteritinib(Kinase inhibitor )	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation;PMID:31665578	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 (D835,I836)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia; PMID:28644114	only alteration type		AML
WP056	VHL MUT* (--)	VHL oncogenic mutation	Belzutifan(hypoxia-inducible factor inhibitor)	Renal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-cancers-associated-von-hippel-lindau-disease	only alteration type		R
WP056	FGFR2 MUT* (--)	FGFR2 fusion	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only gene		BLCA
WP056	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Pembrolizumab(PD-1 blocking antibody) + Trastuzumab(ERBB2 mAb inhibitor) + Fluoropyrimidine (Chemotherapy) + Platinum (Chemotherapy)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer;PMID:34912120	only gene		ST, GEJA
WP056	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP056	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP056	FGFR2 MUT* (--)	FGFR2 fusion	Infigratinib(FGFR kinase inhibitor)	Cholangiocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma	only gene		CH
WP056	FGFR2 MUT* (--)	FGFR2 fusion	Pemigatinib(FGFR kinase inhibitor)	Cholangiocarcinoma	Responsive	A	NO	FDA;PMID:32203698	only gene		CH
WP056	RAD51C (D159Y)	RAD51C oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	complete		PRAD
WP056	RAD54L MUT* (--)	RAD54L oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas	only gene		ST, GEJA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung	only alteration type		NSCLC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype	Tucatinib(ERBB2 inhibitor);Trastuzumab(ERBB2 inhibitor) 	Colorectal adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer	only gene		COREAD
WP056	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Bevacizumab(VEGF mAb inhibitor);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP056	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP056	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Pembrolizumab(PD-1-blocking antibody);Pemetrexed(Chemotherapy);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf	complete		NSCLC
WP056	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Durvalumab(PD-1-blocking antibody);Tremelimumab-actl(CTLA-4 blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non	complete		NSCLC
WP056	FGFR2 MUT* (--)	FGFR2 fusion	Futibatinib(pan-FGFR inhibitor)	Intrahepatic cholangiocarcinoma	Responsive	A	NO	FDA: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-futibatinib-cholangiocarcinoma	only gene		IHCH
WP056	ATM MUT* (--)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP056	RAD51C (D159Y)	RAD51C oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	complete		PRAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-fam-trastuzumab-deruxtecan-nxki-breast-cancer	only gene		BRCA
WP056	EGFR wildtype, ALK wildtype, ROS1 wildtype	EGFR wildtype;ALK wildtype;ROS1 wildtype	Cemiplimab-rwlc(PD-1-blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-combination-platinum-based-chemotherapy-non-small-cell-lung-cancer	complete		NSCLC
WP056	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype + BRAF wildtype	Trastuzumab(ERBB2 mAb inhibitor) + Lapatinib(ERBB2 inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only gene		COREAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf	only gene		BRCA
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 inhibitor) + Carboplatin-Taxol(Chemotherapy)	Uterus	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf	only gene		U
WP056	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP056	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP056	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP056	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP056	FLT3 MUT* (--)	FLT3-ITD	Quizartinib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia	only alteration type		AML
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 inhibitor)+ Trastuzumab(ERBB2 inhibitor) 	Billiary tract	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf	only gene		BT
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype + BRAF wildtype	Trastuzumab(ERBB2 mAb inhibitor) + Lapatinib(ERBB2 inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only gene		COREAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype + BRAF wildtype	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only gene		COREAD
WP056	CTNNB1 MUT* (--)	CTNNB1 oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Resistant	D	NO	PMID:23539443	only alteration type		COREAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	EGFR inhibitors	Lung adenocarcinoma	Resistant	D	NO	PMID:22956644	only gene		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:22586653;PMID:23348520	only gene		COREAD
WP056	FGFR2 MUT* (--), FGFR2 MUT* (--)	FGFR2 (N549H,V564F,K659M,L617V,K641R,R565A) + FGFR2 fusion	FGFR inhibitors	Cholangiocarcinoma	Resistant	C	NO	PMID:28034880;ASCO 2017 (abstr 2500)	only gene		CH
WP056	ATM MUT* (--)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only alteration type		COREAD
WP056	ATM MUT* (--)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
WP056	ATM MUT* (--)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only alteration type		LY
WP056	ATM MUT* (--)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only gene		LY
WP056	ATM MUT* (--)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP056	ATM MUT* (--)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
WP056	ATM MUT* (--)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP056	ATM MUT* (--)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP056	ATM MUT* (--)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP056	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP056	ATM MUT* (--)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP056	BCOR MUT* (T591)	BCOR oncogenic mutation	Enzastaurin(PKCb inhibitor)	Stomach	Responsive	D	NO	PMID:27397505	only alteration type		ST
WP056	CBL MUT* (--)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP056	CBL MUT* (--)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP056	CDKN2A MUT* (--), CDKN2A MUT* (V25G)	CDKN2A oncogenic mutation	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr 2500)	only alteration type		CM
WP056	CDKN2A MUT* (--), CDKN2A MUT* (V25G)	CDKN2A oncogenic mutation	CDK4/6 inhibitors	Glioma, Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22586120;PMID:22711607	only alteration type		G, CANCER
WP056	CDKN2A MUT* (--), CDKN2A MUT* (V25G)	CDKN2A deletion	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr 2500)	only gene		CM
WP056	CDKN2A MUT* (--), CDKN2A MUT* (V25G)	CDKN2A deletion	CDK4/6 inhibitors	Glioma, Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22586120;PMID:22711607	only gene		G, CANCER
WP056	CDKN2A MUT* (--), CDKN2A MUT* (V25G)	CDKN2A oncogenic mutation	Ilorasertib(AURKA-VEGF inhibitor)	Any cancer type	Responsive	C	YES	NCT02478320	only alteration type		CANCER
WP056	CDKN2A MUT* (--), CDKN2A MUT* (V25G)	CDKN2A deletion	Ilorasertib(AURKA-VEGF inhibitor)	Any cancer type	Responsive	C	YES	NCT02478320	only gene		CANCER
WP056	MAP2K2 (V85G), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP056	CTNNB1 MUT* (--)	CTNNB1 (H36Y,S37C,S37Y,D32V)	Everolimus + Letrozole(MTOR inhibitor + Hormonal therapy)	Endometrium	Responsive	C	NO	PMID:25624430	only alteration type		ED
WP056	MAP2K2 (V85G), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP056	MAP2K2 (V85G), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP056	MAP2K2 (V85G), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP056	MCL1 MUT* (--)	MCL1 amplification	Tubulin inhibitors	Any cancer type	Resistant	D	YES	PMID:21368834	only gene		CANCER
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	ERBB2 inhibitor + CDK4/6 inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26977878	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 proximal exon 20	ERBB2 inhibitors(Afatinib,Lapatinib,Neratinib,etc)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547	only alteration type		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 proximal exon 20	ERBB2 mAb inhibitors(Trastuzumab,etc)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547	only alteration type		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 inframe insertion (A775YVMA),inframe insertion (G776VC)	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 8510)	only alteration type		L
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 (V659E,S310F)	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 8510)	only alteration type		L
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Stomach	Responsive	C	NO	AACR 2014 (abstr CT228)	only gene		ST
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Breast adenocarcinoma	Responsive	B	NO	PMID:20142587;PMID:22418700;PMID:23632474	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	PMID:27044931	only gene		BLCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 proximal exon 20	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 (T798I)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Breast adenocarcinoma	Responsive	D	NO	PMID:28274957	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Dacomitinib(Pan ERBB inhibitor)	Non-small cell lung	Responsive	C	NO	PMID:25899785	only alteration type		NSCLC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 (V659E)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma, Lung adenocarcinoma	Responsive	C	NO	PMID:23950206	only alteration type		BRCA, LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 proximal exon 20	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib + Chemotherapy(ERBB2 inhibitor + Chemotherapy)	Stomach	Responsive	C	NO	PMID:25694417;NCT02015169	only gene		ST
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Neratinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ESMO 2014 (abstr LBA39_PR)	only alteration type		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 (K753E)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:27697991	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 proximal exon 20	Neratinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 (L869R)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	C	NO	PMID:28274957	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 (S310,L755,V777)	Neratinib(ERBB2 inhibitor)	Any cancer type	Responsive	C	YES	AACR 2017 (abstr CT001)	only alteration type		CANCER
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 inframe insertion (P780GSP),inframe insertion (781GSP),inframe insertion (A775YVMA),inframe insertion (G776YVMA)	Neratinib(ERBB2 inhibitor)	Any cancer type	Responsive	C	YES	AACR 2017 (abstr CT001)	only alteration type		CANCER
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Stomach	Responsive	C	NO	PMID:24960402	only gene		ST
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Tensirolimus(MTOR inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ESMO 2014 (abstr LBA39_PR)	only alteration type		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Head an neck	Responsive	C	NO	PMID:21380780	only gene		HNC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Ovary	Responsive	C	NO	PMID:20003286;PMID:12525520	only gene		OV
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma, Any cancer type	Responsive	D	YES	PMID:23220880;PMID:22908275	only alteration type		BRCA, CANCER
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	Trastuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:22908275	only alteration type		CANCER
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 (G776L)	Trastuzumab(ERBB2 mAb inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:16775247	only alteration type		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 proximal exon 20	Trastuzumab(ERBB2 mAb inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	http://ascopubs.org/doi/full/10.1200/PO.16.00055	only gene		COREAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab + Everolimus + Chemotherapy(ERBB2 mAb inhibitor + MTOR inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:21107682;PMID:20975068	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab + HSP90 inhibitor(ERBB2 mAb inhibitor + HSP90 inhibitor)	Breast adenocarcinoma	Responsive	C	NO	PMID:21558407	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab + Lapatinib(ERBB2 mAb inhibitor + ERBB2 inhibitor)	Endometrium	Responsive	D	NO	PMID:25294905	only gene		ED
WP056	FGFR2 MUT* (--)	FGFR2 fusion	FGFR inhibitors	Billiary tract	Responsive	C	NO	ASCO 2016 (abstr 109)	only gene		BT
WP056	FGFR2 MUT* (--)	FGFR2 inframe insertion (A266),inframe insertion (S267)	FGFR inhibitors	Lung	Responsive	D	NO	PMID:26048680	only alteration type		L
WP056	FGFR2 MUT* (--)	FGFR2 amplification	FGFR inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2508)	only gene		ST
WP056	FGFR2 MUT* (--)	FGFR2 amplification	FGFR inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:25193991	only gene		BRCA
WP056	FGFR2 MUT* (--)	FGFR2 (S252W,N550K)	FGFR inhibitors	Endometrium	Responsive	D	NO	PMID:18552176;PMID:22238366;PMID:23002168	only alteration type		ED
WP056	FGFR2 MUT* (--)	FGFR2 (V565I)	FGFR inhibitors	Endometrium	Responsive	D	NO	ENA 2014 (abstr 381)	only alteration type		ED
WP056	FGFR2 MUT* (--)	FGFR2 (W290C,S320C,K660N)	FGFR inhibitors	Lung squamous cell	Responsive	D	NO	PMID:23786770;PMID:25035393	only alteration type		LUSC
WP056	FGFR2 MUT* (--)	FGFR2 fusion	FGFR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 2500)	only gene		COREAD
WP056	FGFR2 MUT* (--)	FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Endometrium	Responsive	D	NO	PMID:23908597	only alteration type		ED
WP056	FGFR4 MUT* (T117A)	FGFR4 (N535,V550)	FGFR inhibitors	Rhabdomyosarcoma	Responsive	D	NO	PMID:19809159;PMID:24124571	only alteration type		RHBDS
WP056	FLT3 MUT* (--)	FLT3-ITD	FLT3 inhibitors	Acute myeloid leukemia	Responsive	C	YES	PMID:16857985	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 (F691)	novel FLT3 inhibitors	Acute myeloid leukemia	Responsive	D	YES	PMID:25847190	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 (N676)	Crenolanib(FLT3 inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:24619500	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 (D835)	Lestaurtinib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:16857985	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 (D835)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:20733134	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 (N676)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:24619500	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3-ITD	Sorafenib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:19389879;PMID:22368270	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3-ITD	Sorafenib + Azacytidine(Pan-TK inhibitor + Chemotherapy)	Acute myeloid leukemia	Responsive	C	YES	PMID:23613521	only alteration type		AML
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP056	GATA3 MUT* (--)	GATA3 oncogenic mutation	Aromatase ihibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:24758297	only alteration type		BRCA
WP056	GNAQ MUT* (Y101*), GNAQ MUT* (T96S)	GNAQ (Q209)	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	NCT01587352	only alteration type		CM
WP056	GNAQ MUT* (Y101*), GNAQ MUT* (T96S)	GNAQ (Q209)	PI3K pathway inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22733540;PMID:22808163	only alteration type		CM
WP056	GNAQ MUT* (Y101*), GNAQ MUT* (T96S)	GNAQ (Q209)	PKC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22653968;PMID:22253748	only alteration type		CM
WP056	GNAQ MUT* (Y101*), GNAQ MUT* (T96S)	GNAQ (Q209)	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr CRA9003)	only alteration type		CM
WP056	JAK3 MUT* (--)	JAK3 (A572V,A573V)	JAK inhibitors	Lymphoma	Responsive	D	YES	PMID:22705984	only alteration type		LY
WP056	JAK3 MUT* (--)	JAK3 (R657Q,I87T,Q501H)	JAK inhibitors	Megakaryoblastic leukemia	Responsive	D	YES	PMID:18397343	only alteration type		MKB
WP056	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP056	MDM2 MUT* (--)	MDM2 amplification	Cisplatin(Chemotherapy)	Male germ cell tumor	Resistant	C	NO	PMID:27646943	only gene		MGCT
WP056	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP056	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP056	FGFR2 MUT* (--)	FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)	Dovitinib(FGFR inhibitor)	Endometrium	Resistant	D	NO	PMID:23908597	only alteration type		ED
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP056	MDM2 MUT* (--)	MDM2 amplification	MDM2 inhibitors	Liposarcoma	Responsive	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	only gene		LIP
WP056	SLC29A1 MUT* (--)	SLC29A1 oncogenic mutation	Gemcitabine(Chemotherapy)	Bladder	Resistant	D	NO	PMID:21166756	only alteration type		BLCA
WP056	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP056	MPL (W515K)	MPL (W515F)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:16834459	only alteration type		MDPS
WP056	MYC (T73P)	MYC amplification	BET inhibitors	Myeloma, Neuroblastoma	Responsive	D	YES	PMID:21889194;PMID:23430699	only gene		MYMA, NB
WP056	MYC (T73P)	MYC amplification	CDK7 inhibitors	Neuroblastoma	Responsive	D	NO	PMID:25416950	only gene		NB
WP056	MYC (T73P)	MYC amplification	FACT inhibitors	Neuroblastoma	Responsive	D	NO	PMID:26537256	only gene		NB
WP056	MYC (T73P)	MYC amplification	PIM inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:25505253	only gene		PRAD
WP056	MYC (T73P)	MYC amplification	Temozolomide(Chemotherapy)	Colorectal adenocarcinoma	Responsive	D	NO	PMID:27397505	only gene		COREAD
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP056	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 (K753E)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma	Resistant	D	NO	PMID:27697991	only alteration type		BRCA
WP056	CRBN MUT* (A395E)	CRBN oncogenic mutation	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP056	CRBN MUT* (A395E)	CRBN (Q100*,R283K)	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 (T798I)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:28274957	only alteration type		BRCA
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Osimertinib(3rd generation EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP056	NOTCH2 MUT* (--), NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP056	NOTCH2 MUT* (--), NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP056	NOTCH2 MUT* (--), NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP056	CRBN MUT* (A395E)	CRBN oncogenic mutation	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP056	CRBN MUT* (A395E)	CRBN (Q100*,R283K)	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP056	NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP056	NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP056	FLT3 MUT* (--)	FLT3 (D835,Y842)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Acute myeloid leukemia	Resistant	D	YES	PMID:23430109	only alteration type		AML
WP056	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP056	FLT3 MUT* (--)	FLT3 (F691,D835,N676,Y842)	Quizartinib(Pan-TK inhibitor)	Acute myeloid leukemia	Resistant	D	YES	PMID:22504184;PMID:23878140	only alteration type		AML
WP056	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP056	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Rociletinib(3rd generation EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP056	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP056	RAD51C (D159Y)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	complete		OV
WP056	RAD51C (D159Y)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	complete		OV
WP056	RAF1 MUT* (--)	RAF1 fusion	Pan-RAF inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:20526349	only gene		PRAD
WP056	RAF1 MUT* (--)	RAF1 fusion	Sorafenib(Pan-TK inhibitor)	Prostate adenocarcinoma	Responsive	D	NO	PMID:20526349	only gene		PRAD
WP056	RAF1 MUT* (--)	RAF1 fusion	U0126(MEK inhibitor)	Prostate adenocarcinoma	Responsive	D	NO	PMID:20526349	only gene		PRAD
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP056	RB1 MUT* (--)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
WP056	RB1 MUT* (--)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
WP056	RB1 MUT* (--)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
WP056	RB1 MUT* (--)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
WP056	RB1 MUT* (--)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP056	RB1 MUT* (--)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP056	RICTOR MUT* (--)	RICTOR amplification	MTORC1/2 inhibitors	Lung	Responsive	C	NO	PMID:26370156	only gene		L
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Endometrium	No Responsive	C	NO	PMID:26099744;PMID:19840887	only gene		ED
WP056	STAG2 MUT* (--)	STAG2 oncogenic mutation	PARP inhibitors	Glioma	Responsive	D	NO	PMID:24356817	only alteration type		G
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP056	SUZ12 MUT* (--)	SUZ12 oncogenic mutation	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only alteration type		CANCER
WP056	SUZ12 MUT* (--)	SUZ12 deletion	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only gene		CANCER
WP056	TERT MUT* (--), TERT MUT* (R277S), TERT MUT* (S274)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP056	TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP056	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP056	FLT3 MUT* (--)	FLT3-ITD	Venetoclax(BCL2 inhibitor)	Acute myeloid leukemia	Resistant	C	YES	PMID:27520294	only alteration type		AML
WP056	VHL MUT* (--)	VHL oncogenic mutation	VEGFR inhibitors(Sorafenib,Sunitinib,Bevacizumab,Axitinib,etc)	Renal	Responsive	D	NO	PMID:18635227	only alteration type		R
WP056	FGFR2 MUT* (--)	FGFR2 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Cholangiocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CH
WP056	MDM2 MUT* (--)	MDM2 amplification	Unii-Q8Mi0X869M	Liposarcoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MDM2	only gene		LIP
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 (T862A,L755S,V842I,V777A,D769H,.,R896C,R678W,R784C,V773A,C630Y,G309E,G292R,E645F,T733I,D769Y,G660R,T686A,D769A,Y803N,L651V,A644F,L674V,V839G,R217C,L869R,E719K,G660D,E265K,L785F,P650S,D277H,D808N,G776V,S653C,R487W,L841V,S310F,L755W,E693K,S335C,V659E,V794M,V659K,E321G,L915M,L866M,C311R,S1002R,D277Y,V659G,Q709L,L726I,G309A,N857S,L755P,T798M,L663P,E812K,S656C,T798I,R683Q,I682G,R678Q,V777L,P780L,A710V,R677L,S310Y,S783P,E717K,E719G,H878Y,G776S,L726F,D821N,V777M,I767M,S649T,C334S)	Neratinib	Breast adenocarcinoma	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ERBB2|CIVIC=https://civicdb.org/genes/20/summary	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Neratinib	Breast adenocarcinoma	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ERBB2|CIVIC=https://civicdb.org/genes/20/summary	only gene		BRCA
WP056	CDKN2A MUT* (--), CDKN2A MUT* (V25G)	CDKN2A (R87P,E69G,P48L,R112G,E88K,M53I,R87L,R80L,R99P,V118D,D108N,T77P,A36P,I49S,G101W,R80P,H83N,Q50P,A68T,A60R,G67S,G67R,G35R,L16P,D108H,R87W,N71I,L32P,N71K,P81L,.,R24P,H83Y,D74Y,G35V,G35A,D84Y,G23D,P73L,V126D,S56I,D84N,D74N,D84H,P114L,P114S,D84V,A60V,G93W,N71S,L97R,P81T,R79P,D84G)	Abemaciclib + Palbociclib + Ribociclib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/CDKN2A	only alteration type		CANCER
WP056	CDKN2A MUT* (--), CDKN2A MUT* (V25G)	CDKN2A deletion	Abemaciclib + Palbociclib + Ribociclib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/CDKN2A	only gene		CANCER
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 (T862A,L755S,V842I,V777A,D769H,.,R896C,R678W,R784C,V773A,C630Y,G309E,G292R,E645F,T733I,D769Y,G660R,T686A,D769A,Y803N,L651V,A644F,L674V,V839G,R217C,L869R,E719K,G660D,E265K,L785F,P650S,D277H,D808N,G776V,S653C,R487W,L841V,S310F,E693K,S335C,V659E,V794M,V659K,E321G,L915M,L866M,C311R,S1002R,D277Y,V659G,Q709L,L726I,G309A,N857S,L755P,T798M,L663P,E812K,S656C,T798I,R683Q,I682G,R678Q,V777L,P780L,A710V,R677L,S310Y,S783P,E717K,E719G,H878Y,G776S,L726F,D821N,V777M,I767M,S649T,C334S)	Ado + Trastuzumab + Neratinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERBB2	only alteration type		NSCLC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 amplification	Ado + Trastuzumab + Neratinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERBB2	only gene		NSCLC
WP056	FGFR2 MUT* (--)	FGFR2 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		BLCA
WP056	FGFR2 MUT* (--)	FGFR2 (N549K,K526E,K641R,I547V,Y375C,D101Y,E219K,E565G,C382R,N549H,W290R,L617M,D530N,M535I,P253R,V564I,F276C,S252W,N549T,E731K,G271E,I642V,K641N,R203C,K659E,.,L617F,M537I,T341P,R678G,M391R,Y381D,V564F,K525E,N549S,R251Q,A648T,K659N)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only alteration type		CANCER
WP056	FGFR2 MUT* (--)	FGFR2 amplification	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP056	FGFR2 MUT* (--)	FGFR2-AHCYL1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP056	FGFR2 MUT* (--)	FGFR2-BICC1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP056	FGFR2 MUT* (--)	FGFR2-CCDC6 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP056	FGFR2 MUT* (--)	FGFR2-CIT fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP056	FGFR2 MUT* (--)	FGFR2-FAM76A fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP056	FGFR2 MUT* (--)	FGFR2-KIAA1967 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP056	FGFR2 MUT* (--)	FGFR2-MGEA5 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP056	FGFR2 MUT* (--)	FGFR2-TACC3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP056	FGFR2 MUT* (--)	FGFR2 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP056	NF1 MUT* (--), NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP056	ATM MUT* (--)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only alteration type		CANCER
WP056	ATM MUT* (--)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
WP056	ATM MUT* (--)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	only alteration type		CM
WP056	ATM MUT* (--)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	only alteration type		GB
WP056	ATM MUT* (--)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	only alteration type		PRAD
WP056	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP056	CDKN2A MUT* (--), CDKN2A MUT* (V25G)	CDKN2A Mutation	Palbociclib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7300	only alteration type		CH
WP056	CDKN2A MUT* (--), CDKN2A MUT* (V25G)	CDKN2A Mutation	Palbociclib	Pancreas	Responsive	B	NO	https://civicdb.org/links/evidence_items/7299	only alteration type		PA
WP056	CDKN2A MUT* (--), CDKN2A MUT* (V25G)	CDKN2A Loss	Linsitinib,Palbociclib	Ewing sarcoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1879	only gene		EWS
WP056	CDKN2A MUT* (--), CDKN2A MUT* (V25G)	CDKN2A Loss	Palbociclib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/7444	only gene		NSCLC
WP056	CDKN2A MUT* (--), CDKN2A MUT* (V25G)	CDKN2A Loss	Palbociclib	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/1377	only gene		OV
WP056	CDKN2A MUT* (--), CDKN2A MUT* (V25G)	CDKN2A Loss	Palbociclib	Renal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1373	only gene		R
WP056	CRBN MUT* (A395E)	CRBN Mutation	Lenalidomide,Pomalidomide	Multiple myeloma	Resistant	C	YES	https://civicdb.org/links/evidence_items/1766	only alteration type		MM
WP056	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 D769H	Lapatinib,Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/279	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 D769Y	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/280	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 G309A	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/282	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 G776L	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1889	only alteration type		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 G778_P780DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1890	only alteration type		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 G778_P780DUP	Dacomitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1892	only alteration type		NSCLC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 L755S	Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/241	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 L755S	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/283	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 L755S	Fluorouracil,Trastuzumab,Leucovorin	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4955	only alteration type		COREAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 L755W	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/284	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 L755_T759del	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/281	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 M774DELINSWLV	Dacomitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1894	only alteration type		NSCLC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Mutation	Platinum Compound	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/1694	only alteration type		BLCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Mutation	Neratinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5338	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Mutation	Trastuzumab,Pertuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5980	only alteration type		NSCLC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 P780INS	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/285	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 P780INS	Dacomitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1048	only alteration type		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 R678Q	Lapatinib,Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/286	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 R896C	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/287	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 T798I	Osimertinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6174	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 V777L	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/288	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 V842I	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/289	only alteration type		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1045	only alteration type		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Trastuzumab Emtansine	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1125	only alteration type		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1888	only alteration type		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Sirolimus,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/960	only alteration type		NSCLC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1893	only alteration type		NSCLC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/5982	only gene		BLCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/528	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/529	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	AKTi-1/2	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/760	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Neratinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/761	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib,Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/887	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/961	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1006	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1007	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1008	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1009	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1011	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1012	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1013	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Docetaxel,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1077	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Neratinib,Trastuzumab	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/1113	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/1122	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib,Capecitabine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1132	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Capecitabine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1133	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1159	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1160	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1380	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	A66	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1381	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Tgx 221	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1382	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1432	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Docetaxel,Pertuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1437	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1439	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Pilaralisib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1448	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Palbociclib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1561	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1613	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1764	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2071	only gene		BRCA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Pertuzumab	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7638	only gene		CH
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Capecitabine,Cetuximab,Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/895	only gene		COREAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1686	only gene		COREAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1687	only gene		COREAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1688	only gene		COREAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1993	only gene		COREAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1689	only gene		COREAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5981	only gene		COREAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7302	only gene		COREAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7807	only gene		COREAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/1098	only gene		ED
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1393	only gene		LUAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1041	only gene		NSCLC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1042	only gene		NSCLC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1050	only gene		NSCLC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1891	only gene		NSCLC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Pancreas	Responsive	B	NO	https://civicdb.org/links/evidence_items/5985	only gene		PA
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Pancreas adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/962	only gene		PAAD
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Irinotecan	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1044	only gene		SCLC
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Salivary glands	Responsive	B	NO	https://civicdb.org/links/evidence_items/5984	only gene		SG
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/1022	only gene		ST
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/1023	only gene		ST
WP056	ERBB2 MUT* (--), ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Stomach	Responsive	A	NO	https://civicdb.org/links/evidence_items/1499	only gene		ST
WP056	FGFR2 MUT* (--)	FGFR2 FGFR2::AHCYL1	Infigratinib,PD173074	Cholangiocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1853	only gene		CH
WP056	FGFR2 MUT* (--)	FGFR2 FGFR2::BICC1	PD173074,Infigratinib	Cholangiocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1851	only gene		CH
WP056	FGFR2 MUT* (--)	FGFR2 FGFR2::BICC1	Erdafitinib	Endometrium	Responsive	C	NO	https://civicdb.org/links/evidence_items/1920	only gene		ED
WP056	FGFR2 MUT* (--)	FGFR2 FGFR2::MGEA5	Ponatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/295	only gene		CH
WP056	FGFR2 MUT* (--)	FGFR2 FGFR2::TACC3	Pazopanib,Ponatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/296	only gene		CH
WP056	FGFR2 MUT* (--)	FGFR2 Fusion	Infigratinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1913	only gene		CH
WP056	FGFR2 MUT* (--)	FGFR2 Fusion	Infigratinib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5908	only gene		CH
WP056	FGFR2 MUT* (--)	FGFR2 Fusion	Derazantinib	Intrahepatic cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7329	only gene		IHCH
WP056	FGFR2 MUT* (--)	FGFR2 Mutation	Infigratinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1912	only alteration type		CH
WP056	FGFR2 MUT* (--)	FGFR2 Mutation	Infigratinib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5912	only alteration type		CH
WP056	FGFR2 MUT* (--)	FGFR2 Mutation	Ponatinib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1236	only alteration type		ED
WP056	FGFR2 MUT* (--)	FGFR2 N550K	PD173074	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1322	only alteration type		ED
WP056	FGFR2 MUT* (--)	FGFR2 P253R	Pazopanib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/7833	only alteration type		HNSC
WP056	FGFR2 MUT* (--)	FGFR2 Amplification	Dovitinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1605	only gene		BRCA
WP056	FLT3 MUT* (--)	FLT3 D835	Quizartinib,Ponatinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1036	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 D835	SU5614	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1037	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 D835	Quizartinib,Sorafenib	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/1038	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 D835	Sorafenib	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/1039	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 D835H	Sorafenib	Acute myeloid leukemia	Resistant	C	YES	https://civicdb.org/links/evidence_items/1556	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 D835H	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8517	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 D835H/Y	Sorafenib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1557	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 D835I	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8351	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 D835V	Tandutinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/3007	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 D835V	Sunitinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3008	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 D835V	Sunitinib,Cytarabine	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3009	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 D835V	Daunorubicin,Sunitinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3010	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 D835V	Quizartinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3012	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 D835V	AS602868,Tyrphostin AG 1296	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3034	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 D835V	Sunitinib	Acute myeloid leukemia	Responsive	C	YES	https://civicdb.org/links/evidence_items/4022	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 D835V	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8518	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 D835Y	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8108	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 F691L	Lestaurtinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8341	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 F691L	Midostaurin	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8342	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 Mutation	Midostaurin	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/5261	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 Mutation	Gilteritinib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/7283	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 Mutation	Gilteritinib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/7728	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 Y842C	FLT3/ABL/Aurora Kinase Inhibitor KW-2449	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8336	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 Y842C	Sorafenib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8337	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 Y842C	Sunitinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8338	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 Y842C	Quizartinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8654	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 Y842C	Lestaurtinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8339	only alteration type		AML
WP056	FLT3 MUT* (--)	FLT3 Y842C	Midostaurin	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8340	only alteration type		AML
WP056	GNAQ MUT* (Y101*), GNAQ MUT* (T96S)	GNAQ Mutation	JQ1	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1210	only alteration type		UVM
WP056	GNAQ MUT* (Y101*), GNAQ MUT* (T96S)	GNAQ Mutation	Trametinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1229	only alteration type		UVM
WP056	GNAQ MUT* (Y101*), GNAQ MUT* (T96S)	GNAQ Mutation	Mirdametinib,Sotrastaurin Acetate	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1953	only alteration type		UVM
WP056	GNAQ MUT* (Y101*), GNAQ MUT* (T96S)	GNAQ Mutation	Cabozantinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5068	only alteration type		UVM
WP056	GNAQ MUT* (Y101*), GNAQ MUT* (T96S)	GNAQ Q209	Selumetinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1213	only alteration type		UVM
WP056	GNAQ MUT* (Y101*), GNAQ MUT* (T96S)	GNAQ Q209	Refametinib	Uveal melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1233	only alteration type		UVM
WP056	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP056	KMT2C MUT* (K2797X), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP056	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP056	MRE11 MUT* (--)	MRE11 Loss	Talazoparib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/876	only gene		ED
WP056	NFE2L2 MUT* (--)	NFE2L2 Mutation	Sapanisertib	Lung squamous cell	Responsive	B	NO	https://civicdb.org/links/evidence_items/7446	only alteration type		LUSC
WP056	NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP056	NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP056	NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP056	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP056	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP056	RAD54L MUT* (--)	RAD54L Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11207	only alteration type		PRAD
WP056	RB1 MUT* (--)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
WP056	RICTOR MUT* (--)	RICTOR Amplification	Onatasertib,Sapanisertib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1440	only gene		LUAD
WP056	RICTOR MUT* (--)	RICTOR Amplification	Vistusertib	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7449	only gene		SCLC
WP056	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP056	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP056	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP056	VHL MUT* (--)	VHL Mutation	Pazopanib	Renal	Responsive	B	NO	https://civicdb.org/links/evidence_items/1672	only alteration type		R
WP056	VHL MUT* (--)	VHL Mutation	Anti-VEGF Monoclonal Antibody	Renal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4832	only alteration type		R
WP056	VHL MUT* (--)	VHL Mutation	Everolimus	Renal	Responsive	B	NO	https://civicdb.org/links/evidence_items/5323	only alteration type		R
WP056	VHL MUT* (--)	VHL Loss	Temsirolimus	Renal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1035	only gene		R
WP276	ALK MUT* (--)	ALK fusion	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	FDA	only gene		LUAD
WP276	ALK MUT* (--)	ALK fusion	Alectinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	only gene		NSCLC
WP276	ALK MUT* (--)	ALK fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	only gene		NSCLC
WP276	ALK MUT* (--)	ALK inframe insertion (1151T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165	only alteration type		LUAD
WP276	ALK MUT* (--)	ALK (L1196M,S1206Y,G1269A,I1171T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165;PMID:24327273	only alteration type		LUAD
WP276	ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP276	ALK MUT* (--)	ALK fusion	Brigatinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc	only gene		NSCLC
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP276	KRAS MUT* (--)	KRAS (12,13)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP276	DNMT3A (W860R)	DNMT3A oncogenic mutation	Daunorubicin(Chemotherapy)	Acute myeloid leukemia	Responsive	A	YES	PMID:22417203	complete		AML
WP276	DPYD MUT* (--)	DPYD splice donor variant	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
WP276	DPYD MUT* (--)	DPYD biallelic inactivation	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
WP276	DPYD MUT* (--)	DPYD (I560S,D949V)	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
WP276	DPYD MUT* (--)	DPYD splice donor variant	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
WP276	DPYD MUT* (--)	DPYD biallelic inactivation	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
WP276	DPYD MUT* (--)	DPYD (I560S,D949V)	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
WP276	DPYD MUT* (--)	DPYD splice donor variant	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
WP276	DPYD MUT* (--)	DPYD biallelic inactivation	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
WP276	DPYD MUT* (--)	DPYD (I560S,D949V)	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
WP276	KRAS MUT* (--)	KRAS (12,13,59,61,117,146)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	NCCN guidelines	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	NCCN guidelines	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR inhibitors	Lung	Resistant	A	NO	NCCN guidelines	only alteration type		L
WP276	PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome, Eosinophilic chronic leukemia	Responsive	A	YES	EMA	only gene		HES, ECL
WP276	PDGFRA MUT* (--)	PDGFRA inframe deletion (I843)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type	862.0	GIST
WP276	PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type	862.0	GIST
WP276	PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Regorafenib(Pan-kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
WP276	RET MUT* (--)	RET (618,620,634,768,791,891,918,C634W,M918T)	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	A	NO	PMID:20065189;PMID:22025146	only alteration type		THCA
WP276	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP276	RET MUT* (--)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-ret-altered-thyroid-cancers;ASCO 2020 (abstr 109)	only gene		TH
WP276	RET MUT* (--)	RET oncogenic mutation	Selpercatinib(RET kinase inhibitor)	Thyroid medullary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only alteration type		THM
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP276	ALK MUT* (--)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP276	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP276	CHEK1 MUT* (--)	CHEK1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP276	KRAS MUT* (--)	KRAS (G12C)	Sotorasib(RAS GTPase family inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc	only alteration type		NSCLC
WP276	PDGFRA MUT* (--)	PDGFRA exon 18 mutations	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA (D842V)	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation;PMID:32615108	only alteration type		GIST
WP276	MET MUT* (--)	MET exon 14 skipping mutations	Tepotinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer;PMID:31279006;PMID:34036238	only alteration type		NSCLC
WP276	MET MUT* (--)	MET exon 14 skipping mutations	Capmatinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capmatinib-metastatic-non-small-cell-lung-cancer	only alteration type		NSCLC
WP276	ROS1 MUT* (--)	ROS1 fusion	Entrectinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA;PMID:28183697;ESMO 2019 (abstr 4178) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725s007lbl.pdf	only gene		NSCLC
WP276	RET MUT* (--)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions	only gene		NSCLC
WP276	RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-non-small-cell-lung	only gene		NSCLC
WP276	KRAS MUT* (--)	KRAS (G12C)	Adagrasib(RAS GTPase family inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc	only alteration type		NSCLC
WP276	ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Anaplastic large cell lymphoma	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large	only gene		ALCL
WP276	RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only gene		TH
WP276	RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Solid tumors	Responsive	A	NO	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors	only gene		SOLID
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP276	ATM MUT* (--)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP276	ATR MUT* (--)	ATR oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP276	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP276	PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
WP276	ALK MUT* (--)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP276	MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP276	MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP276	MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP276	MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP276	KRAS MUT* (--)	KRAS (G12C)	Adagrasib(RAS GTPase family inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP276	RET MUT* (--)	RET fusion	Cabozantinib(Kinase inhibitor )	Non-small cell lung	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP276	PDGFRA MUT* (--)	PDGFRA oncogenic mutations (excluding D842V + exon 18 inframe mutations)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type	862.0	GIST
WP276	PDGFRA MUT* (--)	PDGFRA D842V + exon 18 mutations	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
WP276	ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor	only gene		IM
WP276	ALK MUT* (--)	ALK fusion	Alectinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP276	ALK MUT* (--)	ALK fusion	Brigatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP276	ALK MUT* (--)	ALK fusion	Ceritinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP276	ALK MUT* (--)	ALK fusion	Lorlatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP276	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP276	MET MUT* (--)	MET amplification	Capmatinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP276	MET MUT* (--)	MET amplification	Tepotinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP276	MET MUT* (--)	MET exon 14 skipping mutations	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP276	ROS1 MUT* (--)	ROS1 fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP276	ROS1 MUT* (--)	ROS1 fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP276	KRAS MUT* (--)	KRAS (G12C)	Sotorasib(RAS GTPase family inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP276	AKT2 MUT* (--)	AKT2 amplification	MK2206(Allosteric AKT inhibitor)	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 373)	only gene		CANCER
WP276	ALK MUT* (--)	ALK fusion	ALK inhibitor + IGF1R inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25173427	only gene		LUAD
WP276	ALK MUT* (--)	ALK fusion	ALK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:26301689	only gene		LUAD
WP276	ALK MUT* (--)	ALK fusion	ALK inhibitor + SRC inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25394791	only gene		LUAD
WP276	ALK MUT* (--)	ALK fusion	ALK inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560	only gene		COREAD
WP276	ALK MUT* (--)	ALK fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23553849	only gene		LUAD
WP276	ALK MUT* (--)	ALK fusion	novel ALK inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23639470	only gene		LUAD
WP276	ALK MUT* (--)	ALK (F1174L)	novel ALK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24327273	only alteration type		LUAD
WP276	ALK MUT* (--)	ALK amplification	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only gene		LUAD
WP276	ALK MUT* (--)	ALK (E1408V)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP276	ALK MUT* (--)	ALK (L1196M)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP276	ALK MUT* (--)	ALK fusion	Ceritinib(ALK inhibitor)	Colorectal adenocarcinoma, Inflammatory myofibroblastic	Responsive	C	YES	PMID:26633560;PMID:26933125;PMID:27742657	only gene		COREAD, IM
WP276	ALK MUT* (--)	ALK fusion	Ceritinib(ALK inhibitor)	Hematologic malignancies	Responsive	C	YES	NCT02186821	only gene		HEMATO
WP276	ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Lymphoma, Glioblastoma	Responsive	C	YES	PMID:24491302;NCT02270034	only gene		LY, GB
WP276	ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic, Thyroid carcinoma	Responsive	C	YES	PMID:20979472;PMID:24687827	only gene		IM, THCA
WP276	ALK MUT* (--)	ALK (F856S,A348D)	Crizotinib(ALK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:26032424	only alteration type		AML
WP276	ALK MUT* (--)	ALK (L1198F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26698910	only alteration type		LUAD
WP276	ALK MUT* (--)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib(ALK inhibitor)	Glioma	Responsive	D	NO	PMID:22072639	only alteration type		G
WP276	ALK MUT* (--)	ALK fusion	Entrectinib(Pan-TK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560;PMID:26933125	only gene		COREAD
WP276	ALK MUT* (--)	ALK (C1156Y)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27401242	only alteration type		LUAD
WP276	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	complete		CANCER
WP276	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	complete		OV
WP276	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	complete		CANCER
WP276	ATM MUT* (--)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only alteration type		COREAD
WP276	ATM MUT* (--)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
WP276	ATM MUT* (--)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only alteration type		LY
WP276	ATM MUT* (--)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only gene		LY
WP276	ATM MUT* (--)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP276	ATM MUT* (--)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
WP276	ATM MUT* (--)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP276	ATM MUT* (--)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP276	ATM MUT* (--)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP276	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP276	ATM MUT* (--)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP276	ATR MUT* (--)	ATR oncogenic mutation	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only alteration type		OV, CANCER
WP276	ATR MUT* (--)	ATR deletion	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only gene		OV, CANCER
WP276	ATR MUT* (--)	ATR oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Pancreas	No Responsive	C	NO	ASCO 2015 (abstr 4119)	only alteration type		PA
WP276	KRAS MUT* (--)	KRAS (G13D)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	No Responsive	B	NO	PMID:27114605	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	Selumetinib(MEK inhibitor)	Lung	No Responsive	C	NO	PMID:26802155	only alteration type		L
WP276	KRAS MUT* (--)	KRAS amplification	BRAF inhibitor + EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only gene		COREAD
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
WP276	BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP276	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP276	KRAS MUT* (--)	KRAS amplification	BRAF inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only gene		COREAD
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR inhibitors	Non-small cell lung	Resistant	D	NO	PMID:19238210	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR mAb inhibitors	Stomach	Resistant	D	NO	PMID:22614881;PMID:22290393	only alteration type		ST
WP276	CDKN1A MUT* (--)	CDKN1A oncogenic mutation	CDK2/4 inhibitors	Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22997239	only alteration type		CANCER
WP276	CDKN1A MUT* (--)	CDKN1A deletion	CDK2/4 inhibitors	Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22997239	only gene		CANCER
WP276	CSF1R MUT* (L207)	CSF1R (Y571D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:18971950	only alteration type		MDPS
WP276	MAP2K2 MUT* (--)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP276	MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP276	MAP2K2 MUT* (--)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP276	MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP276	MET MUT* (--)	MET amplification	EGFR inhibitor 1st gens	Non-small cell lung, Colorectal adenocarcinoma	Resistant	C	NO	PMID:22189054;PMID:23729478	only gene		NSCLC, COREAD
WP276	MET MUT* (--)	MET amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:23729478	only gene		COREAD
WP276	MET MUT* (--)	MET (D1246V)	MET inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:27694386	only alteration type		LUAD
WP276	MITF MUT* (--)	MITF amplification	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265153	only gene		CM
WP276	MITF MUT* (--)	MITF amplification	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265153	only gene		CM
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP276	NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP276	PDGFRA MUT* (--)	PDGFRA amplification	PDGFR inhibitors	Glioma	No Responsive	D	NO	PMID:23544171	only gene		G
WP276	PIK3CB MUT* (--)	PIK3CB (D1067Y)	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	C	NO	PMID:26759240	only alteration type		BRCA
WP276	PTEN MUT* (--)	PTEN oncogenic mutation	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	B	NO	PMID:21163703;PMID:19398573	only alteration type		COREAD
WP276	PTEN MUT* (--)	PTEN deletion	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	B	NO	PMID:21163703;PMID:19398573	only gene		COREAD
WP276	PTEN MUT* (--)	PTEN oncogenic mutation	MTOR inhibitors	Endometrium	No Responsive	C	NO	PMID:21788564;PMID:23238879	only alteration type		ED
WP276	PTEN MUT* (--)	PTEN deletion	MTOR inhibitors	Endometrium	No Responsive	C	NO	PMID:21788564;PMID:23238879	only gene		ED
WP276	EPHA2 MUT* (--)	EPHA2 (G391R)	MTOR inhibitors	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
WP276	EPHA2 MUT* (--)	EPHA2 (G391R)	MTOR inhibitors	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
WP276	EPHA2 MUT* (--)	EPHA2 amplification	Dasatinib(BCR-ABL inhibitor 2nd gen)	Any cancer type	Responsive	D	YES	PMID:18047674;PMID:19010823;PMID:19861960	only gene		CANCER
WP276	EPHA2 MUT* (--)	EPHA2 amplification	Dasatinib(BCR-ABL inhibitor 2nd gen)	Any cancer type	Responsive	D	YES	PMID:18047674;PMID:19010823;PMID:19861960	only gene		CANCER
WP276	EPHA2 MUT* (--)	EPHA2 (G391R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
WP276	EPHA2 MUT* (--)	EPHA2 (G391R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
WP276	TP53 (K132R)	TP53 oncogenic mutation	MDM2 inhibitors	Liposarcoma	Resistant	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	complete		LIP
WP276	FAT1 MUT* (--)	FAT1 oncogenic mutation	BET inhibitors	Head an neck squamous	Responsive	D	NO	PMID:27397505	only alteration type		HNSC
WP276	TP53 (K132R)	TP53 oncogenic mutation	Abemaciclib(CDK4/CDK6 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:27217383	complete		BRCA
WP276	FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Lung squamous cell	Responsive	C	NO	PMID:27870574	only gene		LUSC
WP276	FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Endometrium	Responsive	C	NO	ASCO 2017 (abstr 2500)	only gene		ED
WP276	FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Lung squamous cell	Responsive	C	NO	AACR 2012 (abstr LB-122);AACR 2013 (abstr LB-145)	only gene		LUSC
WP276	FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Head an neck	Responsive	D	NO	PMID:23418312	only gene		HNC
WP276	FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors(Lucitanib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:25193991	only gene		BRCA
WP276	ALK MUT* (--)	ALK (I1171T)	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:25228534	only alteration type		LUAD
WP276	FGFR4 MUT* (--), FGFR4 MUT* (H399P)	FGFR4 (N535,V550)	FGFR inhibitors	Rhabdomyosarcoma	Responsive	D	NO	PMID:19809159;PMID:24124571	only alteration type		RHBDS
WP276	PTEN MUT* (--)	PTEN biallelic inactivation	BYL719(PIK3CA inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:25409150	only alteration type		BRCA
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP276	NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP276	ALK MUT* (--)	ALK (G1123S)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:26134233	only alteration type		LUAD
WP276	GATA3 MUT* (--)	GATA3 oncogenic mutation	Aromatase ihibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:24758297	only alteration type		BRCA
WP276	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	EZH2 inhibitors	Any cancer type	Resistant	D	YES	PMID:26552009	only alteration type		CANCER
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitors	Endometrium	Resistant	D	NO	PMID:22662154	only alteration type		ED
WP276	JAK3 MUT* (A125V)	JAK3 (A572V,A573V)	JAK inhibitors	Lymphoma	Responsive	D	YES	PMID:22705984	only alteration type		LY
WP276	JAK3 MUT* (A125V)	JAK3 (R657Q,I87T,Q501H)	JAK inhibitors	Megakaryoblastic leukemia	Responsive	D	YES	PMID:18397343	only alteration type		MKB
WP276	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP276	PTEN MUT* (--)	PTEN biallelic inactivation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	Caris molecular intelligence	only alteration type		COREAD
WP276	MDM2 MUT* (--)	MDM2 amplification	Cisplatin(Chemotherapy)	Male germ cell tumor	Resistant	C	NO	PMID:27646943	only gene		MGCT
WP276	TP53 (K132R)	TP53 oncogenic mutation	Cisplatin(Chemotherapy)	Female germ cell tumor, Male germ cell tumor	Resistant	C	NO	PMID:27646943	complete		FGCT, MGCT
WP276	ALK MUT* (--)	ALK inframe insertion (1151T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only alteration type		LUAD
WP276	ALK MUT* (--)	ALK oncogenic mutation	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only alteration type		NSCLC
WP276	ALK MUT* (--)	ALK amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only gene		NSCLC
WP276	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP276	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP276	ALK MUT* (--)	ALK amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only gene		LUAD
WP276	ALK MUT* (--)	ALK (C1156Y,L1196M)	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:20979473	only alteration type		NSCLC
WP276	ALK MUT* (--)	ALK (F1174L)	Crizotinib(ALK inhibitor)	Glioma	Resistant	D	NO	PMID:22072639	only alteration type		G
WP276	KRAS MUT* (--)	KRAS (G12)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	C	NO	PMID:24687822	only alteration type		GIST
WP276	ALK MUT* (--)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784;PMID:25228534	only alteration type		LUAD
WP276	MET MUT* (--)	MET (Y1230C,Y1235D)	Crizotinib(ALK inhibitor)	Any cancer type	Resistant	D	YES	PMID:17483355	only alteration type		CANCER
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	Trastuzumab + Lapatinib(ERBB2 mAb inhibitor + ERBB2 inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	ASCO 2015 (abstr 3508);NCT01104571;EBCC10	only alteration type		COREAD
WP276	ROS1 MUT* (--)	ROS1 (G2032R)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:23724914;PMID:25688157	only alteration type		LUAD
WP276	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	BET inhibitors	Lung	Responsive	D	NO	PMID:23129625;PMID:24045185	only alteration type		L
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4 inhibitors	Lung	Responsive	D	NO	PMID:20609353	only alteration type		L
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Lung	Responsive	C	NO	AACR 2017 (CT046)	only alteration type		L
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Cervix squamous cell	Responsive	D	NO	PMID:27167191	only alteration type		CESC
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR mAb inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24553387	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	ERK inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23614898	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	FAK inhibitors	Lung	Responsive	D	NO	PMID:23358651	only alteration type		L
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	FAS inhibitors	Lung	Responsive	C	NO	AACR 2016;abstr	only alteration type		L
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	FAS inhibitors	Lung	Responsive	C	NO	AACR 2016, abstr LB214	only alteration type		L
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	HSP90 inhibitor(in combination)s	Lung	Responsive	D	NO	PMID:23012248;PMID:21907929	only alteration type		L
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	JAK/TBK1/IKKÎµ inhibitors	Lung	Responsive	D	NO	PMID:24444711	only alteration type		L
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + BCL-XL inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23245996	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + IGF1R inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24045180	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + PI3K pathway inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:22392911	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitors	Lung, Billiary tract	Responsive	C	NO	PMID:23200175;PMID:24947927;PMID:25667274;PMID:25722381;PMID:23391555	only alteration type		L, BT
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitors	Acute myeloid leukemia, Cervix, Ovary	Responsive	D	YES	PMID:22507781;PMID:22169769;PMID:19018267	only alteration type		AML, CER, OV
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP276	KRAS MUT* (--)	KRAS (G12)	MEK inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:18701506	only alteration type		ALL
WP276	NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	MTOR inhibitor + BH3 mimeticss	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24163374	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	pan-RAF inhibitors	Lung	Responsive	C	NO	AACR 2017 (abstr  CT002)	only alteration type		L
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	pan-RAF inhibitors	Endometrium	Responsive	C	NO	AACR 2016 (abstr CT005);AACR 2017 (abstr CT002)	only alteration type		ED
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Endometrium	Responsive	D	NO	PMID:21984976;PMID:22662154	only alteration type		ED
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Lung	Responsive	C	NO	PMID:25516890	only alteration type		L
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	Abemaciclib(CDK4/6 inhibitor)	Lung	Responsive	C	NO	PMID:27217383	only alteration type		L
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP276	NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP276	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP276	NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP276	NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP276	MDM2 MUT* (--)	MDM2 amplification	MDM2 inhibitors	Liposarcoma	Responsive	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	only gene	630.0	LIP
WP276	MET MUT* (--)	MET kinase domain mutation	Savolitinib(MET inhibitor)	Renal	Responsive	C	NO	PMID:28644771	only alteration type		R
WP276	MET MUT* (--)	MET amplification	BCL2 inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:27397505	only gene		COREAD
WP276	MET MUT* (--)	MET amplification	MET inhibitors	Hepatic carcinoma	Responsive	C	NO	ENA 2015 (abstract A55)	only gene		HC
WP276	MET MUT* (--)	MET amplification	MET inhibitors	Stomach	Responsive	D	NO	PMID:22729845;PMID:23327903	only gene		ST
WP276	MET MUT* (--)	MET amplification	MET inhibitors	Renal	Responsive	C	NO	PMID:23213094;AACR 2016 (abstr CT2006)	only gene		R
WP276	MET MUT* (--)	MET (H1112R)	MET inhibitors	Renal	Responsive	C	NO	PMID:23213094	only alteration type		R
WP276	MET MUT* (--)	MET (M1268T)	MET inhibitors	Renal	Responsive	C	NO	PMID:23610116	only alteration type		R
WP276	MET MUT* (--)	MET (H1112L)	MET inhibitors(Crizotinib,etc)	Any cancer type	Responsive	D	YES	AACR 2012 (abstr 1786)	only alteration type		CANCER
WP276	MET MUT* (--)	MET amplification	Cabozantinib + Panitumumab(Pan-kinase inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A52)	only gene		COREAD
WP276	MET MUT* (--)	MET fusion	Crizotinib(ALK inhibitor)	Glioma	Responsive	C	NO	PMID:27748748	only gene		G
WP276	MET MUT* (--)	MET mutation in exon 16-19	Crizotinib(ALK inhibitor)	Renal	Responsive	C	NO	AACR 2016 (abstr CT2006)	only alteration type		R
WP276	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma, Stomach	Responsive	C	NO	ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1)	only gene		LUAD, ST
WP276	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Glioma	Responsive	C	NO	PMID:22162573	only gene		G
WP276	MET MUT* (--)	MET (V1110I,H1112R,M1268T,R988C,T1010I)	Crizotinib(ALK inhibitor)	Any cancer type	Responsive	D	YES	PMID:17483355	only alteration type		CANCER
WP276	PLCG2 MUT* (--)	PLCG2 (R665W,L845F)	Ibrutinib(BTK inhibitor)	Chronic lymphocytic leukemia	Resistant	C	YES	PMID:24869598	only alteration type		CLL
WP276	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	Decitabine + BCL2 inhibitor(Chemotherapy + BCL2 inhibitor)	Ovary	Responsive	D	NO	PMID:25968887	only alteration type		OV
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP276	NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP276	NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP276	NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP276	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP276	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP276	NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP276	NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP276	NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP276	NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP276	PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP276	NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP276	PDGFRA MUT* (--)	PDGFRA (T674I)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome	Resistant	C	YES	PMID:12660384	only alteration type		HES
WP276	CRBN MUT* (--)	CRBN oncogenic mutation	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP276	CRBN MUT* (--)	CRBN (Q100*,R283K)	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP276	NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP276	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP276	LRP1B MUT* (--)	LRP1B oncogenic mutation	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only alteration type		OV
WP276	LRP1B MUT* (--)	LRP1B deletion	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only gene		OV
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP276	NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP276	NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP276	NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP276	NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP276	NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP276	NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP276	NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP276	NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP276	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP276	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP276	NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP276	NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP276	MET MUT* (--)	MET amplification	EGFR inhibitor 3rd gens(Osimertinib,etc)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	Gemcitabine + MEK inhibitor(Chemotherapy + MEK inhibitor)	Pancreas	Responsive	C	NO	PMID:23583440	only alteration type		PA
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	Selumetinib(MEK inhibitor)	Non-small cell lung	Responsive	C	NO	NCT00890825	only alteration type		NSCLC
WP276	NOTCH1 MUT* (T349P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP276	NOTCH1 MUT* (T349P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP276	NOTCH1 MUT* (T349P)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP276	NOTCH1 MUT* (T349P)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP276	NOTCH1 MUT* (T349P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP276	NOTCH1 MUT* (T349P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP276	NOTCH1 MUT* (T349P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP276	NOTCH1 MUT* (T349P)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	only alteration type		MCL
WP276	NOTCH1 MUT* (T349P)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP276	NOTCH1 MUT* (T349P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP276	NOTCH1 MUT* (T349P)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP276	NOTCH2 MUT* (C19W), NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP276	NOTCH2 MUT* (C19W), NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP276	NOTCH2 MUT* (C19W), NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP276	PTEN MUT* (--)	PTEN biallelic inactivation	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	Caris molecular intelligence	only alteration type		COREAD
WP276	CRBN MUT* (--)	CRBN oncogenic mutation	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP276	CRBN MUT* (--)	CRBN (Q100*,R283K)	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP276	NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP276	NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP276	PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP276	PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP276	PDGFRA MUT* (--)	PDGFRA (D842V)	HSP90 inhibitors	Gastrointestinal stromal	Responsive	D	NO	PMID:18794084	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA (D842V)	Crenolanib(FLT3 inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2016 (abstr 11010)	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	Crenolanib(FLT3 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
WP276	RET MUT* (--)	RET (I788N)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Resistant	D	NO	PMID:28615362	only alteration type		LUAD
WP276	PDGFRA MUT* (--)	PDGFRA (P577S,R841K,H845Y,G853D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
WP276	MET MUT* (--)	MET amplification	EGFR inhibitor 3rd gens(Rociletinib,etc)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	Sorafenib + MEK inhibitor(Pan-TK inhibitor + MEK inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:25294897	only alteration type		HC
WP276	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	AKT inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP276	PIK3CB MUT* (--)	PIK3CB (D1067Y)	AKT inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26759240	only alteration type		BRCA
WP276	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	MTORC1/2 inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP276	PIK3CB MUT* (--)	PIK3CB (D1067Y)	MTORC1/2 inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26759240	only alteration type		BRCA
WP276	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP276	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	AKT inhibitors	Glioma	Responsive	D	NO	PMID:23166678	only alteration type		G
WP276	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	PI3K pathway inhibitors	Endometrium	Responsive	C	NO	ASCO 2015 (abstr 11075)	only alteration type		ED
WP276	POLE MUT* (--), POLE MUT* (--)	POLE (268-471)	PD1 Ab inhibitors	Glioma, Endometrium	Responsive	C	NO	PMID:27001570;PMID:27683556;PMID:27159395	only alteration type		G, ED
WP276	POLE MUT* (--), POLE MUT* (--)	POLE oncogenic mutation	PD1 Ab inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28188185	only alteration type		COREAD
WP276	PTEN MUT* (--)	PTEN oncogenic mutation	AKT inhibitors	Pancreas	Responsive	C	NO	PMID:22025163	only alteration type		PA
WP276	PTEN MUT* (--)	PTEN deletion	AKT inhibitors	Pancreas	Responsive	C	NO	PMID:22025163	only gene		PA
WP276	PTEN MUT* (--)	PTEN oncogenic mutation	ATM inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27397505	only alteration type		BRCA
WP276	PTEN MUT* (--)	PTEN oncogenic mutation	PARP inhibitors	Endometrium	Responsive	C	NO	PMID:21468130;PMID:20944090	only alteration type		ED
WP276	PTEN MUT* (--)	PTEN deletion	PARP inhibitors	Endometrium	Responsive	C	NO	PMID:21468130;PMID:20944090	only gene		ED
WP276	PTEN MUT* (--)	PTEN oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26645196	only alteration type		CM
WP276	PTEN MUT* (--)	PTEN deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26645196	only gene		CM
WP276	PTEN MUT* (--)	PTEN oncogenic mutation	PI3K pathway inhibitor + AR antagonists	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575859	only alteration type		PRAD
WP276	PTEN MUT* (--)	PTEN deletion	PI3K pathway inhibitor + AR antagonists	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575859	only gene		PRAD
WP276	PTEN MUT* (--)	PTEN oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Ovary	Responsive	D	NO	PMID:21632463	only alteration type		OV
WP276	PTEN MUT* (--)	PTEN deletion	PI3K pathway inhibitor + MEK inhibitors	Ovary	Responsive	D	NO	PMID:21632463	only gene		OV
WP276	PTEN MUT* (--)	PTEN oncogenic mutation	PI3K pathway inhibitors	Thyroid, Glioma, Lung, Ovary, Breast adenocarcinoma, Any cancer type, Endometrium	Responsive	D	YES	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669	only alteration type		TH, G, L, OV, BRCA, CANCER, ED
WP276	PTEN MUT* (--)	PTEN deletion	PI3K pathway inhibitors	Thyroid, Glioma, Lung, Ovary, Breast adenocarcinoma, Any cancer type, Endometrium	Responsive	D	YES	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669	only gene		TH, G, L, OV, BRCA, CANCER, ED
WP276	PTEN MUT* (--)	PTEN oncogenic mutation	PIK3CB inhibitors	Prostate adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 2514)	only alteration type		PRAD
WP276	PTEN MUT* (--)	PTEN deletion	PIK3CB inhibitors	Prostate adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 2514)	only gene		PRAD
WP276	PTEN MUT* (--)	PTEN oncogenic mutation	Everolimus(MTOR inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:23582881	only alteration type		PRAD
WP276	PTEN MUT* (--)	PTEN deletion	Everolimus(MTOR inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:23582881	only gene		PRAD
WP276	PTEN MUT* (--)	PTEN oncogenic mutation	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	C	YES	ASCO 2013 (abstr 2532)	only alteration type		CANCER
WP276	PTEN MUT* (--)	PTEN deletion	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	C	YES	ASCO 2013 (abstr 2532)	only gene		CANCER
WP276	PDGFRA MUT* (--)	PDGFRA (D842V)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP276	NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP276	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP276	RAF1 MUT* (--)	RAF1 fusion	Pan-RAF inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:20526349	only gene		PRAD
WP276	RAF1 MUT* (--)	RAF1 fusion	Sorafenib(Pan-TK inhibitor)	Prostate adenocarcinoma	Responsive	D	NO	PMID:20526349	only gene		PRAD
WP276	RAF1 MUT* (--)	RAF1 fusion	U0126(MEK inhibitor)	Prostate adenocarcinoma	Responsive	D	NO	PMID:20526349	only gene		PRAD
WP276	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP276	RET MUT* (--)	RET fusion	RET inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:22327624;PMID:22327622	only gene		LUAD
WP276	RET MUT* (--)	RET-TPCN1 fusion	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only gene		TH
WP276	RET MUT* (--)	RET (C634W,M918T)	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only alteration type		TH
WP276	RET MUT* (--)	RET fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP276	RET MUT* (--)	RET-TPCN1 fusion	Cabozantinib(Pan-kinase inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP276	RET MUT* (--)	RET (C634W,M918T)	Cabozantinib(Pan-kinase inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP276	RET MUT* (--)	RET fusion	Nintedanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26787234	only gene		LUAD
WP276	RET MUT* (--)	RET fusion	Sunitinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP276	RET MUT* (--)	RET-TPCN1 fusion	Sunitinib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP276	RET MUT* (--)	RET (C634W,M918T)	Sunitinib(Pan-TK inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP276	RET MUT* (--)	RET fusion	Vandetanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP276	RET MUT* (--)	RET-TPCN1 fusion	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP276	RNF43 MUT* (--)	RNF43 oncogenic mutation	Porcupine inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr C45)	only alteration type		COREAD
WP276	ROS1 MUT* (--)	ROS1 fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:23533265	only gene		LUAD
WP276	ROS1 MUT* (--)	ROS1 fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27370605	only gene		LUAD
WP276	ROS1 MUT* (--)	ROS1 (G2032R)	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:25351743	only alteration type		LUAD
WP276	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	C	YES	PMID:24875859	only gene		IM
WP276	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:25264305	only gene		LUAD
WP276	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27401242	only alteration type		LUAD
WP276	SETD2 MUT* (--)	SETD2 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only alteration type		CANCER
WP276	SETD2 MUT* (--)	SETD2 deletion	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only gene		CANCER
WP276	SF3B1 MUT* (--)	SF3B1 (K700E,K666N)	Spliceosome inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858	only alteration type		CANCER
WP276	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib + Ponatinib(MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27338794	only alteration type		LUAD
WP276	STAG2 MUT* (--)	STAG2 oncogenic mutation	PARP inhibitors	Glioma	Responsive	D	NO	PMID:24356817	only alteration type		G
WP276	NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP276	SUZ12 MUT* (--), SUZ12 MUT* (--)	SUZ12 oncogenic mutation	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only alteration type		CANCER
WP276	SUZ12 MUT* (--), SUZ12 MUT* (--)	SUZ12 deletion	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only gene		CANCER
WP276	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP276	TMPRSS2 MUT* (--)	TMPRSS2 fusion	DNA-PKc inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575865	only gene		PRAD
WP276	TMPRSS2 MUT* (--)	TMPRSS2 fusion	PARP inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575865	only gene		PRAD
WP276	TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP276	TP53 MUT* (T377P), TP53 (K132R)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
WP276	TP53 MUT* (T377P), TP53 (K132R)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
WP276	TP53 (K132R)	TP53 oncogenic mutation	WEE1 inhibitors	Head an neck	Responsive	D	NO	PMID:25125259	complete		HNC
WP276	TP53 (K132R)	TP53 oncogenic mutation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	complete		BCL
WP276	TP53 MUT* (T377P), TP53 (K132R)	TP53 deletion	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only gene		BCL
WP276	TP53 (K132R)	TP53 oncogenic mutation	Decitabine(Chemotherapy)	Acute myeloid leukemia, Myelodisplasic proliferative syndrome	Responsive	C	YES	PMID:27959731	complete		AML, MDPS
WP276	TP53 (K132R)	TP53 oncogenic mutation	Doxorubicin(Anthracycline antitumor antibiotic)	Bladder	Responsive	D	NO	PMID:27397505	complete		BLCA
WP276	TP53 (K132R)	TP53 oncogenic mutation	Gemcitabine(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	complete		BLCA
WP276	TP53 (K132R)	TP53 oncogenic mutation	Mitomycin C(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	complete		BLCA
WP276	TP53 (K132R)	TP53 oncogenic mutation	WEE1 inhibitors	Ovary	Responsive	C	NO	PMID:27998224	complete		OV
WP276	TP53 (K132R)	TP53 oncogenic mutation	Pramlintide(Amylin analogue)	Thymic	Responsive	D	YES	PMID:25409149	complete		THYM
WP276	TP53 MUT* (T377P), TP53 (K132R)	TP53 deletion	Pramlintide(Amylin analogue)	Thymic	Responsive	D	YES	PMID:25409149	only gene		THYM
WP276	PTEN MUT* (--)	PTEN (D326N,G165R,T277A,T160I,G129E,G165V,N48K,H93Y,N94I,D92E,D92G,F21A,R173P,L112R,K289E,L108P,R335L,H123Y,R130G,D92V,G251C,R15S,L181P,V133I,C124R,T131A,.,V343L,A126V,T131L,L112P,R173C,G129A,H61D,C136R,H123Q,H61R,P96Q,D331G,M134L,N276S,K342N,Y68H,D92N,M35R,Y68D,P95S,R130Q,R173H,Y155C,H123D,G20E,K62R,R159G,S10N,L23F,C105F,D162G,T319A,Y16C,A126D,H93R,K128Q,I122S,Y65C,F154L,K128T,R130K,R130L,V343E,G36R,A126S,D252G,G127N,F347L,G127E,K125E,A39P,S170N,G165E,P169H,Y27S,V217D,D162H,H118P,D92A,A34D,D24Y,L345Q,T131I,D92H,K128N,T167A,S170R,T401I,P95L,C124S,P38L,S227F,C124N,A121P,G129D,K128R,C136Y,F341V,K125L,R130A,D24N,H93D,L325F,C71Y,E157G,L42R,Y174N,A121E,A126G,G129R,R161G,G44D,I168F,R15K,H93Q,I122L,F241S,D107Y,K125M,L320S)	Gsk2636771 + Azd8186	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/PTEN	only alteration type		CANCER
WP276	PTEN MUT* (--)	PTEN deletion	Gsk2636771 + Azd8186	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/PTEN	only gene		CANCER
WP276	FGFR1 MUT* (--)	FGFR1 amplification	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Lung squamous cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		LUSC
WP276	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
WP276	BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
WP276	MDM2 MUT* (--)	MDM2 amplification	Unii-Q8Mi0X869M	Liposarcoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MDM2	only gene		LIP
WP276	ALK MUT* (--)	ALK fusion	Crizotinib + Ceritinib	Sarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only gene		S
WP276	ALK MUT* (--)	ALK (G1202R,I1171N)	Alectinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only alteration type		NSCLC
WP276	MET MUT* (--)	MET amplification	Crizotinib	Non-small cell lung	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/52/summary|oncokb=https://www.oncokb.org/gene/MET	only gene		NSCLC
WP276	MET MUT* (--)	MET (D1010H,Y1003N,D1010N,Y1003F,Y1003C,D1010Y)	Crizotinib	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP276	PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib	Gastrointestinal stromal	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP276	MET MUT* (--)	MET (D1010H,Y1003N,D1010N,Y1003F,Y1003C,D1010Y)	Cabozantinib + Capmatinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP276	PDGFRA MUT* (--)	PDGFRA (N659K,V561D,V561A,N659S,A633T,H845Y,T674I,S584L,D842V,N659R,D568N,P577S,D846Y,Q579R,D842Y,Y849S,N848K,H650Q,D842I,V469A,Y288C,Y555C,R748G,Y849C,.,R841K,G853D,V536E,V658A)	Imatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA amplification	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP276	PDGFRA MUT* (--)	PDGFRA-BCR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP276	PDGFRA MUT* (--)	PDGFRA-CDK5RAP2 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP276	PDGFRA MUT* (--)	PDGFRA-ETV6 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP276	PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP276	PDGFRA MUT* (--)	PDGFRA fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP276	PDGFRA MUT* (--)	PDGFRA-KDR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP276	PDGFRA MUT* (--)	PDGFRA-KIF5B fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP276	PDGFRA MUT* (--)	PDGFRA-STRN fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP276	KRAS MUT* (--)	KRAS (D119N,G12F,F156L,G60R,F28L,A18D,Q22K,K147E,D33E,A146T,E62K,A146V,Q61R,Q61H,G12A,G12R,G13E,Q22R,V14I,Y71H,G13D,G12C,T58I,.,D153V,A59G,K117N,S65N,P34L,Y64A,G13V,K5N,Y32S,L19F,T74P,G13C,G12V,G12D,Q22E,Q61L,G12S,P34R)	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/30/summary|oncokb=https://www.oncokb.org/gene/KRAS	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS amplification	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only gene		COREAD
WP276	KRAS MUT* (--)	KRAS (D119N,G12F,F156L,G60R,F28L,A18D,Q22K,K147E,D33E,A146T,E62K,A146V,Q61R,Q61H,G12A,G12R,G13E,Q22R,V14I,Y71H,G13D,G12C,T58I,.,D153V,A59G,K117N,S65N,P34L,Y64A,K5N,Y32S,L19F,T74P,G13C,G12V,G12D,Q22E,Q61L,G12S,P34R)	Cobimetinib + Binimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only alteration type		CANCER
WP276	KRAS MUT* (--)	KRAS amplification	Cobimetinib + Binimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only gene		CANCER
WP276	MET MUT* (--)	MET amplification	Erlotinib + Gefitinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only gene		NSCLC
WP276	NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP276	NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP276	FGFR1 MUT* (--)	FGFR1 amplification	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP276	FGFR1 MUT* (--)	FGFR1-BCR fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP276	FGFR1 MUT* (--)	FGFR1-CEP110 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP276	FGFR1 MUT* (--)	FGFR1-CUX1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP276	FGFR1 MUT* (--)	FGFR1-ERLIN2 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP276	FGFR1 MUT* (--)	FGFR1-TACC1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP276	FGFR1 MUT* (--)	FGFR1-FGFR1OP1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP276	FGFR1 MUT* (--)	FGFR1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP276	FGFR1 MUT* (--)	FGFR1 (V592M,K687E,.,N577K)	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only alteration type		CANCER
WP276	FGFR1 MUT* (--)	FGFR1-ZNF198 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
WP276	ATM MUT* (--)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only alteration type		CANCER
WP276	ATM MUT* (--)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
WP276	ALK MUT* (--)	ALK (C1156Y,F1174L,L1196M,G1269A)	Crizotinib	Non-small cell lung	Resistant	D	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary	only alteration type		NSCLC
WP276	RET MUT* (--)	RET fusion	Cabozantinib + Vandetanib + Larotrectinib + 292 + 667	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		NSCLC
WP276	RET MUT* (--)	RET (C618R,C620R,C609Y,E768D,C630R,S904F,E511K,C634S,C634Y,V648I,I852M,S891A,A883T,A883F,C611Y,T338I,C634W,K603Q,D631Y,M918T,A919V,R833C,.,V804M,C634R,V804L,Y806C,M918V,L790F,M848T,R886W,Y791F)	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only alteration type		THM
WP276	RET MUT* (--)	RET fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP276	RET MUT* (--)	RET-KIF5B fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP276	RET MUT* (--)	RET-CCDC6 fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP276	MET MUT* (--)	MET (D1228N)	Crizotinib + Cabozantinib + Capmatinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP276	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
WP276	BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
WP276	PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP276	MET MUT* (--)	MET amplification	Cabozantinib	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only gene		RCCC
WP276	MET MUT* (--)	MET (Y1230H)	Crizotinib + Capmatinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP276	AKT2 MUT* (--)	AKT2 Amplification	Everolimus,Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1621	only gene		LUAD
WP276	ALK MUT* (--)	ALK CAD::ALK	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7481	only gene		COREAD
WP276	ALK MUT* (--)	ALK CLTC::ALK	TAE684	Difuse large B Cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1261	only gene		DLBCL
WP276	ALK MUT* (--)	ALK CLTC::ALK	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1265	only gene		DLBCL
WP276	ALK MUT* (--)	ALK EML4::ALK	Alectinib	Mesothelioma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9228	only gene		MESO
WP276	ALK MUT* (--)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/262	only gene		NSCLC
WP276	ALK MUT* (--)	ALK EML4::ALK	WHI-P154	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1188	only gene		NSCLC
WP276	ALK MUT* (--)	ALK EML4::ALK	Crizotinib,Retaspimycin Hydrochloride	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1203	only gene		NSCLC
WP276	ALK MUT* (--)	ALK EML4::ALK	Crizotinib,Alvespimycin	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1206	only gene		NSCLC
WP276	ALK MUT* (--)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1207	only gene		NSCLC
WP276	ALK MUT* (--)	ALK EML4::ALK	Lorlatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1332	only gene		NSCLC
WP276	ALK MUT* (--)	ALK F1174L	Crizotinib	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/125	only alteration type		NB
WP276	ALK MUT* (--)	ALK F1174L	Alectinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/37	only alteration type		NB
WP276	ALK MUT* (--)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/38	only alteration type		NB
WP276	ALK MUT* (--)	ALK F1174L	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/142	only alteration type		NB
WP276	ALK MUT* (--)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1271	only alteration type		NB
WP276	ALK MUT* (--)	ALK F1174L	AZD3463	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1327	only alteration type		NB
WP276	ALK MUT* (--)	ALK F1174L	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1329	only alteration type		NB
WP276	ALK MUT* (--)	ALK F1174L	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/33	only alteration type		NSCLC
WP276	ALK MUT* (--)	ALK F1245C	Crizotinib	Neuroblastoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1333	only alteration type		NB
WP276	ALK MUT* (--)	ALK F1245C	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1330	only alteration type		NB
WP276	ALK MUT* (--)	ALK F1245V	Entrectinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2987	only alteration type		NB
WP276	ALK MUT* (--)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1240	only gene		ALCL
WP276	ALK MUT* (--)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/7361	only gene		ALCL
WP276	ALK MUT* (--)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	A	YES	https://civicdb.org/links/evidence_items/11218	only gene		ALCL
WP276	ALK MUT* (--)	ALK Fusion	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1264	only gene		DLBCL
WP276	ALK MUT* (--)	ALK Fusion	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1691	only gene		LUAD
WP276	ALK MUT* (--)	ALK Fusion	Pemetrexed	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/945	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1175	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1187	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1198	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1199	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1200	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1201	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Retaspimycin Hydrochloride	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1202	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1272	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1273	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1279	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1282	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1419	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1577	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4835	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Alectinib,Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4858	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7284	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7285	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Lorlatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7286	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/8657	only gene		NSCLC
WP276	ALK MUT* (--)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11121	only gene		NSCLC
WP276	ALK MUT* (--)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1283	only alteration type		NSCLC
WP276	ALK MUT* (--)	ALK I1171	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1287	only alteration type		NSCLC
WP276	ALK MUT* (--)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1367	only alteration type		NSCLC
WP276	ALK MUT* (--)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1284	only alteration type		NSCLC
WP276	ALK MUT* (--)	ALK I1171	TAE684	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1285	only alteration type		NSCLC
WP276	ALK MUT* (--)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1344	only alteration type		NSCLC
WP276	ALK MUT* (--)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1368	only alteration type		NSCLC
WP276	ALK MUT* (--)	ALK I1171T	Ceritinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9404	only alteration type		NB
WP276	ALK MUT* (--)	ALK KANK4::ALK	Alectinib	Pancreas acinar	Responsive	C	NO	https://civicdb.org/links/evidence_items/10327	only gene		PAAC
WP276	ALK MUT* (--)	ALK Mutation	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1237	only alteration type		NSCLC
WP276	ALK MUT* (--)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1239	only gene		ALCL
WP276	ALK MUT* (--)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/1241	only gene		ALCL
WP276	ALK MUT* (--)	ALK R1275Q	TAE684	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/48	only alteration type		NB
WP276	ALK MUT* (--)	ALK R1275Q	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/39	only alteration type		NB
WP276	ALK MUT* (--)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/143	only alteration type		NB
WP276	ALK MUT* (--)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1270	only alteration type		NB
WP276	ALK MUT* (--)	ALK R1275Q	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1331	only alteration type		NB
WP276	ASS1 MUT* (--)	ASS1 Loss	Carboplatin,Cisplatin,Taxol	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/5989	only gene		OV
WP276	ATM MUT* (--)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	only alteration type		CM
WP276	ATM MUT* (--)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	only alteration type		GB
WP276	ATM MUT* (--)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	only alteration type		PRAD
WP276	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP276	BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
WP276	BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
WP276	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
WP276	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
WP276	BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
WP276	BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
WP276	BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
WP276	BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
WP276	CHEK1 MUT* (--)	CHEK1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11210	only alteration type		PRAD
WP276	CRBN MUT* (--)	CRBN Mutation	Lenalidomide,Pomalidomide	Multiple myeloma	Resistant	C	YES	https://civicdb.org/links/evidence_items/1766	only alteration type		MM
WP276	DNMT3A (W860R)	DNMT3A Mutation	Decitabine	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/1587	complete		AML
WP276	DNMT3A (W860R)	DNMT3A R882	Daunorubicin	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/11	only alteration type		AML
WP276	DNMT3A (W860R)	DNMT3A R882	Idarubicin	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/18	only alteration type		AML
WP276	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP276	FGFR1 MUT* (--)	FGFR1 FGFR1OP2::FGFR1	Ponatinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7380	only gene		AML
WP276	FGFR1 MUT* (--)	FGFR1 Fusion	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7375	only gene		AML
WP276	FGFR1 MUT* (--)	FGFR1 N546K	Pemigatinib	Pilocityc astrocytoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/10325	only alteration type		PIA
WP276	FGFR1 MUT* (--)	FGFR1 ZNF198::FGFR1	Midostaurin	Malignant peripheral nerve sheat tumor	Responsive	C	NO	https://civicdb.org/links/evidence_items/1104	only gene		MPN
WP276	FGFR1 MUT* (--)	FGFR1 Amplification	Infigratinib	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/1911	only gene		BLCA
WP276	FGFR1 MUT* (--)	FGFR1 Amplification	Afimoxifene	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1105	only gene		BRCA
WP276	FGFR1 MUT* (--)	FGFR1 Amplification	Infigratinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1909	only gene		BRCA
WP276	FGFR1 MUT* (--)	FGFR1 Amplification	Dovitinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1604	only gene		BRCA
WP276	FGFR1 MUT* (--)	FGFR1 Amplification	FGFR Inhibitor AZD4547	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1991	only gene		BRCA
WP276	FGFR1 MUT* (--)	FGFR1 Amplification	Pazopanib	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7246	only gene		BRCA
WP276	FGFR1 MUT* (--)	FGFR1 Amplification	Lucitanib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7488	only gene		BRCA
WP276	FGFR1 MUT* (--)	FGFR1 Amplification	PD173074	Lung squamous cell	Responsive	D	NO	https://civicdb.org/links/evidence_items/680	only gene		LUSC
WP276	FGFR1 MUT* (--)	FGFR1 Amplification	Infigratinib	Lung squamous cell	Responsive	B	NO	https://civicdb.org/links/evidence_items/1908	only gene		LUSC
WP276	FGFR1 MUT* (--)	FGFR1 Amplification	PD173074	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/686	only gene		NSCLC
WP276	FGFR1 MUT* (--)	FGFR1 Amplification	Dovitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3027	only gene		NSCLC
WP276	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP276	KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP276	KRAS MUT* (--)	KRAS A146	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3939	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS A146P	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2225	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS A146T	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2943	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS A146T	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3858	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS A146T	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2206	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS A146V	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2209	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS A146V	Abemaciclib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/794	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS G12/G13	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/134	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12/G13	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/135	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12/G13	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2004	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12/G13	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6293	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12/G13	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6294	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12/G13	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6295	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12/G13	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6296	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12/G13	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6363	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12/G13	Gefitinib,Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/35	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS G12/G13	Trametinib,Gemcitabine	Pancreas adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/622	only alteration type		PAAD
WP276	KRAS MUT* (--)	KRAS G12/G13	Trametinib	Pancreas adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/990	only alteration type		PAAD
WP276	KRAS MUT* (--)	KRAS G12A	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3710	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12A	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4429	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12A	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6319	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12A	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/251	only alteration type		LUAD
WP276	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2009	only alteration type		MM
WP276	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2012	only alteration type		MM
WP276	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2013	only alteration type		MM
WP276	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2014	only alteration type		MM
WP276	KRAS MUT* (--)	KRAS G12C	Gefitinib,Erlotinib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1216	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12C	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2253	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12C	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3967	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12C	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3973	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12C	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2212	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2258	only alteration type		MM
WP276	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2261	only alteration type		MM
WP276	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2262	only alteration type		MM
WP276	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2263	only alteration type		MM
WP276	KRAS MUT* (--)	KRAS G12C	Docetaxel,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1142	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS G12C	Sotorasib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/9431	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS G12D	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3957	only alteration type		CM
WP276	KRAS MUT* (--)	KRAS G12D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2193	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2207	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2236	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12D	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3946	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12D	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6316	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12D	Therapeutic Tumor Infiltrating Lymphocytes	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1898	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12D	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2218	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12D	Vemurafenib	Hairy-Cell leukemia	Resistant	C	YES	https://civicdb.org/links/evidence_items/1580	only alteration type		HCL
WP276	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2247	only alteration type		MM
WP276	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2250	only alteration type		MM
WP276	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2251	only alteration type		MM
WP276	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2252	only alteration type		MM
WP276	KRAS MUT* (--)	KRAS G12D	Dabrafenib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/91	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS G12D	Selumetinib,Dactolisib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/305	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS G12D	Cetuximab	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/3958	only alteration type		OV
WP276	KRAS MUT* (--)	KRAS G12R	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2264	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12R	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3987	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12R	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3989	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12R	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3991	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12S	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2269	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12S	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4006	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12S	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4012	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12S	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6314	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2274	only alteration type		MM
WP276	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2277	only alteration type		MM
WP276	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2278	only alteration type		MM
WP276	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2279	only alteration type		MM
WP276	KRAS MUT* (--)	KRAS G12V	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/136	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12V	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2219	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12V	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2232	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12V	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3824	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12V	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3924	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12V	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6323	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12V	Dactolisib,Selumetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2001	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G12V	Palbociclib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/795	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS G12V	Selumetinib,Docetaxel	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1143	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS G13D	Pictilisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2041	only alteration type		BRCA
WP276	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/806	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1180	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1181	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G13D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2178	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3878	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3881	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3882	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G13D	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3889	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G13D	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6320	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G13D	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6322	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/145	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/306	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G13D	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2183	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS G13V	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6312	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Mutation	Vemurafenib,Dabrafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6264	only alteration type		CM
WP276	KRAS MUT* (--)	KRAS Mutation	Bevacizumab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1139	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Mutation	Ixazomib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1182	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1702	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3704	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	A	NO	https://civicdb.org/links/evidence_items/5345	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Mutation	Immunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/943	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Mutation	Cetuximab,Dasatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/947	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Mutation	B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/988	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Mutation	Trametinib,Afatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/991	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Mutation	MEK Inhibitor RO4987655	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/998	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Mutation	Refametinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1001	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Mutation	Selumetinib,Teprotumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1004	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Mutation	Selumetinib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4866	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Mutation	Palbociclib,Binimetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4869	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Mutation	Temsirolimus,Ridaforolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/894	only alteration type		ED
WP276	KRAS MUT* (--)	KRAS Mutation	Sorafenib,Refametinib	Hepatic carcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1642	only alteration type		HC
WP276	KRAS MUT* (--)	KRAS Mutation	Salirasib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1218	only alteration type		LUAD
WP276	KRAS MUT* (--)	KRAS Mutation	MEK Inhibitor RO4987655	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/997	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2242	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Gefitinib,Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2385	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Selumetinib	Non-small cell lung	Resistant	A	NO	https://civicdb.org/links/evidence_items/2998	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/3895	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/989	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Trametinib,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/992	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/999	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1220	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Erlotinib,Teprotumumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3713	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Abemaciclib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4842	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Pemetrexed,Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4862	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Nivolumab,Atezolizumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4863	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4867	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Erlotinib,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4868	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4996	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Docetaxel	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4997	only alteration type		NSCLC
WP276	KRAS MUT* (--)	KRAS Mutation	Decitabine	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/820	only alteration type		OV
WP276	KRAS MUT* (--)	KRAS Mutation	PI3Kbeta Inhibitor AZD8186,SCH772984	Pancreas adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1003	only alteration type		PAAD
WP276	KRAS MUT* (--)	KRAS Q61	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3917	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Q61H	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3861	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Q61H	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3862	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Q61K	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3872	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Q61L	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3867	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Q61R	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3870	only alteration type		COREAD
WP276	KRAS MUT* (--)	KRAS Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6317	only gene		CM
WP276	MET MUT* (--)	MET D1228N	Crizotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1652	only alteration type		NSCLC
WP276	MET MUT* (--)	MET D1228V	Savolitinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1865	only alteration type		NSCLC
WP276	MET MUT* (--)	MET D1228V	Cabozantinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1864	only alteration type		NSCLC
WP276	MET MUT* (--)	MET MET::ATXN7L1	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7793	only gene		NSCLC
WP276	MET MUT* (--)	MET Amplification	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1971	only gene		COREAD
WP276	MET MUT* (--)	MET Amplification	Vemurafenib,Crizotinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1588	only gene		COREAD
WP276	MET MUT* (--)	MET Amplification	Crizotinib,Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1979	only gene		COREAD
WP276	MET MUT* (--)	MET Amplification	Crizotinib	Glioblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1565	only gene		GB
WP276	MET MUT* (--)	MET Amplification	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1392	only gene		LUAD
WP276	MET MUT* (--)	MET Amplification	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/836	only gene		LUAD
WP276	MET MUT* (--)	MET Amplification	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1692	only gene		LUAD
WP276	MET MUT* (--)	MET Amplification	Crizotinib	Lung squamous cell	Responsive	C	NO	https://civicdb.org/links/evidence_items/890	only gene		LUSC
WP276	MET MUT* (--)	MET Amplification	Gefitinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/733	only gene		NSCLC
WP276	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/735	only gene		NSCLC
WP276	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1566	only gene		NSCLC
WP276	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1713	only gene		NSCLC
WP276	MET MUT* (--)	MET Amplification	Onartuzumab	Stomach	Responsive	C	NO	https://civicdb.org/links/evidence_items/689	only gene		ST
WP276	NOTCH1 MUT* (T349P)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP276	NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP276	NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP276	NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP276	PDGFRA MUT* (--)	PDGFRA D842I	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/43	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/15	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/16	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/651	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/738	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2478	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA D842V	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4597	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA D842V	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/44	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA D842Y	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/45	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA D842_I843delinsVM	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/47	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA FIP1L1::PDGFRA	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7378	only gene		AML
WP276	PDGFRA MUT* (--)	PDGFRA G853D	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1977	only alteration type		CM
WP276	PDGFRA MUT* (--)	PDGFRA H845Y	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1976	only alteration type		CM
WP276	PDGFRA MUT* (--)	PDGFRA I843DEL	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/46	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA I843DEL	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1309	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA Mutation	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2487	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA P577S	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1974	only alteration type		CM
WP276	PDGFRA MUT* (--)	PDGFRA R841K	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1975	only alteration type		CM
WP276	PDGFRA MUT* (--)	PDGFRA V561A	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/652	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA V561D	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2474	only alteration type		GIST
WP276	PDGFRA MUT* (--)	PDGFRA Amplification	Sunitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1771	only gene		NSCLC
WP276	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP276	PIK3R1 MUT* (--)	PIK3R1 Mutation	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1612	only alteration type		BRCA
WP276	POLE MUT* (--), POLE MUT* (--)	POLE Mutation	Pembrolizumab	Endometrium	Responsive	C	NO	https://civicdb.org/links/evidence_items/1862	only alteration type		ED
WP276	PTEN MUT* (--)	PTEN Mutation	Taselisib	Head an neck squamous	Resistant	D	NO	https://civicdb.org/links/evidence_items/1467	only alteration type		HNSC
WP276	PTEN MUT* (--)	PTEN R130*	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1627	only alteration type		THCA
WP276	PTEN MUT* (--)	PTEN R233*	MTOR Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/317	only alteration type		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Everolimus	Bladder	Resistant	B	NO	https://civicdb.org/links/evidence_items/644	only gene		BLCA
WP276	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/645	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Alpelisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/716	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1383	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1385	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1386	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2035	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2043	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	PI3Ka/Di	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8022	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8274	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8275	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8276	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Dactolisib,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8278	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Trastuzumab,Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8279	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8706	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	PI3Kbeta Inhibitor AZD8186	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/711	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1297	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	PI3K/BET Inhibitor LY294002,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1455	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1611	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2045	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2074	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8012	only gene		BRCA
WP276	PTEN MUT* (--)	PTEN Loss	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6271	only gene		CM
WP276	PTEN MUT* (--)	PTEN Loss	Uprosertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/708	only gene		CM
WP276	PTEN MUT* (--)	PTEN Loss	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/506	only gene		COREAD
WP276	PTEN MUT* (--)	PTEN Loss	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6315	only gene		COREAD
WP276	PTEN MUT* (--)	PTEN Loss	Ridaforolimus,Temsirolimus	Endometrium	Resistant	B	NO	https://civicdb.org/links/evidence_items/893	only gene		ED
WP276	PTEN MUT* (--)	PTEN Loss	Temsirolimus	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1614	only gene		ED
WP276	PTEN MUT* (--)	PTEN Loss	Cisplatin	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/1492	only gene		OV
WP276	PTEN MUT* (--)	PTEN Loss	Buparlisib,Paclitaxel,Carboplatin	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/5957	only gene		SOLID
WP276	PTEN MUT* (--)	PTEN Loss	Trastuzumab,Lapatinib	Stomach	Resistant	B	NO	https://civicdb.org/links/evidence_items/864	only gene		ST
WP276	RET MUT* (--)	RET CCDC6::RET	Agerafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7480	only gene		COREAD
WP276	RET MUT* (--)	RET CCDC6::RET	Nintedanib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1601	only gene		NSCLC
WP276	RET MUT* (--)	RET Fusion	Cabozantinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4847	only gene		LUAD
WP276	RET MUT* (--)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4848	only gene		NSCLC
WP276	RET MUT* (--)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4849	only gene		NSCLC
WP276	RET MUT* (--)	RET Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4850	only gene		NSCLC
WP276	RET MUT* (--)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7066	only gene		NSCLC
WP276	RET MUT* (--)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/8850	only gene		NSCLC
WP276	RET MUT* (--)	RET Fusion	Pralsetinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11233	only gene		NSCLC
WP276	RET MUT* (--)	RET Fusion	Selpercatinib	Thyroid carcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8852	only gene		THCA
WP276	RET MUT* (--)	RET KIF5B::RET	Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/698	only gene		LUAD
WP276	RET MUT* (--)	RET KIF5B::RET	Vandetanib,Everolimus	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1622	only gene		LUAD
WP276	ROS1 MUT* (--)	ROS1 Rearrangement	Ceritinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1248	only gene		LUAD
WP276	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1690	only gene		LUAD
WP276	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/688	only gene		NSCLC
WP276	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1030	only gene		NSCLC
WP276	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7933	only gene		NSCLC
WP276	ROS1 MUT* (--)	ROS1 FUSIONS	Entrectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11123	only gene		NSCLC
WP276	ROS1 MUT* (--)	ROS1 Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7282	only gene		NSCLC
WP276	ROS1 MUT* (--)	ROS1 G2032R	Crizotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2934	only alteration type		LUAD
WP276	ROS1 MUT* (--)	ROS1 GOPC::ROS1	Lorlatinib	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7483	only gene		GB
WP276	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP276	SF3B1 MUT* (--)	SF3B1 K666N	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1418	only alteration type		BRCA
WP276	SF3B1 MUT* (--)	SF3B1 K700E	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1417	only alteration type		BRCA
WP276	TLK2 MUT* (--)	TLK2 Amplification	Go6983,GF109203X	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6000	only gene		BRCA
WP276	TP53 MUT* (T377P), TP53 (K132R)	TP53 M237I	MDM2 Inhibitor AMGMDS3	Glioblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4885	only alteration type		GB
WP276	TP53 (K132R)	TP53 Mutation	Tamoxifen	Breast adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2784	complete		BRCA
WP276	TP53 (K132R)	TP53 Mutation	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/851	complete		BRCA
WP276	TP53 (K132R)	TP53 Mutation	Selumetinib,Docetaxel	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1145	complete		NSCLC
WP276	TP53 (K132R)	TP53 Mutation	Pazopanib,Vorinostat	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/7540	complete		SOLID
WP276	TP53 (K132R)	TP53 Mutation	Chemotherapy	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/850	complete		ST
WP276	TP53 MUT* (T377P), TP53 (K132R)	TP53 R175H	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/319	only alteration type		BRCA
WP276	TP53 MUT* (T377P), TP53 (K132R)	TP53 R249	Doxorubicin	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/399	only alteration type		BRCA
WP276	TP53 MUT* (T377P), TP53 (K132R)	TP53 R273H	Methotrexate,Doxorubicin	Osteosarcoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/7430	only alteration type		OS
WP276	TP53 MUT* (T377P), TP53 (K132R)	TP53 R273L	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2286	only alteration type		OV
WP276	TP53 MUT* (T377P), TP53 (K132R)	TP53 Y234C	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2745	only alteration type		OV
WP276	TP53 MUT* (T377P), TP53 (K132R)	TP53 Loss	Docetaxel	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1146	only gene		NSCLC
WP180	ABL1 MUT* (--)	ABL1-BCR fusion	Bosutinib(BCR-ABL inhibitor  3rd gen)	Chronic myeloid leukemia	Responsive	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s024lbl.pdf	only gene		CML
WP180	ABL1 MUT* (--)	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	Bosutinib(BCR-ABL inhibitor  3rd gen)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP180	ABL1 MUT* (--)	ABL1-BCR fusion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf	only gene		CML, ALL
WP180	ABL1 MUT* (--)	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP180	ABL1 MUT* (--)	ABL1-BCR fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	EMA	only gene		CML, ALL
WP180	ABL1 MUT* (--)	ABL1-BCR fusion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia	Responsive	A	YES	FDA	only gene		CML
WP180	ABL1 MUT* (--)	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP180	ABL1 MUT* (--)	ABL1-BCR fusion	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	FDA	only gene		CML, ALL
WP180	ABL1 MUT* (--)	ABL1 (T315I)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	FDA	only alteration type		CML, ALL
WP180	ABL1 MUT* (--)	ABL1 (T315I)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP180	ALK (P1329S)	ALK fusion	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	FDA	only gene		LUAD
WP180	ALK (P1329S)	ALK fusion	Alectinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	only gene		NSCLC
WP180	ALK (P1329S)	ALK fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	only gene		NSCLC
WP180	ALK (P1329S)	ALK inframe insertion (1151T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165	only alteration type		LUAD
WP180	ALK (P1329S)	ALK (L1196M,S1206Y,G1269A,I1171T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165;PMID:24327273	only alteration type		LUAD
WP180	ALK (P1329S)	ALK fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene	758.0	NSCLC
WP180	ALK (P1329S)	ALK fusion	Brigatinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc	only gene		NSCLC
WP180	ABL1 MUT* (--)	ABL1 (T315I)	BCR-ABL inhibitor 2nd gens(Nilotinib,Dasatinib,etc)	Chronic myeloid leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML
WP180	ABL1 MUT* (--)	ABL1 (T315I)	Bosutinib(BCR-ABL inhibitor  3rd gen)	Chronic myeloid leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML
WP180	ABL1 MUT* (--)	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML, ALL
WP180	ABL1 MUT* (--)	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Chronic myeloid leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML
WP180	ABL1 MUT* (--)	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Resistant	A	YES	NCCN Guidelines Chronic Myeloid Leukemia 2022;NCCN Guidelines Acute Lymphoblastic Leukemia 2022;PMID:21562040	only alteration type		CML, ALL
WP180	PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome, Eosinophilic chronic leukemia	Responsive	A	YES	EMA	only gene		HES, ECL
WP180	PDGFRA MUT* (--)	PDGFRA inframe deletion (I843)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type	862.0	GIST
WP180	PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type	862.0	GIST
WP180	PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Regorafenib(Pan-kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
WP180	FLT3 MUT* (--)	FLT3-ITD	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia;PMID:28644114	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 (D835,I836)	Gilteritinib(Kinase inhibitor )	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3-ITD	Gilteritinib(Kinase inhibitor )	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation;PMID:31665578	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 (D835,I836)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia; PMID:28644114	only alteration type		AML
WP180	ABL1 MUT* (--)	ABL1 (T315I,V299L,G250E,F317L)	Bosutinib(BCR-ABL inhibitor 3rd gen)	Acute lymphoblastic leukemia, Chronic myeloid leukemia	Resistant	A	YES	NCCN	only alteration type		ALL, CML
WP180	ABL1 MUT* (--)	ABL1 (T315I)	Asciminib(Kinase inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia	only alteration type		CML
WP180	ABL1 MUT* (--)	BCR-ABL1	Asciminib(Kinase inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215358s003lbl.pdf	only gene		CML
WP180	ABL1 MUT* (--)	ABL1 (T315I)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Acute lymphoblastic leukemia	Resistant	A	YES	NCCN Guideline ALL 2022	only alteration type		ALL
WP180	ABL1 MUT* (--)	ABL1 (E255V,Y253H,F359V)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf	only alteration type		CML
WP180	ALK (P1329S)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP180	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP180	FANCL MUT* (--)	FANCL oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP180	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP180	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP180	PDGFRA MUT* (--)	PDGFRA exon 18 mutations	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA (D842V)	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation;PMID:32615108	only alteration type		GIST
WP180	ABL1 MUT* (--)	ABL1 (T315I)	Bosutinib(BCR-ABL inhibitor 3rd gen)	Acute lymphoblastic leukemia	Resistant	A	YES	NCCN Guideline ALL 2022	only alteration type		ALL
WP180	RAD51D MUT* (--)	RAD51D oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP180	RAD54L MUT* (--)	RAD54L oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP180	ALK (P1329S)	ALK fusion	Crizotinib(ALK inhibitor)	Anaplastic large cell lymphoma	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large	only gene		ALCL
WP180	ATM MUT* (--)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP180	ATR (F2495L)	ATR oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	complete		PRAD
WP180	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP180	PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
WP180	BTK MUT* (--)	BTK (C481S)	Ibrutinib(BTK inhibitor)	Chronic lymphocytic leukemia	Resistant	A	YES	PMID: 28418267	only alteration type		CLL
WP180	ALK (P1329S)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP180	MAP2K2 MUT* (--), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP180	MAP2K2 MUT* (--), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP180	MAP2K2 MUT* (--), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP180	MAP2K2 MUT* (--), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP180	ABL1 MUT* (--)	ABL1-BCR fusion	Bosutinib(BCR-ABL inhibitor  3rd gen)	Acute lymphoblastic leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/all.pdf	only gene		ALL
WP180	FLT3 MUT* (--)	FLT3-ITD	Quizartinib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia	only alteration type		AML
WP180	ABL1 MUT* (--)	ABL1-BCR fusion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Acute lymphoblastic leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/all.pdf	only gene		ALL
WP180	PDGFRA MUT* (--)	PDGFRA oncogenic mutations (excluding D842V + exon 18 inframe mutations)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type	862.0	GIST
WP180	PDGFRA MUT* (--)	PDGFRA D842V + exon 18 mutations	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
WP180	ALK (P1329S)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor	only gene		IM
WP180	ALK (P1329S)	ALK fusion	Alectinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP180	ALK (P1329S)	ALK fusion	Brigatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP180	ALK (P1329S)	ALK fusion	Ceritinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP180	ALK (P1329S)	ALK fusion	Lorlatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP180	ABL1 MUT* (--)	ABL1 (T315I)	Axitinib(VEGFR inhibitor)	Any cancer type	Responsive	D	YES	PMID:25686603	only alteration type		CANCER
WP180	ABL1 MUT* (--)	ABL1 (V299L)	Cabozantinib(Pan-kinase inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP180	ABL1 MUT* (--)	ABL1 (V299L)	Crizotinib(ALK inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type	758.0	CANCER
WP180	ABL1 MUT* (--)	ABL1-BCR fusion	Dasatinib + Venetoclax(BCR-ABL inhibitor 2nd gen + BCL2 inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:27582059	only gene		ALL
WP180	ABL1 MUT* (--)	ABL1 (V299L)	ForetinibÂ (MET inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP180	ABL1 MUT* (--)	ABL1 (V299L)	Vandetanib(Pan-TK inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP180	ALK (P1329S)	ALK fusion	ALK inhibitor + IGF1R inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25173427	only gene		LUAD
WP180	ALK (P1329S)	ALK fusion	ALK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:26301689	only gene		LUAD
WP180	ALK (P1329S)	ALK fusion	ALK inhibitor + SRC inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25394791	only gene		LUAD
WP180	ALK (P1329S)	ALK fusion	ALK inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560	only gene		COREAD
WP180	ALK (P1329S)	ALK fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23553849	only gene		LUAD
WP180	ALK (P1329S)	ALK fusion	novel ALK inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23639470	only gene		LUAD
WP180	ALK (P1329S)	ALK (F1174L)	novel ALK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24327273	only alteration type		LUAD
WP180	ALK (P1329S)	ALK amplification	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only gene		LUAD
WP180	ALK (P1329S)	ALK (E1408V)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP180	ALK (P1329S)	ALK (L1196M)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP180	ALK (P1329S)	ALK fusion	Ceritinib(ALK inhibitor)	Colorectal adenocarcinoma, Inflammatory myofibroblastic	Responsive	C	YES	PMID:26633560;PMID:26933125;PMID:27742657	only gene		COREAD, IM
WP180	ALK (P1329S)	ALK fusion	Ceritinib(ALK inhibitor)	Hematologic malignancies	Responsive	C	YES	NCT02186821	only gene		HEMATO
WP180	CTNNB1 MUT* (--)	CTNNB1 oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Resistant	D	NO	PMID:23539443	only alteration type		COREAD
WP180	ALK (P1329S)	ALK fusion	Crizotinib(ALK inhibitor)	Lymphoma, Glioblastoma	Responsive	C	YES	PMID:24491302;NCT02270034	only gene		LY, GB
WP180	ALK (P1329S)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic, Thyroid carcinoma	Responsive	C	YES	PMID:20979472;PMID:24687827	only gene		IM, THCA
WP180	ALK (P1329S)	ALK (F856S,A348D)	Crizotinib(ALK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:26032424	only alteration type		AML
WP180	ALK (P1329S)	ALK (L1198F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26698910	only alteration type	758.0	LUAD
WP180	ALK (P1329S)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib(ALK inhibitor)	Glioma	Responsive	D	NO	PMID:22072639	only alteration type		G
WP180	ALK (P1329S)	ALK fusion	Entrectinib(Pan-TK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560;PMID:26933125	only gene		COREAD
WP180	ALK (P1329S)	ALK (C1156Y)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27401242	only alteration type		LUAD
WP180	ERBB3 MUT* (--)	ERBB3 amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:25520391	only gene		COREAD
WP180	ATM MUT* (--)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only alteration type		COREAD
WP180	ATM MUT* (--)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
WP180	ATM MUT* (--)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only alteration type		LY
WP180	ATM MUT* (--)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only gene		LY
WP180	ATM MUT* (--)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP180	ATM MUT* (--)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
WP180	ATM MUT* (--)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP180	ATM MUT* (--)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP180	ATM MUT* (--)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP180	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP180	ATM MUT* (--)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP180	ATR (F2495L)	ATR oncogenic mutation	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	complete		OV, CANCER
WP180	ATR (F2495L), ATR MUT* (--)	ATR deletion	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only gene		OV, CANCER
WP180	ATR (F2495L)	ATR oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	complete		G
WP180	BCOR MUT* (--)	BCOR oncogenic mutation	Enzastaurin(PKCb inhibitor)	Stomach	Responsive	D	NO	PMID:27397505	only alteration type		ST
WP180	MAP2K2 MUT* (--), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP180	CTNNB1 MUT* (--)	CTNNB1 (H36Y,S37C,S37Y,D32V)	Everolimus + Letrozole(MTOR inhibitor + Hormonal therapy)	Endometrium	Responsive	C	NO	PMID:25624430	only alteration type		ED
WP180	MAP2K2 MUT* (--), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP180	MAP2K2 MUT* (--), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP180	MAP2K2 MUT* (--), MAP2K2 MUT* (V8M), MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP180	MITF MUT* (R386)	MITF amplification	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265153	only gene		CM
WP180	MITF MUT* (R386)	MITF amplification	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265153	only gene		CM
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP180	NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP180	PDGFRA MUT* (--)	PDGFRA amplification	PDGFR inhibitors	Glioma	No Responsive	D	NO	PMID:23544171	only gene		G
WP180	PIK3CB MUT* (--)	PIK3CB (D1067Y)	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	C	NO	PMID:26759240	only alteration type		BRCA
WP180	ERBB3 MUT* (--)	ERBB3 (P262H,G284R)	ERBB3 mAb inhibitors	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP180	ERBB3 MUT* (--)	ERBB3 (P262H,G284R,Q809R)	PI3K pathway inhibitor + MEK inhibitors	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP180	ERBB3 MUT* (--)	ERBB3 (G284R,R103G)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	ASCO 2015 (abstr e15516)	only alteration type		BLCA
WP180	ERBB3 MUT* (--)	ERBB3 (G284R,V104M,R103G)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	PMID:27044931	only alteration type		BLCA
WP180	ERBB3 MUT* (--)	ERBB3 (P262H,G284R,Q809R)	Lapatinib(ERBB2 inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP180	ERBB3 MUT* (--)	ERBB3 (P262H,G284R)	Pertuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP180	ERBB3 MUT* (--)	ERBB3 (P262H,G284R,Q809R)	Trastuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP180	ALK (P1329S)	ALK (I1171T)	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:25228534	only alteration type		LUAD
WP180	FLT3 MUT* (--)	FLT3-ITD	FLT3 inhibitors	Acute myeloid leukemia	Responsive	C	YES	PMID:16857985	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 (F691)	novel FLT3 inhibitors	Acute myeloid leukemia	Responsive	D	YES	PMID:25847190	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 (N676)	Crenolanib(FLT3 inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:24619500	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 (D835)	Lestaurtinib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:16857985	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 (D835)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:20733134	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 (N676)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:24619500	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3-ITD	Sorafenib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:19389879;PMID:22368270	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3-ITD	Sorafenib + Azacytidine(Pan-TK inhibitor + Chemotherapy)	Acute myeloid leukemia	Responsive	C	YES	PMID:23613521	only alteration type		AML
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP180	NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP180	ALK (P1329S)	ALK (G1123S)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:26134233	only alteration type		LUAD
WP180	GATA3 MUT* (--)	GATA3 oncogenic mutation	Aromatase ihibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:24758297	only alteration type		BRCA
WP180	HDAC2 MUT* (--)	HDAC2 biallelic inactivation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP180	KDR MUT* (--)	KDR (A1065T)	VEGFR inhibitors	Any cancer type	Responsive	D	YES	PMID:24569783	only alteration type		CANCER
WP180	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP180	ALK (P1329S)	ALK inframe insertion (1151T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only alteration type		LUAD
WP180	ALK (P1329S)	ALK oncogenic mutation	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	complete		NSCLC
WP180	ALK (P1329S)	ALK amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only gene		NSCLC
WP180	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP180	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP180	ALK (P1329S)	ALK amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only gene		LUAD
WP180	ALK (P1329S)	ALK (C1156Y,L1196M)	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:20979473	only alteration type		NSCLC
WP180	ALK (P1329S)	ALK (F1174L)	Crizotinib(ALK inhibitor)	Glioma	Resistant	D	NO	PMID:22072639	only alteration type		G
WP180	ALK (P1329S)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784;PMID:25228534	only alteration type		LUAD
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP180	NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP180	NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP180	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP180	NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP180	NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP180	BTK MUT* (--)	BTK (C481)	Ibrutinib(BTK inhibitor)	Mantle cell lymphoma	Resistant	C	YES	PMID:25082755	only alteration type		MCL
WP180	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP180	MPL MUT* (--)	MPL (W515F)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:16834459	only alteration type		MDPS
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP180	NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP180	NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP180	NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP180	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP180	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP180	NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP180	NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP180	NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP180	NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP180	PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP180	NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP180	PDGFRA MUT* (--)	PDGFRA (T674I)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome	Resistant	C	YES	PMID:12660384	only alteration type		HES
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP180	NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP180	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP180	LRP1B MUT* (--), LRP1B MUT* (--)	LRP1B oncogenic mutation	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only alteration type		OV
WP180	LRP1B MUT* (--), LRP1B MUT* (--)	LRP1B deletion	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only gene		OV
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP180	NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP180	NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP180	NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP180	NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP180	NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP180	NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP180	NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP180	NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP180	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP180	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP180	NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP180	NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP180	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP180	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP180	NOTCH1 MUT* (T311P)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP180	NOTCH1 MUT* (T311P)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP180	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP180	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP180	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP180	NOTCH1 MUT* (T311P)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	only alteration type		MCL
WP180	NOTCH1 MUT* (T311P)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP180	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP180	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP180	NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP180	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP180	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP180	PBRM1 MUT* (--), PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP180	PBRM1 MUT* (--), PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP180	PDGFRA MUT* (--)	PDGFRA (D842V)	HSP90 inhibitors	Gastrointestinal stromal	Responsive	D	NO	PMID:18794084	only alteration type		GIST
WP180	FLT3 MUT* (--)	FLT3 (D835,Y842)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Acute myeloid leukemia	Resistant	D	YES	PMID:23430109	only alteration type		AML
WP180	PDGFRA MUT* (--)	PDGFRA (D842V)	Crenolanib(FLT3 inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2016 (abstr 11010)	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	Crenolanib(FLT3 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
WP180	FLT3 MUT* (--)	FLT3 (F691,D835,N676,Y842)	Quizartinib(Pan-TK inhibitor)	Acute myeloid leukemia	Resistant	D	YES	PMID:22504184;PMID:23878140	only alteration type		AML
WP180	PDGFRA MUT* (--)	PDGFRA (P577S,R841K,H845Y,G853D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
WP180	PDPK1 MUT* (--)	PDPK1 amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:19602588	only gene		BRCA
WP180	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	AKT inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP180	PIK3CB MUT* (--)	PIK3CB (D1067Y)	AKT inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26759240	only alteration type		BRCA
WP180	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	MTORC1/2 inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP180	PIK3CB MUT* (--)	PIK3CB (D1067Y)	MTORC1/2 inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26759240	only alteration type		BRCA
WP180	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP180	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	AKT inhibitors	Glioma	Responsive	D	NO	PMID:23166678	only alteration type		G
WP180	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	PI3K pathway inhibitors	Endometrium	Responsive	C	NO	ASCO 2015 (abstr 11075)	only alteration type		ED
WP180	PRKCH MUT* (--), ABL1 MUT* (--)	PRKCH amplification + ABL1-BCR fusion	Trametinib + Imatinib(MEK inhibitor + BCR-ABL inhibitor 1st gen&KIT inhibitor)	Chronic myeloid leukemia	Responsive	D	YES	PMID:25186176	only gene		CML
WP180	PDGFRA MUT* (--)	PDGFRA (D842V)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP180	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP180	NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP180	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP180	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP180	RB1 MUT* (--)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
WP180	RB1 MUT* (--)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
WP180	RB1 MUT* (--)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
WP180	RB1 MUT* (--)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
WP180	RB1 MUT* (--)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP180	RB1 MUT* (--)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP180	SETD2 MUT* (--)	SETD2 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only alteration type		CANCER
WP180	SETD2 MUT* (--)	SETD2 deletion	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only gene		CANCER
WP180	SF3B1 MUT* (--)	SF3B1 (K700E,K666N)	Spliceosome inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858	only alteration type		CANCER
WP180	NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP180	SUZ12 MUT* (--)	SUZ12 oncogenic mutation	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only alteration type		CANCER
WP180	SUZ12 MUT* (--)	SUZ12 deletion	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only gene		CANCER
WP180	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP180	TERT MUT* (--)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP180	TMPRSS2 MUT* (--)	TMPRSS2 fusion	DNA-PKc inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575865	only gene		PRAD
WP180	TMPRSS2 MUT* (--)	TMPRSS2 fusion	PARP inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575865	only gene		PRAD
WP180	TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP180	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP180	FLT3 MUT* (--)	FLT3-ITD	Venetoclax(BCL2 inhibitor)	Acute myeloid leukemia	Resistant	C	YES	PMID:27520294	only alteration type		AML
WP180	ALK (P1329S)	ALK fusion	Crizotinib + Ceritinib	Sarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only gene		S
WP180	ALK (P1329S)	ALK (G1202R,I1171N)	Alectinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only alteration type		NSCLC
WP180	PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib	Gastrointestinal stromal	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP180	KDM6A MUT* (--)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
WP180	KDM6A MUT* (--)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only alteration type		BLCA
WP180	PDGFRA MUT* (--)	PDGFRA (N659K,V561D,V561A,N659S,A633T,H845Y,T674I,S584L,D842V,N659R,D568N,P577S,D846Y,Q579R,D842Y,Y849S,N848K,H650Q,D842I,V469A,Y288C,Y555C,R748G,Y849C,.,R841K,G853D,V536E,V658A)	Imatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA amplification	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP180	PDGFRA MUT* (--)	PDGFRA-BCR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP180	PDGFRA MUT* (--)	PDGFRA-CDK5RAP2 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP180	PDGFRA MUT* (--)	PDGFRA-ETV6 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP180	PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP180	PDGFRA MUT* (--)	PDGFRA fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP180	PDGFRA MUT* (--)	PDGFRA-KDR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP180	PDGFRA MUT* (--)	PDGFRA-KIF5B fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP180	PDGFRA MUT* (--)	PDGFRA-STRN fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP180	NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP180	NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP180	ATM MUT* (--)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only alteration type		CANCER
WP180	ATM MUT* (--)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
WP180	ALK (P1329S)	ALK (C1156Y,F1174L,L1196M,G1269A)	Crizotinib	Non-small cell lung	Resistant	D	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary	only alteration type		NSCLC
WP180	PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP180	ABL1 MUT* (--)	ABL1 BCR::ABL	Imatinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/232	only gene		AML
WP180	ABL1 MUT* (--)	ABL1 BCR::ABL	Imatinib	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/259	only gene		AML
WP180	ABL1 MUT* (--)	ABL1 G340L	Imatinib Mesylate,Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4788	only alteration type		NSCLC
WP180	ABL1 MUT* (--)	ABL1 R351W	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4787	only alteration type		NSCLC
WP180	ABL1 MUT* (--)	ABL1 R351W	Imatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/6376	only alteration type		NSCLC
WP180	ALK (P1329S)	ALK CAD::ALK	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7481	only gene		COREAD
WP180	ALK (P1329S)	ALK CLTC::ALK	TAE684	Difuse large B Cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1261	only gene		DLBCL
WP180	ALK (P1329S)	ALK CLTC::ALK	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1265	only gene		DLBCL
WP180	ALK (P1329S)	ALK EML4::ALK	Alectinib	Mesothelioma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9228	only gene		MESO
WP180	ALK (P1329S)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/262	only gene		NSCLC
WP180	ALK (P1329S)	ALK EML4::ALK	WHI-P154	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1188	only gene		NSCLC
WP180	ALK (P1329S)	ALK EML4::ALK	Crizotinib,Retaspimycin Hydrochloride	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1203	only gene		NSCLC
WP180	ALK (P1329S)	ALK EML4::ALK	Crizotinib,Alvespimycin	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1206	only gene		NSCLC
WP180	ALK (P1329S)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1207	only gene		NSCLC
WP180	ALK (P1329S)	ALK EML4::ALK	Lorlatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1332	only gene		NSCLC
WP180	ALK (P1329S)	ALK F1174L	Crizotinib	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/125	only alteration type		NB
WP180	ALK (P1329S)	ALK F1174L	Alectinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/37	only alteration type		NB
WP180	ALK (P1329S)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/38	only alteration type		NB
WP180	ALK (P1329S)	ALK F1174L	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/142	only alteration type		NB
WP180	ALK (P1329S)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1271	only alteration type		NB
WP180	ALK (P1329S)	ALK F1174L	AZD3463	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1327	only alteration type		NB
WP180	ALK (P1329S)	ALK F1174L	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1329	only alteration type		NB
WP180	ALK (P1329S)	ALK F1174L	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/33	only alteration type		NSCLC
WP180	ALK (P1329S)	ALK F1245C	Crizotinib	Neuroblastoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1333	only alteration type		NB
WP180	ALK (P1329S)	ALK F1245C	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1330	only alteration type		NB
WP180	ALK (P1329S)	ALK F1245V	Entrectinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2987	only alteration type		NB
WP180	ALK (P1329S)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1240	only gene		ALCL
WP180	ALK (P1329S)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/7361	only gene		ALCL
WP180	ALK (P1329S)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	A	YES	https://civicdb.org/links/evidence_items/11218	only gene		ALCL
WP180	ALK (P1329S)	ALK Fusion	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1264	only gene		DLBCL
WP180	ALK (P1329S)	ALK Fusion	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1691	only gene		LUAD
WP180	ALK (P1329S)	ALK Fusion	Pemetrexed	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/945	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1175	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1187	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1198	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1199	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1200	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1201	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Retaspimycin Hydrochloride	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1202	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1272	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1273	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1279	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1282	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1419	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1577	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4835	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Alectinib,Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4858	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7284	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7285	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Lorlatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7286	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/8657	only gene		NSCLC
WP180	ALK (P1329S)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11121	only gene		NSCLC
WP180	ALK (P1329S)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1283	only alteration type		NSCLC
WP180	ALK (P1329S)	ALK I1171	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1287	only alteration type		NSCLC
WP180	ALK (P1329S)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1367	only alteration type		NSCLC
WP180	ALK (P1329S)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1284	only alteration type		NSCLC
WP180	ALK (P1329S)	ALK I1171	TAE684	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1285	only alteration type		NSCLC
WP180	ALK (P1329S)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1344	only alteration type		NSCLC
WP180	ALK (P1329S)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1368	only alteration type		NSCLC
WP180	ALK (P1329S)	ALK I1171T	Ceritinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9404	only alteration type		NB
WP180	ALK (P1329S)	ALK KANK4::ALK	Alectinib	Pancreas acinar	Responsive	C	NO	https://civicdb.org/links/evidence_items/10327	only gene		PAAC
WP180	ALK (P1329S)	ALK Mutation	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1237	complete		NSCLC
WP180	ALK (P1329S)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1239	only gene		ALCL
WP180	ALK (P1329S)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/1241	only gene		ALCL
WP180	ALK (P1329S)	ALK R1275Q	TAE684	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/48	only alteration type		NB
WP180	ALK (P1329S)	ALK R1275Q	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/39	only alteration type		NB
WP180	ALK (P1329S)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/143	only alteration type		NB
WP180	ALK (P1329S)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1270	only alteration type		NB
WP180	ALK (P1329S)	ALK R1275Q	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1331	only alteration type		NB
WP180	ATM MUT* (--)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	only alteration type		CM
WP180	ATM MUT* (--)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	only alteration type		GB
WP180	ATM MUT* (--)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	only alteration type		PRAD
WP180	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP180	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP180	ERBB3 MUT* (--)	ERBB3 V855A	Pertuzumab,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1845	only alteration type		NSCLC
WP180	FLT3 MUT* (--)	FLT3 D835	Quizartinib,Ponatinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1036	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 D835	SU5614	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1037	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 D835	Quizartinib,Sorafenib	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/1038	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 D835	Sorafenib	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/1039	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 D835H	Sorafenib	Acute myeloid leukemia	Resistant	C	YES	https://civicdb.org/links/evidence_items/1556	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 D835H	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8517	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 D835H/Y	Sorafenib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1557	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 D835I	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8351	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 D835V	Tandutinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/3007	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 D835V	Sunitinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3008	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 D835V	Sunitinib,Cytarabine	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3009	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 D835V	Daunorubicin,Sunitinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3010	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 D835V	Quizartinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3012	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 D835V	AS602868,Tyrphostin AG 1296	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3034	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 D835V	Sunitinib	Acute myeloid leukemia	Responsive	C	YES	https://civicdb.org/links/evidence_items/4022	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 D835V	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8518	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 D835Y	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8108	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 F691L	Lestaurtinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8341	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 F691L	Midostaurin	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8342	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 Mutation	Midostaurin	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/5261	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 Mutation	Gilteritinib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/7283	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 Mutation	Gilteritinib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/7728	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 Y842C	FLT3/ABL/Aurora Kinase Inhibitor KW-2449	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8336	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 Y842C	Sorafenib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8337	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 Y842C	Sunitinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8338	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 Y842C	Quizartinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8654	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 Y842C	Lestaurtinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8339	only alteration type		AML
WP180	FLT3 MUT* (--)	FLT3 Y842C	Midostaurin	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8340	only alteration type		AML
WP180	KDR MUT* (--)	KDR R1032Q	Cabozantinib,Dovitinib,Axitinib,Lenvatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/9339	only alteration type		COREAD
WP180	KDR MUT* (--)	KDR R961W	Regorafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1191	only alteration type	775.0	COREAD
WP180	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP180	KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (S806), KMT2C MUT* (P309S), KMT2C MUT* (R284Q), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP180	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP180	NFE2L2 MUT* (--)	NFE2L2 Mutation	Sapanisertib	Lung squamous cell	Responsive	B	NO	https://civicdb.org/links/evidence_items/7446	only alteration type		LUSC
WP180	NOTCH1 MUT* (T311P)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP180	PDGFRA MUT* (--)	PDGFRA D842I	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/43	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/15	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/16	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/651	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/738	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2478	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA D842V	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4597	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA D842V	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/44	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA D842Y	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/45	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA D842_I843delinsVM	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/47	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA FIP1L1::PDGFRA	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7378	only gene		AML
WP180	PDGFRA MUT* (--)	PDGFRA G853D	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1977	only alteration type		CM
WP180	PDGFRA MUT* (--)	PDGFRA H845Y	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1976	only alteration type		CM
WP180	PDGFRA MUT* (--)	PDGFRA I843DEL	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/46	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA I843DEL	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1309	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA Mutation	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2487	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA P577S	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1974	only alteration type		CM
WP180	PDGFRA MUT* (--)	PDGFRA R841K	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1975	only alteration type		CM
WP180	PDGFRA MUT* (--)	PDGFRA V561A	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/652	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA V561D	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2474	only alteration type		GIST
WP180	PDGFRA MUT* (--)	PDGFRA Amplification	Sunitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1771	only gene		NSCLC
WP180	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP180	PIK3R1 MUT* (--)	PIK3R1 Mutation	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1612	only alteration type		BRCA
WP180	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP180	RAD51D MUT* (--)	RAD51D Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11214	only alteration type		PRAD
WP180	RAD54L MUT* (--)	RAD54L Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11207	only alteration type		PRAD
WP180	RB1 MUT* (--)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
WP180	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP180	SF3B1 MUT* (--)	SF3B1 K666N	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1418	only alteration type		BRCA
WP180	SF3B1 MUT* (--)	SF3B1 K700E	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1417	only alteration type		BRCA
WP180	TLK2 MUT* (--)	TLK2 Amplification	Go6983,GF109203X	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6000	only gene		BRCA
WP180	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP180	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP078	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP078	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF (V600E,V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF (V600E,V600K)	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s028lbl.pdf	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP078	BRAF MUT* (--)	BRAF (V600E,V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf	only alteration type		CM
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP078	KRAS MUT* (--)	KRAS (12,13)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP078	CHEK2 (--)	CHEK2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;AACR 2015 (abstr CT322);FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	complete		PRAD
WP078	KRAS MUT* (--)	KRAS (12,13,59,61,117,146)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	NCCN guidelines	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	NCCN guidelines	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR inhibitors	Lung	Resistant	A	NO	NCCN guidelines	only alteration type		L
WP078	PDGFB MUT* (--)	PDGFB-COL1A1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Dermatofibrosarcoma	Responsive	A	NO	FDA	only gene		DFS
WP078	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP078	TSC2 MUT* (--)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    , Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		RA, GCA
WP078	EZH2 MUT* (K703)	EZH2 (A692V,Y646C,Y646F,Y646H,Y646N,Y646S,A682G)	Tazemetostat(EZH2 inhibitor)	Follicular lymphoma	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma;PMID:33035457 	only alteration type		FL
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP078	BRAF MUT* (--)	BRAF (V600E)	Trametinib(MEK inhibitor) + Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN Non-Small Cell Lung Cancer guidlines 2022; FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		NSCLC
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP078	CHEK1 MUT* (--)	CHEK1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP078	FGFR3 MUT* (--)	FGFR3 fusion	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only gene		BLCA
WP078	FGFR3 MUT* (--)	FGFR3 (G370C,R248C,S249C,Y373C)	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only alteration type		BLCA
WP078	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation;PMID:31566309	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS (G12C)	Sotorasib(RAS GTPase family inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc	only alteration type		NSCLC
WP078	ROS1 MUT* (--)	ROS1 fusion	Entrectinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA;PMID:28183697;ESMO 2019 (abstr 4178) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725s007lbl.pdf	only gene		NSCLC
WP078	NTRK1 (R748W)	NTRK1 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	NO	FDA:https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
WP078	NTRK1 (R748W)	NTRK1 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
WP078	PALB2 MUT* (--)	PALB2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP078	KRAS MUT* (--)	KRAS (G12C)	Adagrasib(RAS GTPase family inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc	only alteration type		NSCLC
WP078	BRAF MUT* (--)	BRAF (V600)	Atezolizumab(PD-L1 blocking antibody);Vemurafenib(BRAF inhibitor);Cobimetinib(MEK inhibitor) 	Cutaneous melanoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-braf-v600-unresectable-or-metastatic-melanoma	only alteration type		CM
WP078	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Bevacizumab(VEGF mAb inhibitor);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP078	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP078	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Pembrolizumab(PD-1-blocking antibody);Pemetrexed(Chemotherapy);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf	complete		NSCLC
WP078	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		SOLID
WP078	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Lower grade glioma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-trametinib-pediatric-patients-low-grade-glioma-braf-v600e-mutation	only alteration type		LGG
WP078	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Durvalumab(PD-1-blocking antibody);Tremelimumab-actl(CTLA-4 blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non	complete		NSCLC
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP078	CHEK2 (--)	CHEK2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	complete		PRAD
WP078	PALB2 MUT* (--)	PALB2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP078	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP078	BRAF MUT* (--)	BRAF (V600E,V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210496s013lbl.pdf	only alteration type		CM
WP078	NTRK1 (R748W)	NTRK1 (G595R)	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Resistant	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210861s008lbl.pdf	only alteration type		SOLID
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP078	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP078	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP078	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP078	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP078	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP078	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP078	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP078	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP078	KRAS MUT* (--)	KRAS (G12C)	Adagrasib(RAS GTPase family inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP078	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP078	BRAF MUT* (--)	BRAF(V600E)	Vemurafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP078	BRAF MUT* (--)	BRAF (V600)	Dabrafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP078	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Hairy-Cell leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf	only alteration type		HCL
WP078	ROS1 MUT* (--)	ROS1 fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP078	ROS1 MUT* (--)	ROS1 fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP078	KRAS MUT* (--)	KRAS (G12C)	Sotorasib(RAS GTPase family inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP078	PALB2 MUT* (--)	PALB2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP078	EZH2 MUT* (K703)	EZH2 oncogenic mutations (excluding Y646S, Y646H, Y646C, Y646F, Y646N, A682G and A692V)	Tazemetostat(EZH2 inhibitor)	Follicular lymphoma	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf	only alteration type		FL
WP078	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-binimetinib-metastatic-non-small-cell-lung-cancer-braf-v600e-mutation	only alteration type		NSCLC
WP078	BRAF MUT* (--)	BRAF(V600)	Vemurafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		HISEC
WP078	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP078	AKT1 MUT* (--)	AKT1 (Q79K,E17K)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265152	only alteration type		CM
WP078	AKT1 MUT* (--)	AKT1 (E17K)	AKT inhibitors	Any cancer type	Responsive	D	YES	PMID:21464312;PMID:17611497;PMID:23134728; ENA 2015 (abstr B109)	only alteration type		CANCER
WP078	AKT1 MUT* (--)	AKT1 (E17K)	allosteric AKT inhibitors	Any cancer type	Responsive	C	YES	ENA 2015 (abstract B109);PMID:28489509	only alteration type		CANCER
WP078	BRAF MUT* (--)	BRAF (V600E,G469A)	EGFR TK inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:22773810	only alteration type		LUAD
WP078	AKT1 MUT* (--)	AKT1 (E17K)	non-allosteric AKT inhibitors	Any cancer type	Responsive	C	YES	ENA 2015 (abstract B109);PMID:28489509	only alteration type		CANCER
WP078	AKT1 MUT* (--)	AKT1 (E17K)	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26763254	only alteration type		HNSC
WP078	AKT1 MUT* (--)	AKT1 (H238Y)	Everolimus(MTOR inhibitor)	Fibrous histiocytoma	Responsive	C	NO	ASCO 2015 (abstr 11010)	only alteration type		FH
WP078	AKT1 MUT* (--)	AKT1 (E17K)	Tensirolimus(MTOR inhibitor)	Endometrium	Responsive	C	NO	PMID:27016228	only alteration type		ED
WP078	CTNNB1 MUT* (--), CTNNB1 MUT* (D667E)	CTNNB1 oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Resistant	D	NO	PMID:23539443	only alteration type		COREAD
WP078	APC MUT* (--)	APC oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:22440753;PMID:23539443	only alteration type		COREAD
WP078	FGFR3 MUT* (--)	FGFR3 (V555M)	FGFR inhibitors	Myeloma	Resistant	D	YES	PMID:22869148	only alteration type		MYMA
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only alteration type		COREAD
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only alteration type		LY
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only gene		LY
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP078	BCOR MUT* (--), BCOR MUT* (--)	BCOR oncogenic mutation	Enzastaurin(PKCb inhibitor)	Stomach	Responsive	D	NO	PMID:27397505	only alteration type		ST
WP078	JAK1 MUT* (--)	JAK1 oncogenic mutation	PD1 inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:27903500	only alteration type		COREAD
WP078	JAK1 MUT* (--)	JAK1 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + CDK2/4 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22997239	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF (V600)	BRAF inhibitor + EGFR mAb inhibitor +/- PI3K inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28363909	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + HSP90 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22351686	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + MEK inhibitors	Thyroid	Responsive	C	NO	ASCO 2013 (abstr 9029)	only alteration type		TH
WP078	BRAF MUT* (--)	BRAF fusion	BRAF inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9072)	only gene		LUAD
WP078	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + PI3K pathway inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22389471;PMID:21156289	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF (L597R)	BRAF inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:23715574	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Glioma	Responsive	D	NO	PMID:22038996;PMID:22586120	only alteration type		G
WP078	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Ovary	Responsive	C	NO	PMID:22608338	only alteration type		OV
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Pancreas	No Responsive	C	NO	ASCO 2015 (abstr 4119)	only alteration type		PA
WP078	BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:23614898;PMID:22997239	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF (G469A)	ERK inhibitors	Head an neck squamous	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		HNSC
WP078	BRAF MUT* (--)	BRAF (L485W)	ERK inhibitors	Billiary tract	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		BT
WP078	BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		LUAD
WP078	BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Thyroid	Responsive	C	NO	PMID:22241789	only alteration type		TH
WP078	BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Ovary	Responsive	D	NO	PMID:19018267	only alteration type		OV
WP078	BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Pan-RAF inhibitors	Any cancer type	Responsive	D	YES	PMID:26732095	only alteration type		CANCER
WP078	BRAF MUT* (--)	BRAF (V600E)	Pan-RAF inhibitors	Cutaneous melanoma	Responsive	C	NO	ESMO 2015 (abstract 300);AACR 2016 (abstr CT005);AACR 2017 (abstr  CT002)	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF fusion	MEK inhibitors(Trametinib,etc)	Lung adenocarcinoma, Cutaneous melanoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:24727320;PMID:24345920;PMID:20526349	only gene		LUAD, CM, PRAD
WP078	BRAF MUT* (--)	BRAF (K601R,L597R,V600R)	MEK inhibitors(Trametinib,etc)	Cutaneous melanoma	Responsive	C	NO	PMID:23248257;PMID:22805292;PMID:23248257	only alteration type		CM
WP078	KRAS MUT* (--)	KRAS (G13D)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	No Responsive	B	NO	PMID:27114605	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Lung adenocarcinoma, Thyroid	Responsive	C	NO	PMID:23524406;PMID:22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);PMID:20818844;PMID:23489023;PMID:27080216	only alteration type		LUAD, TH
WP078	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Gastrointestinal stromal	Responsive	C	NO	PMID:23470635;PMID:22608338	only alteration type		GIST
WP078	BRAF MUT* (--)	BRAF (V600R)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:23237741	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26392102;ASCO 2015 (abstr 8006)	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Neuroendocrine	Responsive	C	NO	PMID:27048246	only alteration type		NEU
WP078	BRAF MUT* (--)	BRAF (G466V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:22649091	only alteration type		LUAD
WP078	BRAF MUT* (--)	BRAF (Y472C)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	PMID:22649091	only alteration type		LUAD
WP078	BRAF MUT* (--)	BRAF (V600)	Irinotecan + Vemurafenib + Cetuximab(TOPO1 inhibitor + BRAF inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:27729313	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	Selumetinib(MEK inhibitor)	Lung	No Responsive	C	NO	PMID:26802155	only alteration type		L
WP078	BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + BYL719(EGFR mAb inhibitor + BRAF inhibitor + PI3K inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2014 (abstr 11LBA)	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF (V600E)	Panitumumab + Dabrafenib + Trametinib(EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103)	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF (V600E)	PLX4720(BRAF inhibitor)	Malignant astrocytoma	Responsive	D	NO	PMC3638050	only alteration type		MA
WP078	BRAF MUT* (--)	BRAF fusion	Selumetinib(MEK inhibitor)	Ovary	Responsive	C	NO	PMID:26324360	only gene		OV
WP078	BRAF MUT* (--)	BRAF (V600E)	Selumetinib(MEK inhibitor)	Pediatric glioma	Responsive	C	NO	NCT01089101	only alteration type		PG
WP078	BRAF MUT* (--)	BRAF fusion	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma, Lung adenocarcinoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:238900088;PMID:20526349;PMID:24727320	only gene		CM, LUAD, PRAD
WP078	BRAF MUT* (--)	BRAF (D594G,G469E)	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:18794803	only alteration type		CM
WP078	KRAS MUT* (--)	KRAS amplification	BRAF inhibitor + EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only gene		COREAD
WP078	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Lung adenocarcinoma, Hairy-Cell leukemia, Myeloma	Responsive	C	YES	PMID:22743296;PMID:22621641;PMID:23612012	only alteration type		LUAD, HCL, MYMA
WP078	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Malignant astrocytoma	Responsive	C	NO	PMID:22586120	only alteration type		MA
WP078	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:22608338;PMID:20818844;PMID:23489023	only alteration type		THCA
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
WP078	BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP078	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP078	KRAS MUT* (--)	KRAS amplification	BRAF inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only gene		COREAD
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR inhibitors	Non-small cell lung	Resistant	D	NO	PMID:19238210	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR mAb inhibitors	Stomach	Resistant	D	NO	PMID:22614881;PMID:22290393	only alteration type		ST
WP078	CDKN2A MUT* (A36G)	CDKN2A oncogenic mutation	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr 2500)	only alteration type		CM
WP078	CDKN2A MUT* (A36G)	CDKN2A oncogenic mutation	CDK4/6 inhibitors	Glioma, Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22586120;PMID:22711607	only alteration type		G, CANCER
WP078	CDKN2A MUT* (A36G)	CDKN2A deletion	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr 2500)	only gene		CM
WP078	CDKN2A MUT* (A36G)	CDKN2A deletion	CDK4/6 inhibitors	Glioma, Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22586120;PMID:22711607	only gene		G, CANCER
WP078	CDKN2A MUT* (A36G)	CDKN2A oncogenic mutation	Ilorasertib(AURKA-VEGF inhibitor)	Any cancer type	Responsive	C	YES	NCT02478320	only alteration type		CANCER
WP078	CDKN2A MUT* (A36G)	CDKN2A deletion	Ilorasertib(AURKA-VEGF inhibitor)	Any cancer type	Responsive	C	YES	NCT02478320	only gene		CANCER
WP078	CHEK2 (--)	CHEK2 deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	AACR 2015 (abstr CT322)	only gene		PRAD
WP078	MAP2K2 MUT* (--), MAP2K2 (V85G)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP078	CTNNB1 MUT* (--), CTNNB1 MUT* (D667E)	CTNNB1 (H36Y,S37C,S37Y,D32V)	Everolimus + Letrozole(MTOR inhibitor + Hormonal therapy)	Endometrium	Responsive	C	NO	PMID:25624430	only alteration type		ED
WP078	MAP2K2 MUT* (--), MAP2K2 (V85G)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP078	MAP2K2 MUT* (--), MAP2K2 (V85G)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP078	MAP2K2 MUT* (--), MAP2K2 (V85G)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP078	MYCN MUT* (--), MYCN MUT* (--)	MYCN amplification	SMO inhibitors	Medulloblastoma	Resistant	D	NO	PMID:24951114	only gene		MB
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP078	NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP078	ERBB4 MUT* (--)	ERBB4 (E317K,E452K,R544W,R393W,E872K)	Lapatinib(ERBB2 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:19718025	only alteration type		CM
WP078	ERBB4 MUT* (--)	ERBB4 fusion	Lapatinib + Afatinib(ERBB2 inhibitor + ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 oncogenic mutation	MDM2 inhibitors	Liposarcoma	Resistant	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	only alteration type		LIP
WP078	ERCC2 MUT* (--)	ERCC2 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:25096233	only alteration type		BLCA
WP078	NTRK1 (R748W)	NTRK1 (G595R,G667C)	Pan-TK inhibitors(Entrectinib,etc)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:26546295	only alteration type		COREAD
WP078	ERBB4 MUT* (--)	ERBB4 (H809G)	ERBB2 inhibitors(Lapatinib,etc)	Breast adenocarcinoma	Resistant	C	NO	PMID:26530965	only alteration type		BRCA
WP078	EZH2 MUT* (K703)	EZH2 (Y641,A677)	EZH2 inhibitors(EPZ-005687,EPZ-6438,etc)	Lymphoma	Responsive	D	YES	PMID:23023262;PMID:24563539	only alteration type		LY
WP078	FAT1 MUT* (D705N)	FAT1 oncogenic mutation	BET inhibitors	Head an neck squamous	Responsive	D	NO	PMID:27397505	only alteration type		HNSC
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 oncogenic mutation	Abemaciclib(CDK4/CDK6 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:27217383	only alteration type		BRCA
WP078	FGFR3 MUT* (--)	FGFR3 fusion	FGFR inhibitors	Glioma	Responsive	C	NO	PMID:26324363	only gene		G
WP078	FGFR3 MUT* (--)	FGFR3 oncogenic mutation	FGFR inhibitors	Bladder	Responsive	C	NO	PMID:27870574	only alteration type		BLCA
WP078	FGFR3 MUT* (--)	FGFR3 (K650,Y373C)	FGFR inhibitors	Myeloma	Responsive	D	YES	PMID:16091734;PMID:20439987;PMID:22869148	only alteration type		MYMA
WP078	FGFR3 MUT* (--)	FGFR3 (S249C,G691R)	FGFR inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:27998968	only alteration type		LUAD
WP078	FGFR3 MUT* (--)	FGFR3 fusion	FGFR inhibitors	Bladder	Responsive	C	NO	PMID:26324363;ASCO 2017 (abstr 2500)	only gene		BLCA
WP078	FGFR3 MUT* (--)	FGFR3 (K650)	Bortezomib(Proteasome inhibitor)	Myeloma	Responsive	D	YES	PMID:19331127;PMID:21273588	only alteration type		MYMA
WP078	FGFR3 MUT* (--)	FGFR3-TACC3 fusion	FGFR inhibitors(,etc)	Non-small cell lung	Responsive	D	NO	PMID:25294908	only gene		NSCLC
WP078	FGFR3 MUT* (--)	FGFR3 (Y373C)	Bortezomib(Proteasome inhibitor)	Myeloma	Resistant	D	YES	PMID:19331127;PMID:21273588	only alteration type		MYMA
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP078	NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP078	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP078	GNAQ MUT* (T96S), GNAQ MUT* (--)	GNAQ (Q209)	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	NCT01587352	only alteration type		CM
WP078	GNAQ MUT* (T96S), GNAQ MUT* (--)	GNAQ (Q209)	PI3K pathway inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22733540;PMID:22808163	only alteration type		CM
WP078	GNAQ MUT* (T96S), GNAQ MUT* (--)	GNAQ (Q209)	PKC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22653968;PMID:22253748	only alteration type		CM
WP078	GNAQ MUT* (T96S), GNAQ MUT* (--)	GNAQ (Q209)	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr CRA9003)	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF (V600E)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
WP078	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP078	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	EZH2 inhibitors	Any cancer type	Resistant	D	YES	PMID:26552009	only alteration type		CANCER
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitors	Endometrium	Resistant	D	NO	PMID:22662154	only alteration type		ED
WP078	JAK1 MUT* (--)	JAK1 (S646F;R683)	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22955920;PMID:18805579	only alteration type		ALL
WP078	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP078	MDM2 MUT* (--)	MDM2 amplification	Cisplatin(Chemotherapy)	Male germ cell tumor	Resistant	C	NO	PMID:27646943	only gene		MGCT
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 oncogenic mutation	Cisplatin(Chemotherapy)	Female germ cell tumor, Male germ cell tumor	Resistant	C	NO	PMID:27646943	only alteration type		FGCT, MGCT
WP078	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP078	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP078	KRAS MUT* (--)	KRAS (G12)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	C	NO	PMID:24687822	only alteration type		GIST
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	Trastuzumab + Lapatinib(ERBB2 mAb inhibitor + ERBB2 inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	ASCO 2015 (abstr 3508);NCT01104571;EBCC10	only alteration type		COREAD
WP078	ROS1 MUT* (--)	ROS1 (G2032R)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:23724914;PMID:25688157	only alteration type		LUAD
WP078	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	BET inhibitors	Lung	Responsive	D	NO	PMID:23129625;PMID:24045185	only alteration type		L
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4 inhibitors	Lung	Responsive	D	NO	PMID:20609353	only alteration type		L
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Lung	Responsive	C	NO	AACR 2017 (CT046)	only alteration type		L
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Cervix squamous cell	Responsive	D	NO	PMID:27167191	only alteration type		CESC
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR mAb inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24553387	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	ERK inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23614898	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	FAK inhibitors	Lung	Responsive	D	NO	PMID:23358651	only alteration type		L
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	FAS inhibitors	Lung	Responsive	C	NO	AACR 2016;abstr	only alteration type		L
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	FAS inhibitors	Lung	Responsive	C	NO	AACR 2016, abstr LB214	only alteration type		L
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	HSP90 inhibitor(in combination)s	Lung	Responsive	D	NO	PMID:23012248;PMID:21907929	only alteration type		L
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	JAK/TBK1/IKKÎµ inhibitors	Lung	Responsive	D	NO	PMID:24444711	only alteration type		L
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + BCL-XL inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23245996	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + IGF1R inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24045180	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + PI3K pathway inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:22392911	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitors	Lung, Billiary tract	Responsive	C	NO	PMID:23200175;PMID:24947927;PMID:25667274;PMID:25722381;PMID:23391555	only alteration type		L, BT
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitors	Acute myeloid leukemia, Cervix, Ovary	Responsive	D	YES	PMID:22507781;PMID:22169769;PMID:19018267	only alteration type		AML, CER, OV
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP078	KRAS MUT* (--)	KRAS (G12)	MEK inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:18701506	only alteration type		ALL
WP078	NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	MTOR inhibitor + BH3 mimeticss	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24163374	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	pan-RAF inhibitors	Lung	Responsive	C	NO	AACR 2017 (abstr  CT002)	only alteration type		L
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	pan-RAF inhibitors	Endometrium	Responsive	C	NO	AACR 2016 (abstr CT005);AACR 2017 (abstr CT002)	only alteration type		ED
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Endometrium	Responsive	D	NO	PMID:21984976;PMID:22662154	only alteration type		ED
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Lung	Responsive	C	NO	PMID:25516890	only alteration type		L
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	Abemaciclib(CDK4/6 inhibitor)	Lung	Responsive	C	NO	PMID:27217383	only alteration type		L
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP078	NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP078	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP078	NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP078	NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP078	MDM2 MUT* (--)	MDM2 amplification	MDM2 inhibitors	Liposarcoma	Responsive	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	only gene		LIP
WP078	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	Decitabine + BCL2 inhibitor(Chemotherapy + BCL2 inhibitor)	Ovary	Responsive	D	NO	PMID:25968887	only alteration type		OV
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP078	NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP078	NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP078	NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP078	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP078	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP078	NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP078	NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP078	NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP078	NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP078	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP078	NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP078	NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP078	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP078	NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP078	NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP078	NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP078	NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP078	NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP078	NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP078	NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP078	NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP078	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP078	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP078	NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP078	NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP078	BRAF MUT* (--)	BRAF (V600E)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	Gemcitabine + MEK inhibitor(Chemotherapy + MEK inhibitor)	Pancreas	Responsive	C	NO	PMID:23583440	only alteration type		PA
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	Selumetinib(MEK inhibitor)	Non-small cell lung	Responsive	C	NO	NCT00890825	only alteration type		NSCLC
WP078	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP078	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP078	NOTCH1 MUT* (--)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP078	NOTCH1 MUT* (--)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP078	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP078	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP078	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP078	NOTCH1 MUT* (--)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	only alteration type		MCL
WP078	NOTCH1 MUT* (--)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP078	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP078	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP078	NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP078	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP078	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP078	NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP078	NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP078	NTRK1 (R748W)	NTRK1 fusion	Pan-TK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24162815	only gene		LUAD
WP078	NTRK1 (R748W)	NTRK1 fusion	Pan-TKR inhibitors	Any cancer type	Responsive	C	YES	PMID:28183697;ASCO 2017 (LBA2501)	only gene		CANCER
WP078	NTRK1 (R748W)	NTRK1 fusion	Pan-TK inhibitors(Entrectinib,etc)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26546295	only gene		COREAD
WP078	NTRK1 (R748W)	NTRK1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2013 (abstr 8023)	only gene		LUAD
WP078	PALB2 MUT* (--)	PALB2 oncogenic mutation	PARP inhibitors	Prostate adenocarcinoma	Responsive	C	NO	AACR 2015 (abstr CT322);PMID:26510020	only alteration type		PRAD
WP078	PALB2 MUT* (--)	PALB2 oncogenic mutation	PARP inhibitors	Pancreas	Responsive	D	NO	PMID:25263539;NCT01585805	only alteration type		PA
WP078	PALB2 MUT* (--)	PALB2 deletion	PARP inhibitors	Prostate adenocarcinoma	Responsive	C	NO	AACR 2015 (abstr CT322);PMID:26510020	only gene		PRAD
WP078	PALB2 MUT* (--)	PALB2 deletion	PARP inhibitors	Pancreas	Responsive	D	NO	PMID:25263539;NCT01585805	only gene		PA
WP078	PALB2 MUT* (--)	PALB2 oncogenic mutation	Mytomycin C(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:21135251	only alteration type		PA
WP078	PALB2 MUT* (--)	PALB2 deletion	Mytomycin C(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:21135251	only gene		PA
WP078	PALB2 MUT* (--)	PALB2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP078	PALB2 MUT* (--)	PALB2 deletion	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only gene		PA
WP078	PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP078	PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP078	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP078	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP078	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	Sorafenib + MEK inhibitor(Pan-TK inhibitor + MEK inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:25294897	only alteration type		HC
WP078	NF1 MUT* (--), BRAF MUT* (--)	NF1 oncogenic mutation + BRAF oncogenic mutation	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23444215	only alteration type		CM
WP078	NF1 MUT* (--), BRAF MUT* (--)	NF1 deletion + BRAF oncogenic mutation	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23444215	only gene		CM
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP078	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP078	NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP078	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP078	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP078	RB1 MUT* (--), RB1 MUT* (--)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
WP078	RB1 MUT* (--), RB1 MUT* (--)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
WP078	RB1 MUT* (--), RB1 MUT* (--)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
WP078	RB1 MUT* (--), RB1 MUT* (--)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
WP078	RB1 MUT* (--), RB1 MUT* (--)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP078	RB1 MUT* (--), RB1 MUT* (--)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP078	RICTOR MUT* (T1266K), RICTOR MUT* (I1264)	RICTOR amplification	MTORC1/2 inhibitors	Lung	Responsive	C	NO	PMID:26370156	only gene		L
WP078	ROS1 MUT* (--)	ROS1 fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:23533265	only gene		LUAD
WP078	ROS1 MUT* (--)	ROS1 fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27370605	only gene		LUAD
WP078	ROS1 MUT* (--)	ROS1 (G2032R)	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:25351743	only alteration type		LUAD
WP078	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	C	YES	PMID:24875859	only gene		IM
WP078	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:25264305	only gene		LUAD
WP078	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27401242	only alteration type		LUAD
WP078	SETD2 MUT* (--), SETD2 MUT* (P2363)	SETD2 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only alteration type		CANCER
WP078	SETD2 MUT* (--), SETD2 MUT* (P2363)	SETD2 deletion	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only gene		CANCER
WP078	SMARCA4 MUT* (V830G)	SMARCA4 oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	C	NO	ESMO 2015 (abstract 302)	only alteration type		OV
WP078	SMARCA4 MUT* (V830G)	SMARCA4 deletion	EZH2 inhibitors	Ovary	Responsive	C	NO	ESMO 2015 (abstract 302)	only gene		OV
WP078	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib + Ponatinib(MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27338794	only alteration type		LUAD
WP078	BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Vemurafenib(BRAF inhibitor)	Any cancer type	Resistant	D	YES	PMID:26732095	only alteration type		CANCER
WP078	BRAF MUT* (--)	BRAF (V600)	Vemurafenib(BRAF inhibitor)	Colorectal adenocarcinoma	No Responsive	C	NO	PMID:26287849	only alteration type		COREAD
WP078	NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP078	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP078	TERT MUT* (S274)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP078	TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
WP078	NF1 MUT* (--), BRAF MUT* (--)	NF1 oncogenic mutation + BRAF oncogenic mutation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23288408;PMID:231718	only alteration type		CM
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 oncogenic mutation	WEE1 inhibitors	Head an neck	Responsive	D	NO	PMID:25125259	only alteration type		HNC
WP078	NF1 MUT* (--), BRAF MUT* (--)	NF1 deletion + BRAF oncogenic mutation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23288408;PMID:231718	only gene		CM
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 oncogenic mutation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 deletion	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only gene		BCL
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 oncogenic mutation	Decitabine(Chemotherapy)	Acute myeloid leukemia, Myelodisplasic proliferative syndrome	Responsive	C	YES	PMID:27959731	only alteration type		AML, MDPS
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 oncogenic mutation	Doxorubicin(Anthracycline antitumor antibiotic)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 oncogenic mutation	Gemcitabine(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 oncogenic mutation	Mitomycin C(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 oncogenic mutation	WEE1 inhibitors	Ovary	Responsive	C	NO	PMID:27998224	only alteration type		OV
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 oncogenic mutation	Pramlintide(Amylin analogue)	Thymic	Responsive	D	YES	PMID:25409149	only alteration type		THYM
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 deletion	Pramlintide(Amylin analogue)	Thymic	Responsive	D	YES	PMID:25409149	only gene		THYM
WP078	TSC2 MUT* (--)	TSC2 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	only alteration type		RA
WP078	TSC2 MUT* (--)	TSC2 oncogenic mutation	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	only alteration type		LAM
WP078	TSC2 MUT* (--)	TSC2 deletion	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	only gene		LAM
WP078	TSC2 MUT* (--)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	only alteration type		BLCA
WP078	TSC2 MUT* (--)	TSC2 (Q1178*)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:25295501	only alteration type		THCA
WP078	TSC2 MUT* (--)	TSC2 (E66K)	Tensirolimus(MTOR inhibitor)	Endometrium	Responsive	C	NO	PMID:27016228	only alteration type		ED
WP078	VEGFA MUT* (--)	VEGFA amplification	Sorafenib(Pan-TK inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24687604	only gene		HC
WP078	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
WP078	BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
WP078	MDM2 MUT* (--)	MDM2 amplification	Unii-Q8Mi0X869M	Liposarcoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MDM2	only gene		LIP
WP078	ERCC2 MUT* (--)	ERCC2 (G665A,P463L,R601Q,A717G,D423N,R487W,E606G,R631C,V242F,V536M,.,L461V,D609E,Y24C,D513Y,D609G,N238S)	Cisplatin	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERCC2	only alteration type		BLCA
WP078	NTRK1 (R748W)	NTRK1 fusion	Entrectinib	Any cancer type	Responsive	B	YES	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/NTRK1|CIVIC=https://civicdb.org/genes/3983/summary	only gene		CANCER
WP078	BRAF MUT* (--)	BRAF (D594.,G466.,G464.,N581.,D287H,K601.,G469.,G596.,L597.,F595L,S467L,V459L)	Plx8394	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CANCER
WP078	KDM6A MUT* (--)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
WP078	KDM6A MUT* (--)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only alteration type		BLCA
WP078	BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + Trametinib	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF (V600E)	Encorafenib + Binimetinib + Cetuximab	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		OV
WP078	FGFR3 MUT* (--)	FGFR3 (S249C,S371C,R248C,K650.,G380R,Y373C,G370C)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only alteration type		BLCA
WP078	CDKN2A MUT* (A36G)	CDKN2A (R87P,E69G,P48L,R112G,E88K,M53I,R87L,R80L,R99P,V118D,D108N,T77P,A36P,I49S,G101W,R80P,H83N,Q50P,A68T,A60R,G67S,G67R,G35R,L16P,D108H,R87W,N71I,L32P,N71K,P81L,.,R24P,H83Y,D74Y,G35V,G35A,D84Y,G23D,P73L,V126D,S56I,D84N,D74N,D84H,P114L,P114S,D84V,A60V,G93W,N71S,L97R,P81T,R79P,D84G)	Abemaciclib + Palbociclib + Ribociclib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/CDKN2A	only alteration type		CANCER
WP078	CDKN2A MUT* (A36G)	CDKN2A deletion	Abemaciclib + Palbociclib + Ribociclib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/CDKN2A	only gene		CANCER
WP078	TSC2 MUT* (--)	TSC2 (S1653P,Q1503P,R905G,L830R,A889P,L146R,T1203K,V1673F,W1610G,V769E,C696Y,F615S,E75G,L448P,V299G,R611W,R1200W,R505Q,Q1554H,G1567D,G1596V,Y1571N,I427M,S1498N,L1584R,P1709L,L844R,V705E,R905Q,Y598C,L410R,R462C,R611Q,R905W,A614D,.,S1653F,P1675L,H1620R,S1036P,H597Y,L493P,T1623I,V1673D,V705M,L826P,L792R,A328P,L493V)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	only alteration type		RCCC
WP078	TSC2 MUT* (--)	TSC2 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	only gene		RCCC
WP078	FGFR3 MUT* (--)	FGFR3 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		BLCA
WP078	AKT1 MUT* (--)	AKT1 (E17K)	Azd5363	Breast adenocarcinoma	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/AKT1|CIVIC=https://civicdb.org/genes/2/summary	only alteration type		BRCA
WP078	AKT1 MUT* (--)	AKT1 (E17K)	Azd5363	Endometrial adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/AKT1	only alteration type		EDA
WP078	AKT1 MUT* (--)	AKT1 (E17K)	Azd5363	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/AKT1	only alteration type		OV
WP078	KRAS MUT* (--)	KRAS (D119N,G12F,F156L,G60R,F28L,A18D,Q22K,K147E,D33E,A146T,E62K,A146V,Q61R,Q61H,G12A,G12R,G13E,Q22R,V14I,Y71H,G13D,G12C,T58I,.,D153V,A59G,K117N,S65N,P34L,Y64A,G13V,K5N,Y32S,L19F,T74P,G13C,G12V,G12D,Q22E,Q61L,G12S,P34R)	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/30/summary|oncokb=https://www.oncokb.org/gene/KRAS	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS amplification	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only gene		COREAD
WP078	KRAS MUT* (--)	KRAS (D119N,G12F,F156L,G60R,F28L,A18D,Q22K,K147E,D33E,A146T,E62K,A146V,Q61R,Q61H,G12A,G12R,G13E,Q22R,V14I,Y71H,G13D,G12C,T58I,.,D153V,A59G,K117N,S65N,P34L,Y64A,K5N,Y32S,L19F,T74P,G13C,G12V,G12D,Q22E,Q61L,G12S,P34R)	Cobimetinib + Binimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only alteration type		CANCER
WP078	KRAS MUT* (--)	KRAS amplification	Cobimetinib + Binimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only gene		CANCER
WP078	BRAF MUT* (--)	BRAF (V600K,V600.,L597.,K601.,V600E,L597V)	Trametinib	Cutaneous melanoma	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/5/summary|oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CM
WP078	NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP078	NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only alteration type		CANCER
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
WP078	BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Cutaneous melanoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		CM
WP078	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
WP078	BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
WP078	FGFR3 MUT* (--)	FGFR3 (M528I,D641N,R669G,Y373C,K650T,G370C,S249C,S371C,A391E,G380R,I538V,D641G,N540K,R248C,V555M,.,K650E,K650R,K650M,G375C,G382D,N540S,Y647C,K650Q,K650N)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only alteration type		CANCER
WP078	FGFR3 MUT* (--)	FGFR3 amplification	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP078	FGFR3 MUT* (--)	FGFR3-BAIAP2L1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP078	FGFR3 MUT* (--)	FGFR3-TACC3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP078	FGFR3 MUT* (--)	FGFR3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP078	FGFR3 MUT* (--)	FGFR3-IGH fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP078	NTRK1 (R748W)	NTRK1 (G595R)	Larotrectinib	Any cancer type	Resistant	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK1	only alteration type		CANCER
WP078	AKT1 MUT* (--)	AKT1 E17K	Akt Inhibitor MK2206	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/231	only alteration type		BRCA
WP078	AKT1 MUT* (--)	AKT1 E17K	Capivasertib	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/709	only alteration type		BRCA
WP078	AKT1 MUT* (--)	AKT1 E17K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4029	only alteration type		CM
WP078	AKT1 MUT* (--)	AKT1 E17K	Uprosertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/707	only alteration type		CM
WP078	AKT1 MUT* (--)	AKT1 Q79K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/439	only alteration type		CM
WP078	AKT1 MUT* (--)	AKT1 Q79K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4498	only alteration type		CM
WP078	AKT1 MUT* (--)	AKT1 Q79K	Dabrafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6260	only alteration type		CM
WP078	APC MUT* (--)	APC Mutation	G007-LK	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/446	only alteration type		COREAD
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	only alteration type		CM
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	only alteration type		GB
WP078	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	only alteration type		PRAD
WP078	BRAF MUT* (--)	BRAF Non-V600	Trametinib	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/7855	only alteration type		SOLID
WP078	BRAF MUT* (--)	BRAF A598V	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7635	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF AGK::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/724	only gene		CM
WP078	BRAF MUT* (--)	BRAF AGK::BRAF	Sorafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/723	only gene		CM
WP078	BRAF MUT* (--)	BRAF CUX1::BRAF	Vemurafenib	Pancreas	Responsive	C	NO	https://civicdb.org/links/evidence_items/5977	only gene		PA
WP078	BRAF MUT* (--)	BRAF D594G	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1554	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2201	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4472	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF D594K	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6402	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF D594K	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6403	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF G466V	Irinotecan,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7552	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF G466V	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7553	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF G466V	Vemurafenib	Solid tumors	Responsive	D	NO	https://civicdb.org/links/evidence_items/7554	only alteration type		SOLID
WP078	BRAF MUT* (--)	BRAF G469	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7634	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF G596C	Dabrafenib,Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1738	only alteration type		NSCLC
WP078	BRAF MUT* (--)	BRAF G596R	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4729	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1668	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1669	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF L597R	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/728	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1704	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2187	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6303	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6304	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6305	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6306	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1404	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF PAPSS1::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/725	only gene		CM
WP078	BRAF MUT* (--)	BRAF PAPSS1::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/726	only gene		CM
WP078	BRAF MUT* (--)	BRAF TRIM24::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/727	only gene		CM
WP078	BRAF MUT* (--)	BRAF V600	Vemurafenib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5905	only alteration type		CH
WP078	BRAF MUT* (--)	BRAF V600	Refametinib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1000	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/93	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1407	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1422	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1750	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600	Cobimetinib,Vemurafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/6044	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6180	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6937	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6966	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600	Binimetinib,Encorafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7287	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/88	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600	Vemurafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1576	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1415	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1598	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600	Cetuximab,Encorafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6046	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600	Encorafenib,Alpelisib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6047	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600	Vemurafenib,Irinotecan,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7355	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1574	only alteration type		NSCLC
WP078	BRAF MUT* (--)	BRAF V600D	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/94	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4488	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4489	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7616	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7629	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5902	only alteration type		CH
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Irinotecan,Panitumumab	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5906	only alteration type		CH
WP078	BRAF MUT* (--)	BRAF V600E	Trametinib,Mirdametinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/86	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/90	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/994	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/95	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	Pictilisib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/757	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	Dactolisib,Selumetinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1005	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1398	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1421	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1749	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2135	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3750	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3755	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3757	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6178	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6938	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6940	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600E	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/126	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/816	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2115	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2117	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2118	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2121	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3739	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3827	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Sorafenib,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/89	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	PLX4720,Pictilisib Bismesylate	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/96	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	PLX4720,Nutlin-3	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/97	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/98	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/99	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1405	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Dabrafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1406	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Cetuximab,Gefitinib,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1408	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1413	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	GDC-0879,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1428	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1589	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Irinotecan,Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1902	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5960	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Panitumumab,Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6123	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Panitumumab,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6124	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Cetuximab,Encorafenib,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7260	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7612	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cetuximab,Irinotecan	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8506	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Erlotinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8507	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/9851	only alteration type		COREAD
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Hairy-Cell leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/1579	only alteration type		HCL
WP078	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5903	only alteration type		IHCH
WP078	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5904	only alteration type		IHCH
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1698	only alteration type		MM
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1699	only alteration type		MM
WP078	BRAF MUT* (--)	BRAF V600E	Dabrafenib,Trametinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/3017	only alteration type		NSCLC
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5958	only alteration type		NSCLC
WP078	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/5959	only alteration type		OV
WP078	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1399	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1400	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600K	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2505	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600K	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2506	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4180	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6179	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6965	only alteration type		CM
WP078	BRAF MUT* (--)	BRAF ZKSCAN1::BRAF	Trametinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1663	only gene		CM
WP078	BRAF MUT* (--)	BRAF Amplification	Trametinib,Dabrafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/7677	only gene		CM
WP078	BRAF MUT* (--)	BRAF Amplification	Panitumumab,Dabrafenib	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2929	only gene		COREAD
WP078	BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
WP078	BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
WP078	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
WP078	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
WP078	BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
WP078	BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
WP078	BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
WP078	BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
WP078	CDKN2A MUT* (A36G)	CDKN2A Mutation	Palbociclib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7300	only alteration type		CH
WP078	CDKN2A MUT* (A36G)	CDKN2A Mutation	Palbociclib	Pancreas	Responsive	B	NO	https://civicdb.org/links/evidence_items/7299	only alteration type		PA
WP078	CDKN2A MUT* (A36G)	CDKN2A Loss	Linsitinib,Palbociclib	Ewing sarcoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1879	only gene		EWS
WP078	CDKN2A MUT* (A36G)	CDKN2A Loss	Palbociclib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/7444	only gene		NSCLC
WP078	CDKN2A MUT* (A36G)	CDKN2A Loss	Palbociclib	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/1377	only gene		OV
WP078	CDKN2A MUT* (A36G)	CDKN2A Loss	Palbociclib	Renal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1373	only gene		R
WP078	CHEK1 MUT* (--)	CHEK1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11210	only alteration type		PRAD
WP078	CHEK2 (--)	CHEK2 mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11205	complete		PRAD
WP078	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP078	ERBB4 MUT* (--)	ERBB4 Mutation	Lapatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/770	only alteration type		CM
WP078	EZH2 MUT* (K703)	EZH2 Y646H	Tazemetostat	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/9377	only alteration type		DLBCL
WP078	FGFR3 MUT* (--)	FGFR3 FGFR3::BAIAP2L1	PD173074	Bladder	Responsive	D	NO	https://civicdb.org/links/evidence_items/144	only gene		BLCA
WP078	FGFR3 MUT* (--)	FGFR3 Mutation	Infigratinib	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/1910	only alteration type		BLCA
WP078	FGFR3 MUT* (--)	FGFR3 Mutation	Cisplatin,Gemcitabine	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/7566	only alteration type		BLCA
WP078	GNAQ MUT* (T96S), GNAQ MUT* (--)	GNAQ Mutation	JQ1	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1210	only alteration type		UVM
WP078	GNAQ MUT* (T96S), GNAQ MUT* (--)	GNAQ Mutation	Trametinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1229	only alteration type		UVM
WP078	GNAQ MUT* (T96S), GNAQ MUT* (--)	GNAQ Mutation	Mirdametinib,Sotrastaurin Acetate	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1953	only alteration type		UVM
WP078	GNAQ MUT* (T96S), GNAQ MUT* (--)	GNAQ Mutation	Cabozantinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5068	only alteration type		UVM
WP078	GNAQ MUT* (T96S), GNAQ MUT* (--)	GNAQ Q209	Selumetinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1213	only alteration type		UVM
WP078	GNAQ MUT* (T96S), GNAQ MUT* (--)	GNAQ Q209	Refametinib	Uveal melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1233	only alteration type		UVM
WP078	JAK1 MUT* (--)	JAK1 S703I	Ruxolitinib	Hepatic carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1900	only alteration type		HC
WP078	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP078	KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP078	KRAS MUT* (--)	KRAS A146	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3939	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS A146P	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2225	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS A146T	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2943	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS A146T	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3858	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS A146T	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2206	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS A146V	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2209	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS A146V	Abemaciclib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/794	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS G12/G13	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/134	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12/G13	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/135	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12/G13	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2004	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12/G13	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6293	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12/G13	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6294	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12/G13	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6295	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12/G13	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6296	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12/G13	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6363	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12/G13	Gefitinib,Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/35	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS G12/G13	Trametinib,Gemcitabine	Pancreas adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/622	only alteration type		PAAD
WP078	KRAS MUT* (--)	KRAS G12/G13	Trametinib	Pancreas adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/990	only alteration type		PAAD
WP078	KRAS MUT* (--)	KRAS G12A	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3710	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12A	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4429	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12A	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6319	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12A	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/251	only alteration type		LUAD
WP078	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2009	only alteration type		MM
WP078	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2012	only alteration type		MM
WP078	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2013	only alteration type		MM
WP078	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2014	only alteration type		MM
WP078	KRAS MUT* (--)	KRAS G12C	Gefitinib,Erlotinib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1216	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12C	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2253	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12C	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3967	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12C	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3973	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12C	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2212	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2258	only alteration type		MM
WP078	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2261	only alteration type		MM
WP078	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2262	only alteration type		MM
WP078	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2263	only alteration type		MM
WP078	KRAS MUT* (--)	KRAS G12C	Docetaxel,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1142	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS G12C	Sotorasib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/9431	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS G12D	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3957	only alteration type		CM
WP078	KRAS MUT* (--)	KRAS G12D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2193	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2207	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2236	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12D	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3946	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12D	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6316	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12D	Therapeutic Tumor Infiltrating Lymphocytes	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1898	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12D	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2218	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12D	Vemurafenib	Hairy-Cell leukemia	Resistant	C	YES	https://civicdb.org/links/evidence_items/1580	only alteration type		HCL
WP078	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2247	only alteration type		MM
WP078	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2250	only alteration type		MM
WP078	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2251	only alteration type		MM
WP078	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2252	only alteration type		MM
WP078	KRAS MUT* (--)	KRAS G12D	Dabrafenib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/91	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS G12D	Selumetinib,Dactolisib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/305	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS G12D	Cetuximab	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/3958	only alteration type		OV
WP078	KRAS MUT* (--)	KRAS G12R	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2264	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12R	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3987	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12R	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3989	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12R	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3991	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12S	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2269	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12S	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4006	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12S	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4012	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12S	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6314	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2274	only alteration type		MM
WP078	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2277	only alteration type		MM
WP078	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2278	only alteration type		MM
WP078	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2279	only alteration type		MM
WP078	KRAS MUT* (--)	KRAS G12V	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/136	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12V	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2219	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12V	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2232	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12V	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3824	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12V	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3924	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12V	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6323	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12V	Dactolisib,Selumetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2001	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G12V	Palbociclib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/795	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS G12V	Selumetinib,Docetaxel	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1143	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS G13D	Pictilisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2041	only alteration type		BRCA
WP078	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/806	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1180	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1181	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G13D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2178	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3878	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3881	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3882	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G13D	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3889	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G13D	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6320	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G13D	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6322	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/145	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/306	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G13D	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2183	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS G13V	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6312	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Mutation	Vemurafenib,Dabrafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6264	only alteration type		CM
WP078	KRAS MUT* (--)	KRAS Mutation	Bevacizumab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1139	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Mutation	Ixazomib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1182	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1702	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3704	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	A	NO	https://civicdb.org/links/evidence_items/5345	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Mutation	Immunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/943	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Mutation	Cetuximab,Dasatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/947	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Mutation	B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/988	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Mutation	Trametinib,Afatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/991	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Mutation	MEK Inhibitor RO4987655	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/998	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Mutation	Refametinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1001	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Mutation	Selumetinib,Teprotumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1004	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Mutation	Selumetinib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4866	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Mutation	Palbociclib,Binimetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4869	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Mutation	Temsirolimus,Ridaforolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/894	only alteration type		ED
WP078	KRAS MUT* (--)	KRAS Mutation	Sorafenib,Refametinib	Hepatic carcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1642	only alteration type		HC
WP078	KRAS MUT* (--)	KRAS Mutation	Salirasib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1218	only alteration type		LUAD
WP078	KRAS MUT* (--)	KRAS Mutation	MEK Inhibitor RO4987655	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/997	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2242	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Gefitinib,Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2385	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Selumetinib	Non-small cell lung	Resistant	A	NO	https://civicdb.org/links/evidence_items/2998	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/3895	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/989	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Trametinib,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/992	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/999	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1220	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Erlotinib,Teprotumumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3713	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Abemaciclib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4842	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Pemetrexed,Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4862	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Nivolumab,Atezolizumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4863	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4867	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Erlotinib,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4868	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4996	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Docetaxel	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4997	only alteration type		NSCLC
WP078	KRAS MUT* (--)	KRAS Mutation	Decitabine	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/820	only alteration type		OV
WP078	KRAS MUT* (--)	KRAS Mutation	PI3Kbeta Inhibitor AZD8186,SCH772984	Pancreas adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1003	only alteration type		PAAD
WP078	KRAS MUT* (--)	KRAS Q61	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3917	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Q61H	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3861	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Q61H	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3862	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Q61K	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3872	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Q61L	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3867	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Q61R	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3870	only alteration type		COREAD
WP078	KRAS MUT* (--)	KRAS Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6317	only gene		CM
WP078	MYCN MUT* (--), MYCN MUT* (--)	MYCN Amplification	FACT Complex-targeting Curaxin CBL0137	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/744	only gene		NB
WP078	MYCN MUT* (--), MYCN MUT* (--)	MYCN Amplification	Panobinostat,JQ1	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6019	only gene		NB
WP078	NOTCH1 MUT* (--)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP078	NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP078	NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP078	NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP078	NTRK1 (R748W)	NTRK1 Fusion	Larotrectinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/978	only gene		COREAD
WP078	NTRK1 (R748W)	NTRK1 Fusion	Larotrectinib,Lestaurtinib,Crizotinib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1019	only gene		LUAD
WP078	NTRK1 (R748W)	NTRK1 Fusion	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/6567	only gene		SOLID
WP078	NTRK1 (R748W)	NTRK1 Fusion	Entrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/11124	only gene		SOLID
WP078	NTRK1 (R748W)	NTRK1 LMNA::NTRK1	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2960	only gene		COREAD
WP078	NTRK1 (R748W)	NTRK1 LMNA::NTRK1	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/8900	only gene		COREAD
WP078	NTRK1 (R748W)	NTRK1 SQSTM1::NTRK1	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1868	only gene		NSCLC
WP078	NTRK1 (R748W)	NTRK1 SQSTM1::NTRK1	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2950	only gene		NSCLC
WP078	NTRK1 (R748W)	NTRK1 Amplification	Larotrectinib	Solid tumors	Responsive	C	NO	https://civicdb.org/links/evidence_items/10170	only gene		SOLID
WP078	PALB2 MUT* (--)	PALB2 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8504	only alteration type		PRAD
WP078	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP078	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP078	RB1 MUT* (--), RB1 MUT* (--)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
WP078	RICTOR MUT* (T1266K), RICTOR MUT* (I1264)	RICTOR Amplification	Onatasertib,Sapanisertib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1440	only gene		LUAD
WP078	RICTOR MUT* (T1266K), RICTOR MUT* (I1264)	RICTOR Amplification	Vistusertib	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7449	only gene		SCLC
WP078	ROS1 MUT* (--)	ROS1 Rearrangement	Ceritinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1248	only gene		LUAD
WP078	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1690	only gene		LUAD
WP078	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/688	only gene		NSCLC
WP078	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1030	only gene		NSCLC
WP078	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7933	only gene		NSCLC
WP078	ROS1 MUT* (--)	ROS1 FUSIONS	Entrectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11123	only gene		NSCLC
WP078	ROS1 MUT* (--)	ROS1 Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7282	only gene		NSCLC
WP078	ROS1 MUT* (--)	ROS1 G2032R	Crizotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2934	only alteration type		LUAD
WP078	ROS1 MUT* (--)	ROS1 GOPC::ROS1	Lorlatinib	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7483	only gene		GB
WP078	RUNX1 (A235V)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	complete		AML
WP078	SMARCA4 MUT* (V830G)	SMARCA4 Loss	Abemaciclib,Palbociclib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/7155	only gene		NSCLC
WP078	TLK2 MUT* (--)	TLK2 Amplification	Go6983,GF109203X	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6000	only gene		BRCA
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 M237I	MDM2 Inhibitor AMGMDS3	Glioblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4885	only alteration type		GB
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 Mutation	Tamoxifen	Breast adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2784	only alteration type		BRCA
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 Mutation	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/851	only alteration type		BRCA
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 Mutation	Selumetinib,Docetaxel	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1145	only alteration type		NSCLC
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 Mutation	Pazopanib,Vorinostat	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/7540	only alteration type		SOLID
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 Mutation	Chemotherapy	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/850	only alteration type		ST
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 R175H	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/319	only alteration type		BRCA
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 R249	Doxorubicin	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/399	only alteration type		BRCA
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 R273H	Methotrexate,Doxorubicin	Osteosarcoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/7430	only alteration type		OS
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 R273L	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2286	only alteration type		OV
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 Y234C	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2745	only alteration type		OV
WP078	TP53 MUT* (T377P), TP53 MUT* (S371), TP53 MUT* (--)	TP53 Loss	Docetaxel	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1146	only gene		NSCLC
WP078	TSC2 MUT* (--)	TSC2 Q1178*	Everolimus	Thyroid carcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1108	only alteration type		THCA
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	FDA	only gene		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Alectinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK inframe insertion (1151T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165	only alteration type		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK (L1196M,S1206Y,G1269A,I1171T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165;PMID:24327273	only alteration type		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Brigatinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc	only gene		NSCLC
WP164	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Myelofibrosis	Responsive	A	YES	FDA	complete		MY
WP164	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		GCA
WP164	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		RA
WP164	TSC2 MUT* (--)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    , Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		RA, GCA
WP164	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022	only alteration type		BRCA
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP164	BRIP1 MUT* (--)	BRIP1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP164	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP164	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP164	NTRK1 MUT* (--)	NTRK1 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	NO	FDA:https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
WP164	NTRK1 MUT* (--)	NTRK1 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
WP164	RAD51D MUT* (--)	RAD51D oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP164	PIK3CA MUT* (--)	PIK3CA (C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R)	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	only alteration type		BRCA
WP164	NTRK3 MUT* (--)	NTRK3 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
WP164	NTRK3 MUT* (--)	NTRK3 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
WP164	NTRK3 MUT* (--)	NTRK3 (F617L,G623R,G696A)	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Resistant	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf	only alteration type		SOLID
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Crizotinib(ALK inhibitor)	Anaplastic large cell lymphoma	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large	only gene		ALCL
WP164	ATR MUT* (--)	ATR oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP164	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP164	NTRK1 MUT* (--)	NTRK1 (G595R)	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Resistant	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210861s008lbl.pdf	only alteration type		SOLID
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP164	ARAF MUT* (--)	ARAF oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP164	ARAF MUT* (--)	ARAF oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP164	ARAF MUT* (--)	ARAF oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP164	ARAF MUT* (--)	ARAF oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP164	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP164	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP164	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP164	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor	only gene		IM
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Alectinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Brigatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Ceritinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Lorlatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP164	ARAF MUT* (--)	ARAF oncogenic mutation	BRAF inhibitor + EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only alteration type		COREAD
WP164	ARAF MUT* (--)	ARAF oncogenic mutation	BRAF inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only alteration type		COREAD
WP164	AKT2 MUT* (--)	AKT2 amplification	MK2206(Allosteric AKT inhibitor)	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 373)	only gene		CANCER
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	ALK inhibitor + IGF1R inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25173427	only gene		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	ALK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:26301689	only gene		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	ALK inhibitor + SRC inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25394791	only gene		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	ALK inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560	only gene		COREAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23553849	only gene		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	novel ALK inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23639470	only gene		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK (F1174L)	novel ALK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24327273	only alteration type		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK amplification	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only gene		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK (E1408V)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK (L1196M)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Ceritinib(ALK inhibitor)	Colorectal adenocarcinoma, Inflammatory myofibroblastic	Responsive	C	YES	PMID:26633560;PMID:26933125;PMID:27742657	only gene		COREAD, IM
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Ceritinib(ALK inhibitor)	Hematologic malignancies	Responsive	C	YES	NCT02186821	only gene		HEMATO
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Crizotinib(ALK inhibitor)	Lymphoma, Glioblastoma	Responsive	C	YES	PMID:24491302;NCT02270034	only gene		LY, GB
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic, Thyroid carcinoma	Responsive	C	YES	PMID:20979472;PMID:24687827	only gene		IM, THCA
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK (F856S,A348D)	Crizotinib(ALK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:26032424	only alteration type		AML
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK (L1198F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26698910	only alteration type		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib(ALK inhibitor)	Glioma	Responsive	D	NO	PMID:22072639	only alteration type		G
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Entrectinib(Pan-TK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560;PMID:26933125	only gene		COREAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK (C1156Y)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27401242	only alteration type		LUAD
WP164	ERBB3 MUT* (--)	ERBB3 amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:25520391	only gene		COREAD
WP164	FBXW7 MUT* (--)	FBXW7 oncogenic mutation	Tubulin inhibitors	Any cancer type	Resistant	D	YES	PMID:21368834	only alteration type		CANCER
WP164	FBXW7 MUT* (--)	FBXW7 deletion	Tubulin inhibitors	Any cancer type	Resistant	D	YES	PMID:21368834	only gene		CANCER
WP164	ARAF MUT* (--)	ARAF (S214C)	Sorafenib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	http://www.jci.org/articles/view/72763;PMID:24569458	only alteration type		LUAD
WP164	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	complete		CANCER
WP164	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	complete		OV
WP164	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	complete		CANCER
WP164	GLI2 MUT* (--)	GLI2 amplification	SMO inhibitors	Medulloblastoma	Resistant	D	NO	PMID:24951114	only gene		MB
WP164	ATR MUT* (--)	ATR oncogenic mutation	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only alteration type		OV, CANCER
WP164	ATR MUT* (--)	ATR deletion	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only gene		OV, CANCER
WP164	ATR MUT* (--)	ATR oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP164	BCOR MUT* (V1701G)	BCOR oncogenic mutation	Enzastaurin(PKCb inhibitor)	Stomach	Responsive	D	NO	PMID:27397505	only alteration type		ST
WP164	JAK2 (V617F)	JAK2 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	complete		CM
WP164	CBL MUT* (--), CBL MUT* (--), CBL MUT* (--), CBL MUT* (--)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP164	CBL MUT* (--), CBL MUT* (--), CBL MUT* (--), CBL MUT* (--)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP164	CSF1R MUT* (--)	CSF1R (Y571D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:18971950	only alteration type		MDPS
WP164	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP164	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP164	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP164	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP164	MCL1 MUT* (--)	MCL1 amplification	Tubulin inhibitors	Any cancer type	Resistant	D	YES	PMID:21368834	only gene		CANCER
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP164	PIK3CA MUT* (--)	PIK3CA (E545*)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMC3936420	only alteration type		CM
WP164	PIK3CA MUT* (--)	PIK3CA amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	D	NO	PMID:24366379	only gene		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9054)	only alteration type		L
WP164	PIK3CB MUT* (--)	PIK3CB (D1067Y)	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	C	NO	PMID:26759240	only alteration type		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN oncogenic mutation	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	B	NO	PMID:21163703;PMID:19398573	only alteration type		COREAD
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN deletion	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	B	NO	PMID:21163703;PMID:19398573	only gene		COREAD
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN oncogenic mutation	MTOR inhibitors	Endometrium	No Responsive	C	NO	PMID:21788564;PMID:23238879	only alteration type		ED
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN deletion	MTOR inhibitors	Endometrium	No Responsive	C	NO	PMID:21788564;PMID:23238879	only gene		ED
WP164	EPHA3 MUT* (--)	EPHA3 amplification	EPHA3 inhibitors	Any cancer type	Responsive	D	YES	PMID:25125683	only gene		CANCER
WP164	EPHA3 MUT* (--)	EPHA3 amplification	EPHA3 inhibitors	Any cancer type	Responsive	D	YES	PMID:25125683	only gene		CANCER
WP164	ERBB3 MUT* (--)	ERBB3 (P262H,G284R)	ERBB3 mAb inhibitors	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP164	ERBB3 MUT* (--)	ERBB3 (P262H,G284R,Q809R)	PI3K pathway inhibitor + MEK inhibitors	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP164	ERBB3 MUT* (--)	ERBB3 (G284R,R103G)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	ASCO 2015 (abstr e15516)	only alteration type		BLCA
WP164	ERBB3 MUT* (--)	ERBB3 (G284R,V104M,R103G)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	PMID:27044931	only alteration type		BLCA
WP164	ERBB3 MUT* (--)	ERBB3 (P262H,G284R,Q809R)	Lapatinib(ERBB2 inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP164	ERBB3 MUT* (--)	ERBB3 (P262H,G284R)	Pertuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP164	ERBB3 MUT* (--)	ERBB3 (P262H,G284R,Q809R)	Trastuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP164	TP53 (C275Y)	TP53 oncogenic mutation	MDM2 inhibitors	Liposarcoma	Resistant	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	complete		LIP
WP164	NTRK1 MUT* (--)	NTRK1 (G595R,G667C)	Pan-TK inhibitors(Entrectinib,etc)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:26546295	only alteration type		COREAD
WP164	FANCC MUT* (--)	FANCC oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP164	FANCC MUT* (--)	FANCC deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP164	FAT1 MUT* (--)	FAT1 oncogenic mutation	BET inhibitors	Head an neck squamous	Responsive	D	NO	PMID:27397505	only alteration type		HNSC
WP164	FBXW7 MUT* (--)	FBXW7 oncogenic mutation	Steroids	Acute lymphoblastic leukemia	Responsive	B	YES	PMID:20861909	only alteration type		ALL
WP164	TP53 (C275Y)	TP53 oncogenic mutation	Abemaciclib(CDK4/CDK6 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:27217383	complete		BRCA
WP164	FBXW7 MUT* (--)	FBXW7 deletion	Sirolimus(MTOR inhibitor)	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23558291	only gene		COREAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK (I1171T)	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:25228534	only alteration type		LUAD
WP164	FGFR4 MUT* (H399P)	FGFR4 (N535,V550)	FGFR inhibitors	Rhabdomyosarcoma	Responsive	D	NO	PMID:19809159;PMID:24124571	only alteration type		RHBDS
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN biallelic inactivation	BYL719(PIK3CA inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:25409150	only alteration type		BRCA
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK (G1123S)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:26134233	only alteration type		LUAD
WP164	JAK2 (V617F)	JAK2 (V617F)	JAK inhibitor(alone or in combination)s	Acute myeloid leukemia	Responsive	D	YES	PMID:22829971	complete		AML
WP164	JAK2 (V617F)	JAK2 amplification	JAK inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27075627	only gene		BRCA
WP164	JAK2 (V617F)	JAK2-BRAF fusion	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22875628;PMID:22899477	only gene		ALL
WP164	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:22422826	complete		AML
WP164	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP164	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:19223544;PMID:20619739	only alteration type		COREAD
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN biallelic inactivation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	Caris molecular intelligence	only alteration type		COREAD
WP164	MDM2 MUT* (--)	MDM2 amplification	Cisplatin(Chemotherapy)	Male germ cell tumor	Resistant	C	NO	PMID:27646943	only gene		MGCT
WP164	TP53 (C275Y)	TP53 oncogenic mutation	Cisplatin(Chemotherapy)	Female germ cell tumor, Male germ cell tumor	Resistant	C	NO	PMID:27646943	complete		FGCT, MGCT
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK inframe insertion (1151T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only alteration type		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK oncogenic mutation	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only alteration type		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only gene		NSCLC
WP164	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP164	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only gene		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK (C1156Y,L1196M)	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:20979473	only alteration type		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK (F1174L)	Crizotinib(ALK inhibitor)	Glioma	Resistant	D	NO	PMID:22072639	only alteration type		G
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784;PMID:25228534	only alteration type		LUAD
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP164	MTOR MUT* (--)	MTOR (F2108L)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Resistant	C	NO	PMID:25295501	only alteration type		THCA
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP164	MDM2 MUT* (--)	MDM2 amplification	MDM2 inhibitors	Liposarcoma	Responsive	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	only gene	630.0	LIP
WP164	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP164	MTOR MUT* (--)	MTOR (F2108L)	MTOR kinase inhibitors	Any cancer type	Responsive	D	YES	PMID:25295501	only alteration type		CANCER
WP164	MTOR MUT* (--)	MTOR (E2014K,E2419K,N1421D)	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:24625776	only alteration type		BLCA
WP164	MTOR MUT* (--)	MTOR (I1973F)	Everolimus(MTOR inhibitor)	Angiosarcoma, Renal	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		AS, R
WP164	MTOR MUT* (--)	MTOR (K1771R)	Everolimus(MTOR inhibitor)	Stomach, Adrenal gland	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		ST, AG
WP164	MTOR MUT* (--)	MTOR (N1421D)	Everolimus(MTOR inhibitor)	Stomach	Responsive	C	NO	PMID:26859683	only alteration type		ST
WP164	MTOR MUT* (--)	MTOR (Q2223K)	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468	only alteration type		R
WP164	MTOR MUT* (--)	MTOR (L1460P,S2215Y,R2505P)	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	D	YES	PMID:24631838	only alteration type		CANCER
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP164	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP164	CRBN MUT* (--)	CRBN oncogenic mutation	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP164	CRBN MUT* (--)	CRBN (Q100*,R283K)	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP164	LRP1B MUT* (--)	LRP1B oncogenic mutation	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only alteration type		OV
WP164	LRP1B MUT* (--)	LRP1B deletion	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only gene		OV
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN biallelic inactivation	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	Caris molecular intelligence	only alteration type		COREAD
WP164	CRBN MUT* (--)	CRBN oncogenic mutation	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP164	CRBN MUT* (--)	CRBN (Q100*,R283K)	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP164	NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP164	NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP164	NTRK1 MUT* (--)	NTRK1 fusion	Pan-TK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24162815	only gene		LUAD
WP164	NTRK1 MUT* (--)	NTRK1 fusion	Pan-TKR inhibitors	Any cancer type	Responsive	C	YES	PMID:28183697;ASCO 2017 (LBA2501)	only gene		CANCER
WP164	NTRK1 MUT* (--)	NTRK1 fusion	Pan-TK inhibitors(Entrectinib,etc)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26546295	only gene		COREAD
WP164	NTRK1 MUT* (--)	NTRK1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2013 (abstr 8023)	only gene		LUAD
WP164	NTRK3 MUT* (--)	NTRK3 fusion	IGF1R inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP164	NTRK3 MUT* (--)	NTRK3 fusion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP164	NTRK3 MUT* (--)	NTRK3 fusion	Midostaurin(Pan-TK inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP164	PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP164	PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP164	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP164	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP164	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP164	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	AKT inhibitors	Breast adenocarcinoma	Responsive	C	NO	ASCO 2015 (abstr 2500)	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitor(alone or in combination)s	Lung, Colorectal adenocarcinoma	Responsive	D	NO	PMID:23136191;PMID:23475782;PMID:22392911	only alteration type		L, COREAD
WP164	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Bladder, Head an neck, Lung	Responsive	C	NO	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	only alteration type		BLCA, HNC, L
WP164	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma, Ovary, Cervix squamous cell, Endometrium	Responsive	C	NO	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	only alteration type		BRCA, OV, CESC, ED
WP164	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26787751;PMID:26763254	only alteration type		HNSC
WP164	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Glioma, Thyroid carcinoma	Responsive	D	NO	PMID:19671762;PMID:21289267	only alteration type		G, THCA
WP164	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:28331003	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2501)	only alteration type		ST
WP164	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	AKT inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP164	PIK3CB MUT* (--)	PIK3CB (D1067Y)	AKT inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26759240	only alteration type		BRCA
WP164	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	MTORC1/2 inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP164	PIK3CB MUT* (--)	PIK3CB (D1067Y)	MTORC1/2 inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26759240	only alteration type		BRCA
WP164	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP164	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	AKT inhibitors	Glioma	Responsive	D	NO	PMID:23166678	only alteration type		G
WP164	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	PI3K pathway inhibitors	Endometrium	Responsive	C	NO	ASCO 2015 (abstr 11075)	only alteration type		ED
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN oncogenic mutation	AKT inhibitors	Pancreas	Responsive	C	NO	PMID:22025163	only alteration type		PA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN deletion	AKT inhibitors	Pancreas	Responsive	C	NO	PMID:22025163	only gene		PA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN oncogenic mutation	ATM inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27397505	only alteration type		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN oncogenic mutation	PARP inhibitors	Endometrium	Responsive	C	NO	PMID:21468130;PMID:20944090	only alteration type		ED
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN deletion	PARP inhibitors	Endometrium	Responsive	C	NO	PMID:21468130;PMID:20944090	only gene		ED
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26645196	only alteration type		CM
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26645196	only gene		CM
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN oncogenic mutation	PI3K pathway inhibitor + AR antagonists	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575859	only alteration type		PRAD
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN deletion	PI3K pathway inhibitor + AR antagonists	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575859	only gene		PRAD
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Ovary	Responsive	D	NO	PMID:21632463	only alteration type		OV
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN deletion	PI3K pathway inhibitor + MEK inhibitors	Ovary	Responsive	D	NO	PMID:21632463	only gene		OV
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN oncogenic mutation	PI3K pathway inhibitors	Thyroid, Glioma, Lung, Ovary, Breast adenocarcinoma, Any cancer type, Endometrium	Responsive	D	YES	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669	only alteration type		TH, G, L, OV, BRCA, CANCER, ED
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN deletion	PI3K pathway inhibitors	Thyroid, Glioma, Lung, Ovary, Breast adenocarcinoma, Any cancer type, Endometrium	Responsive	D	YES	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669	only gene		TH, G, L, OV, BRCA, CANCER, ED
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN oncogenic mutation	PIK3CB inhibitors	Prostate adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 2514)	only alteration type		PRAD
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN deletion	PIK3CB inhibitors	Prostate adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 2514)	only gene		PRAD
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN oncogenic mutation	Everolimus(MTOR inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:23582881	only alteration type		PRAD
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN deletion	Everolimus(MTOR inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:23582881	only gene		PRAD
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN oncogenic mutation	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	C	YES	ASCO 2013 (abstr 2532)	only alteration type		CANCER
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN deletion	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	C	YES	ASCO 2013 (abstr 2532)	only gene		CANCER
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP164	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP164	RB1 MUT* (--)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
WP164	RB1 MUT* (--)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
WP164	RB1 MUT* (--)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
WP164	RB1 MUT* (--)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
WP164	RB1 MUT* (--)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP164	RB1 MUT* (--)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP164	SETD2 MUT* (--)	SETD2 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only alteration type		CANCER
WP164	SETD2 MUT* (--)	SETD2 deletion	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only gene		CANCER
WP164	SMO MUT* (--)	SMO (P641A)	Vismodegib(SHH inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 9062)	only alteration type		L
WP164	STAG2 MUT* (--)	STAG2 oncogenic mutation	PARP inhibitors	Glioma	Responsive	D	NO	PMID:24356817	only alteration type		G
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP164	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP164	TERT MUT* (--)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP164	TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP164	TP53 (C275Y)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
WP164	TP53 (C275Y)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
WP164	TP53 (C275Y)	TP53 oncogenic mutation	WEE1 inhibitors	Head an neck	Responsive	D	NO	PMID:25125259	complete		HNC
WP164	TP53 (C275Y)	TP53 oncogenic mutation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	complete		BCL
WP164	TP53 (C275Y)	TP53 deletion	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only gene		BCL
WP164	TP53 (C275Y)	TP53 oncogenic mutation	Decitabine(Chemotherapy)	Acute myeloid leukemia, Myelodisplasic proliferative syndrome	Responsive	C	YES	PMID:27959731	complete		AML, MDPS
WP164	TP53 (C275Y)	TP53 oncogenic mutation	Doxorubicin(Anthracycline antitumor antibiotic)	Bladder	Responsive	D	NO	PMID:27397505	complete		BLCA
WP164	TP53 (C275Y)	TP53 oncogenic mutation	Gemcitabine(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	complete		BLCA
WP164	TP53 (C275Y)	TP53 oncogenic mutation	Mitomycin C(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	complete		BLCA
WP164	TP53 (C275Y)	TP53 oncogenic mutation	WEE1 inhibitors	Ovary	Responsive	C	NO	PMID:27998224	complete		OV
WP164	TP53 (C275Y)	TP53 oncogenic mutation	Pramlintide(Amylin analogue)	Thymic	Responsive	D	YES	PMID:25409149	complete		THYM
WP164	TP53 (C275Y)	TP53 deletion	Pramlintide(Amylin analogue)	Thymic	Responsive	D	YES	PMID:25409149	only gene		THYM
WP164	NTRK3 MUT* (--)	NTRK3 (G623R)	novel TRK inhibitors	Any cancer type	Responsive	C	YES	PMID:28578312	only alteration type		CANCER
WP164	TSC1 MUT* (--)	TSC1 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	only alteration type		RA
WP164	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	only alteration type		BLCA
WP164	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;PMID:26859683;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	only alteration type		R
WP164	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Sarcoma, Stomach	Responsive	C	NO	PMID:26859683	only alteration type		S, ST
WP164	TSC1 MUT* (--)	TSC1 deletion	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	only gene		R
WP164	TSC2 MUT* (--)	TSC2 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	only alteration type		RA
WP164	TSC2 MUT* (--)	TSC2 oncogenic mutation	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	only alteration type		LAM
WP164	TSC2 MUT* (--)	TSC2 deletion	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	only gene		LAM
WP164	TSC2 MUT* (--)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	only alteration type		BLCA
WP164	TSC2 MUT* (--)	TSC2 (Q1178*)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:25295501	only alteration type		THCA
WP164	TSC2 MUT* (--)	TSC2 (E66K)	Tensirolimus(MTOR inhibitor)	Endometrium	Responsive	C	NO	PMID:27016228	only alteration type		ED
WP164	SMO MUT* (--)	SMO (D473H)	Vismodegib(SHH inhibitor)	Medulloblastoma	Resistant	C	NO	PMID:19726788;PMID:25759019	only alteration type		MB
WP164	SMO MUT* (--)	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	Vismodegib(SHH inhibitor)	Basal cell carcinoma	Resistant	C	NO	PMID:25759020;PMID:25306392	only alteration type		BCC
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN (D326N,G165R,T277A,T160I,G129E,G165V,N48K,H93Y,N94I,D92E,D92G,F21A,R173P,L112R,K289E,L108P,R335L,H123Y,R130G,D92V,G251C,R15S,L181P,V133I,C124R,T131A,.,V343L,A126V,T131L,L112P,R173C,G129A,H61D,C136R,H123Q,H61R,P96Q,D331G,M134L,N276S,K342N,Y68H,D92N,M35R,Y68D,P95S,R130Q,R173H,Y155C,H123D,G20E,K62R,R159G,S10N,L23F,C105F,D162G,T319A,Y16C,A126D,H93R,K128Q,I122S,Y65C,F154L,K128T,R130K,R130L,V343E,G36R,A126S,D252G,G127N,F347L,G127E,K125E,A39P,S170N,G165E,P169H,Y27S,V217D,D162H,H118P,D92A,A34D,D24Y,L345Q,T131I,D92H,K128N,T167A,S170R,T401I,P95L,C124S,P38L,S227F,C124N,A121P,G129D,K128R,C136Y,F341V,K125L,R130A,D24N,H93D,L325F,C71Y,E157G,L42R,Y174N,A121E,A126G,G129R,R161G,G44D,I168F,R15K,H93Q,I122L,F241S,D107Y,K125M,L320S)	Gsk2636771 + Azd8186	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/PTEN	only alteration type		CANCER
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN deletion	Gsk2636771 + Azd8186	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/PTEN	only gene		CANCER
WP164	MDM2 MUT* (--)	MDM2 amplification	Unii-Q8Mi0X869M	Liposarcoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MDM2	only gene		LIP
WP164	MTOR MUT* (--)	MTOR (L2209V,L1460P,L2427Q)	Temsirolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
WP164	MTOR MUT* (--)	MTOR (Q2223K)	Everolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK fusion	Crizotinib + Ceritinib	Sarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only gene		S
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK (G1202R,I1171N)	Alectinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only alteration type		NSCLC
WP164	NTRK1 MUT* (--)	NTRK1 fusion	Entrectinib	Any cancer type	Responsive	B	YES	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/NTRK1|CIVIC=https://civicdb.org/genes/3983/summary	only gene		CANCER
WP164	MTOR MUT* (--)	MTOR (E2419K,E2014K)	Everolimus	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		BLCA
WP164	MTOR MUT* (--)	MTOR (E2419K,C1483F,L2172M,K1452N,L2230V,L2427Q,L2431P,F1888I,E1799K,L2216P,W1456R,C1483W,A1519T,L1460P,A2210P,T2232I,R2505P,M2327I,C1483R,V2006I,A1428T,Y1463S,I2500M,A1459P,F1888L,S2231W,T1977R,V2006F,T1977K,A2226S,I2500F,L2427R,T1977I,S2215F,.,Q2223K,I1973F,L1433S,F1888V,S2215T,D2512H,E2014K,S2215Y,R2217W,L2209V,V2006L,L2220F,L2427P,S2215P,P2273S,E2288K,C1483Y)	Temsirolimus + Everolimus	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		CANCER
WP164	TSC1 MUT* (--)	TSC1 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	only gene		RCCC
WP164	TSC1 MUT* (--)	TSC1 (H105R,H206D,V220F,L180P,F216A,M224R,H68R,.,S35Q,F158C,L117P,L191H)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	only alteration type		RCCC
WP164	NTRK3 MUT* (--)	NTRK3 fusion	Entrectinib	Any cancer type	Responsive	B	YES	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/3985/summary|oncokb=https://www.oncokb.org/gene/NTRK3	only gene		CANCER
WP164	KDM6A (Q233*), KDM6A MUT* (--)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
WP164	KDM6A (Q233*)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	complete		BLCA
WP164	TSC2 MUT* (--)	TSC2 (S1653P,Q1503P,R905G,L830R,A889P,L146R,T1203K,V1673F,W1610G,V769E,C696Y,F615S,E75G,L448P,V299G,R611W,R1200W,R505Q,Q1554H,G1567D,G1596V,Y1571N,I427M,S1498N,L1584R,P1709L,L844R,V705E,R905Q,Y598C,L410R,R462C,R611Q,R905W,A614D,.,S1653F,P1675L,H1620R,S1036P,H597Y,L493P,T1623I,V1673D,V705M,L826P,L792R,A328P,L493V)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	only alteration type		RCCC
WP164	TSC2 MUT* (--)	TSC2 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	only gene		RCCC
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP164	NF1 MUT* (--), NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP164	ARAF MUT* (--)	ARAF (G322S,S214T,F351L,.,S214C,N217I,S214A,S214F)	Sorafenib	Histiocytoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ARAF	only alteration type		HIS
WP164	PIK3CA MUT* (--)	PIK3CA (P539R,R38H,Q546K,G118D,G106V,Q546E,E579K,N345K,E453K,V344A,E545K,T1025S,E542Q,G1049R,M1043I,E110K,P449T,N1044K,K111E,C378R,H1047R,C420R,E78K,E545A,S629C,D350G,.,G451R,M1043V,E542V,Q546R,E365K,E81K,G106D,R88Q,P366R,R93Q,G914R,H1047Y,K111N,E545Q,E545G,R93W,R108H,G106R,E453Q,E542K,D1029Y,N345I,D549N,A1066V,Q546P,E542G,E453A)	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA amplification	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only gene		BRCA
WP164	JAK2 (V617F)	JAK2-PCM1 fusion	Ruxolitinib	Eosinophilic chronic leukemia	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/JAK2	only gene		ECL
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK (C1156Y,F1174L,L1196M,G1269A)	Crizotinib	Non-small cell lung	Resistant	D	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary	only alteration type		NSCLC
WP164	ARAF MUT* (--)	ARAF (G322S,S214T,F351L,.,S214C,N217I,S214A,S214F)	Sorafenib	Non-small cell lung	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ARAF|CIVIC=https://civicdb.org/genes/3/summary	only alteration type		NSCLC
WP164	NTRK1 MUT* (--)	NTRK1 (G595R)	Larotrectinib	Any cancer type	Resistant	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK1	only alteration type		CANCER
WP164	NTRK3 MUT* (--)	NTRK3 (G623R)	Larotrectinib	Any cancer type	Resistant	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK3	only alteration type		CANCER
WP164	AKT2 MUT* (--)	AKT2 Amplification	Everolimus,Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1621	only gene		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK CAD::ALK	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7481	only gene		COREAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK CLTC::ALK	TAE684	Difuse large B Cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1261	only gene		DLBCL
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK CLTC::ALK	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1265	only gene		DLBCL
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK EML4::ALK	Alectinib	Mesothelioma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9228	only gene		MESO
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/262	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK EML4::ALK	WHI-P154	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1188	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK EML4::ALK	Crizotinib,Retaspimycin Hydrochloride	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1203	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK EML4::ALK	Crizotinib,Alvespimycin	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1206	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1207	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK EML4::ALK	Lorlatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1332	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK F1174L	Crizotinib	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/125	only alteration type		NB
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK F1174L	Alectinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/37	only alteration type		NB
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/38	only alteration type		NB
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK F1174L	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/142	only alteration type		NB
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1271	only alteration type		NB
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK F1174L	AZD3463	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1327	only alteration type		NB
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK F1174L	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1329	only alteration type		NB
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK F1174L	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/33	only alteration type		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK F1245C	Crizotinib	Neuroblastoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1333	only alteration type		NB
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK F1245C	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1330	only alteration type		NB
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK F1245V	Entrectinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2987	only alteration type		NB
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1240	only gene		ALCL
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/7361	only gene		ALCL
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	A	YES	https://civicdb.org/links/evidence_items/11218	only gene		ALCL
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1264	only gene		DLBCL
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1691	only gene		LUAD
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Pemetrexed	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/945	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1175	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1187	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1198	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1199	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1200	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1201	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Retaspimycin Hydrochloride	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1202	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1272	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1273	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1279	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1282	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1419	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1577	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4835	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Alectinib,Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4858	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7284	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7285	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Lorlatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7286	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/8657	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11121	only gene		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1283	only alteration type		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK I1171	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1287	only alteration type		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1367	only alteration type		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1284	only alteration type		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK I1171	TAE684	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1285	only alteration type		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1344	only alteration type		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1368	only alteration type		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK I1171T	Ceritinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9404	only alteration type		NB
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK KANK4::ALK	Alectinib	Pancreas acinar	Responsive	C	NO	https://civicdb.org/links/evidence_items/10327	only gene		PAAC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK Mutation	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1237	only alteration type		NSCLC
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1239	only gene		ALCL
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/1241	only gene		ALCL
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK R1275Q	TAE684	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/48	only alteration type		NB
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK R1275Q	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/39	only alteration type		NB
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/143	only alteration type		NB
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1270	only alteration type		NB
WP164	ALK MUT* (E1028D), ALK MUT* (T1026P)	ALK R1275Q	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1331	only alteration type		NB
WP164	ARAF MUT* (--)	ARAF S214C	Sorafenib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/17	only alteration type		NSCLC
WP164	ARAF MUT* (--)	ARAF S214C	Sorafenib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/40	only alteration type		NSCLC
WP164	ARAF MUT* (--)	ARAF S214C	Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/41	only alteration type		NSCLC
WP164	ARAF MUT* (--)	ARAF S490T	Cetuximab,Irinotecan,Vemurafenib	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1905	only alteration type		COREAD
WP164	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP164	BRIP1 MUT* (--)	BRIP1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11208	only alteration type		PRAD
WP164	CRBN MUT* (--)	CRBN Mutation	Lenalidomide,Pomalidomide	Multiple myeloma	Resistant	C	YES	https://civicdb.org/links/evidence_items/1766	only alteration type		MM
WP164	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP164	ERBB3 MUT* (--)	ERBB3 V855A	Pertuzumab,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1845	only alteration type		NSCLC
WP164	FBXW7 MUT* (--)	FBXW7 Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/718	only alteration type		COREAD
WP164	JAK2 (V617F)	JAK2 Splice Site (c.1641+2T>G)	Pembrolizumab	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4825	only alteration type		CM
WP164	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP164	KMT2C MUT* (K2797X), KMT2C MUT* (S806), KMT2C MUT* (--), KMT2C (G315C)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP164	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP164	MS4A1 MUT* (Q56K), MS4A1 MUT* (--)	MS4A1 Mutation	R-CHOP Regimen	Difuse large B Cell lymphoma	Resistant	B	YES	https://civicdb.org/links/evidence_items/10367	only alteration type		DLBCL
WP164	MTOR MUT* (--)	MTOR A2034V	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1547	only alteration type		BRCA
WP164	MTOR MUT* (--)	MTOR A2034V	RapaLink-1,MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1548	only alteration type		BRCA
WP164	MTOR MUT* (--)	MTOR E1799K	Sirolimus	Renal clear cell	Responsive	D	NO	https://civicdb.org/links/evidence_items/1321	only alteration type		RCCC
WP164	MTOR MUT* (--)	MTOR F2108L	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1543	only alteration type		BRCA
WP164	MTOR MUT* (--)	MTOR F2108L	Everolimus	Thyroid carcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1110	only alteration type		THCA
WP164	MTOR MUT* (--)	MTOR H1968Y	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/713	only alteration type		CM
WP164	MTOR MUT* (--)	MTOR M2327I	MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1544	only alteration type		BRCA
WP164	MTOR MUT* (--)	MTOR M2327I	Sirolimus,RapaLink-1	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1545	only alteration type		BRCA
WP164	MTOR MUT* (--)	MTOR Mutation	Everolimus,Pazopanib	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/705	only alteration type		BLCA
WP164	MTOR MUT* (--)	MTOR P2213S	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/722	only alteration type		CM
WP164	NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP164	NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP164	NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP164	NTRK1 MUT* (--)	NTRK1 Fusion	Larotrectinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/978	only gene		COREAD
WP164	NTRK1 MUT* (--)	NTRK1 Fusion	Larotrectinib,Lestaurtinib,Crizotinib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1019	only gene		LUAD
WP164	NTRK1 MUT* (--)	NTRK1 Fusion	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/6567	only gene		SOLID
WP164	NTRK1 MUT* (--)	NTRK1 Fusion	Entrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/11124	only gene		SOLID
WP164	NTRK1 MUT* (--)	NTRK1 LMNA::NTRK1	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2960	only gene		COREAD
WP164	NTRK1 MUT* (--)	NTRK1 LMNA::NTRK1	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/8900	only gene		COREAD
WP164	NTRK1 MUT* (--)	NTRK1 SQSTM1::NTRK1	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1868	only gene		NSCLC
WP164	NTRK1 MUT* (--)	NTRK1 SQSTM1::NTRK1	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2950	only gene		NSCLC
WP164	NTRK1 MUT* (--)	NTRK1 Amplification	Larotrectinib	Solid tumors	Responsive	C	NO	https://civicdb.org/links/evidence_items/10170	only gene		SOLID
WP164	NTRK3 MUT* (--)	NTRK3 EML4::NTRK3	Entrectinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11099	only gene		LUAD
WP164	NTRK3 MUT* (--)	NTRK3 EML4::NTRK3	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/10636	only gene		NSCLC
WP164	NTRK3 MUT* (--)	NTRK3 ETV6::NTRK3	Entrectinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7994	only gene		AML
WP164	NTRK3 MUT* (--)	NTRK3 ETV6::NTRK3	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/7496	only gene		SOLID
WP164	NTRK3 MUT* (--)	NTRK3 F617L	Larotrectinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/9592	only alteration type		GIST
WP164	NTRK3 MUT* (--)	NTRK3 Fusion	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/6568	only gene		SOLID
WP164	NTRK3 MUT* (--)	NTRK3 Fusion	Entrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/11125	only gene		SOLID
WP164	PDGFRB MUT* (--)	PDGFRB Fusion	Imatinib	Malignant peripheral nerve sheat tumor	Responsive	A	NO	https://civicdb.org/links/evidence_items/1498	only gene		MPN
WP164	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2346	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8549	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA C420R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2078	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA C420R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1999	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA D350G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4784	only alteration type		CM
WP164	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8007	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E542K	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/310	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E542K	Sirolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/311	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2022	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2026	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2058	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E542K	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7315	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8013	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8016	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E542K	Regorafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/83	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA E542K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4424	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA E542K	Apitolisib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/1549	only alteration type		HNSC
WP164	PIK3CA MUT* (--)	PIK3CA E542K	Perifosine,Temsirolimus	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1626	only alteration type		THCA
WP164	PIK3CA MUT* (--)	PIK3CA E545	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7468	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E545G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3724	only alteration type		CM
WP164	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1453	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2036	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6211	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E545K	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6213	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E545K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8008	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8547	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E545K	Akt Inhibitor MK2206,Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/710	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2034	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2062	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8017	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8018	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA E545K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3722	only alteration type		CM
WP164	PIK3CA MUT* (--)	PIK3CA E545K	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/387	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2037	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2217	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib	Lung adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1171	only alteration type		LUAD
WP164	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1670	only alteration type		LUAD
WP164	PIK3CA MUT* (--)	PIK3CA E545K	PI103	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2040	only alteration type		NSCLC
WP164	PIK3CA MUT* (--)	PIK3CA E545Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2213	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA E81K	Oxaliplatin,Fluorouracil,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4464	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA F930S	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10032	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA G1049R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3847	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA H1047L	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2089	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA H1047L	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8009	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA H1047L	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8019	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA H1047L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4432	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2103	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6204	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6206	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8548	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/314	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Capivasertib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1505	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1506	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Everolimus,Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1623	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2096	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2102	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/258	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/388	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Vemurafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3733	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3841	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Akt Inhibitor MK2206,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8364	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1465	only alteration type		HNSC
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1447	only alteration type		LUAD
WP164	PIK3CA MUT* (--)	PIK3CA H1047R	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1625	only alteration type		THCA
WP164	PIK3CA MUT* (--)	PIK3CA H1047X	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7318	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2867	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8663	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2866	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA K111N	Dactolisib,Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8183	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8662	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA K111N	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2085	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA K111N	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8011	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA K111N	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8020	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA K944N	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10031	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA K966E	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10034	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1384	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2087	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2098	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8536	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Capecitabine,Lapatinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8705	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1296	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1504	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1600	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1607	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1610	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Fulvestrant,Alpelisib	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7313	only alteration type		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/915	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1705	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3732	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6298	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6299	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6300	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6301	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6362	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Cabozantinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/771	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6375	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Ridaforolimus,Temsirolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/892	only alteration type		ED
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Pictilisib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1616	only alteration type		ED
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Radiation Therapy,Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1490	only alteration type		HNSC
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin,Sulindac,Celecoxib	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7185	only alteration type		HNSC
WP164	PIK3CA MUT* (--)	PIK3CA Mutation	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2355	only alteration type		NSCLC
WP164	PIK3CA MUT* (--)	PIK3CA N345K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4047	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA Q546K	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2198	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA R88Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3832	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA R93W	Cetuximab,Fluorouracil,Oxaliplatin	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4467	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA S158L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4463	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA V955G	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10033	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA V955I	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/8063	only alteration type		COREAD
WP164	PIK3CA MUT* (--)	PIK3CA Amplification	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8267	only gene		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA Amplification	Lapatinib,Dactolisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8271	only gene		BRCA
WP164	PIK3CA MUT* (--)	PIK3CA Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6275	only gene		CM
WP164	PIK3CA MUT* (--)	PIK3CA Amplification	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1464	only gene		HNSC
WP164	PIK3CA MUT* (--)	PIK3CA Amplification	Sulindac,Aspirin,Ibuprofen	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7186	only gene		HNSC
WP164	PIK3CA MUT* (--)	PIK3CA Amplification	Pictilisib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/756	only gene		OV
WP164	PIK3R1 MUT* (--)	PIK3R1 Mutation	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1612	only alteration type		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Mutation	Taselisib	Head an neck squamous	Resistant	D	NO	https://civicdb.org/links/evidence_items/1467	only alteration type		HNSC
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN R130*	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1627	only alteration type		THCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN R233*	MTOR Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/317	only alteration type		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Everolimus	Bladder	Resistant	B	NO	https://civicdb.org/links/evidence_items/644	only gene		BLCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/645	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Alpelisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/716	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1383	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1385	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1386	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2035	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2043	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	PI3Ka/Di	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8022	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8274	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8275	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8276	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Dactolisib,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8278	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Trastuzumab,Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8279	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8706	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	PI3Kbeta Inhibitor AZD8186	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/711	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1297	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	PI3K/BET Inhibitor LY294002,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1455	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1611	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2045	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2074	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8012	only gene		BRCA
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6271	only gene		CM
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Uprosertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/708	only gene		CM
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/506	only gene		COREAD
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6315	only gene		COREAD
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Ridaforolimus,Temsirolimus	Endometrium	Resistant	B	NO	https://civicdb.org/links/evidence_items/893	only gene		ED
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Temsirolimus	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1614	only gene		ED
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Cisplatin	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/1492	only gene		OV
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Buparlisib,Paclitaxel,Carboplatin	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/5957	only gene		SOLID
WP164	PTEN MUT* (--), PTEN MUT* (--)	PTEN Loss	Trastuzumab,Lapatinib	Stomach	Resistant	B	NO	https://civicdb.org/links/evidence_items/864	only gene		ST
WP164	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP164	RAD51D MUT* (--)	RAD51D Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11214	only alteration type		PRAD
WP164	RB1 MUT* (--)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
WP164	RUNX1 MUT* (L253M), RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP164	SMO MUT* (--)	SMO D473H	Vismodegib	Basal cell carcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/755	only alteration type		BCC
WP164	SMO MUT* (--)	SMO L412F	Vismodegib	Basal cell carcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4653	only alteration type		BCC
WP164	SMO MUT* (--)	SMO L412F	Vismodegib	Basal cell carcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4654	only alteration type		BCC
WP164	SMO MUT* (--)	SMO Mutation	Vismodegib	Basal cell carcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/746	only alteration type		BCC
WP164	SMO MUT* (--)	SMO Mutation	Vismodegib,Sonidegib	Basal cell carcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1477	only alteration type		BCC
WP164	SMO MUT* (--)	SMO Mutation	PSI,Arsenic Trioxide	Basal cell carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/747	only alteration type		BCC
WP164	TOP1 MUT* (--)	TOP1 Amplification	Irinotecan	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/888	only gene		COREAD
WP164	TP53 (C275Y)	TP53 M237I	MDM2 Inhibitor AMGMDS3	Glioblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4885	only alteration type		GB
WP164	TP53 (C275Y)	TP53 Mutation	Tamoxifen	Breast adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2784	complete		BRCA
WP164	TP53 (C275Y)	TP53 Mutation	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/851	complete		BRCA
WP164	TP53 (C275Y)	TP53 Mutation	Selumetinib,Docetaxel	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1145	complete		NSCLC
WP164	TP53 (C275Y)	TP53 Mutation	Pazopanib,Vorinostat	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/7540	complete		SOLID
WP164	TP53 (C275Y)	TP53 Mutation	Chemotherapy	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/850	complete		ST
WP164	TP53 (C275Y)	TP53 R175H	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/319	only alteration type		BRCA
WP164	TP53 (C275Y)	TP53 R249	Doxorubicin	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/399	only alteration type		BRCA
WP164	TP53 (C275Y)	TP53 R273H	Methotrexate,Doxorubicin	Osteosarcoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/7430	only alteration type		OS
WP164	TP53 (C275Y)	TP53 R273L	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2286	only alteration type		OV
WP164	TP53 (C275Y)	TP53 Y234C	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2745	only alteration type		OV
WP164	TP53 (C275Y)	TP53 Loss	Docetaxel	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1146	only gene		NSCLC
WP164	TSC2 MUT* (--)	TSC2 Q1178*	Everolimus	Thyroid carcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1108	only alteration type		THCA
WP204	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP204	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF (V600E,V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF (V600E,V600K)	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s028lbl.pdf	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP204	BRAF MUT* (--)	BRAF (V600E,V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf	only alteration type		CM
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890	only alteration type		PRAD
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP204	DNMT3A (G543C)	DNMT3A oncogenic mutation	Daunorubicin(Chemotherapy)	Acute myeloid leukemia	Responsive	A	YES	PMID:22417203	complete		AML
WP204	JAK2 MUT* (--), JAK2 MUT* (--), JAK2 MUT* (--)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Myelofibrosis	Responsive	A	YES	FDA	only alteration type		MY
WP204	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP204	FLT3 MUT* (--)	FLT3-ITD	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia;PMID:28644114	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 (D835,I836)	Gilteritinib(Kinase inhibitor )	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3-ITD	Gilteritinib(Kinase inhibitor )	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation;PMID:31665578	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 (D835,I836)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia; PMID:28644114	only alteration type		AML
WP204	BRAF MUT* (--)	BRAF (V600E)	Trametinib(MEK inhibitor) + Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN Non-Small Cell Lung Cancer guidlines 2022; FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		NSCLC
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP204	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP204	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation;PMID:31566309	only alteration type		COREAD
WP204	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete	555.0	COREAD
WP204	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete	555.0	COREAD
WP204	ROS1 MUT* (--)	ROS1 fusion	Entrectinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA;PMID:28183697;ESMO 2019 (abstr 4178) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725s007lbl.pdf	only gene		NSCLC
WP204	RAD51C MUT* (G153)	RAD51C oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP204	BRAF MUT* (--)	BRAF (V600)	Atezolizumab(PD-L1 blocking antibody);Vemurafenib(BRAF inhibitor);Cobimetinib(MEK inhibitor) 	Cutaneous melanoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-braf-v600-unresectable-or-metastatic-melanoma	only alteration type		CM
WP204	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Bevacizumab(VEGF mAb inhibitor);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP204	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP204	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Pembrolizumab(PD-1-blocking antibody);Pemetrexed(Chemotherapy);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf	complete		NSCLC
WP204	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		SOLID
WP204	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Lower grade glioma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-trametinib-pediatric-patients-low-grade-glioma-braf-v600e-mutation	only alteration type		LGG
WP204	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Durvalumab(PD-1-blocking antibody);Tremelimumab-actl(CTLA-4 blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non	complete		NSCLC
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP204	ATM MUT* (--)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP204	RAD51C MUT* (G153)	RAD51C oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP204	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete	555.0	COREAD
WP204	BRAF MUT* (--)	BRAF (V600E,V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210496s013lbl.pdf	only alteration type		CM
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP204	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP204	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP204	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP204	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP204	MAP2K1 MUT* (--)	MAP2K1 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP204	MAP2K1 MUT* (--)	MAP2K1 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP204	MAP2K1 MUT* (--)	MAP2K1 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP204	MAP2K1 MUT* (--)	MAP2K1 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP204	FLT3 MUT* (--)	FLT3-ITD	Quizartinib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia	only alteration type		AML
WP204	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP204	BRAF MUT* (--)	BRAF(V600E)	Vemurafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP204	BRAF MUT* (--)	BRAF (V600)	Dabrafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP204	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Hairy-Cell leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf	only alteration type		HCL
WP204	ROS1 MUT* (--)	ROS1 fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP204	ROS1 MUT* (--)	ROS1 fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP204	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-binimetinib-metastatic-non-small-cell-lung-cancer-braf-v600e-mutation	only alteration type		NSCLC
WP204	BRAF MUT* (--)	BRAF(V600)	Vemurafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		HISEC
WP204	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF (V600E,G469A)	EGFR TK inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:22773810	only alteration type		LUAD
WP204	CCND1 MUT* (--)	CCND1 amplification	SMO inhibitors	Medulloblastoma	Resistant	D	NO	PMID:24951114	only gene		MB
WP204	ATM MUT* (--)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only alteration type		COREAD
WP204	ATM MUT* (--)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
WP204	ATM MUT* (--)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only alteration type		LY
WP204	ATM MUT* (--)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only gene		LY
WP204	ATM MUT* (--)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP204	ATM MUT* (--)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
WP204	ATM MUT* (--)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP204	ATM MUT* (--)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP204	ATM MUT* (--)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP204	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP204	ATM MUT* (--)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP204	BAP1 MUT* (--)	BAP1 oncogenic mutation	EZH2 inhibitors	Mesothelioma	Responsive	D	NO	PMID:26437366	only alteration type		MESO
WP204	BAP1 MUT* (--)	BAP1 deletion	EZH2 inhibitors	Mesothelioma	Responsive	D	NO	PMID:26437366	only gene		MESO
WP204	BAP1 MUT* (--)	BAP1 oncogenic mutation	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22038994	only alteration type		CM
WP204	BAP1 MUT* (--)	BAP1 deletion	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22038994	only gene		CM
WP204	BAP1 MUT* (--)	BAP1 oncogenic mutation	PARP inhibitors	Renal, Any cancer type	Responsive	D	YES	PMID:22683710	only alteration type		R, CANCER
WP204	BAP1 MUT* (--)	BAP1 deletion	PARP inhibitors	Renal, Any cancer type	Responsive	D	YES	PMID:22683710	only gene		R, CANCER
WP204	JAK1 MUT* (--)	JAK1 oncogenic mutation	PD1 inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:27903500	only alteration type		COREAD
WP204	JAK1 MUT* (--)	JAK1 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	only alteration type		CM
WP204	JAK2 MUT* (--), JAK2 MUT* (--), JAK2 MUT* (--)	JAK2 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + CDK2/4 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22997239	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF (V600)	BRAF inhibitor + EGFR mAb inhibitor +/- PI3K inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28363909	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + HSP90 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22351686	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + MEK inhibitors	Thyroid	Responsive	C	NO	ASCO 2013 (abstr 9029)	only alteration type		TH
WP204	BRAF MUT* (--)	BRAF fusion	BRAF inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9072)	only gene		LUAD
WP204	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + PI3K pathway inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22389471;PMID:21156289	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF (L597R)	BRAF inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:23715574	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Glioma	Responsive	D	NO	PMID:22038996;PMID:22586120	only alteration type		G
WP204	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Ovary	Responsive	C	NO	PMID:22608338	only alteration type		OV
WP204	BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:23614898;PMID:22997239	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF (G469A)	ERK inhibitors	Head an neck squamous	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		HNSC
WP204	BRAF MUT* (--)	BRAF (L485W)	ERK inhibitors	Billiary tract	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		BT
WP204	BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		LUAD
WP204	BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Thyroid	Responsive	C	NO	PMID:22241789	only alteration type		TH
WP204	BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Ovary	Responsive	D	NO	PMID:19018267	only alteration type		OV
WP204	BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Pan-RAF inhibitors	Any cancer type	Responsive	D	YES	PMID:26732095	only alteration type		CANCER
WP204	BRAF MUT* (--)	BRAF (V600E)	Pan-RAF inhibitors	Cutaneous melanoma	Responsive	C	NO	ESMO 2015 (abstract 300);AACR 2016 (abstr CT005);AACR 2017 (abstr  CT002)	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF fusion	MEK inhibitors(Trametinib,etc)	Lung adenocarcinoma, Cutaneous melanoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:24727320;PMID:24345920;PMID:20526349	only gene		LUAD, CM, PRAD
WP204	BRAF MUT* (--)	BRAF (K601R,L597R,V600R)	MEK inhibitors(Trametinib,etc)	Cutaneous melanoma	Responsive	C	NO	PMID:23248257;PMID:22805292;PMID:23248257	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Lung adenocarcinoma, Thyroid	Responsive	C	NO	PMID:23524406;PMID:22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);PMID:20818844;PMID:23489023;PMID:27080216	only alteration type		LUAD, TH
WP204	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Gastrointestinal stromal	Responsive	C	NO	PMID:23470635;PMID:22608338	only alteration type		GIST
WP204	BRAF MUT* (--)	BRAF (V600R)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:23237741	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26392102;ASCO 2015 (abstr 8006)	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Neuroendocrine	Responsive	C	NO	PMID:27048246	only alteration type		NEU
WP204	BRAF MUT* (--)	BRAF (G466V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:22649091	only alteration type		LUAD
WP204	BRAF MUT* (--)	BRAF (Y472C)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	PMID:22649091	only alteration type		LUAD
WP204	BRAF MUT* (--)	BRAF (V600)	Irinotecan + Vemurafenib + Cetuximab(TOPO1 inhibitor + BRAF inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:27729313	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + BYL719(EGFR mAb inhibitor + BRAF inhibitor + PI3K inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2014 (abstr 11LBA)	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF (V600E)	Panitumumab + Dabrafenib + Trametinib(EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103)	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF (V600E)	PLX4720(BRAF inhibitor)	Malignant astrocytoma	Responsive	D	NO	PMC3638050	only alteration type		MA
WP204	BRAF MUT* (--)	BRAF fusion	Selumetinib(MEK inhibitor)	Ovary	Responsive	C	NO	PMID:26324360	only gene		OV
WP204	BRAF MUT* (--)	BRAF (V600E)	Selumetinib(MEK inhibitor)	Pediatric glioma	Responsive	C	NO	NCT01089101	only alteration type		PG
WP204	BRAF MUT* (--)	BRAF fusion	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma, Lung adenocarcinoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:238900088;PMID:20526349;PMID:24727320	only gene		CM, LUAD, PRAD
WP204	BRAF MUT* (--)	BRAF (D594G,G469E)	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:18794803	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Lung adenocarcinoma, Hairy-Cell leukemia, Myeloma	Responsive	C	YES	PMID:22743296;PMID:22621641;PMID:23612012	only alteration type		LUAD, HCL, MYMA
WP204	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Malignant astrocytoma	Responsive	C	NO	PMID:22586120	only alteration type		MA
WP204	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:22608338;PMID:20818844;PMID:23489023	only alteration type		THCA
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	PARP inhibitors	Pancreas	Responsive	C	NO	PMID:25366685;PMID:25719666;PMID:19553641;PMID:25366685	only alteration type		PA
WP204	BRCA1 MUT* (--)	BRCA1 deletion	PARP inhibitors	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	C	YES	PMID:25964244	only alteration type		CANCER
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467;PMID:25366685	only alteration type		BRCA
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP204	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP204	CBL MUT* (--)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP204	CBL MUT* (--)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP204	CCND1 MUT* (--)	CCND1 amplification	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2014 (abstr 2528)	only gene		CM
WP204	CCND1 MUT* (--)	CCND1 amplification	CDK4/6 inhibitors	Any cancer type	Responsive	D	YES	PMID:22471707	only gene		CANCER
WP204	CDH1 MUT* (--)	CDH1 oncogenic mutation	Bicalutamide(AR inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:27397505	only alteration type		BRCA
WP204	CDKN2A (D74A)	CDKN2A oncogenic mutation	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr 2500)	complete		CM
WP204	CDKN2A (D74A)	CDKN2A oncogenic mutation	CDK4/6 inhibitors	Glioma, Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22586120;PMID:22711607	complete		G, CANCER
WP204	CDKN2A (D74A)	CDKN2A deletion	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr 2500)	only gene		CM
WP204	CDKN2A (D74A)	CDKN2A deletion	CDK4/6 inhibitors	Glioma, Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22586120;PMID:22711607	only gene		G, CANCER
WP204	CDKN2A (D74A)	CDKN2A oncogenic mutation	Ilorasertib(AURKA-VEGF inhibitor)	Any cancer type	Responsive	C	YES	NCT02478320	complete		CANCER
WP204	CDKN2A (D74A)	CDKN2A deletion	Ilorasertib(AURKA-VEGF inhibitor)	Any cancer type	Responsive	C	YES	NCT02478320	only gene		CANCER
WP204	MAP2K1 MUT* (--)	MAP2K1 (P124)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:25370473	only alteration type		CM
WP204	MAP2K1 MUT* (--)	MAP2K1 (Q56P,P124S,P124L;C121S)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:19915144;PMID:21383288	only alteration type		CM
WP204	MAP2K1 MUT* (--)	MAP2K1 oncogenic mutation	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:26030179	only alteration type		COREAD
WP204	MAP2K1 MUT* (--)	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	MEK inhibitors	Any cancer type	Resistant	D	YES	PMID:19915144	only alteration type		CANCER
WP204	MAP2K1 MUT* (--)	MAP2K1 (P124L,K57N,C121S)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:19915144;PMID:23444215;PMID:21383288	only alteration type		CM
WP204	MAP2K1 MUT* (--)	MAP2K1 (Q56P,P124S,P124L)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:19915144	only alteration type		CM
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP204	PTEN (D268E)	PTEN oncogenic mutation	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	B	NO	PMID:21163703;PMID:19398573	complete		COREAD
WP204	PTEN (D268E)	PTEN deletion	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	B	NO	PMID:21163703;PMID:19398573	only gene		COREAD
WP204	PTEN (D268E)	PTEN oncogenic mutation	MTOR inhibitors	Endometrium	No Responsive	C	NO	PMID:21788564;PMID:23238879	complete		ED
WP204	PTEN (D268E)	PTEN deletion	MTOR inhibitors	Endometrium	No Responsive	C	NO	PMID:21788564;PMID:23238879	only gene		ED
WP204	PTEN (D268E), BRAF MUT* (--)	PTEN oncogenic mutation + BRAF oncogenic mutation	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	http://ascopubs.org/doi/abs/10.1200/PO.16.00054	only alteration type		CM
WP204	PTEN (D268E), BRAF MUT* (--)	PTEN deletion + BRAF oncogenic mutation	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	http://ascopubs.org/doi/abs/10.1200/PO.16.00054	only gene		CM
WP204	PTEN (D268E), BRAF MUT* (--)	PTEN oncogenic mutation + BRAF oncogenic mutation	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:23039341	only alteration type		CM
WP204	PTEN (D268E), BRAF MUT* (--)	PTEN deletion + BRAF oncogenic mutation	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:23039341	only gene		CM
WP204	FLT3 MUT* (--)	FLT3-ITD	FLT3 inhibitors	Acute myeloid leukemia	Responsive	C	YES	PMID:16857985	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 (F691)	novel FLT3 inhibitors	Acute myeloid leukemia	Responsive	D	YES	PMID:25847190	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 (N676)	Crenolanib(FLT3 inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:24619500	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 (D835)	Lestaurtinib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:16857985	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 (D835)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:20733134	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 (N676)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:24619500	only alteration type		AML
WP204	PTEN (D268E)	PTEN biallelic inactivation	BYL719(PIK3CA inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:25409150	only alteration type		BRCA
WP204	FLT3 MUT* (--)	FLT3-ITD	Sorafenib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:19389879;PMID:22368270	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3-ITD	Sorafenib + Azacytidine(Pan-TK inhibitor + Chemotherapy)	Acute myeloid leukemia	Responsive	C	YES	PMID:23613521	only alteration type		AML
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP204	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP204	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35)	GNAQ (Q209)	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	NCT01587352	only alteration type		CM
WP204	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35)	GNAQ (Q209)	PI3K pathway inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22733540;PMID:22808163	only alteration type		CM
WP204	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35)	GNAQ (Q209)	PKC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22653968;PMID:22253748	only alteration type		CM
WP204	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35)	GNAQ (Q209)	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr CRA9003)	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF (V600E)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
WP204	INPP4B MUT* (--), INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP204	INPP4B MUT* (--), INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP204	JAK1 MUT* (--)	JAK1 (S646F;R683)	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22955920;PMID:18805579	only alteration type		ALL
WP204	JAK2 MUT* (--), JAK2 MUT* (--), JAK2 MUT* (--)	JAK2 (V617F)	JAK inhibitor(alone or in combination)s	Acute myeloid leukemia	Responsive	D	YES	PMID:22829971	only alteration type		AML
WP204	JAK2 MUT* (--), JAK2 MUT* (--), JAK2 MUT* (--)	JAK2 amplification	JAK inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27075627	only gene		BRCA
WP204	JAK2 MUT* (--), JAK2 MUT* (--), JAK2 MUT* (--)	JAK2-BRAF fusion	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22875628;PMID:22899477	only gene		ALL
WP204	JAK2 MUT* (--), JAK2 MUT* (--), JAK2 MUT* (--)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:22422826	only alteration type		AML
WP204	JAK3 MUT* (--)	JAK3 (A572V,A573V)	JAK inhibitors	Lymphoma	Responsive	D	YES	PMID:22705984	only alteration type		LY
WP204	JAK3 MUT* (--)	JAK3 (R657Q,I87T,Q501H)	JAK inhibitors	Megakaryoblastic leukemia	Responsive	D	YES	PMID:18397343	only alteration type		MKB
WP204	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP204	PTEN (D268E)	PTEN biallelic inactivation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	Caris molecular intelligence	only alteration type		COREAD
WP204	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP204	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP204	ROS1 MUT* (--)	ROS1 (G2032R)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:23724914;PMID:25688157	only alteration type		LUAD
WP204	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP204	MAP2K1 MUT* (--)	MAP2K1 (F129L,L215P,I103N,P124)	ERK inhibitors	Any cancer type	Responsive	D	YES	PMID:23614898	only alteration type		CANCER
WP204	MAP2K1 MUT* (--)	MAP2K1 (P124)	ERK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:25370473	only alteration type		CM
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP204	MAP2K1 MUT* (--)	MAP2K1 (C121S)	novel MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:24448821	only alteration type		CM
WP204	MAP2K1 MUT* (--)	MAP2K1 (K57T)	Panitumumab + Trametinib(EGFR mAb inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26644315	only alteration type		COREAD
WP204	MAP2K1 MUT* (--)	MAP2K1 inframe deletion (56-60)	Selumetinib(MEK inhibitor)	Ovary	Responsive	C	NO	PMID:26324360	only alteration type		OV
WP204	MAP2K1 MUT* (--)	MAP2K1 (Q56P)	Trametinib(MEK inhibitor)	Any cancer type	Responsive	D	YES	PMID:26582713	only alteration type		CANCER
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP204	MAP2K1 MUT* (--), BRAF MUT* (--)	MAP2K1 (P124S,I111S) + BRAF oncogenic mutation	BRAF inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:22588879	only alteration type		CM
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP204	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP204	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP204	CCND1 MUT* (--)	CCND1 amplification	Palbociclib(CDK4/6 inhibitor)	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9056)	only gene		L
WP204	BRAF MUT* (--)	BRAF (V600E)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
WP204	NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP204	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP204	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP204	PTEN (D268E)	PTEN biallelic inactivation	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	Caris molecular intelligence	only alteration type		COREAD
WP204	NRG1 MUT* (P208S)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP204	NRG1 MUT* (P208S)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP204	FLT3 MUT* (--)	FLT3 (D835,Y842)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Acute myeloid leukemia	Resistant	D	YES	PMID:23430109	only alteration type		AML
WP204	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP204	FLT3 MUT* (--)	FLT3 (F691,D835,N676,Y842)	Quizartinib(Pan-TK inhibitor)	Acute myeloid leukemia	Resistant	D	YES	PMID:22504184;PMID:23878140	only alteration type		AML
WP204	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP204	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP204	NF1 MUT* (--), NF1 MUT* (--), BRAF MUT* (--)	NF1 oncogenic mutation + BRAF oncogenic mutation	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23444215	only alteration type		CM
WP204	NF1 MUT* (--), NF1 MUT* (--), BRAF MUT* (--)	NF1 deletion + BRAF oncogenic mutation	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23444215	only gene		CM
WP204	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	AKT inhibitors	Glioma	Responsive	D	NO	PMID:23166678	only alteration type		G
WP204	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	PI3K pathway inhibitors	Endometrium	Responsive	C	NO	ASCO 2015 (abstr 11075)	only alteration type		ED
WP204	PIK3R2 MUT* (R717)	PIK3R2 (A171V,N561D)	MTOR inhibitors	Endometrium	Responsive	D	NO	PMID:21984976;PMID:19962665	only alteration type		ED
WP204	PTEN (D268E)	PTEN oncogenic mutation	AKT inhibitors	Pancreas	Responsive	C	NO	PMID:22025163	complete		PA
WP204	PTEN (D268E)	PTEN deletion	AKT inhibitors	Pancreas	Responsive	C	NO	PMID:22025163	only gene		PA
WP204	PTEN (D268E)	PTEN oncogenic mutation	ATM inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27397505	complete		BRCA
WP204	PTEN (D268E)	PTEN oncogenic mutation	PARP inhibitors	Endometrium	Responsive	C	NO	PMID:21468130;PMID:20944090	complete		ED
WP204	PTEN (D268E)	PTEN deletion	PARP inhibitors	Endometrium	Responsive	C	NO	PMID:21468130;PMID:20944090	only gene		ED
WP204	PTEN (D268E)	PTEN oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26645196	complete		CM
WP204	PTEN (D268E)	PTEN deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26645196	only gene		CM
WP204	PTEN (D268E)	PTEN oncogenic mutation	PI3K pathway inhibitor + AR antagonists	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575859	complete		PRAD
WP204	PTEN (D268E)	PTEN deletion	PI3K pathway inhibitor + AR antagonists	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575859	only gene		PRAD
WP204	PTEN (D268E)	PTEN oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Ovary	Responsive	D	NO	PMID:21632463	complete		OV
WP204	PTEN (D268E)	PTEN deletion	PI3K pathway inhibitor + MEK inhibitors	Ovary	Responsive	D	NO	PMID:21632463	only gene		OV
WP204	PTEN (D268E)	PTEN oncogenic mutation	PI3K pathway inhibitors	Thyroid, Glioma, Lung, Ovary, Breast adenocarcinoma, Any cancer type, Endometrium	Responsive	D	YES	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669	complete		TH, G, L, OV, BRCA, CANCER, ED
WP204	PTEN (D268E)	PTEN deletion	PI3K pathway inhibitors	Thyroid, Glioma, Lung, Ovary, Breast adenocarcinoma, Any cancer type, Endometrium	Responsive	D	YES	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669	only gene		TH, G, L, OV, BRCA, CANCER, ED
WP204	PTEN (D268E)	PTEN oncogenic mutation	PIK3CB inhibitors	Prostate adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 2514)	complete		PRAD
WP204	PTEN (D268E)	PTEN deletion	PIK3CB inhibitors	Prostate adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 2514)	only gene		PRAD
WP204	PTEN (D268E)	PTEN oncogenic mutation	Everolimus(MTOR inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:23582881	complete		PRAD
WP204	PTEN (D268E)	PTEN deletion	Everolimus(MTOR inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:23582881	only gene		PRAD
WP204	PTEN (D268E)	PTEN oncogenic mutation	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	C	YES	ASCO 2013 (abstr 2532)	complete		CANCER
WP204	PTEN (D268E)	PTEN deletion	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	C	YES	ASCO 2013 (abstr 2532)	only gene		CANCER
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP204	PTPRD MUT* (--), PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP204	RAD51C MUT* (G153)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
WP204	RAD51C MUT* (G153)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP204	RB1 MUT* (--)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
WP204	RB1 MUT* (--)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
WP204	RB1 MUT* (--)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
WP204	RB1 MUT* (--)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
WP204	RB1 MUT* (--)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP204	RB1 MUT* (--)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP204	ROS1 MUT* (--)	ROS1 fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:23533265	only gene		LUAD
WP204	ROS1 MUT* (--)	ROS1 fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27370605	only gene		LUAD
WP204	ROS1 MUT* (--)	ROS1 (G2032R)	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:25351743	only alteration type		LUAD
WP204	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	C	YES	PMID:24875859	only gene		IM
WP204	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:25264305	only gene		LUAD
WP204	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27401242	only alteration type		LUAD
WP204	STAG2 MUT* (--)	STAG2 oncogenic mutation	PARP inhibitors	Glioma	Responsive	D	NO	PMID:24356817	only alteration type		G
WP204	BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Vemurafenib(BRAF inhibitor)	Any cancer type	Resistant	D	YES	PMID:26732095	only alteration type		CANCER
WP204	BRAF MUT* (--)	BRAF (V600)	Vemurafenib(BRAF inhibitor)	Colorectal adenocarcinoma	No Responsive	C	NO	PMID:26287849	only alteration type		COREAD
WP204	MAP2K1 MUT* (--)	MAP2K1 (E203K,Q56P,K57E)	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23569304	only alteration type		CM
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP204	SUZ12 MUT* (--)	SUZ12 oncogenic mutation	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only alteration type		CANCER
WP204	SUZ12 MUT* (--)	SUZ12 deletion	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only gene		CANCER
WP204	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP204	NF1 MUT* (--), NF1 MUT* (--), BRAF MUT* (--)	NF1 oncogenic mutation + BRAF oncogenic mutation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23288408;PMID:231718	only alteration type		CM
WP204	NF1 MUT* (--), NF1 MUT* (--), BRAF MUT* (--)	NF1 deletion + BRAF oncogenic mutation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23288408;PMID:231718	only gene		CM
WP204	FLT3 MUT* (--)	FLT3-ITD	Venetoclax(BCL2 inhibitor)	Acute myeloid leukemia	Resistant	C	YES	PMID:27520294	only alteration type		AML
WP204	PTEN (D268E)	PTEN (D326N,G165R,T277A,T160I,G129E,G165V,N48K,H93Y,N94I,D92E,D92G,F21A,R173P,L112R,K289E,L108P,R335L,H123Y,R130G,D92V,G251C,R15S,L181P,V133I,C124R,T131A,.,V343L,A126V,T131L,L112P,R173C,G129A,H61D,C136R,H123Q,H61R,P96Q,D331G,M134L,N276S,K342N,Y68H,D92N,M35R,Y68D,P95S,R130Q,R173H,Y155C,H123D,G20E,K62R,R159G,S10N,L23F,C105F,D162G,T319A,Y16C,A126D,H93R,K128Q,I122S,Y65C,F154L,K128T,R130K,R130L,V343E,G36R,A126S,D252G,G127N,F347L,G127E,K125E,A39P,S170N,G165E,P169H,Y27S,V217D,D162H,H118P,D92A,A34D,D24Y,L345Q,T131I,D92H,K128N,T167A,S170R,T401I,P95L,C124S,P38L,S227F,C124N,A121P,G129D,K128R,C136Y,F341V,K125L,R130A,D24N,H93D,L325F,C71Y,E157G,L42R,Y174N,A121E,A126G,G129R,R161G,G44D,I168F,R15K,H93Q,I122L,F241S,D107Y,K125M,L320S)	Gsk2636771 + Azd8186	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/PTEN	complete		CANCER
WP204	PTEN (D268E)	PTEN deletion	Gsk2636771 + Azd8186	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/PTEN	only gene		CANCER
WP204	BRCA1 MUT* (--)	BRCA1 (G1738R,A1708V,C47G,V1696L,Y1853C,D1739V,F1761I,H1746N,C24Y,K1702E,P1749R,M1775R,W1837C,M1775E,V1736G,V1838E,C44F,A1752V,D1739E,S1715N,.,A1789T,S1164I,T1685A,A1752P,H1686R,H41R,C64G,W1718L,D1692H,V1713A,R1699W,V1653M,Q1756C,C61G,D1739Y,G1770V,V1714G,V1833M,R1835P,R1699Q,G1706E,P1812A,E1836K,C44Y,G1788D,C39Y,M1R,S1715R,Y1703H,F1761S,E33A,M1628V,W1837G,L1705P,M1689R,G1738E,R1751P,V1809F,S1841N,S1722F,I1766S,S1655F,G1788V,L1780P,V1833E,A1708E,E1660G,C27A,Y1703S,I1807S,T1700A,A1843T,F1734L,V1741G,V1810G,F1704S,G1656D,T1685I,L1854P,Q1811R,M18T,C1697R,G1803A,G1743R,G1763V,C24R,T37R,T1773I,D1739G,W1718C,H1686Q,T1691I,L1407P,K1487R,M1652K,S1841R,M1775K,S1841A,F1734S,V1736A,M1689T,W1815X,L1764P,W1837R,T1691K,R1753T,D1692Y,W1718S,L1657P,A1843P,S1715C,R1699L)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/6/summary|oncokb=https://www.oncokb.org/gene/BRCA1	only alteration type		OV
WP204	BRCA1 MUT* (--)	BRCA1 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only gene		OV
WP204	EWSR1 MUT* (G509), EWSR1 MUT* (R511P)	EWSR1-FLI1 fusion	T + K + 2 + 1 + 6	Ewing sarcoma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EWSR1	only gene		EWS
WP204	MAP2K1 MUT* (--)	MAP2K1 (V60E,H119P,L115P,I103N,F53C,R49L,G128V,V60M,L177V,F53S,P124L,T28I,P124S,Q56P,L37P,Y130C,I204T,E203K,I111R,I111A,F53L,.,L177M,V154I,C121S,S123T,P306H,V211D,I111P,K57T,D67N,I111N,P124Q,R47Q,K57N,S218D,F129L,S222D,E144K,L115R,G128D,K57E)	Cobimetinib + Trametinib	Cutaneous melanoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MAP2K1	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF (D594.,G466.,G464.,N581.,D287H,K601.,G469.,G596.,L597.,F595L,S467L,V459L)	Plx8394	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CANCER
WP204	MAP2K1 MUT* (--)	MAP2K1 (V60E,H119P,L115P,I103N,F53C,R49L,G128V,V60M,L177V,F53S,P124L,T28I,P124S,Q56P,L37P,Y130C,I204T,E203K,I111R,I111A,F53L,.,L177M,V154I,C121S,S123T,P306H,V211D,I111P,K57T,D67N,I111N,P124Q,R47Q,K57N,S218D,F129L,S222D,E144K,L115R,G128D,K57E)	Cobimetinib + Trametinib	Histiocytoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MAP2K1	only alteration type		HIS
WP204	BRCA1 MUT* (--)	BRCA1 (G1738R,A1708V,C47G,V1696L,Y1853C,D1739V,F1761I,H1746N,C24Y,K1702E,P1749R,M1775R,W1837C,M1775E,V1736G,V1838E,C44F,A1752V,D1739E,S1715N,.,A1789T,S1164I,T1685A,A1752P,H1686R,H41R,C64G,W1718L,D1692H,V1713A,R1699W,V1653M,Q1756C,C61G,D1739Y,G1770V,V1714G,V1833M,R1835P,R1699Q,G1706E,P1812A,E1836K,C44Y,G1788D,C39Y,M1R,S1715R,Y1703H,F1761S,E33A,M1628V,W1837G,L1705P,M1689R,G1738E,R1751P,V1809F,S1841N,S1722F,I1766S,S1655F,G1788V,L1780P,V1833E,A1708E,E1660G,C27A,Y1703S,I1807S,T1700A,A1843T,F1734L,V1741G,V1810G,F1704S,G1656D,T1685I,L1854P,Q1811R,M18T,C1697R,G1803A,G1743R,G1763V,C24R,T37R,T1773I,D1739G,W1718C,H1686Q,T1691I,L1407P,K1487R,M1652K,S1841R,M1775K,S1841A,F1734S,V1736A,M1689T,L1764P,W1837R,T1691K,R1753T,D1692Y,W1718S,L1657P,A1843P,S1715C,R1699L)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only alteration type		BRCA
WP204	BRCA1 MUT* (--)	BRCA1 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only gene		BRCA
WP204	KDM6A MUT* (--), KDM6A MUT* (--)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
WP204	KDM6A MUT* (--), KDM6A MUT* (--)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only alteration type		BLCA
WP204	BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + Trametinib	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF (V600E)	Encorafenib + Binimetinib + Cetuximab	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		OV
WP204	CDKN2A (D74A)	CDKN2A (R87P,E69G,P48L,R112G,E88K,M53I,R87L,R80L,R99P,V118D,D108N,T77P,A36P,I49S,G101W,R80P,H83N,Q50P,A68T,A60R,G67S,G67R,G35R,L16P,D108H,R87W,N71I,L32P,N71K,P81L,.,R24P,H83Y,D74Y,G35V,G35A,D84Y,G23D,P73L,V126D,S56I,D84N,D74N,D84H,P114L,P114S,D84V,A60V,G93W,N71S,L97R,P81T,R79P,D84G)	Abemaciclib + Palbociclib + Ribociclib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/CDKN2A	complete		CANCER
WP204	CDKN2A (D74A)	CDKN2A deletion	Abemaciclib + Palbociclib + Ribociclib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/CDKN2A	only gene		CANCER
WP204	BRAF MUT* (--)	BRAF (V600K,V600.,L597.,K601.,V600E,L597V)	Trametinib	Cutaneous melanoma	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/5/summary|oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CM
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP204	NF1 MUT* (--), NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP204	ATM MUT* (--)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only alteration type		CANCER
WP204	ATM MUT* (--)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
WP204	MAP2K1 MUT* (--)	MAP2K1 (V60E,H119P,L115P,I103N,F53C,R49L,G128V,V60M,L177V,F53S,P124L,T28I,P124S,Q56P,L37P,Y130C,I204T,E203K,I111R,I111A,F53L,.,L177M,V154I,C121S,S123T,P306H,V211D,I111P,K57T,D67N,I111N,P124Q,R47Q,K57N,S218D,F129L,S222D,E144K,L115R,G128D,K57E)	Cobimetinib + Trametinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MAP2K1	only alteration type		NSCLC
WP204	JAK2 MUT* (--), JAK2 MUT* (--), JAK2 MUT* (--)	JAK2-PCM1 fusion	Ruxolitinib	Eosinophilic chronic leukemia	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/JAK2	only gene		ECL
WP204	BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Cutaneous melanoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		CM
WP204	MAP2K1 MUT* (--)	MAP2K1 (V60E,H119P,L115P,I103N,F53C,R49L,G128V,V60M,L177V,F53S,P124L,T28I,P124S,Q56P,L37P,Y130C,I204T,E203K,I111R,I111A,F53L,.,L177M,V154I,C121S,S123T,P306H,V211D,I111P,K57T,D67N,I111N,P124Q,R47Q,K57N,S218D,F129L,S222D,E144K,L115R,G128D,K57E)	Cobimetinib + Trametinib	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MAP2K1	only alteration type		OV
WP204	ABCC3 MUT* (--)	ABCC3 Amplification	Monomethyl Auristatin E,Paclitaxel	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/951	only gene		BRCA
WP204	ATM MUT* (--)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	only alteration type		CM
WP204	ATM MUT* (--)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	only alteration type		GB
WP204	ATM MUT* (--)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	only alteration type		PRAD
WP204	BAP1 MUT* (--)	BAP1 Mutation	Sunitinib,Everolimus	Renal	Resistant	B	NO	https://civicdb.org/links/evidence_items/5339	only alteration type		R
WP204	BAP1 MUT* (--)	BAP1 Mutation	Valproic Acid,Trichostatin A,Vorinostat,Panobinostat	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1234	only alteration type		UVM
WP204	BRAF MUT* (--)	BRAF Non-V600	Trametinib	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/7855	only alteration type		SOLID
WP204	BRAF MUT* (--)	BRAF A598V	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7635	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF AGK::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/724	only gene		CM
WP204	BRAF MUT* (--)	BRAF AGK::BRAF	Sorafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/723	only gene		CM
WP204	BRAF MUT* (--)	BRAF CUX1::BRAF	Vemurafenib	Pancreas	Responsive	C	NO	https://civicdb.org/links/evidence_items/5977	only gene		PA
WP204	BRAF MUT* (--)	BRAF D594G	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1554	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2201	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4472	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF D594K	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6402	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF D594K	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6403	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF G466V	Irinotecan,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7552	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF G466V	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7553	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF G466V	Vemurafenib	Solid tumors	Responsive	D	NO	https://civicdb.org/links/evidence_items/7554	only alteration type		SOLID
WP204	BRAF MUT* (--)	BRAF G469	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7634	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF G596C	Dabrafenib,Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1738	only alteration type		NSCLC
WP204	BRAF MUT* (--)	BRAF G596R	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4729	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1668	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1669	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF L597R	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/728	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1704	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2187	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6303	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6304	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6305	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6306	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1404	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF PAPSS1::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/725	only gene		CM
WP204	BRAF MUT* (--)	BRAF PAPSS1::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/726	only gene		CM
WP204	BRAF MUT* (--)	BRAF TRIM24::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/727	only gene		CM
WP204	BRAF MUT* (--)	BRAF V600	Vemurafenib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5905	only alteration type		CH
WP204	BRAF MUT* (--)	BRAF V600	Refametinib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1000	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/93	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1407	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1422	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1750	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600	Cobimetinib,Vemurafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/6044	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6180	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6937	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6966	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600	Binimetinib,Encorafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7287	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/88	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600	Vemurafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1576	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1415	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1598	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600	Cetuximab,Encorafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6046	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600	Encorafenib,Alpelisib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6047	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600	Vemurafenib,Irinotecan,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7355	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1574	only alteration type		NSCLC
WP204	BRAF MUT* (--)	BRAF V600D	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/94	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4488	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4489	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7616	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7629	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5902	only alteration type		CH
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Irinotecan,Panitumumab	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5906	only alteration type		CH
WP204	BRAF MUT* (--)	BRAF V600E	Trametinib,Mirdametinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/86	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/90	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/994	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/95	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	Pictilisib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/757	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	Dactolisib,Selumetinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1005	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1398	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1421	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1749	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2135	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3750	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3755	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3757	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6178	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6938	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6940	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600E	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/126	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/816	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2115	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2117	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2118	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2121	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3739	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3827	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Sorafenib,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/89	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	PLX4720,Pictilisib Bismesylate	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/96	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	PLX4720,Nutlin-3	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/97	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/98	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/99	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1405	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Dabrafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1406	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Cetuximab,Gefitinib,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1408	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1413	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	GDC-0879,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1428	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1589	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Irinotecan,Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1902	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5960	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Panitumumab,Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6123	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Panitumumab,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6124	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Cetuximab,Encorafenib,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7260	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7612	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cetuximab,Irinotecan	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8506	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Erlotinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8507	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/9851	only alteration type		COREAD
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Hairy-Cell leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/1579	only alteration type		HCL
WP204	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5903	only alteration type		IHCH
WP204	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5904	only alteration type		IHCH
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1698	only alteration type		MM
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1699	only alteration type		MM
WP204	BRAF MUT* (--)	BRAF V600E	Dabrafenib,Trametinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/3017	only alteration type		NSCLC
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5958	only alteration type		NSCLC
WP204	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/5959	only alteration type		OV
WP204	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1399	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1400	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600K	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2505	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600K	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2506	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4180	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6179	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6965	only alteration type		CM
WP204	BRAF MUT* (--)	BRAF ZKSCAN1::BRAF	Trametinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1663	only gene		CM
WP204	BRAF MUT* (--)	BRAF Amplification	Trametinib,Dabrafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/7677	only gene		CM
WP204	BRAF MUT* (--)	BRAF Amplification	Panitumumab,Dabrafenib	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2929	only gene		COREAD
WP204	BRCA1 MUT* (--)	BRCA1 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/1897	only alteration type		OV
WP204	BRCA1 MUT* (--)	BRCA1 Mutation	Olaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/7275	only alteration type		OV
WP204	BRCA1 MUT* (--)	BRCA1 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11136	only alteration type		OV
WP204	BRCA1 MUT* (--)	BRCA1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11203	only alteration type		PRAD
WP204	BRCA1 MUT* (--)	BRCA1 Q1467*	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2878	only alteration type		OV
WP204	CCND1 MUT* (--)	CCND1 Amplification	Tamoxifen	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/858	only gene		BRCA
WP204	CCND1 MUT* (--)	CCND1 Amplification	Palbociclib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1562	only gene		BRCA
WP204	CCND1 MUT* (--)	CCND1 Amplification	Palbociclib	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/1599	only gene		OV
WP204	CCND1 MUT* (--)	CCND1 Amplification	Palbociclib	Renal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1560	only gene		R
WP204	CDKN2A (D74A)	CDKN2A Mutation	Palbociclib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7300	complete		CH
WP204	CDKN2A (D74A)	CDKN2A Mutation	Palbociclib	Pancreas	Responsive	B	NO	https://civicdb.org/links/evidence_items/7299	complete		PA
WP204	CDKN2A (D74A)	CDKN2A Loss	Linsitinib,Palbociclib	Ewing sarcoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1879	only gene		EWS
WP204	CDKN2A (D74A)	CDKN2A Loss	Palbociclib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/7444	only gene		NSCLC
WP204	CDKN2A (D74A)	CDKN2A Loss	Palbociclib	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/1377	only gene		OV
WP204	CDKN2A (D74A)	CDKN2A Loss	Palbociclib	Renal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1373	only gene		R
WP204	DNMT3A (G543C)	DNMT3A Mutation	Decitabine	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/1587	complete		AML
WP204	DNMT3A (G543C)	DNMT3A R882	Daunorubicin	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/11	only alteration type		AML
WP204	DNMT3A (G543C)	DNMT3A R882	Idarubicin	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/18	only alteration type		AML
WP204	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP204	FLT3 MUT* (--)	FLT3 D835	Quizartinib,Ponatinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1036	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 D835	SU5614	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1037	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 D835	Quizartinib,Sorafenib	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/1038	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 D835	Sorafenib	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/1039	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 D835H	Sorafenib	Acute myeloid leukemia	Resistant	C	YES	https://civicdb.org/links/evidence_items/1556	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 D835H	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8517	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 D835H/Y	Sorafenib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1557	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 D835I	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8351	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 D835V	Tandutinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/3007	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 D835V	Sunitinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3008	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 D835V	Sunitinib,Cytarabine	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3009	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 D835V	Daunorubicin,Sunitinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3010	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 D835V	Quizartinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3012	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 D835V	AS602868,Tyrphostin AG 1296	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3034	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 D835V	Sunitinib	Acute myeloid leukemia	Responsive	C	YES	https://civicdb.org/links/evidence_items/4022	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 D835V	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8518	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 D835Y	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8108	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 F691L	Lestaurtinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8341	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 F691L	Midostaurin	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8342	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 Mutation	Midostaurin	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/5261	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 Mutation	Gilteritinib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/7283	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 Mutation	Gilteritinib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/7728	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 Y842C	FLT3/ABL/Aurora Kinase Inhibitor KW-2449	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8336	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 Y842C	Sorafenib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8337	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 Y842C	Sunitinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8338	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 Y842C	Quizartinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8654	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 Y842C	Lestaurtinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8339	only alteration type		AML
WP204	FLT3 MUT* (--)	FLT3 Y842C	Midostaurin	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8340	only alteration type		AML
WP204	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35)	GNAQ Mutation	JQ1	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1210	only alteration type		UVM
WP204	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35)	GNAQ Mutation	Trametinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1229	only alteration type		UVM
WP204	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35)	GNAQ Mutation	Mirdametinib,Sotrastaurin Acetate	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1953	only alteration type		UVM
WP204	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35)	GNAQ Mutation	Cabozantinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5068	only alteration type		UVM
WP204	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35)	GNAQ Q209	Selumetinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1213	only alteration type		UVM
WP204	GNAQ MUT* (Y101*), GNAQ MUT* (T96S), GNAQ MUT* (D35)	GNAQ Q209	Refametinib	Uveal melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1233	only alteration type		UVM
WP204	JAK1 MUT* (--)	JAK1 S703I	Ruxolitinib	Hepatic carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1900	only alteration type		HC
WP204	JAK2 MUT* (--), JAK2 MUT* (--), JAK2 MUT* (--)	JAK2 Splice Site (c.1641+2T>G)	Pembrolizumab	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4825	only alteration type		CM
WP204	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP204	KMT2C MUT* (--), KMT2C MUT* (S806), KMT2C MUT* (E765G), KMT2C MUT* (G315S), KMT2C MUT* (P309S), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP204	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP204	MAP2K1 MUT* (--)	MAP2K1 C121S	Vemurafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1602	only alteration type		CM
WP204	MAP2K1 MUT* (--)	MAP2K1 K57N	Selumetinib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2936	only alteration type		LUAD
WP204	MAP2K1 MUT* (--)	MAP2K1 P124S	Selumetinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/12	only alteration type		CM
WP204	MAP2K1 MUT* (--)	MAP2K1 Q56P	Selumetinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/13	only alteration type		CM
WP204	NRG1 MUT* (P208S)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP204	NRG1 MUT* (P208S)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP204	NRG1 MUT* (P208S)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP204	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP204	PIK3R1 MUT* (--)	PIK3R1 Mutation	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1612	only alteration type		BRCA
WP204	PIK3R2 MUT* (R717)	PIK3R2 N561D	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4783	only alteration type		CM
WP204	PTEN (D268E)	PTEN Mutation	Taselisib	Head an neck squamous	Resistant	D	NO	https://civicdb.org/links/evidence_items/1467	complete		HNSC
WP204	PTEN (D268E)	PTEN R130*	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1627	only alteration type		THCA
WP204	PTEN (D268E)	PTEN R233*	MTOR Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/317	only alteration type		BRCA
WP204	PTEN (D268E)	PTEN Loss	Everolimus	Bladder	Resistant	B	NO	https://civicdb.org/links/evidence_items/644	only gene		BLCA
WP204	PTEN (D268E)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/645	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	Alpelisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/716	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1383	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1385	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1386	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2035	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2043	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	PI3Ka/Di	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8022	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8274	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8275	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8276	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	Dactolisib,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8278	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	Trastuzumab,Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8279	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8706	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	PI3Kbeta Inhibitor AZD8186	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/711	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1297	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	PI3K/BET Inhibitor LY294002,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1455	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1611	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2045	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2074	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8012	only gene		BRCA
WP204	PTEN (D268E)	PTEN Loss	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6271	only gene		CM
WP204	PTEN (D268E)	PTEN Loss	Uprosertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/708	only gene		CM
WP204	PTEN (D268E)	PTEN Loss	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/506	only gene		COREAD
WP204	PTEN (D268E)	PTEN Loss	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6315	only gene		COREAD
WP204	PTEN (D268E)	PTEN Loss	Ridaforolimus,Temsirolimus	Endometrium	Resistant	B	NO	https://civicdb.org/links/evidence_items/893	only gene		ED
WP204	PTEN (D268E)	PTEN Loss	Temsirolimus	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1614	only gene		ED
WP204	PTEN (D268E)	PTEN Loss	Cisplatin	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/1492	only gene		OV
WP204	PTEN (D268E)	PTEN Loss	Buparlisib,Paclitaxel,Carboplatin	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/5957	only gene		SOLID
WP204	PTEN (D268E)	PTEN Loss	Trastuzumab,Lapatinib	Stomach	Resistant	B	NO	https://civicdb.org/links/evidence_items/864	only gene		ST
WP204	PTPRD MUT* (--), PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP204	RB1 MUT* (--)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
WP204	ROS1 MUT* (--)	ROS1 Rearrangement	Ceritinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1248	only gene		LUAD
WP204	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1690	only gene		LUAD
WP204	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/688	only gene		NSCLC
WP204	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1030	only gene		NSCLC
WP204	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7933	only gene		NSCLC
WP204	ROS1 MUT* (--)	ROS1 FUSIONS	Entrectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11123	only gene		NSCLC
WP204	ROS1 MUT* (--)	ROS1 Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7282	only gene		NSCLC
WP204	ROS1 MUT* (--)	ROS1 G2032R	Crizotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2934	only alteration type		LUAD
WP204	ROS1 MUT* (--)	ROS1 GOPC::ROS1	Lorlatinib	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7483	only gene		GB
WP204	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP204	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP204	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP060	ALK MUT* (H1030P)	ALK fusion	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	FDA	only gene		LUAD
WP060	ALK MUT* (H1030P)	ALK fusion	Alectinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK inframe insertion (1151T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165	only alteration type		LUAD
WP060	ALK MUT* (H1030P)	ALK (L1196M,S1206Y,G1269A,I1171T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165;PMID:24327273	only alteration type		LUAD
WP060	ALK MUT* (H1030P)	ALK fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK fusion	Brigatinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc	only gene		NSCLC
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP060	EGFR (R831S)	EGFR exon 19 inframe deletions	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR (L858R)	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR (L861Q,G719,S768I)	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR exon 19 inframe deletions	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR (L858R)	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR (L861Q,G719,S768I)	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR exon 19 inframe deletions	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR (L858R)	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR (L861Q,G719,S768I)	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR (L858R)	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR (T790M)	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR (T790M)	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR (T790M)	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP060	PDGFB MUT* (--)	PDGFB-COL1A1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Dermatofibrosarcoma	Responsive	A	NO	FDA	only gene		DFS
WP060	RET MUT* (H81)	RET (618,620,634,768,791,891,918,C634W,M918T)	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	A	NO	PMID:20065189;PMID:22025146	only alteration type		THCA
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP060	TSC2 MUT* (--), TSC2 MUT* (--)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    , Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		RA, GCA
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022	only alteration type		BRCA
WP060	RET MUT* (H81)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-ret-altered-thyroid-cancers;ASCO 2020 (abstr 109)	only gene		TH
WP060	RET MUT* (H81)	RET oncogenic mutation	Selpercatinib(RET kinase inhibitor)	Thyroid medullary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only alteration type		THM
WP060	EGFR (R831S)	EGFR (S786I,G719, L861Q)	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP060	ALK MUT* (H1030P)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP060	EGFR (R831S)	EGFR (L858R)	Dacomitinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN Non-Small Cell Lung Cancer guidlines 2022;FDA:https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer-0	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR (T790M)	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP060	FANCL MUT* (--), FANCL MUT* (--)	FANCL oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP060	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP060	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP060	EGFR (R831S)	EGFR exon 20 inframe insertions	Mobocertinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mobocertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR exon 20 inframe insertions	Amivantamab(EGFR mAb inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer	only alteration type		NSCLC
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Entrectinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA;PMID:28183697;ESMO 2019 (abstr 4178) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725s007lbl.pdf	only gene		NSCLC
WP060	RET MUT* (H81)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions	only gene		NSCLC
WP060	RET MUT* (H81)	RET fusion	Selpercatinib(RET kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-non-small-cell-lung	only gene		NSCLC
WP060	RAD51C MUT* (G153)	RAD51C oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP060	RAD51D MUT* (--)	RAD51D oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP060	PIK3CA MUT* (--)	PIK3CA (C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R)	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	only alteration type		BRCA
WP060	ALK MUT* (H1030P)	ALK fusion	Crizotinib(ALK inhibitor)	Anaplastic large cell lymphoma	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large	only gene		ALCL
WP060	RET MUT* (H81)	RET fusion	Selpercatinib(RET kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only gene		TH
WP060	RET MUT* (H81)	RET fusion	Selpercatinib(RET kinase inhibitor)	Solid tumors	Responsive	A	NO	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors	only gene		SOLID
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP060	FANCA MUT* (--)	FANCA oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP060	RAD51C MUT* (G153)	RAD51C oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP060	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP060	BTK (P631S)	BTK (C481S)	Ibrutinib(BTK inhibitor)	Chronic lymphocytic leukemia	Resistant	A	YES	PMID: 28418267	only alteration type		CLL
WP060	ALK MUT* (H1030P)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP060	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP060	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP060	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP060	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP060	EGFR (R831S)	EGFR exon 19 inframe deletions	Erlotinib(EGFR inhibitor 1st gen);Ramucirumab(VEGFR2 antagonist)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR (L858R)	Erlotinib(EGFR inhibitor 1st gen);Ramucirumab(VEGFR2 antagonist)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf	only alteration type		NSCLC
WP060	RET MUT* (H81)	RET fusion	Cabozantinib(Kinase inhibitor )	Non-small cell lung	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor	only gene		IM
WP060	ALK MUT* (H1030P)	ALK fusion	Alectinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP060	ALK MUT* (H1030P)	ALK fusion	Brigatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP060	ALK MUT* (H1030P)	ALK fusion	Ceritinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP060	ALK MUT* (H1030P)	ALK fusion	Lorlatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP060	EGFR (R831S)	EGFR exon 20 inframe insertions	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR exon 20 inframe insertions	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR exon 20 inframe insertions	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP060	EGFR (R831S)	EGFR (S768I,L861Q,G719)	Dacomitinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR exon 19 inframe deletions	Dacomitinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	FDA: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer-0	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR exon 19 inframe deletions	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf	only alteration type		NSCLC
WP060	ALK MUT* (H1030P)	ALK fusion	ALK inhibitor + IGF1R inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25173427	only gene		LUAD
WP060	ALK MUT* (H1030P)	ALK fusion	ALK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:26301689	only gene		LUAD
WP060	ALK MUT* (H1030P)	ALK fusion	ALK inhibitor + SRC inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25394791	only gene		LUAD
WP060	ALK MUT* (H1030P)	ALK fusion	ALK inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560	only gene		COREAD
WP060	ALK MUT* (H1030P)	ALK fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23553849	only gene		LUAD
WP060	ALK MUT* (H1030P)	ALK fusion	novel ALK inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23639470	only gene		LUAD
WP060	ALK MUT* (H1030P)	ALK (F1174L)	novel ALK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24327273	only alteration type		LUAD
WP060	ALK MUT* (H1030P)	ALK amplification	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only gene		LUAD
WP060	ALK MUT* (H1030P)	ALK (E1408V)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP060	ALK MUT* (H1030P)	ALK (L1196M)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP060	ALK MUT* (H1030P)	ALK fusion	Ceritinib(ALK inhibitor)	Colorectal adenocarcinoma, Inflammatory myofibroblastic	Responsive	C	YES	PMID:26633560;PMID:26933125;PMID:27742657	only gene		COREAD, IM
WP060	ALK MUT* (H1030P)	ALK fusion	Ceritinib(ALK inhibitor)	Hematologic malignancies	Responsive	C	YES	NCT02186821	only gene		HEMATO
WP060	ALK MUT* (H1030P)	ALK fusion	Crizotinib(ALK inhibitor)	Lymphoma, Glioblastoma	Responsive	C	YES	PMID:24491302;NCT02270034	only gene		LY, GB
WP060	ALK MUT* (H1030P)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic, Thyroid carcinoma	Responsive	C	YES	PMID:20979472;PMID:24687827	only gene		IM, THCA
WP060	EGFR (R831S)	EGFR inframe deletion (30-336)	EGFR inhibitor 1st gens	Glioma	No Responsive	C	NO	PMID:19204207	only alteration type		G
WP060	EGFR (R831S)	EGFR amplification	EGFR inhibitor 1st gens	Glioma	No Responsive	C	NO	PMID:16282176;PMID:16278407	only gene		G
WP060	EGFR (R831S)	EGFR (D761Y)	EGFR inhibitor 1st gens	Non-small cell lung	Resistant	C	NO	PMID:19680293	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR (T790M)	EGFR inhibitor 1st gens	Non-small cell lung	Resistant	B	NO	PMID:19680293	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR inframe deletion (30-336)	EGFR inhibitor 2nd gens	Glioma	No Responsive	C	NO	PMID:19204207	only alteration type		G
WP060	ALK MUT* (H1030P)	ALK (F856S,A348D)	Crizotinib(ALK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:26032424	only alteration type		AML
WP060	EGFR (R831S)	EGFR amplification	EGFR inhibitor 2nd gens	Glioma	No Responsive	C	NO	PMID:16282176;PMID:16278407	only gene		G
WP060	ALK MUT* (H1030P)	ALK (L1198F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26698910	only alteration type		LUAD
WP060	ALK MUT* (H1030P)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib(ALK inhibitor)	Glioma	Responsive	D	NO	PMID:22072639	only alteration type		G
WP060	ALK MUT* (H1030P)	ALK fusion	Entrectinib(Pan-TK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560;PMID:26933125	only gene		COREAD
WP060	ALK MUT* (H1030P)	ALK (C1156Y)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27401242	only alteration type		LUAD
WP060	APC MUT* (--)	APC oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:22440753;PMID:23539443	only alteration type		COREAD
WP060	EGFR (R831S)	EGFR (T790M)	EGFR inhibitor 2nd gens	Non-small cell lung	Resistant	B	NO	PMID:22452896	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR inframe deletion (30-336)	EGFR inhibitor 3rd gens	Glioma	No Responsive	C	NO	PMID:19204207	only alteration type		G
WP060	EGFR (R831S)	EGFR amplification	EGFR inhibitor 3rd gens	Glioma	No Responsive	C	NO	PMID:16282176;PMID:16278407	only gene		G
WP060	IGF2 MUT* (--)	IGF2 amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:25632036	only gene		COREAD
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
WP060	BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP060	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP060	CBL MUT* (--)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP060	CBL MUT* (--)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP060	MAP2K2 MUT* (--), MAP2K2 (V85G)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP060	MAP2K2 MUT* (--), MAP2K2 (V85G)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP060	MAP2K2 MUT* (--), MAP2K2 (V85G)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP060	MAP2K2 MUT* (--), MAP2K2 (V85G)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP060	MCL1 MUT* (--)	MCL1 amplification	Tubulin inhibitors	Any cancer type	Resistant	D	YES	PMID:21368834	only gene		CANCER
WP060	MITF MUT* (T95)	MITF amplification	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265153	only gene		CM
WP060	MITF MUT* (T95)	MITF amplification	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265153	only gene		CM
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP060	EGFR (R831S)	EGFR (T790M)	EGFR inhibitor 3rd gens	Lung	Responsive	C	NO	ASCO 2014 (abstr 8009);ENA 2014 (abstr 10LBA);ENA 2014 (abstr 9LBA);ASCO 2015 (abstr 8001)	only alteration type		L
WP060	EGFR (R831S)	EGFR amplification	EGFR inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26763254	only gene		HNSC
WP060	EGFR (R831S)	EGFR amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Responsive	B	NO	PMID:18794099;PMID:17664472	only gene		COREAD
WP060	EGFR (R831S)	EGFR exon 19 insertions	EGFR TK inhibitors	Lung	Responsive	B	NO	PMID:22753918	only alteration type		L
WP060	EGFR (R831S)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	EGFR TK inhibitors	Lung	Responsive	B	NO	PMID:22753918	only alteration type		L
WP060	EGFR (R831S)	EGFR exon 19 insertions	HSP90 inhibitors	Lung	Responsive	C	NO	ESMO 2012 (abstr 4380)	only alteration type		L
WP060	EGFR (R831S)	EGFR exon 20 insertions	HSP90 inhibitors	Lung	Responsive	C	NO	ASCO 2014 (abstr 8015)	only alteration type		L
WP060	EGFR (R831S)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	HSP90 inhibitors	Lung	Responsive	C	NO	ESMO 2012 (abstr 4380)	only alteration type		L
WP060	EGFR (R831S)	EGFR (T790M)	HSP90 inhibitors	Lung	Responsive	C	NO	ESMO 2012 (abstr 4380)	only alteration type		L
WP060	EGFR (R831S)	EGFR exon 19 insertions	MEK inhibitor(alone or in combination)s	Lung	Responsive	D	NO	PMID:23102728	only alteration type		L
WP060	EGFR (R831S)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	MEK inhibitor(alone or in combination)s	Lung	Responsive	D	NO	PMID:23102728	only alteration type		L
WP060	EGFR (R831S)	EGFR (S492R)	novel EGFR mAb inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:25962717	only alteration type		COREAD
WP060	EGFR (R831S)	EGFR (T790M)	EGFR inhibitor 3rd gens(Rociletinib,HM61713,etc)	Non-small cell lung	Responsive	B	NO	NCT02322281	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR exon 19 insertions	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Lung	Responsive	B	NO	PMID:22753918;PMID:25589191	only alteration type		L
WP060	NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP060	EGFR (R831S)	EGFR exon 19 insertions	Afatinib + Cetuximab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	ESMO 2012 (abstr 1289)	only alteration type		L
WP060	EGFR (R831S)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	Afatinib + Cetuximab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	ESMO 2012 (abstr 1289)	only alteration type		L
WP060	EGFR (R831S)	EGFR (T790M)	Afatinib + Cetuximab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	PMID:25074459	only alteration type		L
WP060	EGFR (R831S)	EGFR (T790M)	Afatinib + Nimotuzumab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	PMID:26667485	only alteration type		L
WP060	EGFR (R831S)	EGFR (P546S)	Cetuximab(EGFR mAb inhibitor)	Head an neck	Responsive	C	NO	PMID:23578570	only alteration type		HNC
WP060	EGFR (R831S)	EGFR (P753S)	Cetuximab + Sirolimus(EGFR mAb inhibitor + MTOR inhibitor)	Head an neck	Responsive	C	NO	PMID:24934779	only alteration type		HNC
WP060	EGFR (R831S)	EGFR-RAD51 fusion	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	C	NO	PMID:27102076	only gene		NSCLC
WP060	EGFR (R831S)	EGFR-RAD51 fusion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:27102076	only gene		L
WP060	EGFR (R831S)	EGFR exon 19 insertions	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:22190593	only alteration type		L
WP060	EGFR (R831S)	EGFR inframe insertion (769-770)	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:26773740;PMID:23328547	only alteration type		L
WP060	EGFR (R831S)	EGFR (A289V,R108K,G598V,T263P)	Erlotinib(EGFR inhibitor 1st gen)	Glioma	Responsive	D	NO	PMID:17177598	only alteration type		G
WP060	EGFR (R831S)	EGFR (K757R,E746G)	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:26773740	only alteration type		L
WP060	PIK3CA MUT* (--)	PIK3CA (E545*)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMC3936420	only alteration type		CM
WP060	PIK3CA MUT* (--)	PIK3CA amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	D	NO	PMID:24366379	only gene		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9054)	only alteration type		L
WP060	EGFR (R831S)	EGFR amplification	Gefitinib(EGFR inhibitor 1st gen)	Endometrium	Responsive	B	NO	PMID:24950987	only gene		ED
WP060	EGFR (R831S)	EGFR (E690K)	Lapatinib(ERBB2 inhibitor)	Endometrium	Responsive	C	NO	PMID:22885469	only alteration type		ED
WP060	EGFR (R831S)	EGFR exon 19 deletions	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Responsive	C	NO	NCT02465060	only alteration type		L
WP060	EGFR (R831S)	EGFR (S492R)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:22270724	only alteration type		COREAD
WP060	EGFR (R831S)	EGFR inframe deletion (6-273)	Rindopepimut(Vaccine)	Glioblastoma	Responsive	B	NO	NCT01480479	only alteration type		GB
WP060	FANCA MUT* (--)	FANCA oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP060	FANCA MUT* (--)	FANCA deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only gene		PRAD
WP060	ALK MUT* (H1030P)	ALK (I1171T)	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:25228534	only alteration type		LUAD
WP060	FGFR4 MUT* (--)	FGFR4 (N535,V550)	FGFR inhibitors	Rhabdomyosarcoma	Responsive	D	NO	PMID:19809159;PMID:24124571	only alteration type		RHBDS
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP060	NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP060	ALK MUT* (H1030P)	ALK (G1123S)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:26134233	only alteration type		LUAD
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR (S464L,G465R,I491M)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	D	NO	PMID:25623215	only alteration type		COREAD
WP060	EGFR (R831S)	EGFR (S492R,G465R,R451C,K467T)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827	only alteration type		COREAD
WP060	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP060	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:19223544;PMID:20619739	only alteration type		COREAD
WP060	ALK MUT* (H1030P)	ALK inframe insertion (1151T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only alteration type		LUAD
WP060	ALK MUT* (H1030P)	ALK oncogenic mutation	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only alteration type		NSCLC
WP060	ALK MUT* (H1030P)	ALK amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only gene		NSCLC
WP060	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP060	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP060	ALK MUT* (H1030P)	ALK amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only gene		LUAD
WP060	ALK MUT* (H1030P)	ALK (C1156Y,L1196M)	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:20979473	only alteration type		NSCLC
WP060	ALK MUT* (H1030P)	ALK (F1174L)	Crizotinib(ALK inhibitor)	Glioma	Resistant	D	NO	PMID:22072639	only alteration type		G
WP060	ALK MUT* (H1030P)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784;PMID:25228534	only alteration type		LUAD
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 (G2032R)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:23724914;PMID:25688157	only alteration type		LUAD
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP060	NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP060	EGFR (R831S)	EGFR amplification	Erlotinib(EGFR inhibitor 1st gen)	Lung	No Responsive	C	NO	ASCO2015(abstre19028)	only gene		L
WP060	EGFR (R831S)	EGFR (S720)	Erlotinib(EGFR inhibitor 1st gen)	Lung	No Responsive	C	NO	PMID:26773740	only alteration type		L
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP060	NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP060	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP060	NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP060	NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP060	EGFR (R831S)	EGFR inframe deletion (L747),inframe insertion (P753PS)	Gefitinib(EGFR inhibitor 1st gen)	Head an neck	No Responsive	C	NO	PMID:21274259	only alteration type		HNC
WP060	EGFR (R831S)	EGFR amplification	Gefitinib(EGFR inhibitor 1st gen)	Head an neck	No Responsive	C	NO	PMID:21274259;PMID:22261807	only gene		HNC
WP060	EGFR (R831S)	EGFR (V843I)	Gefitinib(EGFR inhibitor 1st gen)	Head an neck	No Responsive	C	NO	PMID:21274259	only alteration type		HNC
WP060	BTK (P631S)	BTK (C481)	Ibrutinib(BTK inhibitor)	Mantle cell lymphoma	Resistant	C	YES	PMID:25082755	only alteration type		MCL
WP060	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP060	NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP060	NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP060	NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP060	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP060	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP060	NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP060	NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP060	NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP060	NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP060	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP060	NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP060	CRBN MUT* (--)	CRBN oncogenic mutation	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP060	CRBN MUT* (--)	CRBN (Q100*,R283K)	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP060	NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP060	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP060	NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP060	NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP060	NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP060	NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP060	NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP060	NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP060	NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP060	NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP060	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP060	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP060	EGFR (R831S)	EGFR (C797S)	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Resistant	C	NO	PMID:25939061	only alteration type		L
WP060	EGFR (R831S)	EGFR (L718)	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Resistant	C	NO	ASCO 2017 (abstr 2572)	only alteration type		L
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP060	NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP060	NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP060	EGFR (R831S)	EGFR (L792)	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Resistant	C	NO	ASCO 2017 (abstr 2572)	only alteration type		L
WP060	EGFR (R831S)	EGFR (G465R)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:26059438	only alteration type		COREAD
WP060	CRBN MUT* (--)	CRBN oncogenic mutation	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP060	CRBN MUT* (--)	CRBN (Q100*,R283K)	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP060	NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP060	NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP060	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP060	RET MUT* (H81)	RET (I788N)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Resistant	D	NO	PMID:28615362	only alteration type		LUAD
WP060	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP060	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP060	EGFR (R831S)	EGFR (L798I)	Rociletinib(EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27283993	only alteration type		LUAD
WP060	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	AKT inhibitors	Breast adenocarcinoma	Responsive	C	NO	ASCO 2015 (abstr 2500)	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitor(alone or in combination)s	Lung, Colorectal adenocarcinoma	Responsive	D	NO	PMID:23136191;PMID:23475782;PMID:22392911	only alteration type		L, COREAD
WP060	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Bladder, Head an neck, Lung	Responsive	C	NO	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	only alteration type		BLCA, HNC, L
WP060	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma, Ovary, Cervix squamous cell, Endometrium	Responsive	C	NO	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	only alteration type		BRCA, OV, CESC, ED
WP060	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26787751;PMID:26763254	only alteration type		HNSC
WP060	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Glioma, Thyroid carcinoma	Responsive	D	NO	PMID:19671762;PMID:21289267	only alteration type		G, THCA
WP060	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:28331003	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2501)	only alteration type		ST
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP060	PTPRD MUT* (--), PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP060	NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP060	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP060	RAD51C MUT* (G153)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
WP060	RAD51C MUT* (G153)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
WP060	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP060	RB1 MUT* (--), RB1 MUT* (--)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
WP060	RB1 MUT* (--), RB1 MUT* (--)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
WP060	RB1 MUT* (--), RB1 MUT* (--)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
WP060	RB1 MUT* (--), RB1 MUT* (--)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
WP060	RB1 MUT* (--), RB1 MUT* (--)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP060	RB1 MUT* (--), RB1 MUT* (--)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP060	RET MUT* (H81)	RET fusion	RET inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:22327624;PMID:22327622	only gene		LUAD
WP060	RET MUT* (H81)	RET-TPCN1 fusion	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only gene		TH
WP060	RET MUT* (H81)	RET (C634W,M918T)	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only alteration type		TH
WP060	RET MUT* (H81)	RET fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP060	RET MUT* (H81)	RET-TPCN1 fusion	Cabozantinib(Pan-kinase inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP060	RET MUT* (H81)	RET (C634W,M918T)	Cabozantinib(Pan-kinase inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP060	RET MUT* (H81)	RET fusion	Nintedanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26787234	only gene		LUAD
WP060	RET MUT* (H81)	RET fusion	Sunitinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP060	RET MUT* (H81)	RET-TPCN1 fusion	Sunitinib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP060	RET MUT* (H81)	RET (C634W,M918T)	Sunitinib(Pan-TK inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP060	RET MUT* (H81)	RET fusion	Vandetanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP060	RET MUT* (H81)	RET-TPCN1 fusion	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP060	RICTOR MUT* (--)	RICTOR amplification	MTORC1/2 inhibitors	Lung	Responsive	C	NO	PMID:26370156	only gene		L
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:23533265	only gene		LUAD
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27370605	only gene		LUAD
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 (G2032R)	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:25351743	only alteration type		LUAD
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	C	YES	PMID:24875859	only gene		IM
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:25264305	only gene		LUAD
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27401242	only alteration type		LUAD
WP060	SRSF2 (P95L)	SRSF2 oncogenic mutation	Spliceosome inhibitors	Acute myeloid leukemia	Responsive	D	YES	PMID:27135740	complete		AML
WP060	NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP060	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP060	TERT MUT* (--)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP060	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP060	TSC2 MUT* (--), TSC2 MUT* (--)	TSC2 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	only alteration type		RA
WP060	TSC2 MUT* (--), TSC2 MUT* (--)	TSC2 oncogenic mutation	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	only alteration type		LAM
WP060	TSC2 MUT* (--), TSC2 MUT* (--)	TSC2 deletion	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	only gene		LAM
WP060	TSC2 MUT* (--), TSC2 MUT* (--)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	only alteration type		BLCA
WP060	TSC2 MUT* (--), TSC2 MUT* (--)	TSC2 (Q1178*)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:25295501	only alteration type		THCA
WP060	TSC2 MUT* (--), TSC2 MUT* (--)	TSC2 (E66K)	Tensirolimus(MTOR inhibitor)	Endometrium	Responsive	C	NO	PMID:27016228	only alteration type		ED
WP060	EGFR (R831S)	EGFR (T790M)	Afatinib + Erlotinib + Gefitinib	Non-small cell lung	Resistant	A	NO	oncokb: oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR (T790M,D761Y)	Gefitinib	Non-small cell lung	Resistant	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/19/summary|oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
WP060	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
WP060	BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
WP060	ALK MUT* (H1030P)	ALK fusion	Crizotinib + Ceritinib	Sarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only gene		S
WP060	ALK MUT* (H1030P)	ALK (G1202R,I1171N)	Alectinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR (R108K,T263P,A289V)	Lapatinib	Glioma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		G
WP060	EGFR (R831S)	EGFR (C797G,C797S)	Osimertinib	Non-small cell lung	Resistant	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/19/summary|oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
WP060	TSC2 MUT* (--), TSC2 MUT* (--)	TSC2 (S1653P,Q1503P,R905G,L830R,A889P,L146R,T1203K,V1673F,W1610G,V769E,C696Y,F615S,E75G,L448P,V299G,R611W,R1200W,R505Q,Q1554H,G1567D,G1596V,Y1571N,I427M,S1498N,L1584R,P1709L,L844R,V705E,R905Q,Y598C,L410R,R462C,R611Q,R905W,A614D,.,S1653F,P1675L,H1620R,S1036P,H597Y,L493P,T1623I,V1673D,V705M,L826P,L792R,A328P,L493V)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	only alteration type		RCCC
WP060	TSC2 MUT* (--), TSC2 MUT* (--)	TSC2 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	only gene		RCCC
WP060	NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP060	NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP060	PIK3CA MUT* (--)	PIK3CA (P539R,R38H,Q546K,G118D,G106V,Q546E,E579K,N345K,E453K,V344A,E545K,T1025S,E542Q,G1049R,M1043I,E110K,P449T,N1044K,K111E,C378R,H1047R,C420R,E78K,E545A,S629C,D350G,.,G451R,M1043V,E542V,Q546R,E365K,E81K,G106D,R88Q,P366R,R93Q,G914R,H1047Y,K111N,E545Q,E545G,R93W,R108H,G106R,E453Q,E542K,D1029Y,N345I,D549N,A1066V,Q546P,E542G,E453A)	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA amplification	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only gene		BRCA
WP060	EGFR (R831S)	EGFR (T790M,D761Y)	Osimertinib	Non-small cell lung	Responsive	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/19/summary|oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
WP060	ALK MUT* (H1030P)	ALK (C1156Y,F1174L,L1196M,G1269A)	Crizotinib	Non-small cell lung	Resistant	D	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary	only alteration type		NSCLC
WP060	RET MUT* (H81)	RET fusion	Cabozantinib + Vandetanib + Larotrectinib + 292 + 667	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		NSCLC
WP060	RET MUT* (H81)	RET (C618R,C620R,C609Y,E768D,C630R,S904F,E511K,C634S,C634Y,V648I,I852M,S891A,A883T,A883F,C611Y,T338I,C634W,K603Q,D631Y,M918T,A919V,R833C,.,V804M,C634R,V804L,Y806C,M918V,L790F,M848T,R886W,Y791F)	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only alteration type		THM
WP060	RET MUT* (H81)	RET fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP060	RET MUT* (H81)	RET-KIF5B fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP060	RET MUT* (H81)	RET-CCDC6 fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP060	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
WP060	BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
WP060	EGFR (R831S)	EGFR amplification	Lapatinib	Glioma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EGFR	only gene		G
WP060	ALK MUT* (H1030P)	ALK CAD::ALK	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7481	only gene		COREAD
WP060	ALK MUT* (H1030P)	ALK CLTC::ALK	TAE684	Difuse large B Cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1261	only gene		DLBCL
WP060	ALK MUT* (H1030P)	ALK CLTC::ALK	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1265	only gene		DLBCL
WP060	ALK MUT* (H1030P)	ALK EML4::ALK	Alectinib	Mesothelioma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9228	only gene		MESO
WP060	ALK MUT* (H1030P)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/262	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK EML4::ALK	WHI-P154	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1188	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK EML4::ALK	Crizotinib,Retaspimycin Hydrochloride	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1203	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK EML4::ALK	Crizotinib,Alvespimycin	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1206	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1207	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK EML4::ALK	Lorlatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1332	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK F1174L	Crizotinib	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/125	only alteration type		NB
WP060	ALK MUT* (H1030P)	ALK F1174L	Alectinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/37	only alteration type		NB
WP060	ALK MUT* (H1030P)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/38	only alteration type		NB
WP060	ALK MUT* (H1030P)	ALK F1174L	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/142	only alteration type		NB
WP060	ALK MUT* (H1030P)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1271	only alteration type		NB
WP060	ALK MUT* (H1030P)	ALK F1174L	AZD3463	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1327	only alteration type		NB
WP060	ALK MUT* (H1030P)	ALK F1174L	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1329	only alteration type		NB
WP060	ALK MUT* (H1030P)	ALK F1174L	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/33	only alteration type		NSCLC
WP060	ALK MUT* (H1030P)	ALK F1245C	Crizotinib	Neuroblastoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1333	only alteration type		NB
WP060	ALK MUT* (H1030P)	ALK F1245C	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1330	only alteration type		NB
WP060	ALK MUT* (H1030P)	ALK F1245V	Entrectinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2987	only alteration type		NB
WP060	ALK MUT* (H1030P)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1240	only gene		ALCL
WP060	ALK MUT* (H1030P)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/7361	only gene		ALCL
WP060	ALK MUT* (H1030P)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	A	YES	https://civicdb.org/links/evidence_items/11218	only gene		ALCL
WP060	ALK MUT* (H1030P)	ALK Fusion	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1264	only gene		DLBCL
WP060	ALK MUT* (H1030P)	ALK Fusion	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1691	only gene		LUAD
WP060	ALK MUT* (H1030P)	ALK Fusion	Pemetrexed	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/945	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1175	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1187	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1198	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1199	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1200	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1201	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Retaspimycin Hydrochloride	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1202	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1272	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1273	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1279	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1282	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1419	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1577	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4835	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Alectinib,Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4858	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7284	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7285	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Lorlatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7286	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/8657	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11121	only gene		NSCLC
WP060	ALK MUT* (H1030P)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1283	only alteration type		NSCLC
WP060	ALK MUT* (H1030P)	ALK I1171	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1287	only alteration type		NSCLC
WP060	ALK MUT* (H1030P)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1367	only alteration type		NSCLC
WP060	ALK MUT* (H1030P)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1284	only alteration type		NSCLC
WP060	ALK MUT* (H1030P)	ALK I1171	TAE684	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1285	only alteration type		NSCLC
WP060	ALK MUT* (H1030P)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1344	only alteration type		NSCLC
WP060	ALK MUT* (H1030P)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1368	only alteration type		NSCLC
WP060	ALK MUT* (H1030P)	ALK I1171T	Ceritinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9404	only alteration type		NB
WP060	ALK MUT* (H1030P)	ALK KANK4::ALK	Alectinib	Pancreas acinar	Responsive	C	NO	https://civicdb.org/links/evidence_items/10327	only gene		PAAC
WP060	ALK MUT* (H1030P)	ALK Mutation	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1237	only alteration type		NSCLC
WP060	ALK MUT* (H1030P)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1239	only gene		ALCL
WP060	ALK MUT* (H1030P)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/1241	only gene		ALCL
WP060	ALK MUT* (H1030P)	ALK R1275Q	TAE684	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/48	only alteration type		NB
WP060	ALK MUT* (H1030P)	ALK R1275Q	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/39	only alteration type		NB
WP060	ALK MUT* (H1030P)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/143	only alteration type		NB
WP060	ALK MUT* (H1030P)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1270	only alteration type		NB
WP060	ALK MUT* (H1030P)	ALK R1275Q	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1331	only alteration type		NB
WP060	APC MUT* (--)	APC Mutation	G007-LK	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/446	only alteration type		COREAD
WP060	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP060	BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
WP060	BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
WP060	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
WP060	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
WP060	BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
WP060	BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
WP060	BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
WP060	BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
WP060	CRBN MUT* (--)	CRBN Mutation	Lenalidomide,Pomalidomide	Multiple myeloma	Resistant	C	YES	https://civicdb.org/links/evidence_items/1766	only alteration type		MM
WP060	EGFR (R831S)	EGFR A763_Y764insFQEA	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4497	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR A763_Y764insFQEA	Osimertinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/9225	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR A767_V769dupASV	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4665	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR A767_V769dupASV	Osimertinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/9220	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR A864T	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4495	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR C797S	Osimertinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1396	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR C797S	Osimertinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/964	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR D761Y	Erlotinib,Gefitinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1763	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR D770_N771insG	Osimertinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/9223	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR D770_N771insGL	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4494	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR D770_N771insGT	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4643	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR D770_N771insNPG	Gefitinib,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/5947	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR D770delinsGY	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4801	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR E746G	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1787	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR E746_A750del	Gefitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2625	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR E746_A750del	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4198	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR EGFR::RAD51	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5909	only gene		LUAD
WP060	EGFR (R831S)	EGFR EGFR::RAD51	Icotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7314	only gene		LUAD
WP060	EGFR (R831S)	EGFR EGFR::RAD51	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11015	only gene		LUAD
WP060	EGFR (R831S)	EGFR EGFR::RAD51	Osimertinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11021	only gene		LUAD
WP060	EGFR (R831S)	EGFR G465R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1058	only alteration type		COREAD
WP060	EGFR (R831S)	EGFR G465R	Futuximab/Modotuximab Mixture	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1057	only alteration type		COREAD
WP060	EGFR (R831S)	EGFR G719	Erlotinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1780	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR G719	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4189	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR G719A	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2508	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR G719A	Erlotinib,Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/6181	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR G719D	Gefitinib,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4210	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR G719S	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/787	only alteration type		COREAD
WP060	EGFR (R831S)	EGFR G719S	Gefitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/274	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR G719S	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1736	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR G719S	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4190	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR G724S	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/786	only alteration type		COREAD
WP060	EGFR (R831S)	EGFR H773_V774insNPH	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4493	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR K467T	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1083	only alteration type		COREAD
WP060	EGFR (R831S)	EGFR K467T	Panitumumab,Futuximab/Modotuximab Mixture	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1082	only alteration type		COREAD
WP060	EGFR (R831S)	EGFR K757R	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1786	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR K806E	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4239	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR KIF5B::EGFR	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11026	only gene		LUAD
WP060	EGFR (R831S)	EGFR L747P	Gefitinib,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4220	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L747_P753delinsS	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4266	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L747_P753delinsS	Erlotinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6005	only alteration type		PAAD
WP060	EGFR (R831S)	EGFR L747_S752delinsQ	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4667	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR L838P	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4252	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Afatinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/879	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR L858R	Afatinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/883	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR L858R	Afatinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/982	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR L858R	Gefitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2624	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR L858R	Gefitinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2634	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR L858R	Erlotinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4290	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR L858R	Erlotinib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4291	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR L858R	Cetuximab	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4292	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR L858R	Gefitinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6183	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR L858R	Crizotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/4288	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Gefitinib,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/229	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/275	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Gefitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/276	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/885	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/968	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1665	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2621	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Lapatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2626	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Dacomitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2627	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Neratinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2628	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2629	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Canertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2631	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2632	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/2994	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Afatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/2997	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4284	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4286	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4287	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Osimertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4294	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4860	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L858R	Erlotinib	Small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4293	only alteration type		SCLC
WP060	EGFR (R831S)	EGFR L861	Gefitinib,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4298	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L861Q	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/3802	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR L861R	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4669	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR M766_A767insAI	Erlotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/4799	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR Mutation	Afatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1728	complete		NSCLC
WP060	EGFR (R831S)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1937	complete		NSCLC
WP060	EGFR (R831S)	EGFR Mutation	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2053	complete		NSCLC
WP060	EGFR (R831S)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2148	complete		NSCLC
WP060	EGFR (R831S)	EGFR Mutation	Afatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2153	complete		NSCLC
WP060	EGFR (R831S)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2559	complete		NSCLC
WP060	EGFR (R831S)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3016	complete		NSCLC
WP060	EGFR (R831S)	EGFR Mutation	Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3794	complete		NSCLC
WP060	EGFR (R831S)	EGFR Mutation	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4201	complete		NSCLC
WP060	EGFR (R831S)	EGFR Mutation	Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7024	complete		NSCLC
WP060	EGFR (R831S)	EGFR N826S	Erlotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/4496	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR N826Y	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4244	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR N842S	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4256	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR P772_H773insYNP	Erlotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/4802	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR R451C	Futuximab/Modotuximab Mixture,Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1081	only alteration type		COREAD
WP060	EGFR (R831S)	EGFR R705K	Erlotinib,Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/6182	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR R776C	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4468	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR S492R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/717	only alteration type		COREAD
WP060	EGFR (R831S)	EGFR S492R	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1080	only alteration type		COREAD
WP060	EGFR (R831S)	EGFR S492R	Panitumumab	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1078	only alteration type		COREAD
WP060	EGFR (R831S)	EGFR S492R	Panitumumab,Futuximab/Modotuximab Mixture	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1079	only alteration type		COREAD
WP060	EGFR (R831S)	EGFR S720	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1782	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR S768I	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4273	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR S768I	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1394	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR S768I	Gefitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1395	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR S768I	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2906	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1391	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR T790M	Osimertinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1397	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR T790M	Osimertinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2157	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR T790M	Erlotinib	Non-small cell lung	Resistant	A	NO	https://civicdb.org/links/evidence_items/238	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/239	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Dacomitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/240	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/1667	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Afatinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/1863	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Gefitinib,Erlotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/2158	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2159	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Lapatinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/2160	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Pemetrexed,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/277	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Rociletinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/646	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Rociletinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/762	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/963	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/965	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/966	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Rociletinib,Osimertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/967	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1592	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1867	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Dacomitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2161	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Neratinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2162	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2163	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2164	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Canertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2165	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR T790M	Osimertinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6006	only alteration type		PAAD
WP060	EGFR (R831S)	EGFR T847I	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4260	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR V742A	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4197	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR V769_D770insASV	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1799	only alteration type		LUAD
WP060	EGFR (R831S)	EGFR V774A	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4226	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR V774M	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4231	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR V834I	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4248	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR V851I	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4264	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR Y764_V765insHH	Erlotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/4800	only alteration type		NSCLC
WP060	EGFR (R831S)	EGFR Amplification	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/854	only gene		COREAD
WP060	EGFR (R831S)	EGFR Amplification	Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/911	only gene		COREAD
WP060	EGFR (R831S)	EGFR Amplification	Platinum Compound,Cetuximab,Fluorouracil	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/691	only gene		HNSC
WP060	EGFR (R831S)	EGFR Amplification	Rociletinib,Osimertinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/3015	only gene		NSCLC
WP060	EGFR (R831S)	EGFR Amplification	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/948	only gene		NSCLC
WP060	EGFR (R831S)	EGFR Amplification	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/977	only gene		NSCLC
WP060	EGFR (R831S)	EGFR Amplification	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5924	only gene		NSCLC
WP060	EGFR (R831S)	EGFR Amplification	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5925	only gene		NSCLC
WP060	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP060	KMT2C MUT* (--), KMT2C MUT* (S806), KMT2C MUT* (E765G), KMT2C MUT* (P335), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP060	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP060	NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP060	NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP060	NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP060	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2346	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8549	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA C420R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2078	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA C420R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1999	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA D350G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4784	only alteration type		CM
WP060	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8007	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E542K	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/310	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E542K	Sirolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/311	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2022	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2026	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2058	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E542K	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7315	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8013	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8016	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E542K	Regorafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/83	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA E542K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4424	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA E542K	Apitolisib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/1549	only alteration type		HNSC
WP060	PIK3CA MUT* (--)	PIK3CA E542K	Perifosine,Temsirolimus	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1626	only alteration type		THCA
WP060	PIK3CA MUT* (--)	PIK3CA E545	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7468	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E545G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3724	only alteration type		CM
WP060	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1453	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2036	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6211	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E545K	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6213	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E545K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8008	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8547	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E545K	Akt Inhibitor MK2206,Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/710	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2034	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2062	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8017	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8018	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA E545K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3722	only alteration type		CM
WP060	PIK3CA MUT* (--)	PIK3CA E545K	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/387	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2037	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2217	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib	Lung adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1171	only alteration type		LUAD
WP060	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1670	only alteration type		LUAD
WP060	PIK3CA MUT* (--)	PIK3CA E545K	PI103	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2040	only alteration type		NSCLC
WP060	PIK3CA MUT* (--)	PIK3CA E545Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2213	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA E81K	Oxaliplatin,Fluorouracil,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4464	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA F930S	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10032	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA G1049R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3847	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA H1047L	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2089	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA H1047L	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8009	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA H1047L	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8019	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA H1047L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4432	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2103	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6204	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6206	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8548	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/314	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Capivasertib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1505	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1506	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Everolimus,Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1623	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2096	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2102	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/258	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/388	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Vemurafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3733	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3841	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Akt Inhibitor MK2206,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8364	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1465	only alteration type		HNSC
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1447	only alteration type		LUAD
WP060	PIK3CA MUT* (--)	PIK3CA H1047R	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1625	only alteration type		THCA
WP060	PIK3CA MUT* (--)	PIK3CA H1047X	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7318	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2867	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8663	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2866	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA K111N	Dactolisib,Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8183	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8662	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA K111N	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2085	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA K111N	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8011	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA K111N	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8020	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA K944N	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10031	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA K966E	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10034	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1384	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2087	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2098	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8536	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Capecitabine,Lapatinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8705	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1296	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1504	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1600	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1607	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1610	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Fulvestrant,Alpelisib	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7313	only alteration type		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/915	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1705	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3732	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6298	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6299	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6300	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6301	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6362	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Cabozantinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/771	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6375	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Ridaforolimus,Temsirolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/892	only alteration type		ED
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Pictilisib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1616	only alteration type		ED
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Radiation Therapy,Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1490	only alteration type		HNSC
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin,Sulindac,Celecoxib	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7185	only alteration type		HNSC
WP060	PIK3CA MUT* (--)	PIK3CA Mutation	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2355	only alteration type		NSCLC
WP060	PIK3CA MUT* (--)	PIK3CA N345K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4047	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA Q546K	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2198	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA R88Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3832	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA R93W	Cetuximab,Fluorouracil,Oxaliplatin	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4467	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA S158L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4463	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA V955G	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10033	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA V955I	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/8063	only alteration type		COREAD
WP060	PIK3CA MUT* (--)	PIK3CA Amplification	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8267	only gene		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA Amplification	Lapatinib,Dactolisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8271	only gene		BRCA
WP060	PIK3CA MUT* (--)	PIK3CA Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6275	only gene		CM
WP060	PIK3CA MUT* (--)	PIK3CA Amplification	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1464	only gene		HNSC
WP060	PIK3CA MUT* (--)	PIK3CA Amplification	Sulindac,Aspirin,Ibuprofen	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7186	only gene		HNSC
WP060	PIK3CA MUT* (--)	PIK3CA Amplification	Pictilisib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/756	only gene		OV
WP060	PTPRD MUT* (--), PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP060	RAD51D MUT* (--)	RAD51D Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11214	only alteration type		PRAD
WP060	RB1 MUT* (--), RB1 MUT* (--)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
WP060	RET MUT* (H81)	RET CCDC6::RET	Agerafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7480	only gene		COREAD
WP060	RET MUT* (H81)	RET CCDC6::RET	Nintedanib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1601	only gene		NSCLC
WP060	RET MUT* (H81)	RET Fusion	Cabozantinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4847	only gene		LUAD
WP060	RET MUT* (H81)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4848	only gene		NSCLC
WP060	RET MUT* (H81)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4849	only gene		NSCLC
WP060	RET MUT* (H81)	RET Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4850	only gene		NSCLC
WP060	RET MUT* (H81)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7066	only gene		NSCLC
WP060	RET MUT* (H81)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/8850	only gene		NSCLC
WP060	RET MUT* (H81)	RET Fusion	Pralsetinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11233	only gene		NSCLC
WP060	RET MUT* (H81)	RET Fusion	Selpercatinib	Thyroid carcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8852	only gene		THCA
WP060	RET MUT* (H81)	RET KIF5B::RET	Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/698	only gene		LUAD
WP060	RET MUT* (H81)	RET KIF5B::RET	Vandetanib,Everolimus	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1622	only gene		LUAD
WP060	RICTOR MUT* (--)	RICTOR Amplification	Onatasertib,Sapanisertib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1440	only gene		LUAD
WP060	RICTOR MUT* (--)	RICTOR Amplification	Vistusertib	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7449	only gene		SCLC
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Rearrangement	Ceritinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1248	only gene		LUAD
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1690	only gene		LUAD
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/688	only gene		NSCLC
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1030	only gene		NSCLC
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7933	only gene		NSCLC
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 FUSIONS	Entrectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11123	only gene		NSCLC
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7282	only gene		NSCLC
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 G2032R	Crizotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2934	only alteration type		LUAD
WP060	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 GOPC::ROS1	Lorlatinib	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7483	only gene		GB
WP060	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP060	SMAD4 MUT* (H291P)	SMAD4 Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/719	only alteration type		COREAD
WP060	TLK2 MUT* (--)	TLK2 Amplification	Go6983,GF109203X	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6000	only gene		BRCA
WP060	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP060	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP060	TSC2 MUT* (--), TSC2 MUT* (--)	TSC2 Q1178*	Everolimus	Thyroid carcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1108	only alteration type		THCA
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	FDA	only gene		LUAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Alectinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK inframe insertion (1151T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165	only alteration type		LUAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK (L1196M,S1206Y,G1269A,I1171T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165;PMID:24327273	only alteration type		LUAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Brigatinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc	only gene		NSCLC
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP216	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR (L858R)	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR (L861Q,G719,S768I)	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR (L858R)	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR (L861Q,G719,S768I)	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR (L858R)	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR (L861Q,G719,S768I)	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR (L858R)	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR (T790M)	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf	only alteration type		NSCLC
WP216	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Myelofibrosis	Responsive	A	YES	FDA	complete		MY
WP216	EGFR MUT* (--)	EGFR (T790M)	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR (T790M)	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP216	PDGFB MUT* (--)	PDGFB-COL1A1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Dermatofibrosarcoma	Responsive	A	NO	FDA	only gene		DFS
WP216	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP216	TPMT MUT* (--)	TPMT splice acceptor variant	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP216	TPMT MUT* (--)	TPMT biallelic inactivation	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP216	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP216	TPMT MUT* (--)	TPMT splice acceptor variant	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP216	TPMT MUT* (--)	TPMT biallelic inactivation	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP216	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP216	TPMT MUT* (--)	TPMT splice acceptor variant	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP216	TPMT MUT* (--)	TPMT biallelic inactivation	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP216	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP216	EGFR MUT* (--)	EGFR (S786I,G719, L861Q)	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP216	EGFR MUT* (--)	EGFR (L858R)	Dacomitinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN Non-Small Cell Lung Cancer guidlines 2022;FDA:https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer-0	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR (T790M)	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP216	FANCL MUT* (--)	FANCL oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP216	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP216	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP216	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Mobocertinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mobocertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Amivantamab(EGFR mAb inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer	only alteration type		NSCLC
WP216	ROS1 MUT* (--)	ROS1 fusion	Entrectinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA;PMID:28183697;ESMO 2019 (abstr 4178) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725s007lbl.pdf	only gene		NSCLC
WP216	RAD54L MUT* (--)	RAD54L oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Crizotinib(ALK inhibitor)	Anaplastic large cell lymphoma	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large	only gene		ALCL
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP216	FANCA MUT* (--), FANCA MUT* (--)	FANCA oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP216	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP216	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Erlotinib(EGFR inhibitor 1st gen);Ramucirumab(VEGFR2 antagonist)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR (L858R)	Erlotinib(EGFR inhibitor 1st gen);Ramucirumab(VEGFR2 antagonist)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf	only alteration type		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor	only gene		IM
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Alectinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Brigatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Ceritinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Lorlatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP216	ROS1 MUT* (--)	ROS1 fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP216	ROS1 MUT* (--)	ROS1 fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP216	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP216	EGFR MUT* (--)	EGFR (S768I,L861Q,G719)	Dacomitinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Dacomitinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	FDA: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer-0	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf	only alteration type		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	ALK inhibitor + IGF1R inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25173427	only gene		LUAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	ALK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:26301689	only gene		LUAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	ALK inhibitor + SRC inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25394791	only gene		LUAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	ALK inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560	only gene		COREAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23553849	only gene		LUAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	novel ALK inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23639470	only gene		LUAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK (F1174L)	novel ALK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24327273	only alteration type		LUAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK amplification	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only gene		LUAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK (E1408V)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK (L1196M)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Ceritinib(ALK inhibitor)	Colorectal adenocarcinoma, Inflammatory myofibroblastic	Responsive	C	YES	PMID:26633560;PMID:26933125;PMID:27742657	only gene		COREAD, IM
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Ceritinib(ALK inhibitor)	Hematologic malignancies	Responsive	C	YES	NCT02186821	only gene		HEMATO
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Crizotinib(ALK inhibitor)	Lymphoma, Glioblastoma	Responsive	C	YES	PMID:24491302;NCT02270034	only gene		LY, GB
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic, Thyroid carcinoma	Responsive	C	YES	PMID:20979472;PMID:24687827	only gene		IM, THCA
WP216	EGFR MUT* (--)	EGFR inframe deletion (30-336)	EGFR inhibitor 1st gens	Glioma	No Responsive	C	NO	PMID:19204207	only alteration type		G
WP216	EGFR MUT* (--)	EGFR amplification	EGFR inhibitor 1st gens	Glioma	No Responsive	C	NO	PMID:16282176;PMID:16278407	only gene		G
WP216	EGFR MUT* (--)	EGFR (D761Y)	EGFR inhibitor 1st gens	Non-small cell lung	Resistant	C	NO	PMID:19680293	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR (T790M)	EGFR inhibitor 1st gens	Non-small cell lung	Resistant	B	NO	PMID:19680293	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR inframe deletion (30-336)	EGFR inhibitor 2nd gens	Glioma	No Responsive	C	NO	PMID:19204207	only alteration type		G
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK (F856S,A348D)	Crizotinib(ALK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:26032424	only alteration type		AML
WP216	EGFR MUT* (--)	EGFR amplification	EGFR inhibitor 2nd gens	Glioma	No Responsive	C	NO	PMID:16282176;PMID:16278407	only gene		G
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK (L1198F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26698910	only alteration type		LUAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib(ALK inhibitor)	Glioma	Responsive	D	NO	PMID:22072639	only alteration type		G
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Entrectinib(Pan-TK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560;PMID:26933125	only gene		COREAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK (C1156Y)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27401242	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR (T790M)	EGFR inhibitor 2nd gens	Non-small cell lung	Resistant	B	NO	PMID:22452896	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR inframe deletion (30-336)	EGFR inhibitor 3rd gens	Glioma	No Responsive	C	NO	PMID:19204207	only alteration type		G
WP216	EGFR MUT* (--)	EGFR amplification	EGFR inhibitor 3rd gens	Glioma	No Responsive	C	NO	PMID:16282176;PMID:16278407	only gene		G
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only alteration type		COREAD
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only alteration type		LY
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only gene		LY
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP216	BAP1 MUT* (--)	BAP1 oncogenic mutation	EZH2 inhibitors	Mesothelioma	Responsive	D	NO	PMID:26437366	only alteration type		MESO
WP216	BAP1 MUT* (--)	BAP1 deletion	EZH2 inhibitors	Mesothelioma	Responsive	D	NO	PMID:26437366	only gene		MESO
WP216	BAP1 MUT* (--)	BAP1 oncogenic mutation	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22038994	only alteration type		CM
WP216	BAP1 MUT* (--)	BAP1 deletion	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22038994	only gene		CM
WP216	BAP1 MUT* (--)	BAP1 oncogenic mutation	PARP inhibitors	Renal, Any cancer type	Responsive	D	YES	PMID:22683710	only alteration type		R, CANCER
WP216	BAP1 MUT* (--)	BAP1 deletion	PARP inhibitors	Renal, Any cancer type	Responsive	D	YES	PMID:22683710	only gene		R, CANCER
WP216	BCOR MUT* (--)	BCOR oncogenic mutation	Enzastaurin(PKCb inhibitor)	Stomach	Responsive	D	NO	PMID:27397505	only alteration type		ST
WP216	JAK2 (V617F)	JAK2 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	complete		CM
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
WP216	BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP216	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP216	CBL MUT* (--)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP216	CBL MUT* (--)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP216	EGFR MUT* (--)	EGFR (T790M)	EGFR inhibitor 3rd gens	Lung	Responsive	C	NO	ASCO 2014 (abstr 8009);ENA 2014 (abstr 10LBA);ENA 2014 (abstr 9LBA);ASCO 2015 (abstr 8001)	only alteration type		L
WP216	EGFR MUT* (--)	EGFR amplification	EGFR inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26763254	only gene		HNSC
WP216	EGFR MUT* (--)	EGFR amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Responsive	B	NO	PMID:18794099;PMID:17664472	only gene		COREAD
WP216	EGFR MUT* (--)	EGFR exon 19 insertions	EGFR TK inhibitors	Lung	Responsive	B	NO	PMID:22753918	only alteration type		L
WP216	EGFR MUT* (--)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	EGFR TK inhibitors	Lung	Responsive	B	NO	PMID:22753918	only alteration type		L
WP216	EGFR MUT* (--)	EGFR exon 19 insertions	HSP90 inhibitors	Lung	Responsive	C	NO	ESMO 2012 (abstr 4380)	only alteration type		L
WP216	EGFR MUT* (--)	EGFR exon 20 insertions	HSP90 inhibitors	Lung	Responsive	C	NO	ASCO 2014 (abstr 8015)	only alteration type		L
WP216	EGFR MUT* (--)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	HSP90 inhibitors	Lung	Responsive	C	NO	ESMO 2012 (abstr 4380)	only alteration type		L
WP216	EGFR MUT* (--)	EGFR (T790M)	HSP90 inhibitors	Lung	Responsive	C	NO	ESMO 2012 (abstr 4380)	only alteration type		L
WP216	EGFR MUT* (--)	EGFR exon 19 insertions	MEK inhibitor(alone or in combination)s	Lung	Responsive	D	NO	PMID:23102728	only alteration type		L
WP216	EGFR MUT* (--)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	MEK inhibitor(alone or in combination)s	Lung	Responsive	D	NO	PMID:23102728	only alteration type		L
WP216	EGFR MUT* (--)	EGFR (S492R)	novel EGFR mAb inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:25962717	only alteration type		COREAD
WP216	EGFR MUT* (--)	EGFR (T790M)	EGFR inhibitor 3rd gens(Rociletinib,HM61713,etc)	Non-small cell lung	Responsive	B	NO	NCT02322281	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR exon 19 insertions	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Lung	Responsive	B	NO	PMID:22753918;PMID:25589191	only alteration type		L
WP216	EGFR MUT* (--)	EGFR exon 19 insertions	Afatinib + Cetuximab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	ESMO 2012 (abstr 1289)	only alteration type		L
WP216	EGFR MUT* (--)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	Afatinib + Cetuximab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	ESMO 2012 (abstr 1289)	only alteration type		L
WP216	EGFR MUT* (--)	EGFR (T790M)	Afatinib + Cetuximab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	PMID:25074459	only alteration type		L
WP216	EGFR MUT* (--)	EGFR (T790M)	Afatinib + Nimotuzumab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	PMID:26667485	only alteration type		L
WP216	EGFR MUT* (--)	EGFR (P546S)	Cetuximab(EGFR mAb inhibitor)	Head an neck	Responsive	C	NO	PMID:23578570	only alteration type		HNC
WP216	EGFR MUT* (--)	EGFR (P753S)	Cetuximab + Sirolimus(EGFR mAb inhibitor + MTOR inhibitor)	Head an neck	Responsive	C	NO	PMID:24934779	only alteration type		HNC
WP216	EGFR MUT* (--)	EGFR-RAD51 fusion	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	C	NO	PMID:27102076	only gene		NSCLC
WP216	EGFR MUT* (--)	EGFR-RAD51 fusion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:27102076	only gene		L
WP216	EGFR MUT* (--)	EGFR exon 19 insertions	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:22190593	only alteration type		L
WP216	EGFR MUT* (--)	EGFR inframe insertion (769-770)	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:26773740;PMID:23328547	only alteration type		L
WP216	EGFR MUT* (--)	EGFR (A289V,R108K,G598V,T263P)	Erlotinib(EGFR inhibitor 1st gen)	Glioma	Responsive	D	NO	PMID:17177598	only alteration type		G
WP216	EGFR MUT* (--)	EGFR (K757R,E746G)	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:26773740	only alteration type		L
WP216	EGFR MUT* (--)	EGFR amplification	Gefitinib(EGFR inhibitor 1st gen)	Endometrium	Responsive	B	NO	PMID:24950987	only gene		ED
WP216	EGFR MUT* (--)	EGFR (E690K)	Lapatinib(ERBB2 inhibitor)	Endometrium	Responsive	C	NO	PMID:22885469	only alteration type		ED
WP216	EGFR MUT* (--)	EGFR exon 19 deletions	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Responsive	C	NO	NCT02465060	only alteration type		L
WP216	EGFR MUT* (--)	EGFR (S492R)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:22270724	only alteration type		COREAD
WP216	EGFR MUT* (--)	EGFR inframe deletion (6-273)	Rindopepimut(Vaccine)	Glioblastoma	Responsive	B	NO	NCT01480479	only alteration type		GB
WP216	FANCA MUT* (--), FANCA MUT* (--)	FANCA oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP216	FANCA MUT* (--), FANCA MUT* (--)	FANCA deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only gene		PRAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK (I1171T)	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:25228534	only alteration type		LUAD
WP216	FGFR4 MUT* (--)	FGFR4 (N535,V550)	FGFR inhibitors	Rhabdomyosarcoma	Responsive	D	NO	PMID:19809159;PMID:24124571	only alteration type		RHBDS
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK (G1123S)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:26134233	only alteration type		LUAD
WP216	GATA3 MUT* (--)	GATA3 oncogenic mutation	Aromatase ihibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:24758297	only alteration type		BRCA
WP216	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP216	HDAC2 MUT* (--)	HDAC2 biallelic inactivation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP216	EGFR MUT* (--)	EGFR (S464L,G465R,I491M)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	D	NO	PMID:25623215	only alteration type		COREAD
WP216	EGFR MUT* (--)	EGFR (S492R,G465R,R451C,K467T)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827	only alteration type		COREAD
WP216	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP216	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP216	JAK2 (V617F)	JAK2 (V617F)	JAK inhibitor(alone or in combination)s	Acute myeloid leukemia	Responsive	D	YES	PMID:22829971	complete		AML
WP216	JAK2 (V617F)	JAK2 amplification	JAK inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27075627	only gene		BRCA
WP216	JAK2 (V617F)	JAK2-BRAF fusion	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22875628;PMID:22899477	only gene		ALL
WP216	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:22422826	complete		AML
WP216	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK inframe insertion (1151T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only alteration type		LUAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK oncogenic mutation	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only alteration type		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only gene		NSCLC
WP216	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP216	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only gene		LUAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK (C1156Y,L1196M)	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:20979473	only alteration type		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK (F1174L)	Crizotinib(ALK inhibitor)	Glioma	Resistant	D	NO	PMID:22072639	only alteration type		G
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784;PMID:25228534	only alteration type		LUAD
WP216	ROS1 MUT* (--)	ROS1 (G2032R)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:23724914;PMID:25688157	only alteration type		LUAD
WP216	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR amplification	Erlotinib(EGFR inhibitor 1st gen)	Lung	No Responsive	C	NO	ASCO2015(abstre19028)	only gene		L
WP216	EGFR MUT* (--)	EGFR (S720)	Erlotinib(EGFR inhibitor 1st gen)	Lung	No Responsive	C	NO	PMID:26773740	only alteration type		L
WP216	EGFR MUT* (--)	EGFR inframe deletion (L747),inframe insertion (P753PS)	Gefitinib(EGFR inhibitor 1st gen)	Head an neck	No Responsive	C	NO	PMID:21274259	only alteration type		HNC
WP216	EGFR MUT* (--)	EGFR amplification	Gefitinib(EGFR inhibitor 1st gen)	Head an neck	No Responsive	C	NO	PMID:21274259;PMID:22261807	only gene		HNC
WP216	EGFR MUT* (--)	EGFR (V843I)	Gefitinib(EGFR inhibitor 1st gen)	Head an neck	No Responsive	C	NO	PMID:21274259	only alteration type		HNC
WP216	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP216	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP216	LRP1B MUT* (--)	LRP1B oncogenic mutation	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only alteration type		OV
WP216	LRP1B MUT* (--)	LRP1B deletion	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only gene		OV
WP216	EGFR MUT* (--)	EGFR (C797S)	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Resistant	C	NO	PMID:25939061	only alteration type		L
WP216	EGFR MUT* (--)	EGFR (L718)	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Resistant	C	NO	ASCO 2017 (abstr 2572)	only alteration type		L
WP216	EGFR MUT* (--)	EGFR (L792)	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Resistant	C	NO	ASCO 2017 (abstr 2572)	only alteration type		L
WP216	EGFR MUT* (--)	EGFR (G465R)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:26059438	only alteration type		COREAD
WP216	NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP216	NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP216	PAK1 MUT* (--)	PAK1 amplification	PAK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:23535073	only gene		CM
WP216	PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP216	PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP216	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP216	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP216	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP216	EGFR MUT* (--)	EGFR (L798I)	Rociletinib(EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27283993	only alteration type		LUAD
WP216	POLE MUT* (--)	POLE (268-471)	PD1 Ab inhibitors	Glioma, Endometrium	Responsive	C	NO	PMID:27001570;PMID:27683556;PMID:27159395	only alteration type		G, ED
WP216	POLE MUT* (--)	POLE oncogenic mutation	PD1 Ab inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28188185	only alteration type		COREAD
WP216	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP216	ROS1 MUT* (--)	ROS1 fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:23533265	only gene		LUAD
WP216	ROS1 MUT* (--)	ROS1 fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27370605	only gene		LUAD
WP216	ROS1 MUT* (--)	ROS1 (G2032R)	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:25351743	only alteration type		LUAD
WP216	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	C	YES	PMID:24875859	only gene		IM
WP216	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:25264305	only gene		LUAD
WP216	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27401242	only alteration type		LUAD
WP216	TERT MUT* (--)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP216	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP216	U2AF1 (S34F)	U2AF1 oncogenic mutation	FLT3 inhibitors	Any cancer type	Responsive	D	YES	PMID:27397505	complete		CANCER
WP216	EGFR MUT* (--)	EGFR (T790M)	Afatinib + Erlotinib + Gefitinib	Non-small cell lung	Resistant	A	NO	oncokb: oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR (T790M,D761Y)	Gefitinib	Non-small cell lung	Resistant	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/19/summary|oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
WP216	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
WP216	BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK fusion	Crizotinib + Ceritinib	Sarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only gene		S
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK (G1202R,I1171N)	Alectinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR (R108K,T263P,A289V)	Lapatinib	Glioma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		G
WP216	EGFR MUT* (--)	EGFR (C797G,C797S)	Osimertinib	Non-small cell lung	Resistant	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/19/summary|oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only alteration type		CANCER
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
WP216	EGFR MUT* (--)	EGFR (T790M,D761Y)	Osimertinib	Non-small cell lung	Responsive	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/19/summary|oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
WP216	JAK2 (V617F)	JAK2-PCM1 fusion	Ruxolitinib	Eosinophilic chronic leukemia	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/JAK2	only gene		ECL
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK (C1156Y,F1174L,L1196M,G1269A)	Crizotinib	Non-small cell lung	Resistant	D	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary	only alteration type		NSCLC
WP216	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
WP216	BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
WP216	EGFR MUT* (--)	EGFR amplification	Lapatinib	Glioma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EGFR	only gene		G
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK CAD::ALK	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7481	only gene		COREAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK CLTC::ALK	TAE684	Difuse large B Cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1261	only gene		DLBCL
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK CLTC::ALK	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1265	only gene		DLBCL
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK EML4::ALK	Alectinib	Mesothelioma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9228	only gene		MESO
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/262	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK EML4::ALK	WHI-P154	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1188	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK EML4::ALK	Crizotinib,Retaspimycin Hydrochloride	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1203	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK EML4::ALK	Crizotinib,Alvespimycin	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1206	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1207	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK EML4::ALK	Lorlatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1332	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK F1174L	Crizotinib	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/125	only alteration type		NB
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK F1174L	Alectinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/37	only alteration type		NB
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/38	only alteration type		NB
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK F1174L	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/142	only alteration type		NB
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1271	only alteration type		NB
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK F1174L	AZD3463	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1327	only alteration type		NB
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK F1174L	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1329	only alteration type		NB
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK F1174L	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/33	only alteration type		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK F1245C	Crizotinib	Neuroblastoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1333	only alteration type		NB
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK F1245C	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1330	only alteration type		NB
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK F1245V	Entrectinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2987	only alteration type		NB
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1240	only gene		ALCL
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/7361	only gene		ALCL
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	A	YES	https://civicdb.org/links/evidence_items/11218	only gene		ALCL
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1264	only gene		DLBCL
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1691	only gene		LUAD
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Pemetrexed	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/945	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1175	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1187	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1198	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1199	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1200	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1201	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Retaspimycin Hydrochloride	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1202	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1272	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1273	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1279	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1282	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1419	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1577	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4835	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Alectinib,Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4858	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7284	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7285	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Lorlatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7286	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/8657	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11121	only gene		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1283	only alteration type		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK I1171	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1287	only alteration type		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1367	only alteration type		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1284	only alteration type		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK I1171	TAE684	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1285	only alteration type		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1344	only alteration type		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1368	only alteration type		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK I1171T	Ceritinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9404	only alteration type		NB
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK KANK4::ALK	Alectinib	Pancreas acinar	Responsive	C	NO	https://civicdb.org/links/evidence_items/10327	only gene		PAAC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK Mutation	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1237	only alteration type		NSCLC
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1239	only gene		ALCL
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/1241	only gene		ALCL
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK R1275Q	TAE684	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/48	only alteration type		NB
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK R1275Q	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/39	only alteration type		NB
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/143	only alteration type		NB
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1270	only alteration type		NB
WP216	ALK MUT* (--), ALK MUT* (G924)	ALK R1275Q	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1331	only alteration type		NB
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	only alteration type		CM
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	only alteration type		GB
WP216	ATM MUT* (--), ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	only alteration type		PRAD
WP216	BAP1 MUT* (--)	BAP1 Mutation	Sunitinib,Everolimus	Renal	Resistant	B	NO	https://civicdb.org/links/evidence_items/5339	only alteration type		R
WP216	BAP1 MUT* (--)	BAP1 Mutation	Valproic Acid,Trichostatin A,Vorinostat,Panobinostat	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1234	only alteration type		UVM
WP216	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP216	BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
WP216	BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
WP216	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
WP216	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
WP216	BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
WP216	BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
WP216	BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
WP216	BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
WP216	EGFR MUT* (--)	EGFR A763_Y764insFQEA	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4497	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR A763_Y764insFQEA	Osimertinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/9225	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR A767_V769dupASV	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4665	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR A767_V769dupASV	Osimertinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/9220	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR A864T	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4495	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR C797S	Osimertinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1396	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR C797S	Osimertinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/964	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR D761Y	Erlotinib,Gefitinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1763	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR D770_N771insG	Osimertinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/9223	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR D770_N771insGL	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4494	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR D770_N771insGT	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4643	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR D770_N771insNPG	Gefitinib,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/5947	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR D770delinsGY	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4801	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR E746G	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1787	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR E746_A750del	Gefitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2625	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR E746_A750del	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4198	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR EGFR::RAD51	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5909	only gene		LUAD
WP216	EGFR MUT* (--)	EGFR EGFR::RAD51	Icotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7314	only gene		LUAD
WP216	EGFR MUT* (--)	EGFR EGFR::RAD51	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11015	only gene		LUAD
WP216	EGFR MUT* (--)	EGFR EGFR::RAD51	Osimertinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11021	only gene		LUAD
WP216	EGFR MUT* (--)	EGFR G465R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1058	only alteration type		COREAD
WP216	EGFR MUT* (--)	EGFR G465R	Futuximab/Modotuximab Mixture	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1057	only alteration type		COREAD
WP216	EGFR MUT* (--)	EGFR G719	Erlotinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1780	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR G719	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4189	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR G719A	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2508	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR G719A	Erlotinib,Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/6181	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR G719D	Gefitinib,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4210	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR G719S	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/787	only alteration type		COREAD
WP216	EGFR MUT* (--)	EGFR G719S	Gefitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/274	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR G719S	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1736	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR G719S	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4190	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR G724S	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/786	only alteration type		COREAD
WP216	EGFR MUT* (--)	EGFR H773_V774insNPH	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4493	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR K467T	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1083	only alteration type		COREAD
WP216	EGFR MUT* (--)	EGFR K467T	Panitumumab,Futuximab/Modotuximab Mixture	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1082	only alteration type		COREAD
WP216	EGFR MUT* (--)	EGFR K757R	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1786	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR K806E	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4239	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR KIF5B::EGFR	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11026	only gene		LUAD
WP216	EGFR MUT* (--)	EGFR L747P	Gefitinib,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4220	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L747_P753delinsS	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4266	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L747_P753delinsS	Erlotinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6005	only alteration type		PAAD
WP216	EGFR MUT* (--)	EGFR L747_S752delinsQ	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4667	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR L838P	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4252	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Afatinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/879	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR L858R	Afatinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/883	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR L858R	Afatinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/982	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR L858R	Gefitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2624	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR L858R	Gefitinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2634	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR L858R	Erlotinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4290	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR L858R	Erlotinib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4291	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR L858R	Cetuximab	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4292	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR L858R	Gefitinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6183	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR L858R	Crizotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/4288	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Gefitinib,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/229	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/275	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Gefitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/276	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/885	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/968	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1665	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2621	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Lapatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2626	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Dacomitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2627	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Neratinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2628	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2629	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Canertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2631	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2632	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/2994	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Afatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/2997	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4284	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4286	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4287	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Osimertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4294	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4860	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L858R	Erlotinib	Small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4293	only alteration type		SCLC
WP216	EGFR MUT* (--)	EGFR L861	Gefitinib,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4298	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L861Q	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/3802	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR L861R	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4669	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR M766_A767insAI	Erlotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/4799	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR Mutation	Afatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1728	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1937	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR Mutation	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2053	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2148	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR Mutation	Afatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2153	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2559	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3016	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR Mutation	Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3794	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR Mutation	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4201	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR Mutation	Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7024	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR N826S	Erlotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/4496	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR N826Y	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4244	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR N842S	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4256	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR P772_H773insYNP	Erlotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/4802	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR R451C	Futuximab/Modotuximab Mixture,Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1081	only alteration type		COREAD
WP216	EGFR MUT* (--)	EGFR R705K	Erlotinib,Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/6182	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR R776C	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4468	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR S492R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/717	only alteration type		COREAD
WP216	EGFR MUT* (--)	EGFR S492R	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1080	only alteration type		COREAD
WP216	EGFR MUT* (--)	EGFR S492R	Panitumumab	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1078	only alteration type		COREAD
WP216	EGFR MUT* (--)	EGFR S492R	Panitumumab,Futuximab/Modotuximab Mixture	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1079	only alteration type		COREAD
WP216	EGFR MUT* (--)	EGFR S720	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1782	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR S768I	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4273	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR S768I	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1394	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR S768I	Gefitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1395	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR S768I	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2906	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1391	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR T790M	Osimertinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1397	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR T790M	Osimertinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2157	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR T790M	Erlotinib	Non-small cell lung	Resistant	A	NO	https://civicdb.org/links/evidence_items/238	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/239	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Dacomitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/240	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/1667	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Afatinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/1863	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Gefitinib,Erlotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/2158	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2159	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Lapatinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/2160	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Pemetrexed,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/277	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Rociletinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/646	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Rociletinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/762	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/963	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/965	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/966	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Rociletinib,Osimertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/967	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1592	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1867	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Dacomitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2161	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Neratinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2162	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2163	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2164	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Canertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2165	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR T790M	Osimertinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6006	only alteration type		PAAD
WP216	EGFR MUT* (--)	EGFR T847I	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4260	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR V742A	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4197	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR V769_D770insASV	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1799	only alteration type		LUAD
WP216	EGFR MUT* (--)	EGFR V774A	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4226	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR V774M	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4231	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR V834I	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4248	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR V851I	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4264	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR Y764_V765insHH	Erlotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/4800	only alteration type		NSCLC
WP216	EGFR MUT* (--)	EGFR Amplification	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/854	only gene		COREAD
WP216	EGFR MUT* (--)	EGFR Amplification	Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/911	only gene		COREAD
WP216	EGFR MUT* (--)	EGFR Amplification	Platinum Compound,Cetuximab,Fluorouracil	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/691	only gene		HNSC
WP216	EGFR MUT* (--)	EGFR Amplification	Rociletinib,Osimertinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/3015	only gene		NSCLC
WP216	EGFR MUT* (--)	EGFR Amplification	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/948	only gene		NSCLC
WP216	EGFR MUT* (--)	EGFR Amplification	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/977	only gene		NSCLC
WP216	EGFR MUT* (--)	EGFR Amplification	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5924	only gene		NSCLC
WP216	EGFR MUT* (--)	EGFR Amplification	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5925	only gene		NSCLC
WP216	JAK2 (V617F)	JAK2 Splice Site (c.1641+2T>G)	Pembrolizumab	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4825	only alteration type		CM
WP216	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP216	KMT2C MUT* (K2797X), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP216	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP216	NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP216	NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP216	NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP216	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP216	POLE MUT* (--)	POLE Mutation	Pembrolizumab	Endometrium	Responsive	C	NO	https://civicdb.org/links/evidence_items/1862	only alteration type		ED
WP216	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP216	RAD54L MUT* (--)	RAD54L Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11207	only alteration type		PRAD
WP216	ROS1 MUT* (--)	ROS1 Rearrangement	Ceritinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1248	only gene		LUAD
WP216	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1690	only gene		LUAD
WP216	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/688	only gene		NSCLC
WP216	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1030	only gene		NSCLC
WP216	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7933	only gene		NSCLC
WP216	ROS1 MUT* (--)	ROS1 FUSIONS	Entrectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11123	only gene		NSCLC
WP216	ROS1 MUT* (--)	ROS1 Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7282	only gene		NSCLC
WP216	ROS1 MUT* (--)	ROS1 G2032R	Crizotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2934	only alteration type		LUAD
WP216	ROS1 MUT* (--)	ROS1 GOPC::ROS1	Lorlatinib	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7483	only gene		GB
WP216	TLK2 MUT* (--)	TLK2 Amplification	Go6983,GF109203X	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6000	only gene		BRCA
WP216	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP216	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP087	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP087	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF (V600E,V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF (V600E,V600K)	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s028lbl.pdf	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP087	BRAF MUT* (--)	BRAF (V600E,V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf	only alteration type		CM
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890	only alteration type		PRAD
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP087	DPYD MUT* (--)	DPYD splice donor variant	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
WP087	DPYD MUT* (--)	DPYD biallelic inactivation	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
WP087	DPYD MUT* (--)	DPYD (I560S,D949V)	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
WP087	DPYD MUT* (--)	DPYD splice donor variant	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
WP087	DPYD MUT* (--)	DPYD biallelic inactivation	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
WP087	DPYD MUT* (--)	DPYD (I560S,D949V)	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
WP087	DPYD MUT* (--)	DPYD splice donor variant	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
WP087	DPYD MUT* (--)	DPYD biallelic inactivation	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
WP087	DPYD MUT* (--)	DPYD (I560S,D949V)	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
WP087	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Myelofibrosis	Responsive	A	YES	FDA	complete		MY
WP087	PDGFB MUT* (--)	PDGFB-COL1A1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Dermatofibrosarcoma	Responsive	A	NO	FDA	only gene		DFS
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022	only alteration type		BRCA
WP087	BRAF MUT* (--)	BRAF (V600E)	Trametinib(MEK inhibitor) + Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN Non-Small Cell Lung Cancer guidlines 2022; FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		NSCLC
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP087	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP087	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation;PMID:31566309	only alteration type		COREAD
WP087	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP087	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA (C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R)	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	only alteration type		BRCA
WP087	NTRK3 MUT* (--)	NTRK3 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
WP087	NTRK3 MUT* (--)	NTRK3 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
WP087	NTRK3 MUT* (--)	NTRK3 (F617L,G623R,G696A)	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Resistant	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf	only alteration type		SOLID
WP087	BRAF MUT* (--)	BRAF (V600)	Atezolizumab(PD-L1 blocking antibody);Vemurafenib(BRAF inhibitor);Cobimetinib(MEK inhibitor) 	Cutaneous melanoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-braf-v600-unresectable-or-metastatic-melanoma	only alteration type		CM
WP087	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Bevacizumab(VEGF mAb inhibitor);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP087	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP087	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Pembrolizumab(PD-1-blocking antibody);Pemetrexed(Chemotherapy);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf	complete		NSCLC
WP087	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		SOLID
WP087	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Lower grade glioma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-trametinib-pediatric-patients-low-grade-glioma-braf-v600e-mutation	only alteration type		LGG
WP087	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Durvalumab(PD-1-blocking antibody);Tremelimumab-actl(CTLA-4 blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non	complete		NSCLC
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP087	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP087	ATR MUT* (--)	ATR oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP087	EGFR wildtype, ALK wildtype, ROS1 wildtype	EGFR wildtype;ALK wildtype;ROS1 wildtype	Cemiplimab-rwlc(PD-1-blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-combination-platinum-based-chemotherapy-non-small-cell-lung-cancer	complete		NSCLC
WP087	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP087	BRAF MUT* (--)	BRAF (V600E,V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210496s013lbl.pdf	only alteration type		CM
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP087	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP087	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP087	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP087	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP087	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP087	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP087	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP087	MAP2K2 (V85G)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP087	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP087	BRAF MUT* (--)	BRAF(V600E)	Vemurafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP087	BRAF MUT* (--)	BRAF (V600)	Dabrafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP087	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Hairy-Cell leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf	only alteration type		HCL
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP087	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-binimetinib-metastatic-non-small-cell-lung-cancer-braf-v600e-mutation	only alteration type		NSCLC
WP087	BRAF MUT* (--)	BRAF(V600)	Vemurafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		HISEC
WP087	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF (V600E,G469A)	EGFR TK inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:22773810	only alteration type		LUAD
WP087	AKT2 MUT* (--)	AKT2 amplification	MK2206(Allosteric AKT inhibitor)	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 373)	only gene		CANCER
WP087	CTNNB1 MUT* (D667E)	CTNNB1 oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Resistant	D	NO	PMID:23539443	only alteration type		COREAD
WP087	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only alteration type		COREAD
WP087	ATM MUT* (--), ATM MUT* (--)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
WP087	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only alteration type		LY
WP087	ATM MUT* (--), ATM MUT* (--)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only gene		LY
WP087	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP087	ATM MUT* (--), ATM MUT* (--)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
WP087	ATM MUT* (--), ATM MUT* (--)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP087	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP087	ATM MUT* (--), ATM MUT* (--)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP087	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP087	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP087	ATR MUT* (--)	ATR oncogenic mutation	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only alteration type		OV, CANCER
WP087	ATR MUT* (--)	ATR deletion	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only gene		OV, CANCER
WP087	ATR MUT* (--)	ATR oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP087	BCOR MUT* (--)	BCOR oncogenic mutation	Enzastaurin(PKCb inhibitor)	Stomach	Responsive	D	NO	PMID:27397505	only alteration type		ST
WP087	JAK2 (V617F)	JAK2 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	complete		CM
WP087	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + CDK2/4 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22997239	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF (V600)	BRAF inhibitor + EGFR mAb inhibitor +/- PI3K inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28363909	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + HSP90 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22351686	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + MEK inhibitors	Thyroid	Responsive	C	NO	ASCO 2013 (abstr 9029)	only alteration type		TH
WP087	BRAF MUT* (--)	BRAF fusion	BRAF inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9072)	only gene		LUAD
WP087	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + PI3K pathway inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22389471;PMID:21156289	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF (L597R)	BRAF inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:23715574	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Glioma	Responsive	D	NO	PMID:22038996;PMID:22586120	only alteration type		G
WP087	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Ovary	Responsive	C	NO	PMID:22608338	only alteration type		OV
WP087	BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:23614898;PMID:22997239	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF (G469A)	ERK inhibitors	Head an neck squamous	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		HNSC
WP087	BRAF MUT* (--)	BRAF (L485W)	ERK inhibitors	Billiary tract	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		BT
WP087	BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		LUAD
WP087	BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Thyroid	Responsive	C	NO	PMID:22241789	only alteration type		TH
WP087	BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Ovary	Responsive	D	NO	PMID:19018267	only alteration type		OV
WP087	BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Pan-RAF inhibitors	Any cancer type	Responsive	D	YES	PMID:26732095	only alteration type		CANCER
WP087	BRAF MUT* (--)	BRAF (V600E)	Pan-RAF inhibitors	Cutaneous melanoma	Responsive	C	NO	ESMO 2015 (abstract 300);AACR 2016 (abstr CT005);AACR 2017 (abstr  CT002)	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF fusion	MEK inhibitors(Trametinib,etc)	Lung adenocarcinoma, Cutaneous melanoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:24727320;PMID:24345920;PMID:20526349	only gene		LUAD, CM, PRAD
WP087	BRAF MUT* (--)	BRAF (K601R,L597R,V600R)	MEK inhibitors(Trametinib,etc)	Cutaneous melanoma	Responsive	C	NO	PMID:23248257;PMID:22805292;PMID:23248257	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Lung adenocarcinoma, Thyroid	Responsive	C	NO	PMID:23524406;PMID:22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);PMID:20818844;PMID:23489023;PMID:27080216	only alteration type		LUAD, TH
WP087	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Gastrointestinal stromal	Responsive	C	NO	PMID:23470635;PMID:22608338	only alteration type		GIST
WP087	BRAF MUT* (--)	BRAF (V600R)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:23237741	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26392102;ASCO 2015 (abstr 8006)	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Neuroendocrine	Responsive	C	NO	PMID:27048246	only alteration type		NEU
WP087	BRAF MUT* (--)	BRAF (G466V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:22649091	only alteration type		LUAD
WP087	BRAF MUT* (--)	BRAF (Y472C)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	PMID:22649091	only alteration type		LUAD
WP087	BRAF MUT* (--)	BRAF (V600)	Irinotecan + Vemurafenib + Cetuximab(TOPO1 inhibitor + BRAF inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:27729313	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + BYL719(EGFR mAb inhibitor + BRAF inhibitor + PI3K inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2014 (abstr 11LBA)	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF (V600E)	Panitumumab + Dabrafenib + Trametinib(EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103)	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF (V600E)	PLX4720(BRAF inhibitor)	Malignant astrocytoma	Responsive	D	NO	PMC3638050	only alteration type		MA
WP087	BRAF MUT* (--)	BRAF fusion	Selumetinib(MEK inhibitor)	Ovary	Responsive	C	NO	PMID:26324360	only gene		OV
WP087	BRAF MUT* (--)	BRAF (V600E)	Selumetinib(MEK inhibitor)	Pediatric glioma	Responsive	C	NO	NCT01089101	only alteration type		PG
WP087	BRAF MUT* (--)	BRAF fusion	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma, Lung adenocarcinoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:238900088;PMID:20526349;PMID:24727320	only gene		CM, LUAD, PRAD
WP087	BRAF MUT* (--)	BRAF (D594G,G469E)	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:18794803	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Lung adenocarcinoma, Hairy-Cell leukemia, Myeloma	Responsive	C	YES	PMID:22743296;PMID:22621641;PMID:23612012	only alteration type		LUAD, HCL, MYMA
WP087	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Malignant astrocytoma	Responsive	C	NO	PMID:22586120	only alteration type		MA
WP087	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:22608338;PMID:20818844;PMID:23489023	only alteration type		THCA
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	PARP inhibitors	Pancreas	Responsive	C	NO	PMID:25366685;PMID:25719666;PMID:19553641;PMID:25366685	only alteration type		PA
WP087	BRCA1 MUT* (--)	BRCA1 deletion	PARP inhibitors	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	C	YES	PMID:25964244	only alteration type		CANCER
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467;PMID:25366685	only alteration type		BRCA
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP087	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
WP087	BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP087	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP087	CDKN2A MUT* (A36G)	CDKN2A oncogenic mutation	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr 2500)	only alteration type		CM
WP087	CDKN2A MUT* (A36G)	CDKN2A oncogenic mutation	CDK4/6 inhibitors	Glioma, Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22586120;PMID:22711607	only alteration type		G, CANCER
WP087	CDKN2A MUT* (A36G)	CDKN2A deletion	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr 2500)	only gene		CM
WP087	CDKN2A MUT* (A36G)	CDKN2A deletion	CDK4/6 inhibitors	Glioma, Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22586120;PMID:22711607	only gene		G, CANCER
WP087	CDKN2A MUT* (A36G)	CDKN2A oncogenic mutation	Ilorasertib(AURKA-VEGF inhibitor)	Any cancer type	Responsive	C	YES	NCT02478320	only alteration type		CANCER
WP087	CDKN2A MUT* (A36G)	CDKN2A deletion	Ilorasertib(AURKA-VEGF inhibitor)	Any cancer type	Responsive	C	YES	NCT02478320	only gene		CANCER
WP087	MAP2K2 (V85G)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP087	CTNNB1 MUT* (D667E)	CTNNB1 (H36Y,S37C,S37Y,D32V)	Everolimus + Letrozole(MTOR inhibitor + Hormonal therapy)	Endometrium	Responsive	C	NO	PMID:25624430	only alteration type		ED
WP087	MAP2K2 (V85G)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP087	MAP2K2 (V85G)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP087	MAP2K2 (V85G)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP087	PIK3CA MUT* (--)	PIK3CA (E545*)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMC3936420	only alteration type		CM
WP087	PIK3CA MUT* (--)	PIK3CA amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	D	NO	PMID:24366379	only gene		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9054)	only alteration type		L
WP087	RAF1 MUT* (--), BRAF MUT* (--)	RAF1 (S257P,G361A,P261P) + BRAF oncogenic mutation	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:23737487	only alteration type		CM
WP087	FGFR4 MUT* (--)	FGFR4 (N535,V550)	FGFR inhibitors	Rhabdomyosarcoma	Responsive	D	NO	PMID:19809159;PMID:24124571	only alteration type		RHBDS
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP087	GNAS MUT* (A416)	GNAS (R201)	JAK inhibitors	Any cancer type	Responsive	D	YES	PMID:21835143	only alteration type		CANCER
WP087	HDAC2 MUT* (--)	HDAC2 biallelic inactivation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP087	BRAF MUT* (--)	BRAF (V600E)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
WP087	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP087	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP087	JAK2 (V617F)	JAK2 (V617F)	JAK inhibitor(alone or in combination)s	Acute myeloid leukemia	Responsive	D	YES	PMID:22829971	complete		AML
WP087	JAK2 MUT* (G281D), JAK2 (V617F)	JAK2 amplification	JAK inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27075627	only gene		BRCA
WP087	JAK2 MUT* (G281D), JAK2 (V617F)	JAK2-BRAF fusion	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22875628;PMID:22899477	only gene		ALL
WP087	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:22422826	complete		AML
WP087	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP087	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:19223544;PMID:20619739	only alteration type		COREAD
WP087	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP087	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP087	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP087	MSH3 MUT* (--)	MSH3 oncogenic mutation	DNA-PKc inhibitors	Any cancer type	Responsive	D	YES	PMID:24556366	only alteration type		CANCER
WP087	MYC (T73P)	MYC amplification	BET inhibitors	Myeloma, Neuroblastoma	Responsive	D	YES	PMID:21889194;PMID:23430699	only gene		MYMA, NB
WP087	MYC (T73P)	MYC amplification	CDK7 inhibitors	Neuroblastoma	Responsive	D	NO	PMID:25416950	only gene		NB
WP087	MYC (T73P)	MYC amplification	FACT inhibitors	Neuroblastoma	Responsive	D	NO	PMID:26537256	only gene		NB
WP087	MYC (T73P)	MYC amplification	PIM inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:25505253	only gene		PRAD
WP087	MYC (T73P)	MYC amplification	Temozolomide(Chemotherapy)	Colorectal adenocarcinoma	Responsive	D	NO	PMID:27397505	only gene		COREAD
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP087	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP087	CRBN MUT* (A395E)	CRBN oncogenic mutation	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP087	CRBN MUT* (A395E)	CRBN (Q100*,R283K)	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP087	BRAF MUT* (--)	BRAF (V600E)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
WP087	NOTCH1 MUT* (T701P), NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP087	NOTCH1 MUT* (T701P), NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP087	NOTCH1 MUT* (T701P), NOTCH1 MUT* (T311P)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP087	NOTCH1 MUT* (T701P), NOTCH1 MUT* (T311P)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP087	NOTCH1 MUT* (T701P), NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP087	NOTCH1 MUT* (T701P), NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP087	NOTCH1 MUT* (T701P), NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP087	NOTCH1 MUT* (T701P), NOTCH1 MUT* (T311P)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	only alteration type		MCL
WP087	NOTCH1 MUT* (T701P), NOTCH1 MUT* (T311P)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP087	NOTCH1 MUT* (T701P), NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP087	NOTCH1 MUT* (T701P), NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP087	NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP087	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP087	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP087	CRBN MUT* (A395E)	CRBN oncogenic mutation	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP087	CRBN MUT* (A395E)	CRBN (Q100*,R283K)	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP087	NTRK3 MUT* (--)	NTRK3 fusion	IGF1R inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP087	NTRK3 MUT* (--)	NTRK3 fusion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP087	NTRK3 MUT* (--)	NTRK3 fusion	Midostaurin(Pan-TK inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP087	PBRM1 MUT* (--), PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP087	PBRM1 MUT* (--), PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP087	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP087	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP087	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP087	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	AKT inhibitors	Breast adenocarcinoma	Responsive	C	NO	ASCO 2015 (abstr 2500)	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitor(alone or in combination)s	Lung, Colorectal adenocarcinoma	Responsive	D	NO	PMID:23136191;PMID:23475782;PMID:22392911	only alteration type		L, COREAD
WP087	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Bladder, Head an neck, Lung	Responsive	C	NO	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	only alteration type		BLCA, HNC, L
WP087	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma, Ovary, Cervix squamous cell, Endometrium	Responsive	C	NO	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	only alteration type		BRCA, OV, CESC, ED
WP087	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26787751;PMID:26763254	only alteration type		HNSC
WP087	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Glioma, Thyroid carcinoma	Responsive	D	NO	PMID:19671762;PMID:21289267	only alteration type		G, THCA
WP087	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:28331003	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2501)	only alteration type		ST
WP087	NF1 MUT* (--), NF1 MUT* (--), BRAF MUT* (--)	NF1 oncogenic mutation + BRAF oncogenic mutation	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23444215	only alteration type		CM
WP087	NF1 MUT* (--), NF1 MUT* (--), BRAF MUT* (--)	NF1 deletion + BRAF oncogenic mutation	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23444215	only gene		CM
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP087	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP087	RAF1 MUT* (--)	RAF1 fusion	Pan-RAF inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:20526349	only gene		PRAD
WP087	RAF1 MUT* (--)	RAF1 fusion	Sorafenib(Pan-TK inhibitor)	Prostate adenocarcinoma	Responsive	D	NO	PMID:20526349	only gene		PRAD
WP087	RAF1 MUT* (--)	RAF1 fusion	U0126(MEK inhibitor)	Prostate adenocarcinoma	Responsive	D	NO	PMID:20526349	only gene		PRAD
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP087	RB1 MUT* (--)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
WP087	RB1 MUT* (--)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
WP087	RB1 MUT* (--)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
WP087	RB1 MUT* (--)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
WP087	RB1 MUT* (--)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP087	RB1 MUT* (--)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP087	BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Vemurafenib(BRAF inhibitor)	Any cancer type	Resistant	D	YES	PMID:26732095	only alteration type		CANCER
WP087	BRAF MUT* (--)	BRAF (V600)	Vemurafenib(BRAF inhibitor)	Colorectal adenocarcinoma	No Responsive	C	NO	PMID:26287849	only alteration type		COREAD
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP087	SUZ12 MUT* (--)	SUZ12 oncogenic mutation	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only alteration type		CANCER
WP087	SUZ12 MUT* (--)	SUZ12 deletion	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only gene		CANCER
WP087	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP087	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP087	NF1 MUT* (--), NF1 MUT* (--), BRAF MUT* (--)	NF1 oncogenic mutation + BRAF oncogenic mutation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23288408;PMID:231718	only alteration type		CM
WP087	NF1 MUT* (--), NF1 MUT* (--), BRAF MUT* (--)	NF1 deletion + BRAF oncogenic mutation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23288408;PMID:231718	only gene		CM
WP087	NTRK3 MUT* (--)	NTRK3 (G623R)	novel TRK inhibitors	Any cancer type	Responsive	C	YES	PMID:28578312	only alteration type		CANCER
WP087	BRCA1 MUT* (--)	BRCA1 (G1738R,A1708V,C47G,V1696L,Y1853C,D1739V,F1761I,H1746N,C24Y,K1702E,P1749R,M1775R,W1837C,M1775E,V1736G,V1838E,C44F,A1752V,D1739E,S1715N,.,A1789T,S1164I,T1685A,A1752P,H1686R,H41R,C64G,W1718L,D1692H,V1713A,R1699W,V1653M,Q1756C,C61G,D1739Y,G1770V,V1714G,V1833M,R1835P,R1699Q,G1706E,P1812A,E1836K,C44Y,G1788D,C39Y,M1R,S1715R,Y1703H,F1761S,E33A,M1628V,W1837G,L1705P,M1689R,G1738E,R1751P,V1809F,S1841N,S1722F,I1766S,S1655F,G1788V,L1780P,V1833E,A1708E,E1660G,C27A,Y1703S,I1807S,T1700A,A1843T,F1734L,V1741G,V1810G,F1704S,G1656D,T1685I,L1854P,Q1811R,M18T,C1697R,G1803A,G1743R,G1763V,C24R,T37R,T1773I,D1739G,W1718C,H1686Q,T1691I,L1407P,K1487R,M1652K,S1841R,M1775K,S1841A,F1734S,V1736A,M1689T,W1815X,L1764P,W1837R,T1691K,R1753T,D1692Y,W1718S,L1657P,A1843P,S1715C,R1699L)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/6/summary|oncokb=https://www.oncokb.org/gene/BRCA1	only alteration type		OV
WP087	BRCA1 MUT* (--)	BRCA1 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only gene		OV
WP087	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
WP087	BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
WP087	BRAF MUT* (--)	BRAF (D594.,G466.,G464.,N581.,D287H,K601.,G469.,G596.,L597.,F595L,S467L,V459L)	Plx8394	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CANCER
WP087	BRCA1 MUT* (--)	BRCA1 (G1738R,A1708V,C47G,V1696L,Y1853C,D1739V,F1761I,H1746N,C24Y,K1702E,P1749R,M1775R,W1837C,M1775E,V1736G,V1838E,C44F,A1752V,D1739E,S1715N,.,A1789T,S1164I,T1685A,A1752P,H1686R,H41R,C64G,W1718L,D1692H,V1713A,R1699W,V1653M,Q1756C,C61G,D1739Y,G1770V,V1714G,V1833M,R1835P,R1699Q,G1706E,P1812A,E1836K,C44Y,G1788D,C39Y,M1R,S1715R,Y1703H,F1761S,E33A,M1628V,W1837G,L1705P,M1689R,G1738E,R1751P,V1809F,S1841N,S1722F,I1766S,S1655F,G1788V,L1780P,V1833E,A1708E,E1660G,C27A,Y1703S,I1807S,T1700A,A1843T,F1734L,V1741G,V1810G,F1704S,G1656D,T1685I,L1854P,Q1811R,M18T,C1697R,G1803A,G1743R,G1763V,C24R,T37R,T1773I,D1739G,W1718C,H1686Q,T1691I,L1407P,K1487R,M1652K,S1841R,M1775K,S1841A,F1734S,V1736A,M1689T,L1764P,W1837R,T1691K,R1753T,D1692Y,W1718S,L1657P,A1843P,S1715C,R1699L)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only alteration type		BRCA
WP087	BRCA1 MUT* (--)	BRCA1 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only gene		BRCA
WP087	NTRK3 MUT* (--)	NTRK3 fusion	Entrectinib	Any cancer type	Responsive	B	YES	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/3985/summary|oncokb=https://www.oncokb.org/gene/NTRK3	only gene		CANCER
WP087	BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + Trametinib	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF (V600E)	Encorafenib + Binimetinib + Cetuximab	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		OV
WP087	CDKN2A MUT* (A36G)	CDKN2A (R87P,E69G,P48L,R112G,E88K,M53I,R87L,R80L,R99P,V118D,D108N,T77P,A36P,I49S,G101W,R80P,H83N,Q50P,A68T,A60R,G67S,G67R,G35R,L16P,D108H,R87W,N71I,L32P,N71K,P81L,.,R24P,H83Y,D74Y,G35V,G35A,D84Y,G23D,P73L,V126D,S56I,D84N,D74N,D84H,P114L,P114S,D84V,A60V,G93W,N71S,L97R,P81T,R79P,D84G)	Abemaciclib + Palbociclib + Ribociclib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/CDKN2A	only alteration type		CANCER
WP087	CDKN2A MUT* (A36G)	CDKN2A deletion	Abemaciclib + Palbociclib + Ribociclib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/CDKN2A	only gene		CANCER
WP087	BRAF MUT* (--)	BRAF (V600K,V600.,L597.,K601.,V600E,L597V)	Trametinib	Cutaneous melanoma	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/5/summary|oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CM
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP087	NF1 MUT* (--), NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP087	PIK3CA MUT* (--)	PIK3CA (P539R,R38H,Q546K,G118D,G106V,Q546E,E579K,N345K,E453K,V344A,E545K,T1025S,E542Q,G1049R,M1043I,E110K,P449T,N1044K,K111E,C378R,H1047R,C420R,E78K,E545A,S629C,D350G,.,G451R,M1043V,E542V,Q546R,E365K,E81K,G106D,R88Q,P366R,R93Q,G914R,H1047Y,K111N,E545Q,E545G,R93W,R108H,G106R,E453Q,E542K,D1029Y,N345I,D549N,A1066V,Q546P,E542G,E453A)	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA amplification	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only gene		BRCA
WP087	ATM MUT* (--), ATM MUT* (--)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only alteration type		CANCER
WP087	ATM MUT* (--), ATM MUT* (--)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
WP087	JAK2 MUT* (G281D), JAK2 (V617F)	JAK2-PCM1 fusion	Ruxolitinib	Eosinophilic chronic leukemia	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/JAK2	only gene		ECL
WP087	BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Cutaneous melanoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		CM
WP087	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
WP087	BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
WP087	NTRK3 MUT* (--)	NTRK3 (G623R)	Larotrectinib	Any cancer type	Resistant	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK3	only alteration type		CANCER
WP087	ABCC3 MUT* (--)	ABCC3 Amplification	Monomethyl Auristatin E,Paclitaxel	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/951	only gene		BRCA
WP087	AKT2 MUT* (--)	AKT2 Amplification	Everolimus,Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1621	only gene		LUAD
WP087	ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	only alteration type		CM
WP087	ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	only alteration type		GB
WP087	ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	only alteration type		PRAD
WP087	BRAF MUT* (--)	BRAF Non-V600	Trametinib	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/7855	only alteration type		SOLID
WP087	BRAF MUT* (--)	BRAF A598V	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7635	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF AGK::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/724	only gene		CM
WP087	BRAF MUT* (--)	BRAF AGK::BRAF	Sorafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/723	only gene		CM
WP087	BRAF MUT* (--)	BRAF CUX1::BRAF	Vemurafenib	Pancreas	Responsive	C	NO	https://civicdb.org/links/evidence_items/5977	only gene		PA
WP087	BRAF MUT* (--)	BRAF D594G	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1554	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2201	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4472	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF D594K	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6402	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF D594K	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6403	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF G466V	Irinotecan,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7552	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF G466V	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7553	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF G466V	Vemurafenib	Solid tumors	Responsive	D	NO	https://civicdb.org/links/evidence_items/7554	only alteration type		SOLID
WP087	BRAF MUT* (--)	BRAF G469	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7634	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF G596C	Dabrafenib,Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1738	only alteration type		NSCLC
WP087	BRAF MUT* (--)	BRAF G596R	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4729	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1668	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1669	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF L597R	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/728	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1704	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2187	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6303	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6304	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6305	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6306	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1404	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF PAPSS1::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/725	only gene		CM
WP087	BRAF MUT* (--)	BRAF PAPSS1::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/726	only gene		CM
WP087	BRAF MUT* (--)	BRAF TRIM24::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/727	only gene		CM
WP087	BRAF MUT* (--)	BRAF V600	Vemurafenib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5905	only alteration type		CH
WP087	BRAF MUT* (--)	BRAF V600	Refametinib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1000	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/93	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1407	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1422	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1750	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600	Cobimetinib,Vemurafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/6044	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6180	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6937	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6966	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600	Binimetinib,Encorafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7287	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/88	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600	Vemurafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1576	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1415	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1598	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600	Cetuximab,Encorafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6046	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600	Encorafenib,Alpelisib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6047	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600	Vemurafenib,Irinotecan,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7355	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1574	only alteration type		NSCLC
WP087	BRAF MUT* (--)	BRAF V600D	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/94	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4488	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4489	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7616	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7629	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5902	only alteration type		CH
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Irinotecan,Panitumumab	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5906	only alteration type		CH
WP087	BRAF MUT* (--)	BRAF V600E	Trametinib,Mirdametinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/86	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/90	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/994	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/95	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	Pictilisib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/757	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	Dactolisib,Selumetinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1005	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1398	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1421	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1749	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2135	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3750	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3755	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3757	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6178	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6938	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6940	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600E	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/126	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/816	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2115	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2117	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2118	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2121	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3739	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3827	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Sorafenib,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/89	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	PLX4720,Pictilisib Bismesylate	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/96	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	PLX4720,Nutlin-3	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/97	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/98	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/99	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1405	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Dabrafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1406	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Cetuximab,Gefitinib,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1408	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1413	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	GDC-0879,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1428	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1589	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Irinotecan,Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1902	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5960	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Panitumumab,Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6123	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Panitumumab,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6124	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Cetuximab,Encorafenib,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7260	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7612	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cetuximab,Irinotecan	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8506	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Erlotinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8507	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/9851	only alteration type		COREAD
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Hairy-Cell leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/1579	only alteration type		HCL
WP087	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5903	only alteration type		IHCH
WP087	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5904	only alteration type		IHCH
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1698	only alteration type		MM
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1699	only alteration type		MM
WP087	BRAF MUT* (--)	BRAF V600E	Dabrafenib,Trametinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/3017	only alteration type		NSCLC
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5958	only alteration type		NSCLC
WP087	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/5959	only alteration type		OV
WP087	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1399	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1400	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600K	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2505	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600K	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2506	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4180	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6179	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6965	only alteration type		CM
WP087	BRAF MUT* (--)	BRAF ZKSCAN1::BRAF	Trametinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1663	only gene		CM
WP087	BRAF MUT* (--)	BRAF Amplification	Trametinib,Dabrafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/7677	only gene		CM
WP087	BRAF MUT* (--)	BRAF Amplification	Panitumumab,Dabrafenib	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2929	only gene		COREAD
WP087	BRCA1 MUT* (--)	BRCA1 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/1897	only alteration type		OV
WP087	BRCA1 MUT* (--)	BRCA1 Mutation	Olaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/7275	only alteration type		OV
WP087	BRCA1 MUT* (--)	BRCA1 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11136	only alteration type		OV
WP087	BRCA1 MUT* (--)	BRCA1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11203	only alteration type		PRAD
WP087	BRCA1 MUT* (--)	BRCA1 Q1467*	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2878	only alteration type		OV
WP087	BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
WP087	BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
WP087	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
WP087	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
WP087	BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
WP087	BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
WP087	BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
WP087	BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
WP087	CDKN2A MUT* (A36G)	CDKN2A Mutation	Palbociclib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7300	only alteration type		CH
WP087	CDKN2A MUT* (A36G)	CDKN2A Mutation	Palbociclib	Pancreas	Responsive	B	NO	https://civicdb.org/links/evidence_items/7299	only alteration type		PA
WP087	CDKN2A MUT* (A36G)	CDKN2A Loss	Linsitinib,Palbociclib	Ewing sarcoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1879	only gene		EWS
WP087	CDKN2A MUT* (A36G)	CDKN2A Loss	Palbociclib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/7444	only gene		NSCLC
WP087	CDKN2A MUT* (A36G)	CDKN2A Loss	Palbociclib	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/1377	only gene		OV
WP087	CDKN2A MUT* (A36G)	CDKN2A Loss	Palbociclib	Renal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1373	only gene		R
WP087	CRBN MUT* (A395E)	CRBN Mutation	Lenalidomide,Pomalidomide	Multiple myeloma	Resistant	C	YES	https://civicdb.org/links/evidence_items/1766	only alteration type		MM
WP087	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP087	GNAS MUT* (A416)	GNAS R201C	Cetuximab,Vemurafenib,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1906	only alteration type		COREAD
WP087	JAK2 MUT* (G281D), JAK2 (V617F)	JAK2 Splice Site (c.1641+2T>G)	Pembrolizumab	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4825	only alteration type		CM
WP087	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP087	KMT2C MUT* (S806), KMT2C MUT* (E765G), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP087	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP087	NOTCH1 MUT* (T701P), NOTCH1 MUT* (T311P)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP087	NTRK3 MUT* (--)	NTRK3 EML4::NTRK3	Entrectinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11099	only gene		LUAD
WP087	NTRK3 MUT* (--)	NTRK3 EML4::NTRK3	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/10636	only gene		NSCLC
WP087	NTRK3 MUT* (--)	NTRK3 ETV6::NTRK3	Entrectinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7994	only gene		AML
WP087	NTRK3 MUT* (--)	NTRK3 ETV6::NTRK3	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/7496	only gene		SOLID
WP087	NTRK3 MUT* (--)	NTRK3 F617L	Larotrectinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/9592	only alteration type		GIST
WP087	NTRK3 MUT* (--)	NTRK3 Fusion	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/6568	only gene		SOLID
WP087	NTRK3 MUT* (--)	NTRK3 Fusion	Entrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/11125	only gene		SOLID
WP087	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2346	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8549	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA C420R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2078	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA C420R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1999	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA D350G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4784	only alteration type		CM
WP087	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8007	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E542K	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/310	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E542K	Sirolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/311	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2022	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2026	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2058	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E542K	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7315	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8013	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8016	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E542K	Regorafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/83	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA E542K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4424	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA E542K	Apitolisib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/1549	only alteration type		HNSC
WP087	PIK3CA MUT* (--)	PIK3CA E542K	Perifosine,Temsirolimus	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1626	only alteration type		THCA
WP087	PIK3CA MUT* (--)	PIK3CA E545	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7468	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E545G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3724	only alteration type		CM
WP087	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1453	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2036	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6211	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E545K	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6213	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E545K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8008	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8547	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E545K	Akt Inhibitor MK2206,Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/710	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2034	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2062	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8017	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8018	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA E545K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3722	only alteration type		CM
WP087	PIK3CA MUT* (--)	PIK3CA E545K	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/387	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2037	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2217	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib	Lung adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1171	only alteration type		LUAD
WP087	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1670	only alteration type		LUAD
WP087	PIK3CA MUT* (--)	PIK3CA E545K	PI103	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2040	only alteration type		NSCLC
WP087	PIK3CA MUT* (--)	PIK3CA E545Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2213	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA E81K	Oxaliplatin,Fluorouracil,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4464	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA F930S	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10032	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA G1049R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3847	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA H1047L	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2089	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA H1047L	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8009	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA H1047L	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8019	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA H1047L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4432	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2103	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6204	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6206	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8548	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/314	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Capivasertib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1505	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1506	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Everolimus,Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1623	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2096	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2102	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/258	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/388	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Vemurafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3733	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3841	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Akt Inhibitor MK2206,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8364	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1465	only alteration type		HNSC
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1447	only alteration type		LUAD
WP087	PIK3CA MUT* (--)	PIK3CA H1047R	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1625	only alteration type		THCA
WP087	PIK3CA MUT* (--)	PIK3CA H1047X	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7318	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2867	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8663	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2866	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA K111N	Dactolisib,Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8183	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8662	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA K111N	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2085	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA K111N	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8011	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA K111N	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8020	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA K944N	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10031	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA K966E	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10034	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1384	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2087	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2098	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8536	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Capecitabine,Lapatinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8705	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1296	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1504	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1600	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1607	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1610	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Fulvestrant,Alpelisib	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7313	only alteration type		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/915	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1705	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3732	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6298	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6299	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6300	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6301	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6362	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Cabozantinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/771	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6375	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Ridaforolimus,Temsirolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/892	only alteration type		ED
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Pictilisib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1616	only alteration type		ED
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Radiation Therapy,Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1490	only alteration type		HNSC
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin,Sulindac,Celecoxib	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7185	only alteration type		HNSC
WP087	PIK3CA MUT* (--)	PIK3CA Mutation	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2355	only alteration type		NSCLC
WP087	PIK3CA MUT* (--)	PIK3CA N345K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4047	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA Q546K	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2198	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA R88Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3832	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA R93W	Cetuximab,Fluorouracil,Oxaliplatin	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4467	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA S158L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4463	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA V955G	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10033	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA V955I	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/8063	only alteration type		COREAD
WP087	PIK3CA MUT* (--)	PIK3CA Amplification	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8267	only gene		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA Amplification	Lapatinib,Dactolisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8271	only gene		BRCA
WP087	PIK3CA MUT* (--)	PIK3CA Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6275	only gene		CM
WP087	PIK3CA MUT* (--)	PIK3CA Amplification	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1464	only gene		HNSC
WP087	PIK3CA MUT* (--)	PIK3CA Amplification	Sulindac,Aspirin,Ibuprofen	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7186	only gene		HNSC
WP087	PIK3CA MUT* (--)	PIK3CA Amplification	Pictilisib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/756	only gene		OV
WP087	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP087	RB1 MUT* (--)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
WP087	TLK2 MUT* (--)	TLK2 Amplification	Go6983,GF109203X	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6000	only gene		BRCA
WP087	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP087	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP064	DPYD MUT* (--)	DPYD splice donor variant	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
WP064	DPYD MUT* (--)	DPYD biallelic inactivation	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
WP064	DPYD MUT* (--)	DPYD (I560S,D949V)	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
WP064	DPYD MUT* (--)	DPYD splice donor variant	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
WP064	DPYD MUT* (--)	DPYD biallelic inactivation	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
WP064	DPYD MUT* (--)	DPYD (I560S,D949V)	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
WP064	DPYD MUT* (--)	DPYD splice donor variant	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
WP064	DPYD MUT* (--)	DPYD biallelic inactivation	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
WP064	DPYD MUT* (--)	DPYD (I560S,D949V)	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
WP064	PTCH1 MUT* (Q11R)	PTCH1 oncogenic mutation	Vismodegib(SHH inhibitor)	Basal cell carcinoma, Medulloblastoma	Responsive	A	NO	PMID:19726763;PMID:19726761	only alteration type		BCC, MB
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP064	EZH2 MUT* (--)	EZH2 (A692V,Y646C,Y646F,Y646H,Y646N,Y646S,A682G)	Tazemetostat(EZH2 inhibitor)	Follicular lymphoma	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma;PMID:33035457 	only alteration type		FL
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022	only alteration type		BRCA
WP064	FLT3 MUT* (--)	FLT3-ITD	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia;PMID:28644114	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 (D835,I836)	Gilteritinib(Kinase inhibitor )	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3-ITD	Gilteritinib(Kinase inhibitor )	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation;PMID:31665578	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 (D835,I836)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia; PMID:28644114	only alteration type		AML
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP064	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP064	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Entrectinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA;PMID:28183697;ESMO 2019 (abstr 4178) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725s007lbl.pdf	only gene		NSCLC
WP064	RAD51D MUT* (--)	RAD51D oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP064	RAD54L MUT* (--)	RAD54L oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP064	PIK3CA MUT* (--)	PIK3CA (C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R)	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	only alteration type		BRCA
WP064	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Bevacizumab(VEGF mAb inhibitor);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP064	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP064	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Pembrolizumab(PD-1-blocking antibody);Pemetrexed(Chemotherapy);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf	complete		NSCLC
WP064	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Durvalumab(PD-1-blocking antibody);Tremelimumab-actl(CTLA-4 blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non	complete		NSCLC
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP064	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP064	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP064	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP064	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP064	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP064	FLT3 MUT* (--)	FLT3-ITD	Quizartinib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	A	YES	FDA  https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia	only alteration type		AML
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP064	EZH2 MUT* (--)	EZH2 oncogenic mutations (excluding Y646S, Y646H, Y646C, Y646F, Y646N, A682G and A692V)	Tazemetostat(EZH2 inhibitor)	Follicular lymphoma	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf	only alteration type		FL
WP064	CTNNB1 (V660F)	CTNNB1 oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Resistant	D	NO	PMID:23539443	complete		COREAD
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
WP064	BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP064	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP064	CBL MUT* (--)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP064	CBL MUT* (--)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP064	CDK6 (V180F)	CDK6 amplification	CDK6 inhibitors	Any cancer type	Responsive	D	YES	PMID:22471707	only gene		CANCER
WP064	CDK6 (V180F)	CDK6 oncogenic mutation	LEE011(CDK4/6 inhibitor)	Liposarcoma, Lymphoma, Any cancer type	Responsive	C	YES	NCT02187783;NCT01237236	complete		LIP, LY, CANCER
WP064	CDK6 (V180F)	CDK6 amplification	LEE011(CDK4/6 inhibitor)	Liposarcoma, Lymphoma, Any cancer type	Responsive	C	YES	NCT02187783;NCT01237236;http://meetinglibrary.asco.org/content/83791-102	only gene		LIP, LY, CANCER
WP064	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP064	CTNNB1 (V660F)	CTNNB1 (H36Y,S37C,S37Y,D32V)	Everolimus + Letrozole(MTOR inhibitor + Hormonal therapy)	Endometrium	Responsive	C	NO	PMID:25624430	only alteration type		ED
WP064	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP064	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP064	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP064	PIK3CA MUT* (--)	PIK3CA (E545*)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMC3936420	only alteration type		CM
WP064	PIK3CA MUT* (--)	PIK3CA amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	D	NO	PMID:24366379	only gene		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9054)	only alteration type		L
WP064	PIK3CB MUT* (--)	PIK3CB (D1067Y)	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	C	NO	PMID:26759240	only alteration type		BRCA
WP064	EZH2 MUT* (--)	EZH2 (Y641,A677)	EZH2 inhibitors(EPZ-005687,EPZ-6438,etc)	Lymphoma	Responsive	D	YES	PMID:23023262;PMID:24563539	only alteration type		LY
WP064	FLT3 MUT* (--)	FLT3-ITD	FLT3 inhibitors	Acute myeloid leukemia	Responsive	C	YES	PMID:16857985	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 (F691)	novel FLT3 inhibitors	Acute myeloid leukemia	Responsive	D	YES	PMID:25847190	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 (N676)	Crenolanib(FLT3 inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:24619500	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 (D835)	Lestaurtinib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:16857985	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 (D835)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:20733134	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 (N676)	Midostaurin(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:24619500	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3-ITD	Sorafenib(Pan-TK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:19389879;PMID:22368270	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3-ITD	Sorafenib + Azacytidine(Pan-TK inhibitor + Chemotherapy)	Acute myeloid leukemia	Responsive	C	YES	PMID:23613521	only alteration type		AML
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP064	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP064	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP064	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP064	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:19223544;PMID:20619739	only alteration type		COREAD
WP064	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP064	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 (G2032R)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:23724914;PMID:25688157	only alteration type		LUAD
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP064	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP064	MYC MUT* (--)	MYC amplification	BET inhibitors	Myeloma, Neuroblastoma	Responsive	D	YES	PMID:21889194;PMID:23430699	only gene		MYMA, NB
WP064	MYC MUT* (--)	MYC amplification	CDK7 inhibitors	Neuroblastoma	Responsive	D	NO	PMID:25416950	only gene		NB
WP064	MYC MUT* (--)	MYC amplification	FACT inhibitors	Neuroblastoma	Responsive	D	NO	PMID:26537256	only gene		NB
WP064	MYC MUT* (--)	MYC amplification	PIM inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:25505253	only gene		PRAD
WP064	MYC MUT* (--)	MYC amplification	Temozolomide(Chemotherapy)	Colorectal adenocarcinoma	Responsive	D	NO	PMID:27397505	only gene		COREAD
WP064	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP064	CRBN MUT* (--)	CRBN oncogenic mutation	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP064	CRBN MUT* (--)	CRBN (Q100*,R283K)	Lenalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP064	NOTCH1 MUT* (T349P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP064	NOTCH1 MUT* (T349P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP064	NOTCH1 MUT* (T349P)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP064	NOTCH1 MUT* (T349P)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP064	NOTCH1 MUT* (T349P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP064	NOTCH1 MUT* (T349P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP064	NOTCH1 MUT* (T349P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP064	NOTCH1 MUT* (T349P)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	only alteration type		MCL
WP064	NOTCH1 MUT* (T349P)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP064	NOTCH1 MUT* (T349P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP064	NOTCH1 MUT* (T349P)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP064	CRBN MUT* (--)	CRBN oncogenic mutation	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:25108355	only alteration type		MYMA
WP064	CRBN MUT* (--)	CRBN (Q100*,R283K)	Pomalidomide(Immunomodulator)	Myeloma	Resistant	C	YES	PMID:23480694	only alteration type		MYMA
WP064	NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP064	NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP064	PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP064	PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP064	FLT3 MUT* (--)	FLT3 (D835,Y842)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Acute myeloid leukemia	Resistant	D	YES	PMID:23430109	only alteration type		AML
WP064	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP064	FLT3 MUT* (--)	FLT3 (F691,D835,N676,Y842)	Quizartinib(Pan-TK inhibitor)	Acute myeloid leukemia	Resistant	D	YES	PMID:22504184;PMID:23878140	only alteration type		AML
WP064	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP064	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP064	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	AKT inhibitors	Breast adenocarcinoma	Responsive	C	NO	ASCO 2015 (abstr 2500)	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitor(alone or in combination)s	Lung, Colorectal adenocarcinoma	Responsive	D	NO	PMID:23136191;PMID:23475782;PMID:22392911	only alteration type		L, COREAD
WP064	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Bladder, Head an neck, Lung	Responsive	C	NO	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	only alteration type		BLCA, HNC, L
WP064	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma, Ovary, Cervix squamous cell, Endometrium	Responsive	C	NO	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	only alteration type		BRCA, OV, CESC, ED
WP064	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26787751;PMID:26763254	only alteration type		HNSC
WP064	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Glioma, Thyroid carcinoma	Responsive	D	NO	PMID:19671762;PMID:21289267	only alteration type		G, THCA
WP064	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:28331003	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2501)	only alteration type		ST
WP064	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	AKT inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP064	PIK3CB MUT* (--)	PIK3CB (D1067Y)	AKT inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26759240	only alteration type		BRCA
WP064	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	MTORC1/2 inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP064	PIK3CB MUT* (--)	PIK3CB (D1067Y)	MTORC1/2 inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26759240	only alteration type		BRCA
WP064	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP064	PTCH1 MUT* (Q11R)	PTCH1 oncogenic mutation	SMO inhibitors	Medulloblastoma	Responsive	D	NO	PMID:24651015	only alteration type		MB
WP064	PTCH1 MUT* (Q11R)	PTCH1 oncogenic mutation	Foretinib(MET inhibitor)	Medulloblastoma	Responsive	D	NO	PMID:25391241	only alteration type		MB
WP064	PTPRD MUT* (--), PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP064	RICTOR MUT* (--)	RICTOR amplification	MTORC1/2 inhibitors	Lung	Responsive	C	NO	PMID:26370156	only gene		L
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:23533265	only gene		LUAD
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27370605	only gene		LUAD
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 (G2032R)	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:25351743	only alteration type		LUAD
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	C	YES	PMID:24875859	only gene		IM
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:25264305	only gene		LUAD
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27401242	only alteration type		LUAD
WP064	SETD2 MUT* (--)	SETD2 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only alteration type		CANCER
WP064	SETD2 MUT* (--)	SETD2 deletion	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only gene		CANCER
WP064	TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP064	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP064	FLT3 MUT* (--)	FLT3-ITD	Venetoclax(BCL2 inhibitor)	Acute myeloid leukemia	Resistant	C	YES	PMID:27520294	only alteration type		AML
WP064	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
WP064	BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
WP064	KDM6A MUT* (--)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
WP064	KDM6A MUT* (--)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only alteration type		BLCA
WP064	PIK3CA MUT* (--)	PIK3CA (P539R,R38H,Q546K,G118D,G106V,Q546E,E579K,N345K,E453K,V344A,E545K,T1025S,E542Q,G1049R,M1043I,E110K,P449T,N1044K,K111E,C378R,H1047R,C420R,E78K,E545A,S629C,D350G,.,G451R,M1043V,E542V,Q546R,E365K,E81K,G106D,R88Q,P366R,R93Q,G914R,H1047Y,K111N,E545Q,E545G,R93W,R108H,G106R,E453Q,E542K,D1029Y,N345I,D549N,A1066V,Q546P,E542G,E453A)	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA amplification	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only gene		BRCA
WP064	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
WP064	BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
WP064	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP064	BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
WP064	BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
WP064	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
WP064	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
WP064	BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
WP064	BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
WP064	BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
WP064	BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
WP064	CRBN MUT* (--)	CRBN Mutation	Lenalidomide,Pomalidomide	Multiple myeloma	Resistant	C	YES	https://civicdb.org/links/evidence_items/1766	only alteration type		MM
WP064	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP064	EZH2 MUT* (--)	EZH2 Y646H	Tazemetostat	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/9377	only alteration type		DLBCL
WP064	FLT3 MUT* (--)	FLT3 D835	Quizartinib,Ponatinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1036	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 D835	SU5614	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1037	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 D835	Quizartinib,Sorafenib	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/1038	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 D835	Sorafenib	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/1039	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 D835H	Sorafenib	Acute myeloid leukemia	Resistant	C	YES	https://civicdb.org/links/evidence_items/1556	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 D835H	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8517	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 D835H/Y	Sorafenib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/1557	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 D835I	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8351	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 D835V	Tandutinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/3007	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 D835V	Sunitinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3008	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 D835V	Sunitinib,Cytarabine	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3009	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 D835V	Daunorubicin,Sunitinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3010	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 D835V	Quizartinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3012	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 D835V	AS602868,Tyrphostin AG 1296	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/3034	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 D835V	Sunitinib	Acute myeloid leukemia	Responsive	C	YES	https://civicdb.org/links/evidence_items/4022	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 D835V	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8518	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 D835Y	Gilteritinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8108	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 F691L	Lestaurtinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8341	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 F691L	Midostaurin	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8342	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 Mutation	Midostaurin	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/5261	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 Mutation	Gilteritinib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/7283	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 Mutation	Gilteritinib	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/7728	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 Y842C	FLT3/ABL/Aurora Kinase Inhibitor KW-2449	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8336	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 Y842C	Sorafenib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8337	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 Y842C	Sunitinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8338	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 Y842C	Quizartinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/8654	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 Y842C	Lestaurtinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8339	only alteration type		AML
WP064	FLT3 MUT* (--)	FLT3 Y842C	Midostaurin	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/8340	only alteration type		AML
WP064	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP064	KMT2C MUT* (K2797X), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP064	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP064	NOTCH1 MUT* (T349P)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP064	NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP064	NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP064	NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP064	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2346	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8549	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA C420R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2078	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA C420R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1999	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA D350G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4784	only alteration type		CM
WP064	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8007	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E542K	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/310	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E542K	Sirolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/311	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2022	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2026	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2058	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E542K	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7315	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8013	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8016	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E542K	Regorafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/83	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA E542K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4424	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA E542K	Apitolisib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/1549	only alteration type		HNSC
WP064	PIK3CA MUT* (--)	PIK3CA E542K	Perifosine,Temsirolimus	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1626	only alteration type		THCA
WP064	PIK3CA MUT* (--)	PIK3CA E545	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7468	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E545G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3724	only alteration type		CM
WP064	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1453	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2036	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6211	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E545K	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6213	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E545K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8008	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8547	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E545K	Akt Inhibitor MK2206,Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/710	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2034	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2062	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8017	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8018	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA E545K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3722	only alteration type		CM
WP064	PIK3CA MUT* (--)	PIK3CA E545K	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/387	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2037	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2217	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib	Lung adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1171	only alteration type		LUAD
WP064	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1670	only alteration type		LUAD
WP064	PIK3CA MUT* (--)	PIK3CA E545K	PI103	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2040	only alteration type		NSCLC
WP064	PIK3CA MUT* (--)	PIK3CA E545Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2213	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA E81K	Oxaliplatin,Fluorouracil,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4464	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA F930S	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10032	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA G1049R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3847	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA H1047L	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2089	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA H1047L	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8009	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA H1047L	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8019	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA H1047L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4432	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2103	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6204	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6206	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8548	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/314	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Capivasertib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1505	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1506	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Everolimus,Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1623	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2096	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2102	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/258	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/388	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Vemurafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3733	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3841	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Akt Inhibitor MK2206,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8364	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1465	only alteration type		HNSC
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1447	only alteration type		LUAD
WP064	PIK3CA MUT* (--)	PIK3CA H1047R	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1625	only alteration type		THCA
WP064	PIK3CA MUT* (--)	PIK3CA H1047X	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7318	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2867	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8663	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2866	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA K111N	Dactolisib,Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8183	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8662	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA K111N	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2085	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA K111N	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8011	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA K111N	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8020	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA K944N	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10031	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA K966E	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10034	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1384	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2087	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2098	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8536	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Capecitabine,Lapatinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8705	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1296	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1504	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1600	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1607	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1610	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Fulvestrant,Alpelisib	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7313	only alteration type		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/915	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1705	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3732	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6298	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6299	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6300	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6301	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6362	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Cabozantinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/771	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6375	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Ridaforolimus,Temsirolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/892	only alteration type		ED
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Pictilisib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1616	only alteration type		ED
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Radiation Therapy,Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1490	only alteration type		HNSC
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin,Sulindac,Celecoxib	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7185	only alteration type		HNSC
WP064	PIK3CA MUT* (--)	PIK3CA Mutation	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2355	only alteration type		NSCLC
WP064	PIK3CA MUT* (--)	PIK3CA N345K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4047	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA Q546K	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2198	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA R88Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3832	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA R93W	Cetuximab,Fluorouracil,Oxaliplatin	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4467	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA S158L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4463	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA V955G	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10033	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA V955I	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/8063	only alteration type		COREAD
WP064	PIK3CA MUT* (--)	PIK3CA Amplification	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8267	only gene		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA Amplification	Lapatinib,Dactolisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8271	only gene		BRCA
WP064	PIK3CA MUT* (--)	PIK3CA Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6275	only gene		CM
WP064	PIK3CA MUT* (--)	PIK3CA Amplification	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1464	only gene		HNSC
WP064	PIK3CA MUT* (--)	PIK3CA Amplification	Sulindac,Aspirin,Ibuprofen	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7186	only gene		HNSC
WP064	PIK3CA MUT* (--)	PIK3CA Amplification	Pictilisib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/756	only gene		OV
WP064	POLD1 MUT* (--)	POLD1 C284Y	Pembrolizumab	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4776	only alteration type		LUAD
WP064	POLD1 MUT* (--)	POLD1 E374K	Pembrolizumab	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4777	only alteration type		NSCLC
WP064	PTPRD MUT* (--), PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP064	RAD51D MUT* (--)	RAD51D Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11214	only alteration type		PRAD
WP064	RAD54L MUT* (--)	RAD54L Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11207	only alteration type		PRAD
WP064	RICTOR MUT* (--)	RICTOR Amplification	Onatasertib,Sapanisertib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1440	only gene		LUAD
WP064	RICTOR MUT* (--)	RICTOR Amplification	Vistusertib	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7449	only gene		SCLC
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Rearrangement	Ceritinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1248	only gene		LUAD
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1690	only gene		LUAD
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/688	only gene		NSCLC
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1030	only gene		NSCLC
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7933	only gene		NSCLC
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 FUSIONS	Entrectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11123	only gene		NSCLC
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7282	only gene		NSCLC
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 G2032R	Crizotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2934	only alteration type		LUAD
WP064	ROS1 MUT* (--), ROS1 MUT* (--)	ROS1 GOPC::ROS1	Lorlatinib	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7483	only gene		GB
WP064	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP064	TLK2 MUT* (--)	TLK2 Amplification	Go6983,GF109203X	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6000	only gene		BRCA
WP064	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP064	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890	only alteration type		PRAD
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP188	KRAS MUT* (--)	KRAS (12,13)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP188	G6PD MUT* (--)	G6PD biallelic inactivation	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP188	G6PD MUT* (--)	G6PD (S218F)	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP188	G6PD MUT* (--), G6PD MUT* (--)	G6PD (V98M) + G6PD (N156D)	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP188	KRAS MUT* (--)	KRAS (12,13,59,61,117,146)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	NCCN guidelines	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	NCCN guidelines	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR inhibitors	Lung	Resistant	A	NO	NCCN guidelines	only alteration type		L
WP188	PTCH1 (F573L)	PTCH1 oncogenic mutation	Vismodegib(SHH inhibitor)	Basal cell carcinoma, Medulloblastoma	Responsive	A	NO	PMID:19726763;PMID:19726761	complete		BCC, MB
WP188	TSC2 (A807D)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    , Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	complete		RA, GCA
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP188	BARD1 MUT* (--)	BARD1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP188	FANCL MUT* (--)	FANCL oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP188	KRAS MUT* (--)	KRAS (G12C)	Sotorasib(RAS GTPase family inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc	only alteration type		NSCLC
WP188	MET MUT* (--)	MET exon 14 skipping mutations	Tepotinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer;PMID:31279006;PMID:34036238	only alteration type		NSCLC
WP188	MET MUT* (--)	MET exon 14 skipping mutations	Capmatinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capmatinib-metastatic-non-small-cell-lung-cancer	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS (G12C)	Adagrasib(RAS GTPase family inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc	only alteration type		NSCLC
WP188	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Bevacizumab(VEGF mAb inhibitor);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP188	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP188	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Pembrolizumab(PD-1-blocking antibody);Pemetrexed(Chemotherapy);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf	complete		NSCLC
WP188	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Durvalumab(PD-1-blocking antibody);Tremelimumab-actl(CTLA-4 blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non	complete		NSCLC
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP188	FANCA MUT* (L721I)	FANCA oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP188	EGFR wildtype, ALK wildtype, ROS1 wildtype	EGFR wildtype;ALK wildtype;ROS1 wildtype	Cemiplimab-rwlc(PD-1-blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-combination-platinum-based-chemotherapy-non-small-cell-lung-cancer	complete		NSCLC
WP188	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP188	KRAS MUT* (--)	KRAS (G12C)	Adagrasib(RAS GTPase family inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP188	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP188	MET MUT* (--)	MET amplification	Capmatinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP188	MET MUT* (--)	MET amplification	Tepotinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP188	MET MUT* (--)	MET exon 14 skipping mutations	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS (G12C)	Sotorasib(RAS GTPase family inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP188	ERBB3 MUT* (--)	ERBB3 amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:25520391	only gene		COREAD
WP188	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	complete		CANCER
WP188	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	complete		OV
WP188	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	complete		CANCER
WP188	BCOR MUT* (--)	BCOR oncogenic mutation	Enzastaurin(PKCb inhibitor)	Stomach	Responsive	D	NO	PMID:27397505	only alteration type		ST
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Pancreas	No Responsive	C	NO	ASCO 2015 (abstr 4119)	only alteration type		PA
WP188	KRAS MUT* (--)	KRAS (G13D)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	No Responsive	B	NO	PMID:27114605	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	Selumetinib(MEK inhibitor)	Lung	No Responsive	C	NO	PMID:26802155	only alteration type		L
WP188	KRAS MUT* (--)	KRAS amplification	BRAF inhibitor + EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only gene		COREAD
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	PARP inhibitors	Pancreas	Responsive	C	NO	PMID:25366685;PMID:25719666;PMID:19553641;PMID:25366685	only alteration type		PA
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 deletion	PARP inhibitors	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	C	YES	PMID:25964244	only alteration type		CANCER
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467;PMID:25366685	only alteration type		BRCA
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
WP188	BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP188	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP188	KRAS MUT* (--)	KRAS amplification	BRAF inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only gene		COREAD
WP188	CBL MUT* (--), CBL MUT* (--)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP188	CBL MUT* (--), CBL MUT* (--)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR inhibitors	Non-small cell lung	Resistant	D	NO	PMID:19238210	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR mAb inhibitors	Stomach	Resistant	D	NO	PMID:22614881;PMID:22290393	only alteration type		ST
WP188	CDH1 MUT* (--)	CDH1 oncogenic mutation	Bicalutamide(AR inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:27397505	only alteration type		BRCA
WP188	MET MUT* (--)	MET amplification	EGFR inhibitor 1st gens	Non-small cell lung, Colorectal adenocarcinoma	Resistant	C	NO	PMID:22189054;PMID:23729478	only gene		NSCLC, COREAD
WP188	MET MUT* (--)	MET amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:23729478	only gene		COREAD
WP188	MET MUT* (--)	MET (D1246V)	MET inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:27694386	only alteration type		LUAD
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP188	ERBB3 MUT* (--)	ERBB3 (P262H,G284R)	ERBB3 mAb inhibitors	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP188	ERBB3 MUT* (--)	ERBB3 (P262H,G284R,Q809R)	PI3K pathway inhibitor + MEK inhibitors	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP188	ERBB3 MUT* (--)	ERBB3 (G284R,R103G)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	ASCO 2015 (abstr e15516)	only alteration type		BLCA
WP188	ERBB3 MUT* (--)	ERBB3 (G284R,V104M,R103G)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	PMID:27044931	only alteration type		BLCA
WP188	ERBB3 MUT* (--)	ERBB3 (P262H,G284R,Q809R)	Lapatinib(ERBB2 inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP188	ERBB3 MUT* (--)	ERBB3 (P262H,G284R)	Pertuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP188	ERBB3 MUT* (--)	ERBB3 (P262H,G284R,Q809R)	Trastuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
WP188	FANCA MUT* (L721I)	FANCA oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP188	FANCA MUT* (L721I)	FANCA deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only gene		PRAD
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP188	HDAC2 MUT* (--)	HDAC2 biallelic inactivation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP188	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP188	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	EZH2 inhibitors	Any cancer type	Resistant	D	YES	PMID:26552009	only alteration type		CANCER
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitors	Endometrium	Resistant	D	NO	PMID:22662154	only alteration type		ED
WP188	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP188	MDM2 MUT* (--)	MDM2 amplification	Cisplatin(Chemotherapy)	Male germ cell tumor	Resistant	C	NO	PMID:27646943	only gene		MGCT
WP188	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP188	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP188	KRAS MUT* (--)	KRAS (G12)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	C	NO	PMID:24687822	only alteration type		GIST
WP188	MET MUT* (--)	MET (Y1230C,Y1235D)	Crizotinib(ALK inhibitor)	Any cancer type	Resistant	D	YES	PMID:17483355	only alteration type		CANCER
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	Trastuzumab + Lapatinib(ERBB2 mAb inhibitor + ERBB2 inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	ASCO 2015 (abstr 3508);NCT01104571;EBCC10	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	BET inhibitors	Lung	Responsive	D	NO	PMID:23129625;PMID:24045185	only alteration type		L
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4 inhibitors	Lung	Responsive	D	NO	PMID:20609353	only alteration type		L
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Lung	Responsive	C	NO	AACR 2017 (CT046)	only alteration type		L
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Cervix squamous cell	Responsive	D	NO	PMID:27167191	only alteration type		CESC
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	EGFR mAb inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24553387	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	ERK inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23614898	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	FAK inhibitors	Lung	Responsive	D	NO	PMID:23358651	only alteration type		L
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	FAS inhibitors	Lung	Responsive	C	NO	AACR 2016;abstr	only alteration type		L
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	FAS inhibitors	Lung	Responsive	C	NO	AACR 2016, abstr LB214	only alteration type		L
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	HSP90 inhibitor(in combination)s	Lung	Responsive	D	NO	PMID:23012248;PMID:21907929	only alteration type		L
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	JAK/TBK1/IKKÎµ inhibitors	Lung	Responsive	D	NO	PMID:24444711	only alteration type		L
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + BCL-XL inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23245996	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + IGF1R inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24045180	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitor + PI3K pathway inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:22392911	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitors	Lung, Billiary tract	Responsive	C	NO	PMID:23200175;PMID:24947927;PMID:25667274;PMID:25722381;PMID:23391555	only alteration type		L, BT
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	MEK inhibitors	Acute myeloid leukemia, Cervix, Ovary	Responsive	D	YES	PMID:22507781;PMID:22169769;PMID:19018267	only alteration type		AML, CER, OV
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP188	KRAS MUT* (--)	KRAS (G12)	MEK inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:18701506	only alteration type		ALL
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	MTOR inhibitor + BH3 mimeticss	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24163374	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	pan-RAF inhibitors	Lung	Responsive	C	NO	AACR 2017 (abstr  CT002)	only alteration type		L
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	pan-RAF inhibitors	Endometrium	Responsive	C	NO	AACR 2016 (abstr CT005);AACR 2017 (abstr CT002)	only alteration type		ED
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Endometrium	Responsive	D	NO	PMID:21984976;PMID:22662154	only alteration type		ED
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Lung	Responsive	C	NO	PMID:25516890	only alteration type		L
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	Abemaciclib(CDK4/6 inhibitor)	Lung	Responsive	C	NO	PMID:27217383	only alteration type		L
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP188	MTOR MUT* (--)	MTOR (F2108L)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Resistant	C	NO	PMID:25295501	only alteration type		THCA
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP188	MDM2 MUT* (--)	MDM2 amplification	MDM2 inhibitors	Liposarcoma	Responsive	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	only gene		LIP
WP188	MET MUT* (--)	MET kinase domain mutation	Savolitinib(MET inhibitor)	Renal	Responsive	C	NO	PMID:28644771	only alteration type		R
WP188	MET MUT* (--)	MET amplification	BCL2 inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:27397505	only gene		COREAD
WP188	MET MUT* (--)	MET amplification	MET inhibitors	Hepatic carcinoma	Responsive	C	NO	ENA 2015 (abstract A55)	only gene		HC
WP188	MET MUT* (--)	MET amplification	MET inhibitors	Stomach	Responsive	D	NO	PMID:22729845;PMID:23327903	only gene		ST
WP188	MET MUT* (--)	MET amplification	MET inhibitors	Renal	Responsive	C	NO	PMID:23213094;AACR 2016 (abstr CT2006)	only gene		R
WP188	MET MUT* (--)	MET (H1112R)	MET inhibitors	Renal	Responsive	C	NO	PMID:23213094	only alteration type		R
WP188	MET MUT* (--)	MET (M1268T)	MET inhibitors	Renal	Responsive	C	NO	PMID:23610116	only alteration type		R
WP188	MET MUT* (--)	MET (H1112L)	MET inhibitors(Crizotinib,etc)	Any cancer type	Responsive	D	YES	AACR 2012 (abstr 1786)	only alteration type		CANCER
WP188	MET MUT* (--)	MET amplification	Cabozantinib + Panitumumab(Pan-kinase inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A52)	only gene		COREAD
WP188	MET MUT* (--)	MET fusion	Crizotinib(ALK inhibitor)	Glioma	Responsive	C	NO	PMID:27748748	only gene		G
WP188	MET MUT* (--)	MET mutation in exon 16-19	Crizotinib(ALK inhibitor)	Renal	Responsive	C	NO	AACR 2016 (abstr CT2006)	only alteration type		R
WP188	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma, Stomach	Responsive	C	NO	ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1)	only gene		LUAD, ST
WP188	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Glioma	Responsive	C	NO	PMID:22162573	only gene		G
WP188	MET MUT* (--)	MET (V1110I,H1112R,M1268T,R988C,T1010I)	Crizotinib(ALK inhibitor)	Any cancer type	Responsive	D	YES	PMID:17483355	only alteration type		CANCER
WP188	PLCG2 MUT* (--)	PLCG2 (R665W,L845F)	Ibrutinib(BTK inhibitor)	Chronic lymphocytic leukemia	Resistant	C	YES	PMID:24869598	only alteration type		CLL
WP188	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP188	MSH3 MUT* (--)	MSH3 oncogenic mutation	DNA-PKc inhibitors	Any cancer type	Responsive	D	YES	PMID:24556366	only alteration type		CANCER
WP188	MTOR MUT* (--)	MTOR (F2108L)	MTOR kinase inhibitors	Any cancer type	Responsive	D	YES	PMID:25295501	only alteration type		CANCER
WP188	MTOR MUT* (--)	MTOR (E2014K,E2419K,N1421D)	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:24625776	only alteration type		BLCA
WP188	MTOR MUT* (--)	MTOR (I1973F)	Everolimus(MTOR inhibitor)	Angiosarcoma, Renal	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		AS, R
WP188	MTOR MUT* (--)	MTOR (K1771R)	Everolimus(MTOR inhibitor)	Stomach, Adrenal gland	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		ST, AG
WP188	MTOR MUT* (--)	MTOR (N1421D)	Everolimus(MTOR inhibitor)	Stomach	Responsive	C	NO	PMID:26859683	only alteration type		ST
WP188	MTOR MUT* (--)	MTOR (Q2223K)	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468	only alteration type		R
WP188	MTOR MUT* (--)	MTOR (L1460P,S2215Y,R2505P)	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	D	YES	PMID:24631838	only alteration type		CANCER
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	Decitabine + BCL2 inhibitor(Chemotherapy + BCL2 inhibitor)	Ovary	Responsive	D	NO	PMID:25968887	only alteration type		OV
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP188	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP188	MET MUT* (--)	MET amplification	EGFR inhibitor 3rd gens(Osimertinib,etc)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	Gemcitabine + MEK inhibitor(Chemotherapy + MEK inhibitor)	Pancreas	Responsive	C	NO	PMID:23583440	only alteration type		PA
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	Selumetinib(MEK inhibitor)	Non-small cell lung	Responsive	C	NO	NCT00890825	only alteration type		NSCLC
WP188	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP188	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP188	NOTCH1 MUT* (--)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP188	NOTCH1 MUT* (--)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP188	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP188	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP188	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP188	NOTCH1 MUT* (--)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	only alteration type		MCL
WP188	NOTCH1 MUT* (--)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP188	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP188	NOTCH1 MUT* (--)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP188	NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP188	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP188	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP188	PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP188	PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP188	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP188	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP188	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP188	MET MUT* (--)	MET amplification	EGFR inhibitor 3rd gens(Rociletinib,etc)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	Sorafenib + MEK inhibitor(Pan-TK inhibitor + MEK inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:25294897	only alteration type		HC
WP188	PTCH1 (F573L)	PTCH1 oncogenic mutation	SMO inhibitors	Medulloblastoma	Responsive	D	NO	PMID:24651015	complete		MB
WP188	PTCH1 (F573L)	PTCH1 oncogenic mutation	Foretinib(MET inhibitor)	Medulloblastoma	Responsive	D	NO	PMID:25391241	complete		MB
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP188	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP188	RICTOR MUT* (--)	RICTOR amplification	MTORC1/2 inhibitors	Lung	Responsive	C	NO	PMID:26370156	only gene		L
WP188	KRAS MUT* (--)	KRAS oncogenic mutation	Trametinib + Ponatinib(MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27338794	only alteration type		LUAD
WP188	STAG2 MUT* (--)	STAG2 oncogenic mutation	PARP inhibitors	Glioma	Responsive	D	NO	PMID:24356817	only alteration type		G
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP188	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP188	TSC2 (A807D)	TSC2 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	complete		RA
WP188	TSC2 (A807D)	TSC2 oncogenic mutation	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	complete		LAM
WP188	TSC2 (A807D)	TSC2 deletion	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	only gene		LAM
WP188	TSC2 (A807D)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	complete		BLCA
WP188	TSC2 (A807D)	TSC2 (Q1178*)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:25295501	only alteration type		THCA
WP188	TSC2 (A807D)	TSC2 (E66K)	Tensirolimus(MTOR inhibitor)	Endometrium	Responsive	C	NO	PMID:27016228	only alteration type		ED
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 (G1738R,A1708V,C47G,V1696L,Y1853C,D1739V,F1761I,H1746N,C24Y,K1702E,P1749R,M1775R,W1837C,M1775E,V1736G,V1838E,C44F,A1752V,D1739E,S1715N,.,A1789T,S1164I,T1685A,A1752P,H1686R,H41R,C64G,W1718L,D1692H,V1713A,R1699W,V1653M,Q1756C,C61G,D1739Y,G1770V,V1714G,V1833M,R1835P,R1699Q,G1706E,P1812A,E1836K,C44Y,G1788D,C39Y,M1R,S1715R,Y1703H,F1761S,E33A,M1628V,W1837G,L1705P,M1689R,G1738E,R1751P,V1809F,S1841N,S1722F,I1766S,S1655F,G1788V,L1780P,V1833E,A1708E,E1660G,C27A,Y1703S,I1807S,T1700A,A1843T,F1734L,V1741G,V1810G,F1704S,G1656D,T1685I,L1854P,Q1811R,M18T,C1697R,G1803A,G1743R,G1763V,C24R,T37R,T1773I,D1739G,W1718C,H1686Q,T1691I,L1407P,K1487R,M1652K,S1841R,M1775K,S1841A,F1734S,V1736A,M1689T,W1815X,L1764P,W1837R,T1691K,R1753T,D1692Y,W1718S,L1657P,A1843P,S1715C,R1699L)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/6/summary|oncokb=https://www.oncokb.org/gene/BRCA1	only alteration type		OV
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only gene		OV
WP188	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
WP188	BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
WP188	MDM2 MUT* (--)	MDM2 amplification	Unii-Q8Mi0X869M	Liposarcoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MDM2	only gene		LIP
WP188	MTOR MUT* (--)	MTOR (L2209V,L1460P,L2427Q)	Temsirolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
WP188	MTOR MUT* (--)	MTOR (Q2223K)	Everolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
WP188	MET MUT* (--)	MET amplification	Crizotinib	Non-small cell lung	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/52/summary|oncokb=https://www.oncokb.org/gene/MET	only gene		NSCLC
WP188	MET MUT* (--)	MET (D1010H,Y1003N,D1010N,Y1003F,Y1003C,D1010Y)	Crizotinib	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 (G1738R,A1708V,C47G,V1696L,Y1853C,D1739V,F1761I,H1746N,C24Y,K1702E,P1749R,M1775R,W1837C,M1775E,V1736G,V1838E,C44F,A1752V,D1739E,S1715N,.,A1789T,S1164I,T1685A,A1752P,H1686R,H41R,C64G,W1718L,D1692H,V1713A,R1699W,V1653M,Q1756C,C61G,D1739Y,G1770V,V1714G,V1833M,R1835P,R1699Q,G1706E,P1812A,E1836K,C44Y,G1788D,C39Y,M1R,S1715R,Y1703H,F1761S,E33A,M1628V,W1837G,L1705P,M1689R,G1738E,R1751P,V1809F,S1841N,S1722F,I1766S,S1655F,G1788V,L1780P,V1833E,A1708E,E1660G,C27A,Y1703S,I1807S,T1700A,A1843T,F1734L,V1741G,V1810G,F1704S,G1656D,T1685I,L1854P,Q1811R,M18T,C1697R,G1803A,G1743R,G1763V,C24R,T37R,T1773I,D1739G,W1718C,H1686Q,T1691I,L1407P,K1487R,M1652K,S1841R,M1775K,S1841A,F1734S,V1736A,M1689T,L1764P,W1837R,T1691K,R1753T,D1692Y,W1718S,L1657P,A1843P,S1715C,R1699L)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only alteration type		BRCA
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only gene		BRCA
WP188	MTOR MUT* (--)	MTOR (E2419K,E2014K)	Everolimus	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		BLCA
WP188	MTOR MUT* (--)	MTOR (E2419K,C1483F,L2172M,K1452N,L2230V,L2427Q,L2431P,F1888I,E1799K,L2216P,W1456R,C1483W,A1519T,L1460P,A2210P,T2232I,R2505P,M2327I,C1483R,V2006I,A1428T,Y1463S,I2500M,A1459P,F1888L,S2231W,T1977R,V2006F,T1977K,A2226S,I2500F,L2427R,T1977I,S2215F,.,Q2223K,I1973F,L1433S,F1888V,S2215T,D2512H,E2014K,S2215Y,R2217W,L2209V,V2006L,L2220F,L2427P,S2215P,P2273S,E2288K,C1483Y)	Temsirolimus + Everolimus	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		CANCER
WP188	MET MUT* (--)	MET (D1010H,Y1003N,D1010N,Y1003F,Y1003C,D1010Y)	Cabozantinib + Capmatinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP188	TSC2 (A807D)	TSC2 (S1653P,Q1503P,R905G,L830R,A889P,L146R,T1203K,V1673F,W1610G,V769E,C696Y,F615S,E75G,L448P,V299G,R611W,R1200W,R505Q,Q1554H,G1567D,G1596V,Y1571N,I427M,S1498N,L1584R,P1709L,L844R,V705E,R905Q,Y598C,L410R,R462C,R611Q,R905W,A614D,.,S1653F,P1675L,H1620R,S1036P,H597Y,L493P,T1623I,V1673D,V705M,L826P,L792R,A328P,L493V)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	complete		RCCC
WP188	TSC2 (A807D)	TSC2 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	only gene		RCCC
WP188	KRAS MUT* (--)	KRAS (D119N,G12F,F156L,G60R,F28L,A18D,Q22K,K147E,D33E,A146T,E62K,A146V,Q61R,Q61H,G12A,G12R,G13E,Q22R,V14I,Y71H,G13D,G12C,T58I,.,D153V,A59G,K117N,S65N,P34L,Y64A,G13V,K5N,Y32S,L19F,T74P,G13C,G12V,G12D,Q22E,Q61L,G12S,P34R)	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/30/summary|oncokb=https://www.oncokb.org/gene/KRAS	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS amplification	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only gene		COREAD
WP188	KRAS MUT* (--)	KRAS (D119N,G12F,F156L,G60R,F28L,A18D,Q22K,K147E,D33E,A146T,E62K,A146V,Q61R,Q61H,G12A,G12R,G13E,Q22R,V14I,Y71H,G13D,G12C,T58I,.,D153V,A59G,K117N,S65N,P34L,Y64A,K5N,Y32S,L19F,T74P,G13C,G12V,G12D,Q22E,Q61L,G12S,P34R)	Cobimetinib + Binimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only alteration type		CANCER
WP188	KRAS MUT* (--)	KRAS amplification	Cobimetinib + Binimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only gene		CANCER
WP188	MET MUT* (--)	MET amplification	Erlotinib + Gefitinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only gene		NSCLC
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP188	NF1 MUT* (--), NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP188	MET MUT* (--)	MET (D1228N)	Crizotinib + Cabozantinib + Capmatinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP188	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
WP188	BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
WP188	MET MUT* (--)	MET amplification	Cabozantinib	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only gene		RCCC
WP188	MET MUT* (--)	MET (Y1230H)	Crizotinib + Capmatinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP188	BARD1 MUT* (--)	BARD1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11209	only alteration type		PRAD
WP188	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/1897	only alteration type		OV
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 Mutation	Olaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/7275	only alteration type		OV
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11136	only alteration type		OV
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11203	only alteration type		PRAD
WP188	BRCA1 MUT* (--), BRCA1 MUT* (--)	BRCA1 Q1467*	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2878	only alteration type		OV
WP188	BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
WP188	BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
WP188	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
WP188	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
WP188	BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
WP188	BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
WP188	BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
WP188	BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
WP188	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP188	ERBB3 MUT* (--)	ERBB3 V855A	Pertuzumab,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1845	only alteration type		NSCLC
WP188	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP188	KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (S806), KMT2C MUT* (S768), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP188	KRAS MUT* (--)	KRAS A146	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3939	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS A146P	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2225	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS A146T	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2943	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS A146T	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3858	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS A146T	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2206	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS A146V	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2209	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS A146V	Abemaciclib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/794	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS G12/G13	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/134	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12/G13	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/135	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12/G13	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2004	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12/G13	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6293	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12/G13	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6294	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12/G13	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6295	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12/G13	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6296	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12/G13	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6363	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12/G13	Gefitinib,Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/35	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS G12/G13	Trametinib,Gemcitabine	Pancreas adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/622	only alteration type		PAAD
WP188	KRAS MUT* (--)	KRAS G12/G13	Trametinib	Pancreas adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/990	only alteration type		PAAD
WP188	KRAS MUT* (--)	KRAS G12A	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3710	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12A	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4429	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12A	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6319	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12A	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/251	only alteration type		LUAD
WP188	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2009	only alteration type		MM
WP188	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2012	only alteration type		MM
WP188	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2013	only alteration type		MM
WP188	KRAS MUT* (--)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2014	only alteration type		MM
WP188	KRAS MUT* (--)	KRAS G12C	Gefitinib,Erlotinib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1216	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12C	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2253	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12C	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3967	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12C	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3973	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12C	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2212	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2258	only alteration type		MM
WP188	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2261	only alteration type		MM
WP188	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2262	only alteration type		MM
WP188	KRAS MUT* (--)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2263	only alteration type		MM
WP188	KRAS MUT* (--)	KRAS G12C	Docetaxel,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1142	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS G12C	Sotorasib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/9431	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS G12D	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3957	only alteration type		CM
WP188	KRAS MUT* (--)	KRAS G12D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2193	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2207	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2236	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12D	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3946	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12D	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6316	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12D	Therapeutic Tumor Infiltrating Lymphocytes	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1898	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12D	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2218	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12D	Vemurafenib	Hairy-Cell leukemia	Resistant	C	YES	https://civicdb.org/links/evidence_items/1580	only alteration type		HCL
WP188	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2247	only alteration type		MM
WP188	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2250	only alteration type		MM
WP188	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2251	only alteration type		MM
WP188	KRAS MUT* (--)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2252	only alteration type		MM
WP188	KRAS MUT* (--)	KRAS G12D	Dabrafenib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/91	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS G12D	Selumetinib,Dactolisib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/305	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS G12D	Cetuximab	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/3958	only alteration type		OV
WP188	KRAS MUT* (--)	KRAS G12R	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2264	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12R	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3987	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12R	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3989	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12R	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3991	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12S	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2269	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12S	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4006	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12S	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4012	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12S	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6314	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2274	only alteration type		MM
WP188	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2277	only alteration type		MM
WP188	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2278	only alteration type		MM
WP188	KRAS MUT* (--)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2279	only alteration type		MM
WP188	KRAS MUT* (--)	KRAS G12V	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/136	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12V	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2219	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12V	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2232	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12V	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3824	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12V	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3924	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12V	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6323	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12V	Dactolisib,Selumetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2001	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G12V	Palbociclib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/795	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS G12V	Selumetinib,Docetaxel	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1143	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS G13D	Pictilisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2041	only alteration type		BRCA
WP188	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/806	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1180	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1181	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G13D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2178	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3878	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3881	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3882	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G13D	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3889	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G13D	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6320	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G13D	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6322	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/145	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/306	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G13D	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2183	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS G13V	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6312	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Mutation	Vemurafenib,Dabrafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6264	only alteration type		CM
WP188	KRAS MUT* (--)	KRAS Mutation	Bevacizumab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1139	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Mutation	Ixazomib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1182	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1702	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3704	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	A	NO	https://civicdb.org/links/evidence_items/5345	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Mutation	Immunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/943	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Mutation	Cetuximab,Dasatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/947	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Mutation	B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/988	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Mutation	Trametinib,Afatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/991	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Mutation	MEK Inhibitor RO4987655	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/998	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Mutation	Refametinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1001	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Mutation	Selumetinib,Teprotumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1004	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Mutation	Selumetinib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4866	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Mutation	Palbociclib,Binimetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4869	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Mutation	Temsirolimus,Ridaforolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/894	only alteration type		ED
WP188	KRAS MUT* (--)	KRAS Mutation	Sorafenib,Refametinib	Hepatic carcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1642	only alteration type		HC
WP188	KRAS MUT* (--)	KRAS Mutation	Salirasib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1218	only alteration type		LUAD
WP188	KRAS MUT* (--)	KRAS Mutation	MEK Inhibitor RO4987655	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/997	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2242	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Gefitinib,Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2385	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Selumetinib	Non-small cell lung	Resistant	A	NO	https://civicdb.org/links/evidence_items/2998	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/3895	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/989	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Trametinib,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/992	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/999	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1220	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Erlotinib,Teprotumumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3713	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Abemaciclib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4842	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Pemetrexed,Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4862	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Nivolumab,Atezolizumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4863	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4867	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Erlotinib,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4868	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Docetaxel,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4996	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Docetaxel	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4997	only alteration type		NSCLC
WP188	KRAS MUT* (--)	KRAS Mutation	Decitabine	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/820	only alteration type		OV
WP188	KRAS MUT* (--)	KRAS Mutation	PI3Kbeta Inhibitor AZD8186,SCH772984	Pancreas adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1003	only alteration type		PAAD
WP188	KRAS MUT* (--)	KRAS Q61	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3917	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Q61H	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3861	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Q61H	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3862	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Q61K	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3872	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Q61L	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3867	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Q61R	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3870	only alteration type		COREAD
WP188	KRAS MUT* (--)	KRAS Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6317	only gene		CM
WP188	MET MUT* (--)	MET D1228N	Crizotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1652	only alteration type		NSCLC
WP188	MET MUT* (--)	MET D1228V	Savolitinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1865	only alteration type		NSCLC
WP188	MET MUT* (--)	MET D1228V	Cabozantinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1864	only alteration type		NSCLC
WP188	MET MUT* (--)	MET MET::ATXN7L1	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7793	only gene		NSCLC
WP188	MET MUT* (--)	MET Amplification	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1971	only gene		COREAD
WP188	MET MUT* (--)	MET Amplification	Vemurafenib,Crizotinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1588	only gene		COREAD
WP188	MET MUT* (--)	MET Amplification	Crizotinib,Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1979	only gene		COREAD
WP188	MET MUT* (--)	MET Amplification	Crizotinib	Glioblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1565	only gene		GB
WP188	MET MUT* (--)	MET Amplification	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1392	only gene		LUAD
WP188	MET MUT* (--)	MET Amplification	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/836	only gene		LUAD
WP188	MET MUT* (--)	MET Amplification	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1692	only gene		LUAD
WP188	MET MUT* (--)	MET Amplification	Crizotinib	Lung squamous cell	Responsive	C	NO	https://civicdb.org/links/evidence_items/890	only gene		LUSC
WP188	MET MUT* (--)	MET Amplification	Gefitinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/733	only gene		NSCLC
WP188	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/735	only gene		NSCLC
WP188	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1566	only gene		NSCLC
WP188	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1713	only gene		NSCLC
WP188	MET MUT* (--)	MET Amplification	Onartuzumab	Stomach	Responsive	C	NO	https://civicdb.org/links/evidence_items/689	only gene		ST
WP188	MRE11 MUT* (--), MRE11 MUT* (--)	MRE11 Loss	Talazoparib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/876	only gene		ED
WP188	MTOR MUT* (--)	MTOR A2034V	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1547	only alteration type		BRCA
WP188	MTOR MUT* (--)	MTOR A2034V	RapaLink-1,MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1548	only alteration type		BRCA
WP188	MTOR MUT* (--)	MTOR E1799K	Sirolimus	Renal clear cell	Responsive	D	NO	https://civicdb.org/links/evidence_items/1321	only alteration type		RCCC
WP188	MTOR MUT* (--)	MTOR F2108L	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1543	only alteration type		BRCA
WP188	MTOR MUT* (--)	MTOR F2108L	Everolimus	Thyroid carcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1110	only alteration type		THCA
WP188	MTOR MUT* (--)	MTOR H1968Y	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/713	only alteration type		CM
WP188	MTOR MUT* (--)	MTOR M2327I	MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1544	only alteration type		BRCA
WP188	MTOR MUT* (--)	MTOR M2327I	Sirolimus,RapaLink-1	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1545	only alteration type		BRCA
WP188	MTOR MUT* (--)	MTOR Mutation	Everolimus,Pazopanib	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/705	only alteration type		BLCA
WP188	MTOR MUT* (--)	MTOR P2213S	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/722	only alteration type		CM
WP188	NOTCH1 MUT* (--)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP188	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP188	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP188	RICTOR MUT* (--)	RICTOR Amplification	Onatasertib,Sapanisertib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1440	only gene		LUAD
WP188	RICTOR MUT* (--)	RICTOR Amplification	Vistusertib	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7449	only gene		SCLC
WP188	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP188	TLK2 MUT* (--)	TLK2 Amplification	Go6983,GF109203X	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6000	only gene		BRCA
WP188	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP188	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP188	TSC2 (A807D)	TSC2 Q1178*	Everolimus	Thyroid carcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1108	only alteration type		THCA
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890	only alteration type		PRAD
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP196	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Myelofibrosis	Responsive	A	YES	FDA	complete		MY
WP196	RET MUT* (--)	RET (618,620,634,768,791,891,918,C634W,M918T)	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	A	NO	PMID:20065189;PMID:22025146	only alteration type		THCA
WP196	TPMT MUT* (--)	TPMT splice acceptor variant	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP196	TPMT MUT* (--)	TPMT biallelic inactivation	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP196	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP196	TPMT MUT* (--)	TPMT splice acceptor variant	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP196	TPMT MUT* (--)	TPMT biallelic inactivation	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP196	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP196	TPMT MUT* (--)	TPMT splice acceptor variant	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP196	TPMT MUT* (--)	TPMT biallelic inactivation	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP196	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP196	TSC2 (R751*)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    , Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	complete		RA, GCA
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP196	RET MUT* (--)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-ret-altered-thyroid-cancers;ASCO 2020 (abstr 109)	only gene		TH
WP196	RET MUT* (--)	RET oncogenic mutation	Selpercatinib(RET kinase inhibitor)	Thyroid medullary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only alteration type		THM
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP196	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP196	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP196	RET MUT* (--)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions	only gene		NSCLC
WP196	RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-non-small-cell-lung	only gene		NSCLC
WP196	RAD51C MUT* (G153)	RAD51C oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP196	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Bevacizumab(VEGF mAb inhibitor);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP196	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP196	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Pembrolizumab(PD-1-blocking antibody);Pemetrexed(Chemotherapy);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf	complete		NSCLC
WP196	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Durvalumab(PD-1-blocking antibody);Tremelimumab-actl(CTLA-4 blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non	complete		NSCLC
WP196	RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only gene		TH
WP196	RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Solid tumors	Responsive	A	NO	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors	only gene		SOLID
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP196	ATR MUT* (--)	ATR oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP196	RAD51C MUT* (G153)	RAD51C oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP196	EGFR wildtype, ALK wildtype, ROS1 wildtype	EGFR wildtype;ALK wildtype;ROS1 wildtype	Cemiplimab-rwlc(PD-1-blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-combination-platinum-based-chemotherapy-non-small-cell-lung-cancer	complete		NSCLC
WP196	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP196	RET MUT* (--)	RET fusion	Cabozantinib(Kinase inhibitor )	Non-small cell lung	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP196	B2M MUT* (--)	B2M oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	only alteration type		CM
WP196	AKT2 MUT* (--)	AKT2 amplification	MK2206(Allosteric AKT inhibitor)	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 373)	only gene		CANCER
WP196	CTNNB1 MUT* (--), CTNNB1 MUT* (--)	CTNNB1 oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Resistant	D	NO	PMID:23539443	only alteration type		COREAD
WP196	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	complete		CANCER
WP196	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	complete		OV
WP196	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	complete		CANCER
WP196	ATR MUT* (--)	ATR oncogenic mutation	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only alteration type		OV, CANCER
WP196	ATR MUT* (--)	ATR deletion	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only gene		OV, CANCER
WP196	ATR MUT* (--)	ATR oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP196	JAK2 (V617F)	JAK2 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	complete		CM
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	PARP inhibitors	Pancreas	Responsive	C	NO	PMID:25366685;PMID:25719666;PMID:19553641;PMID:25366685	only alteration type		PA
WP196	BRCA1 MUT* (--)	BRCA1 deletion	PARP inhibitors	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	C	YES	PMID:25964244	only alteration type		CANCER
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467;PMID:25366685	only alteration type		BRCA
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP196	BRCA1 MUT* (--)	BRCA1 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP196	CTNNB1 MUT* (--), CTNNB1 MUT* (--)	CTNNB1 (H36Y,S37C,S37Y,D32V)	Everolimus + Letrozole(MTOR inhibitor + Hormonal therapy)	Endometrium	Responsive	C	NO	PMID:25624430	only alteration type		ED
WP196	MYCN MUT* (--)	MYCN amplification	SMO inhibitors	Medulloblastoma	Resistant	D	NO	PMID:24951114	only gene		MB
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP196	NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP196	STK11 MUT* (M51L), STK11 MUT* (--)	STK11 oncogenic mutation	BET inhibitors	Lung	Resistant	D	NO	PMID:23129625;PMID:24045185	only alteration type		L
WP196	ERCC2 MUT* (--)	ERCC2 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:25096233	only alteration type		BLCA
WP196	FGFR4 MUT* (--), FGFR4 (C714R)	FGFR4 (N535,V550)	FGFR inhibitors	Rhabdomyosarcoma	Responsive	D	NO	PMID:19809159;PMID:24124571	only alteration type		RHBDS
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP196	NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP196	GNAQ MUT* (T96S)	GNAQ (Q209)	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	NCT01587352	only alteration type		CM
WP196	GNAQ MUT* (T96S)	GNAQ (Q209)	PI3K pathway inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22733540;PMID:22808163	only alteration type		CM
WP196	GNAQ MUT* (T96S)	GNAQ (Q209)	PKC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22653968;PMID:22253748	only alteration type		CM
WP196	GNAQ MUT* (T96S)	GNAQ (Q209)	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr CRA9003)	only alteration type		CM
WP196	HDAC2 MUT* (--)	HDAC2 biallelic inactivation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP196	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP196	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP196	JAK2 (V617F)	JAK2 (V617F)	JAK inhibitor(alone or in combination)s	Acute myeloid leukemia	Responsive	D	YES	PMID:22829971	complete		AML
WP196	JAK2 (V617F)	JAK2 amplification	JAK inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27075627	only gene		BRCA
WP196	JAK2 (V617F)	JAK2-BRAF fusion	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22875628;PMID:22899477	only gene		ALL
WP196	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:22422826	complete		AML
WP196	JAK3 (S1029I), JAK3 MUT* (--)	JAK3 (A572V,A573V)	JAK inhibitors	Lymphoma	Responsive	D	YES	PMID:22705984	only alteration type		LY
WP196	JAK3 (S1029I), JAK3 MUT* (--)	JAK3 (R657Q,I87T,Q501H)	JAK inhibitors	Megakaryoblastic leukemia	Responsive	D	YES	PMID:18397343	only alteration type		MKB
WP196	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP196	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP196	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP196	NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP196	NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP196	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP196	NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP196	NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP196	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP196	NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP196	NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP196	NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP196	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP196	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP196	NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP196	NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP196	NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP196	NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP196	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP196	NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP196	NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP196	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP196	LRP1B (--)	LRP1B oncogenic mutation	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	complete		OV
WP196	LRP1B (--)	LRP1B deletion	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only gene		OV
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP196	NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP196	NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP196	NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP196	NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP196	NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP196	NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP196	NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP196	NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP196	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP196	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP196	NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP196	NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP196	NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP196	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP196	NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP196	PBRM1 MUT* (--), PBRM1 MUT* (--), PBRM1 MUT* (--), PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP196	PBRM1 MUT* (--), PBRM1 MUT* (--), PBRM1 MUT* (--), PBRM1 MUT* (--), PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP196	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP196	RET MUT* (--)	RET (I788N)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Resistant	D	NO	PMID:28615362	only alteration type		LUAD
WP196	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP196	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP196	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	AKT inhibitors	Glioma	Responsive	D	NO	PMID:23166678	only alteration type		G
WP196	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	PI3K pathway inhibitors	Endometrium	Responsive	C	NO	ASCO 2015 (abstr 11075)	only alteration type		ED
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP196	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP196	NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP196	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP196	RAD51C MUT* (G153)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
WP196	RAD51C MUT* (G153)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
WP196	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP196	RB1 MUT* (--)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
WP196	RB1 MUT* (--)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
WP196	RB1 MUT* (--)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
WP196	RB1 MUT* (--)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
WP196	RB1 MUT* (--)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP196	RB1 MUT* (--)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP196	RET MUT* (--)	RET fusion	RET inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:22327624;PMID:22327622	only gene		LUAD
WP196	RET MUT* (--)	RET-TPCN1 fusion	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only gene		TH
WP196	RET MUT* (--)	RET (C634W,M918T)	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only alteration type		TH
WP196	RET MUT* (--)	RET fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP196	RET MUT* (--)	RET-TPCN1 fusion	Cabozantinib(Pan-kinase inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP196	RET MUT* (--)	RET (C634W,M918T)	Cabozantinib(Pan-kinase inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP196	RET MUT* (--)	RET fusion	Nintedanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26787234	only gene		LUAD
WP196	RET MUT* (--)	RET fusion	Sunitinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP196	RET MUT* (--)	RET-TPCN1 fusion	Sunitinib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP196	RET MUT* (--)	RET (C634W,M918T)	Sunitinib(Pan-TK inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP196	RET MUT* (--)	RET fusion	Vandetanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP196	RET MUT* (--)	RET-TPCN1 fusion	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP196	RICTOR MUT* (--)	RICTOR amplification	MTORC1/2 inhibitors	Lung	Responsive	C	NO	PMID:26370156	only gene		L
WP196	SETD2 MUT* (--), SETD2 MUT* (--)	SETD2 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only alteration type		CANCER
WP196	SETD2 MUT* (--), SETD2 MUT* (--)	SETD2 deletion	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only gene		CANCER
WP196	SF3B1 (E622D)	SF3B1 (K700E,K666N)	Spliceosome inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858	only alteration type		CANCER
WP196	SH2B3 MUT* (G109A)	SH2B3 oncogenic mutation	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:20404132	only alteration type		MDPS
WP196	SH2B3 MUT* (G109A)	SH2B3 deletion	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:20404132	only gene		MDPS
WP196	STAG2 MUT* (--)	STAG2 oncogenic mutation	PARP inhibitors	Glioma	Responsive	D	NO	PMID:24356817	only alteration type		G
WP196	STK11 MUT* (M51L), STK11 MUT* (--)	STK11 oncogenic mutation	MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:19165201	only alteration type		LUAD
WP196	STK11 MUT* (M51L), STK11 MUT* (--)	STK11 deletion	MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:19165201	only gene		LUAD
WP196	STK11 MUT* (M51L), STK11 MUT* (--)	STK11 oncogenic mutation	MTOR inhibitors	Any cancer type	Responsive	D	YES	PMID:19541609	only alteration type		CANCER
WP196	STK11 MUT* (M51L), STK11 MUT* (--)	STK11 deletion	MTOR inhibitors	Any cancer type	Responsive	D	YES	PMID:19541609	only gene		CANCER
WP196	STK11 MUT* (M51L), STK11 MUT* (--)	STK11 oncogenic mutation	SRC inhibitor + PI3K/MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:20541700	only alteration type		LUAD
WP196	STK11 MUT* (M51L), STK11 MUT* (--)	STK11 deletion	SRC inhibitor + PI3K/MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:20541700	only gene		LUAD
WP196	STK11 MUT* (M51L), STK11 MUT* (--)	STK11 (D194E)	Everolimus(MTOR inhibitor)	Pancreas	Responsive	C	NO	PMID:21189378	only alteration type		PA
WP196	STK11 MUT* (M51L), STK11 MUT* (--)	STK11 oncogenic mutation	Phenformin(Anti-diabetic)	Lung adenocarcinoma	Responsive	D	NO	PMID:23352126	only alteration type		LUAD
WP196	STK11 MUT* (M51L), STK11 MUT* (--)	STK11 deletion	Phenformin(Anti-diabetic)	Lung adenocarcinoma	Responsive	D	NO	PMID:23352126	only gene		LUAD
WP196	NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP196	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP196	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP196	TSC2 (R751*)	TSC2 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	complete		RA
WP196	TSC2 (R751*)	TSC2 oncogenic mutation	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	complete		LAM
WP196	TSC2 MUT* (--), TSC2 (R751*)	TSC2 deletion	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	only gene		LAM
WP196	TSC2 (R751*)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	complete		BLCA
WP196	TSC2 MUT* (--), TSC2 (R751*)	TSC2 (Q1178*)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:25295501	only alteration type		THCA
WP196	TSC2 MUT* (--), TSC2 (R751*)	TSC2 (E66K)	Tensirolimus(MTOR inhibitor)	Endometrium	Responsive	C	NO	PMID:27016228	only alteration type		ED
WP196	BRCA1 MUT* (--)	BRCA1 (G1738R,A1708V,C47G,V1696L,Y1853C,D1739V,F1761I,H1746N,C24Y,K1702E,P1749R,M1775R,W1837C,M1775E,V1736G,V1838E,C44F,A1752V,D1739E,S1715N,.,A1789T,S1164I,T1685A,A1752P,H1686R,H41R,C64G,W1718L,D1692H,V1713A,R1699W,V1653M,Q1756C,C61G,D1739Y,G1770V,V1714G,V1833M,R1835P,R1699Q,G1706E,P1812A,E1836K,C44Y,G1788D,C39Y,M1R,S1715R,Y1703H,F1761S,E33A,M1628V,W1837G,L1705P,M1689R,G1738E,R1751P,V1809F,S1841N,S1722F,I1766S,S1655F,G1788V,L1780P,V1833E,A1708E,E1660G,C27A,Y1703S,I1807S,T1700A,A1843T,F1734L,V1741G,V1810G,F1704S,G1656D,T1685I,L1854P,Q1811R,M18T,C1697R,G1803A,G1743R,G1763V,C24R,T37R,T1773I,D1739G,W1718C,H1686Q,T1691I,L1407P,K1487R,M1652K,S1841R,M1775K,S1841A,F1734S,V1736A,M1689T,W1815X,L1764P,W1837R,T1691K,R1753T,D1692Y,W1718S,L1657P,A1843P,S1715C,R1699L)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/6/summary|oncokb=https://www.oncokb.org/gene/BRCA1	only alteration type		OV
WP196	BRCA1 MUT* (--)	BRCA1 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only gene		OV
WP196	ERCC2 MUT* (--)	ERCC2 (G665A,P463L,R601Q,A717G,D423N,R487W,E606G,R631C,V242F,V536M,.,L461V,D609E,Y24C,D513Y,D609G,N238S)	Cisplatin	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERCC2	only alteration type		BLCA
WP196	BRCA1 MUT* (--)	BRCA1 (G1738R,A1708V,C47G,V1696L,Y1853C,D1739V,F1761I,H1746N,C24Y,K1702E,P1749R,M1775R,W1837C,M1775E,V1736G,V1838E,C44F,A1752V,D1739E,S1715N,.,A1789T,S1164I,T1685A,A1752P,H1686R,H41R,C64G,W1718L,D1692H,V1713A,R1699W,V1653M,Q1756C,C61G,D1739Y,G1770V,V1714G,V1833M,R1835P,R1699Q,G1706E,P1812A,E1836K,C44Y,G1788D,C39Y,M1R,S1715R,Y1703H,F1761S,E33A,M1628V,W1837G,L1705P,M1689R,G1738E,R1751P,V1809F,S1841N,S1722F,I1766S,S1655F,G1788V,L1780P,V1833E,A1708E,E1660G,C27A,Y1703S,I1807S,T1700A,A1843T,F1734L,V1741G,V1810G,F1704S,G1656D,T1685I,L1854P,Q1811R,M18T,C1697R,G1803A,G1743R,G1763V,C24R,T37R,T1773I,D1739G,W1718C,H1686Q,T1691I,L1407P,K1487R,M1652K,S1841R,M1775K,S1841A,F1734S,V1736A,M1689T,L1764P,W1837R,T1691K,R1753T,D1692Y,W1718S,L1657P,A1843P,S1715C,R1699L)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only alteration type		BRCA
WP196	BRCA1 MUT* (--)	BRCA1 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA1	only gene		BRCA
WP196	TSC2 (R751*)	TSC2 (S1653P,Q1503P,R905G,L830R,A889P,L146R,T1203K,V1673F,W1610G,V769E,C696Y,F615S,E75G,L448P,V299G,R611W,R1200W,R505Q,Q1554H,G1567D,G1596V,Y1571N,I427M,S1498N,L1584R,P1709L,L844R,V705E,R905Q,Y598C,L410R,R462C,R611Q,R905W,A614D,.,S1653F,P1675L,H1620R,S1036P,H597Y,L493P,T1623I,V1673D,V705M,L826P,L792R,A328P,L493V)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	complete		RCCC
WP196	TSC2 MUT* (--), TSC2 (R751*)	TSC2 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	only gene		RCCC
WP196	NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP196	NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP196	JAK2 (V617F)	JAK2-PCM1 fusion	Ruxolitinib	Eosinophilic chronic leukemia	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/JAK2	only gene		ECL
WP196	RET MUT* (--)	RET fusion	Cabozantinib + Vandetanib + Larotrectinib + 292 + 667	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		NSCLC
WP196	RET MUT* (--)	RET (C618R,C620R,C609Y,E768D,C630R,S904F,E511K,C634S,C634Y,V648I,I852M,S891A,A883T,A883F,C611Y,T338I,C634W,K603Q,D631Y,M918T,A919V,R833C,.,V804M,C634R,V804L,Y806C,M918V,L790F,M848T,R886W,Y791F)	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only alteration type		THM
WP196	RET MUT* (--)	RET fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP196	RET MUT* (--)	RET-KIF5B fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP196	RET MUT* (--)	RET-CCDC6 fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP196	AKT2 MUT* (--)	AKT2 Amplification	Everolimus,Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1621	only gene		LUAD
WP196	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP196	BRCA1 MUT* (--)	BRCA1 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/1897	only alteration type		OV
WP196	BRCA1 MUT* (--)	BRCA1 Mutation	Olaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/7275	only alteration type		OV
WP196	BRCA1 MUT* (--)	BRCA1 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11136	only alteration type		OV
WP196	BRCA1 MUT* (--)	BRCA1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11203	only alteration type		PRAD
WP196	BRCA1 MUT* (--)	BRCA1 Q1467*	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2878	only alteration type		OV
WP196	CEBPA MUT* (PP188-189P)	CEBPA Mutation	Tretinoin	Acute myeloid leukemia	Responsive	B	YES	https://civicdb.org/links/evidence_items/122	only alteration type		AML
WP196	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP196	GNAQ MUT* (T96S)	GNAQ Mutation	JQ1	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1210	only alteration type		UVM
WP196	GNAQ MUT* (T96S)	GNAQ Mutation	Trametinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1229	only alteration type		UVM
WP196	GNAQ MUT* (T96S)	GNAQ Mutation	Mirdametinib,Sotrastaurin Acetate	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1953	only alteration type		UVM
WP196	GNAQ MUT* (T96S)	GNAQ Mutation	Cabozantinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5068	only alteration type		UVM
WP196	GNAQ MUT* (T96S)	GNAQ Q209	Selumetinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1213	only alteration type		UVM
WP196	GNAQ MUT* (T96S)	GNAQ Q209	Refametinib	Uveal melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1233	only alteration type		UVM
WP196	JAK2 (V617F)	JAK2 Splice Site (c.1641+2T>G)	Pembrolizumab	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4825	only alteration type		CM
WP196	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP196	KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP196	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP196	MYCN MUT* (--)	MYCN Amplification	FACT Complex-targeting Curaxin CBL0137	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/744	only gene		NB
WP196	MYCN MUT* (--)	MYCN Amplification	Panobinostat,JQ1	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6019	only gene		NB
WP196	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP196	PIK3R1 MUT* (--)	PIK3R1 Mutation	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1612	only alteration type		BRCA
WP196	POLD1 MUT* (Q490)	POLD1 C284Y	Pembrolizumab	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4776	only alteration type		LUAD
WP196	POLD1 MUT* (Q490)	POLD1 E374K	Pembrolizumab	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4777	only alteration type		NSCLC
WP196	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP196	RB1 MUT* (--)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
WP196	RET MUT* (--)	RET CCDC6::RET	Agerafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7480	only gene		COREAD
WP196	RET MUT* (--)	RET CCDC6::RET	Nintedanib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1601	only gene		NSCLC
WP196	RET MUT* (--)	RET Fusion	Cabozantinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4847	only gene		LUAD
WP196	RET MUT* (--)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4848	only gene		NSCLC
WP196	RET MUT* (--)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4849	only gene		NSCLC
WP196	RET MUT* (--)	RET Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4850	only gene		NSCLC
WP196	RET MUT* (--)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7066	only gene		NSCLC
WP196	RET MUT* (--)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/8850	only gene		NSCLC
WP196	RET MUT* (--)	RET Fusion	Pralsetinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11233	only gene		NSCLC
WP196	RET MUT* (--)	RET Fusion	Selpercatinib	Thyroid carcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8852	only gene		THCA
WP196	RET MUT* (--)	RET KIF5B::RET	Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/698	only gene		LUAD
WP196	RET MUT* (--)	RET KIF5B::RET	Vandetanib,Everolimus	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1622	only gene		LUAD
WP196	RICTOR MUT* (--)	RICTOR Amplification	Onatasertib,Sapanisertib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1440	only gene		LUAD
WP196	RICTOR MUT* (--)	RICTOR Amplification	Vistusertib	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7449	only gene		SCLC
WP196	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP196	SF3B1 (E622D)	SF3B1 K666N	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1418	only alteration type		BRCA
WP196	SF3B1 (E622D)	SF3B1 K700E	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1417	only alteration type		BRCA
WP196	STK11 MUT* (M51L), STK11 MUT* (--)	STK11 Mutation	Pembrolizumab,Nivolumab,Atezolizumab	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6441	only alteration type		LUAD
WP196	STK11 MUT* (M51L), STK11 MUT* (--)	STK11 Loss	Selumetinib,Docetaxel	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1144	only gene		NSCLC
WP196	STK11 MUT* (M51L), STK11 MUT* (--)	STK11 Loss	Everolimus,Sirolimus	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1620	only gene		NSCLC
WP196	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP196	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP196	TSC2 MUT* (--), TSC2 (R751*)	TSC2 Q1178*	Everolimus	Thyroid carcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1108	only alteration type		THCA
WP280	G6PD MUT* (--)	G6PD biallelic inactivation	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP280	G6PD MUT* (--)	G6PD (S218F)	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP280	G6PD MUT* (--), G6PD MUT* (--)	G6PD (V98M) + G6PD (N156D)	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP280	RET MUT* (--)	RET (618,620,634,768,791,891,918,C634W,M918T)	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	A	NO	PMID:20065189;PMID:22025146	only alteration type		THCA
WP280	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022	only alteration type		BRCA
WP280	RET MUT* (--)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-ret-altered-thyroid-cancers;ASCO 2020 (abstr 109)	only gene		TH
WP280	RET MUT* (--)	RET oncogenic mutation	Selpercatinib(RET kinase inhibitor)	Thyroid medullary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only alteration type		THM
WP280	FGFR2 MUT* (E756)	FGFR2 fusion	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only gene		BLCA
WP280	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP280	FANCL MUT* (--)	FANCL oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP280	FGFR3 MUT* (--)	FGFR3 fusion	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only gene		BLCA
WP280	FGFR3 MUT* (--)	FGFR3 (G370C,R248C,S249C,Y373C)	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only alteration type		BLCA
WP280	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP280	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP280	FGFR2 MUT* (E756)	FGFR2 fusion	Infigratinib(FGFR kinase inhibitor)	Cholangiocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma	only gene		CH
WP280	FGFR2 MUT* (E756)	FGFR2 fusion	Pemigatinib(FGFR kinase inhibitor)	Cholangiocarcinoma	Responsive	A	NO	FDA;PMID:32203698	only gene		CH
WP280	NTRK1 MUT* (--)	NTRK1 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	NO	FDA:https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
WP280	NTRK1 MUT* (--)	NTRK1 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
WP280	RET MUT* (--)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions	only gene		NSCLC
WP280	RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-non-small-cell-lung	only gene		NSCLC
WP280	PIK3CA MUT* (--)	PIK3CA (C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R)	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	only alteration type		BRCA
WP280	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Bevacizumab(VEGF mAb inhibitor);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP280	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP280	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Pembrolizumab(PD-1-blocking antibody);Pemetrexed(Chemotherapy);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf	complete		NSCLC
WP280	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Durvalumab(PD-1-blocking antibody);Tremelimumab-actl(CTLA-4 blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non	complete		NSCLC
WP280	RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only gene		TH
WP280	RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Solid tumors	Responsive	A	NO	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors	only gene		SOLID
WP280	FGFR2 MUT* (E756)	FGFR2 fusion	Futibatinib(pan-FGFR inhibitor)	Intrahepatic cholangiocarcinoma	Responsive	A	NO	FDA: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-futibatinib-cholangiocarcinoma	only gene		IHCH
WP280	ATM MUT* (--)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP280	FANCA MUT* (--)	FANCA oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP280	EGFR wildtype, ALK wildtype, ROS1 wildtype	EGFR wildtype;ALK wildtype;ROS1 wildtype	Cemiplimab-rwlc(PD-1-blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-combination-platinum-based-chemotherapy-non-small-cell-lung-cancer	complete		NSCLC
WP280	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP280	NTRK1 MUT* (--)	NTRK1 (G595R)	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Resistant	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210861s008lbl.pdf	only alteration type		SOLID
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP280	RET MUT* (--)	RET fusion	Cabozantinib(Kinase inhibitor )	Non-small cell lung	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP280	AR MUT* (--), AR MUT* (--)	AR amplification	AR inhibitor next gens	Prostate adenocarcinoma	Responsive	D	NO	PMID:23589709;PMID:21859989	only gene		PRAD
WP280	AR MUT* (--), AR MUT* (--), AR MUT* (--), AR MUT* (--)	AR (F877L) + AR (T878A)	Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	D	NO	PMID:27196756	only alteration type		PRAD
WP280	FGFR2 MUT* (E756), FGFR2 MUT* (E756)	FGFR2 (N549H,V564F,K659M,L617V,K641R,R565A) + FGFR2 fusion	FGFR inhibitors	Cholangiocarcinoma	Resistant	C	NO	PMID:28034880;ASCO 2017 (abstr 2500)	only gene		CH
WP280	ARID1A MUT* (G1257)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	only alteration type		CANCER
WP280	ARID1A MUT* (G1257)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	only alteration type		OV
WP280	ARID1A MUT* (G1257)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	only alteration type		CANCER
WP280	FGFR3 MUT* (--)	FGFR3 (V555M)	FGFR inhibitors	Myeloma	Resistant	D	YES	PMID:22869148	only alteration type		MYMA
WP280	ATM MUT* (--)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only alteration type		COREAD
WP280	ATM MUT* (--)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
WP280	ATM MUT* (--)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only alteration type		LY
WP280	ATM MUT* (--)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only gene		LY
WP280	ATM MUT* (--)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP280	ATM MUT* (--)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
WP280	ATM MUT* (--)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP280	ATM MUT* (--)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP280	ATM MUT* (--)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP280	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP280	ATM MUT* (--)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP280	JAK1 MUT* (--)	JAK1 oncogenic mutation	PD1 inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:27903500	only alteration type		COREAD
WP280	JAK1 MUT* (--)	JAK1 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	only alteration type		CM
WP280	CBL MUT* (--)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP280	CBL MUT* (--)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP280	NF1 MUT* (S521G)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP280	PIK3CA MUT* (--)	PIK3CA (E545*)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMC3936420	only alteration type		CM
WP280	PIK3CA MUT* (--)	PIK3CA amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	D	NO	PMID:24366379	only gene		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9054)	only alteration type		L
WP280	TP53 MUT* (--)	TP53 oncogenic mutation	MDM2 inhibitors	Liposarcoma	Resistant	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	only alteration type		LIP
WP280	NTRK1 MUT* (--)	NTRK1 (G595R,G667C)	Pan-TK inhibitors(Entrectinib,etc)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:26546295	only alteration type		COREAD
WP280	FANCA MUT* (--)	FANCA oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP280	FANCA MUT* (--)	FANCA deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only gene		PRAD
WP280	TP53 MUT* (--)	TP53 oncogenic mutation	Abemaciclib(CDK4/CDK6 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:27217383	only alteration type		BRCA
WP280	AR MUT* (--), AR MUT* (--)	AR amplification	Abiraterone(AR inhibitor)	Prostate adenocarcinoma	Resistant	C	NO	PMID:26537258	only gene		PRAD
WP280	AR MUT* (--), AR MUT* (--)	AR (L702H,T878A)	Abiraterone(AR inhibitor)	Prostate adenocarcinoma	Resistant	C	NO	PMID:26537258	only alteration type		PRAD
WP280	FGFR2 MUT* (E756)	FGFR2 fusion	FGFR inhibitors	Billiary tract	Responsive	C	NO	ASCO 2016 (abstr 109)	only gene		BT
WP280	FGFR2 MUT* (E756)	FGFR2 inframe insertion (A266),inframe insertion (S267)	FGFR inhibitors	Lung	Responsive	D	NO	PMID:26048680	only alteration type		L
WP280	FGFR2 MUT* (E756)	FGFR2 amplification	FGFR inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2508)	only gene		ST
WP280	FGFR2 MUT* (E756)	FGFR2 amplification	FGFR inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:25193991	only gene		BRCA
WP280	FGFR2 MUT* (E756)	FGFR2 (S252W,N550K)	FGFR inhibitors	Endometrium	Responsive	D	NO	PMID:18552176;PMID:22238366;PMID:23002168	only alteration type		ED
WP280	FGFR2 MUT* (E756)	FGFR2 (V565I)	FGFR inhibitors	Endometrium	Responsive	D	NO	ENA 2014 (abstr 381)	only alteration type		ED
WP280	FGFR2 MUT* (E756)	FGFR2 (W290C,S320C,K660N)	FGFR inhibitors	Lung squamous cell	Responsive	D	NO	PMID:23786770;PMID:25035393	only alteration type		LUSC
WP280	FGFR2 MUT* (E756)	FGFR2 fusion	FGFR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 2500)	only gene		COREAD
WP280	FGFR2 MUT* (E756)	FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Endometrium	Responsive	D	NO	PMID:23908597	only alteration type		ED
WP280	FGFR3 MUT* (--)	FGFR3 fusion	FGFR inhibitors	Glioma	Responsive	C	NO	PMID:26324363	only gene		G
WP280	FGFR3 MUT* (--)	FGFR3 oncogenic mutation	FGFR inhibitors	Bladder	Responsive	C	NO	PMID:27870574	only alteration type		BLCA
WP280	FGFR3 MUT* (--)	FGFR3 (K650,Y373C)	FGFR inhibitors	Myeloma	Responsive	D	YES	PMID:16091734;PMID:20439987;PMID:22869148	only alteration type		MYMA
WP280	FGFR3 MUT* (--)	FGFR3 (S249C,G691R)	FGFR inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:27998968	only alteration type		LUAD
WP280	AR MUT* (--), AR MUT* (--)	AR (F877L)	Arn-509(AR inhibitor)	Prostate adenocarcinoma	Resistant	C	NO	PMID:23779130	only alteration type		PRAD
WP280	FGFR3 MUT* (--)	FGFR3 fusion	FGFR inhibitors	Bladder	Responsive	C	NO	PMID:26324363;ASCO 2017 (abstr 2500)	only gene		BLCA
WP280	FGFR3 MUT* (--)	FGFR3 (K650)	Bortezomib(Proteasome inhibitor)	Myeloma	Responsive	D	YES	PMID:19331127;PMID:21273588	only alteration type		MYMA
WP280	FGFR3 MUT* (--)	FGFR3-TACC3 fusion	FGFR inhibitors(,etc)	Non-small cell lung	Responsive	D	NO	PMID:25294908	only gene		NSCLC
WP280	FGFR3 MUT* (--)	FGFR3 (Y373C)	Bortezomib(Proteasome inhibitor)	Myeloma	Resistant	D	YES	PMID:19331127;PMID:21273588	only alteration type		MYMA
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP280	NF1 MUT* (S521G)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP280	GATA3 MUT* (--)	GATA3 oncogenic mutation	Aromatase ihibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:24758297	only alteration type		BRCA
WP280	GNAQ MUT* (T96S)	GNAQ (Q209)	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	NCT01587352	only alteration type		CM
WP280	GNAQ MUT* (T96S)	GNAQ (Q209)	PI3K pathway inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22733540;PMID:22808163	only alteration type		CM
WP280	GNAQ MUT* (T96S)	GNAQ (Q209)	PKC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22653968;PMID:22253748	only alteration type		CM
WP280	GNAQ MUT* (T96S)	GNAQ (Q209)	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr CRA9003)	only alteration type		CM
WP280	INPP4B MUT* (K903), INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP280	INPP4B MUT* (K903), INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP280	JAK1 MUT* (--)	JAK1 (S646F;R683)	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22955920;PMID:18805579	only alteration type		ALL
WP280	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP280	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:19223544;PMID:20619739	only alteration type		COREAD
WP280	TP53 MUT* (--)	TP53 oncogenic mutation	Cisplatin(Chemotherapy)	Female germ cell tumor, Male germ cell tumor	Resistant	C	NO	PMID:27646943	only alteration type		FGCT, MGCT
WP280	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP280	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP280	NF1 MUT* (S521G)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP280	FGFR2 MUT* (E756)	FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)	Dovitinib(FGFR inhibitor)	Endometrium	Resistant	D	NO	PMID:23908597	only alteration type		ED
WP280	AR MUT* (--), AR MUT* (--)	AR (F877L)	Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Resistant	C	NO	PMID:23779130	only alteration type		PRAD
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP280	NF1 MUT* (S521G)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP280	NF1 MUT* (S521G)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP280	NF1 MUT* (S521G)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP280	NF1 MUT* (S521G)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP280	AR MUT* (--), AR MUT* (--)	AR (T878A)	Flutamide(AR inhibitor)	Prostate adenocarcinoma	Resistant	C	NO	PMID:2260966	only alteration type		PRAD
WP280	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP280	MYC (T73P)	MYC amplification	BET inhibitors	Myeloma, Neuroblastoma	Responsive	D	YES	PMID:21889194;PMID:23430699	only gene		MYMA, NB
WP280	MYC (T73P)	MYC amplification	CDK7 inhibitors	Neuroblastoma	Responsive	D	NO	PMID:25416950	only gene		NB
WP280	MYC (T73P)	MYC amplification	FACT inhibitors	Neuroblastoma	Responsive	D	NO	PMID:26537256	only gene		NB
WP280	MYC (T73P)	MYC amplification	PIM inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:25505253	only gene		PRAD
WP280	MYC (T73P)	MYC amplification	Temozolomide(Chemotherapy)	Colorectal adenocarcinoma	Responsive	D	NO	PMID:27397505	only gene		COREAD
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP280	NF1 MUT* (S521G)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP280	NF1 MUT* (S521G)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP280	NF1 MUT* (S521G)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP280	NF1 MUT* (S521G)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP280	NF1 MUT* (S521G)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP280	NF1 MUT* (S521G)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP280	NF1 MUT* (S521G)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP280	NF1 MUT* (S521G)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP280	NF1 MUT* (S521G)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP280	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP280	NF1 MUT* (S521G)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP280	NF1 MUT* (S521G)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP280	NF1 MUT* (S521G)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP280	LRP1B MUT* (--)	LRP1B oncogenic mutation	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only alteration type		OV
WP280	LRP1B MUT* (--)	LRP1B deletion	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only gene		OV
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP280	NF1 MUT* (S521G)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP280	NF1 MUT* (S521G)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP280	NF1 MUT* (S521G)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP280	NF1 MUT* (S521G)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP280	NF1 MUT* (S521G)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP280	NF1 MUT* (S521G)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP280	NF1 MUT* (S521G)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP280	NF1 MUT* (S521G)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP280	NF1 MUT* (S521G)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP280	NF1 MUT* (S521G)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP280	NF1 MUT* (S521G)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP280	NF1 MUT* (S521G)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP280	NOTCH1 MUT* (I1440T), NOTCH1 MUT* (A1436), NOTCH1 MUT* (G1434)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP280	NOTCH1 MUT* (I1440T), NOTCH1 MUT* (A1436), NOTCH1 MUT* (G1434)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP280	NOTCH1 MUT* (I1440T), NOTCH1 MUT* (A1436), NOTCH1 MUT* (G1434)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP280	NOTCH1 MUT* (I1440T), NOTCH1 MUT* (A1436), NOTCH1 MUT* (G1434)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP280	NOTCH1 MUT* (I1440T), NOTCH1 MUT* (A1436), NOTCH1 MUT* (G1434)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP280	NOTCH1 MUT* (I1440T), NOTCH1 MUT* (A1436), NOTCH1 MUT* (G1434)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP280	NOTCH1 MUT* (I1440T), NOTCH1 MUT* (A1436), NOTCH1 MUT* (G1434)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP280	NOTCH1 MUT* (I1440T), NOTCH1 MUT* (A1436), NOTCH1 MUT* (G1434)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	only alteration type		MCL
WP280	NOTCH1 MUT* (I1440T), NOTCH1 MUT* (A1436), NOTCH1 MUT* (G1434)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP280	NOTCH1 MUT* (I1440T), NOTCH1 MUT* (A1436), NOTCH1 MUT* (G1434)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP280	NOTCH1 MUT* (I1440T), NOTCH1 MUT* (A1436), NOTCH1 MUT* (G1434)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP280	NOTCH2 MUT* (A21T), NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP280	NOTCH2 MUT* (A21T), NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	YES	PMID:25564152	only alteration type		BRCA, AML, ALL
WP280	NOTCH2 MUT* (A21T), NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	NO	NCT01859741;NCT01277146	only alteration type		SOLID
WP280	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP280	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP280	NTRK1 MUT* (--)	NTRK1 fusion	Pan-TK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24162815	only gene		LUAD
WP280	NTRK1 MUT* (--)	NTRK1 fusion	Pan-TKR inhibitors	Any cancer type	Responsive	C	YES	PMID:28183697;ASCO 2017 (LBA2501)	only gene		CANCER
WP280	NTRK1 MUT* (--)	NTRK1 fusion	Pan-TK inhibitors(Entrectinib,etc)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26546295	only gene		COREAD
WP280	NTRK1 MUT* (--)	NTRK1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2013 (abstr 8023)	only gene		LUAD
WP280	PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP280	PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
WP280	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP280	RET MUT* (--)	RET (I788N)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Resistant	D	NO	PMID:28615362	only alteration type		LUAD
WP280	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP280	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP280	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	AKT inhibitors	Breast adenocarcinoma	Responsive	C	NO	ASCO 2015 (abstr 2500)	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitor(alone or in combination)s	Lung, Colorectal adenocarcinoma	Responsive	D	NO	PMID:23136191;PMID:23475782;PMID:22392911	only alteration type		L, COREAD
WP280	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Bladder, Head an neck, Lung	Responsive	C	NO	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	only alteration type		BLCA, HNC, L
WP280	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma, Ovary, Cervix squamous cell, Endometrium	Responsive	C	NO	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	only alteration type		BRCA, OV, CESC, ED
WP280	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26787751;PMID:26763254	only alteration type		HNSC
WP280	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Glioma, Thyroid carcinoma	Responsive	D	NO	PMID:19671762;PMID:21289267	only alteration type		G, THCA
WP280	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:28331003	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2501)	only alteration type		ST
WP280	POLE MUT* (T258P)	POLE (268-471)	PD1 Ab inhibitors	Glioma, Endometrium	Responsive	C	NO	PMID:27001570;PMID:27683556;PMID:27159395	only alteration type		G, ED
WP280	POLE MUT* (T258P)	POLE oncogenic mutation	PD1 Ab inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28188185	only alteration type		COREAD
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP280	PTPRD MUT* (--), PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP280	NF1 MUT* (S521G)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP280	NF1 MUT* (S521G)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP280	NF1 MUT* (S521G)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP280	RET MUT* (--)	RET fusion	RET inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:22327624;PMID:22327622	only gene		LUAD
WP280	RET MUT* (--)	RET-TPCN1 fusion	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only gene		TH
WP280	RET MUT* (--)	RET (C634W,M918T)	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only alteration type		TH
WP280	RET MUT* (--)	RET fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP280	RET MUT* (--)	RET-TPCN1 fusion	Cabozantinib(Pan-kinase inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP280	RET MUT* (--)	RET (C634W,M918T)	Cabozantinib(Pan-kinase inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP280	RET MUT* (--)	RET fusion	Nintedanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26787234	only gene		LUAD
WP280	RET MUT* (--)	RET fusion	Sunitinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP280	RET MUT* (--)	RET-TPCN1 fusion	Sunitinib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP280	RET MUT* (--)	RET (C634W,M918T)	Sunitinib(Pan-TK inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP280	RET MUT* (--)	RET fusion	Vandetanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP280	RET MUT* (--)	RET-TPCN1 fusion	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP280	RICTOR MUT* (--)	RICTOR amplification	MTORC1/2 inhibitors	Lung	Responsive	C	NO	PMID:26370156	only gene		L
WP280	NF1 MUT* (S521G)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP280	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP280	TERT MUT* (--)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP280	TMPRSS2 MUT* (--), TMPRSS2 MUT* (Q430H)	TMPRSS2 fusion	DNA-PKc inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575865	only gene		PRAD
WP280	TMPRSS2 MUT* (--), TMPRSS2 MUT* (Q430H)	TMPRSS2 fusion	PARP inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:21575865	only gene		PRAD
WP280	TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP280	TP53 MUT* (--)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
WP280	TP53 MUT* (--)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
WP280	TP53 MUT* (--)	TP53 oncogenic mutation	WEE1 inhibitors	Head an neck	Responsive	D	NO	PMID:25125259	only alteration type		HNC
WP280	TP53 MUT* (--)	TP53 oncogenic mutation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP280	TP53 MUT* (--)	TP53 deletion	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only gene		BCL
WP280	TP53 MUT* (--)	TP53 oncogenic mutation	Decitabine(Chemotherapy)	Acute myeloid leukemia, Myelodisplasic proliferative syndrome	Responsive	C	YES	PMID:27959731	only alteration type		AML, MDPS
WP280	TP53 MUT* (--)	TP53 oncogenic mutation	Doxorubicin(Anthracycline antitumor antibiotic)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP280	TP53 MUT* (--)	TP53 oncogenic mutation	Gemcitabine(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP280	TP53 MUT* (--)	TP53 oncogenic mutation	Mitomycin C(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP280	TP53 MUT* (--)	TP53 oncogenic mutation	WEE1 inhibitors	Ovary	Responsive	C	NO	PMID:27998224	only alteration type		OV
WP280	TP53 MUT* (--)	TP53 oncogenic mutation	Pramlintide(Amylin analogue)	Thymic	Responsive	D	YES	PMID:25409149	only alteration type		THYM
WP280	TP53 MUT* (--)	TP53 deletion	Pramlintide(Amylin analogue)	Thymic	Responsive	D	YES	PMID:25409149	only gene		THYM
WP280	FGFR2 MUT* (E756)	FGFR2 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Cholangiocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CH
WP280	NTRK1 MUT* (--)	NTRK1 fusion	Entrectinib	Any cancer type	Responsive	B	YES	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/NTRK1|CIVIC=https://civicdb.org/genes/3983/summary	only gene		CANCER
WP280	FGFR3 MUT* (--)	FGFR3 (S249C,S371C,R248C,K650.,G380R,Y373C,G370C)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only alteration type		BLCA
WP280	FGFR2 MUT* (E756)	FGFR2 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		BLCA
WP280	FGFR2 MUT* (E756)	FGFR2 (N549K,K526E,K641R,I547V,Y375C,D101Y,E219K,E565G,C382R,N549H,W290R,L617M,D530N,M535I,P253R,V564I,F276C,S252W,N549T,E731K,G271E,I642V,K641N,R203C,K659E,.,L617F,M537I,T341P,R678G,M391R,Y381D,V564F,K525E,N549S,R251Q,A648T,K659N)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only alteration type		CANCER
WP280	FGFR2 MUT* (E756)	FGFR2 amplification	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP280	FGFR2 MUT* (E756)	FGFR2-AHCYL1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP280	FGFR2 MUT* (E756)	FGFR2-BICC1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP280	FGFR2 MUT* (E756)	FGFR2-CCDC6 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP280	FGFR2 MUT* (E756)	FGFR2-CIT fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP280	FGFR2 MUT* (E756)	FGFR2-FAM76A fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP280	FGFR2 MUT* (E756)	FGFR2-KIAA1967 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP280	FGFR2 MUT* (E756)	FGFR2-MGEA5 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP280	FGFR2 MUT* (E756)	FGFR2-TACC3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP280	FGFR2 MUT* (E756)	FGFR2 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
WP280	FGFR3 MUT* (--)	FGFR3 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		BLCA
WP280	NF1 MUT* (S521G)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP280	NF1 MUT* (S521G)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP280	PIK3CA MUT* (--)	PIK3CA (P539R,R38H,Q546K,G118D,G106V,Q546E,E579K,N345K,E453K,V344A,E545K,T1025S,E542Q,G1049R,M1043I,E110K,P449T,N1044K,K111E,C378R,H1047R,C420R,E78K,E545A,S629C,D350G,.,G451R,M1043V,E542V,Q546R,E365K,E81K,G106D,R88Q,P366R,R93Q,G914R,H1047Y,K111N,E545Q,E545G,R93W,R108H,G106R,E453Q,E542K,D1029Y,N345I,D549N,A1066V,Q546P,E542G,E453A)	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA amplification	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only gene		BRCA
WP280	ATM MUT* (--)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only alteration type		CANCER
WP280	ATM MUT* (--)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
WP280	RET MUT* (--)	RET fusion	Cabozantinib + Vandetanib + Larotrectinib + 292 + 667	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		NSCLC
WP280	RET MUT* (--)	RET (C618R,C620R,C609Y,E768D,C630R,S904F,E511K,C634S,C634Y,V648I,I852M,S891A,A883T,A883F,C611Y,T338I,C634W,K603Q,D631Y,M918T,A919V,R833C,.,V804M,C634R,V804L,Y806C,M918V,L790F,M848T,R886W,Y791F)	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only alteration type		THM
WP280	RET MUT* (--)	RET fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP280	RET MUT* (--)	RET-KIF5B fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP280	RET MUT* (--)	RET-CCDC6 fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP280	FGFR3 MUT* (--)	FGFR3 (M528I,D641N,R669G,Y373C,K650T,G370C,S249C,S371C,A391E,G380R,I538V,D641G,N540K,R248C,V555M,.,K650E,K650R,K650M,G375C,G382D,N540S,Y647C,K650Q,K650N)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only alteration type		CANCER
WP280	FGFR3 MUT* (--)	FGFR3 amplification	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP280	FGFR3 MUT* (--)	FGFR3-BAIAP2L1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP280	FGFR3 MUT* (--)	FGFR3-TACC3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP280	FGFR3 MUT* (--)	FGFR3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP280	FGFR3 MUT* (--)	FGFR3-IGH fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
WP280	NTRK1 MUT* (--)	NTRK1 (G595R)	Larotrectinib	Any cancer type	Resistant	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK1	only alteration type		CANCER
WP280	AR MUT* (--), AR MUT* (--)	AR W742	Bicalutamide	Prostate adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/448	only alteration type		PRAD
WP280	ATM MUT* (--)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	only alteration type		CM
WP280	ATM MUT* (--)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	only alteration type		GB
WP280	ATM MUT* (--)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	only alteration type		PRAD
WP280	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP280	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP280	FGFR2 MUT* (E756)	FGFR2 FGFR2::AHCYL1	Infigratinib,PD173074	Cholangiocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1853	only gene		CH
WP280	FGFR2 MUT* (E756)	FGFR2 FGFR2::BICC1	PD173074,Infigratinib	Cholangiocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1851	only gene		CH
WP280	FGFR2 MUT* (E756)	FGFR2 FGFR2::BICC1	Erdafitinib	Endometrium	Responsive	C	NO	https://civicdb.org/links/evidence_items/1920	only gene		ED
WP280	FGFR2 MUT* (E756)	FGFR2 FGFR2::MGEA5	Ponatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/295	only gene		CH
WP280	FGFR2 MUT* (E756)	FGFR2 FGFR2::TACC3	Pazopanib,Ponatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/296	only gene		CH
WP280	FGFR2 MUT* (E756)	FGFR2 Fusion	Infigratinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1913	only gene		CH
WP280	FGFR2 MUT* (E756)	FGFR2 Fusion	Infigratinib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5908	only gene		CH
WP280	FGFR2 MUT* (E756)	FGFR2 Fusion	Derazantinib	Intrahepatic cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7329	only gene		IHCH
WP280	FGFR2 MUT* (E756)	FGFR2 Mutation	Infigratinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1912	only alteration type		CH
WP280	FGFR2 MUT* (E756)	FGFR2 Mutation	Infigratinib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5912	only alteration type		CH
WP280	FGFR2 MUT* (E756)	FGFR2 Mutation	Ponatinib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1236	only alteration type		ED
WP280	FGFR2 MUT* (E756)	FGFR2 N550K	PD173074	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1322	only alteration type		ED
WP280	FGFR2 MUT* (E756)	FGFR2 P253R	Pazopanib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/7833	only alteration type		HNSC
WP280	FGFR2 MUT* (E756)	FGFR2 Amplification	Dovitinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1605	only gene		BRCA
WP280	FGFR3 MUT* (--)	FGFR3 FGFR3::BAIAP2L1	PD173074	Bladder	Responsive	D	NO	https://civicdb.org/links/evidence_items/144	only gene		BLCA
WP280	FGFR3 MUT* (--)	FGFR3 Mutation	Infigratinib	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/1910	only alteration type		BLCA
WP280	FGFR3 MUT* (--)	FGFR3 Mutation	Cisplatin,Gemcitabine	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/7566	only alteration type		BLCA
WP280	GNAQ MUT* (T96S)	GNAQ Mutation	JQ1	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1210	only alteration type		UVM
WP280	GNAQ MUT* (T96S)	GNAQ Mutation	Trametinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1229	only alteration type		UVM
WP280	GNAQ MUT* (T96S)	GNAQ Mutation	Mirdametinib,Sotrastaurin Acetate	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1953	only alteration type		UVM
WP280	GNAQ MUT* (T96S)	GNAQ Mutation	Cabozantinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5068	only alteration type		UVM
WP280	GNAQ MUT* (T96S)	GNAQ Q209	Selumetinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1213	only alteration type		UVM
WP280	GNAQ MUT* (T96S)	GNAQ Q209	Refametinib	Uveal melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1233	only alteration type		UVM
WP280	JAK1 MUT* (--)	JAK1 S703I	Ruxolitinib	Hepatic carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1900	only alteration type		HC
WP280	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP280	KMT2C MUT* (--), KMT2C MUT* (S806), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP280	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP280	MRE11 MUT* (--)	MRE11 Loss	Talazoparib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/876	only gene		ED
WP280	NOTCH1 MUT* (I1440T), NOTCH1 MUT* (A1436), NOTCH1 MUT* (G1434)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP280	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP280	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP280	NRG1 MUT* (--), NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP280	NTRK1 MUT* (--)	NTRK1 Fusion	Larotrectinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/978	only gene		COREAD
WP280	NTRK1 MUT* (--)	NTRK1 Fusion	Larotrectinib,Lestaurtinib,Crizotinib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1019	only gene		LUAD
WP280	NTRK1 MUT* (--)	NTRK1 Fusion	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/6567	only gene		SOLID
WP280	NTRK1 MUT* (--)	NTRK1 Fusion	Entrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/11124	only gene		SOLID
WP280	NTRK1 MUT* (--)	NTRK1 LMNA::NTRK1	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2960	only gene		COREAD
WP280	NTRK1 MUT* (--)	NTRK1 LMNA::NTRK1	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/8900	only gene		COREAD
WP280	NTRK1 MUT* (--)	NTRK1 SQSTM1::NTRK1	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1868	only gene		NSCLC
WP280	NTRK1 MUT* (--)	NTRK1 SQSTM1::NTRK1	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2950	only gene		NSCLC
WP280	NTRK1 MUT* (--)	NTRK1 Amplification	Larotrectinib	Solid tumors	Responsive	C	NO	https://civicdb.org/links/evidence_items/10170	only gene		SOLID
WP280	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2346	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8549	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA C420R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2078	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA C420R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1999	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA D350G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4784	only alteration type		CM
WP280	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8007	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E542K	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/310	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E542K	Sirolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/311	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2022	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2026	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2058	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E542K	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7315	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8013	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8016	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E542K	Regorafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/83	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA E542K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4424	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA E542K	Apitolisib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/1549	only alteration type		HNSC
WP280	PIK3CA MUT* (--)	PIK3CA E542K	Perifosine,Temsirolimus	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1626	only alteration type		THCA
WP280	PIK3CA MUT* (--)	PIK3CA E545	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7468	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E545G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3724	only alteration type		CM
WP280	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1453	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2036	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6211	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E545K	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6213	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E545K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8008	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8547	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E545K	Akt Inhibitor MK2206,Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/710	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2034	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2062	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8017	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8018	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA E545K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3722	only alteration type		CM
WP280	PIK3CA MUT* (--)	PIK3CA E545K	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/387	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2037	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2217	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib	Lung adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1171	only alteration type		LUAD
WP280	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1670	only alteration type		LUAD
WP280	PIK3CA MUT* (--)	PIK3CA E545K	PI103	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2040	only alteration type		NSCLC
WP280	PIK3CA MUT* (--)	PIK3CA E545Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2213	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA E81K	Oxaliplatin,Fluorouracil,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4464	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA F930S	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10032	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA G1049R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3847	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA H1047L	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2089	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA H1047L	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8009	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA H1047L	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8019	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA H1047L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4432	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2103	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6204	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6206	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8548	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/314	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Capivasertib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1505	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1506	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Everolimus,Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1623	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2096	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2102	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/258	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/388	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Vemurafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3733	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3841	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Akt Inhibitor MK2206,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8364	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1465	only alteration type		HNSC
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1447	only alteration type		LUAD
WP280	PIK3CA MUT* (--)	PIK3CA H1047R	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1625	only alteration type		THCA
WP280	PIK3CA MUT* (--)	PIK3CA H1047X	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7318	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2867	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8663	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2866	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA K111N	Dactolisib,Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8183	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8662	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA K111N	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2085	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA K111N	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8011	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA K111N	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8020	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA K944N	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10031	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA K966E	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10034	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1384	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2087	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2098	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8536	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Capecitabine,Lapatinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8705	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1296	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1504	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1600	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1607	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1610	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Fulvestrant,Alpelisib	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7313	only alteration type		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/915	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1705	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3732	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6298	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6299	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6300	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6301	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6362	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Cabozantinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/771	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6375	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Ridaforolimus,Temsirolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/892	only alteration type		ED
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Pictilisib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1616	only alteration type		ED
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Radiation Therapy,Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1490	only alteration type		HNSC
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin,Sulindac,Celecoxib	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7185	only alteration type		HNSC
WP280	PIK3CA MUT* (--)	PIK3CA Mutation	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2355	only alteration type		NSCLC
WP280	PIK3CA MUT* (--)	PIK3CA N345K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4047	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA Q546K	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2198	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA R88Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3832	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA R93W	Cetuximab,Fluorouracil,Oxaliplatin	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4467	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA S158L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4463	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA V955G	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10033	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA V955I	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/8063	only alteration type		COREAD
WP280	PIK3CA MUT* (--)	PIK3CA Amplification	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8267	only gene		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA Amplification	Lapatinib,Dactolisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8271	only gene		BRCA
WP280	PIK3CA MUT* (--)	PIK3CA Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6275	only gene		CM
WP280	PIK3CA MUT* (--)	PIK3CA Amplification	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1464	only gene		HNSC
WP280	PIK3CA MUT* (--)	PIK3CA Amplification	Sulindac,Aspirin,Ibuprofen	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7186	only gene		HNSC
WP280	PIK3CA MUT* (--)	PIK3CA Amplification	Pictilisib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/756	only gene		OV
WP280	POLD1 MUT* (--), POLD1 MUT* (--)	POLD1 C284Y	Pembrolizumab	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4776	only alteration type		LUAD
WP280	POLD1 MUT* (--), POLD1 MUT* (--)	POLD1 E374K	Pembrolizumab	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4777	only alteration type		NSCLC
WP280	POLE MUT* (T258P)	POLE Mutation	Pembrolizumab	Endometrium	Responsive	C	NO	https://civicdb.org/links/evidence_items/1862	only alteration type		ED
WP280	PTPRD MUT* (--), PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP280	RET MUT* (--)	RET CCDC6::RET	Agerafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7480	only gene		COREAD
WP280	RET MUT* (--)	RET CCDC6::RET	Nintedanib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1601	only gene		NSCLC
WP280	RET MUT* (--)	RET Fusion	Cabozantinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4847	only gene		LUAD
WP280	RET MUT* (--)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4848	only gene		NSCLC
WP280	RET MUT* (--)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4849	only gene		NSCLC
WP280	RET MUT* (--)	RET Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4850	only gene		NSCLC
WP280	RET MUT* (--)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7066	only gene		NSCLC
WP280	RET MUT* (--)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/8850	only gene		NSCLC
WP280	RET MUT* (--)	RET Fusion	Pralsetinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11233	only gene		NSCLC
WP280	RET MUT* (--)	RET Fusion	Selpercatinib	Thyroid carcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8852	only gene		THCA
WP280	RET MUT* (--)	RET KIF5B::RET	Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/698	only gene		LUAD
WP280	RET MUT* (--)	RET KIF5B::RET	Vandetanib,Everolimus	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1622	only gene		LUAD
WP280	RICTOR MUT* (--)	RICTOR Amplification	Onatasertib,Sapanisertib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1440	only gene		LUAD
WP280	RICTOR MUT* (--)	RICTOR Amplification	Vistusertib	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7449	only gene		SCLC
WP280	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP280	SMAD4 (A459D)	SMAD4 Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/719	complete		COREAD
WP280	TP53 MUT* (--)	TP53 M237I	MDM2 Inhibitor AMGMDS3	Glioblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4885	only alteration type		GB
WP280	TP53 MUT* (--)	TP53 Mutation	Tamoxifen	Breast adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2784	only alteration type		BRCA
WP280	TP53 MUT* (--)	TP53 Mutation	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/851	only alteration type		BRCA
WP280	TP53 MUT* (--)	TP53 Mutation	Selumetinib,Docetaxel	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1145	only alteration type		NSCLC
WP280	TP53 MUT* (--)	TP53 Mutation	Pazopanib,Vorinostat	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/7540	only alteration type		SOLID
WP280	TP53 MUT* (--)	TP53 Mutation	Chemotherapy	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/850	only alteration type		ST
WP280	TP53 MUT* (--)	TP53 R175H	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/319	only alteration type		BRCA
WP280	TP53 MUT* (--)	TP53 R249	Doxorubicin	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/399	only alteration type		BRCA
WP280	TP53 MUT* (--)	TP53 R273H	Methotrexate,Doxorubicin	Osteosarcoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/7430	only alteration type		OS
WP280	TP53 MUT* (--)	TP53 R273L	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2286	only alteration type		OV
WP280	TP53 MUT* (--)	TP53 Y234C	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2745	only alteration type		OV
WP280	TP53 MUT* (--)	TP53 Loss	Docetaxel	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1146	only gene		NSCLC
WP140	ABL1 MUT* (--)	ABL1-BCR fusion	Bosutinib(BCR-ABL inhibitor  3rd gen)	Chronic myeloid leukemia	Responsive	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s024lbl.pdf	only gene		CML
WP140	ABL1 MUT* (--)	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	Bosutinib(BCR-ABL inhibitor  3rd gen)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP140	ABL1 MUT* (--)	ABL1-BCR fusion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf	only gene		CML, ALL
WP140	ABL1 MUT* (--)	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP140	ABL1 MUT* (--)	ABL1-BCR fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	EMA	only gene		CML, ALL
WP140	ABL1 MUT* (--)	ABL1-BCR fusion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia	Responsive	A	YES	FDA	only gene		CML
WP140	ABL1 MUT* (--)	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP140	ABL1 MUT* (--)	ABL1-BCR fusion	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	FDA	only gene		CML, ALL
WP140	ABL1 MUT* (--)	ABL1 (T315I)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Responsive	A	YES	FDA	only alteration type		CML, ALL
WP140	ABL1 MUT* (--)	ABL1 (T315I)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	PMID:21562040	only alteration type		CML
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Ado-Trastuzumab Emtansine(EGFR mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor);Capecitabine(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s023lbl.pdf;PMID:17192538	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf	only gene		ST, GEJA
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf	only gene		BRCA
WP140	ABL1 MUT* (--)	ABL1 (T315I)	BCR-ABL inhibitor 2nd gens(Nilotinib,Dasatinib,etc)	Chronic myeloid leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML
WP140	ABL1 MUT* (--)	ABL1 (T315I)	Bosutinib(BCR-ABL inhibitor  3rd gen)	Chronic myeloid leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML
WP140	ABL1 MUT* (--)	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML, ALL
WP140	ABL1 MUT* (--)	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Chronic myeloid leukemia	Resistant	A	YES	PMID:21562040	only alteration type		CML
WP140	ABL1 MUT* (--)	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Chronic myeloid leukemia, Acute lymphoblastic leukemia	Resistant	A	YES	NCCN Guidelines Chronic Myeloid Leukemia 2022;NCCN Guidelines Acute Lymphoblastic Leukemia 2022;PMID:21562040	only alteration type		CML, ALL
WP140	PDGFB MUT* (--)	PDGFB-COL1A1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Dermatofibrosarcoma	Responsive	A	NO	FDA	only gene		DFS
WP140	TPMT MUT* (--)	TPMT splice acceptor variant	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP140	TPMT MUT* (--)	TPMT biallelic inactivation	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP140	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type		CANCER
WP140	TPMT MUT* (--)	TPMT splice acceptor variant	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP140	TPMT MUT* (--)	TPMT biallelic inactivation	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP140	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP140	TPMT MUT* (--)	TPMT splice acceptor variant	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP140	TPMT MUT* (--)	TPMT biallelic inactivation	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP140	TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
WP140	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		GCA
WP140	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		RA
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Neratinib(ERBB2 inhibitor) + Capecitabine(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer;PMID:30860945	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 inhibitor)+ Trastuzumab(ERBB2 inhibitor) + Docetaxel(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor) + Letrozole(Hormone therapy)	Breast adenocarcinoma	Responsive	A	NO	FDA;PMID:19786658	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Margetuximab(ERBB2 inhibitor) 	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Tucatinib(ERBB2 inhibitor) + Trastuzumab(ERBB2 inhibitor) + Capecitabine(chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer;PMID:31825569	only gene		BRCA
WP140	ABL1 MUT* (--)	ABL1 (T315I,V299L,G250E,F317L)	Bosutinib(BCR-ABL inhibitor 3rd gen)	Acute lymphoblastic leukemia, Chronic myeloid leukemia	Resistant	A	YES	NCCN	only alteration type		ALL, CML
WP140	ABL1 MUT* (--)	ABL1 (T315I)	Asciminib(Kinase inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia	only alteration type		CML
WP140	ABL1 MUT* (--)	BCR-ABL1	Asciminib(Kinase inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215358s003lbl.pdf	only gene		CML
WP140	ABL1 MUT* (--)	ABL1 (T315I)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Acute lymphoblastic leukemia	Resistant	A	YES	NCCN Guideline ALL 2022	only alteration type		ALL
WP140	ABL1 MUT* (--)	ABL1 (E255V,Y253H,F359V)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Chronic myeloid leukemia	Responsive	A	YES	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf	only alteration type		CML
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Pembrolizumab(PD-1 blocking antibody) + Trastuzumab(ERBB2 mAb inhibitor) + Fluoropyrimidine (Chemotherapy) + Platinum (Chemotherapy)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer;PMID:34912120	only gene		ST, GEJA
WP140	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP140	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP140	ABL1 MUT* (--)	ABL1 (T315I)	Bosutinib(BCR-ABL inhibitor 3rd gen)	Acute lymphoblastic leukemia	Resistant	A	YES	NCCN Guideline ALL 2022	only alteration type		ALL
WP140	RAD51D MUT* (--)	RAD51D oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP140	RAD54L MUT* (--)	RAD54L oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas	only gene		ST, GEJA
WP140	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung	only alteration type		NSCLC
WP140	NTRK3 MUT* (A8T)	NTRK3 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
WP140	NTRK3 MUT* (A8T)	NTRK3 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	NO	FDA https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
WP140	NTRK3 MUT* (A8T)	NTRK3 (F617L,G623R,G696A)	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Resistant	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf	only alteration type		SOLID
WP140	ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype	Tucatinib(ERBB2 inhibitor);Trastuzumab(ERBB2 inhibitor) 	Colorectal adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer	only gene		COREAD
WP140	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Bevacizumab(VEGF mAb inhibitor);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP140	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP140	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Pembrolizumab(PD-1-blocking antibody);Pemetrexed(Chemotherapy);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf	complete		NSCLC
WP140	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Durvalumab(PD-1-blocking antibody);Tremelimumab-actl(CTLA-4 blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non	complete		NSCLC
WP140	FANCA MUT* (--), FANCA MUT* (--)	FANCA oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP140	MLH1 MUT* (--), MLH1 MUT* (--)	MLH1 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-fam-trastuzumab-deruxtecan-nxki-breast-cancer	only gene		BRCA
WP140	EGFR wildtype, ALK wildtype, ROS1 wildtype	EGFR wildtype;ALK wildtype;ROS1 wildtype	Cemiplimab-rwlc(PD-1-blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-combination-platinum-based-chemotherapy-non-small-cell-lung-cancer	complete		NSCLC
WP140	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP140	ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype + BRAF wildtype	Trastuzumab(ERBB2 mAb inhibitor) + Lapatinib(ERBB2 inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only gene		COREAD
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 inhibitor) + Carboplatin-Taxol(Chemotherapy)	Uterus	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf	only gene		U
WP140	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP140	ABL1 MUT* (--)	ABL1-BCR fusion	Bosutinib(BCR-ABL inhibitor  3rd gen)	Acute lymphoblastic leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/all.pdf	only gene		ALL
WP140	ABL1 MUT* (--)	ABL1-BCR fusion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Acute lymphoblastic leukemia	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/all.pdf	only gene		ALL
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 inhibitor)+ Trastuzumab(ERBB2 inhibitor) 	Billiary tract	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf	only gene		BT
WP140	ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype + BRAF wildtype	Trastuzumab(ERBB2 mAb inhibitor) + Lapatinib(ERBB2 inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only gene		COREAD
WP140	ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype + BRAF wildtype	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only gene		COREAD
WP140	ABL1 MUT* (--)	ABL1 (T315I)	Axitinib(VEGFR inhibitor)	Any cancer type	Responsive	D	YES	PMID:25686603	only alteration type		CANCER
WP140	ABL1 MUT* (--)	ABL1 (V299L)	Cabozantinib(Pan-kinase inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP140	ABL1 MUT* (--)	ABL1 (V299L)	Crizotinib(ALK inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP140	ABL1 MUT* (--)	ABL1-BCR fusion	Dasatinib + Venetoclax(BCR-ABL inhibitor 2nd gen + BCL2 inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:27582059	only gene		ALL
WP140	ABL1 MUT* (--)	ABL1 (V299L)	ForetinibÂ (MET inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP140	ABL1 MUT* (--)	ABL1 (V299L)	Vandetanib(Pan-TK inhibitor)	Any cancer type	Responsive	D	YES	PMID:26924578	only alteration type		CANCER
WP140	CTNNB1 MUT* (--)	CTNNB1 oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Resistant	D	NO	PMID:23539443	only alteration type		COREAD
WP140	ERBB2 MUT* (--)	ERBB2 amplification	EGFR inhibitors	Lung adenocarcinoma	Resistant	D	NO	PMID:22956644	only gene		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:22586653;PMID:23348520	only gene		COREAD
WP140	FBXW7 MUT* (--)	FBXW7 oncogenic mutation	Tubulin inhibitors	Any cancer type	Resistant	D	YES	PMID:21368834	only alteration type		CANCER
WP140	FBXW7 MUT* (--)	FBXW7 deletion	Tubulin inhibitors	Any cancer type	Resistant	D	YES	PMID:21368834	only gene		CANCER
WP140	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	complete		CANCER
WP140	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	complete		OV
WP140	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	complete		CANCER
WP140	CTNNB1 MUT* (--)	CTNNB1 (H36Y,S37C,S37Y,D32V)	Everolimus + Letrozole(MTOR inhibitor + Hormonal therapy)	Endometrium	Responsive	C	NO	PMID:25624430	only alteration type		ED
WP140	PIK3CB MUT* (--)	PIK3CB (D1067Y)	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	C	NO	PMID:26759240	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 amplification	ERBB2 inhibitor + CDK4/6 inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26977878	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 proximal exon 20	ERBB2 inhibitors(Afatinib,Lapatinib,Neratinib,etc)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547	only alteration type		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 proximal exon 20	ERBB2 mAb inhibitors(Trastuzumab,etc)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547	only alteration type		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 inframe insertion (A775YVMA),inframe insertion (G776VC)	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 8510)	only alteration type		L
WP140	ERBB2 MUT* (--)	ERBB2 (V659E,S310F)	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 8510)	only alteration type		L
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Stomach	Responsive	C	NO	AACR 2014 (abstr CT228)	only gene		ST
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Breast adenocarcinoma	Responsive	B	NO	PMID:20142587;PMID:22418700;PMID:23632474	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	PMID:27044931	only gene		BLCA
WP140	ERBB2 MUT* (--)	ERBB2 proximal exon 20	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 (T798I)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Breast adenocarcinoma	Responsive	D	NO	PMID:28274957	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Dacomitinib(Pan ERBB inhibitor)	Non-small cell lung	Responsive	C	NO	PMID:25899785	only alteration type		NSCLC
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
WP140	ERBB2 MUT* (--)	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 (V659E)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma, Lung adenocarcinoma	Responsive	C	NO	PMID:23950206	only alteration type		BRCA, LUAD
WP140	ERBB2 MUT* (--)	ERBB2 proximal exon 20	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib + Chemotherapy(ERBB2 inhibitor + Chemotherapy)	Stomach	Responsive	C	NO	PMID:25694417;NCT02015169	only gene		ST
WP140	ERBB2 MUT* (--)	ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Neratinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ESMO 2014 (abstr LBA39_PR)	only alteration type		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 (K753E)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:27697991	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 proximal exon 20	Neratinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 (L869R)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	C	NO	PMID:28274957	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 (S310,L755,V777)	Neratinib(ERBB2 inhibitor)	Any cancer type	Responsive	C	YES	AACR 2017 (abstr CT001)	only alteration type		CANCER
WP140	ERBB2 MUT* (--)	ERBB2 inframe insertion (P780GSP),inframe insertion (781GSP),inframe insertion (A775YVMA),inframe insertion (G776YVMA)	Neratinib(ERBB2 inhibitor)	Any cancer type	Responsive	C	YES	AACR 2017 (abstr CT001)	only alteration type		CANCER
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Stomach	Responsive	C	NO	PMID:24960402	only gene		ST
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
WP140	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Tensirolimus(MTOR inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ESMO 2014 (abstr LBA39_PR)	only alteration type		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Head an neck	Responsive	C	NO	PMID:21380780	only gene		HNC
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Ovary	Responsive	C	NO	PMID:20003286;PMID:12525520	only gene		OV
WP140	ERBB2 MUT* (--)	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma, Any cancer type	Responsive	D	YES	PMID:23220880;PMID:22908275	only alteration type		BRCA, CANCER
WP140	ERBB2 MUT* (--)	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	Trastuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:22908275	only alteration type		CANCER
WP140	ERBB2 MUT* (--)	ERBB2 (G776L)	Trastuzumab(ERBB2 mAb inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:16775247	only alteration type		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 proximal exon 20	Trastuzumab(ERBB2 mAb inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	http://ascopubs.org/doi/full/10.1200/PO.16.00055	only gene		COREAD
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab + Everolimus + Chemotherapy(ERBB2 mAb inhibitor + MTOR inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:21107682;PMID:20975068	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab + HSP90 inhibitor(ERBB2 mAb inhibitor + HSP90 inhibitor)	Breast adenocarcinoma	Responsive	C	NO	PMID:21558407	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab + Lapatinib(ERBB2 mAb inhibitor + ERBB2 inhibitor)	Endometrium	Responsive	D	NO	PMID:25294905	only gene		ED
WP140	TP53 MUT* (T377P)	TP53 oncogenic mutation	MDM2 inhibitors	Liposarcoma	Resistant	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	only alteration type		LIP
WP140	FANCA MUT* (--), FANCA MUT* (--)	FANCA oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP140	FANCA MUT* (--), FANCA MUT* (--)	FANCA deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only gene		PRAD
WP140	FBXW7 MUT* (--)	FBXW7 oncogenic mutation	Steroids	Acute lymphoblastic leukemia	Responsive	B	YES	PMID:20861909	only alteration type		ALL
WP140	TP53 MUT* (T377P)	TP53 oncogenic mutation	Abemaciclib(CDK4/CDK6 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:27217383	only alteration type		BRCA
WP140	FBXW7 MUT* (--)	FBXW7 deletion	Sirolimus(MTOR inhibitor)	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23558291	only gene		COREAD
WP140	GNAQ MUT* (T96S)	GNAQ (Q209)	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	NCT01587352	only alteration type		CM
WP140	GNAQ MUT* (T96S)	GNAQ (Q209)	PI3K pathway inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22733540;PMID:22808163	only alteration type		CM
WP140	GNAQ MUT* (T96S)	GNAQ (Q209)	PKC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22653968;PMID:22253748	only alteration type		CM
WP140	GNAQ MUT* (T96S)	GNAQ (Q209)	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr CRA9003)	only alteration type		CM
WP140	HDAC2 MUT* (--), HDAC2 MUT* (--)	HDAC2 biallelic inactivation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP140	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP140	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP140	JAK3 MUT* (C811Y), JAK3 MUT* (--)	JAK3 (A572V,A573V)	JAK inhibitors	Lymphoma	Responsive	D	YES	PMID:22705984	only alteration type		LY
WP140	JAK3 MUT* (C811Y), JAK3 MUT* (--)	JAK3 (R657Q,I87T,Q501H)	JAK inhibitors	Megakaryoblastic leukemia	Responsive	D	YES	PMID:18397343	only alteration type		MKB
WP140	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP140	MDM2 MUT* (--)	MDM2 amplification	Cisplatin(Chemotherapy)	Male germ cell tumor	Resistant	C	NO	PMID:27646943	only gene		MGCT
WP140	TP53 MUT* (T377P)	TP53 oncogenic mutation	Cisplatin(Chemotherapy)	Female germ cell tumor, Male germ cell tumor	Resistant	C	NO	PMID:27646943	only alteration type		FGCT, MGCT
WP140	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP140	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP140	MDM2 MUT* (--)	MDM2 amplification	MDM2 inhibitors	Liposarcoma	Responsive	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	only gene		LIP
WP140	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP140	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP140	ERBB2 MUT* (--)	ERBB2 (K753E)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma	Resistant	D	NO	PMID:27697991	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 (T798I)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:28274957	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Osimertinib(3rd generation EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP140	NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP140	NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP140	NTRK3 MUT* (A8T)	NTRK3 fusion	IGF1R inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP140	NTRK3 MUT* (A8T)	NTRK3 fusion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP140	NTRK3 MUT* (A8T)	NTRK3 fusion	Midostaurin(Pan-TK inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
WP140	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP140	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP140	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Rociletinib(3rd generation EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP140	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	AKT inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP140	PIK3CB MUT* (--)	PIK3CB (D1067Y)	AKT inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26759240	only alteration type		BRCA
WP140	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	MTORC1/2 inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP140	PIK3CB MUT* (--)	PIK3CB (D1067Y)	MTORC1/2 inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26759240	only alteration type		BRCA
WP140	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP140	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	AKT inhibitors	Glioma	Responsive	D	NO	PMID:23166678	only alteration type		G
WP140	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	PI3K pathway inhibitors	Endometrium	Responsive	C	NO	ASCO 2015 (abstr 11075)	only alteration type		ED
WP140	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Endometrium	No Responsive	C	NO	PMID:26099744;PMID:19840887	only gene		ED
WP140	SMARCA1 MUT* (L707), SMARCA1 MUT* (--)	SMARCA1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
WP140	TERT MUT* (--)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP140	TP53 MUT* (T377P)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
WP140	TP53 MUT* (T377P)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
WP140	TP53 MUT* (T377P)	TP53 oncogenic mutation	WEE1 inhibitors	Head an neck	Responsive	D	NO	PMID:25125259	only alteration type		HNC
WP140	TP53 MUT* (T377P)	TP53 oncogenic mutation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP140	TP53 MUT* (T377P)	TP53 deletion	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only gene		BCL
WP140	TP53 MUT* (T377P)	TP53 oncogenic mutation	Decitabine(Chemotherapy)	Acute myeloid leukemia, Myelodisplasic proliferative syndrome	Responsive	C	YES	PMID:27959731	only alteration type		AML, MDPS
WP140	TP53 MUT* (T377P)	TP53 oncogenic mutation	Doxorubicin(Anthracycline antitumor antibiotic)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP140	TP53 MUT* (T377P)	TP53 oncogenic mutation	Gemcitabine(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP140	TP53 MUT* (T377P)	TP53 oncogenic mutation	Mitomycin C(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	only alteration type		BLCA
WP140	TP53 MUT* (T377P)	TP53 oncogenic mutation	WEE1 inhibitors	Ovary	Responsive	C	NO	PMID:27998224	only alteration type		OV
WP140	TP53 MUT* (T377P)	TP53 oncogenic mutation	Pramlintide(Amylin analogue)	Thymic	Responsive	D	YES	PMID:25409149	only alteration type		THYM
WP140	TP53 MUT* (T377P)	TP53 deletion	Pramlintide(Amylin analogue)	Thymic	Responsive	D	YES	PMID:25409149	only gene		THYM
WP140	NTRK3 MUT* (A8T)	NTRK3 (G623R)	novel TRK inhibitors	Any cancer type	Responsive	C	YES	PMID:28578312	only alteration type		CANCER
WP140	TSC1 MUT* (--)	TSC1 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	only alteration type		RA
WP140	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	only alteration type		BLCA
WP140	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;PMID:26859683;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	only alteration type		R
WP140	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Sarcoma, Stomach	Responsive	C	NO	PMID:26859683	only alteration type		S, ST
WP140	TSC1 MUT* (--)	TSC1 deletion	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	only gene		R
WP140	MDM2 MUT* (--)	MDM2 amplification	Unii-Q8Mi0X869M	Liposarcoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MDM2	only gene		LIP
WP140	ERBB2 MUT* (--)	ERBB2 (T862A,L755S,V842I,V777A,D769H,.,R896C,R678W,R784C,V773A,C630Y,G309E,G292R,E645F,T733I,D769Y,G660R,T686A,D769A,Y803N,L651V,A644F,L674V,V839G,R217C,L869R,E719K,G660D,E265K,L785F,P650S,D277H,D808N,G776V,S653C,R487W,L841V,S310F,L755W,E693K,S335C,V659E,V794M,V659K,E321G,L915M,L866M,C311R,S1002R,D277Y,V659G,Q709L,L726I,G309A,N857S,L755P,T798M,L663P,E812K,S656C,T798I,R683Q,I682G,R678Q,V777L,P780L,A710V,R677L,S310Y,S783P,E717K,E719G,H878Y,G776S,L726F,D821N,V777M,I767M,S649T,C334S)	Neratinib	Breast adenocarcinoma	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ERBB2|CIVIC=https://civicdb.org/genes/20/summary	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Neratinib	Breast adenocarcinoma	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ERBB2|CIVIC=https://civicdb.org/genes/20/summary	only gene		BRCA
WP140	TSC1 MUT* (--)	TSC1 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	only gene		RCCC
WP140	TSC1 MUT* (--)	TSC1 (H105R,H206D,V220F,L180P,F216A,M224R,H68R,.,S35Q,F158C,L117P,L191H)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	only alteration type		RCCC
WP140	NTRK3 MUT* (A8T)	NTRK3 fusion	Entrectinib	Any cancer type	Responsive	B	YES	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/3985/summary|oncokb=https://www.oncokb.org/gene/NTRK3	only gene		CANCER
WP140	ERBB2 MUT* (--)	ERBB2 (T862A,L755S,V842I,V777A,D769H,.,R896C,R678W,R784C,V773A,C630Y,G309E,G292R,E645F,T733I,D769Y,G660R,T686A,D769A,Y803N,L651V,A644F,L674V,V839G,R217C,L869R,E719K,G660D,E265K,L785F,P650S,D277H,D808N,G776V,S653C,R487W,L841V,S310F,E693K,S335C,V659E,V794M,V659K,E321G,L915M,L866M,C311R,S1002R,D277Y,V659G,Q709L,L726I,G309A,N857S,L755P,T798M,L663P,E812K,S656C,T798I,R683Q,I682G,R678Q,V777L,P780L,A710V,R677L,S310Y,S783P,E717K,E719G,H878Y,G776S,L726F,D821N,V777M,I767M,S649T,C334S)	Ado + Trastuzumab + Neratinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERBB2	only alteration type		NSCLC
WP140	ERBB2 MUT* (--)	ERBB2 amplification	Ado + Trastuzumab + Neratinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERBB2	only gene		NSCLC
WP140	NTRK3 MUT* (A8T)	NTRK3 (G623R)	Larotrectinib	Any cancer type	Resistant	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK3	only alteration type		CANCER
WP140	ABL1 MUT* (--)	ABL1 BCR::ABL	Imatinib	Acute myeloid leukemia	Resistant	D	YES	https://civicdb.org/links/evidence_items/232	only gene		AML
WP140	ABL1 MUT* (--)	ABL1 BCR::ABL	Imatinib	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/259	only gene		AML
WP140	ABL1 MUT* (--)	ABL1 G340L	Imatinib Mesylate,Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4788	only alteration type		NSCLC
WP140	ABL1 MUT* (--)	ABL1 R351W	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4787	only alteration type		NSCLC
WP140	ABL1 MUT* (--)	ABL1 R351W	Imatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/6376	only alteration type		NSCLC
WP140	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP140	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP140	ERBB2 MUT* (--)	ERBB2 D769H	Lapatinib,Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/279	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 D769Y	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/280	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 G309A	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/282	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 G776L	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1889	only alteration type		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 G778_P780DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1890	only alteration type		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 G778_P780DUP	Dacomitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1892	only alteration type		NSCLC
WP140	ERBB2 MUT* (--)	ERBB2 L755S	Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/241	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 L755S	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/283	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 L755S	Fluorouracil,Trastuzumab,Leucovorin	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4955	only alteration type		COREAD
WP140	ERBB2 MUT* (--)	ERBB2 L755W	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/284	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 L755_T759del	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/281	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 M774DELINSWLV	Dacomitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1894	only alteration type		NSCLC
WP140	ERBB2 MUT* (--)	ERBB2 Mutation	Platinum Compound	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/1694	only alteration type		BLCA
WP140	ERBB2 MUT* (--)	ERBB2 Mutation	Neratinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5338	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Mutation	Trastuzumab,Pertuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5980	only alteration type		NSCLC
WP140	ERBB2 MUT* (--)	ERBB2 P780INS	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/285	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 P780INS	Dacomitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1048	only alteration type		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 R678Q	Lapatinib,Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/286	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 R896C	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/287	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 T798I	Osimertinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6174	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 V777L	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/288	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 V842I	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/289	only alteration type		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1045	only alteration type		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Trastuzumab Emtansine	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1125	only alteration type		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1888	only alteration type		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Sirolimus,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/960	only alteration type		NSCLC
WP140	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1893	only alteration type		NSCLC
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/5982	only gene		BLCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/528	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/529	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	AKTi-1/2	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/760	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Neratinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/761	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib,Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/887	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/961	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1006	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1007	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1008	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1009	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1011	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1012	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1013	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Docetaxel,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1077	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Neratinib,Trastuzumab	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/1113	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/1122	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib,Capecitabine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1132	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Capecitabine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1133	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1159	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1160	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1380	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	A66	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1381	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Tgx 221	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1382	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1432	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Docetaxel,Pertuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1437	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1439	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Pilaralisib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1448	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Palbociclib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1561	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1613	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1764	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2071	only gene		BRCA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Pertuzumab	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7638	only gene		CH
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Capecitabine,Cetuximab,Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/895	only gene		COREAD
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1686	only gene		COREAD
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1687	only gene		COREAD
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1688	only gene		COREAD
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1993	only gene		COREAD
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1689	only gene		COREAD
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5981	only gene		COREAD
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7302	only gene		COREAD
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7807	only gene		COREAD
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/1098	only gene		ED
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1393	only gene		LUAD
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1041	only gene		NSCLC
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1042	only gene		NSCLC
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1050	only gene		NSCLC
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1891	only gene		NSCLC
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Pancreas	Responsive	B	NO	https://civicdb.org/links/evidence_items/5985	only gene		PA
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Pancreas adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/962	only gene		PAAD
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Irinotecan	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1044	only gene		SCLC
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Salivary glands	Responsive	B	NO	https://civicdb.org/links/evidence_items/5984	only gene		SG
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/1022	only gene		ST
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/1023	only gene		ST
WP140	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Stomach	Responsive	A	NO	https://civicdb.org/links/evidence_items/1499	only gene		ST
WP140	FBXW7 MUT* (--)	FBXW7 Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/718	only alteration type		COREAD
WP140	GNAQ MUT* (T96S)	GNAQ Mutation	JQ1	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1210	only alteration type		UVM
WP140	GNAQ MUT* (T96S)	GNAQ Mutation	Trametinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1229	only alteration type		UVM
WP140	GNAQ MUT* (T96S)	GNAQ Mutation	Mirdametinib,Sotrastaurin Acetate	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1953	only alteration type		UVM
WP140	GNAQ MUT* (T96S)	GNAQ Mutation	Cabozantinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5068	only alteration type		UVM
WP140	GNAQ MUT* (T96S)	GNAQ Q209	Selumetinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1213	only alteration type		UVM
WP140	GNAQ MUT* (T96S)	GNAQ Q209	Refametinib	Uveal melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1233	only alteration type		UVM
WP140	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP140	KMT2C MUT* (--), KMT2C MUT* (K2797X), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP140	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP140	MS4A1 MUT* (--)	MS4A1 Mutation	R-CHOP Regimen	Difuse large B Cell lymphoma	Resistant	B	YES	https://civicdb.org/links/evidence_items/10367	only alteration type		DLBCL
WP140	NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP140	NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP140	NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP140	NTRK3 MUT* (A8T)	NTRK3 EML4::NTRK3	Entrectinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11099	only gene		LUAD
WP140	NTRK3 MUT* (A8T)	NTRK3 EML4::NTRK3	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/10636	only gene		NSCLC
WP140	NTRK3 MUT* (A8T)	NTRK3 ETV6::NTRK3	Entrectinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7994	only gene		AML
WP140	NTRK3 MUT* (A8T)	NTRK3 ETV6::NTRK3	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/7496	only gene		SOLID
WP140	NTRK3 MUT* (A8T)	NTRK3 F617L	Larotrectinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/9592	only alteration type		GIST
WP140	NTRK3 MUT* (A8T)	NTRK3 Fusion	Larotrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/6568	only gene		SOLID
WP140	NTRK3 MUT* (A8T)	NTRK3 Fusion	Entrectinib	Solid tumors	Responsive	A	NO	https://civicdb.org/links/evidence_items/11125	only gene		SOLID
WP140	PIK3CA wildtype	PIK3CA Wildtype	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2038	complete		COREAD
WP140	PIK3R1 MUT* (--)	PIK3R1 Mutation	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1612	only alteration type		BRCA
WP140	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP140	RAD51D MUT* (--)	RAD51D Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11214	only alteration type		PRAD
WP140	RAD54L MUT* (--)	RAD54L Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11207	only alteration type		PRAD
WP140	TP53 MUT* (T377P)	TP53 M237I	MDM2 Inhibitor AMGMDS3	Glioblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4885	only alteration type		GB
WP140	TP53 MUT* (T377P)	TP53 Mutation	Tamoxifen	Breast adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2784	only alteration type		BRCA
WP140	TP53 MUT* (T377P)	TP53 Mutation	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/851	only alteration type		BRCA
WP140	TP53 MUT* (T377P)	TP53 Mutation	Selumetinib,Docetaxel	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1145	only alteration type		NSCLC
WP140	TP53 MUT* (T377P)	TP53 Mutation	Pazopanib,Vorinostat	Solid tumors	Responsive	B	NO	https://civicdb.org/links/evidence_items/7540	only alteration type		SOLID
WP140	TP53 MUT* (T377P)	TP53 Mutation	Chemotherapy	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/850	only alteration type		ST
WP140	TP53 MUT* (T377P)	TP53 R175H	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/319	only alteration type		BRCA
WP140	TP53 MUT* (T377P)	TP53 R249	Doxorubicin	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/399	only alteration type		BRCA
WP140	TP53 MUT* (T377P)	TP53 R273H	Methotrexate,Doxorubicin	Osteosarcoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/7430	only alteration type		OS
WP140	TP53 MUT* (T377P)	TP53 R273L	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2286	only alteration type		OV
WP140	TP53 MUT* (T377P)	TP53 Y234C	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2745	only alteration type		OV
WP140	TP53 MUT* (T377P)	TP53 Loss	Docetaxel	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1146	only gene		NSCLC
WP048	ALK MUT* (--)	ALK fusion	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	FDA	only gene		LUAD
WP048	ALK MUT* (--)	ALK fusion	Alectinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	only gene		NSCLC
WP048	ALK MUT* (--)	ALK fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	only gene		NSCLC
WP048	ALK MUT* (--)	ALK inframe insertion (1151T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165	only alteration type		LUAD
WP048	ALK MUT* (--)	ALK (L1196M,S1206Y,G1269A,I1171T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165;PMID:24327273	only alteration type		LUAD
WP048	ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP048	ALK MUT* (--)	ALK fusion	Brigatinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc	only gene		NSCLC
WP048	NRAS (G13D)	NRAS (12,13,59,61,117,146)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	PMID:24024839;PMID:20619739;PMID:23325582	complete		COREAD
WP048	G6PD MUT* (--)	G6PD biallelic inactivation	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP048	G6PD MUT* (--)	G6PD (S218F)	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP048	G6PD MUT* (--), G6PD MUT* (--)	G6PD (V98M) + G6PD (N156D)	Dabrafenib(BRAF inhibitor)	Any cancer type	Increased Toxicity (Haemolytic Anemia)	A	YES	FDA	only alteration type		CANCER
WP048	NRAS (G13D)	NRAS (12,13,59,61,117,146)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	complete		COREAD
WP048	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Myelofibrosis	Responsive	A	YES	FDA	complete		MY
WP048	KIT MUT* (P36Q)	KIT mutation in exon 9,11,13,14 or 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA	only alteration type	907.0	GIST
WP048	KIT MUT* (P36Q)	KIT mutation in exon 9,11,13,14 or 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN	only alteration type		CM
WP048	KIT MUT* (P36Q)	KIT mutation in exon 9,11,13,14 or 17	Regorafenib(Pan-kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT mutation in exon 9,11,13,14 or 17	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT (D816)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal, Myelodisplasic syndrome, Myelodisplasic proliferative syndrome, Hyper eosinophilic advanced snydrome, Eosinophilic chronic leukemia, Chronic myeloid leukemia, Acute lymphoblastic leukemia, Systemic mastocytosis	Resistant	A	YES	FDA	only alteration type		GIST, MDS, MDPS, HES, ECL, CML, ALL, SM
WP048	KIT MUT* (P36Q)	KIT (T670I)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	A	NO	PMID:24687822	only alteration type		GIST
WP048	PDGFB MUT* (--)	PDGFB-COL1A1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Dermatofibrosarcoma	Responsive	A	NO	FDA	only gene		DFS
WP048	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022	only alteration type		BRCA
WP048	ALK MUT* (--)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP048	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete	65.0	COREAD
WP048	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete	22.0	COREAD
WP048	KIT MUT* (P36Q)	KIT (Y823D,N822,C809G,D820,A829P,D816,T670I)	Ripretinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ripretinib-advanced-gastrointestinal-stromal-tumor;PMID:32511981	only alteration type		GIST
WP048	RAD51D MUT* (--)	RAD51D oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP048	RAD54L MUT* (--)	RAD54L oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP048	PIK3CA MUT* (--)	PIK3CA (C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R)	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	only alteration type		BRCA
WP048	ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Anaplastic large cell lymphoma	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large	only gene		ALCL
WP048	ATR MUT* (--), ATR MUT* (--)	ATR oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP048	ALK MUT* (--)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
WP048	IDH2 MUT* (--)	IDH2 oncogenic mutation	Enasidenib(IDH2 inhibitor)	Acute lymphoblastic leukemia	Responsive	A	YES	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209606s004lbl.pdf	only alteration type		ALL
WP048	ARAF MUT* (--)	ARAF oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP048	ARAF MUT* (--)	ARAF oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP048	ARAF MUT* (--)	ARAF oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP048	ARAF MUT* (--)	ARAF oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP048	NRAS (G13D)	NRAS oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP048	NRAS (G13D)	NRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP048	NRAS (G13D)	NRAS oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP048	NRAS (G13D)	NRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP048	ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor	only gene		IM
WP048	ALK MUT* (--)	ALK fusion	Alectinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP048	ALK MUT* (--)	ALK fusion	Brigatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP048	ALK MUT* (--)	ALK fusion	Ceritinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP048	ALK MUT* (--)	ALK fusion	Lorlatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	YES	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
WP048	IDH2 MUT* (--)	IDH2 oncogenic mutation	Venetoclax(BCL2 inhibitor)	Acute myeloid leukemia	Responsive	A	YES	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf	only alteration type		AML
WP048	ARAF MUT* (--)	ARAF oncogenic mutation	BRAF inhibitor + EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only alteration type		COREAD
WP048	ARAF MUT* (--)	ARAF oncogenic mutation	BRAF inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only alteration type		COREAD
WP048	AKT2 MUT* (--)	AKT2 amplification	MK2206(Allosteric AKT inhibitor)	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 373)	only gene		CANCER
WP048	ALK MUT* (--)	ALK fusion	ALK inhibitor + IGF1R inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25173427	only gene		LUAD
WP048	ALK MUT* (--)	ALK fusion	ALK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:26301689	only gene		LUAD
WP048	ALK MUT* (--)	ALK fusion	ALK inhibitor + SRC inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25394791	only gene		LUAD
WP048	ALK MUT* (--)	ALK fusion	ALK inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560	only gene		COREAD
WP048	ALK MUT* (--)	ALK fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23553849	only gene		LUAD
WP048	ALK MUT* (--)	ALK fusion	novel ALK inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23639470	only gene		LUAD
WP048	ALK MUT* (--)	ALK (F1174L)	novel ALK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24327273	only alteration type		LUAD
WP048	CCND1 MUT* (--)	CCND1 amplification	SMO inhibitors	Medulloblastoma	Resistant	D	NO	PMID:24951114	only gene		MB
WP048	ALK MUT* (--)	ALK amplification	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only gene		LUAD
WP048	ALK MUT* (--)	ALK (E1408V)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP048	ALK MUT* (--)	ALK (L1196M)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
WP048	ALK MUT* (--)	ALK fusion	Ceritinib(ALK inhibitor)	Colorectal adenocarcinoma, Inflammatory myofibroblastic	Responsive	C	YES	PMID:26633560;PMID:26933125;PMID:27742657	only gene		COREAD, IM
WP048	ALK MUT* (--)	ALK fusion	Ceritinib(ALK inhibitor)	Hematologic malignancies	Responsive	C	YES	NCT02186821	only gene		HEMATO
WP048	CTNNB1 MUT* (--)	CTNNB1 oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Resistant	D	NO	PMID:23539443	only alteration type		COREAD
WP048	ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Lymphoma, Glioblastoma	Responsive	C	YES	PMID:24491302;NCT02270034	only gene		LY, GB
WP048	ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic, Thyroid carcinoma	Responsive	C	YES	PMID:20979472;PMID:24687827	only gene		IM, THCA
WP048	ALK MUT* (--)	ALK (F856S,A348D)	Crizotinib(ALK inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:26032424	only alteration type		AML
WP048	ALK MUT* (--)	ALK (L1198F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26698910	only alteration type		LUAD
WP048	ALK MUT* (--)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib(ALK inhibitor)	Glioma	Responsive	D	NO	PMID:22072639	only alteration type		G
WP048	ALK MUT* (--)	ALK fusion	Entrectinib(Pan-TK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560;PMID:26933125	only gene		COREAD
WP048	ALK MUT* (--)	ALK (C1156Y)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27401242	only alteration type		LUAD
WP048	ESR1 MUT* (H112P)	ESR1-YAP1 fusion	ESR1 inhibitors	Breast adenocarcinoma	Resistant	D	NO	PMID:24055055	only gene		BRCA
WP048	ARAF MUT* (--)	ARAF (S214C)	Sorafenib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	http://www.jci.org/articles/view/72763;PMID:24569458	only alteration type		LUAD
WP048	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	complete		CANCER
WP048	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	complete		OV
WP048	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	complete		CANCER
WP048	ATR MUT* (--), ATR MUT* (--)	ATR oncogenic mutation	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only alteration type		OV, CANCER
WP048	ATR MUT* (--), ATR MUT* (--)	ATR deletion	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only gene		OV, CANCER
WP048	ATR MUT* (--), ATR MUT* (--)	ATR oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP048	BCOR MUT* (V1701G)	BCOR oncogenic mutation	Enzastaurin(PKCb inhibitor)	Stomach	Responsive	D	NO	PMID:27397505	only alteration type		ST
WP048	JAK2 (V617F)	JAK2 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	complete		CM
WP048	CCND1 MUT* (--)	CCND1 amplification	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2014 (abstr 2528)	only gene		CM
WP048	CCND1 MUT* (--)	CCND1 amplification	CDK4/6 inhibitors	Any cancer type	Responsive	D	YES	PMID:22471707	only gene		CANCER
WP048	CTNNB1 MUT* (--)	CTNNB1 (H36Y,S37C,S37Y,D32V)	Everolimus + Letrozole(MTOR inhibitor + Hormonal therapy)	Endometrium	Responsive	C	NO	PMID:25624430	only alteration type		ED
WP048	NRAS (G13D)	NRAS (Q61)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:23569304;PMID:24265153	only alteration type		CM
WP048	PIK3CA MUT* (--)	PIK3CA (E545*)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMC3936420	only alteration type		CM
WP048	PIK3CA MUT* (--)	PIK3CA amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	D	NO	PMID:24366379	only gene		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9054)	only alteration type		L
WP048	PIK3CB MUT* (--)	PIK3CB (D1067Y)	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	C	NO	PMID:26759240	only alteration type		BRCA
WP048	ERCC1 MUT* (D2Y)	ERCC1 oncogenic mutation	PARP inhibitors	Lung	Responsive	D	NO	PMID:23934192	only alteration type		L
WP048	ERCC1 MUT* (D2Y)	ERCC1 deletion	PARP inhibitors	Lung	Responsive	D	NO	PMID:23934192	only gene		L
WP048	ERCC1 MUT* (D2Y)	ERCC1 oncogenic mutation	Cisplatin(Chemotherapy)	Lung	Responsive	D	NO	PMID:23275151;PMID:23934192	only alteration type		L
WP048	ERCC1 MUT* (D2Y)	ERCC1 deletion	Cisplatin(Chemotherapy)	Lung	Responsive	D	NO	PMID:23275151;PMID:23934192	only gene		L
WP048	ESR1 MUT* (H112P)	ESR1 (E380Q,537,538,L536,P535H)	novel ER degraders(GDC-0810,etc)	Breast adenocarcinoma	Responsive	C	NO	AACR 2015 (abstr CT231)	only alteration type		BRCA
WP048	ESR1 MUT* (H112P)	ESR1 oncogenic mutation	Fluvestrant(Hormonal therapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:27269946	only alteration type		BRCA
WP048	FANCC MUT* (R488)	FANCC oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP048	FANCC MUT* (R488)	FANCC deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP048	FGF4 MUT* (--)	FGF4 amplification	Dovitinib(FGFR inhibitor)	Breast adenocarcinoma	Responsive	C	NO	PMID:23658459	only gene		BRCA
WP048	FGF4 MUT* (--)	FGF4 amplification	Lucitanib(FGFR inhibitor)	Breast adenocarcinoma	Responsive	C	NO	PMID:25193991	only gene		BRCA
WP048	ALK MUT* (--)	ALK (I1171T)	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:25228534	only alteration type		LUAD
WP048	ALK MUT* (--)	ALK (G1123S)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:26134233	only alteration type		LUAD
WP048	IDH2 MUT* (--)	IDH2 (R140K,R172K)	AG-221(IDH2 inhibitor)	Hematologic malignancies	Responsive	C	YES	AACR 2014 (abstr CT103)	only alteration type		HEMATO
WP048	IDH2 MUT* (--)	IDH2 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Cholangiocarcinoma	Responsive	C	NO	NCT02428855	only alteration type		CH
WP048	IDH2 MUT* (--)	IDH2 (R172)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Billiary tract	Responsive	D	NO	PMID:27231123	only alteration type		BT
WP048	JAK2 (V617F)	JAK2 (V617F)	JAK inhibitor(alone or in combination)s	Acute myeloid leukemia	Responsive	D	YES	PMID:22829971	complete		AML
WP048	JAK2 (V617F)	JAK2 amplification	JAK inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27075627	only gene		BRCA
WP048	JAK2 (V617F)	JAK2-BRAF fusion	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22875628;PMID:22899477	only gene		ALL
WP048	JAK2 (V617F)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:22422826	complete		AML
WP048	KIT MUT* (P36Q)	KIT mutation in exon 11	HSP90 inhibitors	Gastrointestinal stromal	Responsive	C	NO	PMID:22898035	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT mutation in exon 9 or 17	HSP90 inhibitors	Gastrointestinal stromal	Responsive	D	NO	PMID:21737509	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT mutation in exon 9,11,13,14 or 17	Dasatinib(BCR-ABL inhibitor 2nd gen)	Cutaneous melanoma	Responsive	C	NO	PMID:19671763	only alteration type		CM
WP048	KIT MUT* (P36Q)	KIT (D816V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Systemic mastocytosis	Responsive	C	YES	PMID:18559612	only alteration type		SM
WP048	KIT MUT* (P36Q)	KIT (D816V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Acute myeloid leukemia	Responsive	C	YES	PMID:18986703	only alteration type		AML
WP048	KIT MUT* (P36Q)	KIT (D816Y,D816F,D816V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Any cancer type	Responsive	D	YES	PMID:16397263	only alteration type		CANCER
WP048	KIT MUT* (P36Q)	KIT (N822K)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Acute myeloid leukemia	Responsive	D	YES	PMID:23149070	only alteration type		AML
WP048	KIT MUT* (P36Q)	KIT inframe deletion (416-422),inframe insertion (416-422)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Acute myeloid leukemia	Responsive	D	YES	PMID:15618474	only alteration type		AML
WP048	KIT MUT* (P36Q)	KIT inframe deletion (V560)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Thymic	Responsive	C	YES	PMID:15201427	only alteration type		THYM
WP048	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:19223544;PMID:20619739	only alteration type		COREAD
WP048	KIT MUT* (P36Q)	KIT mutation in exon 9,11,13,14 or 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	B	NO	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812	only alteration type		CM
WP048	ALK MUT* (--)	ALK inframe insertion (1151T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only alteration type		LUAD
WP048	KIT MUT* (P36Q)	KIT (D820Y)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:23775962	only alteration type		CM
WP048	ALK MUT* (--)	ALK oncogenic mutation	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only alteration type		NSCLC
WP048	ALK MUT* (--)	ALK amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only gene		NSCLC
WP048	KIT MUT* (P36Q)	KIT (Y553N)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Thymic	Responsive	C	YES	PMID:21969494	only alteration type		THYM
WP048	KIT MUT* (P36Q)	KIT mutation in exon 9,11,13,14 or 17	Nilotinib(BCR-ABL inhibitor 2nd gen)	Cutaneous melanoma	Responsive	C	NO	PMID:22068222;PMID:25695690	only alteration type		CM
WP048	KIT MUT* (P36Q)	KIT mutation in exon 17	Nilotinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	C	NO	PMID:22119758;PMID:21456006	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT (D820Y)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Cutaneous melanoma	Responsive	C	NO	PMID:25695690	only alteration type		CM
WP048	KIT MUT* (P36Q)	KIT (788-828,829-860,550-592)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2015 (abstr 10517);PMID:25239608;ASCO 2015 (abstr 10535)	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT (A829P,V654A,T670I)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	D	NO	PMID:25239608	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT inframe deletion (577-579)	Sorafenib(Pan-TK inhibitor)	Thymic	Responsive	C	YES	PMID:20970876	only alteration type		THYM
WP048	KIT MUT* (P36Q)	KIT mutation in exon 9 or 11	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	PMID:22270258	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT (550-592,627-664,788-828,829-860)	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:18936790;PMID:20372153	only alteration type		CM
WP048	KIT MUT* (P36Q)	KIT mutation in exon 17	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	D	NO	PMID:23840364	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT (D820E)	Sorafenib(Pan-TK inhibitor)	Thymic	Responsive	C	YES	PMID:19461405	only alteration type		THYM
WP048	ALK MUT* (--)	ALK amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only gene		LUAD
WP048	KIT MUT* (P36Q)	KIT mutation in exon 9,11,13,14 or 17	Sunitinib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	B	NO	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812	only alteration type		CM
WP048	ALK MUT* (--)	ALK (C1156Y,L1196M)	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:20979473	only alteration type		NSCLC
WP048	ALK MUT* (--)	ALK (F1174L)	Crizotinib(ALK inhibitor)	Glioma	Resistant	D	NO	PMID:22072639	only alteration type		G
WP048	KIT MUT* (P36Q)	KIT (H697Y)	Sunitinib(Pan-TK inhibitor)	Thymic	Responsive	D	YES	PMID:19861435	only alteration type		THYM
WP048	KIT MUT* (P36Q)	KIT (H697Y)	Sunitinib(Pan-TK inhibitor)	Thymic	Responsive	D	YES	PMID:19861435	only alteration type		THYM
WP048	KIT MUT* (P36Q)	KIT (Y553N)	Sunitinib(Pan-TK inhibitor)	Thymic	Responsive	C	YES	PMID:23375402	only alteration type		THYM
WP048	ALK MUT* (--)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784;PMID:25228534	only alteration type		LUAD
WP048	ESR1 MUT* (H112P)	ESR1 oncogenic mutation	Exemestane(Hormonal therapy)	Breast adenocarcinoma	Resistant	B	NO	PMID:27269946	only alteration type		BRCA
WP048	ESR1 MUT* (H112P)	ESR1 (Y537S)	Fulvestrant(Hormonal therapy)	Breast adenocarcinoma	Resistant	D	NO	PMID:27986707	only alteration type		BRCA
WP048	KIT MUT* (P36Q)	KIT (627-664,664-714,449-514)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458;PMID:18955451;PMID:16624552	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT mutation in exon 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:23840364	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT mutation in exon 17 or 18	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:21690468;PMID:21642685	only alteration type		CM
WP048	KIT MUT* (P36Q)	KIT amplification	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	No Responsive	C	NO	PMID:23775962	only gene		CM
WP048	KIT MUT* (P36Q)	KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:23582185;PMID:21689725;PMID:17259998	only alteration type		GIST
WP048	MYC (T73P)	MYC amplification	BET inhibitors	Myeloma, Neuroblastoma	Responsive	D	YES	PMID:21889194;PMID:23430699	only gene		MYMA, NB
WP048	MYC (T73P)	MYC amplification	CDK7 inhibitors	Neuroblastoma	Responsive	D	NO	PMID:25416950	only gene		NB
WP048	MYC (T73P)	MYC amplification	FACT inhibitors	Neuroblastoma	Responsive	D	NO	PMID:26537256	only gene		NB
WP048	MYC (T73P)	MYC amplification	PIM inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:25505253	only gene		PRAD
WP048	MYC (T73P)	MYC amplification	Temozolomide(Chemotherapy)	Colorectal adenocarcinoma	Responsive	D	NO	PMID:27397505	only gene		COREAD
WP048	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP048	CCND1 MUT* (--)	CCND1 amplification	Palbociclib(CDK4/6 inhibitor)	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9056)	only gene		L
WP048	NRAS (G13D)	NRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26658964;NCT01781572;NCT02065063;NCT02022982;ASCO 2014 (abstr 9009)	complete		CM
WP048	NRAS (G13D)	NRAS (G12C)	ERK inhibitors	Any cancer type	Responsive	D	YES	PMID:23614898	only alteration type		CANCER
WP048	NRAS (G13D)	NRAS oncogenic mutation	ERK inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2017 (abstr 2508)	complete		CM
WP048	NRAS (G13D)	NRAS oncogenic mutation	HSP90 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:23538902	complete		CM
WP048	NRAS (G13D)	NRAS oncogenic mutation	MEK inhibitor +/- PI3K pathway inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23274911;PMID:22392911	complete		COREAD
WP048	NRAS (G13D)	NRAS oncogenic mutation	MEK inhibitors	Acute myeloid leukemia, Lung adenocarcinoma, Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22507781;PMID:23515407;PMID:18701506	complete		AML, LUAD, ALL
WP048	NRAS (G13D)	NRAS (Q61)	MEK inhibitors	Cutaneous melanoma	Responsive	B	NO	PMID:23414587,ASCO 2016 (abstr 9500)	only alteration type		CM
WP048	NRAS (G13D)	NRAS oncogenic mutation	Pan-RAF inhibitors	Cutaneous melanoma	Responsive	C	NO	ESMO 2015 (abstract 300);AACR 2017 (abstr CT002)	complete		CM
WP048	NRAS (G13D)	NRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Myeloma	Responsive	D	YES	PMID:22985491	complete		MYMA
WP048	NRAS (G13D)	NRAS oncogenic mutation	Sorafenib + MEK inhibitor(Pan-TK inhibitor + MEK inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:25294897	complete		HC
WP048	NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP048	NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP048	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP048	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP048	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP048	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	AKT inhibitors	Breast adenocarcinoma	Responsive	C	NO	ASCO 2015 (abstr 2500)	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitor(alone or in combination)s	Lung, Colorectal adenocarcinoma	Responsive	D	NO	PMID:23136191;PMID:23475782;PMID:22392911	only alteration type		L, COREAD
WP048	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Bladder, Head an neck, Lung	Responsive	C	NO	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	only alteration type		BLCA, HNC, L
WP048	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma, Ovary, Cervix squamous cell, Endometrium	Responsive	C	NO	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	only alteration type		BRCA, OV, CESC, ED
WP048	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26787751;PMID:26763254	only alteration type		HNSC
WP048	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Glioma, Thyroid carcinoma	Responsive	D	NO	PMID:19671762;PMID:21289267	only alteration type		G, THCA
WP048	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:28331003	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2501)	only alteration type		ST
WP048	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	AKT inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP048	PIK3CB MUT* (--)	PIK3CB (D1067Y)	AKT inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26759240	only alteration type		BRCA
WP048	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	MTORC1/2 inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP048	PIK3CB MUT* (--)	PIK3CB (D1067Y)	MTORC1/2 inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26759240	only alteration type		BRCA
WP048	PIK3CB MUT* (--)	PIK3CB oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	D	NO	PMID:23619167	only alteration type		HNSC
WP048	KIT MUT* (P36Q)	KIT mutation in exon 11	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT mutation in exon 17	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:23840364	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT amplification	Sunitinib(Pan-TK inhibitor)	Cutaneous melanoma	No Responsive	C	NO	PMID:22261812	only gene		CM
WP048	ESR1 MUT* (H112P)	ESR1 (E380Q,537,538,L536,P535H)	Tamoxifen(Hormonal therapy)	Breast adenocarcinoma	Resistant	C	NO	PMID:24185512;PMID:24185510;PMID:24398047	only alteration type		BRCA
WP048	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP048	RICTOR MUT* (--), RICTOR MUT* (T1266K)	RICTOR amplification	MTORC1/2 inhibitors	Lung	Responsive	C	NO	PMID:26370156	only gene		L
WP048	SERPINB3 MUT* (--), SERPINB3 MUT* (--), SERPINB3 MUT* (--)	SERPINB3 oncogenic mutation	CTLA4 inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:27668655	only alteration type		CM
WP048	SMARCA4 MUT* (I823)	SMARCA4 oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	C	NO	ESMO 2015 (abstract 302)	only alteration type		OV
WP048	SMARCA4 MUT* (I823)	SMARCA4 deletion	EZH2 inhibitors	Ovary	Responsive	C	NO	ESMO 2015 (abstract 302)	only gene		OV
WP048	STAG2 MUT* (--)	STAG2 oncogenic mutation	PARP inhibitors	Glioma	Responsive	D	NO	PMID:24356817	only alteration type		G
WP048	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP048	TERT MUT* (S274)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP048	TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP048	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP048	NRAS (G13D)	NRAS oncogenic mutation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:20179705	complete		CM
WP048	ALK MUT* (--)	ALK fusion	Crizotinib + Ceritinib	Sarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only gene		S
WP048	ALK MUT* (--)	ALK (G1202R,I1171N)	Alectinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only alteration type		NSCLC
WP048	NRAS (G13D)	NRAS (Q61K,T50I,G13D,G60E,G12C,G12V,T58I,.,Q61H,G12R,G12D,Q61L,G13V,Q61R)	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	oncokb: oncokb=https://www.oncokb.org/gene/NRAS	complete		COREAD
WP048	KIT MUT* (P36Q)	KIT (F522C,W557R,N463S,V654A,N822H,A829P,D820A,D572A,P838L,R634W,N822K,Y578C,N822Y,D816G,D816A,T670I,D820G,V560E,K558N,C809G,D820E,D820Y,D816Y,L576P,N822I,W557G,H697Y,I653T,V559A,V530I,V559I,S476I,V559G,D52N,.,N505I,S709F,V559C,D816N,D816V,M541L,V559D,Y823D,C443Y,D816E,Y553N,V560G,V852I,D816F,Y570H,K509I,E490K,D816.,N655K,K642E,V560D,W557C,D60N,D816H)	Sunitinib + Sorafenib	Thymic	Responsive	B	YES	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only alteration type		THYM
WP048	KIT MUT* (P36Q)	KIT (Y823D,T670I,V654A,D820G,C809G,D820A,N822K,D816H)	Imatinib	Gastrointestinal stromal	Resistant	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/KIT|CIVIC=https://civicdb.org/genes/29/summary	only alteration type		GIST
WP048	NRAS (G13D)	NRAS (Q61K,T50I,G13D,G60E,G12C,G12V,T58I,.,Q61H,G12R,G12D,Q61L,G13V,Q61R)	Binimetinib + Binimetinib + Ribociclib	Cutaneous melanoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/NRAS	complete		CM
WP048	ESR1 MUT* (H112P)	ESR1 (L536P,S463P,L469V,L536Q,Y537N,.,L536H,Y537C,Y537S,D538G,L536R,E380Q)	Azd9496 + Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ESR1	only alteration type		BRCA
WP048	ESR1 MUT* (H112P)	ESR1-CCDC170 fusion	Azd9496 + Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ESR1	only gene		BRCA
WP048	ESR1 MUT* (H112P)	ESR1-DAB2 fusion	Azd9496 + Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ESR1	only gene		BRCA
WP048	ESR1 MUT* (H112P)	ESR1-GYG1 fusion	Azd9496 + Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ESR1	only gene		BRCA
WP048	ESR1 MUT* (H112P)	ESR1-SOX9 fusion	Azd9496 + Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ESR1	only gene		BRCA
WP048	ESR1 MUT* (H112P)	ESR1-YAP1 fusion	Azd9496 + Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ESR1	only gene		BRCA
WP048	ESR1 MUT* (H112P)	ESR1 fusion	Azd9496 + Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ESR1	only gene		BRCA
WP048	KIT MUT* (P36Q)	KIT (F522C,W557R,N463S,V654A,N822H,A829P,D820A,D572A,P838L,R634W,N822K,Y578C,N822Y,D816G,D816A,T670I,D820G,V560E,K558N,C809G,D820E,D820Y,D816Y,L576P,N822I,W557G,H697Y,I653T,V559A,V530I,V559I,S476I,V559G,D52N,.,N505I,S709F,V559C,D816N,D816V,M541L,V559D,Y823D,C443Y,D816E,Y553N,V560G,V852I,D816F,Y570H,K509I,E490K,N655K,V560D,K642E,D816.,W557C,D60N,D816H)	Imatinib	Cutaneous melanoma	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/KIT|CIVIC=https://civicdb.org/genes/29/summary	only alteration type		CM
WP048	KIT MUT* (P36Q)	KIT amplification	Imatinib	Cutaneous melanoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only gene		CM
WP048	KIT MUT* (P36Q)	KIT (D816)	Blu-285	Mastocytosis	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only alteration type		MAS
WP048	ARAF MUT* (--)	ARAF (G322S,S214T,F351L,.,S214C,N217I,S214A,S214F)	Sorafenib	Histiocytoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ARAF	only alteration type		HIS
WP048	PIK3CA MUT* (--)	PIK3CA (P539R,R38H,Q546K,G118D,G106V,Q546E,E579K,N345K,E453K,V344A,E545K,T1025S,E542Q,G1049R,M1043I,E110K,P449T,N1044K,K111E,C378R,H1047R,C420R,E78K,E545A,S629C,D350G,.,G451R,M1043V,E542V,Q546R,E365K,E81K,G106D,R88Q,P366R,R93Q,G914R,H1047Y,K111N,E545Q,E545G,R93W,R108H,G106R,E453Q,E542K,D1029Y,N345I,D549N,A1066V,Q546P,E542G,E453A)	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA amplification	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only gene		BRCA
WP048	JAK2 (V617F)	JAK2-PCM1 fusion	Ruxolitinib	Eosinophilic chronic leukemia	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/JAK2	only gene		ECL
WP048	ALK MUT* (--)	ALK (C1156Y,F1174L,L1196M,G1269A)	Crizotinib	Non-small cell lung	Resistant	D	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary	only alteration type		NSCLC
WP048	KIT MUT* (P36Q)	KIT amplification	Sunitinib + Sorafenib	Thymic	Responsive	B	YES	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only gene		THYM
WP048	NRAS (G13D)	NRAS (Q61K,T50I,G13D,G60E,G12C,G12V,T58I,.,Q61H,G12R,G12D,Q61L,G13V,Q61R)	Selumetinib	Thyroid carcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/NRAS	complete		THCA
WP048	ARAF MUT* (--)	ARAF (G322S,S214T,F351L,.,S214C,N217I,S214A,S214F)	Sorafenib	Non-small cell lung	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ARAF|CIVIC=https://civicdb.org/genes/3/summary	only alteration type		NSCLC
WP048	AKT2 MUT* (--)	AKT2 Amplification	Everolimus,Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1621	only gene		LUAD
WP048	ALK MUT* (--)	ALK CAD::ALK	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7481	only gene		COREAD
WP048	ALK MUT* (--)	ALK CLTC::ALK	TAE684	Difuse large B Cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1261	only gene		DLBCL
WP048	ALK MUT* (--)	ALK CLTC::ALK	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1265	only gene		DLBCL
WP048	ALK MUT* (--)	ALK EML4::ALK	Alectinib	Mesothelioma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9228	only gene		MESO
WP048	ALK MUT* (--)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/262	only gene		NSCLC
WP048	ALK MUT* (--)	ALK EML4::ALK	WHI-P154	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1188	only gene		NSCLC
WP048	ALK MUT* (--)	ALK EML4::ALK	Crizotinib,Retaspimycin Hydrochloride	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1203	only gene		NSCLC
WP048	ALK MUT* (--)	ALK EML4::ALK	Crizotinib,Alvespimycin	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1206	only gene		NSCLC
WP048	ALK MUT* (--)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1207	only gene		NSCLC
WP048	ALK MUT* (--)	ALK EML4::ALK	Lorlatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1332	only gene		NSCLC
WP048	ALK MUT* (--)	ALK F1174L	Crizotinib	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/125	only alteration type		NB
WP048	ALK MUT* (--)	ALK F1174L	Alectinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/37	only alteration type		NB
WP048	ALK MUT* (--)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/38	only alteration type		NB
WP048	ALK MUT* (--)	ALK F1174L	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/142	only alteration type		NB
WP048	ALK MUT* (--)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1271	only alteration type		NB
WP048	ALK MUT* (--)	ALK F1174L	AZD3463	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1327	only alteration type		NB
WP048	ALK MUT* (--)	ALK F1174L	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1329	only alteration type		NB
WP048	ALK MUT* (--)	ALK F1174L	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/33	only alteration type		NSCLC
WP048	ALK MUT* (--)	ALK F1245C	Crizotinib	Neuroblastoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1333	only alteration type		NB
WP048	ALK MUT* (--)	ALK F1245C	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1330	only alteration type		NB
WP048	ALK MUT* (--)	ALK F1245V	Entrectinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2987	only alteration type		NB
WP048	ALK MUT* (--)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1240	only gene		ALCL
WP048	ALK MUT* (--)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/7361	only gene		ALCL
WP048	ALK MUT* (--)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	A	YES	https://civicdb.org/links/evidence_items/11218	only gene		ALCL
WP048	ALK MUT* (--)	ALK Fusion	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	YES	https://civicdb.org/links/evidence_items/1264	only gene		DLBCL
WP048	ALK MUT* (--)	ALK Fusion	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1691	only gene		LUAD
WP048	ALK MUT* (--)	ALK Fusion	Pemetrexed	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/945	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1175	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1187	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1198	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1199	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1200	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1201	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Retaspimycin Hydrochloride	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1202	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1272	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1273	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1279	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1282	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1419	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1577	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4835	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Alectinib,Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4858	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7284	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7285	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Lorlatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7286	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/8657	only gene		NSCLC
WP048	ALK MUT* (--)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11121	only gene		NSCLC
WP048	ALK MUT* (--)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1283	only alteration type		NSCLC
WP048	ALK MUT* (--)	ALK I1171	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1287	only alteration type		NSCLC
WP048	ALK MUT* (--)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1367	only alteration type		NSCLC
WP048	ALK MUT* (--)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1284	only alteration type		NSCLC
WP048	ALK MUT* (--)	ALK I1171	TAE684	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1285	only alteration type		NSCLC
WP048	ALK MUT* (--)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1344	only alteration type		NSCLC
WP048	ALK MUT* (--)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1368	only alteration type		NSCLC
WP048	ALK MUT* (--)	ALK I1171T	Ceritinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9404	only alteration type		NB
WP048	ALK MUT* (--)	ALK KANK4::ALK	Alectinib	Pancreas acinar	Responsive	C	NO	https://civicdb.org/links/evidence_items/10327	only gene		PAAC
WP048	ALK MUT* (--)	ALK Mutation	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1237	only alteration type		NSCLC
WP048	ALK MUT* (--)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	D	YES	https://civicdb.org/links/evidence_items/1239	only gene		ALCL
WP048	ALK MUT* (--)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	YES	https://civicdb.org/links/evidence_items/1241	only gene		ALCL
WP048	ALK MUT* (--)	ALK R1275Q	TAE684	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/48	only alteration type		NB
WP048	ALK MUT* (--)	ALK R1275Q	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/39	only alteration type		NB
WP048	ALK MUT* (--)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/143	only alteration type		NB
WP048	ALK MUT* (--)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1270	only alteration type		NB
WP048	ALK MUT* (--)	ALK R1275Q	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1331	only alteration type		NB
WP048	ARAF MUT* (--)	ARAF S214C	Sorafenib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/17	only alteration type		NSCLC
WP048	ARAF MUT* (--)	ARAF S214C	Sorafenib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/40	only alteration type		NSCLC
WP048	ARAF MUT* (--)	ARAF S214C	Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/41	only alteration type		NSCLC
WP048	ARAF MUT* (--)	ARAF S490T	Cetuximab,Irinotecan,Vemurafenib	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1905	only alteration type		COREAD
WP048	ASS1 MUT* (--)	ASS1 Loss	Carboplatin,Cisplatin,Taxol	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/5989	only gene		OV
WP048	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP048	CCND1 MUT* (--)	CCND1 Amplification	Tamoxifen	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/858	only gene		BRCA
WP048	CCND1 MUT* (--)	CCND1 Amplification	Palbociclib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1562	only gene		BRCA
WP048	CCND1 MUT* (--)	CCND1 Amplification	Palbociclib	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/1599	only gene		OV
WP048	CCND1 MUT* (--)	CCND1 Amplification	Palbociclib	Renal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1560	only gene		R
WP048	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP048	ESR1 MUT* (H112P)	ESR1 D538G	Hormone Therapy	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/243	only alteration type		BRCA
WP048	ESR1 MUT* (H112P)	ESR1 D538G	Fulvestrant,Tamoxifen	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/291	only alteration type		BRCA
WP048	ESR1 MUT* (H112P)	ESR1 D538G	Letrozole,Palbociclib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4814	only alteration type		BRCA
WP048	ESR1 MUT* (H112P)	ESR1 L536Q	Hormone Therapy	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/242	only alteration type		BRCA
WP048	ESR1 MUT* (H112P)	ESR1 L536Q	Fulvestrant,Tamoxifen	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/290	only alteration type		BRCA
WP048	ESR1 MUT* (H112P)	ESR1 MUTATION	Elacestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11443	only alteration type		BRCA
WP048	ESR1 MUT* (H112P)	ESR1 Y537C	Hormone Therapy	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/244	only alteration type		BRCA
WP048	ESR1 MUT* (H112P)	ESR1 Y537C	Fulvestrant,Tamoxifen	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/292	only alteration type		BRCA
WP048	ESR1 MUT* (H112P)	ESR1 Y537N	Hormone Therapy	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/245	only alteration type		BRCA
WP048	ESR1 MUT* (H112P)	ESR1 Y537N	Tamoxifen,Fulvestrant	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/293	only alteration type		BRCA
WP048	ESR1 MUT* (H112P)	ESR1 Y537S	Hormone Therapy	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/246	only alteration type		BRCA
WP048	ESR1 MUT* (H112P)	ESR1 Y537S	Tamoxifen,Fulvestrant	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/294	only alteration type		BRCA
WP048	IDH2 MUT* (--)	IDH2 Mutation	Enasidenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/4833	only alteration type		AML
WP048	IDH2 MUT* (--)	IDH2 Mutation	Enasidenib	Acute myeloid leukemia	Responsive	A	YES	https://civicdb.org/links/evidence_items/5069	only alteration type		AML
WP048	IDH2 MUT* (--)	IDH2 Mutation	Venetoclax	Acute myeloid leukemia	Responsive	C	YES	https://civicdb.org/links/evidence_items/8857	only alteration type		AML
WP048	JAK2 (V617F)	JAK2 Splice Site (c.1641+2T>G)	Pembrolizumab	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4825	only alteration type		CM
WP048	KIT MUT* (P36Q)	KIT A502_Y503insAY	Regorafenib,Imatinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4630	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT A502_Y503insAY	Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/7392	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT A829P	Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7413	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT A829P	Sunitinib,Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7415	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT C809G	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2920	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT D579del	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4142	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT D816E	Sunitinib,Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4631	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT D816E	Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7401	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT D816H	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2923	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT D816V	Midostaurin	Systemic mastocytosis	Responsive	B	YES	https://civicdb.org/links/evidence_items/1725	only alteration type		SM
WP048	KIT MUT* (P36Q)	KIT D820A	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2921	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT D820G	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2922	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT D820Y	Imatinib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2886	only alteration type		CM
WP048	KIT MUT* (P36Q)	KIT D820Y	Sunitinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2888	only alteration type		CM
WP048	KIT MUT* (P36Q)	KIT D820Y	Regorafenib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/4589	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT K550_K558del	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4062	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT K550_W557del	Ponatinib,Regorafenib,Imatinib,Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4583	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT K558delinsNP	Imatinib,Regorafenib,Sunitinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4594	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT K642E	Dasatinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4147	only alteration type		CM
WP048	KIT MUT* (P36Q)	KIT K642E	Sunitinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/7397	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT L576P	Nilotinib,Sorafenib,Imatinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/34	only alteration type		CM
WP048	KIT MUT* (P36Q)	KIT L576P	Dasatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/42	only alteration type		CM
WP048	KIT MUT* (P36Q)	KIT L576P	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4136	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT L576P	Nilotinib,Dasatinib,Imatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/303	only alteration type		NSCLC
WP048	KIT MUT* (P36Q)	KIT Mutation	Imatinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1222	only alteration type		CM
WP048	KIT MUT* (P36Q)	KIT Mutation	Pictilisib,Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/919	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT N822K	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7370	only alteration type		AML
WP048	KIT MUT* (P36Q)	KIT N822K	Ponatinib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7379	only alteration type		AML
WP048	KIT MUT* (P36Q)	KIT N822K	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2918	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT N822K	Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4167	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT N822K	Regorafenib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4169	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT N822K	Sunitinib,Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7414	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT N822K	Regorafenib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/4595	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT S628N	Imatinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7463	only alteration type		CM
WP048	KIT MUT* (P36Q)	KIT T670I	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2924	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT T670I	Regorafenib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4510	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT T670I	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7416	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT T670I	Sunitinib,Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7417	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT V559D	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/3028	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT V559D	Imatinib,Regorafenib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4459	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT V560D	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4122	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT V560D	Regorafenib,Ponatinib,Imatinib,Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4127	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT V560G	Ponatinib,Regorafenib,Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/7395	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT V654A	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/249	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT V654A	Sunitinib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/304	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT W557_K558del	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4082	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT W557_K558del	Imatinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4084	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT W557_K558del	Regorafenib,Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4087	only alteration type		GIST
WP048	KIT MUT* (P36Q)	KIT Y823D	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2919	only alteration type		GIST
WP048	KMT2C (L1386P), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP048	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP048	NFE2L2 MUT* (--)	NFE2L2 Mutation	Sapanisertib	Lung squamous cell	Responsive	B	NO	https://civicdb.org/links/evidence_items/7446	only alteration type		LUSC
WP048	NRAS (G13D)	NRAS G12C	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3845	only alteration type		COREAD
WP048	NRAS (G13D)	NRAS G12D	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2002	only alteration type		COREAD
WP048	NRAS (G13D)	NRAS G12D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3693	only alteration type		COREAD
WP048	NRAS (G13D)	NRAS G13D	Tanespimycin	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/21	complete		CM
WP048	NRAS (G13D)	NRAS G13R	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2204	only alteration type		COREAD
WP048	NRAS (G13D)	NRAS G13R	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3842	only alteration type		COREAD
WP048	NRAS (G13D)	NRAS Mutation	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/996	complete		CM
WP048	NRAS (G13D)	NRAS Mutation	Dabrafenib,Vemurafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6263	complete		CM
WP048	NRAS (G13D)	NRAS Mutation	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1227	complete		CM
WP048	NRAS (G13D)	NRAS Mutation	Trametinib,Omipalisib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1429	complete		CM
WP048	NRAS (G13D)	NRAS Mutation	Binimetinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1509	complete		CM
WP048	NRAS (G13D)	NRAS Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1703	complete		COREAD
WP048	NRAS (G13D)	NRAS Mutation	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2210	complete		COREAD
WP048	NRAS (G13D)	NRAS Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	A	NO	https://civicdb.org/links/evidence_items/5344	complete		COREAD
WP048	NRAS (G13D)	NRAS Q179X	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4785	only alteration type		COREAD
WP048	NRAS (G13D)	NRAS Q61	Vemurafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/14	only alteration type		CM
WP048	NRAS (G13D)	NRAS Q61	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/36	only alteration type		COREAD
WP048	NRAS (G13D)	NRAS Q61	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/124	only alteration type		COREAD
WP048	NRAS (G13D)	NRAS Q61H	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3690	only alteration type		COREAD
WP048	NRAS (G13D)	NRAS Q61K	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2189	only alteration type		COREAD
WP048	NRAS (G13D)	NRAS Q61K	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2192	only alteration type		COREAD
WP048	NRAS (G13D)	NRAS Q61K	Everolimus,Binimetinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1002	only alteration type		NB
WP048	NRAS (G13D)	NRAS Q61K	Selumetinib,Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2907	only alteration type		NSCLC
WP048	NRAS (G13D)	NRAS Q61L	Temozolomide	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/22	only alteration type		CM
WP048	NRAS (G13D)	NRAS Q61L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2181	only alteration type		COREAD
WP048	NRAS (G13D)	NRAS Q61R	Temozolomide	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/23	only alteration type		CM
WP048	NRAS (G13D)	NRAS Q61R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2184	only alteration type		COREAD
WP048	NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP048	NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP048	NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP048	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2346	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8549	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA C420R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2078	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA C420R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1999	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA D350G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4784	only alteration type		CM
WP048	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8007	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E542K	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/310	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E542K	Sirolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/311	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2022	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2026	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2058	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E542K	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7315	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8013	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8016	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E542K	Regorafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/83	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA E542K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4424	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA E542K	Apitolisib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/1549	only alteration type		HNSC
WP048	PIK3CA MUT* (--)	PIK3CA E542K	Perifosine,Temsirolimus	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1626	only alteration type		THCA
WP048	PIK3CA MUT* (--)	PIK3CA E545	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7468	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E545G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3724	only alteration type		CM
WP048	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1453	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2036	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6211	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E545K	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6213	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E545K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8008	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8547	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E545K	Akt Inhibitor MK2206,Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/710	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2034	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2062	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8017	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8018	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA E545K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3722	only alteration type		CM
WP048	PIK3CA MUT* (--)	PIK3CA E545K	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/387	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2037	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2217	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib	Lung adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1171	only alteration type		LUAD
WP048	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1670	only alteration type		LUAD
WP048	PIK3CA MUT* (--)	PIK3CA E545K	PI103	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2040	only alteration type		NSCLC
WP048	PIK3CA MUT* (--)	PIK3CA E545Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2213	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA E81K	Oxaliplatin,Fluorouracil,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4464	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA F930S	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10032	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA G1049R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3847	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA H1047L	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2089	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA H1047L	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8009	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA H1047L	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8019	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA H1047L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4432	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2103	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6204	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6206	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8548	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/314	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Capivasertib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1505	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1506	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Everolimus,Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1623	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2096	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2102	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/258	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/388	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Vemurafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3733	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3841	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Akt Inhibitor MK2206,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8364	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1465	only alteration type		HNSC
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1447	only alteration type		LUAD
WP048	PIK3CA MUT* (--)	PIK3CA H1047R	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1625	only alteration type		THCA
WP048	PIK3CA MUT* (--)	PIK3CA H1047X	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7318	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2867	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8663	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2866	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA K111N	Dactolisib,Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8183	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8662	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA K111N	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2085	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA K111N	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8011	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA K111N	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8020	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA K944N	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10031	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA K966E	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10034	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1384	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2087	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2098	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8536	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Capecitabine,Lapatinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8705	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1296	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1504	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1600	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1607	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1610	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Fulvestrant,Alpelisib	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7313	only alteration type		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/915	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1705	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3732	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6298	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6299	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6300	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6301	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6362	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Cabozantinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/771	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6375	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Ridaforolimus,Temsirolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/892	only alteration type		ED
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Pictilisib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1616	only alteration type		ED
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Radiation Therapy,Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1490	only alteration type		HNSC
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin,Sulindac,Celecoxib	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7185	only alteration type		HNSC
WP048	PIK3CA MUT* (--)	PIK3CA Mutation	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2355	only alteration type		NSCLC
WP048	PIK3CA MUT* (--)	PIK3CA N345K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4047	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA Q546K	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2198	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA R88Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3832	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA R93W	Cetuximab,Fluorouracil,Oxaliplatin	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4467	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA S158L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4463	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA V955G	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10033	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA V955I	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/8063	only alteration type		COREAD
WP048	PIK3CA MUT* (--)	PIK3CA Amplification	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8267	only gene		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA Amplification	Lapatinib,Dactolisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8271	only gene		BRCA
WP048	PIK3CA MUT* (--)	PIK3CA Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6275	only gene		CM
WP048	PIK3CA MUT* (--)	PIK3CA Amplification	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1464	only gene		HNSC
WP048	PIK3CA MUT* (--)	PIK3CA Amplification	Sulindac,Aspirin,Ibuprofen	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7186	only gene		HNSC
WP048	PIK3CA MUT* (--)	PIK3CA Amplification	Pictilisib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/756	only gene		OV
WP048	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP048	RAD51D MUT* (--)	RAD51D Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11214	only alteration type		PRAD
WP048	RAD54L MUT* (--)	RAD54L Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11207	only alteration type		PRAD
WP048	RICTOR MUT* (--), RICTOR MUT* (T1266K)	RICTOR Amplification	Onatasertib,Sapanisertib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1440	only gene		LUAD
WP048	RICTOR MUT* (--), RICTOR MUT* (T1266K)	RICTOR Amplification	Vistusertib	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7449	only gene		SCLC
WP048	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP048	SMAD4 MUT* (H291P)	SMAD4 Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/719	only alteration type		COREAD
WP048	SMARCA4 MUT* (I823)	SMARCA4 Loss	Abemaciclib,Palbociclib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/7155	only gene		NSCLC
WP048	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP048	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP270	KRAS (G60R)	KRAS (12,13)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP270	JAK2 MUT* (--)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Myelofibrosis	Responsive	A	YES	FDA	only alteration type		MY
WP270	KRAS (G60R)	KRAS (12,13,59,61,117,146)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	FDA guidelines	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS oncogenic mutation	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	NCCN guidelines	complete		COREAD
WP270	KRAS (G60R)	KRAS oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	A	NO	NCCN guidelines	complete		COREAD
WP270	KRAS (G60R)	KRAS oncogenic mutation	EGFR inhibitors	Lung	Resistant	A	NO	NCCN guidelines	complete		L
WP270	RET MUT* (R297S), RET MUT* (--)	RET (618,620,634,768,791,891,918,C634W,M918T)	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	A	NO	PMID:20065189;PMID:22025146	only alteration type		THCA
WP270	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		GCA
WP270	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		RA
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022	only alteration type		BRCA
WP270	RET MUT* (R297S), RET MUT* (--)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-ret-altered-thyroid-cancers;ASCO 2020 (abstr 109)	only gene		TH
WP270	RET MUT* (R297S), RET MUT* (--)	RET oncogenic mutation	Selpercatinib(RET kinase inhibitor)	Thyroid medullary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only alteration type		THM
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP270	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP270	BARD1 MUT* (--)	BARD1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP270	CDK12 MUT* (--)	CDK12 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP270	KRAS (G60R)	KRAS (G12C)	Sotorasib(RAS GTPase family inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc	only alteration type		NSCLC
WP270	RET MUT* (R297S), RET MUT* (--)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions	only gene		NSCLC
WP270	RET MUT* (R297S), RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-non-small-cell-lung	only gene		NSCLC
WP270	RAD54L MUT* (--)	RAD54L oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP270	PIK3CA MUT* (--)	PIK3CA (C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R)	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	only alteration type		BRCA
WP270	KRAS (G60R)	KRAS (G12C)	Adagrasib(RAS GTPase family inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc	only alteration type		NSCLC
WP270	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Bevacizumab(VEGF mAb inhibitor);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP270	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP270	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Pembrolizumab(PD-1-blocking antibody);Pemetrexed(Chemotherapy);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf	complete		NSCLC
WP270	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Durvalumab(PD-1-blocking antibody);Tremelimumab-actl(CTLA-4 blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non	complete		NSCLC
WP270	RET MUT* (R297S), RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only gene		TH
WP270	RET MUT* (R297S), RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Solid tumors	Responsive	A	NO	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors	only gene		SOLID
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP270	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP270	ATR MUT* (--)	ATR oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP270	CDK12 MUT* (--)	CDK12 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP270	EGFR wildtype, ALK wildtype, ROS1 wildtype	EGFR wildtype;ALK wildtype;ROS1 wildtype	Cemiplimab-rwlc(PD-1-blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-combination-platinum-based-chemotherapy-non-small-cell-lung-cancer	complete		NSCLC
WP270	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete	72.0	COREAD
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP270	KRAS (G60R)	KRAS oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP270	KRAS (G60R)	KRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISEC
WP270	KRAS (G60R)	KRAS oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP270	KRAS (G60R)	KRAS oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	complete		HISLC
WP270	MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP270	MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP270	MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP270	MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP270	KRAS (G60R)	KRAS (G12C)	Adagrasib(RAS GTPase family inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP270	RET MUT* (R297S), RET MUT* (--)	RET fusion	Cabozantinib(Kinase inhibitor )	Non-small cell lung	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP270	KRAS (G60R)	KRAS (G12C)	Sotorasib(RAS GTPase family inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP270	CTNNB1 MUT* (--), CTNNB1 MUT* (D667E)	CTNNB1 oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Resistant	D	NO	PMID:23539443	only alteration type		COREAD
WP270	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	complete		CANCER
WP270	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	complete	729.0	OV
WP270	ARID1A (PQ1326-1327P)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	complete		CANCER
WP270	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only alteration type		COREAD
WP270	ATM MUT* (--), ATM MUT* (--)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
WP270	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only alteration type		LY
WP270	ATM MUT* (--), ATM MUT* (--)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only gene		LY
WP270	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP270	ATM MUT* (--), ATM MUT* (--)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
WP270	ATM MUT* (--), ATM MUT* (--)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP270	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP270	ATM MUT* (--), ATM MUT* (--)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP270	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP270	ATM MUT* (--), ATM MUT* (--)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP270	ATR MUT* (--)	ATR oncogenic mutation	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only alteration type		OV, CANCER
WP270	ATR MUT* (--)	ATR deletion	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only gene		OV, CANCER
WP270	ATR MUT* (--)	ATR oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP270	BCOR MUT* (--)	BCOR oncogenic mutation	Enzastaurin(PKCb inhibitor)	Stomach	Responsive	D	NO	PMID:27397505	only alteration type		ST
WP270	JAK2 MUT* (--)	JAK2 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	only alteration type		CM
WP270	KRAS (G60R)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Pancreas	No Responsive	C	NO	ASCO 2015 (abstr 4119)	complete		PA
WP270	KRAS (G60R)	KRAS (G13D)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	No Responsive	B	NO	PMID:27114605	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS oncogenic mutation	Selumetinib(MEK inhibitor)	Lung	No Responsive	C	NO	PMID:26802155	complete		L
WP270	KRAS (G60R)	KRAS amplification	BRAF inhibitor + EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only gene		COREAD
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
WP270	BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP270	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP270	KRAS (G60R)	KRAS amplification	BRAF inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only gene		COREAD
WP270	CBL MUT* (--)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP270	CBL MUT* (--)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP270	KRAS (G60R)	KRAS oncogenic mutation	EGFR inhibitors	Non-small cell lung	Resistant	D	NO	PMID:19238210	complete		NSCLC
WP270	KRAS (G60R)	KRAS oncogenic mutation	EGFR mAb inhibitors	Stomach	Resistant	D	NO	PMID:22614881;PMID:22290393	complete		ST
WP270	CDK12 MUT* (--)	CDK12 oncogenic mutation	PARP inhibitors	Ovary	Responsive	D	NO	PMID:24240700;PMID:24554720	only alteration type		OV
WP270	CDK12 MUT* (--)	CDK12 amplification	PARP inhibitors	Ovary	Responsive	D	NO	PMID:24240700;PMID:24554720	only gene		OV
WP270	CSF1R MUT* (R106)	CSF1R (Y571D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:18971950	only alteration type		MDPS
WP270	MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP270	CTNNB1 MUT* (--), CTNNB1 MUT* (D667E)	CTNNB1 (H36Y,S37C,S37Y,D32V)	Everolimus + Letrozole(MTOR inhibitor + Hormonal therapy)	Endometrium	Responsive	C	NO	PMID:25624430	only alteration type		ED
WP270	MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP270	MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP270	MAP2K2 MUT* (--), MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP270	NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP270	PIK3CA MUT* (--)	PIK3CA (E545*)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMC3936420	only alteration type		CM
WP270	PIK3CA MUT* (--)	PIK3CA amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	D	NO	PMID:24366379	only gene		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9054)	only alteration type		L
WP270	FANCC MUT* (S459R)	FANCC oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP270	FANCC MUT* (S459R)	FANCC deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP270	NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP270	GATA3 MUT* (--)	GATA3 oncogenic mutation	Aromatase ihibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:24758297	only alteration type		BRCA
WP270	HDAC2 MUT* (--)	HDAC2 biallelic inactivation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP270	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
WP270	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
WP270	KRAS (G60R)	KRAS oncogenic mutation	EZH2 inhibitors	Any cancer type	Resistant	D	YES	PMID:26552009	complete		CANCER
WP270	KRAS (G60R)	KRAS oncogenic mutation	PI3K pathway inhibitors	Endometrium	Resistant	D	NO	PMID:22662154	complete		ED
WP270	JAK2 MUT* (--)	JAK2 (V617F)	JAK inhibitor(alone or in combination)s	Acute myeloid leukemia	Responsive	D	YES	PMID:22829971	only alteration type		AML
WP270	JAK2 MUT* (--)	JAK2 amplification	JAK inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27075627	only gene		BRCA
WP270	JAK2 MUT* (--)	JAK2-BRAF fusion	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22875628;PMID:22899477	only gene		ALL
WP270	JAK2 MUT* (--)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:22422826	only alteration type		AML
WP270	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP270	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:19223544;PMID:20619739	only alteration type		COREAD
WP270	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP270	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP270	KRAS (G60R)	KRAS (G12)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	C	NO	PMID:24687822	only alteration type		GIST
WP270	KRAS (G60R)	KRAS oncogenic mutation	Trastuzumab + Lapatinib(ERBB2 mAb inhibitor + ERBB2 inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	ASCO 2015 (abstr 3508);NCT01104571;EBCC10	complete		COREAD
WP270	KRAS (G60R)	KRAS oncogenic mutation	BET inhibitors	Lung	Responsive	D	NO	PMID:23129625;PMID:24045185	complete		L
WP270	KRAS (G60R)	KRAS oncogenic mutation	CDK4 inhibitors	Lung	Responsive	D	NO	PMID:20609353	complete		L
WP270	KRAS (G60R)	KRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Lung	Responsive	C	NO	AACR 2017 (CT046)	complete		L
WP270	KRAS (G60R)	KRAS oncogenic mutation	CDK4/6 inhibitor + MEK inhibitors	Cervix squamous cell	Responsive	D	NO	PMID:27167191	complete		CESC
WP270	KRAS (G60R)	KRAS oncogenic mutation	EGFR mAb inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24553387	complete		COREAD
WP270	KRAS (G60R)	KRAS oncogenic mutation	ERK inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23614898	complete		COREAD
WP270	KRAS (G60R)	KRAS oncogenic mutation	FAK inhibitors	Lung	Responsive	D	NO	PMID:23358651	complete		L
WP270	KRAS (G60R)	KRAS oncogenic mutation	FAS inhibitors	Lung	Responsive	C	NO	AACR 2016;abstr	complete		L
WP270	KRAS (G60R)	KRAS oncogenic mutation	FAS inhibitors	Lung	Responsive	C	NO	AACR 2016, abstr LB214	complete		L
WP270	KRAS (G60R)	KRAS oncogenic mutation	HSP90 inhibitor(in combination)s	Lung	Responsive	D	NO	PMID:23012248;PMID:21907929	complete		L
WP270	KRAS (G60R)	KRAS oncogenic mutation	JAK/TBK1/IKKÎµ inhibitors	Lung	Responsive	D	NO	PMID:24444711	complete		L
WP270	KRAS (G60R)	KRAS oncogenic mutation	MEK inhibitor + BCL-XL inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23245996	complete		COREAD
WP270	KRAS (G60R)	KRAS oncogenic mutation	MEK inhibitor + IGF1R inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24045180	complete		COREAD
WP270	KRAS (G60R)	KRAS oncogenic mutation	MEK inhibitor + PI3K pathway inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:22392911	complete		COREAD
WP270	KRAS (G60R)	KRAS oncogenic mutation	MEK inhibitors	Lung, Billiary tract	Responsive	C	NO	PMID:23200175;PMID:24947927;PMID:25667274;PMID:25722381;PMID:23391555	complete		L, BT
WP270	KRAS (G60R)	KRAS oncogenic mutation	MEK inhibitors	Acute myeloid leukemia, Cervix, Ovary	Responsive	D	YES	PMID:22507781;PMID:22169769;PMID:19018267	complete		AML, CER, OV
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP270	KRAS (G60R)	KRAS (G12)	MEK inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:18701506	only alteration type		ALL
WP270	NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP270	KRAS (G60R)	KRAS oncogenic mutation	MTOR inhibitor + BH3 mimeticss	Colorectal adenocarcinoma	Responsive	D	NO	PMID:24163374	complete		COREAD
WP270	KRAS (G60R)	KRAS oncogenic mutation	pan-RAF inhibitors	Lung	Responsive	C	NO	AACR 2017 (abstr  CT002)	complete		L
WP270	KRAS (G60R)	KRAS oncogenic mutation	pan-RAF inhibitors	Endometrium	Responsive	C	NO	AACR 2016 (abstr CT005);AACR 2017 (abstr CT002)	complete		ED
WP270	KRAS (G60R)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Endometrium	Responsive	D	NO	PMID:21984976;PMID:22662154	complete	730.0	ED
WP270	KRAS (G60R)	KRAS oncogenic mutation	PI3K pathway inhibitor + MEK inhibitors	Lung	Responsive	C	NO	PMID:25516890	complete		L
WP270	KRAS (G60R)	KRAS oncogenic mutation	Abemaciclib(CDK4/6 inhibitor)	Lung	Responsive	C	NO	PMID:27217383	complete		L
WP270	IGF1R MUT* (--)	IGF1R amplification	Erlotinib(EGFR inhibitor 1st gen)	Lung adenocarcinoma	Resistant	D	NO	PMID:24458568	only gene		LUAD
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP270	NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP270	MTOR MUT* (E1854*)	MTOR (F2108L)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Resistant	C	NO	PMID:25295501	only alteration type		THCA
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP270	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP270	NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP270	NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP270	MDM4 MUT* (--)	MDM4 amplification	MDM2/MDMX inhibitors	Sarcoma	Responsive	D	NO	PMID:24336067	only gene		S
WP270	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP270	MTOR MUT* (E1854*)	MTOR (F2108L)	MTOR kinase inhibitors	Any cancer type	Responsive	D	YES	PMID:25295501	only alteration type		CANCER
WP270	MTOR MUT* (E1854*)	MTOR (E2014K,E2419K,N1421D)	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:24625776	only alteration type		BLCA
WP270	MTOR MUT* (E1854*)	MTOR (I1973F)	Everolimus(MTOR inhibitor)	Angiosarcoma, Renal	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		AS, R
WP270	MTOR MUT* (E1854*)	MTOR (K1771R)	Everolimus(MTOR inhibitor)	Stomach, Adrenal gland	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		ST, AG
WP270	MTOR MUT* (E1854*)	MTOR (N1421D)	Everolimus(MTOR inhibitor)	Stomach	Responsive	C	NO	PMID:26859683	only alteration type		ST
WP270	MTOR MUT* (E1854*)	MTOR (Q2223K)	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468	only alteration type		R
WP270	MTOR MUT* (E1854*)	MTOR (L1460P,S2215Y,R2505P)	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	D	YES	PMID:24631838	only alteration type		CANCER
WP270	KRAS (G60R)	KRAS oncogenic mutation	Decitabine + BCL2 inhibitor(Chemotherapy + BCL2 inhibitor)	Ovary	Responsive	D	NO	PMID:25968887	complete		OV
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP270	NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP270	NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP270	NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP270	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP270	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP270	NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP270	NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP270	NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP270	NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP270	PDGFRA wildtype	PDGFRA wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:14645423;PMID:18955458	complete		GIST
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP270	NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP270	NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP270	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP270	LRP1B MUT* (--), LRP1B MUT* (--)	LRP1B oncogenic mutation	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only alteration type		OV
WP270	LRP1B MUT* (--), LRP1B MUT* (--)	LRP1B deletion	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only gene		OV
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP270	NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP270	NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP270	NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP270	NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP270	NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP270	NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP270	NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP270	NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP270	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP270	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP270	NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP270	NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP270	KRAS (G60R)	KRAS oncogenic mutation	Gemcitabine + MEK inhibitor(Chemotherapy + MEK inhibitor)	Pancreas	Responsive	C	NO	PMID:23583440	complete		PA
WP270	KRAS (G60R)	KRAS oncogenic mutation	Selumetinib(MEK inhibitor)	Non-small cell lung	Responsive	C	NO	NCT00890825	complete		NSCLC
WP270	NOTCH1 MUT* (N685T)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP270	NOTCH1 MUT* (N685T)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP270	NOTCH1 MUT* (N685T)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP270	NOTCH1 MUT* (N685T)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP270	NOTCH1 MUT* (N685T)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP270	NOTCH1 MUT* (N685T)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP270	NOTCH1 MUT* (N685T)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP270	NOTCH1 MUT* (N685T)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	only alteration type		MCL
WP270	NOTCH1 MUT* (N685T)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP270	NOTCH1 MUT* (N685T)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP270	NOTCH1 MUT* (N685T)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP270	NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene	74.0	LUAD
WP270	NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP270	PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type	729.0	CANCER
WP270	PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene	729.0	CANCER
WP270	PDGFRA wildtype	PDGFRA wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP270	RET MUT* (R297S), RET MUT* (--)	RET (I788N)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Resistant	D	NO	PMID:28615362	only alteration type		LUAD
WP270	PDGFRA wildtype	PDGFRA wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP270	PDGFRA wildtype	PDGFRA wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP270	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	AKT inhibitors	Breast adenocarcinoma	Responsive	C	NO	ASCO 2015 (abstr 2500)	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitor(alone or in combination)s	Lung, Colorectal adenocarcinoma	Responsive	D	NO	PMID:23136191;PMID:23475782;PMID:22392911	only alteration type		L, COREAD
WP270	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Bladder, Head an neck, Lung	Responsive	C	NO	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	only alteration type		BLCA, HNC, L
WP270	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma, Ovary, Cervix squamous cell, Endometrium	Responsive	C	NO	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	only alteration type	730.0	BRCA, OV, CESC, ED
WP270	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26787751;PMID:26763254	only alteration type		HNSC
WP270	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Glioma, Thyroid carcinoma	Responsive	D	NO	PMID:19671762;PMID:21289267	only alteration type		G, THCA
WP270	KRAS (G60R)	KRAS oncogenic mutation	Sorafenib + MEK inhibitor(Pan-TK inhibitor + MEK inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:25294897	complete		HC
WP270	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:28331003	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2501)	only alteration type		ST
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP270	PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP270	NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP270	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP270	RAD50 MUT* (--), ATM MUT* (--), ATM MUT* (--)	RAD50 (L1237F) + ATM deletion	Irinotecan + CHK1/2 inhibitor(TOPO1 inhibitor + CHK1/2 inhibitor)	Any cancer type	Responsive	C	YES	PMID:24934408	only gene		CANCER
WP270	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP270	RET MUT* (R297S), RET MUT* (--)	RET fusion	RET inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:22327624;PMID:22327622	only gene		LUAD
WP270	RET MUT* (R297S), RET MUT* (--)	RET-TPCN1 fusion	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only gene		TH
WP270	RET MUT* (R297S), RET MUT* (--)	RET (C634W,M918T)	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only alteration type		TH
WP270	RET MUT* (R297S), RET MUT* (--)	RET fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP270	RET MUT* (R297S), RET MUT* (--)	RET-TPCN1 fusion	Cabozantinib(Pan-kinase inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP270	RET MUT* (R297S), RET MUT* (--)	RET (C634W,M918T)	Cabozantinib(Pan-kinase inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP270	RET MUT* (R297S), RET MUT* (--)	RET fusion	Nintedanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26787234	only gene		LUAD
WP270	RET MUT* (R297S), RET MUT* (--)	RET fusion	Sunitinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP270	RET MUT* (R297S), RET MUT* (--)	RET-TPCN1 fusion	Sunitinib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP270	RET MUT* (R297S), RET MUT* (--)	RET (C634W,M918T)	Sunitinib(Pan-TK inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP270	RET MUT* (R297S), RET MUT* (--)	RET fusion	Vandetanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP270	RET MUT* (R297S), RET MUT* (--)	RET-TPCN1 fusion	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP270	RICTOR MUT* (--)	RICTOR amplification	MTORC1/2 inhibitors	Lung	Responsive	C	NO	PMID:26370156	only gene		L
WP270	KRAS (G60R)	KRAS oncogenic mutation	Trametinib + Ponatinib(MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27338794	complete		LUAD
WP270	STAG2 MUT* (--)	STAG2 oncogenic mutation	PARP inhibitors	Glioma	Responsive	D	NO	PMID:24356817	only alteration type		G
WP270	NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP270	SUZ12 MUT* (T160X)	SUZ12 oncogenic mutation	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only alteration type		CANCER
WP270	SUZ12 MUT* (T160X)	SUZ12 deletion	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only gene		CANCER
WP270	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP270	TERT MUT* (--)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
WP270	TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP270	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP270	TSC1 MUT* (--)	TSC1 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	only alteration type		RA
WP270	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	only alteration type		BLCA
WP270	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;PMID:26859683;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	only alteration type		R
WP270	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Sarcoma, Stomach	Responsive	C	NO	PMID:26859683	only alteration type		S, ST
WP270	TSC1 MUT* (--)	TSC1 deletion	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	only gene		R
WP270	EWSR1 MUT* (--)	EWSR1-FLI1 fusion	T + K + 2 + 1 + 6	Ewing sarcoma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EWSR1	only gene		EWS
WP270	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
WP270	BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
WP270	MTOR MUT* (E1854*)	MTOR (L2209V,L1460P,L2427Q)	Temsirolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
WP270	MTOR MUT* (E1854*)	MTOR (Q2223K)	Everolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
WP270	MTOR MUT* (E1854*)	MTOR (E2419K,E2014K)	Everolimus	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		BLCA
WP270	MTOR MUT* (E1854*)	MTOR (E2419K,C1483F,L2172M,K1452N,L2230V,L2427Q,L2431P,F1888I,E1799K,L2216P,W1456R,C1483W,A1519T,L1460P,A2210P,T2232I,R2505P,M2327I,C1483R,V2006I,A1428T,Y1463S,I2500M,A1459P,F1888L,S2231W,T1977R,V2006F,T1977K,A2226S,I2500F,L2427R,T1977I,S2215F,.,Q2223K,I1973F,L1433S,F1888V,S2215T,D2512H,E2014K,S2215Y,R2217W,L2209V,V2006L,L2220F,L2427P,S2215P,P2273S,E2288K,C1483Y)	Temsirolimus + Everolimus	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		CANCER
WP270	TSC1 MUT* (--)	TSC1 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	only gene		RCCC
WP270	TSC1 MUT* (--)	TSC1 (H105R,H206D,V220F,L180P,F216A,M224R,H68R,.,S35Q,F158C,L117P,L191H)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	only alteration type		RCCC
WP270	KDM6A MUT* (--)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
WP270	KDM6A MUT* (--)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only alteration type		BLCA
WP270	KRAS (G60R)	KRAS (D119N,G12F,F156L,G60R,F28L,A18D,Q22K,K147E,D33E,A146T,E62K,A146V,Q61R,Q61H,G12A,G12R,G13E,Q22R,V14I,Y71H,G13D,G12C,T58I,.,D153V,A59G,K117N,S65N,P34L,Y64A,G13V,K5N,Y32S,L19F,T74P,G13C,G12V,G12D,Q22E,Q61L,G12S,P34R)	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/30/summary|oncokb=https://www.oncokb.org/gene/KRAS	complete		COREAD
WP270	KRAS (G60R)	KRAS amplification	Panitumumab + Cetuximab	Colorectal adenocarcinoma	Resistant	A	NO	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only gene		COREAD
WP270	KRAS (G60R)	KRAS (D119N,G12F,F156L,G60R,F28L,A18D,Q22K,K147E,D33E,A146T,E62K,A146V,Q61R,Q61H,G12A,G12R,G13E,Q22R,V14I,Y71H,G13D,G12C,T58I,.,D153V,A59G,K117N,S65N,P34L,Y64A,K5N,Y32S,L19F,T74P,G13C,G12V,G12D,Q22E,Q61L,G12S,P34R)	Cobimetinib + Binimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	complete		CANCER
WP270	KRAS (G60R)	KRAS amplification	Cobimetinib + Binimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/KRAS	only gene		CANCER
WP270	NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP270	NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP270	PIK3CA MUT* (--)	PIK3CA (P539R,R38H,Q546K,G118D,G106V,Q546E,E579K,N345K,E453K,V344A,E545K,T1025S,E542Q,G1049R,M1043I,E110K,P449T,N1044K,K111E,C378R,H1047R,C420R,E78K,E545A,S629C,D350G,.,G451R,M1043V,E542V,Q546R,E365K,E81K,G106D,R88Q,P366R,R93Q,G914R,H1047Y,K111N,E545Q,E545G,R93W,R108H,G106R,E453Q,E542K,D1029Y,N345I,D549N,A1066V,Q546P,E542G,E453A)	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA amplification	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only gene		BRCA
WP270	ATM MUT* (--), ATM MUT* (--)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only alteration type		CANCER
WP270	ATM MUT* (--), ATM MUT* (--)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
WP270	JAK2 MUT* (--)	JAK2-PCM1 fusion	Ruxolitinib	Eosinophilic chronic leukemia	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/JAK2	only gene		ECL
WP270	RET MUT* (R297S), RET MUT* (--)	RET fusion	Cabozantinib + Vandetanib + Larotrectinib + 292 + 667	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		NSCLC
WP270	RET MUT* (R297S), RET MUT* (--)	RET (C618R,C620R,C609Y,E768D,C630R,S904F,E511K,C634S,C634Y,V648I,I852M,S891A,A883T,A883F,C611Y,T338I,C634W,K603Q,D631Y,M918T,A919V,R833C,.,V804M,C634R,V804L,Y806C,M918V,L790F,M848T,R886W,Y791F)	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only alteration type		THM
WP270	RET MUT* (R297S), RET MUT* (--)	RET fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP270	RET MUT* (R297S), RET MUT* (--)	RET-KIF5B fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP270	RET MUT* (R297S), RET MUT* (--)	RET-CCDC6 fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP270	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
WP270	BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
WP270	ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	only alteration type		CM
WP270	ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	only alteration type		GB
WP270	ATM MUT* (--), ATM MUT* (--)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	only alteration type		PRAD
WP270	BARD1 MUT* (--)	BARD1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11209	only alteration type		PRAD
WP270	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP270	BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
WP270	BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
WP270	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
WP270	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
WP270	BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
WP270	BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
WP270	BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
WP270	BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
WP270	CDK12 MUT* (--)	CDK12 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11204	only alteration type		PRAD
WP270	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP270	JAK2 MUT* (--)	JAK2 Splice Site (c.1641+2T>G)	Pembrolizumab	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4825	only alteration type		CM
WP270	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP270	KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (E765G), KMT2C MUT* (P335), KMT2C (--), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP270	KRAS (G60R)	KRAS A146	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3939	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS A146P	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2225	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS A146T	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2943	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS A146T	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3858	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS A146T	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2206	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS A146V	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2209	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS A146V	Abemaciclib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/794	only alteration type		NSCLC
WP270	KRAS (G60R)	KRAS G12/G13	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/134	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12/G13	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/135	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12/G13	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2004	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12/G13	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6293	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12/G13	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6294	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12/G13	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6295	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12/G13	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6296	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12/G13	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6363	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12/G13	Gefitinib,Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/35	only alteration type		NSCLC
WP270	KRAS (G60R)	KRAS G12/G13	Trametinib,Gemcitabine	Pancreas adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/622	only alteration type		PAAD
WP270	KRAS (G60R)	KRAS G12/G13	Trametinib	Pancreas adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/990	only alteration type		PAAD
WP270	KRAS (G60R)	KRAS G12A	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3710	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12A	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4429	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12A	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6319	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12A	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/251	only alteration type		LUAD
WP270	KRAS (G60R)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2009	only alteration type		MM
WP270	KRAS (G60R)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2012	only alteration type		MM
WP270	KRAS (G60R)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2013	only alteration type		MM
WP270	KRAS (G60R)	KRAS G12A	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2014	only alteration type		MM
WP270	KRAS (G60R)	KRAS G12C	Gefitinib,Erlotinib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1216	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12C	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2253	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12C	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3967	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12C	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3973	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12C	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2212	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2258	only alteration type		MM
WP270	KRAS (G60R)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2261	only alteration type		MM
WP270	KRAS (G60R)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2262	only alteration type		MM
WP270	KRAS (G60R)	KRAS G12C	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2263	only alteration type		MM
WP270	KRAS (G60R)	KRAS G12C	Docetaxel,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1142	only alteration type	753.0	NSCLC
WP270	KRAS (G60R)	KRAS G12C	Sotorasib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/9431	only alteration type		NSCLC
WP270	KRAS (G60R)	KRAS G12D	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3957	only alteration type		CM
WP270	KRAS (G60R)	KRAS G12D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2193	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2207	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2236	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12D	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3946	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12D	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6316	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12D	Therapeutic Tumor Infiltrating Lymphocytes	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1898	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12D	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2218	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12D	Vemurafenib	Hairy-Cell leukemia	Resistant	C	YES	https://civicdb.org/links/evidence_items/1580	only alteration type		HCL
WP270	KRAS (G60R)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2247	only alteration type		MM
WP270	KRAS (G60R)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2250	only alteration type		MM
WP270	KRAS (G60R)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2251	only alteration type		MM
WP270	KRAS (G60R)	KRAS G12D	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2252	only alteration type		MM
WP270	KRAS (G60R)	KRAS G12D	Dabrafenib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/91	only alteration type		NSCLC
WP270	KRAS (G60R)	KRAS G12D	Selumetinib,Dactolisib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/305	only alteration type		NSCLC
WP270	KRAS (G60R)	KRAS G12D	Cetuximab	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/3958	only alteration type		OV
WP270	KRAS (G60R)	KRAS G12R	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2264	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12R	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3987	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12R	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3989	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12R	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3991	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12S	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2269	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12S	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/4006	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12S	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4012	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12S	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6314	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	B	YES	https://civicdb.org/links/evidence_items/2274	only alteration type		MM
WP270	KRAS (G60R)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2277	only alteration type		MM
WP270	KRAS (G60R)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2278	only alteration type		MM
WP270	KRAS (G60R)	KRAS G12S	Melphalan	Multiple myeloma	Resistant	D	YES	https://civicdb.org/links/evidence_items/2279	only alteration type		MM
WP270	KRAS (G60R)	KRAS G12V	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/136	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12V	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2219	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12V	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2232	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12V	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3824	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12V	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3924	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12V	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6323	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12V	Dactolisib,Selumetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2001	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G12V	Palbociclib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/795	only alteration type		NSCLC
WP270	KRAS (G60R)	KRAS G12V	Selumetinib,Docetaxel	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1143	only alteration type		NSCLC
WP270	KRAS (G60R)	KRAS G13D	Pictilisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2041	only alteration type		BRCA
WP270	KRAS (G60R)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/806	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1180	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1181	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G13D	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2178	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3878	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3881	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3882	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G13D	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3889	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G13D	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6320	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G13D	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6322	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/145	only alteration type	735.0	COREAD
WP270	KRAS (G60R)	KRAS G13D	Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/306	only alteration type	735.0	COREAD
WP270	KRAS (G60R)	KRAS G13D	Selumetinib,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2183	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS G13V	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6312	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS Mutation	Vemurafenib,Dabrafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6264	complete		CM
WP270	KRAS (G60R)	KRAS Mutation	Bevacizumab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1139	complete		COREAD
WP270	KRAS (G60R)	KRAS Mutation	Ixazomib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1182	complete		COREAD
WP270	KRAS (G60R)	KRAS Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1702	complete		COREAD
WP270	KRAS (G60R)	KRAS Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3704	complete		COREAD
WP270	KRAS (G60R)	KRAS Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	A	NO	https://civicdb.org/links/evidence_items/5345	complete		COREAD
WP270	KRAS (G60R)	KRAS Mutation	Immunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/943	complete		COREAD
WP270	KRAS (G60R)	KRAS Mutation	Cetuximab,Dasatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/947	complete		COREAD
WP270	KRAS (G60R)	KRAS Mutation	B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/988	complete		COREAD
WP270	KRAS (G60R)	KRAS Mutation	Trametinib,Afatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/991	complete		COREAD
WP270	KRAS (G60R)	KRAS Mutation	MEK Inhibitor RO4987655	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/998	complete		COREAD
WP270	KRAS (G60R)	KRAS Mutation	Refametinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1001	complete		COREAD
WP270	KRAS (G60R)	KRAS Mutation	Selumetinib,Teprotumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1004	complete		COREAD
WP270	KRAS (G60R)	KRAS Mutation	Selumetinib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4866	complete		COREAD
WP270	KRAS (G60R)	KRAS Mutation	Palbociclib,Binimetinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4869	complete		COREAD
WP270	KRAS (G60R)	KRAS Mutation	Temsirolimus,Ridaforolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/894	complete		ED
WP270	KRAS (G60R)	KRAS Mutation	Sorafenib,Refametinib	Hepatic carcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1642	complete		HC
WP270	KRAS (G60R)	KRAS Mutation	Salirasib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1218	complete		LUAD
WP270	KRAS (G60R)	KRAS Mutation	MEK Inhibitor RO4987655	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/997	complete		NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2242	complete		NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Gefitinib,Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2385	complete		NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Docetaxel,Selumetinib	Non-small cell lung	Resistant	A	NO	https://civicdb.org/links/evidence_items/2998	complete		NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Erlotinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/3895	complete		NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/989	complete		NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Trametinib,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/992	complete		NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Docetaxel,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/999	complete	753.0	NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1220	complete		NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Erlotinib,Teprotumumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3713	complete		NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Abemaciclib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4842	complete		NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Docetaxel,Pemetrexed,Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4862	complete		NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Nivolumab,Atezolizumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4863	complete		NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Trametinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4867	complete		NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Erlotinib,Selumetinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4868	complete		NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Docetaxel,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4996	complete		NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Docetaxel	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4997	complete		NSCLC
WP270	KRAS (G60R)	KRAS Mutation	Decitabine	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/820	complete		OV
WP270	KRAS (G60R)	KRAS Mutation	PI3Kbeta Inhibitor AZD8186,SCH772984	Pancreas adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1003	complete		PAAD
WP270	KRAS (G60R)	KRAS Q61	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3917	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS Q61H	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3861	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS Q61H	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3862	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS Q61K	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3872	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS Q61L	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3867	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS Q61R	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3870	only alteration type		COREAD
WP270	KRAS (G60R)	KRAS Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6317	only gene		CM
WP270	MTOR MUT* (E1854*)	MTOR A2034V	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1547	only alteration type		BRCA
WP270	MTOR MUT* (E1854*)	MTOR A2034V	RapaLink-1,MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1548	only alteration type		BRCA
WP270	MTOR MUT* (E1854*)	MTOR E1799K	Sirolimus	Renal clear cell	Responsive	D	NO	https://civicdb.org/links/evidence_items/1321	only alteration type		RCCC
WP270	MTOR MUT* (E1854*)	MTOR F2108L	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1543	only alteration type		BRCA
WP270	MTOR MUT* (E1854*)	MTOR F2108L	Everolimus	Thyroid carcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1110	only alteration type		THCA
WP270	MTOR MUT* (E1854*)	MTOR H1968Y	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/713	only alteration type		CM
WP270	MTOR MUT* (E1854*)	MTOR M2327I	MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1544	only alteration type		BRCA
WP270	MTOR MUT* (E1854*)	MTOR M2327I	Sirolimus,RapaLink-1	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1545	only alteration type		BRCA
WP270	MTOR MUT* (E1854*)	MTOR Mutation	Everolimus,Pazopanib	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/705	only alteration type		BLCA
WP270	MTOR MUT* (E1854*)	MTOR P2213S	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/722	only alteration type		CM
WP270	NOTCH1 MUT* (N685T)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP270	NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP270	NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP270	NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP270	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2346	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8549	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA C420R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2078	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA C420R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1999	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA D350G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4784	only alteration type		CM
WP270	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8007	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E542K	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/310	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E542K	Sirolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/311	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2022	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2026	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2058	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E542K	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7315	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8013	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8016	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E542K	Regorafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/83	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA E542K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4424	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA E542K	Apitolisib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/1549	only alteration type		HNSC
WP270	PIK3CA MUT* (--)	PIK3CA E542K	Perifosine,Temsirolimus	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1626	only alteration type		THCA
WP270	PIK3CA MUT* (--)	PIK3CA E545	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7468	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E545G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3724	only alteration type		CM
WP270	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1453	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2036	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6211	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E545K	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6213	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E545K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8008	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8547	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E545K	Akt Inhibitor MK2206,Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/710	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2034	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2062	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8017	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8018	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA E545K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3722	only alteration type		CM
WP270	PIK3CA MUT* (--)	PIK3CA E545K	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/387	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2037	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2217	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib	Lung adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1171	only alteration type		LUAD
WP270	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1670	only alteration type		LUAD
WP270	PIK3CA MUT* (--)	PIK3CA E545K	PI103	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2040	only alteration type		NSCLC
WP270	PIK3CA MUT* (--)	PIK3CA E545Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2213	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA E81K	Oxaliplatin,Fluorouracil,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4464	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA F930S	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10032	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA G1049R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3847	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA H1047L	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2089	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA H1047L	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8009	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA H1047L	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8019	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA H1047L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4432	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2103	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6204	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6206	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8548	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/314	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Capivasertib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1505	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1506	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Everolimus,Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1623	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2096	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2102	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/258	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/388	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Vemurafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3733	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3841	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Akt Inhibitor MK2206,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8364	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1465	only alteration type		HNSC
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1447	only alteration type		LUAD
WP270	PIK3CA MUT* (--)	PIK3CA H1047R	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1625	only alteration type		THCA
WP270	PIK3CA MUT* (--)	PIK3CA H1047X	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7318	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2867	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8663	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2866	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA K111N	Dactolisib,Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8183	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8662	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA K111N	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2085	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA K111N	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8011	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA K111N	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8020	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA K944N	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10031	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA K966E	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10034	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1384	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2087	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2098	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8536	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Capecitabine,Lapatinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8705	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1296	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1504	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1600	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1607	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1610	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Fulvestrant,Alpelisib	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7313	only alteration type		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/915	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1705	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3732	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6298	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6299	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6300	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6301	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6362	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Cabozantinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/771	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6375	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Ridaforolimus,Temsirolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/892	only alteration type		ED
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Pictilisib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1616	only alteration type		ED
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Radiation Therapy,Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1490	only alteration type		HNSC
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin,Sulindac,Celecoxib	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7185	only alteration type		HNSC
WP270	PIK3CA MUT* (--)	PIK3CA Mutation	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2355	only alteration type		NSCLC
WP270	PIK3CA MUT* (--)	PIK3CA N345K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4047	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA Q546K	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2198	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA R88Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3832	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA R93W	Cetuximab,Fluorouracil,Oxaliplatin	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4467	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA S158L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4463	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA V955G	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10033	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA V955I	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/8063	only alteration type		COREAD
WP270	PIK3CA MUT* (--)	PIK3CA Amplification	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8267	only gene		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA Amplification	Lapatinib,Dactolisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8271	only gene		BRCA
WP270	PIK3CA MUT* (--)	PIK3CA Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6275	only gene		CM
WP270	PIK3CA MUT* (--)	PIK3CA Amplification	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1464	only gene		HNSC
WP270	PIK3CA MUT* (--)	PIK3CA Amplification	Sulindac,Aspirin,Ibuprofen	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7186	only gene		HNSC
WP270	PIK3CA MUT* (--)	PIK3CA Amplification	Pictilisib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/756	only gene		OV
WP270	PREX2 MUT* (--)	PREX2 R172I	Vemurafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6268	only alteration type		CM
WP270	PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP270	RAD54L MUT* (--)	RAD54L Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11207	only alteration type		PRAD
WP270	RET MUT* (R297S), RET MUT* (--)	RET CCDC6::RET	Agerafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7480	only gene		COREAD
WP270	RET MUT* (R297S), RET MUT* (--)	RET CCDC6::RET	Nintedanib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1601	only gene		NSCLC
WP270	RET MUT* (R297S), RET MUT* (--)	RET Fusion	Cabozantinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4847	only gene		LUAD
WP270	RET MUT* (R297S), RET MUT* (--)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4848	only gene		NSCLC
WP270	RET MUT* (R297S), RET MUT* (--)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4849	only gene		NSCLC
WP270	RET MUT* (R297S), RET MUT* (--)	RET Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4850	only gene		NSCLC
WP270	RET MUT* (R297S), RET MUT* (--)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7066	only gene		NSCLC
WP270	RET MUT* (R297S), RET MUT* (--)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/8850	only gene		NSCLC
WP270	RET MUT* (R297S), RET MUT* (--)	RET Fusion	Pralsetinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11233	only gene		NSCLC
WP270	RET MUT* (R297S), RET MUT* (--)	RET Fusion	Selpercatinib	Thyroid carcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8852	only gene		THCA
WP270	RET MUT* (R297S), RET MUT* (--)	RET KIF5B::RET	Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/698	only gene		LUAD
WP270	RET MUT* (R297S), RET MUT* (--)	RET KIF5B::RET	Vandetanib,Everolimus	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1622	only gene		LUAD
WP270	RICTOR MUT* (--)	RICTOR Amplification	Onatasertib,Sapanisertib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1440	only gene		LUAD
WP270	RICTOR MUT* (--)	RICTOR Amplification	Vistusertib	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7449	only gene		SCLC
WP270	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	YES	https://civicdb.org/links/evidence_items/411	only alteration type		AML
WP270	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP270	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
WP291	JAK2 MUT* (--)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Myelofibrosis	Responsive	A	YES	FDA	only alteration type		MY
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome, Eosinophilic chronic leukemia	Responsive	A	YES	EMA	only gene		HES, ECL
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA inframe deletion (I843)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type	862.0	GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type	862.0	GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Regorafenib(Pan-kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
WP291	RET MUT* (--)	RET (618,620,634,768,791,891,918,C634W,M918T)	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	A	NO	PMID:20065189;PMID:22025146	only alteration type		THCA
WP291	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
WP291	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		GCA
WP291	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		RA
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022	only alteration type		BRCA
WP291	RET MUT* (--)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-ret-altered-thyroid-cancers;ASCO 2020 (abstr 109)	only gene		TH
WP291	RET MUT* (--)	RET oncogenic mutation	Selpercatinib(RET kinase inhibitor)	Thyroid medullary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only alteration type		THM
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
WP291	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
WP291	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP291	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA exon 18 mutations	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation;PMID:32615108	only alteration type		GIST
WP291	MET MUT* (--)	MET exon 14 skipping mutations	Tepotinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer;PMID:31279006;PMID:34036238	only alteration type		NSCLC
WP291	MET MUT* (--)	MET exon 14 skipping mutations	Capmatinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capmatinib-metastatic-non-small-cell-lung-cancer	only alteration type		NSCLC
WP291	ROS1 MUT* (--)	ROS1 fusion	Entrectinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA;PMID:28183697;ESMO 2019 (abstr 4178) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725s007lbl.pdf	only gene		NSCLC
WP291	RET MUT* (--)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions	only gene		NSCLC
WP291	RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-non-small-cell-lung	only gene		NSCLC
WP291	RAD54L MUT* (--)	RAD54L oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
WP291	PIK3CA MUT* (--)	PIK3CA (C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R)	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	only alteration type		BRCA
WP291	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Bevacizumab(VEGF mAb inhibitor);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP291	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Atezolizumab(PDL1 blocking antibody);Paclitaxel(Chemotherapy);Carboplatin(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	complete		NSCLC
WP291	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Pembrolizumab(PD-1-blocking antibody);Pemetrexed(Chemotherapy);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf	complete		NSCLC
WP291	EGFR wildtype, ALK wildtype	EGFR wildtype;ALK wildtype	Durvalumab(PD-1-blocking antibody);Tremelimumab-actl(CTLA-4 blocking antibody);Platinum(Chemotherapy)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non	complete		NSCLC
WP291	RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only gene		TH
WP291	RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Solid tumors	Responsive	A	NO	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors	only gene		SOLID
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
WP291	ATM MUT* (--)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP291	FANCA MUT* (Q652H)	FANCA oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
WP291	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
WP291	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP291	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
WP291	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP291	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
WP291	RET MUT* (--)	RET fusion	Cabozantinib(Kinase inhibitor )	Non-small cell lung	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA oncogenic mutations (excluding D842V + exon 18 inframe mutations)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type	862.0	GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V + exon 18 mutations	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
WP291	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP291	MET MUT* (--)	MET amplification	Capmatinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP291	MET MUT* (--)	MET amplification	Tepotinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP291	MET MUT* (--)	MET exon 14 skipping mutations	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
WP291	ROS1 MUT* (--)	ROS1 fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP291	ROS1 MUT* (--)	ROS1 fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
WP291	ATM MUT* (--)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only alteration type		COREAD
WP291	ATM MUT* (--)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
WP291	ATM MUT* (--)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only alteration type		LY
WP291	ATM MUT* (--)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	YES	PMID:23761041	only gene		LY
WP291	ATM MUT* (--)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP291	ATM MUT* (--)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
WP291	ATM MUT* (--)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	YES	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
WP291	ATM MUT* (--)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP291	ATM MUT* (--)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP291	ATM MUT* (--)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only alteration type		ST
WP291	ATM MUT* (--)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
WP291	BAP1 MUT* (F122L)	BAP1 oncogenic mutation	EZH2 inhibitors	Mesothelioma	Responsive	D	NO	PMID:26437366	only alteration type		MESO
WP291	BAP1 MUT* (F122L)	BAP1 deletion	EZH2 inhibitors	Mesothelioma	Responsive	D	NO	PMID:26437366	only gene		MESO
WP291	BAP1 MUT* (F122L)	BAP1 oncogenic mutation	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22038994	only alteration type		CM
WP291	BAP1 MUT* (F122L)	BAP1 deletion	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22038994	only gene		CM
WP291	BAP1 MUT* (F122L)	BAP1 oncogenic mutation	PARP inhibitors	Renal, Any cancer type	Responsive	D	YES	PMID:22683710	only alteration type		R, CANCER
WP291	BAP1 MUT* (F122L)	BAP1 deletion	PARP inhibitors	Renal, Any cancer type	Responsive	D	YES	PMID:22683710	only gene		R, CANCER
WP291	BCOR MUT* (--)	BCOR oncogenic mutation	Enzastaurin(PKCb inhibitor)	Stomach	Responsive	D	NO	PMID:27397505	only alteration type		ST
WP291	JAK1 MUT* (Q437K)	JAK1 oncogenic mutation	PD1 inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:27903500	only alteration type		COREAD
WP291	JAK1 MUT* (Q437K)	JAK1 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	only alteration type		CM
WP291	JAK2 MUT* (--)	JAK2 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	only alteration type		CM
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
WP291	CBL MUT* (--)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP291	CBL MUT* (--)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	YES	PMID:23696637	only alteration type		MDPS
WP291	CDKN1A MUT* (--)	CDKN1A oncogenic mutation	CDK2/4 inhibitors	Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22997239	only alteration type		CANCER
WP291	CDKN1A MUT* (--)	CDKN1A deletion	CDK2/4 inhibitors	Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22997239	only gene		CANCER
WP291	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP291	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP291	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
WP291	MAP2K2 MUT* (--), MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
WP291	MET MUT* (--)	MET amplification	EGFR inhibitor 1st gens	Non-small cell lung, Colorectal adenocarcinoma	Resistant	C	NO	PMID:22189054;PMID:23729478	only gene		NSCLC, COREAD
WP291	MET MUT* (--)	MET amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:23729478	only gene		COREAD
WP291	MET MUT* (--)	MET (D1246V)	MET inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:27694386	only alteration type		LUAD
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
WP291	NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA amplification	PDGFR inhibitors	Glioma	No Responsive	D	NO	PMID:23544171	only gene		G
WP291	PIK3CA MUT* (--)	PIK3CA (E545*)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMC3936420	only alteration type		CM
WP291	PIK3CA MUT* (--)	PIK3CA amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	D	NO	PMID:24366379	only gene		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9054)	only alteration type		L
WP291	FANCA MUT* (Q652H)	FANCA oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
WP291	FANCA MUT* (Q652H)	FANCA deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only gene		PRAD
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
WP291	NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
WP291	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP291	JAK1 MUT* (Q437K)	JAK1 (S646F;R683)	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22955920;PMID:18805579	only alteration type		ALL
WP291	JAK2 MUT* (--)	JAK2 (V617F)	JAK inhibitor(alone or in combination)s	Acute myeloid leukemia	Responsive	D	YES	PMID:22829971	only alteration type		AML
WP291	JAK2 MUT* (--)	JAK2 amplification	JAK inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:27075627	only gene		BRCA
WP291	JAK2 MUT* (--)	JAK2-BRAF fusion	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:22875628;PMID:22899477	only gene		ALL
WP291	JAK2 MUT* (--)	JAK2 (V617F)	Ruxolitinib(JAK inhibitor)	Acute myeloid leukemia	Responsive	C	YES	PMID:22422826	only alteration type		AML
WP291	JAK3 MUT* (--)	JAK3 (A572V,A573V)	JAK inhibitors	Lymphoma	Responsive	D	YES	PMID:22705984	only alteration type		LY
WP291	JAK3 MUT* (--)	JAK3 (R657Q,I87T,Q501H)	JAK inhibitors	Megakaryoblastic leukemia	Responsive	D	YES	PMID:18397343	only alteration type		MKB
WP291	KIT wildtype	KIT wildtype	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	D	NO	PMID:16397263	complete		GIST
WP291	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:19223544;PMID:20619739	only alteration type		COREAD
WP291	KIT wildtype	KIT wildtype	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2011 (abstr 10009)	complete		GIST
WP291	KIT wildtype	KIT wildtype	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	B	NO	PMID:18955458	complete		GIST
WP291	MET MUT* (--)	MET (Y1230C,Y1235D)	Crizotinib(ALK inhibitor)	Any cancer type	Resistant	D	YES	PMID:17483355	only alteration type		CANCER
WP291	ROS1 MUT* (--)	ROS1 (G2032R)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:23724914;PMID:25688157	only alteration type		LUAD
WP291	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
WP291	NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
WP291	NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
WP291	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
WP291	NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
WP291	NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
WP291	MET MUT* (--)	MET kinase domain mutation	Savolitinib(MET inhibitor)	Renal	Responsive	C	NO	PMID:28644771	only alteration type		R
WP291	MET MUT* (--)	MET amplification	BCL2 inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:27397505	only gene		COREAD
WP291	MET MUT* (--)	MET amplification	MET inhibitors	Hepatic carcinoma	Responsive	C	NO	ENA 2015 (abstract A55)	only gene		HC
WP291	MET MUT* (--)	MET amplification	MET inhibitors	Stomach	Responsive	D	NO	PMID:22729845;PMID:23327903	only gene		ST
WP291	MET MUT* (--)	MET amplification	MET inhibitors	Renal	Responsive	C	NO	PMID:23213094;AACR 2016 (abstr CT2006)	only gene		R
WP291	MET MUT* (--)	MET (H1112R)	MET inhibitors	Renal	Responsive	C	NO	PMID:23213094	only alteration type		R
WP291	MET MUT* (--)	MET (M1268T)	MET inhibitors	Renal	Responsive	C	NO	PMID:23610116	only alteration type		R
WP291	MET MUT* (--)	MET (H1112L)	MET inhibitors(Crizotinib,etc)	Any cancer type	Responsive	D	YES	AACR 2012 (abstr 1786)	only alteration type		CANCER
WP291	MET MUT* (--)	MET amplification	Cabozantinib + Panitumumab(Pan-kinase inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A52)	only gene		COREAD
WP291	MET MUT* (--)	MET fusion	Crizotinib(ALK inhibitor)	Glioma	Responsive	C	NO	PMID:27748748	only gene		G
WP291	MET MUT* (--)	MET mutation in exon 16-19	Crizotinib(ALK inhibitor)	Renal	Responsive	C	NO	AACR 2016 (abstr CT2006)	only alteration type		R
WP291	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma, Stomach	Responsive	C	NO	ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1)	only gene		LUAD, ST
WP291	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Glioma	Responsive	C	NO	PMID:22162573	only gene		G
WP291	MET MUT* (--)	MET (V1110I,H1112R,M1268T,R988C,T1010I)	Crizotinib(ALK inhibitor)	Any cancer type	Responsive	D	YES	PMID:17483355	only alteration type		CANCER
WP291	KIT wildtype	KIT wildtype	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	complete		GIST
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP291	NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
WP291	NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
WP291	NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only alteration type		G, LK
WP291	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
WP291	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	YES	PMID:22573716;PMID:19727076	only gene		G, LK
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
WP291	NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
WP291	NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	YES	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
WP291	NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
WP291	NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
WP291	NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (T674I)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome	Resistant	C	YES	PMID:12660384	only alteration type		HES
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
WP291	NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
WP291	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
WP291	NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
WP291	NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
WP291	NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
WP291	NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
WP291	NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
WP291	NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
WP291	NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
WP291	NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
WP291	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
WP291	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
WP291	NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
WP291	NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
WP291	MET MUT* (--)	MET amplification	EGFR inhibitor 3rd gens(Osimertinib,etc)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP291	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19318552	only alteration type		ALL
WP291	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:19246562	only alteration type		ALL
WP291	NOTCH1 MUT* (T311P)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:16688224;PMID:23033986	only gene		ALL
WP291	NOTCH1 MUT* (T311P)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
WP291	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	YES	ASCO 2006 (abstr 6585)	only alteration type		ALL
WP291	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	YES	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
WP291	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
WP291	NOTCH1 MUT* (T311P)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	YES	PMID:22210878	only alteration type		MCL
WP291	NOTCH1 MUT* (T311P)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
WP291	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
WP291	NOTCH1 MUT* (T311P)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
WP291	NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
WP291	NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	HSP90 inhibitors	Gastrointestinal stromal	Responsive	D	NO	PMID:18794084	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Crenolanib(FLT3 inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2016 (abstr 11010)	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	Crenolanib(FLT3 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
WP291	RET MUT* (--)	RET (I788N)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Resistant	D	NO	PMID:28615362	only alteration type		LUAD
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (P577S,R841K,H845Y,G853D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
WP291	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	AKT inhibitors	Breast adenocarcinoma	Responsive	C	NO	ASCO 2015 (abstr 2500)	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitor(alone or in combination)s	Lung, Colorectal adenocarcinoma	Responsive	D	NO	PMID:23136191;PMID:23475782;PMID:22392911	only alteration type		L, COREAD
WP291	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Bladder, Head an neck, Lung	Responsive	C	NO	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	only alteration type		BLCA, HNC, L
WP291	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma, Ovary, Cervix squamous cell, Endometrium	Responsive	C	NO	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	only alteration type		BRCA, OV, CESC, ED
WP291	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26787751;PMID:26763254	only alteration type		HNSC
WP291	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Glioma, Thyroid carcinoma	Responsive	D	NO	PMID:19671762;PMID:21289267	only alteration type		G, THCA
WP291	MET MUT* (--)	MET amplification	EGFR inhibitor 3rd gens(Rociletinib,etc)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
WP291	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:28331003	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2501)	only alteration type		ST
WP291	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	AKT inhibitors	Glioma	Responsive	D	NO	PMID:23166678	only alteration type		G
WP291	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	PI3K pathway inhibitors	Endometrium	Responsive	C	NO	ASCO 2015 (abstr 11075)	only alteration type		ED
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
WP291	PTPRD MUT* (--), PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
WP291	NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
WP291	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
WP291	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
WP291	RB1 MUT* (--), RB1 MUT* (--)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
WP291	RB1 MUT* (--), RB1 MUT* (--)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
WP291	RB1 MUT* (--), RB1 MUT* (--)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
WP291	RB1 MUT* (--), RB1 MUT* (--)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
WP291	RB1 MUT* (--), RB1 MUT* (--)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
WP291	RB1 MUT* (--), RB1 MUT* (--)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
WP291	RET MUT* (--)	RET fusion	RET inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:22327624;PMID:22327622	only gene		LUAD
WP291	RET MUT* (--)	RET-TPCN1 fusion	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only gene		TH
WP291	RET MUT* (--)	RET (C634W,M918T)	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only alteration type		TH
WP291	RET MUT* (--)	RET fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP291	RET MUT* (--)	RET-TPCN1 fusion	Cabozantinib(Pan-kinase inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP291	RET MUT* (--)	RET (C634W,M918T)	Cabozantinib(Pan-kinase inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP291	RET MUT* (--)	RET fusion	Nintedanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26787234	only gene		LUAD
WP291	RET MUT* (--)	RET fusion	Sunitinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP291	RET MUT* (--)	RET-TPCN1 fusion	Sunitinib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP291	RET MUT* (--)	RET (C634W,M918T)	Sunitinib(Pan-TK inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
WP291	RET MUT* (--)	RET fusion	Vandetanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
WP291	RET MUT* (--)	RET-TPCN1 fusion	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
WP291	ROS1 MUT* (--)	ROS1 fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:23533265	only gene		LUAD
WP291	ROS1 MUT* (--)	ROS1 fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27370605	only gene		LUAD
WP291	ROS1 MUT* (--)	ROS1 (G2032R)	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:25351743	only alteration type		LUAD
WP291	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	C	YES	PMID:24875859	only gene		IM
WP291	ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:25264305	only gene		LUAD
WP291	ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27401242	only alteration type		LUAD
WP291	STAG2 MUT* (--)	STAG2 oncogenic mutation	PARP inhibitors	Glioma	Responsive	D	NO	PMID:24356817	only alteration type		G
WP291	NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
WP291	SUZ12 MUT* (AS54-55A), SUZ12 MUT* (--)	SUZ12 oncogenic mutation	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only alteration type		CANCER
WP291	SUZ12 MUT* (AS54-55A), SUZ12 MUT* (--)	SUZ12 deletion	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only gene		CANCER
WP291	SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	YES	PMID:16409295;PMID:19549911	only gene		MCL, CLL
WP291	TOP2A MUT* (--), TOP2A MUT* (R1215L)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
WP291	TP53 wildtype	TP53 wildtype	HDM2 inhibitors	Acute myeloid leukemia	Responsive	C	YES	AACR 2017 (abstr CT152)	complete		AML
WP291	TSC1 MUT* (--)	TSC1 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	only alteration type		RA
WP291	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	only alteration type		BLCA
WP291	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;PMID:26859683;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	only alteration type		R
WP291	TSC1 MUT* (--)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Sarcoma, Stomach	Responsive	C	NO	PMID:26859683	only alteration type		S, ST
WP291	TSC1 MUT* (--)	TSC1 deletion	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	only gene		R
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
WP291	MET MUT* (--)	MET amplification	Crizotinib	Non-small cell lung	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/52/summary|oncokb=https://www.oncokb.org/gene/MET	only gene		NSCLC
WP291	MET MUT* (--)	MET (D1010H,Y1003N,D1010N,Y1003F,Y1003C,D1010Y)	Crizotinib	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP291	TSC1 MUT* (--)	TSC1 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	only gene		RCCC
WP291	TSC1 MUT* (--)	TSC1 (H105R,H206D,V220F,L180P,F216A,M224R,H68R,.,S35Q,F158C,L117P,L191H)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	only alteration type		RCCC
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib	Gastrointestinal stromal	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP291	MET MUT* (--)	MET (D1010H,Y1003N,D1010N,Y1003F,Y1003C,D1010Y)	Cabozantinib + Capmatinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (N659K,V561D,V561A,N659S,A633T,H845Y,T674I,S584L,D842V,N659R,D568N,P577S,D846Y,Q579R,D842Y,Y849S,N848K,H650Q,D842I,V469A,Y288C,Y555C,R748G,Y849C,.,R841K,G853D,V536E,V658A)	Imatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA amplification	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-BCR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-CDK5RAP2 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-ETV6 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-KDR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-KIF5B fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-STRN fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
WP291	MET MUT* (--)	MET amplification	Erlotinib + Gefitinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only gene		NSCLC
WP291	NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
WP291	NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
WP291	PIK3CA MUT* (--)	PIK3CA (P539R,R38H,Q546K,G118D,G106V,Q546E,E579K,N345K,E453K,V344A,E545K,T1025S,E542Q,G1049R,M1043I,E110K,P449T,N1044K,K111E,C378R,H1047R,C420R,E78K,E545A,S629C,D350G,.,G451R,M1043V,E542V,Q546R,E365K,E81K,G106D,R88Q,P366R,R93Q,G914R,H1047Y,K111N,E545Q,E545G,R93W,R108H,G106R,E453Q,E542K,D1029Y,N345I,D549N,A1066V,Q546P,E542G,E453A)	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA amplification	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only gene		BRCA
WP291	ATM MUT* (--)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only alteration type		CANCER
WP291	ATM MUT* (--)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
WP291	JAK2 MUT* (--)	JAK2-PCM1 fusion	Ruxolitinib	Eosinophilic chronic leukemia	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/JAK2	only gene		ECL
WP291	RET MUT* (--)	RET fusion	Cabozantinib + Vandetanib + Larotrectinib + 292 + 667	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		NSCLC
WP291	RET MUT* (--)	RET (C618R,C620R,C609Y,E768D,C630R,S904F,E511K,C634S,C634Y,V648I,I852M,S891A,A883T,A883F,C611Y,T338I,C634W,K603Q,D631Y,M918T,A919V,R833C,.,V804M,C634R,V804L,Y806C,M918V,L790F,M848T,R886W,Y791F)	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only alteration type		THM
WP291	RET MUT* (--)	RET fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP291	RET MUT* (--)	RET-KIF5B fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP291	RET MUT* (--)	RET-CCDC6 fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
WP291	MET MUT* (--)	MET (D1228N)	Crizotinib + Cabozantinib + Capmatinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
WP291	MET MUT* (--)	MET amplification	Cabozantinib	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only gene		RCCC
WP291	MET MUT* (--)	MET (Y1230H)	Crizotinib + Capmatinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
WP291	ATM MUT* (--)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	only alteration type		CM
WP291	ATM MUT* (--)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	only alteration type		GB
WP291	ATM MUT* (--)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	only alteration type		PRAD
WP291	BAP1 MUT* (F122L)	BAP1 Mutation	Sunitinib,Everolimus	Renal	Resistant	B	NO	https://civicdb.org/links/evidence_items/5339	only alteration type		R
WP291	BAP1 MUT* (F122L)	BAP1 Mutation	Valproic Acid,Trichostatin A,Vorinostat,Panobinostat	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1234	only alteration type		UVM
WP291	BRAF wildtype	BRAF WILD TYPE	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/995	complete		CM
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
WP291	BRCA2 MUT* (--), BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
WP291	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
WP291	JAK1 MUT* (Q437K)	JAK1 S703I	Ruxolitinib	Hepatic carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1900	only alteration type		HC
WP291	JAK2 MUT* (--)	JAK2 Splice Site (c.1641+2T>G)	Pembrolizumab	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4825	only alteration type		CM
WP291	KIT wildtype	KIT WILDTYPE	Regorafenib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/4144	complete		GIST
WP291	KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
WP291	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
WP291	MET MUT* (--)	MET D1228N	Crizotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1652	only alteration type		NSCLC
WP291	MET MUT* (--)	MET D1228V	Savolitinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1865	only alteration type		NSCLC
WP291	MET MUT* (--)	MET D1228V	Cabozantinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1864	only alteration type		NSCLC
WP291	MET MUT* (--)	MET MET::ATXN7L1	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7793	only gene		NSCLC
WP291	MET MUT* (--)	MET Amplification	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1971	only gene		COREAD
WP291	MET MUT* (--)	MET Amplification	Vemurafenib,Crizotinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1588	only gene		COREAD
WP291	MET MUT* (--)	MET Amplification	Crizotinib,Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1979	only gene		COREAD
WP291	MET MUT* (--)	MET Amplification	Crizotinib	Glioblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1565	only gene		GB
WP291	MET MUT* (--)	MET Amplification	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1392	only gene		LUAD
WP291	MET MUT* (--)	MET Amplification	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/836	only gene		LUAD
WP291	MET MUT* (--)	MET Amplification	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1692	only gene		LUAD
WP291	MET MUT* (--)	MET Amplification	Crizotinib	Lung squamous cell	Responsive	C	NO	https://civicdb.org/links/evidence_items/890	only gene		LUSC
WP291	MET MUT* (--)	MET Amplification	Gefitinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/733	only gene		NSCLC
WP291	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/735	only gene		NSCLC
WP291	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1566	only gene		NSCLC
WP291	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1713	only gene		NSCLC
WP291	MET MUT* (--)	MET Amplification	Onartuzumab	Stomach	Responsive	C	NO	https://civicdb.org/links/evidence_items/689	only gene		ST
WP291	NOTCH1 MUT* (T311P)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
WP291	NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
WP291	NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
WP291	NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842I	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/43	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/15	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/16	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/651	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/738	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2478	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4597	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/44	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842Y	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/45	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842_I843delinsVM	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/47	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA FIP1L1::PDGFRA	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	YES	https://civicdb.org/links/evidence_items/7378	only gene		AML
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA G853D	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1977	only alteration type		CM
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA H845Y	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1976	only alteration type		CM
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA I843DEL	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/46	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA I843DEL	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1309	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA Mutation	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2487	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA P577S	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1974	only alteration type		CM
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA R841K	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1975	only alteration type		CM
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA V561A	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/652	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA V561D	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2474	only alteration type		GIST
WP291	PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA Amplification	Sunitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1771	only gene		NSCLC
WP291	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2346	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8549	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA C420R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2078	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA C420R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1999	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA D350G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4784	only alteration type		CM
WP291	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8007	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E542K	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/310	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E542K	Sirolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/311	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2022	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2026	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2058	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E542K	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7315	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8013	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8016	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E542K	Regorafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/83	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA E542K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4424	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA E542K	Apitolisib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/1549	only alteration type		HNSC
WP291	PIK3CA MUT* (--)	PIK3CA E542K	Perifosine,Temsirolimus	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1626	only alteration type		THCA
WP291	PIK3CA MUT* (--)	PIK3CA E545	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7468	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E545G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3724	only alteration type		CM
WP291	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1453	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2036	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6211	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E545K	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6213	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E545K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8008	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8547	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E545K	Akt Inhibitor MK2206,Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/710	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2034	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2062	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8017	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8018	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA E545K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3722	only alteration type		CM
WP291	PIK3CA MUT* (--)	PIK3CA E545K	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/387	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2037	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2217	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib	Lung adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1171	only alteration type		LUAD
WP291	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1670	only alteration type		LUAD
WP291	PIK3CA MUT* (--)	PIK3CA E545K	PI103	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2040	only alteration type		NSCLC
WP291	PIK3CA MUT* (--)	PIK3CA E545Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2213	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA E81K	Oxaliplatin,Fluorouracil,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4464	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA F930S	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10032	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA G1049R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3847	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA H1047L	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2089	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA H1047L	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8009	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA H1047L	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8019	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA H1047L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4432	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2103	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6204	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6206	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8548	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/314	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Capivasertib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1505	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1506	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Everolimus,Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1623	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2096	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2102	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/258	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/388	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Vemurafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3733	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3841	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Akt Inhibitor MK2206,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8364	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1465	only alteration type		HNSC
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1447	only alteration type		LUAD
WP291	PIK3CA MUT* (--)	PIK3CA H1047R	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1625	only alteration type		THCA
WP291	PIK3CA MUT* (--)	PIK3CA H1047X	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7318	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2867	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8663	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2866	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA K111N	Dactolisib,Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8183	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8662	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA K111N	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2085	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA K111N	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8011	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA K111N	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8020	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA K944N	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10031	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA K966E	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10034	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1384	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2087	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2098	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8536	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Capecitabine,Lapatinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8705	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1296	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1504	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1600	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1607	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1610	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Fulvestrant,Alpelisib	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7313	only alteration type		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/915	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1705	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3732	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6298	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6299	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6300	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6301	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6362	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Cabozantinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/771	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6375	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Ridaforolimus,Temsirolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/892	only alteration type		ED
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Pictilisib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1616	only alteration type		ED
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Radiation Therapy,Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1490	only alteration type		HNSC
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin,Sulindac,Celecoxib	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7185	only alteration type		HNSC
WP291	PIK3CA MUT* (--)	PIK3CA Mutation	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2355	only alteration type		NSCLC
WP291	PIK3CA MUT* (--)	PIK3CA N345K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4047	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA Q546K	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2198	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA R88Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3832	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA R93W	Cetuximab,Fluorouracil,Oxaliplatin	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4467	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA S158L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4463	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA V955G	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10033	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA V955I	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/8063	only alteration type		COREAD
WP291	PIK3CA MUT* (--)	PIK3CA Amplification	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8267	only gene		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA Amplification	Lapatinib,Dactolisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8271	only gene		BRCA
WP291	PIK3CA MUT* (--)	PIK3CA Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6275	only gene		CM
WP291	PIK3CA MUT* (--)	PIK3CA Amplification	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1464	only gene		HNSC
WP291	PIK3CA MUT* (--)	PIK3CA Amplification	Sulindac,Aspirin,Ibuprofen	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7186	only gene		HNSC
WP291	PIK3CA MUT* (--)	PIK3CA Amplification	Pictilisib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/756	only gene		OV
WP291	PIK3R1 MUT* (--)	PIK3R1 Mutation	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1612	only alteration type		BRCA
WP291	PTPRD MUT* (--), PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
WP291	RAD54L MUT* (--)	RAD54L Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11207	only alteration type		PRAD
WP291	RB1 MUT* (--), RB1 MUT* (--)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
WP291	RET MUT* (--)	RET CCDC6::RET	Agerafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7480	only gene		COREAD
WP291	RET MUT* (--)	RET CCDC6::RET	Nintedanib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1601	only gene		NSCLC
WP291	RET MUT* (--)	RET Fusion	Cabozantinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4847	only gene		LUAD
WP291	RET MUT* (--)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4848	only gene		NSCLC
WP291	RET MUT* (--)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4849	only gene		NSCLC
WP291	RET MUT* (--)	RET Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4850	only gene		NSCLC
WP291	RET MUT* (--)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7066	only gene		NSCLC
WP291	RET MUT* (--)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/8850	only gene		NSCLC
WP291	RET MUT* (--)	RET Fusion	Pralsetinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11233	only gene		NSCLC
WP291	RET MUT* (--)	RET Fusion	Selpercatinib	Thyroid carcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8852	only gene		THCA
WP291	RET MUT* (--)	RET KIF5B::RET	Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/698	only gene		LUAD
WP291	RET MUT* (--)	RET KIF5B::RET	Vandetanib,Everolimus	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1622	only gene		LUAD
WP291	ROS1 MUT* (--)	ROS1 Rearrangement	Ceritinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1248	only gene		LUAD
WP291	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1690	only gene		LUAD
WP291	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/688	only gene		NSCLC
WP291	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1030	only gene		NSCLC
WP291	ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7933	only gene		NSCLC
WP291	ROS1 MUT* (--)	ROS1 FUSIONS	Entrectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11123	only gene		NSCLC
WP291	ROS1 MUT* (--)	ROS1 Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7282	only gene		NSCLC
WP291	ROS1 MUT* (--)	ROS1 G2032R	Crizotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2934	only alteration type		LUAD
WP291	ROS1 MUT* (--)	ROS1 GOPC::ROS1	Lorlatinib	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7483	only gene		GB
WP291	SOX10 MUT* (--)	SOX10 Loss	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1710	only gene		CM
WP291	TLK2 MUT* (--)	TLK2 Amplification	Go6983,GF109203X	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6000	only gene		BRCA
WP291	TP53 wildtype	TP53 Wildtype	Cetuximab,Oxaliplatin,Capecitabine	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/875	complete		COREAD
WP291	TP53 wildtype	TP53 Wildtype	Adjuvant Chemotherapy	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1149	complete		NSCLC
